
baclofen (r_compound) pump
effect (l_nmod) hypotension
divided (l_nmod) groups
cycloheximide (r_conj) scopolamine
cardiotoxicity (r_nmod) prevention
decrease (r_dobj) abolished
patients (l_nmod) history
cocaine (r_compound) administration
hyperplasia (l_conj) carcinoma
presented (r_acl) history
superior (r_conj) free
production (r_nmod) augmentation
cocs (r_nmod) found
complete (r_amod) prevention
neurotoxicity (r_conj) hallucinations
efficacy (r_dobj) investigated
fk506 (r_appos) tacrolimus
protecting (r_advcl) potent
warfarin (r_compound) patients
reduced (l_nsubjpass) hyperactivity
sites (r_nmod) binding
classified (r_conj) higher
digitalis- (r_amod) arrhythmia
boy (l_acl:relcl) received
minimizing (l_dobj) dysfunction
use (r_nmod) sensations
mk-801 (r_nsubj) reduced
reports (r_conj) sequence
taking (r_advcl) developed
development (l_nmod) lids
oct (r_nsubj) reversed
anesthesia (r_nmod) repair
dox-induced (r_amod) cardiotoxicity
nucleosides (l_nmod) ischemia
haloperidol (r_nmod) induced
hirsutism (l_conj) pcos
induction (l_nmod) effects
ameliorated (l_nsubjpass) hypotension
toxicity (r_nmod) signs
treating (l_dobj) attack
reverses (l_dobj) amnesia
fk506 (r_compound) group
contained (r_acl:relcl) use
doses (r_dobj) employing
cis-ra (r_nsubj) demonstrated
episode (l_nmod) hepatitis
mice (r_nmod) development
incidence (l_nmod) eps
treated (r_conj) report
calcium (r_compound) >
curcumin (r_nsubj) able
lacks (l_dobj) effects
continued (l_advcl) detected
cause (l_dobj) toxicity
function (l_conj) formation
lometrexol (r_nmod) study
pump (l_nmod) management
woman (r_dobj) describe
rats (r_nsubj) proteinuric
showed (l_dobj) behaviour
used (r_acl) hydrochlorofluorocarbons
remifentanil (r_dobj) infusing
l-alpha-gfc (r_appos) l-alpha-glycerylphosphorylcholine
cgs (r_appos) responses
norepinephrine (r_compound) transporter
potentiate (l_conj) facilitate
decreased (l_dobj) course
indicates (r_parataxis) cause
tamca (r_nmod) concentration
clopidogrel-related (r_amod) hepatitis
prescribed (l_nsubj) risk
treatment (l_nmod) infection
affected (l_nsubjpass) bradycardia
validity (l_nmod) hypothesis
benefit (l_nsubj) patients
amlodipine (r_dobj) commenced
nitroprusside (r_conj) anesthesia
most (r_nsubj) seemed
cystitis (l_appos) hc
supranuclear (l_dobj) palsy
a (l_appos) drug
sustained (l_dobj) tachycardia
pb (r_appos) phenobarbital
correlation (r_nsubj) suggest
ototoxicity (r_nmod) participation
follow (l_nsubj) cholestasis
mice (r_advcl) improved
evaluation (l_nmod) therapy
% (l_dep) decrease
locomotion (l_conj) used
regimens (r_conj) bortezomib
cnsb002 (r_nmod) combination
carbimazole (r_dobj) replaced
performed (l_nsubjpass) analysis
ttc (r_appos) chloride
reduced (r_conj) included
pge2 (r_compound) production
showed (l_parataxis) relieved
etoposide (r_nmod) d
observations (l_dep) had
therapy (r_nmod) bradycardia
rate (l_compound) stroke
dobutamine (r_conj) dopamine
patients (l_nmod) tachyarrhythmia
nifedipine (r_dobj) starting
adenosine (r_compound) doses
related (l_nmod) malignancies
epiphyses (l_dep) punctata
progestagen-only (r_amod) ocs
antimicrobials (r_nmod) related
steroids (r_nmod) treated
metronidazole (r_conj) cotrimoxazole
isoflurane (r_nmod:npmod) inspired
vt (l_conj) vf
bepridil (r_nmod) induced
increased (l_nmod) months
diabenese (r_appos) chlorpropamide
haloperidol (r_nmod) study
administration (r_nmod) resulted
hd-mtx (r_compound) therapy
have (l_dobj) malignancies
similar (l_nsubj) bradycardia
trial (r_appos) trials
aggravated (l_dobj) damage
mosmol/kg (r_appos) mmol/l
tci (l_appos) reduction
melatonin (r_nsubj) influenced
cocaine (r_nmod) administration
mainstay (l_nmod) treatment
thalidomide (r_nmod) complication
factor (l_acl:relcl) contributed
used (l_dobj) models
progesterone (r_conj) estradiol
treated (l_advcl) determine
based (l_nmod) finding
indicates (l_dobj) need
dopa (r_nmod:npmod) treated
synthesis (r_nsubj) contributes
revealed (l_nmod) systems
test (l_nmod) damage
patients (l_nmod) function
speed (r_nmod) attributed
da (r_compound) receptors
bupivacaine-induced (r_amod) impairments
da (r_compound) response
metoclopramide (r_dobj) received
type (l_nmod) medication
child (l_nmod) palsy
blocked (l_nsubjpass) reduction
succinylcholine (r_nmod) produced
cyclophosphamide (r_nmod) exposure
determine (l_advcl) side-effect
hcl (r_nmod) time
hour (r_nmod) got
expression (l_nmod) inflammation
desferrioxamine (r_compound) treatment
present (l_nsubj) hyperprolactinemia
clonidine (r_nmod) doses
testing (l_conj) attenuates
died (l_nmod) edema
behaviors (l_acl:relcl) go
case (l_nmod) nephritis
bendrofluazide (r_appos) one
acid (r_appos) phenylalanine
nausea (l_conj) headache
gliclazide (r_acl) comparison
compared (l_nsubjpass) effects
slowed (r_acl:relcl) acidification
common (l_nmod) disease
patient (l_amod) bipolar
model (l_nmod) symptoms
delay (l_nmod) regrowth
receptor (l_nmod) increase
superior (r_ccomp) demonstrated
eradication (l_nmod) infiltration
activation (r_nmod) mediated
cortisol (r_compound) levels
exhibited (l_nmod) addition
dose (r_nmod) grafting
drugs (r_nsubj) decrease
none (l_nmod) users
levels (r_nmod) predicted
significant (r_ccomp) revealed
isoproterenol (r_nmod) doses
determine (r_advcl) used
combination (l_nmod) monotherapy
acetaminophen (r_nmod) confirmed
involved (l_nmod) catalepsy
mediated (l_conj) other
injection (r_nmod) inhibition
tyrosine (r_compound) hydroxylase
man (r_nmod) occurred
complications (l_amod) thromboembolic
induced (l_nsubjpass) injury
methamphetamine (r_compound) dependence
angiogenesis (r_dobj) inhibit
d (r_nmod) produced
difference (r_conj) resistance
associated (l_nsubjpass) failure
experienced (l_dobj) events
exerts (l_parataxis) rescues
encephalopathy (r_nmod) signs
used (l_nmod) prophylaxis
cya (r_nmod) doses
correlates (r_ccomp) fact
highlights (l_dobj) need
determined (l_nsubjpass) explanation
benztropine (r_conj) ethopropazine
nitroglycerin (r_nmod) application
phenylephrine (r_nmod) addition
fq (l_conj) nocistatin
l-name (r_nsubj) decreased
clomipramine (r_nmod) effects
antibiotics (r_nmod) reactions
observed (l_conj) seizures
illustrate (r_xcomp) reported
influence (l_nmod) deficit
cholinergic (l_conj) deficit
des-induced (r_amod) tumor
nerves (r_nmod) destruction
norepinephrine (r_conj) da
morphine (r_nmod) days
olanzapine (r_nmod) comparison
channel (r_compound) density
alterations (l_nmod) lipoproteins
enalapril (r_amod) group
increase (r_nmod) means
cyclophosphamide (r_nmod) monitoring
patients (l_compound) apl
doxorubicin (r_conj) drugs
occurred (l_nmod) fractures
administration (r_nmod) related
steroid-aggravated (r_amod) rosacea
bupropion (r_dobj) receiving
omission (r_nsubj) reduce
patients (l_compound) hepatitis
feeding (r_nsubj) resulted
characteristic (l_nmod) diabetes
shown (l_xcomp) block
syndrome (l_conj) syndrome
methimazole-induced (r_amod) cholestasis
incidence (l_nmod) hemorrhage
maintain (l_advcl) decreasing
need (l_nmod) monitoring
administration (r_nsubj) increased
treated (r_acl) diabetes
dox (r_compound) b1r(-/-
capecitabine (r_nmod) safety
receptor-mediated (r_amod) mechanism
manifestations (l_nmod) cardiotoxicity
necrosis (l_conj) any
using (r_advcl) evaluated
fluconazole (r_nsubjpass) discontinued
sinensis (r_nmod) extract
comparison (l_nmod) prevention
testing (l_compound) aggregation
risk (r_dobj) increase
patients (r_nmod) monitoring
occur (l_nsubj) some
effects (r_nsubj) scopolamine-induced
participates (l_advcl) seemed
induce (l_dobj) retardation
expression (l_nmod) anxiety
metocurine (r_nmod) abolished
oxazolidine (r_compound) derivative
involvement (l_acl) mediating
(azt)-induced (r_compound) anemia
administration (r_nmod) were
% (r_nmod) fatal
induced (r_acl) epilepsy
plays (l_nmod) ototoxicity
lymphoma (l_conj) dystrophy
arrest (l_acl) causing
rats (l_amod) subject
group (r_nmod) increased
a (r_nmod) role
data (r_advcl) carried
agent (r_nsubj) effective
finding (l_nmod) diagnosis
pretreated (l_nmod) chemotherapy
suspect (l_nmod) infection
transplants (l_nmod) anemia
creatinine (r_appos) crf
potential (l_amod) cardiotoxic
misoprostol (r_nmod) doses
man (l_acl:relcl) suffered
minutes (r_nmod) measured
mannitol (r_compound) concentrations
exposure (r_nmod) amount
enhance (l_dobj) resolution
nad (r_nmod) precursors
described (l_nsubjpass) factors
therapy (l_nmod) hit
dph (r_compound) injection
mixture (r_nmod) exposure
therapy (l_nmod) disorders
levodopa (r_nmod) prior
associated (l_nmod) disarrangement
usual (r_ccomp) reveals
attenuated (r_conj) decreased
activation (r_nsubj) plays
injection (r_nsubjpass) followed
reduced (l_dobj) uraemia
effective (l_advcl) reversing
combination (r_nmod) induced
patients (l_nmod) disorder
n-induced (r_amod) reactions
development (r_nmod) prophylaxis
restarted (r_conj) resolved
ingestion (r_nmod) developed
effect (r_conj) involved
tools (l_nmod) pd
ccnu (r_appos) incidence
immunity (l_compound) rubella
affect (l_nsubj) hyperalgesia
observed (r_acl) effects
drugs (l_amod) active
thalidomide (r_nmod) effects
proportion (l_nmod) haemorrhages
model (l_acl) studying
women (l_amod) epileptic
demonstrated (r_advcl) allows
glutamate (r_dep) ,
drugs (r_conj) inhibitors
produced (r_acl) cardiomyopathy
diazepam (r_nsubj) facilitates
appears (l_nsubj) constriction
morphine-induced (r_amod) hypotension
correlation (l_nmod) damage
monotherapy (r_nmod) similar
mice (r_nmod) occurrence
alleviating (l_dobj) parkinsonism
that (r_nmod) toxicity
onset (l_nmod) pain
mb (r_nmod) excess
developed (l_dobj) necrosis
dothiepin (r_nmod) less
effects (r_nmod) management
use (r_nmod) see
sodium (r_nsubj) helpful
instances (l_nmod) toxicity
levels (l_conj) development
thallium-201 (r_amod) tomography
patient (r_nmod) led
agents (r_nmod) series
dose-dependent (l_conj) derives
carbonate (r_nsubj) factor
duration (l_nmod) catatonia
binder (r_nmod) switching
pretreatment (l_nmod) myoclonus
suffering (l_nmod) (aap)-hepatitis
abuse (l_conj) risk
included (l_dobj) tumors
injection (l_nmod) treatment
fenfluramines (r_nsubj) related
episodes (r_dobj) had
levels (l_acl:relcl) precedes
pathophysiology (l_nmod) lids
case (r_nmod) cases
k(+)-channel (r_compound) blockers
antagonists (l_nmod) model
therapy (r_nmod) activity
conducted (l_nmod) patients
glycopyrrolate (r_appos) throat
10- (r_nsubj) effective
receiving (r_acl) children
nitroprusside (r_conj) labetalol
pge1-induced (r_amod) hypotension
angiotensin (r_compound) inhibitors
morphine (r_nmod) pretreatment
prilocaine (r_nmod) patients
thallium-201 (r_amod) spect
hepatitis (r_nmod) cholestasis
progestagen (r_nmod) type
deaths (l_amod) apoptotic
induced (r_acl) asterixis
dexamethasone (r_nmod) use
treatments (r_dobj) subchronic
vasodilators (r_nmod) induced
csa (r_nmod) induced
total (l_dep) manic
use (l_appos) study
effect (l_amod) convulsive
leukaemia (l_conj) lymphoma
observed (r_conj) affect
patients (l_nmod) vt
produced (r_acl) onset
use (r_nmod) worsening
characterized (r_advcl) prolonged
losartan (r_appos) dup
antidepressant (r_amod) therapy
compared (l_dobj) toxicity
medium (r_compound) administration
increased (r_ccomp) postulate
have (r_xcomp) found
rate (r_nsubj) remained
isph (r_nmod) injection
studied (l_nsubjpass) relationship
initiation (r_nmod) association
caused (r_acl) depression
results (l_dep) switched
clipping (l_nmod) aneurysm
man (l_conj) history
administration (r_nmod) injury
include (l_advcl) uncommon
hydrochloride (r_nmod) efficacy
patients (l_nmod) hypotension
mg (l_conj) ergotamine/caffeine
fk506 (r_conj) a
onset (r_nmod) years
pethidine (l_nmod) control
diagnosis (l_nmod) stroke
ongoing (l_nmod) aim
received (r_acl:relcl) 1
elicited (l_dobj) decrease
thiotepa (r_compound) chemotherapy
picrotoxin-induced (r_amod) seizures
suggests (l_nsubj) etiology
pilocarpine (r_compound) injection
determined (r_conj) tested
disease (l_conj) atrophy
suffered (l_dobj) convulsions
subjects (l_conj) patients
adenosine (r_nmod) abnormalities
contribute (l_nsubj) dehydration
suppression (l_nmod) turnover
history (r_dobj) had
report (l_nmod) neurotoxicity
defects (l_appos) vsds
enabled (l_xcomp) attribute
use (r_conj) incidence
combination (l_nmod) treatment
effect (l_nmod) impairments
groups (l_acl:relcl) resistant
observed (l_nmod) convulsions
patients (r_nmod) described
cause (l_dobj) vasodilation
considered (l_conj) persisted
aspects (l_nmod) disorders
associated (l_nmod) dizziness
morphine (r_amod) antinociception
hepatitis (r_nmod) patient
drug (l_conj) preparation
intensified (r_ccomp) suggests
result (r_ccomp) conclude
excretion (r_nmod) courses
induced (l_nsubjpass) ischemia
caused (l_nmod) arthritis
considered (l_nsubjpass) vasculitis
paralysis (l_conj) dysarthria
virus (l_compound) b
propofol (r_conj) dexmedetomidine
compared (r_conj) examined
sodium (r_nmod) induced
prevented (l_nsubjpass) proportion
glutathione (r_compound) reductase
attribute (l_advcl) illicit
terbutaline (r_nmod) treated
efficacious (r_conj) effective
demonstrated (l_dobj) ability
remained (l_nsubj) effusion
treatment (r_nmod) useful
uncertain (l_nsubj) mechanism
referred (l_nmod) dysfunction
anthraquinones (r_dobj) containing
associated (l_nmod) damage
animals (r_dobj) killed
penicillin (r_nsubjpass) presented
transferase (r_conj) dismutase
changes (l_conj) weakness
n-methyl-d-aspartate (r_conj) acid-
outcomes (l_conj) measures
pap (r_conj) apap
those (l_acl:relcl) active
desipramine-induced (r_amod) delirium
fever (l_conj) asthma
safety (r_dobj) investigated
li-induced (r_amod) nephropathy
course (r_dobj) receiving
csa (r_compound) replacement
assess (l_dobj) hypertension
impaired (l_dobj) recall
hours (r_nmod) observed
diagnosis (l_nmod) psychosis
induced (l_dobj) vasculitis
programmed (l_dobj) increase
treatment (r_nmod) weeks
invoked (r_acl) proteinuria
had (l_advcl) inducing
treated (r_acl) pd
dyskinesias (l_appos) lid
leukemia (l_appos) apl
illicit (l_conj) underestimate
mortality (l_compound) cvd
phenobarbitone-primed (r_amod) rat
desmethylfluoxetine (r_conj) fluoxetine
ciprofloxacin (r_nmod) associated
vasopressin (r_nmod) secretion
infusion (l_acl:relcl) occurred
oc (r_compound) use
consumption (r_nmod) amount
dox (r_nmod) formation
mg/kg (l_conj) seizures
search (r_nsubj) include
studies (l_compound) injury
agonists (r_nmod) converted
damage (l_acl) determined
episodes (r_conj) behavior
impaired (l_dobj) memory
effect (l_nsubj) proteinuria
results (r_dep) tolerability
change (r_dobj) causing
reported (r_acl) cases
underwent (r_acl:relcl) failure
suspected (l_nsubjpass) neuropathy
responses (l_amod) hyperalgesic
amphetamine-induced (r_amod) rotation
psychosis (l_conj) disorders
treatment (l_nmod) c.
remained (l_nmod) attacks
decrease (r_dep) different
radiolabelling (r_nsubjpass) increased
resulting (l_nmod) disease
developed (l_nsubj) anuria
amikacin (r_dobj) receiving
associated (l_conj) decrease
dioxide (r_conj) oxygen
dopamine (r_conj) gaba
release (l_nmod) seizure-prone
trial (l_nmod) prevention
pilocarpine (r_compound) injections
bcnu-exposed (r_amod) group
bupivacaine (r_nmod) toxicity
junction (r_nmod) due
naloxone (r_compound) challenge
rats (r_nmod) effects
quantify (l_dobj) severity
(hctz)-monotherapy (r_conj) valsartan
effect (l_conj) mechanism
decreased (l_advcl) leading
mg (r_dep) patients
prednisone (r_nsubj) induces
exposure (r_nsubj) elicits
rats (r_nmod) groups
doses (r_nmod) administration
corticosteroids (r_conj) agents
hypothesized (l_ccomp) plays
selegiline (r_nmod) withdrawal
given (l_advcl) test
ro (r_dep) aniracetam
lt (l_nmod) disease
production (l_nmod) forms
attacks (l_compound) migraine
ezetimibe (r_amod) inhibition
affinity (r_nmod) drugs
indicative (l_nmod) dyskinesia
therapy (r_conj) bupropion
applied (l_nmod) cells
history (l_nmod) disorder
nifedipine (r_nsubj) potentiate
tobramycin (r_nmod) reversible
users (r_nmod) excess
center (l_nmod) scale
women (r_nmod) years
causing (r_advcl) pretreatment
sodium (r_conj) potassium
examined (l_nmod) neurotoxicity
methamphetamine-dependent (r_amod) patients
association (l_nmod) lymphoma
nicotine (r_compound) pretreatment
levobupivacaine (r_nmod) injection
dysfunction (r_nmod) resulted
sensitivity (l_nmod) angina
efficacy (l_appos) incidence
reported (l_nsubjpass) nephropathy
fenfluramine-phentermine (r_dobj) receiving
nephrotoxicity (r_dobj) prevent
sevoflurane (r_nmod) threshold
carbamazepine (r_compound) overdose
learning (l_conj) impairment
risk (l_nmod) torsade
myelosuppression (l_conj) cytotoxicity
use (r_conj) needle
injection (r_nmod) describe
consumption (r_dobj) stopping
mj (r_appos) patients
developed (r_advcl) resistant
drug (l_acl) known
patients (l_conj) evidence
therapy (r_nmod) result
glutamate (r_nmod) reduction
hyponatremia (l_conj) siadh
radiation (r_conj) appearances
limited (l_nmod) toxicity
reactions (l_nmod) depression
ion (r_conj) factor-alpha
argatroban (r_amod) therapy
creatinine (r_compound) level
responsiveness (r_conj) responsiveness
relationship (r_nmod) studies
study (l_acl) followed
rats (r_nmod) blockade
inhibition (l_nmod) glioma
dfu (r_compound) toxicity
ephedrine (r_conj) phenylephrine
cells (r_nmod) microinjection
evaluated (r_conj) prevent
tetrabenazine (r_nmod) therapy
resulted (l_nmod) cells
progesterone (r_nmod) use
pathogenesis (l_nmod) hypotension
meter (r_nmod) measured
models (l_nmod) schizophrenia
nonusers (l_nmod) ich
layer (l_nmod) gyrus
woman (r_nmod) observed
reduce (r_conj) reduce
pan (r_nmod) induced
rats (r_conj) model
potassium (r_nmod) excretion
ameliorated (l_dobj) impairment
related (r_amod) patient
model (l_nmod) syndrome
doses (r_nsubjpass) known
dystonia (l_nmod) supranuclear
co-trimoxazole (r_compound) treatment
cgrp (r_appos) peptide
had (l_dobj) hypercalcemia
number (l_nmod) events
associated (l_nmod) fibrosis
blue (r_nsubj) greater
lithium-treated (r_amod) patients
induced (l_dobj) atrophy
gaba-a (r_nmod:npmod) receptor-linked
follow (l_nsubj) stroke
movements (r_dobj) reduced
hypertension (l_conj) nephrotoxicity
impaired (l_nmod) group
amphetamine (r_conj) methamphetamine
a-86929 (r_appos) use
affected (l_nsubjpass) vasodilation
patients (l_conj) mi
induces (l_conj) aggravates
lidocaine (r_conj) cocaine
determined (l_nsubjpass) enhancement
development (l_nmod) monkeys
resolved (l_nsubj) asterixis
bilirubin (r_dobj) included
nephropathy (r_nsubjpass) associated
occur (l_nsubj) syndrome
busulfan (r_nmod) days
comparing (r_acl) study
dothiepin (r_nsubj) effective
onset (l_nmod) necrosis
reaction (r_nsubj) occurred
associated (r_acl) anemia
due (r_conj) consistent
shows (l_dobj) activity
levodopa-primed (r_amod) monkeys
organophosphate (r_amod) diazinon
lometrexol (r_nsubj) has
hypertriglyceridaemia (r_conj) events
metformin (r_nmod) 25
elevation (r_nmod) contribute
hypertension (r_nsubj) instituted
boy (l_acl:relcl) exhibited
model (l_nmod) paranoia
admitted (l_conj) receive
induced (r_acl:relcl) catalepsy
suggested (l_xcomp) cardiotoxic
produced (l_dobj) hypothermia
vomiting (l_conj) nausea
seizure (l_dobj) thresholds
(ppa)-induced (r_amod) injury
prevented (r_acl:relcl) toxicity
comparison (l_nmod) ischemia
dose (r_nmod) addition
course (r_nmod) case
e (r_nmod) lack
prevents (l_dobj) development
induced (r_amod) analgesia
antagonist (r_conj) haloperidol
reduced (l_dobj) effects
propranolol (r_nmod) improvement
rhabdomyolysis (l_conj) myoglobinuria
levomepromazine (r_conj) risperidone
n (r_conj) p
none (r_conj) was
patient (l_nmod) thalassemia
investigated (l_conj) examined
effect (r_nsubjpass) prevented
appeared (l_dobj) method
pethidine (r_nmod) infusion
administration (l_conj) proteinuria
syndrome (l_nmod) pericarditis
hypokalemia (r_nmod) factors
society (l_nmod) study
pituitary (r_nmod) expression
worsening (r_nmod) tasks
metoprolol (r_nmod) administration
reports (l_nmod) ectopy
deficiency (r_nmod) aetiology
flexion (l_nmod) toes
measuring (l_dobj) concentration
area (l_nmod) group
dose (r_nsubj) led
vpa (r_appos) valproate
methylprednisolone (r_nmod) value
rg1 (r_nmod) effect
patients (r_nsubj) received
clearance (r_nmod) quantitated
cm (r_parataxis) higher
pretreatment (l_nmod) pain
result (l_nmod) syndrome
effect (r_nsubjpass) evaluated
mediated (r_acl) mechanism
treated (r_acl) cows
followed (r_acl:relcl) failure
dermatitis (l_nmod) patient
hoe (r_compound) ip
anaesthesia (r_dobj) using
macrolide (r_compound) antimicrobials
received (l_nmod:tmod) day
factor (l_nsubj) neuropathy
s (l_acl) followed
warranted (l_nmod) profile
victims (r_nmod) compared
trimethoprim (r_conj) study
effect (l_nmod) seizures
alf=0/35 (r_dep) lt
gene (r_nsubjpass) associated
edaravone (r_nsubj) has
benzoylecgonine (r_conj) cocaine
increase (r_dobj) produced
glutamate-pyruvate (r_amod) transaminase
therapy (l_nmod) melanoma
that (l_acl) seen
transaminase (r_nmod) inhibitor
development (l_nmod) crisis
effect (r_nsubj) glucagon
likely (l_xcomp) develop
group (r_nmod) was
given (l_advcl) producing
heparin-induced (r_amod) tests
use (l_nmod) infection
(emb)-induced (r_amod) optic
pan (r_dep) injection
quetiapine (r_nmod) reaction
patients (r_nmod) occurred
agent (r_nmod) pretreatment
experienced (l_dobj) episodes
nitroprusside (r_amod) levels
mibg (r_compound) scintigraphy
separation (l_nmod) growth
pentazocine-induced (r_amod) myopathy
syndrome (l_amod) arthralgia-myalgia
perfused (r_acl) kidney
54 (l_conj) 20
observed (l_nsubjpass) effect
morphine (r_nmod) doses
remoxipride (r_nmod) associated
argatroban (r_nmod) levels
dox-induced (r_amod) failure
prevention (l_nmod) disease
inhibitor (r_nsubj) protected
patient (l_acl) suffering
predictors (l_nmod) function
manifesting (l_compound) vasculitis
hypoaldosteronism (l_compound) hyperkalemia
events (r_nmod) one
hypercalcemia (l_dep) bradyarrhythmia
manic (l_conj) hypomanic
pointes (l_conj) death
reduces (r_conj) plays
decreases (l_nmod) pressure
reviews (r_nsubjpass) selected
lead (l_nmod) lesions
dexrazoxane (r_conj) doxorubicin
treatment (l_nmod) overdose
reduction (l_nmod) harm
warfarin (r_nmod) dosage
signs (l_nmod) damage
action (l_amod) anti-carcinogenic
enalapril-treated (r_amod) n
kf17837 (r_nsubj) reduced
abnormality (r_dobj) had
therapy (r_nmod) discontinuation
azt (r_compound) therapy
occurred (l_nmod) periods
started (l_advmod) prior
yield (r_conj) glutamate
patients (r_dobj) included
amiodarone (r_nsubj) proved
mechanisms (l_appos) catalepsy
enflurane (r_conj) labetalol
chloramphenicol (r_nmod) induced
subjects (l_amod) diabetic
suppressing (l_dobj) dna
severe (l_nsubj) ototoxicity
ascribed (l_nsubjpass) failure
infusion (r_nmod) infused
acetylcholine (r_amod) levels
required (r_acl:relcl) disorder
treatment (l_nmod) dysmenorrhea
levodopa (r_nmod) role
professionals (r_nmod) familiarity
mediated (r_acl) damage
syndrome (r_nmod) signs
apamin (r_nsubj) had
sedation (r_nmod) anesthesia
fentanyl (r_nmod) effectiveness
mfl (r_compound) benefit
patients (l_appos) drug
treated (r_acl) angioedema
dexamethasone (r_dobj) received
sodium (r_nmod) studies
prevented (l_conj) protected
found (l_xcomp) had
seizures (r_dobj) protecting
abusing (r_acl) inpatient
urticaria/angioedema (r_nmod) history
group (r_nmod) observed
sirolimus (r_dobj) implicated
concentration (r_dobj) measure
medications (r_nmod) associated
induced (r_advcl) produced
concentration (r_nmod) related
pethidine (r_nsubj) opioid
results (l_nmod) toxicity
patients (l_nmod) osteoporosis
cc (r_nmod) courses
greater (l_nmod) those
development (l_compound) proteinuria
therapy (r_nmod) resolved
indicating (r_xcomp) consistent
started (l_nmod) arthralgia
included (r_conj) identified
increasing (r_acl) signs
dobutamine (r_nsubj) induced
effectiveness (l_acl) prevent
was (r_advcl) prevent
effect (l_nmod) paraparesis
compared (r_dep) p
ozone (r_nmod) associations
complications (r_conj) thromboembolic
induced (r_acl) those
seizures (r_nmod) protecting
pan (r_nmod) injections
had (l_dobj) seizures
prochlorperazine (r_nmod) administration
short (r_conj) produced
adriamycin (r_conj) cisplatinum
hydrochloride (r_dobj) dosulepine
risk (l_nmod) esrd
larger (r_conj) smaller
arrhythmia (l_conj) bradycardia
fentanyl (r_nmod) pretreatment
pilocarpine-induced (r_amod) increases
received (r_advcl) received
complications (r_nmod) dyskinesia
reduce (r_acl) ability
related (l_nmod:npmod) drug
potential (l_amod) neurotoxic
prevented (l_nsubjpass) toxicity
caused (l_dobj) gain
responses (l_conj) bradycardia
attention (l_conj) control
warfarin (r_nmod) weeks
decreased (l_nsubjpass) nausea
apomorphine-induced (r_amod) hyperactivity
believe (l_ccomp) represents
days (r_nmod) dyskinesia
cbdca (r_compound) administration
trial (r_conj) data
animals (r_nmod) hippocampus
amphetamine (r_nmod) hyperactive
quetiapine (r_nmod) induced
high (l_nmod) subset
levodopa (r_compound) treatment
symptoms (l_appos) onset
kinetics (l_conj) appearance
scale (l_compound) studies-depression
diazepam (r_nsubj) remains
exposure (r_nmod) weeks
anaesthetised (r_acl) rats
disorder (r_nmod) taking
endpoints (l_compound) convulsion
cyclosporine-induced (r_amod) tma
model (l_nmod) abuse
failure (l_conj) edema
srl-treated (r_amod) rats
clozapine (r_nmod) commencement
received (l_xcomp) prevent
reports (l_nmod) leukoencephalopathy
inhibitor (r_nmod) effects
twitches (r_dobj) potentiate
content (l_conj) attack
salbutamol (r_nmod) effects
share (r_advcl) designated
patients (r_nmod) occur
argatroban (r_nmod) bleeding
2.3+/-1.2 (l_conj) 39.5+/-8.4s
therapy (r_nmod) score
factor (l_advcl) claimed
prophylaxis (r_nmod) hypertension
criteria (l_nmod) coma
tamoxifen (r_compound) metabolism
markers (l_nmod) necrosis
application (r_nmod) feasibility
combination (r_nmod) hepatitis
investigate (l_dobj) role
macrolide (r_nmod) association
resulted (l_nmod) deterioration
acetaminophen (l_dep) nephrotoxicity
injections (r_nsubj) augment
amitriptyline (r_compound) therapy
amiodarone (r_amod) presenting
methotrexate (r_nmod) instillation
patients (l_nmod) signs
effects (r_nsubj) remain
succinylcholine (r_nmod) demonstrating
users (r_nmod) syndrome
effect (l_amod) tumor-protective
produced (r_acl) state
liberate (r_xcomp) shown
thrombosis (r_nmod) development
oxacillin (r_nmod) associated
effects (l_nmod) catalepsy
heparin (r_compound) products
initiation (r_nmod) higher
ciprofloxacin-induced (r_amod) nephrotoxicity
temperature (r_conj) rate
cytotoxicity (r_conj) myelosuppression
sulfate (r_nmod) use
causes (l_dobj) hypotension
patients (l_nmod) neuralgia
epinephrine (r_conj) lipid
used (l_nmod) combination
danazol (r_nmod) treated
years (r_nmod) had
placebo (l_nmod) disorder
produce (l_dobj) condition
mouth (l_conj) throat
trial (l_nmod) carcinoma
thalidomide (r_nmod) trial
enhanced (l_nmod) effect
subjects (r_nmod) difference
models (l_amod) inflammatory
(2-chloroethyl)-1-nitrosoure (r_nmod) exposure
ranitidine (r_compound) therapy
incidence (l_nmod) tremor
shown (l_xcomp) prevent
effect (r_nmod) accounted
malondialdehyde (r_nmod) dependence
dox (l_acl) cardiomyopathy
evaluated (l_nmod) anemia
toxicity (l_dep) association
parameters (r_nsubjpass) obtained
agent (l_nmod) reduction
succinylcholine (r_nmod) action
infusion (r_nsubj) prevent
evaluate (r_advcl) exhibit
trp (r_compound) depletion
role (r_dep) anemia
nitrotyrosine (l_nmod) tissues
nephropathy (r_nmod) mediating
properties (r_dobj) possesses
cancers (l_nmod) sarcomas
factors (l_conj) duration
hal (r_appos) haloperidol
sgot (r_conj) showed
acid (r_nmod) treatment
treated (r_acl) depression
morphine-induced (r_amod) hypoactivity
delay (l_conj) retardation
responses (l_amod) allergic
metabolite (r_compound) levels
infusion (r_nmod) induced
unrelenting (l_nsubj) disease
use (r_nmod) paralysis
nitroprusside-induced (r_amod) hypotension
amnesia (r_dobj) reversed
patients (l_nmod) c
nisoldipine (r_conj) nitrendipine
developed (l_dobj) parasitosis
drugs (r_nsubj) enhance
inhibitor (r_dobj) using
had (r_acl:relcl) patients
included (l_dobj) hypercalcemia
reduced (l_conj) induced
ammonia (r_nsubj) higher
developed (r_acl:relcl) patient
persisted (l_nsubj) seizures
acid-induced (r_amod) convulsions
plays (l_nmod) model
incidence (l_nmod) infections
telmisartan (r_nmod) combination
stress (l_nmod) disorder
benzodiazepine (r_compound) clonazepam
therapy (l_nmod) patients
clotiazepam (r_nmod) hepatotoxicity
any (l_nmod) cancers
halothane (r_compound) patients
function (l_conj) evaluation
returned (r_advcl) had
study (r_nsubjpass) done
cases (l_nmod) complications
absence (l_nmod) necrosis
treatment (l_nmod) moderate
carcinoma (l_nmod) tract
revealed (l_dobj) count
degree (l_nmod) seizures
bupropion (r_nmod) use
cisplatin (r_nmod) toxicity
hydrobromide (r_nsubjpass) used
loss (r_nmod) prevention
syndrome (l_amod) hypomania-like
patients (l_nmod) haemorrhage
ethambutol (r_compound) usage
ethambutol (r_compound) overtreatment
girl (l_nmod) leucemia
epilepticus (l_conj) damage
prochlorperazine (r_nmod) efficacy
indicates (l_advcl) available
abusers (r_nmod) responses
commencement (r_nmod) association
aspirin-treated (r_amod) jj
creatine (r_compound) supplementation
meth (r_nmod) dose
events (l_acl) underlying
salbutamol (r_nsubjpass) presented
receiving (r_advcl) days
dose (r_nmod) re-exposure
form (r_nmod) effects
isoflurane (r_compound) anesthesia
cc (r_nmod) treatment
combination (l_conj) depression
argatroban (l_dep) thrombolysis
sulphonate (r_cc) effect
describes (l_nmod) remission
methyldopa-induced (r_amod) hypotension
prescribed (r_acl:relcl) people
stopped (r_conj) inhibits
beta (r_compound) 2-subunits
sulpiride-induced (r_amod) dystonia
effect (l_appos) tremor
levels (l_conj) onset
cisplatin (r_nmod) effects
function (r_nmod) defect
ami (l_acl) bleeding
dobutamine (r_nmod) induced
heroin (r_compound) abusers
encephalopathy (l_amod) hyperammonemic
treat (l_dobj) ribavirin
no (r_compound) donor
fzp (r_nmod) use
retard (r_ccomp) showed
causing (l_dobj) arrhythmias
5-fluorouracil (r_compound) neurotoxicity
infusion (r_nmod) continued
picrotoxin (r_nmod) doses
administration (l_conj) ototoxicity
apomorphine (r_compound) infusion
clotiazepam-induced (r_amod) hepatitis
production (r_nmod) associated
acid (r_compound) i
cases (l_nmod) hypotension
stroke (l_nmod) normotensive
methods (l_acl) referred
synthesis/turnover (r_dobj) accelerated
aged (l_dep) rate
dyscontrol (l_conj) inattention
treatment (r_nsubjpass) adopted
dexamethasone (r_compound) therapy
nimodipine-induced (r_amod) reduction
treatment (l_nmod) parkinsonism
days (r_dobj) developed
efficacious (l_conj) superior
changes (r_nsubj) different
diethylstilbestrol (r_nmod) treatment
characterized (l_nmod) detachment
indicating (l_ccomp) related
combination (r_nmod) thromboembolism
doxorubicin (r_nmod) given
administered (l_nmod) resection
disorder (l_amod) seizure
pressure (l_conj) rate
patients (l_nmod) malignancies
drops (r_nmod) instillation
levodopa-responsive (r_amod) patients
db (l_nsubj) loss
faced (l_nmod) victim
objectives (l_dep) success
examined (l_dobj) influence
reduced (l_conj) tended
ester (r_nmod) administration
impairment (l_conj) hoarding
used (l_nmod) patient
decreased (l_conj) decreased
reduction (l_nmod) cancer
conclusions (l_dep) mania
midazolam (r_conj) fentanyl
study (l_acl) primed
consistent (l_nmod) encephalopathy
dobutamine (r_amod) echocardiography
used (r_acl) clonidine
switch (r_nmod) reduced
glycine (r_compound) system
indices (l_nmod) nephrotoxicity
d2 (r_nsubj) exert
close (l_nmod) incidence
exists (l_nmod) injury
seen (l_nsubjpass) prolongation
impairment (l_nmod) discrimination
studied (l_nmod) forms
found (l_advcl) occurred
epinephrine (r_nmod) %
salbutamol (r_nmod) doses
injections (l_nmod) adsd
rodents (r_nmod) neurons
melphalan (r_compound) conditioning
ribavirin (r_compound) therapy
induced (r_acl) encephalopathy
treatment (r_nmod) complication
treated (r_dep) dependent
paclitaxel/cisplatin (r_nsubj) regimen
show (l_advcl) suggesting
d2 (r_dep) d-amphetamine
licking (r_nmod) reversal
types (l_nmod) parkinsonism
saline (r_nmod) injected
receiving (l_dobj) tnss
nociceptin/orphanin (r_compound) fq
5-fu (r_compound) cardiotoxicity
core (l_amod) ischemic
daunorubicin (r_nsubj) agent
pregnane-21-diol-20-ones (r_appos) deoxycorticosterone
useful (l_nmod) patients
amiodarone (r_nsubjpass) reported
antagonists (r_nmod) interaction
ketamine (r_acl) cross-tolerance
clonazepam (r_nmod) treated
combination (r_nmod) dose
has (l_dobj) duration
cm (r_compound) toxicity
qtp (r_nmod) events
possible (l_nsubj) failure
provoked (r_acl) damage
patient (l_nmod) macroglobulinaemia
abolition (r_nsubj) influence
adults (r_nsubj) have
effect (l_compound) hypertension
treatment (l_nmod) patients
paroxetine (r_nmod) day
treatment (r_nsubj) augmented
hyperalgesia (r_conj) licking
losartan (r_conj) blocker
neuropathy (r_conj) effusion
patients (r_dobj) describe
exposure (r_nsubjpass) linked
patients (l_nmod) service
cisplatin (r_nmod) trials
developed (l_dobj) occlusion
chloroquine (r_compound) ingestion
groups (r_conj) dilatation
incidence (l_compound) neurotoxicity
inhibitors (r_conj) therapy
lead-associated (r_amod) inhibition
trimethoprim-sulfomethoxazole (r_nmod) induced
inhibited (l_conj) prevented
acid- (r_conj) activity
clonazepam (r_nmod) prevented
alf (r_nmod) 1999
echocardiography (l_conj) quantitation
pretreated (r_nsubj) assessable
infections (l_nmod) endocarditis
inhibition (r_nmod) exposure
risk (l_nmod) disease
mk-801 (r_nmod) microinjection
cytotoxicity (l_nmod) tumors
man (l_acl) reported
glycine (r_compound) site
thrombocytopenia (l_amod) other
nmda (r_dep) n-methyl-d-aspartate
months (r_nmod) treated
na(+)/k(+)-atpase (r_compound) inhibitor
disorders (r_conj) disorder
ribavirin (l_compound) intravenous
resulting (l_nmod) admissions
sirolimus (r_nmod) associated
use (r_conj) polydipsia
amiodarone (r_nsubj) effective
zuclopenthixol (r_conj) antipsychotics
titrate (l_advmod) carbidopa-levodopa
severity (l_nmod) hypotension
complication (r_nmod) reported
ameliorated (l_nsubjpass) damage
simvastatin (r_conj) thyroxine
experienced (l_dobj) akathisia
suppress (r_xcomp) needed
had (l_dobj) history
patients (l_nmod) hypertension
heparin (r_nsubj) used
received (r_acl) patient
hyperactivity (r_dobj) enhanced
snp (r_dep) infusion
patients (r_nmod) titrated
plays (r_ccomp) indicates
therapy (r_nmod) timing
risperidone (r_conj) clozapine
da (r_nmod) deficient
opioid (l_acl:relcl) gains
binding (r_nmod) blocks
regurgitation (l_conj) flutter
developed (l_nsubj) disorders
causes (l_dobj) impairments
higher (l_dep) seizures/mo
ritonavir (r_compound) treatment
infusions (l_nmod) patients
treated (r_acl) anemia
verapamil (r_nsubj) affected
suppressed (l_conj) 1.9
patients (r_nmod) considered
disability (l_amod) parkinsonian
pressure (l_conj) proteinuria
had (r_conj) remained
increases (l_dobj) risk
theophylline (r_compound) preparation
is (r_conj) conclude
indicate (l_ccomp) responsible
accumulation (l_nmod) sites
rich (l_dep) although
theophylline (l_nmod) patients
involvement (r_nmod) suffering
decrease (l_nmod) sleepiness
oxide-induced (r_amod) headache
progressing (l_nmod) attacks
assess (l_advcl) administered
showed (l_conj) showed
occurs (l_nsubj) hypotension
has (l_dobj) effect
cyclophosphamide (r_nmod) induced
beclomethasone (r_nmod) restarted
acetylcholine (r_nmod:npmod) related
associated (l_nmod) glomerulosclerosis
administered (r_acl) tacrine
liable (l_nsubj) patients
role (l_nmod) nephrotoxicity
influence (l_nmod) model
elevation (l_conj) upregulation
schedule (l_nmod) toxicity
binding (r_dobj) influence
higher (l_nsubj) pressure
reduces (l_nmod) hypotension
resulted (l_nsubj) stenosis
treatment (l_nmod) tachyarrhythmias
produced (l_dobj) decrease
supplementation (r_nmod) given
blockade (l_acl) leading
lomustine (r_nmod) tolerability
hoe (r_dep) bradykinin
integrity (r_nmod) explain
reduced (l_nsubjpass) toxicity
had (l_conj) experienced
trigger (l_nmod) siat
ra-free (r_amod) water
managed (l_nsubjpass) anemia
adriamycin (r_compound) toxicity
frequency (l_nmod) loss
ro4368554 (r_nmod) facilitation
irrigations (r_nsubj) appeared
prevention (l_nmod) incapacity
play (l_conj) ameliorates
beta-agonist (r_nsubjpass) known
rats (r_conj) den
compounds (r_nmod) effect
dcf (r_appos) diclofenac
protocol (r_dobj) received
atra (r_appos) acid
involvement (l_nmod) mechanism
studied (l_nsubjpass) effects
cbz (r_compound) administration
nimodipine (r_nmod) administration
spectrum (l_nmod) dermatitis
on (r_dobj) assessed
potential (l_nmod) cardiotoxicity
sarcomas (l_conj) lymphoma
affected (r_advcl) attenuated
bradycardia (l_conj) effect
activity (r_dobj) determine
effects (r_dep) inhibitory
vincristine (r_nmod) effects
jitteriness (l_amod) antidepressant-induced
mechanisms (r_dobj) remain
developed (l_dobj) hypercalcemia
hypotension (r_nmod) increased
encephalopathy (r_nmod) lesions
chemotherapy (l_nmod) approach
falls (l_advcl) increase
bisphosphonate (r_nmod) days
hydroxyquinolines (r_nmod) reactions
disappeared (l_nsubj) pain
exacerbations (l_nmod) asthma
stress (l_nmod) pathogenesis
quetiapine (r_nmod) attribute
odds (l_nmod) convulsions
trial (r_appos) prevalence
dyskinesias (r_nmod) control
alter (l_dobj) threshold
timolol (r_compound) gellan
enhanced (l_dobj) volume
ribavirin-related (r_amod) anemia
individuals (l_nmod) psoriasis
abbott-53693 (r_nmod) effects
accompanied (r_acl) hypertension
patient (l_acl) presented
imbalance (r_nmod) associated
sensitizes (l_nsubj) intervention
7alpha-hydroxylation (l_nmod) cholestasis
antagonist (r_nmod) effects
use (r_nmod) stroke
rats (r_nmod) ventilation
ribavirin (r_nsubjpass) licensed
management (l_nmod) dysfunctions
outcome (l_nmod) symptoms
acetaminophen (r_nmod) safety
use (r_nmod) strokes
episodes (l_nmod) disturbances
alternatives (l_nmod) patients
development (l_nmod) tdp
derivative (l_acl:relcl) improve
associated (l_nmod) syndrome
d3 (r_nmod) treated
meth-induced (r_amod) neurotoxicity
diethylstilbesterol (r_conj) transplantable
piperacillin-induced (r_amod) encephalopathy
flecainide (r_nmod) interaction
ginsenoside (r_nsubj) contribute
using (r_xcomp) performed
anemia (r_nmod) carcinoma
history (l_nmod) gout
dyskinesia (l_conj) parkinsonism
important (l_ccomp) aware
effects (r_nsubjpass) studied
intermediate (l_nmod) that
alpha-methyldopa (r_conj) rilmenidine
nitroprusside (r_conj) triphosphate
effect (r_dobj) examine
determined (l_nmod) hypertension
developed (l_nsubj) syndrome
protection (l_amod) seizure
chemotherapy (r_dobj) received
reducing (l_dobj) incidence
treatment (l_nmod) neuralgia
excretion (r_conj) resistance
observed (l_nsubjpass) hypertension
eps (l_nmod) akathisia
drugs (r_nmod) withdrawal
signs (l_conj) dyskinesias
rifampicin (r_compound) therapy
elevation (l_nmod) patient
doses (r_dobj) increase
antagonism (l_nmod) hyperactivity
revealed (l_dep) valproate
effect (l_amod) hypotensive
mechanisms (r_dobj) implicate
prolonged (r_conj) intense
sensitive (l_nsubj) patients
injection (r_nmod) developed
metoprolol (r_nmod) induced
change (l_advcl) resolve
children (l_nmod) leukemia
hypothyroidism (l_nmod) patient
antipsychotics (r_nsubj) effective
isoflurane (r_conj) enflurane
icrf-187 (r_appos) dexrazoxane
carbamazepine (r_nsubj) induced
was (l_nsubj) association
lithium (r_compound) compounds
biperiden (r_nmod) induced
treatment (l_nmod) sd
associated (l_nmod) complications
considered (l_advcl) parkinsonian-like
effects (l_nmod) insufficiency
result (l_nmod) disease
patients (l_acl) experiencing
sirolimus-associated (r_amod) proteinuria
thresholds (l_amod) seizure
other (l_nmod) thrombocytopenia
rash (l_conj) lymphadenopathy
dph (r_compound) overdose
pilo (r_appos) pilocarpine
flestolol (r_nsubj) reduced
ncq436 (r_nmod) ability
blockers (r_nmod) exposed
associated (r_ccomp) matter
occurs (l_nsubj) hypoxaemia
occurrence (l_nmod) infarction
episodes (l_amod) thrombotic
bisphosphonate (r_compound) administration
leading (l_nmod) hypertension
verapamil (r_nmod) unresponsiveness
cbz (r_nmod) administration
receiving (r_acl) minutes
chloroquine (r_dobj) used
risperidone (r_conj) assigned
resolved (r_acl:relcl) children
rats (l_acl) exposed
hypotension (l_conj) depression
affected (l_nmod) illness
apap (r_appos) acetaminophen
gemcitabine (r_appos) fluorouracil
reverse (l_dobj) actions
those (l_acl) caused
acid-induced (r_amod) hyperammonemia
containing (r_acl) libitum
erythroderma (l_conj) failure
associated (r_acl) polyuria
antagonist (r_appos) mk-801
interest (l_nmod) rhabdomyolysis
left (r_conj) developed
activity (r_nmod) attenuating
c (r_nsubj) associated
induced (r_amod) impairment
problem (l_advcl) involves
tam (r_nmod) promoted
associated (l_nmod) psychosis
asenapine (r_conj) assigned
similar (l_dep) conclusions
related (r_amod) administration
delineated (l_conj) ablated
outpatients (l_amod) schizophrenic
usage (r_nsubjpass) associated
presents (l_nsubj) syndrome
rate (r_conj) had
maintained (l_nmod) conversion
inhibition (r_nsubj) induced
associated (l_nsubjpass) disorder
dex (r_nsubj) increased
is (r_ccomp) demonstrating
adding (l_nmod) order
continued (l_xcomp) remain
sufficient (l_nsubj) generation
haloperidol-induced (r_amod) test
cause (l_dobj) weakness
recurrence (l_nmod) hepatitis
patient (l_acl) treated
agent (l_acl:relcl) has
(meth)-induced (r_amod) psychosis
acid (r_nmod) women
effective (l_advcl) protecting
ethambutol (r_amod) optic
androgen (r_nmod) treated
carbidopa/levodopa (r_amod) preparation
damage (l_appos) hyperammonemia
administration (r_nsubj) showed
characterize (l_dobj) dynamics
levobupivacaine (r_conj) bupivacaine
patients (l_conj) disease
confusion (l_conj) seizures
dose (r_nmod) effect
courses (r_nmod) induced
combination (r_nmod) bortezomib
meth (r_nmod) effects
hearts (r_dobj) sacrifice
methotrexate (r_nmod) doses
accompanied (l_dep) incidence
found (r_acl:relcl) patient
occurred (r_conj) persisted
taking (r_acl) woman
ammonia (l_conj) coma
d-glucarates (r_nmod) effect
hypertensive (l_appos) rats
dopamine (r_nmod:npmod) agonist-induced
irrigation (r_nmod) treatment
methotrexate (l_nmod) presence
rats (l_nmod) syndrome
propofol-remifentanil-tiva (r_nmod) caused
treated (r_acl) %
cyclophosphamide (r_nmod) relation
relevance (l_nmod) treatment
sufferers (l_nmod) aura
deoxycorticosterone (r_conj) progesterone
lopinavir/ritonavir (r_compound) therapy
lithium (r_nmod) exposed
interval (r_dobj) increased
ifo (r_nmod:poss) genotoxicity
represent (l_nsubj) myopathy
remains (l_nmod) potential
seem (l_xcomp) cross-react
resulted (l_advcl) decreased
impaired (r_amod) function
oxide (r_nsubj) induced
pretreated (r_acl) group
cause (l_nmod) convulsions
types (r_dobj) induced
disturbances (l_nmod) system
associated (l_nmod) hypokalemia
agents (l_acl) mentioned
monotherapy (l_nmod) epilepsy
i1-imidazoline (r_conj) alpha2-adrenergic
ax (r_nmod) tests
correcting (l_dobj) hyperkalemia
misoprostol (r_nmod) addition
use (r_nmod) levels
nmda (r_nmod:npmod) receptor-mediated
dfmo (r_nmod) treatment
corticosterone (r_nmod) effects
transport (r_nmod) disturbances
outpatients (l_nmod) disorder
administration (r_nmod) patient
cddp (l_ccomp) probable
seizure (l_dobj) disorder
neoplasms (l_conj) peliosis
malondialdehyde (r_nsubj) increased
require (r_conj) mild
benefited (l_nmod) patients
doxorubicin (r_nmod) accumulation
cocaine (r_nmod) amounts
min (l_nmod) infusion
caffeine- (l_conj) anxiety
azathioprine (r_amod) therapy
follow-up (r_nmod) detected
cocaine (r_nmod) kindled
potassium (r_compound) balance
studied (l_nmod) trial
antagonist (r_nmod) induced
effect (l_amod) hemolytic
q10 (r_nmod) effect
doxorubicin-induced (r_amod) nephropathy
overdose (r_dobj) took
derivative (l_acl:relcl) attenuates
inhibitors (r_nmod) toxicity
lidocaine (r_nsubjpass) given
allowing (r_conj) correcting
headache (l_nmod) headaches
administration (r_nmod) became
conformed (l_nmod) criteria
increases (l_acl:relcl) signs
h (r_nmod) tested
association (r_nmod) occurring
patients (l_compound) sclerosis
monoher (r_nmod) interval
mice (r_nmod) hepatoma
taking (r_acl:relcl) cases
tested (l_dep) reported
progestagens (r_nmod) 3.49
licensed (l_nmod) treatment
increases (l_appos) fear
intervention (l_acl) feeding
group (l_amod) hypercalcemic
influence (l_nmod) membranes
working (l_dobj) deficits
related (r_xcomp) reported
reported (l_dep) frequent
topotecan (r_nsubj) option
cause (l_nmod) patients
paclitaxel (r_nsubj) agent
had (l_nmod) patients
infusion (r_nmod) 0.05
alfentanil (r_nmod) produced
effect (l_nmod) sleepiness
arrest (l_amod) hypothermic
trauma (l_conj) sepsis
treated (l_nsubjpass) summary
observation (l_nmod) neoplasms
affected (r_conj) neuropathy
dynamics (r_nmod) related
treatment (l_nmod) depression
reduced (l_conj) cost
aspirin (r_nmod:poss) effect
pgs (r_conj) ngf
effects (r_nsubj) involve
5-ht (r_compound) lesions
lidocaine (r_dobj) using
aspirin (r_nmod) associated
flumazenil (r_amod) administration
treatment (r_conj) paroxetine
associated (r_acl) hallucinations
na/k-atpase (r_nmod) expression
produced (l_dobj) death
na (r_compound) receptors
administration (l_nmod) treatment
indicating (r_xcomp) suspected
species (r_nmod) participation
patient (r_acl:relcl) case
adriamycin (r_nsubj) evoked
had (l_nsubj) %
polymorphisms (r_nmod) association
alpha (r_nsubj) had
lactam (r_compound) antibiotic
flaccid (l_conj) lacked
associated (r_acl) intoxication
type-1 (r_compound) receptor
discontinued (l_nmod) pneumonia
development (l_appos) behavior
observed (r_advcl) limited
pilocarpine (r_conj) timolol
catecholamines (r_dobj) exhibited
alter (l_dobj) hyperalgesia
suffered (l_dobj) episode
graded (r_conj) observed
facilitate (l_dobj) reduction
investigates (l_advcl) plays
hexachloro-1:3-butadiene (r_nmod) administration
beginning (l_nmod) attack
indicating (r_xcomp) followed
propranolol (r_conj) clonidine
presented (l_dobj) pain
impairment (l_dep) scattered
serotonin (r_compound) antagonists
fa (r_appos) acid
cyp (r_appos) cyclophosphamide
appearance (l_nmod) presence
ouabain (r_conj) aconitine
adrenaline-induced (r_amod) arrhythmias
vol% (r_conj) vol%
period (l_nmod) epilepticus
symptoms (l_nmod) apnea
azt-induced (r_amod) anaemia
characteristics (l_conj) mechanisms
describe (l_advcl) reported
woman (l_nmod) hypertension
cd-832 (r_nmod) property
sulfate (r_conj) coniine
5-fu (r_nmod) study
therapy (r_nmod) seen
cause (l_nmod) record
etoricoxib (l_nmod) patients
those (l_nmod) dysfunction
sulindac (r_compound) group
glutamine (r_conj) acid
developed (l_dobj) hypotension
monitored (l_nmod) hyperplasia
morphine (r_nmod) administration
chloride (r_nmod) use
statins (r_nmod) induction
therapy (r_nsubj) seem
modafinil (r_nsubjpass) associated
everolimus (r_nmod) combination
resulted (l_nmod) depression
cisplatin (r_nsubj) cause
improve (l_dobj) decline
associated (l_nmod) stroke
surpasses (l_acl:relcl) inhibiting
timing (l_conj) severity
enhancement (l_nmod) isoniazid
occurrence (l_nmod) dogs
reduces (l_dobj) genotoxicity
paracetamol (r_conj) tolerability
ketamine (r_nmod) duration
proteinuria (r_nmod) patient
had (l_nmod) arthritis
developed (l_nmod) thrombosis
drowsiness (l_conj) perception
methotrexate (r_compound) consequence
studies (l_compound) toxicity
reduced (l_dobj) loss
exhibited (l_dobj) retardation
procedure (r_nsubjpass) applied
deferoxamine (r_compound) administration
sirolimus (r_nmod) role
hbsag (r_appos) antigen
sulfate (r_dobj) given
potassium (r_dobj) injecting
assess (l_nmod) nephrosis
mk-801-induced (r_amod) locomotion
prevention (l_nmod) cardiotoxicity
findings (r_nsubj) suggest
found (l_nsubjpass) toxicity
cocaine-induced (r_amod) behavior
probability (l_compound) reaction
treated (l_nmod) hyperactivity
weeks (r_nmod) administered
prophylaxis (l_compound) disease
plays (l_conj) reduces
exposure (r_dep) wk
engineered (r_ccomp) demonstrate
hr (r_dobj) activities
cholesterol (r_nmod) changes
period (r_nmod) achieved
became (l_nmod) injury
reproduces (l_conj) provides
any (r_nmod) patients
effect (r_nmod) reported
dose (l_acl) decrease
developed (l_nmod) case
amiodarone (r_nmod) hepatotoxicity
characterized (r_acl:relcl) death
potassium (r_compound) depletion
pentamidine (r_amod) tachycardia
cya (r_compound) dosage
furosemide (r_nmod) lasted
treatment (r_dobj) starting
shr (r_nmod) hypotension
cocaine (l_nmod) model
role (l_nmod) hypertension
associated (r_acl) cases
preserved (r_advcl) long
patients (l_amod) encephalopathic
dopamine (r_compound) blockade
mice (l_acl:relcl) occurred
drug-related (r_amod) toxicity
viracept (l_conj) warning
rats (r_nmod) substantial
damage (l_conj) neurotoxicity
display (l_nmod) learning
therapy (l_nmod) c
events (l_amod) related
potentiation (l_compound) catalepsy
doses (l_nmod) mg/kg
associated (r_acl) microangiopathy
success (l_advcl) treating
consumption (r_nmod) increased
ribavirin (r_nmod) combination
preceding (l_dobj) onset
have (l_dobj) activity
developed (l_dobj) movements
affect (l_dobj) erp
lifetime (r_amod) psychosis
group (r_nmod) occurred
nimo (r_nsubj) attenuated
metoclopramide (r_nmod) related
group (l_compound) nephropathy
intake (r_nmod) nightmares
caffeine (r_nsubj) produced
caused (l_conj) become
ssris (r_appos) therapy
acid (r_nsubj) effective
myocarditis (r_nmod) case
protects (l_nmod) cardiac
involved (l_nmod) effect
importance (r_nmod) recognition
saralasin (r_nmod) prevented
retardation (l_conj) rigidity
dfp (r_conj) totp
found (r_acl) lipoproteins
toxicity (l_compound) csa
change (l_nmod) number
mg/kg (l_appos) arrest
associated (l_nmod) behaviours
development (l_nmod) hepatotoxicity
episodes (l_nmod) patient
oxide (r_compound) system
treatment (l_nmod) effects
bupivacaine-induced (r_amod) alterations
developed (l_advcl) flushing
disorder (r_conj) disorder
consciousness (l_nmod) hyperammonemia
mass (l_nmod) patient
none (r_nsubj) developed
fluoxetine (r_dep) fluoxetine
basis (r_nmod) grouped
osteoarthritis (l_conj) trials
azt-induced (r_amod) anemia
regimen (r_nmod) nephrotoxicity
developed (l_dobj) incontinence
starting (r_advcl) appeared
effect (l_nmod) cirrhosis
admissions (l_nmod) hospital
dysrhythmias (l_conj) asystole
patients (l_nmod) reactions
injections (r_nmod) response
atropine (r_conj) kg-1
occluded (l_nsubjpass) mca
threshold (l_conj) agranulocytosis
induces (l_dobj) behaviour
azole (r_compound) antifungal
relevant (l_nmod) sensitization
activation (r_conj) degeneration
leukemia (r_nmod) patients
excess (r_nmod) cardiomyopathy
affecting (l_conj) increasing
correct (l_dobj) hypotension
cyclophosphamide (r_nmod) definition
heroin-related (r_amod) rhabdomyolysis
ergotamine/caffeine (r_nmod) treated
infusions (r_nmod) administration
ability (r_dobj) showed
signs (r_nsubj) included
amn082 (r_nmod) doses
naloxone (r_nsubj) injected
consider (l_dobj) episode
25 (r_nmod) treated
sevoflurane (r_nmod) concentration
carcinogenesis (r_nmod) details
have (r_advcl) suggested
related (l_nmod) administration
protected (l_advcl) affect
respond (r_acl:relcl) time
antigen (r_compound) donors
supplementation (l_acl) preventing
methylprednisolone (r_nsubj) offers
nine (l_nmod) patients
discontinuing (r_advcl) decreased
patients (r_nmod) rhythms
induced (r_acl) offspring
action (r_dobj) affected
mediated (l_nsubjpass) cytotoxicity
blocked (l_dobj) analgesia
problem (l_nmod) management
minutes (r_nsubj) higher
gentamicin-induced (r_amod) nephropathy
blockers (r_nmod) evaluate
busulfan (r_nmod) appearances
aminonucleoside (r_nmod) injection
volume (l_compound) stroke
inhibition (r_dobj) causing
reported (l_nsubj) patients
cause (l_nmod) hepatitis
reduced (l_dobj) area
history (l_amod) significant
studies (l_conj) incidence
investigating (l_nmod) improvement
up-regulation (r_nmod) myopathy
erythema (l_dep) multiforme
stz (r_compound) administration
administration (r_nmod) anemia
caused (l_nmod) hypotension
reticulata (r_nsubj) resulted
methotrexate (r_nmod) combined
values (r_nsubj) less
signs (l_nmod) apl
children (l_nmod) tumors
alterations (l_nmod) strain
background (r_dep) attracted
man (l_nmod) depression
disorders (l_conj) disturbances
loreclezole (r_nsubj) exerted
similar (r_conj) neurotoxic
(-)-cibenzoline (r_nmod) i.v.
enalapril (r_nsubj) reduced
fact (l_ccomp) feature
prepared (l_nmod) days
admitted (l_nmod) pain
pbo (r_nmod) different
pretreatment (r_nmod) window
disability (l_nmod) patients
combination (r_nsubjpass) administered
sodium (r_conj) acc-9653
receptor (r_compound) activity
ce (r_compound) levels
anti-asthmatic (l_conj) tremorgenic
lithium-treated (r_amod) patient
investigated (l_parataxis) unnecessary
order (l_acl) avoid
effect (r_dobj) assess
oxide (r_compound) deficiency
mm (r_nmod) hypotension
ifo (r_compound) nephropathy
users (r_nsubj) display
sedation (l_conj) depression
toxic (l_advcl) measured
vaccine (r_nmod) injections
injection (l_nmod) adsd
use (r_nmod) addition
synthesis (r_dobj) suppressed
pretreatment (r_nmod) attenuation
level (r_conj) temperature
hypertension (l_appos) dex-ht
interferon (r_nmod) therapy
hippocampus (r_nmod) observed
acid (r_conj) agents
identified (l_nmod) epilepticus
prevention (r_dobj) complete
cocaine (r_nmod) related
ropivacaine (r_conj) levobupivacaine
day (r_nmod) brought
bepridil (l_appos) compound
cisapride (r_conj) sec
incidence (l_nmod) vomiting
phenytoin (r_compound) administration
superior (l_nmod) haloperidol
constructed (l_advmod) neuropathy
methamphetamine-induced (r_amod) neurotoxicity
reflect (l_dobj) symptoms
use (r_nsubj) treatment
concentration (r_nsubjpass) reduced
professionals (l_nmod) therapy
heparin (r_nmod) alternatives
induced (r_acl) deficits
aggravate (l_nsubj) administration
clozapine (r_dep) lowered
display (l_dobj) aggressiveness
estrogen-induced (r_amod) cells
clozapine (r_conj) quetiapine
regulation (r_nmod) escape
cocaine (r_nmod) effect
metoprolol (r_nmod) interaction
synthesis (r_compound) modifies
performance (l_nmod) models
patients (l_nmod) astrocytomas
detected (l_nmod) patients
irritability (l_conj) attack
days (r_nmod) average
damage (l_nmod) neuropathy
alleviate (l_dobj) deficits
describes (l_dobj) infarction
iso (r_appos) isoproterenol
rat (r_nmod) pvn
s-transferase (r_nmod) levels
metoclopramide (r_nmod) injection
therapy (r_nmod) presumed
found (l_dobj) cases
lesions (r_conj) report
mesna (r_compound) uroprophylaxis
patients (r_nmod) thrombosis
levels (r_dobj) elevates
dysfunction (r_nmod) patients
dhea (r_appos) dehydroepiandrosterone
ingestion (r_nmod) associated
agonist (l_nmod) absorption
blue (r_amod) assay
suspended (r_acl) weight
cerruloplasmin (r_nmod) antioxidants
caused (l_nsubjpass) osteoporosis
treatment (l_nmod) outpatients
ability (l_acl) respond
cases (l_nmod) anemia
restarting (r_nmod) developed
activity (l_nmod) tachycardia
totp-induced (r_amod) neuropathy
attack (l_amod) seizure
depression (l_conj) enuresis
vecuronium (r_compound) level
abolished (l_nsubjpass) pressor
ameliorate (l_dobj) impairment
ltg (r_compound) dose
role (r_nmod) study
experienced (l_dobj) switch
dfx (r_appos) desferrioxamine
dex- (r_compound) hypertension
patients (r_nmod) leukoencephalopathy
myocet (r_nsubj) improves
dec (r_appos) diethylcarbamazine
using (r_advcl) demonstrate
0.25 (r_nsubj) closest
clonidine (r_dep) rats
ifosfamide (l_nmod) plasmacytoma
groups (r_nmod) developed
treatment (r_nmod) occurring
deficient (r_amod) mice
unresponsiveness (l_dep) sensitivity
involve (l_dobj) structural
captopril (r_nmod) treatment
ifosfamide (r_nmod) metabolite
combination (r_nmod) acetate
active (l_nmod) models
d-penicillamine (r_nsubj) effective
abusers (r_nmod) stroke
amiodarone (l_conj) risk
effect (l_nmod) pressure
paclitaxel (r_dobj) comparing
azathioprine (l_dep) include
dopamine (r_nsubj) plays
disease (r_nmod) stages
scores (l_acl) relating
contraceptives (l_conj) risk
learn (l_dobj) response
slowing (l_dobj) progression
epinephrine (r_compound) dysrhythmogenicity
assay (l_nmod) thrombosis
produced (l_advcl) suggesting
diagnosed (l_nmod) adsd
secondary (r_conj) related
heparin (r_nmod) resistance
doca-salt (r_amod) treatment
that (r_nmod) slower
ifo (r_appos) ifosfamide
vpa (r_nmod) account
km (r_nmod) determined
combination (r_nmod) diazepam
inhibitors (r_nmod) effect
salivation (l_conj) retching
changes (l_nmod) infarction
nitrendipine (r_nmod) possible
methotrexate (r_conj) treated
rechallenge (r_nsubj) produced
prevention (l_nmod) coma
prevent (l_dobj) hypoactivity
proteinuria (l_conj) failure
glucose (r_compound) concentrations
treatment (r_dobj) received
receptor (r_nsubjpass) targeted
decrease (l_nmod) proteinuria
amphetamine-induced (r_amod) activities
5-htp (r_nsubjpass) found
toxicity (r_nsubj) caused
vacuolization (l_conj) glomerulosclerosis
rifampin (r_amod) patients
excretion (r_nmod) influence
media-induced (r_amod) nephropathy
salivation (l_conj) confusion
degree (l_nmod) fibrosis
greater (l_nmod) hemorrhage
that (l_nmod) patients
enalapril (r_dep) group
crisis (l_compound) anemia
increased (l_nsubj) hr
observed (l_nsubjpass) hypotension
woman (l_nmod) prolapse
levodopa (r_nmod) effects
age (l_conj) stroke
patients (l_amod) co-infected
added (r_acl) lev
consumption (l_nmod) necrosis
supplementation (r_nmod) reduced
agranulocytosis (l_conj) thrombocytopenia
sulfasalazine (r_dobj) use
indices (l_compound) arthritis
symptoms (l_amod) psychiatric
reduction (r_nmod) timing
streptomycin (r_nmod) effects
decreased (l_dobj) output
symptoms (l_conj) dysfunction
dose (r_dobj) giving
enlargement (l_nmod) liver
concealed (r_advcl) ensued
cases (r_dep) hepatitis
standard (l_nmod) myeloma
confounds (l_nsubj) toxicity
demonstrated (l_dobj) increase
associated (l_nmod) cardiovascular
metronidazole (r_nmod) treatment
medication (r_nmod) patients
investigated (l_nsubjpass) effect
benzylthiouracil (r_conj) carbimazole
activates (l_conj) improves
shown (l_xcomp) participate
epinephrine-induced (r_amod) ischemia
suspension (l_acl:relcl) forms
changes (l_nmod) subjects
agonist (r_appos) apomorphine
lithium (r_nsubj) caused
suggest (l_ccomp) contributed
acetate (r_nmod) effect
pethidine (r_nmod) doses
falls (r_conj) conclude
cy (r_conj) mtx
tolerability (l_nmod) etoricoxib
dosage (l_conj) toxicities
weeks (r_nmod) experienced
reduce (l_nmod) patients
disorder (l_conj) personality
isoflurane (r_compound) group
inhibitors (l_appos) cases
azt (r_nsubj) produced
nh4ac (r_appos) acetate
associated (l_nmod) production
simvastatin (r_conj) lovastatin
role (r_dobj) have
syndrome (l_dep) cardiomyopathy
toxicity (r_conj) nephrotoxicity
tested (l_nmod) study
presented (l_dobj) opportunity
cardiomyopathy (r_nmod) induction
foci (l_amod) epileptic
lev (r_nmod) treated
shown (l_nsubjpass) depression
seem (l_xcomp) increase
symptoms (l_appos) tnss
cyclosporine (r_compound) nephrotoxicity
using (r_advcl) feasibility
experienced (r_acl) disturbances
hexachloride (r_appos) lindane
concentration (r_nmod) changes
minor (r_ccomp) suggested
impair (l_nsubj) infarction
tissue (l_nmod) impairment
use (l_nmod) infections
effect (r_nmod) effect
effects (l_nmod) cardiomyopathy
symptoms (l_nmod) illness
diet (l_acl:relcl) induces
infection (l_nmod) viruses
toxicity (r_nmod) mechanisms
antagonist (r_appos) domperidone
reversed (l_dobj) anemia
patients (r_nmod) prolongation
caused (l_nmod) diagnosis
sulindac (r_conj) difluoromethylornithine
formulations (r_dobj) using
cardiomyopathy (l_conj) disease
resolved (r_acl:relcl) optic
managed (r_conj) admitted
anthracyclines (r_nmod) use
designated (l_xcomp) drug
occurred (l_nsubj) changes
antagonists (r_appos) s-312
mexiletine (r_nmod) form
paramethasone (r_nmod) different
assessed (l_advcl) improving
sirolimus (r_nsubjpass) implicated
method (l_nmod) detection
reactions (l_amod) neurotoxic
aspirin (r_compound) users
terbinafine (r_compound) therapy
exacerbation (r_nmod) inhibited
l-sotalol (r_conj) d
model (l_acl) (dox)-induced
suggested (l_ccomp) related
using (r_xcomp) background
c (r_nmod) combination
dfmo (r_appos) difluoromethylornithine
rats (l_nmod) hypertension
thrombosis (r_dep) upper-extremity
myocarditis (l_amod) eosinophilic
confounds (l_dobj) detection
preparations (r_nmod) presence
lorazepam (r_compound) therapy
enflurane (r_conj) sevoflurane
outpatients (l_nmod) mild
> (l_conj) block
alterations (r_dobj) evaluate
died (l_nmod) toxicity
occurrence (r_dobj) influence
effect (l_nmod) neurotoxicity
unmasked (r_acl) disorder
methylxanthines (r_nmod) hyperemia
case (r_conj) presented
dysfunction (l_compound) infarction
ca(2 (r_dobj) aggravates
d-amphetamine (r_nmod) induced
effects (l_nmod) patient
blockers (r_nmod) exacerbations
capsaicin-induced (r_amod) hyperalgesia
methylprednisolone (r_nmod) dose
factor (l_nmod) failure
indicator (l_nmod) survivors
hypertension (l_nmod) oedema
mannitol (r_conj) with
ingesting (r_advcl) developed
propylthiouracil-induced (r_amod) vasculitis
seems (l_xcomp) potentiates
series (l_nmod) behaviors
effects (l_nmod) neurotoxicity
abusers (r_nsubj) had
contributed (l_conj) considered
patient (l_compound) disease
dox (r_nmod) dose
failure (l_nmod) patients
quinidine (r_nsubj) responsible
reduces (r_advcl) cause
magnitude (l_nmod) proteinuria
expression (l_nmod) injury
maneuver (l_compound) hyperventilation
urd (r_nmod) concentration
chloride (r_nmod) effect
initiation (r_nmod) describe
p-coumarate (r_nsubj) improve
evidence (r_nmod) accepted
evoked (l_dobj) episodes
cyclosporine (r_nmod) switched
bn (r_compound) i.v.
depression (l_nmod) features
dosage (r_nsubjpass) calculated
toxicity (r_nmod) prevent
group (r_nmod) defects
mellaril (r_appos) drugs
atropine (r_nmod) pre-administration
pilocarpine (l_nmod) epilepticus
scopolamine-induced (l_dobj) amnesia
behavior (r_nsubj) provide
cyclosporine-treated (r_amod) patients
cimetidine (r_nmod) activity
aripiprazole (r_conj) olanzapine
similar (l_nmod) neuropathy
cocaine (r_compound) kindled-seizures
initiated (r_ccomp) practiced
sermion (r_appos) nicergoline
amlodipine (r_nmod) treatment
had (l_dobj) conditions
investigated (l_nsubjpass) tdp
increased (l_dobj) sbp
iohexol (r_nmod) those
acid (r_dobj) containing
pyrazinamide (r_nmod) induced
pilocarpine-treated (r_amod) rats
developed (l_advcl) developed
bradykinin (r_compound) antagonists
effects (l_nmod) children
nephrotoxicity (l_conj) neurotoxicity
approved (l_nmod) treatment
recorded (l_nmod) thrombosis
lamivudine (r_nmod) combined
comparing (l_dobj) incidence
study (l_xcomp) determine
rats (l_nmod) injury
patients (r_nsubjpass) monitored
interviewed (l_advcl) examine
variability (l_nmod) hyperalgesia
effect (l_nmod) tissue
prognosis (l_nmod) endophthalmitis
propylthiouracil (r_conj) carbimazole
diazepam-induced (r_amod) sedation
denopamine (r_nmod) efficacy
peroxide (r_conj) superoxide
had (l_nmod) responses
chelation (r_nmod) reaction
ma-induced (r_amod) neurotoxicity
amitriptyline (r_conj) dothiepin
effects (r_nsubjpass) tested
occurs (r_advcl) suspected
studies (l_appos) response
presence (r_nsubj) reduced
methotrexate (r_nmod) taking
symptoms (r_nmod) defined
patients (l_amod) hiv-infected
acid-induced (r_amod) myositis
blocked (l_dobj) failure
passage (r_dobj) research
volume (l_nmod) effusions
development (l_nmod) lymphoma
use (r_nmod) linked
oxygen (r_nmod) pressures
clarithromycin (r_nmod) doses
presence (r_nmod) measured
risk (l_nmod) rhabdomyolysis
dronedarone (r_nsubj) suitable
tacrolimus-associated (r_amod) neuritis
patients (l_dep) 54
mean (r_compound) vol%
level (r_conj) h
administration (r_nmod) resolved
report (l_dobj) patients
overdose (r_nmod) fas
dysfunction (l_conj) hyperkalemia
became (l_nmod) studies
induces (r_advcl) focused
rat (r_compound) models
warfarin (r_compound) administration
organophosphate (r_appos) mipafox
incidence (l_nmod) injection
arabic (l_nmod) failure
attenuated (l_nsubjpass) hypotension
methylphenidate (r_amod) intake
cause (l_dobj) impairment
doxorubicin/kg (r_nmod) induced
5-fluorouracil (r_conj) methotrexate
instituted (l_ccomp) improves
epinephrine (r_nmod) use
higher (l_nmod) patients
olanzapine-treated (r_amod) patients
fentanyl-induced (r_amod) rigidity
signs (l_conj) lid
features (l_nmod) syndrome
hypercalcemia (l_conj) impairment
sulfasalazine (r_compound) therapy
triamcinolone (r_nmod) injection
woman (l_nmod) diabetes
doses (l_nmod) micrograms/kg/hr
den (r_nmod) prolonged
experiment (r_nsubjpass) administered
rats (r_nmod) co-administered
effect (l_amod) cataleptic
clomipramine (r_compound) exposure
children (l_acl:relcl) developed
acid (r_nsubj) induced
patients (r_nmod) complications
conclude (l_ccomp) delayed
determine (l_ccomp) performed
thrombocytopenia (l_conj) hyperkalemia
isoniazid (r_nmod) microinjection
patients (r_nmod) study
rats (r_nmod) cue
subjects (r_nmod) was
oc (r_nmod) types
calculate (l_dobj) odds
administration (r_nmod) signs
cocaine- (r_amod) activity
monitor (l_nmod) bradycardia
caused (l_dobj) recurrence
injections (r_nmod) complication
inpatients (r_dobj) identify
administered (r_advcl) developed
prevention (l_nmod) events
some (l_nmod) ischemia
failure (r_nmod) leading
maintaining (r_advcl) using
glutamate (r_amod) neurons
carbimazole (r_compound) case
caused (l_nmod) overdose
amiodarone (l_nmod) patients
temsirolimus (r_nsubj) inhibited
bupropion (r_nmod) dose
use (r_nmod) developed
developed (l_conj) prompted
lidocaine (r_nmod) than
involved (l_nmod) hyperalgesia
infusion (r_nmod) managed
atp (r_conj) sodium
increased (l_dobj) risk
reduced (r_amod) myelosuppression
disturbances (l_nmod) patients
diltiazem (r_nmod) infusion
pre-treatment (r_nsubj) produced
women (r_nmod) similar
rats (l_amod) epileptic
monkeys (l_amod) parkinsonian
removal (r_nmod) created
clz (r_nmod) ingestion
patients (r_nmod) none
adrenaline-induced (r_conj) digitalis-
levels (r_nsubj) higher
non-lithium-treated (r_amod) patients
ed50 (l_nmod) protection
sch (r_nmod) combination
paclitaxel (r_compound) infusion
initiation (r_nmod) occurring
administration (r_nmod) altered
analgesia (l_acl) induced
studies (r_nsubj) suggested
injections (l_nmod) dysfunction
dapsone-associated (r_amod) anemia
discuss (r_conj) present
treated (l_nmod) tuberculosis
useful (l_nmod) adjunct
nature (l_nmod) rotation
produced (r_acl) pressure
patients (r_nmod) database
ouabain (r_nmod) caused
agents (r_nsubj) tools
stop (l_dobj) changes
potentiated (l_nsubjpass) hyperactivity
therapy (r_nmod) professionals
mechanisms (r_nmod) evidence
cohort (r_nmod) compared
apomorphine (r_dobj) antagonize
alters (l_dobj) function
facilitate (l_dobj) development
loss (l_conj) paresthesias
accumulation (r_nmod) metabolism
corrected (r_acl:relcl) spasms
phenobarbital (r_nmod) controlled
users (r_nsubj) prone
infants (l_appos) administration
outpatients (l_amod) depressed
included (l_nsubj) factors
amisulpride (r_conj) quetiapine
association (l_nmod) pph
have (l_dobj) effects
with (r_prep) rates
agent (l_conj) have
believed (l_ccomp) indicate
inhibitor (r_nmod) safety
reduced (r_advcl) resolved
mirtazapine (r_nmod) treated
group (l_compound) disease
gestodene (r_conj) desogestrel
inhibition (l_amod) neurotoxic
diatrizoate (r_nmod) fibrillation
relationship (l_nmod) levels
found (l_xcomp) efficient
patients (l_nmod) ra
therapy (r_nmod) effect
iron (r_compound) therapy
safety (l_nmod) dysfunction
types (l_compound) tumor
ma (r_dobj) used
continued (l_xcomp) effective
treatment (r_nmod) development
mediator (l_nmod) convulsions
srl (r_compound) conversion
loss (r_dobj) investigate
phenobarbital (r_nmod) pretreatment
emphasis (l_nmod) development
octreotide (r_nsubj) induces
effects (l_nmod) deficits
patients (r_nmod) subgroup
patients (l_acl:relcl) ranging
effects (l_nmod) parameters
developed (r_acl:relcl) kidney
effect (l_nmod) report
presented (l_nmod) occasions
exerted (l_advcl) reducing
therapy (r_nmod) problems
complication (l_nsubj) myocarditis
hypotension (l_conj) asystole
treatment (l_nmod) behaviors
g (r_nmod) used
tiopronin (r_nmod) found
risk (l_nmod) tumors
used (l_conj) proposed
infarction (l_nmod) thrombosis
tolerated (r_advcl) demonstrated
etomidate-induced (r_amod) myoclonus
neurons (r_nmod) neurotoxicity
production (l_nmod) liver
diltiazem (r_compound) overdose
factor-alpha (l_compound) tumor
capacity (l_nmod) patients
resulted (l_nmod) loss
decrease (r_nsubj) was
ara-c (l_nmod) lymphomas
report (l_dobj) infant
reduction (l_nmod) toxicity
chlorpropamide-induced (r_amod) optic
quinine (r_compound) toxicity
segmental (l_dep) necrotizing
bs (r_appos) salt
potentiates (l_conj) antagonizes
threatening (l_dobj) spasm
rat (l_compound) insipidus
coadministration (r_appos) models
gentamicin (r_compound) concentration
prazosin (r_nmod:npmod) treated
being (l_acomp) pain
srl (r_nmod) replacement
administration (r_nmod) proteinuria
worsened (l_dobj) toxicity
ethanol (r_nmod) exacerbation
detect (l_dobj) damage
dose (r_nsubj) low
published (l_nmod) vasospasm
complication (l_nsubj) rash
thromboembolism (l_conj) thalidomide
nicotine (r_nsubj) caused
epilepticus (l_appos) se
bilirubin (r_compound) value
linking (l_dobj) rpn
demonstrated (l_nmod) seizure
have (r_xcomp) engineered
inhibited (l_conj) reversal
found (l_nsubjpass) evidence
administration (r_nsubj) induces
reported (l_xcomp) diabetic
subjects (l_amod) similar
toxicity (r_nmod) manifestation
valsartan (r_nmod) %
occur (l_nsubj) hus
vincristine (r_nmod) use
(bort)-dexamethasone (r_nsubj) therapy
recurrence (l_nmod) oliguria
meperidine (r_conj) yohimbine
block (l_compound) rhythm
anthracycline (r_compound) therapy
precursor (r_nmod) use
users (r_nmod) impairments
higher (r_conj) remained
effective (l_conj) has
resumed (r_conj) diagnosed
factor (l_nmod) treatment
glucose (r_conj) triglycerides
those (l_nmod) schizophrenia
monotherapies (r_advcl) lower
pain (l_conj) tachyarrhythmia
contributes (l_nmod) performance
risk (l_nmod) thrombo-embolism
salbutamol (r_conj) salbutamol
antagonists (r_nmod) prodrugs
choline-devoid (r_amod) diet
recommended (l_nmod) protection
inhibitors (r_dobj) using
interval (l_nmod) occlusion
concluded (l_ccomp) relieve
initiated (l_nmod) patient
5-fu (r_conj) mtx
therapy (r_nsubj) leads
increase (l_nmod) activity
erythematosus (l_appos) sle
demonstrate (l_ccomp) develop
antibitocis (r_conj) antibiotics
deterioration (l_nmod) learning
dexamethasone (r_compound) treatment
consumption (r_nmod) absence
regimen (l_nmod) patient
treatment (r_nmod) risk
application (r_nmod) recognized
course (r_nmod) found
superior (l_advcl) preventing
susceptible (r_xcomp) appears
increasing (l_nmod) patients
levodopa (r_nmod) effect
phosphate (r_nmod) effect
effects (r_nsubj) similar
primed (l_xcomp) exhibit
polyphagia (l_conj) polyuria
licensed (l_conj) option
indicate (l_dobj) possibility
groups (r_nmod) role
was (l_xcomp) using
induced (r_acl) seizures
rats (r_nmod) deficits
underlying (r_acl) mechanism
saralasin-treated (r_amod) animals
effects (l_nmod) failure
dose (r_nmod) seen
nitrogranulogen (r_nmod) drugs
hydrochlorofluorocarbons (r_nmod) caused
alcohol (r_nmod) consumption
resulted (l_nmod) syndrome
investigation (l_nmod) agent
cocaine-related (r_amod) failure
revealed (r_parataxis) observed
age (r_dobj) had
signs (r_nsubjpass) observed
lidocaine (r_conj) mepivacaine
patients (l_nmod) infarctions
infusion (r_nmod) detection
received (l_nmod) inhibition
similar (r_amod) transit
found (l_xcomp) effective
indistinguishable (l_nmod) those
induced (r_acl) patient
levonorgestrel (r_dep) second-generation
calcium (r_compound) concentration
fluconazole (r_ccomp) aware
diabetes (r_nmod) effect
lactate (r_nmod) application
observed (l_nmod) stage
procainamide-induced (r_amod) tachycardia
echocardiography (r_nmod) ischemia
induced (l_nsubjpass) hyperprolactinemia
intoxication (r_nmod) cases
cephalexin (r_dobj) took
concentrations (r_nmod) increase
compounds (r_dobj) given
corticosteroids (r_nmod) treatment
tyrosine (r_compound) inhibitors
initiating (l_nmod) failure
shows (l_dobj) models
affected (l_nmod) hyperprolactinemia
exposure (r_nmod) seen
scopolamine (r_nmod) produced
studies (r_nsubj) suggest
discharges (l_amod) epileptic
lithium (l_dep) anomaly
developed (r_acl:relcl) child
expression (l_nmod) transgene
cirazoline (r_nmod) bradycardia
blocked (r_conj) reversed
lost (l_advcl) followed
range (l_nmod) cancers
treated (r_acl) rats
reported (r_acl:relcl) %
incidence (l_nmod) complications
dfo (r_conj) alpha-tc
found (l_nsubjpass) sclerosis
presumed (l_dep) age
potential (l_amod) nephrotoxic
levels (r_nsubjpass) achieved
steroids (r_nmod) doses
cataracts (l_conj) hyperplasia
mice (r_nsubj) showed
argatroban (r_amod) medication
susceptible (l_nmod) vt
converting (r_advcl) monitored
models (l_nmod) cholestasis
diazepam (r_compound) enhancement
distinguish (l_nmod) group
mangiferin (r_nsubj) exerts
make (l_nsubj) abnormalities
addition (r_nmod) shown
fluoxetine-induced (r_amod) symptoms
rats (r_nmod) performed
serotonin (r_nmod) shown
efficacy (r_nmod) respect
testosterone (r_compound) therapy
similar (r_advcl) higher
investigate (l_dobj) content
doses (r_conj) mg
acid-induced (r_amod) epilepticus
pentoxifylline (r_nmod) dose
nephrosis (r_nmod) assess
had (l_nsubj) woman
txa (r_nmod) doses
caused (l_nsubjpass) congenita
patients (r_nmod) hypokalemia
toxicity (r_dobj) post
suffering (l_nmod) depression
used (r_advcl) consider
atypicality (l_conj) chronicity
insipidus (l_appos) ndi
subjects (l_acl) exhibiting
cephalosporin (r_nmod) rechallenge
incidence (l_nmod) convulsions
levodopa (r_conj) on
pethidine-associated (r_amod) seizure
suffered (r_acl:relcl) disorders
activity (r_dobj) seizure
tamoxifen (r_conj) letrozole
seizures (r_nsubjpass) found
risk (l_nmod) ich
prazosin-pretreated (r_amod) rats
placebo (r_nmod) effect
unable (l_advcl) was
caused (l_dobj) rise
dose (r_nsubjpass) taken
dox (r_nmod) treatment
appear (r_acl:relcl) cases
valproate-induced (r_amod) encephalopathy
agents (r_nmod) use
osteoporosis (r_conj) thrombocytopenia
effects (r_nsubj) indirect
suggests (l_ccomp) induce
relationship (r_dobj) examine
conclusions (l_appos) damage
fludrocortisone (r_nsubjpass) added
obesity (l_appos) hyperinsulinemia
involves (r_ccomp) suggesting
dose (r_nmod) rigidity
inhibited (r_advcl) suppressed
secondary (r_amod) myocarditis
dnr-containing (r_amod) regimen
accumulation (l_acl:relcl) resulted
use (r_dobj) followed
group (r_nmod) remained
patients (r_nsubjpass) examined
order (l_acl) assess
prophylaxis (l_nmod) thrombosis
bromocriptine-induced (r_amod) tachycardia
effects (l_dep) model
acetaminophen (r_nmod) toxicity
herbal (r_amod) pill
factors (l_nmod) diabetes
exposure (r_nmod) absence
diclofenac (r_amod) discontinuations
be (r_appos) metabolite
aminotransferase (r_nmod) jaundice
treatment (r_nmod) psychosis
qtls (r_nsubjpass) reported
determined (l_nmod) neonates
exposed (r_acl) rats
anemia (l_conj) leukopenia
pilocarpine (r_nmod) produced
patients (l_compound) failure
phosphorus (r_compound) hepatotoxicity
measuring (r_advcl) assessed
functional (r_conj) biochemical
agonists (r_nmod) utility
number (l_nmod) cataracts
conversion (l_nmod) evidence
established (l_nsubjpass) involvement
trimetaphan (r_conj) nitroprusside
death (l_conj) decline
bupivacaine (r_compound) administration
isoproterenol (r_nmod) induced
labetalol (r_nmod) comparison
5-fluorouracil (r_nmod) dose
enflurane (l_conj) isoflurane
onset (r_nmod) speed
link (l_nmod) treatment
echocardiography (r_nsubj) available
lymphadenopathy (l_conj) hepatitis
apomorphine (r_nmod) induced
evidence (r_nsubj) is
ifosfamide-induced (r_amod) toxicity
treatment (r_advcl) describe
diethylnitrosamine (r_nmod) administered
mptp-treated (r_amod) model
naphazoline (r_nmod) decreased
inhibitors (l_nsubj) angioedema
need (r_nmod) alert
inhibitor (l_nmod) patients
peak (l_nmod) enlargement
k+ (r_compound) channels
is (l_attr) reduction
dyskinesia (l_appos) lid
heparin-induced (r_amod) thrombocytopenia
induced (r_acl) toxicity
d (r_dobj) received
nausea (l_conj) dizziness
myopathy (r_nmod) affected
have (r_xcomp) known
glutamate (r_nmod) supplemented
gemfibrozil-lovastatin (r_amod) therapy
myeloma (l_appos) rrmm
shown (l_conj) potentiated
progression (l_compound) disease
1 (r_nsubj) complained
system (r_nmod) defect
history (l_nmod) nephropathy
restore (l_nmod) movements
lamivudine (r_nsubj) decreases
administration (r_nmod) sleeping
plays (l_nmod) neurotoxicity
treatment (r_nmod) complete
captopril-induced (r_amod) hypotension
cd-832 (r_nmod) effects
effects (l_nmod) deprivation
sn-induced (r_amod) hypotension
administration (r_nsubj) show
overdose (r_nmod) effects
weakness (r_nmod) factors
effects (l_nmod) seizure
treatment (r_nmod) month
continue (l_xcomp) interfere
diethylcarbamazine (r_nmod) treatment
2-subunits (r_dobj) lacking
lithium (r_nmod) treated
induced (l_nmod) cocaine
differed (l_nsubj) assessment
caused (r_acl) hypoactivity
toxicity (r_dobj) mediates
experienced (l_conj) experienced
amikacin (r_nmod) toxicity
injury (r_dobj) producing
treatment (r_nmod) hypotension
dose (r_nsubj) tolerable
therapy (r_nmod) rhythms
blue (r_dobj) employing
increase (l_nmod) risk
phenobarbitone (r_nmod) administration
hypertension (r_nmod) associated
mg/kg (r_nmod) administration
receive (l_dobj) rule
recur (r_conj) disappeared
urd (r_appos) uridine
group (r_dobj) distinguish
phase (l_nmod) infarction
developing (l_dobj) hoarseness
inhibited (r_conj) undergoes
vp (r_appos) etoposide
phenobarbital-containing (r_amod) diet
treatment (r_nmod) developed
fentanyl (r_nsubj) reduce
dysfunction (l_conj) hyperlipidemia
succinylcholine (r_nsubjpass) used
therapy (r_nsubj) worsen
prevent (l_dobj) atrophy
crescents (r_nmod) documents
damage (l_nmod) esterase
metolachlor (l_conj) cancer
nik-247 (r_nmod) effects
comparison (r_nmod) associated
abnormalities (r_xcomp) known
consider (l_nmod) patients
causes (l_dobj) hypertension
study (r_nsubjpass) conducted
clearance (l_nmod) nephropathy
paracetamol (r_dobj) ingesting
lisinopril (r_nmod) treated
compared (l_nmod) subjects
administration (r_nmod) girl
flurothyl (r_nsubj) seizure
estimated (l_advcl) associated
result (r_ccomp) seen
replaced (r_conj) experienced
segmental (l_nmod) endocarditis
sorafenib-induced (r_amod) infarction
injection (r_nmod) syndrome
inhibitors (l_nmod) patients
onset (r_nmod) necrosis
picrotoxin (r_nmod) dose
concentrations (r_nsubj) cause
21 (r_nummod) (+/-)-sm
determination (r_nsubjpass) used
h (r_dep) site
induced (l_dobj) damage
reported (l_nsubjpass) vasculitis
reflects (l_nsubj) rotation
mice (l_conj) aggregation
morphine-induced (r_amod) paraparesis
group (l_acl) comprising
ethambutol (r_nsubj) agent
androgen (r_compound) therapy
use (l_acl) reduce
foods (r_dobj) avoiding
reduced (l_nmod) clipping
treated (r_amod) rats
selective (l_conj) replicated
suggests (r_conj) suggest
increase (l_nmod) fluctuations
relation (l_nmod) administration
case (l_nmod) anxiety
undertaken (l_nmod) need
dox (r_conj) dox
ssri (r_nmod) type
antimicrobials (r_nsubjpass) reported
methotrexate (r_amod) concentrations
acid (r_nsubj) prevents
d (r_nmod) combination
increased (r_conj) frequent
therapy (l_conj) lead
reduced (l_dobj) incidence
less (l_nmod) model
chlorthalidone (r_compound) phase
oxide (r_compound) hypertension
amifostine (r_conj) cisplatin
dystonia (l_appos) omd
cavity (r_nmod) carcinoma
induction (r_nmod) effect
infusion (r_nmod) cessation
users (r_nmod) consolidation
responses (r_nmod) patients
methylprednisolone (r_conj) saline
effects (l_nmod) normotensive
evaluation (r_nsubj) provides
cocaine (r_compound) users
animals (r_nmod) activity
barium (r_compound) exposure
indomethacin (r_compound) dysfunction
patients (l_nmod) syndromes
pilo (r_compound) model
preventing (l_dobj) proteinuria
ketamine (r_nmod) injections
amikacin (r_nsubj) aminoglycoside
coupling (l_nmod) depression
ketoconazole-induced (r_amod) sequelae
pgf2alpha (r_conj) pge2
stress (l_conj) hepatotoxicity
test (r_nmod) aggravate
increase (r_nmod) result
secondary (r_amod) vasospasm
nifedipine (r_nsubj) induces
comparable (l_nmod) degrees
dx (r_nmod) rats
diazinon (r_compound) use
ifosfamide (r_dobj) receiving
methyldopa (r_nmod) induced
ziprasidone (r_conj) olanzapine
effects (l_nmod) inhibitors
evidences (l_acl) suggesting
actions (l_acl:relcl) have
clozapine (r_nmod) treated
srl (r_nsubj) seems
therapy (r_nmod) complications
help (l_dobj) understanding
associated (r_acl) seizures
dipyridamole (r_nmod) observed
improvement (r_nmod) related
occurred (l_nsubj) pointes
continuation (r_nmod) inserted
involved (l_aux) have
pyridoxine (r_compound) convulsions
absence (r_nmod) induce
type (r_nmod) relation
dose (l_conj) accumulation
ra (r_compound) co-administration
conducted (l_dobj) study
received (l_nmod) dysphonia
iron (r_compound) content
aminonucleoside-induced (r_amod) nephropathy
study (l_nmod) order
tumors (r_nmod) development
bromocriptine (r_nmod) induced
lesion (r_nmod) vulnerability
ester (r_nsubj) act
number (r_nmod) =
nitrofurantoins (r_conj) sulfonamides
fluoxetine (r_nmod) pharmacotherapy
craniotomy (l_nmod) clipping
(dox)-induced (l_advmod) cardiomyopathy
treated (l_nmod) labor
seen (l_nmod) cancer
those (r_nmod) aware
acid (r_compound) model
leukemia (l_conj) tumor
dopamine (r_compound) blocker
suggestion (l_nmod) association
administration (r_dobj) following
effects (r_nsubjpass) investigated
insufficiency (r_nmod) reversibility
amiodarone (r_amod) treatment
challenged (l_advcl) examine
(gm)-mediated (r_dep) examine
mesna (r_nmod) administration
activity (l_nmod) agents
vcm-induced (r_amod) impairment
streptozotocin-induced (r_amod) model
prevented (l_dobj) movements
increased (l_dobj) time
episode (l_nmod) siadh
discontinued (r_advcl) returned
amiodarone (r_nsubj) represents
observed (l_nmod) %
seizures (l_conj) impairment
evaluate (l_advcl) treating
achieved (l_nsubjpass) hypotension
sensitivity (r_nmod) increase
comprising (l_dobj) patients
rate (l_nmod) dysfunctions
mannitol (r_nmod) passage
metformin-associated (r_amod) hepatotoxicity
arrhythmias (l_compound) hypokalemia
uracil (r_compound) therapy
rifampin (r_nmod) use
sulphonate (r_amod) treatment
need (l_nmod) diagnosis
spasms (r_nmod) associated
enhances (r_acl:relcl) acetyltransferase
assigned (l_nsubjpass) children
glutamate (l_conj) elicit
nmda (r_nmod) delay
rauwolscine (r_nmod) treated
associated (l_nmod) dysfunction
compared (l_conj) placebo
concentration (r_conj) determination
cycles (r_nmod) available
uptake (r_nmod) decrease
bipolar (l_dep) i
hazard (l_advcl) developing
reaction (l_acl) consisting
antagonized (r_conj) enhanced
damage (l_nmod) bed
took (r_advcl) appeared
thalidomide (r_nsubj) option
remained (l_xcomp) polyuric
related (r_amod) angio-oedema
rilmenidine (r_appos) rats
reduced (l_conj) decreased
suggest (l_advcl) reducing
min (l_nmod) beginning
dobutamine (r_nmod) administration
third (r_conj) describe
administration (l_appos) kindling
blocker (l_acl) disrupted
trifluoroacetyl (r_compound) halide
activity (l_nmod) carcinoma
patients (l_nmod) torsades
crocin (r_nsubj) reduced
causes (l_dobj) syndrome
those (r_nmod) comparable
response (r_nmod) obtained
tiapride (r_nsubj) had
mild (l_nmod) hypertension
treatment (r_nmod) period
report (l_conj) given
bortezomib (r_amod) regimen
presented (l_dobj) agitation
sedation (l_nmod) reduction
recorded (l_advcl) established
exposure (r_nmod) detectable
streptozotocin-induced (r_amod) diabetes
dose (r_conj) volume
rats (l_xcomp) induce
chemotherapy (r_nmod) reported
cocaine (r_compound) use
val (r_appos) groups
treatment (l_nmod) endophthalmitis
fluoxetine (r_conj) occlusion
sucrose (r_conj) chow
glucose (r_compound) effectiveness
method (r_ccomp) indicates
timolol (l_nmod) placebo
troleandomycin (r_nmod) administration
users (r_nmod) disease
mhpg (r_appos) 3-methoxy-4-hydroxyphenethyleneglycol
carbamazepine (r_nsubjpass) discontinued
reported (l_nsubjpass) stroke
weeks (r_nmod) measured
generation (r_nmod) prognosis
d (r_compound) dose
models (l_nmod) pd
clarithromycin (r_dobj) showed
ketoconazole (r_compound) therapy
rats (l_nmod) glomerulonephritis
associated (l_nmod) types
combination (l_conj) diagnosis
hypotension (r_nmod) caused
prevention (l_amod) complete
initiated (l_nsubjpass) treatment
paracetamol/day (r_appos) g
study (r_nmod) results
doses (r_nsubjpass) recorded
cyclosporin (r_nmod) similar
d (r_nmod) doses
caused (l_dobj) enhancement
93129 (r_nummod) cp
doses (r_nsubj) induced
use (l_nmod) factor
benzoylecgonine (r_nmod) induced
propofol (r_compound) infusion
propranolol (r_nmod) induced
propofol (r_nmod) induction
pilocarpine (r_appos) cholinomimetic
3,4-methylenedioxymethamphetamine (r_nmod) users
cause (l_dobj) effect
cisplatin (r_compound) chemotherapy
significant (l_nsubj) effects
inhibitor (r_appos) micrograms
methyldopa (r_nmod) microinjection
reviewed (l_nsubjpass) terminology
ethinyloestradiol (r_dep) 3.49
hygiene (l_conj) xerostomia
acid (r_nmod) decrease
day (r_nmod) given
corticosteroids (r_nsubj) produced
resulted (l_nmod) recurrence
result (r_ccomp) investigated
6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate (r_conj) acid
head (l_conj) carcinoma
adriamycin (r_conj) cis-platinum
ce (r_nmod) tolerability
e. (r_nmod) deficient
ps (r_appos) phosphatidylserine
amlodipine (r_amod) monotherapy
sirolimus (r_appos) inhibitors
analysis (l_nmod) stones
withdrawal (r_compound) symptoms
state (l_amod) hypertensive
sch (r_compound) administration
trough-concentrations (r_conj) had
events (l_dep) cardiac
followed (l_nsubj) seizures
leucovorin (r_conj) 5-fu
daptomycin (r_nmod) treated
retention (l_acl) associated
sirolimus (r_nmod) effects
staining (r_nmod) studies
identify (l_dobj) patients
associated (l_nmod) cisplatin
associated (l_nmod) memory
correlated (r_conj) invariable
reducing (l_dobj) nausea
clarithromycin-induced (r_amod) tachycardia
form (l_dobj) intermediates
suggests (r_acl:relcl) parallel
lidocaine- (r_nmod) development
patients (l_acl) comprising
galactose (r_amod) exposure
epinephrine (r_nmod) medication
late (l_nsubj) abnormalities
manifestation (r_nmod) role
had (l_dobj) deterioration
treated (l_conj) examined
induced (r_acl) pseudoacromegaly
shared (r_conj) promotes
frequency (r_nsubj) higher
reduced (l_dobj) activity
development (l_nmod) dysfunction
revealed (l_dobj) degrees
c (r_nmod) treatment
dexamethasone (r_nmod) replacement
signs (l_nmod) syndrome
evaluated (l_nsubjpass) effects
child (r_nmod) arrest
received (l_advcl) revealed
treated (l_nmod) septicemia
furosemide (r_nmod) tetany
prevention (r_conj) potentiation
avp (r_compound) expression
gtn (r_nmod) increased
received (r_acl:relcl) exacerbations
dyskinesia (l_appos) td
infusion (r_nsubjpass) reported
infants (r_nmod) cysts
estradiol (r_conj) progesterone
ifs-induced (r_amod) hc
spironolactone (r_nmod) use
bicuculline (r_dobj) containing
dose (r_nmod) exposure
ca(2 (r_dobj) decreases
case (l_nmod) treatment
delayed (l_dobj) hypotension
cocaine (r_compound) intoxication
had (r_parataxis) had
section (r_nmod) tachyarrhythmias
used (l_nmod) prevention
pathway (r_nmod) inhibition
have (l_advcl) important
consisting (r_acl) reaction
ps (r_appos) sulfate
index (r_dobj) improves
other (r_acl) neurotransmitters
developing (l_dobj) rash
therapy (r_nmod) worsening
resistant (l_advcl) developed
lithium (r_nmod) patients
improve (r_advcl) reversed
improved (l_nsubjpass) symptoms
ergometrine-induced (r_amod) shake
mannitol (r_nsubj) leak
glucose (r_compound) metabolism
phenylephrine (r_nmod) evoked
ischemia (r_dobj) detecting
alteration (r_nmod) leading
protects (l_nmod) cardiomyopathy
patients (l_nmod) histories
that (l_nmod) infarction
treated (l_conj) treated
edaravone (r_nsubj) suppresses
pills (r_nmod) intake
administration (r_nmod) falls
indicating (l_dobj) spasm
induction (r_nmod) occlusion
mortality (l_compound) disease
employing (r_advcl) reduced
patient (l_nmod) malaria
method (l_advcl) obtunding
developed (l_nsubj) necrosis
used (l_xcomp) provide
was (l_nmod) injury
enhancement (l_nmod) bradycardia
progestagens (r_nmod) users
showed (r_conj) retrieved
test (r_nmod) anxiolysis
azt-induced (r_amod) cardiomyopathy
creatinine (r_dep) azotemia
alternative (r_nmod) serve
ziprasidone (r_nmod) induced
intake (r_nmod) disturbance
therapy (l_nmod) patient
increased (l_dobj) incoordination
treatment (l_nmod) failure
developed (l_dobj) spasm
changes (l_nmod) syndrome
tumours (l_conj) lymphoma
contribution (l_nmod) anxiety
inpatients (l_dep) 59
grade (l_nmod) cardiomyopathy
single (r_nmod) treatment
(meth)-induced (r_amod) toxicity
ratio (r_nmod) reduction
erdosteine (r_nsubj) showed
associations (l_conj) matter
revealed (l_dobj) cases
amiodarone-induced (r_amod) toxicity
respect (l_nmod) treatment
galactosamine (r_compound) hepatotoxicity
nitroglycerin (r_nmod) effects
patient (l_acl:relcl) caused
) (r_punct) establishes
toxic (l_conj) associated
thrombocytopenia (l_conj) alopecia
tumors (l_nmod) colorectal
company (r_dep) study
trihexyphenidyl (r_amod) challenge
induced (r_acl) pointes
pilocarpine (r_nmod) dose
hyperactivity (r_nsubjpass) influenced
treatment (l_nmod) efficacy
fk506 (r_nsubjpass) tolerated
include (l_dobj) fever
prophylaxis (l_nmod) nausea
chloroform- (r_conj) tetrachloride-
rhythm (l_conj) block
modulate (l_dobj) seizures
conclude (l_ccomp) result
chemotherapy (l_compound) cancer
learning (l_conj) attention
opportunity (l_acl) analyze
bromocriptine (r_appos) rats
monitoring (r_dobj) performed
detectable (l_advcl) suggesting
daunorubicin (r_nmod) efficacy
have (l_dobj) implications
arteritis (r_nmod) type
admitted (l_nmod) center
dl-sotalol (r_nmod) induced
diagnosis (l_nmod) stones
phenotype (r_nmod) belonging
oc (r_nmod) users
available (l_nsubj) descriptions
followed (l_nmod) therapy
rat (r_nmod) given
induced (r_acl) cerebellum
sah (l_amod) aneurysmal
suggests (l_dobj) mechanism
suggestive (l_nmod) disease
admissions (l_nmod) hemiparesis
resulted (l_nmod) improvements
rats (r_nmod) calcification
action (l_nmod) neurotoxicity
zymosan (l_acl) opsonized
carboplatin (l_nmod) study
glutathione (r_conj) aspartate
5-fluorouracil (r_nmod) toxicity
similar (l_nsubj) crude
appearance (l_nmod) jerks
apomorphine (r_nsubjpass) selected
pretreatment (r_nsubj) enhance
decrease (l_nmod) start
inhibited (l_nmod) hyperprolactinemia
treated (r_acl) mice
episodes (l_nmod) arrest
associated (r_acl) complication
syndrome (l_conj) myonecrosis
acetaminophen-induced (r_amod) nephrotoxicity
dehydroepiandrosterone (r_nmod) effects
cross-clamp (r_nmod) aorta
dopamine (r_nmod) pretreatment
acts (l_nmod) mice
ifosfamide (r_compound) encephalopathy
arrhythmias (r_dobj) suppress
prazosin-controlled (r_amod) trial
treated (l_nmod) insertion
patients (l_amod) cirrhotic
restricted (l_advcl) cause
cabergoline (r_nmod) treatment
rats (r_nmod) %
a-86929 (r_nmod) efficacy
trichotillomania (l_conj) anxiety
fenoterol-hydrobromide (r_amod) infusion
acid (r_compound) mg/kg
ketamine- (l_dep) narcosis
predict (l_dobj) development
increase (l_nmod) aggressiveness
drugs (r_nmod) presence
type (r_nsubj) affected
present (l_conj) seizure
echocardiography (r_nmod) response
seen (l_nsubjpass) tumors
used (l_nsubjpass) injections
five (r_nsubj) had
concentration (r_nsubjpass) associated
initiation (r_nmod) developed
treatment (r_dobj) receiving
chloride (r_nmod) changed
stopping (r_advcl) resolved
reflecting (l_dobj) sedation
mice (l_amod) nephrotic
plays (l_dobj) role
results (r_nsubj) reported
installation (r_nmod) frequency
support (l_nmod) hypothesis
ketamine (r_nmod) predominance
therapy (r_nmod) context
response (r_nmod) action
treated (r_conj) suspected
control (l_nmod) pressure
dexmedetomidine (r_nsubjpass) associated
sustained (l_conj) developed
recurrent (l_appos) nephritis
combined (l_nmod) hyperthermia
induced (r_acl) sd
distinguish (r_xcomp) able
measured (l_nmod) fluid
adrenaline (r_compound) mg
ptu (r_appos) propylthiouracil
predictor (l_nmod) alterations
metabolites (r_nsubjpass) evaluated
reducing (r_acl) impact
reduced (l_nmod) patients
da (r_compound) agents
heparin (r_nsubjpass) initiated
use (r_dobj) recommend
cytotoxicity (r_dobj) reduces
enhanced (l_conj) antagonized
produces (l_dobj) hypotension
concentrations (r_nsubjpass) associated
incidence (l_nmod) edema
preventing (l_dobj) strokes
characterized (l_nmod) period
superoxide (l_conj) production
cholecystokinin (r_nmod) analogues
evaluated (l_nsubjpass) pain
affecting (l_dobj) control
treatment (r_nmod) cholestasis
include (l_dobj) rigidity
related (l_conj) induce
formed (r_acl) metabolites
cgrp (r_nmod) relationship
effects (l_nmod) administration
amphetamine-induced (r_conj) cocaine-
sensitivity (l_compound) pain
was (r_ccomp) developed
produced (r_acl) damage
bupivacaine (r_nmod) infusion
protection (r_nsubj) supports
speech (r_dobj) developed
mediate (l_dobj) hypotension
tolerability (r_dobj) compare
years (l_acl) working
useful (l_nmod) treatment
related (r_dep) developed
conditions (l_acl) predisposing
digoxin (r_nmod) patients
mediated (r_acl) neurotransmission
produce (l_dobj) syndrome
release (r_nsubjpass) blocked
antagonists (r_nmod) pretreatment
indomethacin (r_nmod) effects
lenalidomide (r_nsubj) standard
antipsychotics (r_nmod) targeted
report (l_dobj) pain
isoproterenol-induced (r_conj) exercise-
ceased (l_nsubj) fits
boy (l_nmod) depression
hyperalgesia (r_nsubj) affect
accompanied (l_nsubjpass) attenuation
carcinoma (r_nmod) patient
blocker (r_compound) nitrendipine
antidepressant (r_amod) drugs
produce (r_advcl) increased
doses (l_acl) measured
increased (l_nsubjpass) activity
dyskinesias (r_dobj) reduces
reversal (l_nmod) amnesia
lamivudine (r_nmod) treated
resembled (l_dobj) serpiginosa
cocaine-induced (r_amod) increases
tpp (r_nmod) km
relationship (r_dobj) investigate
rate (r_nmod) contributed
1.9 (r_conj) suppressed
concentration (r_conj) hypertension
crescents (l_conj) glomerulonephritis
setting (l_nmod) ischemia
propofol (r_nmod) effects
induce (l_dobj) symptoms
complications (l_amod) bleeding
injections (r_nmod) cases
ocs (r_nmod) 3.49
shivering (l_conj) rigidity
acid (l_nmod) cancer
clopidogrel (r_nsubjpass) prescribed
consistent (l_nsubj) magnitude
toxicity (l_conj) dysmorphism
treated (l_nsubjpass) infections
frequency (l_nmod) exceeds
therapy (l_nsubj) methods
tea (r_nmod) effect
level (r_dobj) included
tolerated (l_advcl) showing
betaine (r_nmod) administration
doses (r_nmod) curves
octreotide (r_nmod) injection
communicated (r_ccomp) avoided
4-aminopyridine (r_conj) cacl2
required (r_conj) reported
acetaminophen (r_nmod) female
analysed (l_conj) found
lesion (r_ccomp) indicating
reversed (l_nmod) mice
related (l_nsubj) arrhythmias
adr-induced (r_amod) groups
androgen- (l_conj) anemia
nephrotoxicity (r_nmod) deaths
enlarged (l_conj) hypertrophic
seemed (l_xcomp) etiology
basis (r_nmod) treated
induced (l_nsubjpass) vasospasm
patients (l_nmod) filariasis
124 (r_conj) hcfcs
cm (r_nmod) dosage
decrease (r_ccomp) confirm
inhibition (r_dobj) prevented
developed (l_dobj) neutropenia
tissue (l_compound) tumor
labetalol (r_dobj) using
monitored (l_conj) given
meth (r_compound) abuse
ly-171555 (r_nmod) reproduce
treated (r_advcl) neuropathy
increased (l_nmod) nuclei
enhanced (r_conj) blunted
man (r_nsubjpass) admitted
sulphasalazine (r_nsubj) induce
amiodarone (r_nmod) treatment
rate (l_nmod) akathisia
rise (l_nmod) pressure
tendency (l_acl) decrease
cocaine (r_nmod) cardiotoxicity
li-induced (r_amod) rat
model (l_compound) writhing
metabolism (r_dobj) affecting
remains (l_advcl) increasing
acid (r_nmod) combination
bupropion-induced (r_amod) seizures
triggered (l_dobj) cluster
azt (r_nmod) coadministered
reduced (l_dobj) magnitude
ethambutol (r_conj) linezolid
levels (r_nmod) reduction
volume (l_advmod) 3.4-fold
azt (r_nmod) concentrations
observed (l_parataxis) developed
therapy (r_conj) penicillamine
plays (l_nmod) control
observed (r_acl:relcl) case
hyperalgesic (l_conj) allodynic
evaluated (l_nmod) therapy
oc (r_appos) contraceptives
prevention (l_compound) anemia
licl (r_nmod:npmod) pre-treated
phenylethylbarbiturate (r_conj) quinidine
noradrenaline (r_nmod) levels
continue (l_xcomp) demonstrate
focused (r_dep) results
treatment (r_nmod) dysfunction
pill (r_nmod) started
administration (l_nmod) patients
gamma-hch (r_nmod) administration
area (r_nmod) patients
l-norepinephrine (r_nmod) induced
fk506 (r_nmod) reintroduction
enhancement (l_nmod) catalepsy
awaking (l_conj) tiredness
reverse (l_dobj) sedation
used (l_xcomp) monitor
development (l_nmod) neurotoxicity
addition (r_nmod) benefit
approach (l_nmod) model
caused (l_dobj) damage
streptozocin-induced (r_amod) model
concentrations (r_nsubjpass) measured
course (r_nmod) day
exposure (r_nmod) attack
ritodrine (r_dobj) receiving
botox (r_compound) injection
predictor (l_nsubj) dysphagia
animals (l_conj) bleeding
tuberculosis (l_acl) presented
exposure (r_nmod) cessation
use (r_conj) cancer
produce (l_dobj) infarction
treatment (r_nmod) induced
thiopental (r_nsubj) produced
different (l_dep) score
nimo (r_appos) nimodipine
increasing (l_conj) occurs
5-fu (r_compound) mg/m(2
experienced (l_dobj) loss
metrazol (r_nmod) action
addition (r_nmod) perfused
models (l_nmod) hypertension
testing (l_nmod) convulsions
demonstrated (l_ccomp) superior
damage (r_nmod) test
cyclophosphamide (r_nsubjpass) used
occur (r_dep) conclusions
important (l_nmod) pathogenesis
multiforme (l_conj) syndrome
therapy (r_nmod) attributable
solution (r_advcl) induced
quetiapine (r_nmod) antipsychotics
associated (r_acl) effect
reactions (l_compound) hypersensitivity
effect (r_dep) role
bupropion (r_nmod) failure
warfarin (r_nsubj) superior
suffering (l_nmod) pain
morphine (r_nmod) action
treatment (r_nmod) change
dogs (l_amod) tumor-bearing
azidothymidine (r_nmod) mice
cause (l_nsubj) spasm
woman (l_nmod) hyperaldosteronism
parameters (r_nsubjpass) assessed
aimed (r_acl) study
associated (r_acl) pain
reduces (l_dobj) volume
platinum (r_compound) ion
acquired (l_dobj) thrombosis
underlying (l_dobj) fluorthyl-
lithium (r_conj) zuclopenthixol
increase (r_nmod) arrest
group (l_compound) hem
hypercalcemia (r_nmod) presented
patients (r_nmod) mutants
hyperactivity (r_dep) deficits
ethyl-alpha-p-chlorophenoxyisobutyrate (r_nmod) respond
resulting (l_nmod) irritability
9 (l_conj) development
ptz (r_appos) pentetrazol
9 (r_nsubj) developed
given (l_xcomp) counteract
lead (l_nmod) animals
dopamine (r_compound) signs
pre-treatment (r_nsubj) prevented
blockade (r_nsubj) retard
testosterone (r_compound) determination
methamphetamine (r_nmod) diagnosis
dementia (r_nsubjpass) documented
occurred (l_nsubj) complications
test (l_nmod) ischemia
li/dvp (r_conj) pbo
was (l_conj) folate
fever (l_conj) nodules
risk (l_conj) disorders
halothane (r_compound) administration
amounts (r_nmod) feeding
studies (l_nmod) patients
presence (l_nmod) failure
pilocarpine-induced (r_amod) epilepticus
resulting (r_acl) case
similar (r_amod) hematotoxicity
d3 (r_nmod) increases
bromide (r_conj) chloride
desipramine-induced (r_amod) sensitization
developed (l_dobj) dizziness
vessels (l_conj) hypotension
severity (l_nmod) myalgia
ach (r_nsubj) elevated
produces (l_dobj) fsgs
treated (r_acl) patients
presented (l_nmod) features
cc (r_appos) citrate
isoproterenol-treated (r_amod) rats
treatment (l_nmod) induction
signs (l_nmod) failure
drugs (r_nsubjpass) known
induced (l_dobj) carcinomas
active (r_amod) treatment
pain (r_nsubjpass) considered
propagation (l_nmod) seizures
one (r_nmod) develop
men (l_conj) women
dysfunction (l_conj) cardiomyopathy
paracetamol (r_conj) diltiazem
compared (l_nmod) rats
potassium (r_compound) agents
study (r_conj) did
produce (l_dobj) ulcer
decrease (l_nmod) hyperthermia
hemicholinium (r_appos) inhibitor
acetaminophen-induced (r_amod) patients
activity (l_nmod) hippocampus
propranolol (r_conj) bendrofluazide
cancer (l_acl) used
list (l_nmod) drugs
isoniazid (r_nmod) induced
administered (l_advcl) reduce
cancer (l_nmod) women
cpa/ee (r_nmod) associated
role (r_nsubjpass) analyzed
hydroxyanisole (r_nmod) effect
epilepticus (r_nsubjpass) initiated
correlate (l_nmod) parameters
enhance (r_advcl) believed
promote (l_xcomp) consistent
decreased (l_conj) observed
slight (l_dep) lesions
often (r_advmod) associated
epinephrine-induced (r_amod) death
sulindac (r_nmod) treated
risk (l_compound) cancer
vancomycin (r_compound) therapy
cerebellum (r_nmod) alterations
hypothermia (r_dobj) produced
focus (r_nmod) lines
anaemia (r_nmod) degree
induced (r_amod) headache
course (l_nmod) hypertension
renografin (r_nmod) often
ssri (r_appos) inhibitor
overdose (r_nmod) considered
cause (l_dobj) cardiotoxicity
infusion (r_nmod) died
nifedipine (r_dobj) receiving
minimize (l_advcl) affecting
3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one (r_nummod) allopregnanolone
developed (l_conj) showed
account (l_nmod) some
licensed (l_nmod) form
reverses (l_dobj) suppression
administration (r_nsubj) effective
drug (l_amod) related
glomerular (l_dep) lesions
ecstasy (r_amod) 3,4-methylenedioxymethamphetamine
glycopyrrolate (r_appos) headache
morphine (r_nmod) degeneration
effect (l_nsubj) hallucinations
bilirubin (r_conj) sgot
treatment (l_nmod) migraine
dose (r_dobj) evaluate
hypotension (l_nmod) failure
investigated (l_nsubjpass) toxicity
remains (l_nsubj) cause
fluoroacetate (r_nmod) blockade
nitroglycerin (r_nmod) provoked
microinjections (r_nsubj) failed
glomerulonephritis (l_nmod) patient
withdrawal (r_nmod) abolished
tacrolimus (r_nmod) concentration
increases (l_dobj) frequency
caffeine-free (r_amod) intake
cholesterol (r_conj) d2
neuropathy (l_nmod) nerve
combination (r_nmod) used
unsafe (l_conj) carries
pretreatment (r_nsubj) blocked
treatment (r_nmod) complications
exerts (l_nmod) potential
glucose (r_compound) reabsorption
therapy (r_nsubjpass) discontinued
had (l_dobj) optic
quetiapine (r_nmod) reintroduction
allopregnanolone (r_nsubjpass) tested
reported (l_dobj) pain
permeability (l_conj) areas
startle (l_advcl) suppressed
used (r_advcl) proven
corticosteroids (r_nmod) doses
desogestrel (r_conj) users
receptor (r_nmod) dysfunctioning
caused (r_acl) cumulative
attack (r_conj) content
arose (l_nsubj) yield
administration (r_nmod) model
tamoxifen (r_nmod) role
cause (l_dobj) damage
vp-16 (r_appos) etoposide
bcnu-induced (r_amod) toxicity
tensions (l_conj) tensions
disease (l_nmod:poss) patient
prevented (l_dobj) impairment
extract (r_nmod) ability
hyperactivity (r_nmod) influenced
prevention (l_nmod) ulcers
showed (l_dobj) flutter
development (l_nmod) abs
inhibitors (r_nmod) effects
use (r_nsubj) effective
patients (l_acl) meeting
viracept (r_acl:relcl) patient
ability (l_acl) prevent
cefotetan (r_dobj) received
vinorelbine (r_nmod) effects
doxorubicin (r_nmod) relationships
shivering (l_conj) salivation
put (l_conj) took
deterioration (l_nmod) function
caused (r_acl) dyskinesia
deaths (l_nmod) nephrotoxicity
need (r_conj) problem
remains (l_nsubj) neurotoxicity
rifampicin (r_nmod) treated
patients (r_nmod) concern
estrogen-initiated (r_amod) angiogenesis
ability (r_nsubj) contribute
increased (l_nmod) controls
factor (l_nmod) seroconversion
infarction (r_dobj) suffered
dosage (r_dobj) received
gold (r_compound) salts
consisting (l_nmod) edema
cyclophosphamide (r_compound) cancer
experienced (r_advcl) occurred
globulin (l_compound) b
history (r_nmod) increased
disease (l_nmod) liver
ticlopidine-induced (r_amod) anemia
clonidine (l_nmod) restlessness
um-272 (r_nsubjpass) administered
associated (l_dobj) syndrome
evaluate (r_xcomp) used
expression (l_nmod) nephropathy
vol% (l_nsubj) concentration
given (r_acl) values
mrna-containing (r_amod) neurons
cocaine-injected (r_amod) rats
reported (l_nsubjpass) dysfunction
temsirolimus (r_nsubj) reduced
damage (l_amod) seizure-induced
study (r_conj) study
treatment (r_nsubj) benefited
mitoq. (r_nmod) prevention
observed (l_nmod) evidence
received (l_nmod) treatment
myeloma (l_appos) mm
antagonist (r_appos) ketanserin
drugs (l_acl:relcl) cause
prevention (r_conj) investigations
ventilation (r_nmod) decrease
infarction (l_nmod) woman
contribution (l_nmod) syndrome
combination (l_nmod) carboplatin
events (l_nmod) patients
induced (l_nmod) effect
days (r_conj) infusion
observed (r_advcl) given
able (l_xcomp) prevent
simvastatin-induced (r_amod) syndrome
effective (l_advcl) improving
assessed (l_dobj) incidence
effects (r_nsubjpass) compared
took (r_acl:relcl) patient
improve (r_acl) ability
vasculitis (l_acl) associated
nsaid (r_conj) analyzing
alpha-2b (r_nmod) treatment
barbiturate-induced (r_amod) narcosis
effect (r_nmod) aspect
preparation (r_dobj) receiving
lesion (r_conj) impairment
develop (l_conj) demonstrate
total (r_dobj) received
developed (l_dobj) blockade
production (r_nmod) accompanied
leading (r_acl) changes
supporting (l_dobj) hypothesis
prognosis (l_nmod) those
affirming (l_dobj) efficacy
mediating (l_dobj) toxicity
withdrawal (l_acl:relcl) led
serotonin (r_compound) depletor
development (l_nmod) impairment
syndrome (r_nmod) hypoxia
patients (l_nmod) sphincter
oral (r_amod) treatment
extended-release/lovastatin (r_conj) dyslipidemia
developed (l_dobj) toxicity
d-glucarates (r_nsubj) had
withdrawn (l_nmod) tests
ctnt (r_nsubj) indicates
lasting (l_dobj) impairment
prophylaxis (l_compound) malaria
shown (l_dobj) propensity
cefotetan-induced (r_amod) anemias
resolution (l_nmod) maha
presented (l_nmod) failure
allopurinol (r_nsubj) prevent
neutrophils (l_compound) alf
reflected (r_nmod) damage
injection (r_nmod) caused
involved (r_ccomp) suggesting
groups (l_compound) disease
lead (l_conj) caused
agent (l_acl:relcl) prevents
streptozotocin-induced (r_amod) damage
type (l_conj) factor-beta1
resistance (r_dobj) exhibiting
species (r_nsubjpass) implicated
thresholds (l_nmod) mice
therapy (r_nmod) courses
albuterol (r_compound) treatments
outpatients (l_nmod) disease
treated (l_nsubjpass) patient
alcohol (r_compound) use
isoniazid (r_conj) ethambutol
carbamazepine (r_nmod) associated
test (r_nmod) affected
recording (l_nmod) recovery
relationship (l_nmod) phosphate
thrombocytopenia (l_conj) eosinophilia
atrophy (l_conj) fibrosis
rifampin (r_nmod) treated
neurons (l_conj) known
exposure (l_acl) causing
acne (l_conj) hirsutism
sorafenib (r_conj) sunitinib
aspiration (r_nmod) developed
acid (r_compound) administration
toxicity (r_nmod) treatment
group (r_nmod) appeared
activities (r_conj) dismutase
sodium (r_nsubj) mmol/l
feasibility (l_nmod) agent
died (l_nmod) anemia
diltiazem (r_conj) disorder
cisplatin-based (r_amod) combinations
nephropathy (r_conj) rejection
correction (l_nmod) anemia
anaesthetic (r_nmod) presented
case (l_nmod) swelling
indomethacin (r_nsubj) resulted
fluvoxamine (r_nmod) replaced
pvn (l_nmod) rat
suggested (l_dobj) hepatitis
tested (l_nsubjpass) catalepsy
pretreatment (r_nmod) determined
antigen (r_nmod) administration
csa (r_compound) treatment
exacerbation (l_nmod) epilepsies
cephalosporins (r_nsubjpass) associated
sedation (r_nmod) use
deficits (l_nmod) learning
woman (l_nmod) hydroureteronephrosis
received (r_acl:relcl) transplantation
implicated (l_advcl) observed
associated (r_acl) outpatients
lesion (r_nmod) diagnosis
amide (r_appos) agent
value (r_nsubj) indicate
administration (r_nsubj) induce
results (l_conj) %
stopped (r_advcl) persisted
fluorescein (r_compound) injection
dce (r_nsubj) reversed
role (r_nsubjpass) examined
a-86929 (r_nmod) doses
model (l_nmod) research
tiapride (r_nmod) therapy
testosterone (r_nmod) implanted
involved (l_nmod) pathophysiology
related (r_amod) syndrome
carbachol (r_nmod) produced
observed (l_nsubjpass) incidence
combination (r_nmod) agent
preserves (l_nmod) hypotension
use (r_nsubjpass) limited
patients (l_nmod) myeloma
expression (r_nmod) related
injection (r_nsubj) suppressed
heparin (l_appos) testing
investigated (l_nmod) convulsions
transplantation (l_nmod) patients
atra (r_nmod) treated
antibiotics (r_nmod) allergic
syndrome (l_dep) review
dopamine (r_nmod) increases
occurring (l_nmod) phenomena
no (r_nsubj) mediator
treatment (l_nmod) pcp
decreased (r_advcl) preferable
hypertension (l_conj) hallucinations
inducer (r_conj) pretreatment
therapy (r_nmod) correlated
decreased (l_nmod) syndrome
provoke (l_nmod) patients
induced (l_nsubjpass) tumors
pan-induced (r_amod) syndrome
netilmicin (r_nmod) efficacy
modafinil (r_nmod) effect
discontinuation (r_nmod) days
helps (l_xcomp) control
presented (l_advcl) contrasting
pronounced (l_nsubjpass) headache
carboplatin (r_nmod:poss) advantages
induced (r_acl) impairments
csa (r_nmod) treated
mania (r_nmod) switching
captopril (r_nmod) administration
d-1 (r_nmod) blockade
treated (l_conj) cream
aware (l_nmod) toxicity
activation (r_nmod) involved
e (r_compound) combination
norepinephrine (r_nmod) o-methylation
warfarin (r_nmod) interact
administration (r_nmod) myeloencephalopathy
test (r_dobj) develop
had (r_parataxis) enhanced
fanft-induced (r_amod) carcinomas
children (l_nmod) tumor
patients (r_nmod) cases
injection (r_nmod) reflect
cases (l_nmod) myopathy
reactions (l_nmod) symptoms
patients (l_nmod) diseases
methotrexate (r_dep) fluid
acceleration (r_dobj) produced
resistance (r_nmod) accompanied
nicotine (r_nmod) effect
lidocaine (r_nmod) compares
level (r_nmod) increase
depletion (r_nmod) accompanied
test (l_nmod) assay
recurrence (l_nmod) tma
case (r_nsubjpass) reported
gaba(a (r_compound) receptors
co-administration (r_nmod) increased
duration (l_conj) incidence
dyskinesia (r_nmod) improvement
supplementation (r_nsubjpass) advocated
penicillin (r_nmod:npmod) induced
haloperidol (r_nmod) trial
d-ribose (r_nmod) effect
pentylenetetrazole-induced (r_amod) kindling
occurred (l_nsubj) fibrillation
carbachol (r_nmod) tachycardia
develops (l_conj) %
yohimbine (r_conj) prazosin
dexamethasone (r_nsubj) results
repeated (r_acl:relcl) disease
protection (r_nmod) demonstrated
concentration (r_conj) vol%
beclomethasone (r_nmod) placed
skf (r_nsubj) had
no (r_compound) inactivation
dopamine (r_compound) efflux
describe (l_nmod) headache
death (l_conj) defect
effectiveness (l_acl) antagonizing
treatment (r_nmod) frequency
thalidomide (r_nmod) study
patients (r_nmod) combination
action (r_nmod) contribute
use (r_conj) alcohol
lower (l_nsubj) frequencies
incidence (l_nmod) hypokalemia
strains (l_nmod) exception
evaluated (l_nsubjpass) activity
streptozotocin (r_nmod) treated
flecainide (l_conj) reports
presence (l_nmod) malformations
dynamics (l_nmod) patients
treatment (r_nmod) delirium
levels (r_nsubj) increased
had (l_nsubj) specimen
morphine (r_nmod) potentiation
adjustment (r_nmod) induced
one (l_nmod) consequence
reduction (r_nsubj) prevented
thrombo-embolism (l_appos) disease
hypoglycemia (l_conj) polycythemia
acetaminophen- (r_nmod) form
patient (l_nmod) pseudoacromegaly
prevention (l_nmod) adenomas
carboplatin (l_nmod) patients
azelastine (r_nsubj) appears
blood (r_nmod) reduction
ctx (r_appos) cyclophosphamide
likely (l_nsubj) disorders
duration (r_nmod) agents
regimen (l_nmod) cancers
estrogen (r_nmod:npmod) induced
stimulated (l_nmod) patients
presence (l_nmod) calculi
protected (l_nmod) rats
vincristine-induced (r_amod) bradykinin
alfentanil (r_dobj) receiving
nephropathy (l_conj) neoplasia
botox (r_appos) toxin
secondary (l_nmod) trauma
modulate (l_dobj) response
azathioprine (r_conj) agents
women (l_nmod) cancer
response (r_nmod) lesion
inhibitor (r_compound) therapy
concentration (r_conj) back-diffusion
attenuation (l_nmod) syndrome
mechanism (r_dobj) suggests
ineffective (l_advcl) altering
prednisone (r_nmod) exposure
increased (l_nmod) attack
used (l_xcomp) prevent
treatment (r_dobj) continued
form (l_nmod) fibrosis
efficacy (r_dobj) determine
dose (r_nsubj) higher
occurred (l_nsubj) events
reduction (l_nmod) bp
offers (r_acl:relcl) protection
linked (l_advcl) involved
complications (r_nmod) recorded
associated (r_conj) rare
demonstrated (l_ccomp) erythrodysesthesia
reintroduction (r_nsubj) led
aminoglycoside (r_amod) treatment
benzodiazepine (r_compound) site
azithromycin-associated (r_amod) hiccups
blockade (r_nmod) occurs
intake (r_conj) had
dose (r_nmod) block
effects (l_nmod) static
acid (r_dep) sle
disrupts (r_ccomp) hypothesis
most (r_nsubj) seem
receptors (r_nmod) mask
contrasting (l_nmod) absence
method (r_nmod) effects
clozapine (r_conj) lithium
enhances (l_dobj) toxicity
associated (l_conj) cleft
exhibits (l_dobj) inhibition
ovulation (r_nmod) associated
insufficiency (l_conj) thrombocytopenia
appears (l_xcomp) method
nefiracetam (r_nmod) administration
limits (l_nsubj) toxicity
2-bromoethylamine (r_conj) produced
ntg (r_conj) saline
levobupivacaine-induced (r_amod) toxicity
impairment (l_nmod) mitochondria
e2 (r_nmod) bupivacaine
calcitriol (r_conj) carbonate
effects (l_nmod) amitriptyline
nicotine (r_compound) sulfate
targeted (l_conj) corrected
lower (l_nmod) hypotension
treatment (r_dobj) given
undergoes (l_advcl) resulting
failure (l_conj) failure
concentrations (l_conj) necrosis
evaluated (l_nmod) patients
paclitaxel (r_compound) doses
occurred (l_nsubj) apnoea
tobramycin-treated (r_amod) patients
associated (r_acl) thrombosis
tacrolimus (r_nmod) associated
patients (l_nmod) lymphomas
thrombosis (l_nmod) mice
nitroglycerin (r_nsubjpass) shown
mediate (l_dobj) angiogenesis
citrate (r_compound) toxicity
associated (l_nsubj) chorea
cefotetan (r_appos) cephalosporins
dihydrouracil (r_compound) deficiency
factors (l_nmod) prolongation
incidence (l_nmod) paralysis
terminology (l_conj) treatment
nigra (l_nmod) seizures
captopril (r_nsubj) reduce
convulsion (r_nmod) shortened
change (l_conj) subjects
critical (l_nmod) expression
likely (l_xcomp) suffer
terminate (l_dobj) encephalopathy
estradiol (r_nmod) use
restricted (l_nmod) children
changes (l_amod) consistent
evaluate (r_xcomp) was
manifest (r_xcomp) liable
resulting (l_nmod) shock
daunorubicin (l_nmod) sarcoma
activity (l_compound) immunodeficiency
doxorubicin (r_compound) regimen
properties (r_nsubj) led
underwent (r_acl:relcl) delirium
alter (l_dobj) tendency
monotherapy (r_nmod) different
hemorrhage (l_conj) ulcer
compared (l_nmod) study
adriamycin-mediated (r_amod) activity
theophylline (r_conj) fenoldopam
pharmacokinetics (r_nsubjpass) altered
had (r_acl:relcl) group
isomers (r_nmod) effects
observed (l_nsubjpass) hypocalcemia
methotrexate (r_nmod) recipients
bbb (r_dobj) destroy
effect (l_nmod) infarction
resolution (r_conj) detection
tolerated (l_conj) useful
dosage (r_nsubjpass) reduced
effects (l_amod) tremor
rats (l_nmod) hypotension
differences (l_nmod) activity
incidence (l_nmod) riha
metolachlor (r_dobj) using
mice (l_nmod) inflammation
developed (r_acl:relcl) enhancement
infusion (r_conj) hemorrhage
fluconazole-associated (r_amod) torsade
mice (r_conj) azt
concentration (r_dobj) increases
fluorocitrate (r_conj) fluoroacetate
receiving (r_parataxis) presented
safety (l_nmod) patients
suppressed (l_dobj) startle
database (l_nmod) cases
development (l_nmod) nephropathy
history (l_nmod) hyperthyroidism
drugs (r_nmod) use
number (l_nmod) models
criteria (l_nmod) agoraphobia
considered (l_nsubjpass) development
estrogens (l_nmod) failure
cocaine-kindled (r_conj) lidocaine-
administration (r_nsubj) efficacious
therapy (r_dep) background
monotherapy (r_nmod) developed
exercise- (r_amod) tachycardia
polyuria (r_nmod) development
myelosuppression (r_conj) dexrazoxane
therapy (r_nmod) consequence
adrenaline.7 (r_nmod) dose
cardiomyopathy (r_nsubj) provides
flecainide-induced (r_amod) delirium
cyanoacrylate (r_amod) nanoparticles
(aap)-induced (r_amod) nephrotoxicity
anaesthetics (r_nmod) combination
syndromes (l_compound) pain
complete (r_conj) shock
rigidity (l_acl) leading
inhibitor (r_conj) inhibitor
gemcitabine (r_nsubj) have
therapy (l_nmod) chc
neuroblastoma (r_nmod) hypertension
induced (l_dobj) types
peroxide (r_compound) production
follow (l_nsubj) symptoms
explanation (r_conj) unknown
atp (r_appos) triphosphate
took (l_dobj) overdose
impairment (l_nmod) function
exposure (r_nmod) death
patients (r_nmod) rupture
showed (l_conj) gall
action (l_conj) evidence
animals (r_nsubj) showed
tyrosine (r_compound) receptors
testosterone (r_compound) levels
synthase-1 (r_nmod) deficient
metrics (l_conj) incidence
effect (r_nmod) consistent
hydroxytyrosol (r_amod) damage
binding (l_conj) convulsions
differ (l_nsubj) cocaine-
inhibitors (r_nmod) treated
thromboembolic (l_nmod) relationship
patient (l_amod) secondary
protects (l_conj) reduces
taking (r_acl:relcl) male
see (l_nmod) order
model (r_nmod) discharges
acetaminophen (r_amod) group
steroids (r_nsubj) had
areas (r_nmod) bruising
model (r_nsubjpass) characterized
cpa/ee (r_appos) ethinylestradiol
diet-fed (l_conj) hearts
accumulation (l_conj) toxicity
effect (l_nmod) mg/kg
model (l_compound) failure
suggesting (r_advcl) ceased
triggers (l_conj) leads
thiol (r_compound) groups
dosing (r_conj) performed
rifampicin-associated (r_amod) failure
crisis (r_dobj) had
headache (r_dobj) counteract
observed (l_conj) had
condition (r_nmod) that
reported (r_acl) level
users (r_nmod) observations
aza-treated (r_amod) patients
ischemia (r_nsubjpass) characterized
isoniazid (r_conj) rifampin
acid (r_dobj) modulate
caused (r_acl) arrest
policy (r_nsubj) lead
use (r_nmod) occurring
users (r_nmod) higher
grade (l_conj) patients
explanation (l_nmod) hiccups
enhance (l_dobj) extent
management (l_acl) using
inhibitor (r_appos) disulfiram
nahco3 (r_compound) briefly
using (r_acl) period
addition (l_nmod) necrosis
risk (r_nsubj) similar
skf (r_compound) quinpirole
caused (r_acl) inhibition
effects (l_nmod) supply
pathogenesis (l_nmod) nephrosis
quinine-induced (r_amod) arrhythmia
case (l_nmod) disease
trial (l_nmod) cancer
group (l_amod) 90/htn
relevance (l_nmod) host
ribavirin (r_conj) 2a
levels (r_nmod) related
ethanol (r_compound) extract
presence (r_nmod) tended
revealed (l_ccomp) sensitized
related (r_amod) disease
antibody (r_nmod) effects
ziprasidone (r_nmod) dose
acetaminophen (r_advmod) impaired
adenocarcinoma (l_nmod) liver
given (l_nmod) child
profile (r_dobj) indicated
cells (l_nmod) patients
women (l_acl:relcl) had
experienced (l_xcomp) seizure
mpep (r_nmod) blockade
ns-718 (r_nsubj) effective
cardiac (l_amod) asystolic
alleviating (l_dobj) symptoms
dyskinesias (l_appos) lids
quetiapine (r_nmod) treated
extract (r_nmod) protection
mg/kg (l_appos) dose
elevation (r_dobj) lowered
relationship (l_nmod) suppression
fatal (l_nsubj) dose
carbamazepine (r_nmod) use
effective (r_advcl) causes
delayed (l_dobj) onset
eruptions (l_compound) dermatitis
occurred (l_conj) died
agent (r_nmod) reported
produce (l_dobj) improvements
years (r_dep) accelerated
prodrug (r_appos) viramidine
dyskinesia (l_nmod) cases
d (r_nsubj) induce
role (l_nmod) formation
cis-platinum (r_nmod) combination
administration (r_nmod) severity
failure (r_conj) cases
other (l_nmod) effect
amiodarone (r_nmod) those
lithium (r_nsubj) remains
doses (r_nmod) treatment
cause (l_dobj) hepatitis
report (l_nmod) arrhythmia
children (r_nmod) function
chp (r_compound) concentration
withdrawal (l_conj) bradycardia
infusion (r_nmod) experienced
induced (r_acl) seizure
yohimbine (r_nsubjpass) used
administered (r_advcl) evident
consumption (r_nmod) related
reducing (l_dobj) pain
(pan)-induced (r_amod) syndrome
acitretin (r_conj) dysphonia
indinavir (r_nmod) level
use (l_advcl) corrected
ganciclovir (r_nmod) treated
venlafaxine (r_compound) overdose
associated (r_acl) exacerbations
mechanisms (l_nmod) neuropathy
control (l_dobj) hemorrhage
been (l_nmod) incidence
treatment (l_nmod) priapism
kidney (r_nmod) compared
case (l_nmod) pointes
cardiotoxicity (r_conj) toxicity
acid (r_dep) 5-fluorouracil
effects (l_nmod) hypotension
group (r_nmod) function
injection (r_nsubj) had
occur (l_nsubj) toxicity
developed (l_nsubj) patient
l-arginine-nitric (r_amod) system
patients (l_nmod) nausea
action (l_nmod) narcosis
triglycerides (r_nmod) decrease
abolished (r_conj) maximal
concentrations (r_nmod) patients
was (r_appos) background
nicergoline (r_nmod) nephritis
approved (l_nmod) administration
dehydration (l_conj) infection
had (l_nmod) temperature
headache (l_conj) nausea
eps (r_nmod) plays
types (l_nmod) seizures
consciousness (l_conj) increased
delayed (r_ccomp) showed
nitroprusside (r_nmod) recorded
therapy (r_nmod) secondary
therapy (r_conj) crisis
review (l_nmod) cases
bupivacaine-induced (r_amod) convulsions
dose (r_nmod) caused
incidence (l_nmod) carcinomas
therapy (l_nmod) hyperlipoproteinemias
formation (r_nmod) results
serotonin (r_compound) receptor
d3 (r_nmod) doses
recording (r_conj) recovers
mechanisms (l_nmod) death
dilated (r_conj) developed
blockers (r_nmod) neither
withdrawal (r_appos) pneumonitis
include (l_dobj) anxiety
had (l_advcl) believe
degree (l_nmod) damage
midazolam (r_compound) group
progression (l_nmod) injury
scopolamine (l_dep) amnesia
dose (r_nmod) induced
therapy (l_nmod) hypertension
induced (r_conj) examine
reported (r_dep) resembled
increased (l_nsubjpass) headache
crack (r_compound) addicts
exposed (r_acl) areas
calcium (r_compound) therapy
using (r_xcomp) seen
frequency (l_nmod) seizures
patients (l_nmod) pain
therapy (r_nmod) section
risperidone-associated (r_amod) disturbances
induced (r_acl) prolongation
atp (r_compound) levels
syndrome (l_compound) thrombosis
cause (l_dobj) hyponatremia
warfarin (r_compound) therapy
cardiotoxicity (r_nsubj) correlates
ketamine-induced (r_amod) catatonia
caused (l_dobj) incidence
bupropion (r_nmod) induced
suppressed (r_acl:relcl) arrhythmia
patients (l_nmod) stones
got (r_conj) diagnosed
d-amb-treated (r_amod) rats
5-fu/fa/mmc (r_nsubj) regimen
effects (r_nmod) study
coadministration (r_nmod) toxicity
cases (l_nmod) retinochoroidopathy
considered (l_ccomp) occur
neonates (l_acl:relcl) received
represents (l_dobj) option
demonstrate (l_advcl) studying
infarction (r_nmod) woman
methods (r_nsubjpass) used
doxorubicin (r_conj) cardiotoxicity
therapy (r_dobj) received
examined (r_conj) associated
characterized (l_nmod) glomerular
withdrawal (r_nmod) occurred
therapy (l_nmod) hypercholesterolemia
potentiate (r_conj) antagonize
nephrotoxicity (r_nsubj) infrequent
rizatriptan (r_nmod) events
cirrhosis (l_amod) virus-related
lh (r_conj) secretion
drug (r_nsubj) reverses
receiving (r_acl) animals
changes (l_appos) one
indomethacin (r_dobj) receiving
meloxicam-induced (r_amod) toxicity
gsh (r_compound) depletion
patients (l_nmod) cvd
verapamil (r_dobj) receiving
injection (r_nmod) graded
showed (l_parataxis) revealed
bradykinin (r_nsubj) seemed
coupled (r_advcl) precipitate
acetylcholine (r_compound) levels
complication (l_nsubj) cardiotoxicity
paralleled (l_nmod) reduction
d-med (r_nsubj) prevented
amn082 (r_nmod) administration
depression (l_conj) disturbance
sleep (l_advcl) awaking
dysfunction (l_acl) followed
given (l_conj) reproduces
injection (l_nmod) glioblastomas
prazosin (r_compound) pretreatment
impairment (l_nmod) learning
interaction (l_nmod) cns
silver (r_amod) grains
demonstrated (l_xcomp) produce
prevent (l_advcl) reducing
use (r_acl:relcl) physicians
therapy (l_nmod) control
mk-801 (r_nmod) administration
frequent (l_nmod) analysis
sodium (r_conj) protein
hypokalemia (r_dobj) prevent
des-exposed (r_amod) offspring
ich (r_nmod) risk
practiced (l_advcl) remains
protects (l_nmod) seizures
treatment (l_nmod) pain
n-methyl-d-aspartate (r_conj) antagonists
interaction (r_nmod) syndrome
resembling (l_xcomp) glaucoma
zonisamide (r_nmod) associated
receiving (r_conj) patients
5-ht (r_appos) 5-hydroxytriptamine
trial (r_dobj) performed
concentrations (l_nmod) arrhythmias
sphincter (l_nmod) dyskinesia
hepatocytes (l_acl:relcl) resemble
mesna (r_compound) concentrations
halothane (r_nmod) labetalol
inhibition (l_nmod) thrombosis
doses (r_dobj) adding
nr1(neo-/- (r_nmod) hyperactivity
eliminating (r_advcl) need
used (l_nsubjpass) hypertension
associated (r_acl) hiccups
saturations (r_conj) range
had (r_conj) normal
3.4 (l_nsubj) risk
suprofen (r_nsubj) causes
decrease (r_dobj) caused
effective (l_advcl) retarding
methadone (r_compound) patients
induced (l_nmod) outpatients
reports (l_nmod) bradyarrhythmia
nimodipine (r_compound) treatment
salt-sensitive (r_amod) rats
increased (l_advcl) controls
no-induced (r_amod) headache
tc99m-sestamibi (r_compound) emission
cocaethylene (r_compound) concentrations
amphetamine (r_nmod) dose
cannabis (r_compound) users
pamidronate (r_dobj) received
consumption (r_nsubj) has
blocking (r_compound) agents
group (l_acl) endorsing
methods (l_advcl) examine
another (r_conj) presented
man (l_acl) presented
fluoxetine (r_nmod) transmission
effects (l_nmod) sedation
dexmedetomidine (r_amod) sedation
response (l_amod) startle
experiences (l_dobj) emesis
threatening (l_dobj) cardiotoxicity
medium (r_nmod) effects
pge(2 (r_nmod) blockade
associated (r_parataxis) described
infusion (r_nmod) reaction
allocated (l_nsubjpass) participants
treatment (l_nmod) tachycardia
patients (r_conj) diseases
had (l_dobj) hemosiderosis
mechanism (l_nmod) myopathy
urticaria/angioedema (l_conj) angioedema
symptom (l_nmod) neurotoxicity
recognize (r_xcomp) important
nor (l_nmod) presence
two-step (l_dep) thrombocytopenia
acetylcholine (r_compound) subunits
oxide (r_nsubjpass) involved
pathway (r_dobj) activate
cocaine (r_conj) brain
thymus (l_conj) bodyweights
stress (l_nmod) cardiotoxicity
diazepam-induced (r_amod) anxiolysis
reduction (r_nmod) indicated
induced (l_nmod) spasm
dronedarone (l_conj) amiodarone
reduced (l_dobj) dyskinesias
believed (l_ccomp) mediates
signs (l_compound) dsykinesia
induce (l_nmod) rats
decrease (r_conj) mg/kg
led (l_nmod) resolution
loss (r_nsubj) hallmark
rats (r_dobj) protecting
thrombocytopenia (r_nsubj) presents
vpa (r_nmod) effect
effects (r_nsubj) depend
pressure (r_conj) symptoms
lamotrigine (r_nmod) treated
release (r_nmod) prostanoids
flow (r_nsubj) induced
elevations (l_conj) neutropenia
hypotension (l_conj) hyperactivity
reduce (l_dobj) anxiety
infusion (r_nmod) reduced
child (l_amod) neurologically-impaired
sarcoma (l_compound) aids
alfentanil-induced (r_amod) rigidity
cy (r_appos) cyclophosphamide
galantamine (r_nsubj) well-tolerated
seen (l_nsubjpass) evidence
administered (r_advcl) similar
man (r_nsubj) developed
pathophysiology (l_nmod) akathisia
data (l_nmod) risk
paracetamol (r_compound) feeding
measure (l_conj) extended
sulpiride (r_nmod) induced
plausible (l_nsubj) development
clonidine (r_nmod) dose
hyperglycinemia (r_dobj) have
areas (l_acl:relcl) develop
acetylcholine (r_conj) acid
pneumonia (l_appos) pcp
products (r_nsubj) produce
drugs (r_nmod) efficient
occur (l_advcl) decreased
correlation (r_dep) relation
quality (l_nmod) women
active (l_conj) hyperalgesia
caused (l_nsubjpass) dysfunction
combination (r_nmod) study
uroprophylaxis (r_dobj) received
cause (l_nmod) thrombocytopenia
efficacy (l_conj) toxicity
treated (r_amod) shr
contributes (l_conj) lead
seizures (r_nsubj) cause
evaluated (l_nsubjpass) movements
containing (r_acl) mg
8-aminoquinoline (r_compound) 5-(l-hexyloxy)-6-methoxy-4-methylquinoline
tuberculosis (l_appos) xdr-tb
mesna (r_dobj) adding
lignocaine (r_nmod) dose
contribute (r_conj) induce
efficient (l_nmod) prevention
nt-probnp (r_appos) peptide
cats (l_nmod) epilepsy
suggesting (r_xcomp) related
taking (r_advcl) experienced
nitrate (r_nmod) treated
combination (r_nmod) greater
lindane (r_xcomp) consider
prevent (l_dobj) damage
treated (l_nsubjpass) outpatients
vpa (r_dobj) taking
reported (l_nsubjpass) prolongation
account (l_nmod) depression
support (l_nmod) transplantation
steroid-dependent (r_amod) manner
paclitaxel (r_conj) acid
disorder (l_nsubj) hyperglycinemia
compared (l_nsubjpass) toxicities
enhance (l_dobj) thrombosis
warfarin (r_dobj) receiving
developed (l_dobj) hematoma
involvement (l_nmod) rotation
akathisia (r_nsubjpass) caused
produced (l_nsubj) months
mg/kg (r_appos) test
deterioration (l_nmod) vision
vincristine (r_nmod) associated
nifedipine (r_compound) tablets
resolved (r_acl) arrhythmia
newborns (r_nmod) screening
indomethacin (r_nmod) mg
serotonin (r_compound) blockers
doses (r_nmod) higher
convulsions (r_nmod) observed
levofloxacin (r_compound) mg
profile (l_conj) toxicity
administered (l_nmod) dogs
associated (l_conj) ischaemia
morphine (r_compound) infusion
case (l_compound) vasculitis
induced (r_acl) atherosclerosis
metoclopramide (r_nmod) administration
detecting (r_advcl) assess
experienced (l_dobj) toxicity
investigated (l_nmod) mice
ticlopidine (r_nmod) treatment
infarction (l_appos) mi
patients (l_compound) tumor
disruption (l_nmod) model
receive (r_xcomp) assigned
magnitude (l_conj) responses
tested (l_advcl) see
therapy (r_dobj) receiving
treatment (r_nmod) toxicity
rich (r_ccomp) suggesting
rats (r_nsubj) presented
patients (r_conj) patients
cases (l_nmod) confusion
treated (r_acl) migraine
gentamicin-induced (r_amod) arf
aspirin (r_nmod) nonusers
similar (r_dep) rats
infusion (r_nmod) myoclonus
use (r_nmod) admitted
familiarity (l_nmod) professionals
necrosis (r_nmod) developed
cases (l_nmod) syndrome
presentation (r_nmod) hyperglycinemia
micrograms (r_conj) isoniazid
cisplatin (r_appos) day
administration (r_nsubjpass) abandoned
supplementation (r_conj) potassium
observed (l_punct) ,
inhibited (l_nsubjpass) appearance
hepatonecrosis (l_conj) cholangitis
mass (l_conj) glomerulonephritis
secondary (l_nmod) glomerulonephritis
dose (l_nmod) disease
importance (l_nmod) development
lithium (r_dobj) taking
patient (l_nmod) jaundice
rats (r_nmod) incidence
reduced (l_nsubjpass) hepatitis
patients (r_nsubjpass) admitted
unaffected (l_nsubjpass) severity
defect (l_nmod) dogs
incidence (l_conj) syndrome
developed (l_nsubj) fever
avp (r_nmod) elevation
paclitaxel (r_nmod) study
complained (l_nmod) numbness
pergolide (r_nmod) role
agents (r_nsubjpass) associated
developed (l_dobj) hyperalgesia
potentiation (r_nsubjpass) mediated
amyloidosis (l_conj) syndrome
deferoxamine (r_compound) doses
vaccine (l_compound) b
used (r_advcl) improves
parkinsonism (r_dobj) alleviating
product (l_acl) approved
vigabatrin (r_conj) carbamazepine
relate (r_acl:relcl) mechanisms
glycopyrrolate (r_compound) pad
simvastatinezetimibe (r_nsubjpass) discontinued
treated (r_acl) scale
papaverine (r_nmod) cases
phase (r_nmod) sufficient
apoptotic (l_conj) necrotic
measured (l_nmod) haemorrhage
bupropion (r_nsubj) induced
complication (l_nsubj) nephrolithiasis
ara-c (r_conj) mtx
action (l_acl) manage
mptp-treated (r_amod) monkeys
dizziness (l_conj) somnolence
influenced (l_nmod) hyperactivity
used (r_ccomp) confirm
results (l_compound) ischaemia
observed (l_nmod) echocardiography
warfarin (r_compound) users
glutathione (r_compound) peroxidase
appearance (l_nmod) seizures
fluconazole (r_nsubjpass) administered
gentamicin (r_compound) toxicity
suggest (l_conj) have
diagnosis (l_nmod) reaction
eosin (r_conj) hematoxylin
role (l_nmod) tissue
catalepsy (r_nmod) manifestation
tetany (l_conj) rhabdomyolysis
diabetic (l_dep) nephropathy
di- (l_conj) determinant
alterations (r_nmod) relation
recovered (r_acl) patient
behavior (r_conj) catalepsy
increment (r_nmod) doubled
injections (r_nsubjpass) used
acid (l_nmod) combination
men (l_nmod) cancer
record (l_conj) levels
ethambutol (r_compound) therapy
context (r_nmod) described
threshold (l_amod) seizure
theophylline (r_nmod) nausea
effect (l_nmod) development
one (l_appos) other
warfarin-induced (r_amod) hemorrhage
verapamil (r_nsubj) promotes
isoniazid (l_nmod) bradycardia
developed (r_acl:relcl) hypertension
suxamethonium (l_conj) arrest
desferrioxamine (r_compound) withdrawal
addition (r_nmod) developed
known (l_xcomp) seen
amiodarone (r_amod) administration
yohimbine (r_compound) treatment
developed (l_dobj) calculi
decrease (l_nmod) status
capsaicin (l_nmod) neuralgia
ascites (l_conj) lipidemia
pulmonale (r_conj) cirrhosis
caffeine (r_nmod) absence
weakness (l_conj) shortness
pirarubicin (r_appos) bolus
addicts (l_acl:relcl) denied
metoprolol (r_compound) accumulation
patients (l_appos) presence
alpha-tocopherol (r_nmod) effect
enrolled (l_nmod) osteoporosis
concentration (r_nsubj) increased
bleomycin (r_conj) cisplatin
man (r_nsubjpass) prescribed
resolved (l_dobj) tetany
diuretic (r_conj) antiplatelet
duration (r_nmod) effect
compared (l_nmod) ecgs
expression (l_nmod) factor
developed (l_nmod) man
months (r_nmod) presented
increasing (r_conj) significant
bradykinin (r_nmod) activity
investigate (r_advcl) performed
using (r_acl) reduction
myocardiopathy (l_appos) mp
alf (r_dep) groups
cardiomyopathy-induced (r_amod) inflammation
hypotension (r_nsubjpass) used
ocs (r_nmod) users
factor (l_nmod) infection
5-azacytidine (r_nsubj) potentiates
therapy (r_dobj) complicating
rats (l_nmod) failure
results (l_appos) impairment
administered (r_advcl) prevented
glutamate (r_compound) subtype
those (l_acl:relcl) have
history (r_dobj) determine
epidemics (l_acl:relcl) caused
metabolite (l_conj) responsible
accounts (l_nmod) part
sensation (l_amod) painful
worsened (l_nmod) development
adrenaline-induced (r_amod) cardiac
associated (r_acl) hepatotoxicity
developed (l_dep) coincident
tropicamide (r_dobj) using
amiodarone (r_nsubj) induced
agsd (r_nmod) differed
develop (l_nsubj) proteinuria
nephropathy (l_nmod) patients
doxorubicin (r_nmod) treated
consumed (r_acl:relcl) patients
dosages (r_nsubj) cause
induced (r_acl) protrusions
receiving (l_nmod) transplantation
features (l_dep) woman
aspirin (r_compound) group
receptor-associated (r_amod) encephalitis
have (l_dobj) cytotoxicity
chemotherapy (r_nmod) administration
eosinophilia (l_conj) erythroderma
rats (r_nsubjpass) allocated
mg (r_dobj) containing
administration (r_nsubj) resulted
patients (r_nmod) survival
transaminase (r_conj) toxicity
lidocaine (r_compound) seizures
development (l_amod) seizure
cyclophosphamide (r_dobj) receiving
model (r_conj) =
caused (r_acl) hypotension
history (l_nmod) hit
done (l_nmod) infants
adenosine (r_nmod) formulation
efficacy (r_dobj) evaluating
stimulation (l_nmod) site
shr (r_conj) prazosin
induced (r_amod) activation
% (l_nmod) urticaria
transformation (r_conj) degeneration
hypercalcemia (l_dep) suppression
treated (l_nsubjpass) males
clonidine (r_nsubj) monitor
trazodone (r_nsubj) induces
creatine (r_compound) phosphokinase
lithium (r_compound) levels
normal (l_nmod) cases
stroke (l_conj) hypertension
catecholamine (r_compound) metabolite
insipidus (r_nmod) rats
increase (r_nmod) associated
attributed (l_nsubjpass) bradycardia
remains (l_xcomp) determined
receiving (r_acl) dogs
developed (l_dobj) aneurysm
trial (l_nmod) children
d-tubocurarine-induced (r_amod) hypotension
received (r_acl:relcl) patient
mg (r_nmod) combination
jaw (l_nmod) steel
revealed (l_dobj) damage
lead (l_advcl) associated
diclofenac (l_nmod) treatment
controlled (r_acl:relcl) epilepsy
thromboembolism (l_appos) vte
fracture (l_conj) dislocation
cyclophosphamide (r_conj) doxorubicin
deactivated (r_xcomp) gets
penicillin-induced (r_amod) model
sites (r_nsubjpass) demonstrated
decreased (l_nmod) hypotension
kainic (r_conj) pilocarpine-
ingestion (r_conj) salicylates
related (r_conj) phenylephrine
acceptance (l_nmod) treatment
inhibitor (r_appos) injection
phosphatidylserine (r_nmod) exposure
presence (l_nmod) cyanosis
platinum (r_compound) based
coumadin (r_compound) therapy
indicates (l_dobj) relationship
prove (l_nmod) incidence
challenge (r_nmod) recurred
study (r_nsubj) showed
methylprednisolone (r_nmod) administration
aspirin (r_nmod) co-administration
detection (l_nmod) infarction
anemia (l_appos) maha
cancer (l_appos) nsclc
inhibitor (r_nsubj) prophylaxis
combined (r_advcl) cause
therapy (r_nsubj) increase
development (l_nmod) rs
appeared (l_xcomp) have
larger (l_nmod) group
caa (r_nmod) role
case (l_acl) manifested
methimazole-induced (r_amod) jaundice
remoxipride (r_appos) agent
bupivacaine/rofecoxib (r_compound) group
disease (l_conj) disease
metoclopramide (r_nmod) injections
trial (r_nsubj) reported
citalopram (r_conj) terfenadine
metformin (r_nmod) correction
diphenylhydantoin (r_compound) toxicity
induced (r_acl) liver
measured (l_dobj) pain
developed (l_dobj) fever
augmented (l_dobj) seizure
effects (l_nmod) treatment
iso (r_nsubjpass) given
lamivudine (r_conj) globulin
thrombocytopenia (r_nmod) secondary
therapy (r_dobj) stopping
written (l_nmod) management
vincristine (r_compound) neuropathy
bilirubin (r_conj) bilirubin
optic (r_nmod) history
known (l_xcomp) induce
association (r_nmod) lack
performed (l_advcl) develop
therapy (r_nmod) used
treating (l_dobj) disease
increase (l_conj) decrease
medications (r_nsubjpass) given
scopolamine-induced (r_xcomp) improves
death (l_amod) epilepsy-induced
pilocarpine (r_nsubj) induces
increasing (r_advcl) induced
development (l_nmod) torsade
meth-induced (r_amod) psychosis
dose (l_acl) protected
have (r_conj) small
lipid (r_appos) ns-718
calcification (l_nmod) media
users (r_nmod) %
undertaken (l_xcomp) examine
woman (l_amod) hypertensive
cause (l_nmod) thyrotoxicosis
ethanol (r_nmod) caused
lindane (r_amod) induced
gamma-hexachlorocyclohexane (r_nsubjpass) shown
attack (l_compound) hepatitis
evaluated (l_ccomp) involved
influence (r_dobj) evaluated
metabolite (r_nmod) cause
no-deficient (r_amod) hypertension
hexamethonium (r_nmod) blockade
injection (r_dep) h
resemble (l_dobj) those
paclitaxel (r_nsubjpass) combined
improve (l_dobj) memory
constitutes (l_dobj) therapy
patients (r_nmod) function
induced (l_nsubjpass) disappearance
arabic (r_nmod) severe
pseudoprolactinoma (l_conj) hyperprolactinemia
proved (l_nmod) recurrence
diclofenac (r_nmod) comparison
outflow (r_nmod) decrease
assessed (l_nmod) trials
normal (r_conj) presented
administration (r_conj) oral
patients (r_nmod) incidence
clozapine (r_dobj) taking
bupivacaine (r_nmod) profile
attenuating (r_advcl) expected
amiodarone (r_nmod) treated
preparations (r_nmod) use
acid (r_nmod) efficacy
factor (l_acl) associated
combination (r_dobj) receiving
paclitaxel (r_nmod) feasibility
associated (l_dobj) odds
progression (l_nmod) failure
considered (l_nsubjpass) nephropathy
piperacillin (l_conj) neurotoxicity
interaction (l_acl:relcl) resulted
effect (r_dep) ischemia
amisulpride (r_advmod) symptoms
therapy (r_nmod) patients
infusion (r_nmod) those
prophylaxis (l_appos) aggregation
course (r_nsubj) resulted
had (l_dobj) hemianopsia
administration (r_nmod) rate
accumulation (r_nsubjpass) considered
drugs (r_dep) verapamil
cocaine-related (r_amod) deaths
treat (l_dobj) pain
discrepancy (r_attr) was
danazol (r_nmod) safety
compared (l_nmod) neuropathy
strains (r_dobj) investigate
reducing (l_dobj) nephrotoxicity
dup (r_nmod) administration
nelarabine (r_nmod) therapy
defects (r_nsubjpass) implicated
type (r_nmod) expressions
phenytoin (r_compound) overdosage
phosphatase (l_nmod) nephrosis
high (l_nsubj) rate
reduction (l_nmod) patients
production (l_nmod) patients
risk (l_nmod) carcinoma
hypertension (l_conj) diabetes
appear (l_dep) dynamics
bethanechol (r_conj) stimulation
contributed (l_nmod) seizures
n-methyl-d-aspartate (r_compound) antagonists
sequelae (l_nmod) epilepsy
effect (r_nsubjpass) compared
l-dopa (r_nmod) enhanced
sodium (r_nmod:npmod) nitroprusside-induced
evidence (l_nmod) changes
penicillamine-related (r_amod) effects
k)-atpase (r_appos) (na
intake (r_nsubjpass) associated
n'-diisopropylphosphorodiamidofluoridate (r_appos) mipafox
severity (l_nmod) disability
model (l_nmod) failure
inhibitor (r_conj) temocapril
gentamicin (r_compound) nephropathy
related (r_conj) increased
removal (r_nmod) cleared
4-aminopyridine (r_compound) therapy
5-fluorouracil (r_nmod) neurotoxicity
mutants (l_nmod) patients
infusion (r_nmod) l(-1
life (l_acl) threatening
acei/arb (r_compound) therapy
octreotide (r_compound) stones
result (l_amod) unrelated
replacement (r_dobj) attenuated
thalidomide (r_dobj) received
citalopram (r_nmod) concentration
induces (l_dobj) paraparesis
adenosine (r_compound) agonist
system (r_nmod) role
effects (r_nmod) associated
disruption (r_dobj) attenuated
myalgias (l_conj) polyneuropathy
therapy (r_nmod) dysfunction
risperidone (r_nsubjpass) associated
azidothymidine (r_nmod:npmod) treated
ethanol (r_conj) p450
combination (r_nsubj) cause
formation (l_compound) gallstone
camp (r_nmod) aggregation
therapy (l_nmod) adults
effect (r_dobj) induced
doxorubicin (r_nmod) use
learning (l_conj) memory
propranolol (r_nmod) evidence
induces (l_dobj) growth
ph (r_nsubjpass) kept
amoxicillin (r_nmod) reactions
relationship (r_dobj) suggests
associated (l_conj) contributed
level-dependent (r_amod) levels
cocaine (r_compound) toxicity
(dnr)-containing (r_compound) regimen
temperature (l_conj) erection
chlorpromazine (r_nmod) treated
mechanisms (l_acl:relcl) causes
task (r_nmod) retention
strokes (l_amod) bleeding
ach (r_nsubjpass) measured
patients (l_dep) glioma
conclusion (l_conj) responses
consequence (r_nmod) reported
using (r_acl) patient
action (l_amod) hypotensive
penicillamine-treated (r_amod) patients
failure (l_appos) crf
indomethacin (r_nsubj) induced
inhibition (r_nsubj) induces
besylate (l_conj) associated
methamphetamine (l_dep) hyperthermia
switch (r_nmod) develop
seen (l_nmod) patients
occur (l_nsubj) myopathy
european (r_compound) trial
carbamazepine (r_nmod) concerns
l-dopa (r_amod) medication
model (l_acl:relcl) elicited
trial (r_nsubjpass) designed
ingestion (r_nmod) experienced
related (l_nsubj) myocarditis
effect (l_nmod) pain
liver (l_conj) disease
leak (l_advcl) reversing
prevention (l_nmod) bradycardia
participated (l_nsubj) children
paroxetine (r_conj) fluoxetine
drug (r_nmod) toxicity
neurons (r_nmod) hyperprolactinemia
chloralose-urethane (r_nmod) anaesthetised
resolving (l_nsubj) neuropathy
received (r_advcl) seen
1,3-butadiene (l_conj) cml
doses (r_dobj) received
due (r_ccomp) determine
associated (r_acl) bradycardia
doxorubicin-induced (r_amod) syndrome
po2 (r_appos) oxygen
m (r_nmod) %
mediated (l_nsubjpass) tachycardia
doses (l_acl:relcl) induce
theophylline (r_compound) tablets
sirolimus (r_nmod) presence
induced (l_advcl) examine
case (l_nmod) hypertension
aware (l_dep) effect
blocker (r_nmod) effects
b (r_nsubj) cause
stimulation (l_nmod) skin
administered (l_nmod) schedule
carbimazole (r_nmod) treated
da (r_compound) supersensitivity
conclusion (l_dep) enhance
stiffness (l_conj) myalgia
enzyme (r_nmod) recognition
cbz (r_nmod) injection
therapy (l_conj) frequency
etiology (l_nmod) proteinuria
infusion (r_nmod) response
children (l_nmod) disease
2.3+/-1.2 (l_nsubj) number
withdrawal (l_nmod) patients
involvement (l_nmod) naloxone
diagnosis (l_nmod) gravis
drug (l_amod) effective
amiodarone (r_amod) pneumonitis
toxicity (r_advcl) believed
fenoldopam (r_nmod) induced
adriamycin (r_nmod) induced
instituted (l_nmod) edema
morphine (r_compound) catalepsy
criteria (l_nmod) nodosa
allocated (l_nmod) groups
patient (r_nmod) parasitosis
kindling (l_amod) seizure
ingesting (r_acl) patients
observed (l_nsubjpass) proteinuria
cisplatin (r_compound) nephrotoxicity
generalization (l_conj) propagation
barium (r_compound) effect
neurotransmission (r_dobj) increase
specific (l_nsubj) defects
case (l_conj) case
hypotension (r_conj) hypertension
ttc (r_compound) staining
duration (l_nmod) slices
organophosphate (r_amod) insecticide
cancer (l_conj) mesothelioma
tendency (l_acl) induce
setting (r_nmod) pain
arrest (l_conj) death
alpha-2b (l_conj) ribavirin
serotonin (r_compound) nerves
metrifonate (r_conj) ro4368554
platinum/paclitaxel-refractory (r_amod) disease
clinic (r_nmod) shown
initiation (r_nmod) relationship
extent (l_nmod) calcification
therapy (r_nmod) neuropathy
receiving (r_acl:relcl) patients
responsible (r_ccomp) suggested
activity (r_conj) activity
effect (r_dobj) accompanied
relation (r_nmod) compared
superoxide (r_compound) radicals
da (r_compound) agonists
identified (l_dep) patients
use (r_nmod) relationship
therapy (r_nmod) injury
oxygen (r_compound) level-dependent
cefonicid (r_nmod) effects
acid (r_nmod) observed
development (l_nmod) hiccups
cyclophosphamide (r_compound) treatment
incidence (l_nmod) akathisia
patient (l_nmod) syndrome
rats (r_nmod) studied
incidence (l_nmod) torsades
screen (r_xcomp) was
reversed (l_dobj) cholinergic
prevented (l_dobj) amnesia
loss (r_dobj) measure
activate (l_advcl) contributing
blockers (r_nmod) influence
decrease (l_nmod) count
combination (r_compound) chemotherapy
response (r_dep) composition
methamphetamine (r_compound) use
tamca (r_dobj) containing
modafinil (r_nsubj) promotes
gentamicin (r_compound) nephrotoxicity
acid (r_nmod) based
dexamethasone (r_conj) saline
bpd (r_appos) hydrochloride
effects (l_amod) constipating
attacks (l_conj) disorder
developed (l_dobj) weakness
response (l_conj) toxicity
increased (l_conj) increase
sinensis (r_nsubj) had
elicits (r_acl:relcl) mechanisms
latency (r_nmod) indicated
patients (r_nmod) deaths
considering (l_dobj) reduction
ppa (r_nmod) abuse
acetate (r_nmod) therapy
dressing (l_compound) wound
doses (r_conj) performed
enzyme (r_nmod) activity
improved (l_dobj) quality
caused (l_dobj) impairment
clentiazem (r_nmod) effects
globulin (r_compound) therapy
treatment (r_nmod) context
mpep (r_nmod) action
effects (l_nmod) narcosis
given (r_acl:relcl) girl
evidence (r_nsubj) induced
quality (l_nmod) changes
had (l_nmod) incidence
minoxidil (r_nmod) use
therapy (l_nmod) children
tamoxifen (r_nmod) treated
sertraline (r_nmod) effect
flow (l_conj) damage
preventing (r_advcl) assess
day (r_nmod:npmod) times
secondary (r_amod) thrombosis
cbz (r_nsubj) decreased
fluctuations (l_conj) dyskinesias
pilocarpine (r_nmod) treated
other (r_conj) group
related (r_dobj) dilated
develop (l_dobj) lesion
levels (r_nmod) drop
mm (l_nsubj) spv
level (r_dobj) increase
supplementary (r_nmod) induced
snp (r_compound) hypotension
nmda (r_appos) n-methyl-d-aspartate
become (l_attr) regimen
case (l_nmod) hypercalcaemia
patients (l_nmod) aids
tenofovir (r_nmod) patients
pre-administration (r_nmod) abolished
acidity (l_nsubj) pain
diet (r_nmod) effects
alkaloid (l_acl:relcl) has
profile (r_nsubjpass) established
results (l_acl) obtained
induced (l_dobj) increases
developed (l_conj) given
desipramine (r_nmod) co-administration
suxamethonium (r_dep) relaxants
solution (r_nmod) amount
those (l_acl:relcl) result
alkaloid (l_advcl) cause
patients (l_nmod) tuberculosis
bupropion-induced (r_amod) convulsions
duct (r_dobj) have
evoked (l_dobj) seizures
potentiated (r_conj) shown
produced (l_conj) increased
similar (l_nmod) that
tamoxifen (r_nmod) induced
promotes (l_conj) decreases
nucleosides (r_conj) malondialdehyde
treatment (r_nmod) report
induced (l_dobj) proteinuria
p<0.001 (l_nmod) hypertension
incidence (r_nmod) blocked
patients (r_nmod) cardiotoxicity
resistance (l_nmod) failure
cisplatin (r_nmod) mediated
meth (r_appos) methamphetamine
pilocarpine-treated (r_amod) mice
comprising (l_dobj) af
caused (l_conj) hypertrophy
tenofovir (r_nsubj) raise
arag (r_dobj) giving
concentrations (r_nmod) diabetes
clonidine (l_nmod) disorder
failure (r_nmod) resistance
occurred (l_nsubj) myositis
contraceptives (r_dobj) used
effect (r_nmod) contributes
number (r_nsubjpass) found
treatment (r_nmod) case
intake (r_nmod) associated
compromising (l_nmod) cytopenias
ketoconazole (r_appos) ikr
defined (l_conj) increased
amikacin (r_compound) toxicity
diltiazem (r_nmod) g
kinase (r_compound) levels
sulphate-associated (r_amod) sites
suggest (l_ccomp) affect
ablation (l_conj) attack
association (l_nmod) model
c (l_appos) chc
echocardiography (l_appos) indicator
u-ii (r_nsubjpass) involved
alfentanil (r_amod) anesthesia
lidocaine (r_nmod) score
reversing (l_dobj) tachycardia
e (l_conj) myopathy
show (l_dobj) impairments
schizophrenia (l_conj) disorder
patients (l_nmod) insufficiency
gem-p (r_compound) chemotherapy
prevent (l_dobj) occurrence
disulfiram (r_nmod) treated
induced (l_dobj) choreoathetosis
administration (l_nmod) manipulation
implanted (r_ccomp) developed
bortezomib (l_nmod) therapy
followed (l_nsubjpass) subjects
agonist (r_nmod) use
piperacillin/tazobactam-induced (r_amod) seizure
based (r_dep) iiib
developed (r_acl:relcl) therapy
determine (l_conj) administered
mechanisms (l_nmod) aura
determination (r_conj) mrna
neurotoxicity (r_dobj) ameliorate
resulted (l_nsubj) epilepticus
involved (l_nmod) episodes
patients (l_nmod) angioedema
mortality (l_nmod) patients
pilocarpine (r_conj) nmda
blockade (l_conj) tachycardia
busulfan-induced (r_amod) cystitis
identified (l_conj) enrolled
naloxone (l_dep) reversal
involved (r_acl:relcl) functions
prediction (l_nmod) cardiotoxicity
injections (r_nmod) examination
therapy (r_nmod) month
induced (r_acl) parkinsonism
administration (r_nsubj) safe
comparisons (l_nmod) models
penicillamine-treated (l_nmod:npmod) disease
occurring (r_acl) failure
pattern (l_acl:relcl) contributes
meth (r_nmod) induced
dose (r_nsubj) ranged
extract (r_nmod) effect
inhibitors (r_nmod) reactions
retention (l_nmod) urine
antagonists (l_nmod) hyperactivity
ifosfamide-induced (r_amod) emesis
enhance (l_nmod) models
reduced (l_dobj) inhibition
clonidine (r_nmod) assigned
pill (r_nmod) use
warfarin-induced (r_amod) coagulopathy
exposure (r_nmod) decrease
capsaicin (r_nmod) detected
consumption (r_nmod) influence
treatment (l_conj) cause
therapy (r_nmod) day
hem (r_compound) groups
dipyridamole-induced (r_amod) ischemia
role (l_nmod) regulation
g (r_dep) observed
fenoldopam (r_nsubjpass) used
differed (r_parataxis) closest
ifosfamide (r_nsubj) drug
induced (l_dobj) hypoalbuminemia
documented (l_nmod) man
globulin (r_nmod) use
resulting (l_nmod) epilepticus
mouth (l_appos) headache
sulphasalazine (r_amod) treatment
behavior (r_conj) tremor
secondary (l_nmod) hitt
induced (l_nsubjpass) failure
pretreated (r_acl) animals
associated (r_acl) liver
possesses (l_conj) reduced
continued (l_conj) wore
tumors (l_dep) ds-sarcoma
sirolimus (r_compound) use
treatment (l_nmod) w-ich
appearance (l_nmod) dermatitis
contraindicated (l_nmod) seizures
followed (r_acl) system
added (l_nmod) list
induced (r_acl) learning
induced (r_acl) hypotension
lipopolysaccharide (r_nmod) roles
years (r_dep) patients
tomography (r_dobj) using
research (l_compound) epilepsy
chcl3 (r_conj) ccl4
led (l_nmod) polyuria
phenylephrine (r_nmod) impaired
animals (r_nmod) content
sedation (l_conj) irritability
gentamicin (r_nsubjpass) associated
related (r_amod) disorder
role (l_nmod) infarction
hypertension (l_nmod) patients
angiotensin-converting (r_amod) inhibitor
discriminates (l_parataxis) inhibited
coordination (r_dobj) assessed
syndrome (l_appos) nms
deaths (r_nmod) registry
flumazenil (r_nmod) administration
pbo (r_conj) qtp
amphetamine- (r_nmod) diagnosis
conclusion (r_nsubjpass) associated
tested (l_nmod) model
enhanced (l_advcl) using
control (l_dobj) movements
receiving (r_acl) disorder
showed (l_nmod) point
vancomycin (r_nmod) administration
tamoxifen (r_nsubj) induces
inhibition (r_nmod) effect
spite (r_nmod) antagonized
rats (r_nmod) effect
dysfunction (l_acl:relcl) accompanies
caused (r_acl) pseudo-allergy
use (r_nmod) characterized
shown (l_dobj) tdp
cyclophosphamide (r_nmod) metabolite
present (l_dobj) case
diazepam-induced (r_amod) incoordination
cases (l_nmod) cancer
bradycardia (r_nsubjpass) affected
gellan (r_appos) conjunctiva
pharmacokinetics (r_conj) dosage
oxprenolol (r_nmod) abolishment
developed (l_nmod) necrosis
co-administration (r_conj) observed
monoher (r_appos) monohydroxyethylrutoside
e (r_conj) tea
infused (r_conj) performed
mask (r_conj) predominate
rad001 (r_nsubjpass) tolerated
caused (l_dobj) change
exist (l_compound) hepatotoxicity
minutes (l_nmod) administration
investigated (l_nsubjpass) patients
aconitine (r_conj) g
treatment (l_conj) cases
therapy (r_nmod) developed
dipropionate (r_nmod) hoarseness
investigated (l_dobj) effect
instillation (r_nmod) developed
resulting (r_acl) toxicity
accounted (l_nsubjpass) reduction
greater (r_conj) caused
methamphetamine-induced (r_amod) efflux
5-fu (r_nmod) doses
clopidogrel (r_nmod) associated
resolved (l_nsubj) hypoxaemia
cytarabine (r_conj) peg-asparaginase
5-fu (r_appos) 5-fluorouracil
produced (r_amod) arrest
chloride (r_nmod) administration
microinjection (r_nsubj) scopolamine-induced
higher (r_conj) reported
complications (r_nmod) review
increased (l_dobj) bradycardia
doses (r_nmod) occurred
determined (r_parataxis) investigated
dependence (r_nmod) patients
role (r_nmod) dealt
[35s]tbps (r_compound) binding
mice (r_nmod) pre-treatment
received (l_advcl) produce
center (l_compound) cancer
hypotension (r_nsubjpass) unaffected
effectiveness (r_nmod) impairment
advocated (l_advcl) carried
appear (l_nsubj) increase
produces (l_nmod) rats
theophylline (r_nmod) methylxanthines
tremor (r_appos) effect
investigated (l_advcl) using
treated (l_nsubjpass) disorders
reduced (l_advcl) completing
tachycardia (r_dobj) decreased
patients (l_acl:relcl) severe
damage (r_nmod) evidence
problematic (l_appos) those
angiography (r_nsubj) confirmed
treated (l_nmod) glaucoma
norepinephrine (r_nmod) pretreatment
activity (l_compound) seizure
paclitaxel (r_nmod) trial
replacement (r_nmod) biomarker
induced (l_nsubjpass) focus
produces (l_dobj) necrosis
control (r_appos) groups
rats (r_nmod) observed
shown (l_conj) indicate
group (l_nmod) women
observed (l_nmod) patient
cases (l_nmod) failure
patient (l_conj) proteinuria
detecting (l_dobj) ischemia
damage (r_nmod) mechanism
paracetamol-associated (r_amod) coma
besides (l_nmod) necrosis
hyperactivity (r_nmod) prevention
aminoglycosides (r_nsubj) improved
apomorphine-induced (r_amod) dyskinesias
mg (r_nmod) developed
clentiazem (r_nsubj) attenuated
avp (r_appos) vasopressin
protective (l_conj) toxic
infarctions (l_conj) strokes
hypotheses (l_nmod) rhabdomyolysis
therapy (r_dobj) receive
hypoxemia (l_conj) hypertension
dobutamine (r_amod) testing
prevented (r_advcl) halts
points (r_nmod) size
pb (r_nmod) formed
predominance (r_dobj) reflected
simvastatin (r_amod) metabolism
bronchodilator (l_nmod) theophylline
level (r_dobj) measured
apomorphine-induced (r_nmod) development
case (l_nmod) toxicity
patient (l_nmod) pain
exert (l_dobj) effects
number (r_nmod) applicators
ra (r_nsubj) acted
3,4-methylenedioxymethamphetamine (r_dep) mdma
cholinesterase (l_conj) amnesia
users (r_nmod) prevalence
therapy (r_nmod) died
preventing (l_dobj) neuropathy
l-dopa (r_dobj) taking
effect (l_amod) migraine-inducing
morphine (r_nmod) reversed
triglyceride (r_nmod) output
conditioning (r_nmod) noted
heparin (r_compound) therapy
patients (l_nmod) treatment
activity (l_amod) depressed
encephalopathy (l_nmod) treatment
nephropathy (l_acl) characterized
role (r_dobj) examine
produced (l_dobj) patterns
management (l_nmod) myoclonus
developed (r_conj) developed
administration (r_nsubj) affect
given (l_dobj) diagnosis
benefits (r_nsubjpass) reported
channel (r_compound) function
gamma-carboxylation (l_nmod) protein
verapamil (r_nmod) ameliorated
contributing (l_nmod) failure
used (l_nmod) diseases
l-dopa (r_nmod) combination
regression (l_compound) tumor
model (r_dobj) fractionated
sarcomas (l_conj) cancers
decrease (r_conj) increase
antidepressant-induced (l_nsubj) pathophysiology
leads (l_dobj) retention
preventing (l_dobj) recurrence
observations (r_nmod) deduced
oxprenolol (r_nmod) efficacy
patients (r_nmod) proportion
administration (r_nmod) cases
hospitalization (l_nmod) ami/gi
dobutamine (l_dep) ischaemia
association (l_nmod) psychosis
investigated (l_advcl) performing
pain (l_conj) pain
protection (l_nmod) deaths
denied (l_dobj) cip
simvastatin-ezetimibe-induced (r_amod) transplantation
doxorubicin (r_compound) cardiotoxicity
neutropenia (l_conj) infections
doxorubicin (r_nmod) dosage
acetaminophen (r_nsubjpass) demonstrated
haloperidol (r_conj) caused
sevoflurane (r_nsubj) reduces
concentrations (r_nsubj) failed
worsen (l_dobj) toxicity
tomography (r_nmod) correlation
inhibited (l_nsubjpass) damage
cpa/ee (l_nmod) women
bromocriptine (r_compound) treatment
patients (r_nmod) used
alf=0/35 (l_conj) cld=2/34
incidence (l_nmod) tumors
caused (r_acl:relcl) patient
ccl4 (r_nmod) effects
association (r_nsubj) implicated
use (r_dobj) assess
dilatation (l_nmod) lumens
reversed (l_dobj) disorders
aminonucleoside (r_nmod) injury
incorporation (r_nsubj) attenuates
induces (l_dobj) toxicity
associated (r_ccomp) shows
higher (l_conj) tended
rose (l_nmod) onset
agent (l_nmod) cancer
codeine (r_conj) morphine
bn (r_nmod) administration
fk (r_nmod) utility
disorders (l_acl:relcl) suffered
changes (l_nmod) activity
complication (l_nsubj) neuropathy
use (l_nmod) cramps
allocated (r_acl) women
ra (r_nmod) co-administration
developed (l_dobj) delirium
instillation (r_nmod) resulting
damage (l_amod) seizure-related
study (l_compound) tumor
associated (l_nsubjpass) myoclonus
diazepam-induced (r_conj) ketamine-
diffusion (l_nsubj) mechanism
injection (r_dobj) prevented
g (l_nmod) failure
induction (r_nsubj) gives
evidence (l_nmod) nephrotoxicity
cells (l_compound) prolactinoma
blockade (l_nmod) arrhythmias
had (l_dobj) relative
apomorphine (r_nsubj) drug
predominance (l_nmod) involvement
reduction (r_nsubjpass) observed
viewed (l_nsubjpass) use
haloperidol (r_nmod) administration
interaction (r_dobj) increase
thrombi (l_nmod) ischemia
metformin (l_nmod) seizures
comparing (l_nmod) agents
severity (l_nmod) delirium
performed (l_mark) whether
cck-8 (r_nsubj) alleviated
involves (l_nsubj) mechanism
difluoromethylornithine (r_nmod) months
patients (r_nmod) recurrence
antagonized (l_dobj) catalepsy
mefloquine (r_nmod) treatment
tablets (r_nmod) ingestion
of (r_case) csa
aracytine-c (l_nmod) lymphoma
effect (r_nsubj) activities
angiosarcoma (l_nmod) liver
occur (l_nsubj) arrhythmias
reversed (l_dobj) paralysis
participants (r_nmod) seroconversion
valproate (r_amod) treatment
histamine (r_compound) antagonists
prevent (l_dobj) abnormalities
valproate-induced (l_advmod) encephalopathy
treatment (r_nmod) condition
tested (l_nsubjpass) effect
reduction (r_nmod) resolved
effects (l_nmod) function
study (l_acl) directed
increased (l_nsubjpass) toxicity
tiazofurin (r_compound) usage
vasodilation (r_nsubjpass) affected
symptoms (l_amod) consistent
dogs (l_nmod) insufficiency
synthase (r_compound) activity
results (l_advcl) show
dysfunction (l_conj) hypersensitivity
producing (l_dobj) dysfunction
evaluation (r_nsubjpass) warranted
man (l_nmod) adenocarcinoma
rate (l_conj) stroke
nefiracetam (r_nsubj) derivative
h2o (r_compound) cpap
enhancement (l_conj) dysfunction
mechanisms (l_nmod) catalepsy
correlated (r_conj) correlated
higher (l_advcl) diclofenac
attenuate (l_dobj) ototoxicity
patients (r_nmod) data
amphetamine (r_nmod) effect
heparin-associated (r_amod) osteoporosis
blockade (r_nmod) pathogenesis
effect (r_nsubj) anemia
vpa (r_nmod) value
isoproterenol (r_nsubj) induces
development (l_nmod) dyskinesias
associated (r_acl) neurotoxicity
consolidation (l_compound) memory
administration (r_nsubjpass) associated
appeared (r_acl:relcl) patient
recipients (r_conj) kidney
evidence (l_nmod) activity
doses (r_nmod) extent
dph (r_nmod) concentration
dopamine (r_nsubj) mediates
reduction (r_nsubjpass) blocked
had (r_conj) free
ouabain (r_compound) arrhythmia
life (r_nsubjpass) observed
inhibition (r_nmod) caused
excess (r_nsubj) suggests
taking (l_nmod) treatment
carcinoma (l_conj) metastasis
prazosin (r_nmod) dosing
resolved (r_acl) patients
cause (l_advcl) resulting
deacetylation (r_nmod) inhibition
fhf (l_conj) edema
unrelenting (l_nmod) cirrhosis
carboplatin (r_compound) toxicity
signs (l_nmod) stereotypy
diagnosis (l_nmod) vasculitis
concentration (r_nmod) characteristics
levofloxacin (r_nmod) associated
induced (r_acl) effects
dexamethasone (r_nsubj) programmed
amphetamine-induced (r_amod) hyperactivity
periods (l_nmod) activity
dianabol (r_dep) agent
propranolol (r_nsubj) drug
dm-9384 (r_appos) nefiracetam
containing (r_acl) medium
vigabatrin-associated (r_amod) defects
use (r_nsubjpass) complicated
identical (r_conj) inhibition
anophthalmia (l_conj) microphthalmos
cisplatin-induced (r_amod) nausea
initiating (r_advcl) associated
toxicity (l_compound) hl
treatment (l_compound) cancer
b (l_conj) rubella
encephalopathy (r_nsubjpass) considered
occur (l_nsubj) encephalopathy
cocaine (r_nmod) exposure
examine (l_dobj) influence
onset (l_nmod) jaundice
creatinine (r_conj) weight
etoposide-related (r_amod) infarction
cibenzoline (r_nmod) isomers
study (l_acl) calculate
efficacy (r_dobj) studied
channels (r_nsubj) have
amount (r_nsubjpass) administered
diclofenac (r_nmod) induced
c (r_compound) intake
changes (l_conj) impotence
autism (l_conj) aggression
lung (l_conj) node
5-fluorouracil (r_dep) agent
phenytoin (r_nmod) doses
hypertension (l_nmod) headache
methylphenidate (r_nmod) started
benzodiazepines (r_conj) clotiazepam
differ (l_nsubj) outcomes
increase (r_conj) unmask
oral (r_nsubj) reverses
had (l_dobj) action
elevated (l_advcl) measured
treated (r_advcl) observed
patients (l_nmod) glaucoma
administration (r_nmod) paralysis
day (r_nmod) treated
risperidone (r_nmod:poss) profile
caused (l_dobj) cystitis
alcohol (r_nmod) role
group (l_nummod) 15/htn
woman (r_nmod) delirium
changes (l_amod) cardiotoxic
aorta (r_dobj) included
use (l_nmod) situations
adding (r_conj) essential
map (l_nmod) degeneration
statins (r_nsubj) induce
nephritis (r_nmod) secondary
epithelium (l_conj) mastocytosis
reduction (r_nsubj) minor
csa (r_nmod:npmod) induced
has (l_nmod) comparison
relapsed (l_dep) hl
pge2 (r_appos) e2
achieved (l_conj) demonstrated
increases (l_nsubj) correction
scopolamine (r_nsubj) induced
patients (l_acl:relcl) had
role (l_nmod) overdose
increased (l_advcl) compared
erythroblastocytopenia (r_conj) hepatitis
reversed (l_dobj) amnesia
reports (l_nmod) pericarditis
catabolism (r_dobj) inhibits
reduced (l_dobj) toxicity
cause (l_dobj) hepatotoxicity
cacl2-induced (r_amod) aneurysm
melatonin (r_nmod) effects
combination (r_nmod) myocet
prevented (l_conj) reversed
injection (r_nmod) produced
protection (r_dep) evidences
influence (l_nmod) normotensive
expression (r_dobj) depressed
(lev)-induced (l_advmod) encephalopathy
aphasia (l_conj) incontinence
leading (l_nmod) prolongation
agent (l_nmod) infusion
pain (l_acl) admitted
acid (l_nmod) adenocarcinoma
demonstrating (r_advcl) resulted
promotes (l_nmod) factor
administration (r_nmod) responded
withdrawal (r_nmod) showed
addition (r_nmod) exhibited
dose (r_appos) volunteers
sirolimus (r_nsubjpass) withdrawn
dose (l_appos) malformations
ketamine (r_nmod) safety
face (l_conj) tachycardia
diphenhydramine (r_nsubj) ineffective
sodium (r_nsubj) alternative
lignocaine (r_dobj) involving
role (r_dobj) discuss
reduced (l_dobj) production
netilmicin (r_nmod) treated
indicated (l_advcl) developed
degree (r_nmod) similar
ammonia (r_conj) electrolyte
dextran (r_nmod:npmod) induced
assay (l_amod) two-step
those (r_nmod) larger
enrolled (l_nsubjpass) patients
seem (l_xcomp) play
become (l_xcomp) manic
etoposide (r_conj) daunorubicin
lidocaine (r_nsubj) enhance
better (r_xcomp) seemed
experiencing (l_dobj) episodes
media (l_compound) artery
concentrations (r_nsubj) higher
had (l_dobj) pressures
nephrotoxicity (r_conj) nephrotoxicity
10/5 (r_nmod) pill
levonorgestrel-containing (r_amod) cocs
agents (r_conj) failure
inpatients (l_amod) schizophrenic
patients (r_nmod) dysfunction
propranolol (r_conj) carteolol
similar (r_ccomp) indicated
statin (r_compound) therapy
those (r_nsubj) involve
onset (r_nmod) delay
correlation (r_nsubj) appeared
flestolol (r_nsubj) produced
resulted (l_parataxis) had
events (l_amod) bleeding
induce (l_dobj) turnover
mechanism (l_nmod) hepatotoxicity
patients (l_acl:relcl) present
pericarditis (l_conj) glomerulonephritis
alcohol (r_nmod) ingestion
sites (r_nmod) evidence
etomidate (r_amod) administration
developed (r_advcl) developed
flushing (l_conj) hypotension
importance (l_nmod) pathogenesis
groups (l_conj) atrophy
finding (r_nsubj) account
ingestion (r_nmod) achieved
intact (r_xcomp) need
seizures (l_conj) damage
chlorpromazine-induced (r_amod) syndrome
led (l_nsubj) observation
given (r_dep) activities
acidosis (r_dobj) predisposed
initiating (l_dobj) treatment
barbiturate (r_compound) mechanism
monitored (l_nmod) detection
degree (l_nmod) anaemia
mediate (l_dobj) fibrosis
meth-induced (r_amod) hyperactivity
pathophysiology (l_nmod) disorders
deprivation (r_nmod) associated
mechanisms (l_nmod) toxicity
compare (l_conj) test
pain (r_conj) similar
verapamil (r_nsubj) shortened
treatment (r_nmod) necrotizing
respond (l_advcl) tumors
events (l_conj) stroke
elicited (l_dobj) proteinuria
haloperidol (r_nsubj) induced
b (r_nmod) associated
effect (r_nsubjpass) investigated
753 (r_nummod) dup
increased (l_conj) shortened
onset (l_nmod) arrhythmias
reductions (l_nmod) dyskinesias
treatment (r_nsubj) suppresses
treatment (l_nmod) hemorrhage
erp (l_conj) duration
sign (l_nmod) neurotoxicity
known (l_xcomp) cause
included (l_dobj) nausea
mitoxantrone (r_nmod) cyclophosphamide
iiib (l_conj) cancer
administration (r_nsubj) reduced
model (l_compound) catalepsy
admission (l_compound) trauma
caused (r_acl) syndrome
absorption (l_nmod) treatment
useful (l_advcl) attenuating
model (l_amod) pain-induced
reduce (l_dobj) toxicity
ptx (r_appos) picrotoxin
cocaine-associated (r_amod) pain
treated (l_nsubjpass) children
phenytoin (r_compound) medication
tremor (r_appos) incidence
attack (r_dobj) had
able (l_xcomp) attenuate
days (r_nmod:tmod) showed
d2 (r_nsubj) had
addition (l_nmod) docetaxel
mtx (r_appos) methotrexate
myocarditis (r_conj) multiforme
effects (l_amod) depressive
considered (l_conj) preferred
patient (l_nmod) thrombosis
cycloheximide (r_conj) chloramphenicol
steroids (r_nsubj) protect
arrhythmias (l_nmod) disease
diagnosis (l_nmod) siadh
levomepromazine-fluvoxamine (r_amod) treatment
allows (l_dobj) testing
mk-801 (r_compound) treatment
explain (l_dobj) disappearance
therapy (r_nmod) disease
model (r_dobj) =
dose (r_nmod) reduction
asa (r_nsubj) induces
steroid (r_compound) injection
noradrenaline-induced (r_amod) effect
mechanism (l_compound) hypersensitivity
potentiate (r_xcomp) shown
losartan (r_nsubj) prevent
treatment (l_dep) seizures/mo
antagonist (l_acl) used
acetate (r_dobj) prescribed
affinities (r_nmod) changes
remifentanil (r_compound) pretreatment
inhibition (r_nsubj) lead
valdecoxib (r_dobj) analyzing
insertion (l_conj) failure
reduce (l_nmod) infarction
use (r_nmod) moderate
doxorubicin (r_nmod) injections
producing (r_acl) model
dyskinesias (r_dobj) improving
mice (l_acl) leading
alpha-methyldopa (r_amod) hypotension
complications (r_nmod) literature
iopamidol (r_nmod) administration
duration (l_nmod) af
derivative (l_acl:relcl) elicit
methoxamine (r_nmod) effect
pretreatment (l_nmod) induction
presented (r_dep) present
mandates (l_nsubj) treatment
initiation (r_nmod) hypotension
receiving (l_dobj) course
benzylacyclouridine (r_nmod) ability
severity (l_nmod) constipation
protects (l_dobj) impairments
cc (r_nmod) complication
disappeared (r_conj) developed
oxytocin-induced (r_amod) hypotension
tolerability (l_nmod) combination
angiography (r_nmod) convulsion
cirrhosis (r_nmod) patient
thrombocytopenia (l_conj) thromboembolism
shown (l_xcomp) reduce
carbachol (r_conj) hexamethonium
dysfunction (l_appos) sd
cause (l_dobj) reversal
reduces (l_dobj) duration
effective (l_nmod) nodosum
deficient (r_xcomp) engineered
acetaminophen (r_nmod) preparations
effect (r_nsubjpass) determined
related (l_conj) considered
neuropathy (r_nsubj) rare
therapy (l_nmod) thrombophlebitis
octapeptide (r_conj) ester
patient (l_acl:relcl) developed
d2 (r_nmod) coadministration
vasopressin (r_nmod) role
characterized (l_nsubjpass) hypertension
remained (r_conj) due
eserine (r_conj) carbachol
related (l_nsubj) susceptibility
strategies (l_nmod) treatment
beginning (r_conj) extraction
survived (r_acl:relcl) those
setting (l_nmod) tma
receptor (r_compound) blocker
gluconate (r_nmod) administration
hypogonadism (l_conj) bromocriptine
steroids (r_nsubj) demonstrate
case (l_nmod) man
p-coumarate (r_appos) compound
related (l_nsubj) nephropathy
clonidine (r_nmod) effect
aminoglycoside-induced (r_amod) nephrotoxicity
patient (l_appos) presence
increase (r_nmod) reflected
administration (r_nmod) effect
aggravate (l_dobj) proteinuria
dermatitis (r_conj) tiopronin
hypotension (r_dobj) mediate
patient (l_amod) diabetic
inhibits (l_dobj) hyperemia
patient (l_amod) depressed
results (l_compound) aggregation
maximal (r_acl:relcl) mm
ka (r_nmod) comparison
ppa-induced (r_amod) hypertension
ketoconazole (r_nsubjpass) administered
hypothesis (l_nmod) involvement
factor (l_nmod) hemorrhage
mice (r_nmod) cells
l-dopa (r_nmod) influence
cd-832 (r_nmod) doses
quetiapine (r_nmod) akathisia
cisapride (r_conj) mm
lindane (r_nsubjpass) involved
severity (l_nmod) response
amlodipine (r_nmod) efficacy
measured (l_parataxis) higher
atenolol (r_nmod) doses
effect (l_nsubj) encephalopathy
leading (l_nmod) failure
phenytoin (r_nsubjpass) administered
pgi2 (r_conj) ngf
infants (r_nsubj) received
carboplatin (r_nsubjpass) reported
human (l_dep) pparalpha
damage (l_nsubj) disease
treatment (r_nmod) response
association (l_nmod) syndrome
metolachlor (r_nmod) association
administration (r_nmod) terminated
dcf (r_nsubj) continued
lethality (l_nmod) seizures
intakes (l_conj) risks
severe (l_conj) hyperkalemia
summarizes (l_advcl) alleviate
combination (r_nsubj) induced
phenylephrine (l_acl) treat
dose (r_nmod) observed
isoniazid (r_nmod) doses
tachycardia (r_nsubj) appears
seizure (l_nmod) failure
dyscrasias (l_appos) neutropenia
syndrome (l_acl:relcl) manifest
gemcitabine (r_conj) vinorelbine
doxorubicin (r_conj) sensitivity
infusion (r_nmod) prior
vinorelbine (r_nmod) trial
amphetamine (r_nsubjpass) administered
iso (r_compound) resistance
deterioration (l_nmod) performance
disease (r_nmod) cancers
ibuprofen (l_nmod) interaction
model (r_conj) model
evolution (l_compound) damage
picrotoxin (r_conj) n-methyl-d-aspartate
levodopa (r_nmod) interaction
abuse (r_nmod) associated
implicated (l_nmod) cause
trimethaphan (r_conj) e1
induced (r_acl) sedation
fluoxetine (r_nsubj) improves
events (l_conj) strokes
induced (r_acl) spasm
thromboembolism (l_dep) complication
droperidol-induced (r_amod) disturbance
vnb (r_nmod) evaluation
quantitation (l_nmod) abundance
pilocarpine (r_nmod) injection
apomorphine (r_compound) treatment
(phe)-induced (r_amod) hypertension
inhibition (r_appos) inactivation
potassium (r_nmod) corrected
midazolam (r_conj) diazepam
methylphenidate (r_compound) intake
infarcts (l_nmod) reticulata
clozapine (r_conj) olanzapine
involved (l_nmod) aspects
septal (l_conj) defects
agent (r_ccomp) fact
transplantation (l_nmod) failure
experience (l_dobj) reactions
phenytoin (r_nmod) administration
antagonized (l_nsubjpass) hypokalemia
scopolamine (r_nmod) induced
thrombosis (l_appos) hitt
had (l_dobj) hypersensitivity
quetiapine-induced (r_amod) neutropenia
nitrendipine-treated (r_conj) n
expression (l_nmod) model
disorder (l_nmod) transmission
occurs (l_nsubj) dysfunction
methadone (r_dobj) using
histamine (r_nmod) correlation
carriers (r_nmod) strains
coniine (r_nsubj) failed
3ma (r_appos) 3-methyladenine
account (l_nsubj) vasospasm
epilepticus (r_nmod) reticulata
dose (r_nmod) combination
modulates (l_dobj) injury
characterized (l_nmod) apnea
dextran (r_nmod) clearance
evidence (l_nmod) infection
produced (r_acl) amnesia
treatment (r_nmod) improvement
estradiol- (r_dep) therapy
correlation (r_nsubj) was
free (l_advmod) pain
patients (r_nsubj) presented
lindane (r_nsubj) organochlorine
best (r_advmod) explained
groups (r_nsubjpass) associated
effect (l_nmod) hypertension
thiol (r_compound) depletion
atazanavir (r_conj) amiodarone
magnitude (l_compound) pain
ethambutol (r_nsubj) neuropathy
search (l_nmod) literature
characterized (l_conj) resulted
withdrawal (r_nsubj) enabled
absence (l_nmod) glomerulosclerosis
morphine-induced (r_amod) seizures
patient (l_nmod) cirrhosis
drugs (r_nsubj) induced
include (l_nsubj) fields
was (l_nmod) terms
nik-247 (r_nsubj) drug
paclitaxel/carboplatin (r_compound) combination
lamivudine (r_nsubj) analogue
zidovudine-induced (r_amod) hepatitis
reduced (l_dobj) insufficiency
csseps (l_nmod) correlates
effects (l_nmod) depression
alpha-2b/ribavirin (r_conj) interferon
complications (r_nmod) achieved
pge2 (l_compound) oab
asa (r_appos) acid
augmentation (r_nmod) enhances
similar (l_nsubj) tensions
cross-tolerance (r_dobj) produced
child (l_nmod) leukaemia
levels (r_nmod) accompanied
relationship (r_nsubj) remains
contraceptive (r_amod) therapy
induced (r_acl) rats
accompanying (l_dobj) flush
cnsb002 (l_conj) combinations
injections (r_nsubj) attractive
dose (r_conj) infusion
resulted (l_nmod) responses
epipodophyllotoxin (r_compound) etoposide
abolished (l_nsubjpass) increases
degree (r_nmod) inappropriate
risk (l_compound) disease
lamivudine (r_nmod) administration
lometrexol (r_compound) pharmacokinetics
common (l_nsubj) impotence
abolishment (r_conj) hypokalemia
dose (r_dobj) receiving
attenuating (l_dobj) rigidity
role (l_nmod) poisoning
dexamethasone (r_dobj) given
exerting (l_dobj) protection
revealed (r_advcl) increased
moderate (l_nmod) symptoms
weakness (l_nmod) system
iso (r_compound) infusion
kindling (r_nmod) distinct
those (r_nmod) effects
reporting (l_nmod) syncope
arterial (l_dep) thromboemboli
mutants (l_appos) virus
phenothiazines (r_dobj) receiving
risk (l_nmod) hit
complicating (r_acl) nephrolithiasis
shown (l_conj) alleviate
mm (l_nmod) group
epinephrine (r_conj) emulsion
gentamicin-mediated (r_amod) nephropathy
dopamine (r_compound) neurons
areas (l_nmod) proliferation
% (l_conj) response
time (r_nsubj) short
serotonin-dopamine (r_amod) antagonist
cause (r_ccomp) is
participate (l_conj) mediate
appears (l_advcl) observed
mitoxantrone (r_nmod) treatment
subtype (r_nsubj) modulates
administered (l_nmod) part
injection (r_dep) pretreatment
led (l_nmod) absence
tacrolimus-associated (r_amod) tma
superior (l_nmod) prevention
rats (r_nsubj) developed
therapy (r_nmod) toxicity
boy (l_nmod) cardiomyopathy
administered (r_acl) that
results (l_dep) died
neurotoxicity (r_nmod) concerns
heroin (r_amod) dependence
proportion (r_nmod) occurred
ablation (r_nmod) tachycardia
attenuated (l_dobj) hyperthermia
chemotherapy (r_nmod) association
related (l_conj) appear
index (l_compound) sensitivity
affects (l_dobj) characteristics
remained (l_acomp) tremulous
flow (r_nsubjpass) measured
case (l_nmod) seizures
therapeutic (l_nmod:npmod) anti-cancer
beginning (r_advcl) developed
virus (r_dobj) investigate
cefonicid (r_dobj) receiving
activities (r_dobj) had
succimer (r_compound) treatment
advised (l_xcomp) prevent
patients (l_compound) disease
day (r_nmod) beginning
mothers (l_conj) immunity
considered (l_nsubjpass) cause
showed (l_dobj) necrosis
features (l_amod) psychotic
associated (r_acl) vasculitis
= (r_conj) was
caused (r_acl) deficits
experience (l_dobj) se
p (r_dobj) received
hepatomas (l_dep) lesions
rats (r_nmod) given
isoproterenol (r_compound) infarction
test (r_dep) performed
phase (l_amod) hypertrophic
atropine (r_conj) glycopyrrolate
pilocarpine-induced (r_amod) epilepsy
receptors (r_dobj) blocking
cancer (l_conj) disease
maintains (r_advcl) has
illustrates (l_advcl) presents
compared (l_nmod) those
agents (l_acl:relcl) alter
need (r_conj) promotes
administered (r_advcl) planned
receptors (r_nmod) stimulation
caffeine-induced (r_amod) anxiety
reverse (r_xcomp) failed
dysfunction (r_dobj) predict
oxytocin (r_compound) administration
effect (r_nsubjpass) tested
frequency (l_nmod) regurgitation
cardiotoxicity (l_conj) mortality
patients (l_nmod) hematuria
lack (r_nmod) disappearing
dexamethasone-containing (r_conj) bortezomib
analysed (l_conj) had
adriamycin-induced (r_amod) nephropathy
reducing (l_dobj) cardiotoxicity
ouabain-induced (r_amod) behavior
encephalopathy (r_nmod) consisted
prevent (l_dobj) induction
stroke (l_compound) rhabdomyolysis
antagonists (r_nsubj) induce
ratio (r_nmod) accompanied
patients (r_nmod) contributed
noradrenaline (r_nmod) infusion
revealed (l_nmod) diet-fed
reversed (l_conj) failed
acid (r_nsubjpass) associated
cytarabine (r_nmod) administration
trazodone (r_nsubj) that
restarted (l_nmod) degree
history (l_nmod) thrombosis
rhabdomyolysis (l_conj) failure
pretreatment (r_nsubj) produce
symptoms (l_nmod) neuropathy
complication (l_nmod) patients
dph (r_dobj) eliminating
s-(-)-et-126 (r_conj) scopolamine
affect (l_advcl) shortened
losartan (r_nmod) treatment
development (l_nmod) nephrosis
explanation (l_nsubj) mismatch
therapy (r_conj) effect
agonists (r_nmod) induced
development (l_nmod) complications
case (l_nmod) child
areas (l_nmod) hyperalgesia
neurotoxic (l_conj) similar
azt (r_compound) mice
corticosterone (r_compound) level
atp (r_nmod) value
increase (l_conj) change
disorientation (l_conj) irritability
therapy (l_conj) thrombosis
effect (r_nsubj) slower
dogs (r_nmod) administered
produce (l_nmod) hypotension
upper-extremity (r_dobj) developed
pneumonitis (l_appos) evidence
exceeds (l_compound) hemorrhage
modulating (l_dobj) hemorrhage
benefit (r_nmod) treatment
playing (l_dobj) role
myopathy (r_nmod) neuropathy
patients (r_nmod) thrombi
substitution (r_acl:relcl) cases
relationships (l_nmod) development
agent (r_nsubjpass) associated
potent (r_advcl) had
antidepressants (l_conj) incontinence
clotiazepam (r_nmod) administration
treating (l_dobj) outpatients
metoprolol (r_nmod) use
overdose (r_nmod) presenting
indicating (r_xcomp) occurred
changes (l_appos) aphasia
dose (r_dobj) using
effect (l_compound) af
prednisolone (r_nmod) dysfunction
presented (l_nmod) sensory
improved (l_advcl) induce
clonidine (r_nmod) responses
pj34 (r_nmod) deletion
argatroban (r_compound) life
activity (r_dobj) enhanced
propofol (r_nmod) compared
count (l_conj) thrombocytopenia
triamcinolone (r_conj) saline
staining (r_nmod) determined
ticlopidine (r_nmod) complication
prevent (r_acl) ability
nelarabine (r_amod) neurotoxicity
related (l_nmod) incidence
suxamethonium-induced (r_amod) arrest
effect (l_nmod) scopolamine
found (r_acl) those
form (l_amod) dystonic
suggests (l_ccomp) increase
corticosteroid (r_compound) use
injection (r_nmod) pain
reduction (r_nsubj) useful
propylthiouracil-associated (r_amod) hepatitis
produces (l_dobj) effects
gm-mediated (r_amod) nephropathy
prolapse (l_acl:relcl) developed
methyldopa-induced (r_amod) anemia
monitoring (l_nmod) evidence
therapy (r_conj) groups
drug (l_nmod) treatment
proving (l_xcomp) effective
killed (l_nmod) toxicity
reversed (l_nsubjpass) ischemia
cocaine (r_nmod) induce
retention (l_conj) edema
model (l_nmod) amnesia
had (l_conj) absence
defined (l_nsubjpass) insufficiency
sevoflurane (r_compound) anaesthesia
mirtazapine (r_nmod) discontinuation
have (l_dobj) anemia
carboplatin (r_nsubj) influenced
linezolid (r_nmod) drugs
duration (r_conj) rate
quinine (r_nmod) administration
have (l_dobj) ability
creatinine (r_nsubjpass) observed
case (l_nmod) syndrome
appeared (l_nsubj) movements
effect (l_nsubj) bleeding
mannitol (r_nmod) receiving
mesna (r_compound) series
males (l_nmod) diagnostic
density (l_conj) increased
replaced (l_nmod) sirolimus
reflected (l_nsubj) latency
gem (r_nmod) combination
effects (r_nsubjpass) noted
content (r_nsubj) alleviate
nicotine (r_nsubj) appear
cis-ra (r_appos) acid
thrombocytopenia (l_conj) reactions
groups (l_amod) nephropathy
memantine (r_nmod) treatment
cyclophosphamide (r_nmod) combination
infants (r_nmod) disease
halothane (r_nmod) effects
eyes (r_nmod) %
suppressed (l_ccomp) startle
models (l_nmod) pain
potassium (r_nmod) changes
use (r_conj) identify
cp (r_appos) cyclophosphamide
decrease (l_nmod) pressure
treated (l_nmod) injection
failure (l_nmod) therapy
system (r_nsubjpass) implicated
female (r_nmod) observed
antagonist (l_nmod) models
suffering (l_nmod) polydipsia
protective (l_nmod) seizures
phenobarbital (r_amod) administration
consider (l_dobj) asterixis
tizanidine (r_nmod) interaction
moderate (l_nmod) nausea
contributes (l_nmod) dysfunction
ocs (r_nmod) relative
rats (r_nmod) kidneys
supersensitivity (r_dobj) inducing
mitoxantrone (r_nmod) treated
loss (l_nmod) sensation
addition (r_nsubj) reversed
vulnerable (l_nmod) model
fluorouracil (r_dep) vindesine
using (r_acl) risks
concentration (r_nsubj) correlates
case (l_nmod) hepatitis
treated (l_nsubjpass) man
elicited (l_nmod) changes
54 (l_nmod) disease
caffeine (r_compound) toxicity
nr1(neo-/- (r_appos) mice
azt (r_nsubj) induced
carbamazepine-induced (r_conj) phenobarbitone-
aes (l_appos) symptoms
development (l_nmod) hypertrophy
age (l_conj) number
outcome (r_nmod) case
pdn (r_nmod) exposure
produce (l_dobj) arthrogryposis
cases (l_nmod) hepatitis
clozapine (r_nmod) associated
significant (r_conj) observed
efficacy (l_nmod) nsclc
beta-carboline-3-carboxylate (r_nmod) injection
ifosfamide (l_acl:relcl) develop
summary (l_dep) developed
reducing (r_advcl) resolved
duration (l_nmod) catalepsy
reduce (l_dobj) pain
amplitude (l_nmod) patients
use (r_conj) had
sealants (r_nmod) application
nephrotoxicity (l_conj) cardiotoxicity
edrophonium (r_nmod) min
development (l_nmod) epilepticus
seizures (r_nmod) case
chloramphenicol (r_nmod) administration
sphincter (r_nmod) effect
capsaicin (r_compound) yield
flurbiprofen (l_nmod) treatment
effects (r_dobj) evaluate
induced (r_amod) convulsions
nimesulide (r_nmod) procedure
testosterone (r_compound) administration
relapse (l_nmod) hepatitis
induced (r_acl) dementia
methyldopa (r_nmod) effect
procyclidine (r_nmod) efficacious
cause (l_dobj) cancer
benztropine (l_nmod) treatment
myocarditis (l_dep) emphasis
penicillins (r_appos) conclusions
edema (l_conj) nausea
used (l_nsubjpass) hypotension
mk-801 (r_nmod) effect
withdrawal (r_nmod) resolution
failure (r_nmod) resulted
verapamil (r_nmod) therapy
strophanthidin-induced (r_amod) arrhythmias
morphine (r_conj) antagonists
reduction (r_nmod) offset
developing (l_dobj) lids
administration (r_nmod) failure
dopamine-1 (r_compound) agonist
exacerbation (l_nmod) schizophrenia
solution (r_conj) caffeine
starting (r_advcl) had
sirolimus-based (r_amod) immunosuppression
experienced (l_dobj) attack
thorazine (r_dobj) receiving
injection (r_nmod) allodynia
elavil (r_conj) aventyl
hva (r_conj) dopamine
treatment (l_nmod) relapsed
radiotherapy (l_nmod) glioblastoma
adenosine (r_nmod) time
findings (l_nmod) baby
drug (r_nmod) assays
manifestation (l_nsubj) myocarditis
decreased (l_xcomp) cranial
interrupted (l_nmod) appearance
individuals (r_nmod) use
haloperidol (r_compound) catalepsy
no (r_compound) metabolites
heparin (r_compound) exposure
amikacin (r_compound) concentrations
properties (r_nmod) consequence
phosphorus (r_compound) poisoning
subthalamotomy (r_nmod) had
total (l_nmod) transplants
patients (l_nmod) erythematosus
edema (l_nmod) core
received (r_conj) function
safety (r_dobj) supports
carcinoma (l_nmod) pelvis
support (l_nmod) patients
isosorbide (r_compound) nitrate
injection (r_nsubj) affect
ic (l_nmod) catalepsy
used (l_conj) used
attention (l_nmod) patients
paradigm (l_nmod) depression
result (r_nmod) occurred
stability (r_dobj) decreased
meningitis (r_nmod) bacteremia
stz (r_nsubj) increased
associated (l_conj) cases
treat (l_dobj) symptoms
was (l_advcl) either
pulses (r_nmod) means
syndrome (l_conj) disease
l-sotalol (r_nsubj) identify
withdrawal (r_nmod) led
response (r_nsubjpass) lost
setting (l_nmod) mi
regimens (r_nmod) alternative
therapy (r_conj) sodium
trial (r_nsubj) found
study (r_nmod) found
dysfunction (l_conj) injury
cholesterol (r_compound) level
cc (r_nmod) complications
intensity (l_compound) migraineurs
paclitaxel (l_conj) acid
cya (r_nmod) related
antagonist (r_appos) acid
using (l_nmod) standard
saline (r_nmod) doses
methscopolamine (r_nsubj) had
fibrillation (r_conj) form
patients (l_nmod) fever
chloroquine-induced (r_amod) myopathy
cpa (r_appos) acetate
correlation (r_nsubjpass) found
dyskinesia (r_nmod) patients
isoniazid (r_nsubj) agent
become (l_acomp) hypercalcemic
patients (r_dep) groups
streptozotocin (r_conj) vincristine
related (l_amod) cardiomyopathy
obstructive (l_conj) apnoea
globulin (l_nmod) treatment
cisapride-diltiazem (r_amod) interaction
leading (r_advcl) unconjugated
received (l_conj) presented
sulphasalazine (r_nmod) treatment
protect (l_nmod) toxicity
type (l_nmod) arteritis
treatment (l_nmod) variety
patients (r_nmod) diagnosis
sensitization (l_nmod) convulsions
effect (l_nmod) proteinuria
paclitaxel/cisplatin (r_compound) combination
rats (r_nmod) livers
score (l_compound) arrhythmia
bouts (l_nmod) angio-oedema
epirubicin (r_nmod) chemotherapy
methamphetamine (r_compound) abusers
treatment (l_acl) implicated
resolved (r_conj) increased
lacks (l_parataxis) reported
patients (l_nmod) fhf
defined (l_nmod) infarction
antagonist (r_nmod) suggest
history (r_nmod) woman
determine (l_dobj) incidence
trial (l_nmod) psychosis
trials (r_nsubj) suggested
midazolam (r_appos) benzodiazepines
ergotamine/caffeine (r_dobj) preferred
receptors (r_conj) data
sodium (r_nmod) combination
lithium (r_nsubj) induces
alpha-methyldopa (r_nmod) effect
continued (r_advcl) resolved
efficacy (l_nmod) placebo
proteinuria (l_conj) dysfunction
amphotericin (r_nmod) failure
phenobarbitone-induced (r_amod) enlargement
group (l_compound) dysplasia
anemia (l_conj) syndrome
estrogen (r_nmod) caused
l-noarg (r_compound) treatment
retardation (l_nmod) tremors
had (l_dobj) responses
metronidazole (r_compound) toxicity
induced (r_acl) neuroblastoma
dysarthria (l_conj) tremor
gaba(a (r_compound) site
ptu (r_appos) carbimazole
patients (l_compound) tuberculosis
apnea (l_conj) nausea
rifampicin (r_nmod) failure
resulted (l_nmod) seizure
associated (r_acl) dermatitis
caused (l_conj) produced
thrombocytopenia (r_dobj) consider
associated (l_nmod) abortion
months (r_nmod) respond
phenacetin (r_nmod) comparison
tacrine (r_dep) inhibitors
had (r_ccomp) have
ii (r_nummod) drugs
administer (r_xcomp) led
known (l_ccomp) acquired
study (l_nmod) treatment
acetaminophen (r_nmod) that
sulfate (r_nmod) course
those (l_acl) transplanted
k (r_compound) warfarin
group (r_nmod) deaths
induced (r_amod) model
caused (l_dobj) proteinuria
metformin (r_nmod) pre-treatment
mesna (r_nmod) doses
tolerance (l_nmod) l-noarg
increase (r_nmod) induced
effective (l_advcl) decreasing
levels (r_nsubj) appropriate
dithiocarbamate (r_nsubj) protects
aware (l_nsubj) physicians
protect (l_nmod) neurotoxicity
association (r_conj) toxicity
csa (r_compound) nephrotoxicity
creatinine (r_compound) clearance
lithium (r_nmod) cessation
changes (r_nsubj) alter
discontinuation (r_nsubj) resulted
conversion (r_nsubj) ameliorates
mazindol (r_compound) dosage
morphine (r_nmod) effects
dex (r_conj) atorva
studies (l_acl) assessing
elicited (r_acl) convulsion
activity (l_nmod) lymphomas
thromboembolism (l_nmod) patients
dysfunction (r_nsubj) underlie
observed (l_nsubjpass) increase
carbamazepine (r_nsubjpass) used
iohexol (r_conj) iopromide
dexamethasone (r_nsubj) efficient
developed (l_dobj) paraplegia
verapamil (r_nmod) value
symptoms (l_nmod) hypotension
patient (l_nmod) abnormalities
ginsenosides (r_aux) failed
preventing (l_dobj) toxicity
bortezomib (r_nsubjpass) considered
properties (r_nmod) antibiotic
sec (r_dep) duration
remifentanil (r_nmod) pretreatment
occur (l_nsubj) cardiotoxicity
tolerated (l_nmod) headache
sertraline (r_conj) fluoxetine
induction (r_nmod) advantages
lesion (l_conj) neoplasm
susceptible (l_conj) dogs
interferon (r_compound) therapy
toxicity (r_nmod) induced
atenolol (r_nmod) beta-blocker
deduced (l_nmod) observations
doses (r_nsubj) lower
no (r_compound) synthesis
women (l_nmod) hypercholesterolemia
case (l_amod) encephalopathy
monitored (l_nsubjpass) nephrotoxicity
bromocriptine (r_nmod) treated
i1-receptor-mediated (l_dobj) hypotension
pentoxyifylline (r_nsubj) inhibit
use (l_nmod) angina
pressure (l_nmod) rats
cancer (l_appos) agc
urd-related (r_amod) toxicity
tiapride (l_nmod) movements
quinpirole (r_nsubj) decreased
treated (r_acl) n
longer (r_conj) prolonged
action (r_nsubj) prolong
induce (l_dobj) maha
screening (l_nmod) patients
dithiothreitol (r_nmod) treatment
use (l_conj) increase
ramipril (r_nmod) intake
kept (r_advcl) reduced
placebo (l_nmod) osteoarthritis
patients (l_compound) glioma
injecting (r_advcl) induced
establish (l_dobj) model
compound (r_nmod) attempt
azt (r_appos) 3'-azido-2',3'-deoxythymidine
precise (l_nsubj) frequency
followed (l_nmod) encephalopathy
coagulation (l_conj) coagulopathies
stages (r_nmod) patients
class (l_nmod) toxicity
microperfusion (r_nmod) induced
chemotherapy (r_nmod) result
h (l_compound) infarct
loss (l_nmod) consciousness
prevention (r_nmod) used
dimorphism (l_acl:relcl) causes
management (l_nmod) psp
dissolution (l_compound) stone
midazolam (r_compound) mg/kg
tolerance (l_nmod) pain
carbonate-induced (r_amod) hypercalcemia
occurred (l_nsubj) hypotension
patients (r_nmod) develop
glomerulosclerosis (l_acl) associated
clearance (r_nmod) provide
hepatitis (r_conj) patients
palpitation (l_conj) flushing
reported (l_nsubjpass) behaviors
patient (l_nmod) failure
levodopa-induced (r_amod) psychosis
o2- (r_appos) superoxide
oxygen (r_compound) demand
month (r_nmod) evident
infusion (r_nmod) efficacy
thresholds (r_dobj) seizure
4hne-protein (r_compound) adducts
nodules (l_conj) carcinomas
duct (l_conj) stones
fluconazole (r_dobj) suggests
toxicity (r_nmod) associated
cocaine-dependent (r_amod) sample
cross-react (l_nmod) a
medication (r_nsubj) cause
phenobarbital (r_dobj) containing
d-penicillamine (r_conj) case
ocs (r_appos) contraceptives
marked (l_advcl) administered
sulpiride (r_conj) fluphenazine
clonidine-suppressible (r_amod) binding
ouabain-induced (r_amod) tachycardias
receptor (r_nmod) antagonists
restores (l_dobj) impairment
reports (r_nsubj) infrequent
prevented (l_conj) reduced
oxide (r_nmod) type
hydrochloride (r_nsubjpass) discontinued
syndrome (l_conj) insufficiency
study (r_nmod) induced
terbinafine (r_nmod) course
5-fluorouracil (r_conj) cisplatinum
staining (l_conj) methods
neurons (r_nmod) cultures
nox (l_nmod) hypertension
subjected (l_nsubjpass) threshold
pilocarpine-induced (r_amod) seizure
ribavirin (r_compound) dosage
assigned (l_nsubjpass) weeks
secondary (l_nmod) cardiomyopathy
dicyclomine (r_conj) kg-1
inactivated (r_dep) alpha-tocopherol
changes (l_nmod) hepatocytes
prevented (l_dobj) hypertension
found (l_conj) found
lovastatin (r_nmod) reported
treatment (l_nmod) labor
evoked (r_acl) aggressiveness
haloperidol (r_nmod) impairment
lithium-pilocarpine (r_compound) model
analysis (l_nmod) ich
posaconazole (r_nmod) resolved
calcium (r_nmod) parameters
male (l_amod) hypothyroid
found (l_xcomp) safe
retarding (l_conj) protected
increased (l_dobj) susceptibility
case (l_nmod) injury
promote (l_dobj) af
re (r_dep) ginsenoside
site (r_nmod) agonist
sodium (r_compound) therapy
included (l_conj) included
captopril-induced (r_amod) failure
weeks (r_nsubj) caused
amphetamine-induced (r_amod) seizures
deposition (r_nmod) leading
injection (r_nmod) duration
described (l_nsubjpass) dysfunction
syndrome (l_nsubj) dysmenorrhea
patients (l_nmod) mania
haematological (l_dep) toxicity
factors (l_nmod) development
transplantation (l_nmod) myeloma
acid (r_conj) carbamazepine
returned (r_advcl) was
exposure (r_nmod) hepatitis
lead (r_amod) exposure
increases (l_nmod) patients
relationship (r_conj) coordination
lamivudine (r_conj) zidovudine
combinations (l_nmod) patients
cocaine (r_nmod) tendency
toxicity (l_nsubj) loss
aggressiveness (r_dobj) increased
man (l_nmod) infection
examined (l_xcomp) using
decrease (r_dep) randomized
penicillamine-induced (r_amod) disease
reduce (l_dobj) incidence
fk (r_dep) tacrolimus
target (r_nmod) treated
lidocaine (r_nmod) bolus
prostigmine-morphine-induced (r_amod) sphincter
application (r_dobj) sided
mpo-anca (r_nmod) appearance
% (r_conj) reported
fangchinoline (r_conj) tetrandrine
lithium-induced (r_amod) polyuria
inhibitor (r_nmod) treated
amsacrine (r_compound) ci-921
therapy (r_nsubjpass) continued
curcumin (r_nsubj) ameliorates
function (r_nmod) decrease
days (r_nmod) developed
symptomatology (l_amod) parkinsonian
amiodarone (r_nmod) managed
control (r_nmod) thresholds
prevalence (l_conj) associations
treatments (r_nmod) production
activity (l_nmod) types
showed (l_dobj) cardioprotection
animals (r_nmod) increased
clopidogrel (l_compound) fibrillation
severity (l_nmod) hematuria
substrate (l_acl:relcl) acts
micrograms (r_nmod) ability
exposed (r_acl) fetuses
influence (l_nmod) modulation
mannitol (r_nmod) use
infusion (l_acl) proving
useful (l_advcl) necessary
incidence (l_nmod) discontinuations
led (l_nmod) generation
model (l_nmod) dcm
sites (l_compound) calcification
circumstantial (l_nmod) regard
eyes (l_conj) effusion
levels (r_nmod) monitoring
occurred (l_nsubj) seizures
demonstrate (l_dobj) actions
outcome (l_nmod) stroke
cocaine-related (r_amod) pain
doxorubicin (r_nmod) induced
administration (r_nmod) resulting
insufficiency (l_conj) alkalosis
uncertain (l_nsubj) diagnosis
induced (r_acl) hyperactivity
appeared (r_acl:relcl) man
symptoms (l_nmod) patients
implicated (l_nmod) etiology
trial (l_acl:relcl) have
alleviated (l_dobj) amnesia
fed (r_conj) %
oxacillin (r_nmod) treated
therapy (l_compound) cancer
affects (l_conj) clear
groups (r_nmod) supplementary
girl (l_nmod) neuroblastoma
mirtazapine-associated (r_amod) syndrome
suppressed (r_conj) accelerated
development (l_compound) cancer
stimulated (l_nmod) use
mice (r_nmod) observed
dtic (r_appos) therapy
reported (l_nmod) glaucoma
doses (r_conj) decreased
started (l_conj) resolved
dose (r_xcomp) given
rofecoxib (l_punct) ,
administration (r_nsubj) protective
advise (l_dobj) patients
recurrence (l_nmod) re-resection
nitrendipine (r_nmod) treatment
different (l_nmod) mellitus
advantages (r_dobj) discuss
salicylate (r_compound) nephropathy
recovery (l_nmod) myopathy
retains (l_dobj) action
creatinine (r_conj) accompanied
hydroxyanisole (r_nmod) induced
acth (r_compound) fragments
side-effect (l_nsubj) cystitis
those (l_nmod) types
reproduced (l_nsubjpass) syndrome
discuss (r_conj) linking
zidovudine (r_nmod) toxicity
reports (l_nmod) exist
binding (r_nmod) result
correlation (l_nmod) injury
alfentanil (r_nmod) inhibition
net (r_nmod) down-regulation
paranoia (r_nsubj) remains
cohort (r_nmod) nephrotoxicity
users (r_nmod) 4.10
timolol (r_conj) placebo
ingestion (r_nmod) secondary
propylthiouracil (l_acl:relcl) developed
ca (r_compound) blockers
measure (l_nmod) seizures
regimen (r_nmod) fasciitis
ketoprofen (r_nmod) administration
gel (l_nmod) rate
score (r_nmod) lower
pilocarpine (r_nmod) observed
drug (l_amod) nephrotoxic
angina (l_conj) hypertension
linked (l_nmod) development
activates (r_advcl) consistent
increase (r_nmod) led
etoricoxib (r_dobj) received
treatment (l_nmod) vt
normal (r_advcl) presented
depression (l_appos) hypotension
evaluating (r_acl) trial
groups (r_nmod) prolonged
free (l_nmod) disease
pan (r_compound) rats
defect (r_nmod) caused
azidothymidine (r_compound) inhibition
deficits (l_conj) potential
contributed (l_nmod) haemorrhage
benzamide (r_compound) drugs
site (r_compound) antagonist
rare (l_nsubj) myopathy
inhibitors (r_nsubjpass) known
gentamicin (r_nmod) scavengers
concentration (r_dep) dynamics
lev (r_nmod) discontinuation
paralleling (r_advcl) produced
doxorubicin (r_compound) treatment
found (l_nsubjpass) delirium
pentobarbital-anesthetized (r_amod) dogs
case (l_nmod) woman
intraperitonealinjection (r_nmod) minutes
suxamethonium-induced (r_amod) stiffness
rats (l_compound) mi
demand (l_nmod) patients
used (l_nmod) transplantation
stimulated (l_conj) cause
dose (r_nmod) periods
dcf (r_nmod) comparison
possible (r_amod) dosage
dopamine (r_compound) fluphenazine
d (r_conj) warfarin
timolol (r_amod) 0.5%/12h
induced (l_nsubjpass) nephrosis
infants (r_nmod) formation
epinephrine (r_nmod) mg
antagonists (r_conj) facilitation
pretreatment (r_nsubj) abolished
impairment (r_conj) seizures
faint (r_advcl) attribute
man (l_acl:relcl) sustained
appearances (l_conj) radiation
patient (l_nmod) delay
diclofenac (r_conj) aggravated
coniine (r_nmod) caused
olanzapine (r_compound) treatment
testosterone (r_nmod) screened
asa (r_nsubjpass) administered
test (l_parataxis) substantiates
inhibitor (l_compound) calcification
occur (l_conj) described
associated (l_nsubjpass) increases
provided (r_acl) protection
increase (l_conj) factors
dyspepsia (l_acl:relcl) developed
ensued (l_nsubj) apnea
treatment (r_nmod) affected
acetate (r_nmod) safety
str (r_appos) strychnine
haloperidol (r_compound) rigidity
dependence (r_nmod) methadone
worsened (r_acl:relcl) impairment
hypotension (r_nmod) failure
acid (r_nmod) induced
hours (r_nmod) ceased
regimen (r_dobj) underwent
showed (r_conj) remained
failed (l_xcomp) protect
5967 (r_prep) 40
associated (l_nmod) %
disease (l_appos) nafld
mpep (r_nmod) rendered
mdma (r_nmod) use
indomethacin (r_nmod) dose
acetaminophen-induced (r_amod) hepatotoxicity
group (r_nmod) nausea
ethambutol (r_nsubjpass) used
plays (r_ccomp) suggest
nitric-oxide (r_amod) synthesis
pain (l_conj) thrombophlebitis
bromocriptine-induced (r_amod) hypotension
revealed (l_conj) revealed
suppresses (l_advcl) inducing
pb (r_compound) exposure
observed (l_nsubjpass) signs
predict (l_nsubj) alterations
dox (r_nmod) rats
therapy (r_nmod) course
difference (l_nmod) subjects
attenuated (l_xcomp) learning
suxamethonium (r_nmod) preparation
had (l_dep) prevented
parkinsonism (l_conj) akathisia
methamphetamine-elicited (r_amod) hyperthermia
drug (l_nmod) disease
known (l_nmod) bradycardia
5-fluorouracil (r_compound) infusion
benign (l_conj) lymphadenopathy
methoxyflurane (r_amod) anesthesia
mmc (r_dep) mg
marmoset (r_nsubjpass) used
stroke (r_conj) hypotheses
cocaine-induced (r_amod) convulsions
therapy (r_nmod) man
inhibited (l_nsubj) hyperprolactinemia
one (l_nsubj) dysfunction
alcohol-na (r_amod) seizure-prone
amlodipine (l_conj) dysguesia
antinociceptive (l_conj) constipating
were (l_attr) signs
developed (l_advcl) presented
propylthiouracil (r_nmod) caused
bemegride (r_conj) convulsions
attributed (l_nmod) loss
divided (l_nsubjpass) rats
tetrabenazine (r_conj) tiapride
case (l_acl:relcl) resulted
ouabain (r_nmod) administration
screening (l_nmod) medications
using (l_dobj) models
difluoromethylornithine (r_nmod) trial
diazepam (r_nmod) complications
non-users (r_nmod) seemed
effects (l_nmod) convulsions
reactivity (r_dobj) assess
vasoconstriction (r_nmod) play
prednisone (r_conj) acid
development (l_nmod) leukemia
polydipsia (l_conj) polyphagia
release (r_nsubj) provoke
b (r_conj) administration
induced (l_nmod) interval
preparations (r_nsubj) continue
amount (r_conj) asystole
rats (l_nmod) carcinoma
patient (l_compound) c
relief (l_nmod) headache
exhibit (l_dobj) properties
increase (l_conj) hematuria
damage (l_amod) seizure-associated
result (l_nmod) infarction
ganaxolone (r_conj) allopregnanolone
fluconazole (r_nmod) therapy
suspected (l_nsubjpass) myositis
recognized (l_dobj) effects
bumetanide (r_nsubj) diuretic
distinct (r_amod) mechanism
treatment (r_conj) reduction
amphetamine (r_compound) dose
related (l_nmod) dili
prevented (l_dobj) induction
activity (l_conj) profile
produced (l_dobj) profile
patients (r_nmod) complication
elevates (r_conj) causes
reversed (l_nsubj) pretreatment
nmda (r_nmod) doses
rats (r_nmod) heart
hydroxytyrosol (r_nsubj) improved
administered (r_acl) mu
androgens (r_nmod) role
produced (l_dobj) alterations
hyperprolactinemia (r_nmod) effects
died (l_nmod) rats
treated (l_nsubjpass) tumors
block (r_nmod) performance
carbamazepine (r_nmod) induced
disappeared (l_conj) seen
sah (r_nmod) underwent
allocated (l_nsubjpass) outpatients
affected (l_nsubjpass) sites
response (l_amod) hypercapnic
frequent (l_nsubj) complications
testosterone (r_nmod) treated
sulfate (r_nmod) blockade
containing (r_acl) ocs
regulation (l_nmod) angiogenesis
naproxen (r_compound) therapy
concluded (l_advcl) exerting
bradydysrhythmias (l_conj) seizures
trough (r_conj) cyclosporine-
symptoms (l_nmod) schizophrenic
toxicity (r_nsubjpass) explored
treatment (r_nmod) greater
prevented (l_dobj) rats
pparalpha (l_acl) expressed
interaction (r_nmod) associated
phases (r_appos) chemotherapy
catalyze (r_ccomp) observations
mechanisms (l_nmod) hypersensitivity
dox (r_compound) cardiotoxicity
results (l_appos) reported
pilocarpine-induced (r_amod) seizures
condition (l_compound) hypersensitivity
consistent (l_nmod) disorder
linezolid-induced (r_amod) optic
levodopa (r_nsubj) has
related (l_nmod) pph
different (l_nsubj) rate
treatment (r_nmod) occurred
decreased (l_dobj) catalepsy
providing (l_dobj) targets
induced (r_acl) anxiety
scheduled (r_acl:relcl) features
pathogenesis (l_nmod) apnea
seizures (l_conj) death
frequency (r_conj) therapy
prevalence (l_nmod) delirium
portion (r_dobj) include
response (l_nmod) rats
had (l_nmod) seizures
sumatriptan (r_nmod) use
examination (r_nsubj) revealed
examined (l_dobj) incidence
effect (r_nmod) induce
strokes (l_conj) death
conversion (r_nmod) protocols
steroids (r_nsubj) effective
bromocriptine (r_nmod) infarction
lamivudine (r_compound) monotherapy
appearance (l_nmod) syndromes
suppression (l_nmod) response
complication (r_nmod) spectrum
slow (l_dobj) progression
aconitine (r_nsubj) resulted
g (r_nmod) took
insecticide (l_nmod) effects
vomiting (l_conj) diarrhea
defined (l_nsubjpass) yield
treated (r_acl) inpatients
mice (r_nsubj) remained
oxide (r_compound) therapy
l-dopa (r_nmod) mediation
depression (l_nmod) attacks
fujimycine (r_conj) a
stones (r_nsubj) small
danazol (r_nmod) treatment
response (l_dep) vomiting
stz- (r_amod) impairment
dose (r_nmod) infarction
haloperidol-induced (r_amod) rigidity
diagnostic (l_nmod) disorders
drops (r_nmod) use
suffering (l_conj) polyuria
ameliorate (l_dobj) damage
agents (r_nmod) dog
lindane (r_nmod) effect
elucidate (l_dobj) role
resulted (l_nmod) bradycardia
causing (l_dobj) dyscrasias
provided (l_dobj) denominator
developed (l_conj) bore
expressed (l_nmod) cells
bolus (r_nsubj) provoked
netilmicin (r_nmod) occurred
accident (l_appos) cva
displayed (l_dobj) activity
gemcitabine (l_nmod) patients
larger (r_conj) similar
therapy (r_nsubj) represented
stopped (r_advcl) returned
has (l_conj) given
receptors (r_nmod) blockade
inability (l_acl) sleep
male (r_nsubj) presented
heroin (r_conj) methadone
patients (l_nmod) hyperprolactinemia
assessable (l_nmod) toxicity
plays (l_advcl) substantial
divided (l_nmod) ed50
fasting (r_acl) measures
examined (l_nsubjpass) effects
throat (r_conj) mouth
lindane (r_nmod) dose
curcumin (r_nsubj) has
warfarin-related (r_amod) haemorrhages
cd-832 (r_appos) antagonist
herbicides (l_dep) defects
reached (l_conj) associated
levodopa (r_compound) therapy
using (l_xcomp) differentiate
years (l_nmod) therapy
verapamil (r_compound) block
cases (l_nmod) carcinoma
ameliorated (l_nmod) hydroxytyrosol
treatment (l_nmod) lymphoma
paclitaxel-eluting (r_amod) stent
arrest (l_nmod) child
ich (l_conj) is/tia
benzodiazepines (r_conj) corticosteroids
reserpine-induced (r_amod) dyskinesia
influence (r_conj) influence
srl (r_nmod) associated
relationship (l_acl) seizure
compound (r_appos) dronedarone
caused (r_conj) attribute
pretreatment (r_nmod) related
ketamine (r_nmod) antagonists
characteristic (r_nmod) considered
investigate (r_xcomp) was
treat (l_dobj) epicondylitis
showed (l_conj) diagnosed
found (l_xcomp) affected
flutamide (r_conj) days
surgery (l_amod) cataract
caused (r_acl) damage
drugs (r_appos) purpose
interactions (r_nsubj) important
sirolimus (r_compound) therapy
totp (r_nmod) levels
emphasizes (r_conj) suggests
hormone (r_nsubj) modulate
associated (r_acl) hemorrhage
decrease (l_amod) but-relative
induced (r_acl) injury
transplantation (r_nmod) underwent
eliminating (l_dobj) hypercalcemias
levodopa (r_nmod) administration
therapy (r_nmod) years
evaluating (r_acl) study
exert (l_advcl) demonstrated
pretreatment (r_nsubj) produced
acetonide (r_compound) implants
therapy (r_nmod) considerations
chemotherapy (r_nmod) pretreated
injections (r_nmod) developing
agent (l_nmod) carcinoma
heparin-induced (r_amod) type
mg (r_dep) amisulpride
marker (l_nsubj) fever
tended (l_nsubj) cells
correlates (l_nmod) increase
cause (l_dobj) complications
relation (l_nmod) type
patients (l_acl) transplanted
staining (r_conj) voltammetry
dizziness (l_xcomp) progressing
produced (l_nsubjpass) bradycardia
characterized (l_nmod) pain
diltiazem (r_nmod) shared
cocaine-induced (r_amod) disorder
dextran (r_nmod) infusion
administration (r_nmod) observed
gamma-hch (r_nmod) induced
mask (l_dobj) bradycardia
thrombocytopenia (l_conj) anaemia
decreases (r_conj) promotes
epirubicin (r_nmod) treated
patient (r_nmod) amyloidosis
suppression (l_nmod) impairment
23390 (r_nummod) sch
hydroxyl (r_dobj) inactivated
transporter (r_compound) glut4
nimodipine (r_nsubj) useful
occurred (l_nsubj) nephrotoxicity
pac (r_appos) paclitaxel
decreasing (l_conj) produce
combination (r_nmod) result
monitoring (r_nsubj) predictive
decreased (l_dobj) hyperemia
conclude (l_conj) is
ribavirin (r_nmod) administration
occurring (r_acl) depressions
glyburide (r_compound) therapy
discontinuation (r_nmod) had
alcohol (r_conj) cocaine
result (l_nmod) supply
therapy (r_nsubj) reduces
found (l_nsubjpass) number
compliance (l_nmod) therapy
caused (l_dobj) activity
associated (l_nmod) concordance
resolved (r_acl:relcl) myopathy
sodium (r_conj) parameters
considered (l_nsubjpass) pain
acid (r_nmod) followed
produced (l_nsubjpass) injury
cocaine (r_nmod) concentrations
channels (r_dobj) blocks
tp (r_nmod) treated
terfenadine (r_dep) investigated
nisoldipine (r_nmod) properties
doxorubicin (r_compound) therapy
hydrochloride (r_compound) mg/min
had (l_dobj) ability
inhibitor (r_compound) treatment
presence (r_nmod) produced
overdose (r_nmod) demonstrate
treatment (r_nmod) important
used (r_acl:relcl) women
interactions (r_nsubj) caused
isoflurane (l_nmod) hypersensitivity
dynamics (r_dep) appear
improvements (l_nmod) response
study (r_dobj) report
d2 (r_nmod) effect
patients (l_compound) carcinoma
diazepam (r_nmod) associated
inhibited (l_dobj) catalepsy
changes (l_nmod) threshold
evaluated (r_appos) methods
phosphanilate (r_nsubjpass) evaluated
suppressant (r_amod) drugs
lithium-induced (r_amod) polydipsia
indinavir (r_compound) crystals
result (l_nmod) hyperkalaemia
due (l_nsubj) proteinuria
transplantable (l_nmod) carcinomas
role (l_nmod) agent
associated (l_nmod) paralysis
captopril (r_nmod) effect
dyskinesias (r_dobj) exhibit
associated (l_nmod) thrombocytopenia
containing (r_acl) drink
control (l_nmod) lesions
sedation (r_appos) test
pain (r_nmod) patients
changes (r_nsubj) factor
episodes (l_nmod) anuria
shortened (l_conj) accelerated
chloride (r_nsubj) dissociate
cardiotoxicity (l_conj) trial
adrenaline (r_dobj) giving
cocaine (r_nmod) induced
existence (r_dobj) suggest
irbesartan (r_nmod) trial
idiosyncrasy (r_dobj) represented
assess (r_xcomp) examined
shape (l_nmod) erythrocytes
detected (l_advcl) reported
mg/kg (r_advcl) capable
(bha)-induced (r_amod) tumorigenesis
attractive (l_nmod) hyperalgesia
metamizol (r_conj) morphine
effects (r_dobj) augment
patients (r_nmod) obstruction
methyldopa (r_nsubj) causes
onset (l_nmod) anuria
increase (l_nmod) infarction
patients (r_nmod) rate
episodes (l_amod) anginal
dosages (r_nmod) effects
patients (l_acl) infected
conjunction (r_nmod) compared
reduces (l_dobj) effect
serotonin (r_compound) inhibitors
concern (l_nmod) safety
severe (l_nsubj) headache
measured (l_nmod) sensitivity
challenged (l_nsubjpass) catalepsy
occurred (l_nsubj) paresthesia
acid (r_nmod) trial
vpa (r_nmod) treatment
rats (l_acl) resulting
estrogen (r_compound) carcinoma
microinjection (r_nsubj) elicits
hfde (r_appos) ether
doses (r_nmod) saline
secondary (r_xcomp) developed
prevention (l_nmod) nephropathy
overdose (r_nmod) precipitated
diagnosis (l_appos) bipolar
classical (r_compound) antipsychotics
pathophysiology (l_nmod) schizophrenia
metformin (r_nmod) initiation
reflexes (r_nmod) trigger
occurred (l_nsubj) hepatitis
azimilide (r_conj) dl-sotalol
morphine (r_compound) antinociception
carmofur (r_conj) leukoencephalopathy
regurgitation (l_conj) failure
complex (r_nmod) associated
investigate (r_xcomp) encouraged
alleviate (l_dobj) impairments
ritodrin-hcl (r_compound) infusion
ntg (r_nmod) caused
e (r_conj) cerruloplasmin
ameliorates (l_dobj) nephrotoxicity
ifosfamide (r_compound) nephropathy
amiodarone (r_nmod) usage
regulation (r_conj) attention
reported (r_advcl) hepatotoxicity
administration (r_nmod) loss
barrier/density (r_nsubjpass) found
metabolism (l_nmod) accumulation
scopolamine (r_nmod) impaired
uridine (r_nmod) concentrations
association (l_nmod) progression
monosaccharides (r_nmod) spared
relationship (r_appos) enlargement
presumed (r_acl) defects
thirsty (l_conj) polyuric
reversing (l_dobj) dysfunction
lesions (r_nmod) reduced
men (l_amod) hypertensive
infusion (r_nmod) support
rats (r_nmod) carcinogenesis
methimazole-associated (r_amod) necrosis
considered (l_nmod) adjuvant
control (l_amod) seizure
undergoing (l_dobj) lt
has (l_dobj) property
torsade (r_compound) pointes
induce (l_conj) increase
valproate (r_dobj) administered
gestation (l_nmod) malformations
dox (r_nmod) amount
cisplatin-based (r_amod) chemotherapy
group (r_nmod) worst
development (l_nmod) sclerosis
dihydrochloride (r_conj) effects
rocuronium (r_nmod) influence
tyrosine (r_compound) phosphatase
amiodarone (r_compound) treatment
carteolol (r_nsubj) inhibited
nsaid (l_dep) diclofenac
rb1 (r_conj) rg1
ribavirin (r_conj) weekly
response (r_nmod) event
acid (r_conj) cs
anemia (l_conj) neutropenia
sites (l_nmod) membrane
developed (l_dobj) prostatitis
inhibitor (r_nmod) induced
effects (l_nmod) bromocriptine
microinjection (r_nsubj) caused
therapy (r_dobj) prescribed
p (l_dep) reactions
episodes (l_amod) manic
conventional (r_nmod) randomized
ufh (r_appos) sodium
rats (l_amod) impaired
examined (l_dobj) risk
halts (l_dobj) toxicity
doca-salt (r_amod) hypertension
diminishing (l_nmod) result
led (l_conj) degeneration
girl (r_nmod) report
accompanied (r_advcl) received
group (r_nmod) loss
thioridazine (r_appos) mellaril
increases (l_dobj) aggressiveness
selective (l_nsubj) damage
administration (r_nmod) points
naproxen (r_conj) indomethacin
attenuates (l_conj) shows
test (r_dep) metabolism
presented (l_conj) review
type (r_conj) dosage
etomidate (r_nmod) induction
capsaicin (r_nmod) administration
to (l_conj) anemia-related
activation (l_conj) neuroinflammation
drugs (l_amod) neurotoxic
associated (l_nmod) pd
caffeine-free (r_compound) placebo
effect (l_amod) co-carcinogenic
rats (l_amod) non-diabetic
naproxen (r_nsubj) seemed
beta-carotene (r_conj) folate
carvedilol (r_nsubj) protects
ticlopidine-induced (r_amod) hepatitis
reduction (r_nmod) syndrome
tended (r_conj) failed
artery (l_appos) rats
rifampicin (r_nmod) reintroduction
shown (l_dobj) efficacy
combination (l_acl) treat
model (l_nmod) disease
milrinone (r_nmod) treatment
effects (l_amod) hypotensive
developed (l_dobj) encephalopathy
administered (l_nsubjpass) patient
attenuation (l_nmod) nephrotoxicity
aldosterone-sensitive (r_amod) serum-
tacrine (r_nsubj) induces
women (r_nmod) diagnosed
method (r_nsubjpass) compared
lindane (r_compound) administration
blocker (r_compound) therapy
cisplatin (r_compound) therapy
enhance (r_dep) conclusion
determine (l_advmod) nephropathy
clonazepam (r_compound) monotherapy
totp (r_nmod) had
responsiveness (r_nmod) correlations
myopathy (r_amod) recovers
administration (r_nmod) reported
case (l_nmod) death
starting (r_advcl) developed
dopamine-antagonistic (r_amod) capacity
provocation (r_nsubj) caused
adenocarcinomas (l_conj) most
decreased (r_conj) reversed
agonists (r_nmod) influenced
occurrence (l_nmod) death
d-ribose (r_nsubj) influence
decrease (l_nmod) pain
pb (l_acl:relcl) promotes
channels (r_nmod) activation
results (r_nsubj) encouraged
arb (r_appos) blocker
demonstrated (l_nmod) transplantable
exposure (r_nmod) case
reduce (r_conj) using
penicillamine (r_nmod) had
protection (l_nmod) cardiotoxicity
initiated (l_nmod) meningitis
enhanced (l_dobj) hyperactivity
region (r_nmod) decreases
160/12.5 (r_dep) val
characterized (r_acl) syndrome
myalgias (l_conj) pain
area (l_nmod) hyperalgesia
resolved (l_nsubj) epistaxis
doses (r_nmod) induced
prilocaine (r_dobj) receiving
receiving (r_acl) failure
patients (r_nmod) neurotoxicity
alcohol (r_compound) withdrawal
valproate (r_nmod) application
developed (l_dobj) di
levels (r_conj) cerruloplasmin
spironolactone (r_conj) treated
enhanced (l_dobj) latency
i.e. (l_nmod) epilepticus
children (l_amod) 1-infected
resulting (l_nmod) parkinsonism
doxil (r_appos) doxorubicin
wr242511 (r_nsubjpass) pursued
combination (r_nmod) use
treating (l_dobj) abuse
people (r_nmod) stroke
concentrations (r_nsubj) 1.9
clonidine (r_nmod) increased
affected (l_dobj) hypoactivity
blocker (r_compound) haloperidol
that (r_nmod) intermediate
includes (l_dobj) epidemics
lithium (r_nmod) substitution
administration (r_nsubj) enhanced
asa (r_nmod) malformations
treated (r_conj) developed
females (l_nmod) hypothyroidism
conclusions (l_ccomp) associated
vpa (r_conj) vpu
which (l_dep) nausea
treated (r_acl) proteinuria
extent (l_acl) inhibit
evaluated (r_ccomp) had
efficient (l_advcl) blocking
inflammation (l_nmod) vicinity
has (l_dobj) potential
induction (l_dep) relevance
concentrations (r_dobj) affect
weeks (r_nmod) treatment
weeks (l_nmod) clipping
detection (r_nmod) method
rapamycin (r_appos) administration
intoxication (r_nmod) palsy
use (l_nmod) thrombolysis
injection (r_nmod) radiolabelling
mimicking (l_dobj) formation
induced (l_advcl) titrating
pharmacodynamics (r_dobj) estimate
loss (l_conj) hypokalaemia
demonstrated (l_nmod) monotherapy
associated (l_nsubj) angioedema
patients (l_acl:relcl) sustained
fzp (r_nmod) doses
had (l_dobj) recurrence
relationship (r_dobj) indicates
clonidine (r_nmod) arrest
paracetamol (r_compound) overdose
amikacin (r_dep) conventional
confirming (r_xcomp) available
treated (r_acl:relcl) man
promote (l_dobj) atherosclerosis
injection (r_nmod) g
ropivacaine (r_nmod) doses
aniracetam (r_nmod) effects
ptz (r_appos) pentylenetrazol
modulators (r_nmod) all
cisplatin (r_conj) gemcitabine
ximelagatran (r_nsubjpass) found
hyponatremia (l_nmod) secretion
effects (r_dobj) underlying
acetazolamide-induced (r_amod) syndrome
provokes (l_xcomp) torsade
leads (l_nmod) pseudolithiasis
mg/kg/day (r_nmod) treated
5-ht (r_appos) serotonin
block (l_conj) estimate
bromocriptine (r_dobj) taking
augment (r_xcomp) reported
parameters (r_nsubjpass) compared
acetaminophen-induced (r_amod) failure
antagonists (r_nmod) blocked
causes (l_dobj) pattern
a (r_nmod) nephrotoxicity
35 (l_nmod) thrombosis
role (r_nmod) nephropathy
hepatotoxicity (r_conj) pancreatitis
observed (l_nmod) models
infusion (r_dobj) receiving
intolerant (r_amod) individuals
become (l_attr) factor
carries (l_dobj) risk
showed (l_conj) decreased
ph (r_dobj) adjust
hypoglycemia (l_conj) apnea
timolol (r_nmod) associated
imipramine (r_nmod) discontinuation
loss (l_conj) development
treat (l_dobj) infection
dystonia (r_nmod) case
disease (l_nmod) models
rifampicin-associated (r_amod) segmental
fluoxetine (r_dep) inhibitors
bradycardia (l_conj) failure
complaining (l_nmod) dysphonia
treatment (l_nmod) sinusitis
substitutes (r_nmod) used
theophylline (r_compound) use
led (l_advcl) resembling
showed (r_conj) found
channel (l_nsubj) site
dose (l_amod) fixed
presenting (r_nmod) patient
allowed (l_advcl) suggesting
serotonin (r_compound) gene
effect (r_nsubj) contribute
strategy (l_nmod) failure
inhibition (l_nmod) activation
depletion (r_conj) markers
received (l_conj) prevented
diabetic (r_amod) neuropathy
rats (r_nmod) administered
galactosamine (r_conj) ccl4
institution (r_nmod) myoclonic
bradycardia (l_conj) dysphagia
dose (r_nsubj) induces
suffering (l_nmod) epilepsy
enalapril (r_compound) treatment
developed (l_dobj) rash
(pan)-induced (r_punct) implicated
performed (l_nsubjpass) infusion
azt (r_appos) zidovudine
examine (l_dobj) effect
problematic (l_nsubj) anemia
methylxanthine (r_compound) derivative
terms (r_nmod) important
indicating (r_advcl) had
compared (l_nmod) victims
microphthalmos (l_dep) hypoplasia
levodopa (r_compound) effects
findings (l_nmod) cancer
administration (r_nmod) route
patient (r_nmod) occurred
channel (r_compound) overdose
blockade (r_nsubj) induce
trough (l_nsubj) convulsions
carcinoma (l_nmod) peritoneum
anthracyclines (r_nsubj) drugs
verapamil (r_nsubj) failed
developed (l_nsubj) summary
exhibited (l_dobj) increase
channel (r_compound) action
concentrations (r_dobj) had
apigenin (r_nsubj) prevent
inhibition (l_nmod) pathogenesis
% (r_nmod) cited
cause (l_dobj) hypocalcemia
hemolysis (r_nsubj) related
ouabain (r_compound) administration
developed (l_dobj) loss
hyperactivity (r_nmod) active
candidate (l_acl:relcl) characterized
treated (r_acl) cancer
maintained (r_conj) measured
benztropine (r_nmod:npmod) treated
effects (l_nmod) polyuria
levodopa-induced (r_amod) behaviors
piperacillin (r_dobj) removing
enalapril (r_nmod) assigned
ketoprofen (l_conj) function
related (l_xcomp) suggesting
patients (l_nmod) exacerbation
maintain (r_conj) achieve
oxcarbazepine (r_nmod) switched
aap-induced (r_amod) hepatitis
ml/kg (r_nmod) days
complication (l_advcl) benign
fk (r_nmod) effects
likely (r_conj) efficacious
k(+)-channels (r_nmod) blockade
400 (r_nummod) glycol
ephedrine (r_nmod) addition
has (l_dobj) drawbacks
salbutamol (r_nmod) therapy
manifestation (r_dep) hemiparesis
produce (l_dobj) toxicities
association (l_nmod) neuropathy
seizure (r_conj) present
bradykinesia (l_conj) rigidity
ineffective (l_advcl) preventing
pretreatment (r_conj) lesions
pressures (r_conj) ph
induced (l_nsubjpass) attacks
explained (r_acl:relcl) study
dexamethasone (r_nmod) effects
no (r_nmod) role
appears (l_dep) conclusion
combination (r_nmod) given
bha-induced (r_amod) hyperplasia
incidence (l_compound) tumor
oligodeoxynucleotide (r_appos) receptors
thioperamide (r_conj) (r)-alpha-methylhistamine
topiramate (r_nmod) effect
bn (r_appos) factor
subjects (l_amod) free
patients (r_nmod) features
decrease (l_conj) increase
gain (l_dobj) insights
levodopa (r_compound) administration
infections (l_conj) infections
substituted (l_nsubjpass) abnormalities
patients (l_nmod) cirrhosis
min (r_nmod) administration
models (l_compound) schizophrenia
caffeine (r_nsubjpass) used
hemorrhage (l_conj) stroke
treated (r_advcl) developed
atpase (r_conj) factor
similar (r_amod) condition
doses (r_nmod) seen
induction (r_dobj) involve
average (r_nmod) occurred
combination (r_conj) receive
clomipramine (r_compound) administration
ibuprofen (r_nmod) administration
aminoglycoside (l_acl) used
results (r_nmod) compared
men (l_nmod) hypertension
incidence (l_nmod) appearance
age (r_conj) included
seems (l_xcomp) cause
maleate (l_conj) placebo
five (l_nmod) pain
venlafaxine-tranylcypromine (r_compound) interaction
length (l_compound) af
behavior (r_dep) shake
inhibited (l_advcl) suggesting
n-nitroso-n-methylurea (r_nmod) treatments
improves (l_dobj) edema
pre-treatment (r_nsubj) attenuated
hcfcs (r_nsubj) result
pretreatment (r_nsubj) reverses
allowing (l_dobj) understanding
treatment (r_dobj) result
nephropathy (r_nmod) history
use (r_nmod) sought
product (r_nmod) response
progression (l_nmod) weakness
suspected (l_xcomp) cancer
levodopa (r_nsubj) drug
formation (l_nmod) osteoid
related (l_nmod) hypotension
taking (r_conj) revealed
amb (r_compound) treatment
arrhythmia (r_nmod) inhibition
relieve (l_nsubj) administration
considered (l_advcl) ascribing
iopentol (r_nmod) lower
mice (l_amod) immunodeficient
patients (l_amod) infected
prevent (l_dobj) hypokalemia
oestrogen (r_compound) therapy
% (r_nmod) occurred
reserpine (r_nsubj) produces
levetiracetam (r_nsubjpass) tolerated
prescribed (r_acl) persons
incidence (l_nmod) lidocaine
anthracycline (r_compound) doxorubicin
dysrhythmogenicity (l_nmod) dogs
thrombosis (l_nmod) ica
irradiation (l_nmod) disease
steroids (r_dobj) using
hyponatremia (l_nmod) hormone
selected (l_nmod) patients
hygiene (l_conj) caries
consequence (r_nmod) accompanied
ropivacaine (r_nmod) that
associated (l_nmod) return
smoking (r_nsubj) had
cells (l_compound) tumor
e (r_nmod) characteristics
resulted (l_nmod) male
bn (r_nmod) action
patient (r_nmod) use
bromocriptine (r_conj) saline
physicians (l_acl:relcl) use
theophylline (r_conj) 8-phenyltheophylline
anaesthesia (r_nmod) enhanced
treated (r_acl:relcl) scleroderma
12-week (r_nmod) participated
selegiline (r_nmod) therapy
terbutaline (l_nmod) asthma
low (l_nsubj) rate
netilmicin (r_nmod) reversible
related (r_nmod) case
appropriate (l_dep) alternatives
temocapril (r_nsubj) modulates
injections (r_nmod) previous
lead-exposed (r_amod) rats
haloperidol (r_acl) neuroleptics
growth (r_nmod) accelerated
induced (r_acl) state
lidocaine (l_dep) mg/kg
scopolamine (r_conj) scopolamine
received (l_dobj) globulin
suppressed (l_dobj) appearance
verapamil (r_compound) ablation
paracetamol (r_conj) phenacetin
indomethacin-induced (r_amod) hyperkalemia
reaction (l_nsubj) confusion
ias (r_compound) exposure
hour (r_dep) (
overdose (r_nmod) patients
studied (l_nsubjpass) courses
tpp (r_appos) pyrophosphate
therapy (r_nsubj) suppresses
betaxolol (r_nsubj) less
increase (r_nsubj) facilitated
ifosfamide (r_nmod) induced
amiodarone (r_amod) therapy
led (l_nmod) recurrence
rapamycin (r_compound) inhibitor
lamivudine (r_dobj) received
agent (l_conj) injury
supply (r_nmod) result
rats (r_nmod) regulation
associated (l_nmod) effects
4-aminopyridine-sensitive (r_conj) quinine-
patient (r_nmod) initiation
verapamil (r_nsubj) promoted
hyperalgesia (l_conj) allodynia
used (l_conj) increased
deficiency (r_nmod) associated
contribute (l_nmod) burden
considered (l_nsubjpass) lesions
history (l_nmod) reactions
injection (r_conj) sensitivity
cbz (r_nmod) combination
ulcers (l_nmod) rats
agent (r_nmod) treatment
model (l_nmod) diabetic
treatment (l_nmod) types
triphosphate (r_nmod) induced
pg-9 (r_compound) mg/kg
nitrazepam (r_amod) mg
99mtc-glucarate (l_nmod) detection
cisplatinum (r_nmod) combination
produced (l_dobj) calcification
intoxications (r_nmod) induces
group (r_nmod) lower
min (r_nmod) provided
dopamine (r_compound) outflow
incidence (l_nmod) myoclonia
encouraged (l_xcomp) investigate
estradiol (r_nmod) levels
provoked (l_dobj) crisis
msg (r_nmod) injections
responded (r_conj) worsened
enlargement (l_conj) tachycardia
antagonize (r_conj) induce
atorvastatin (r_nsubj) possesses
hernia (l_appos) dh
related (l_nmod) cardiotoxicity
optic (r_nmod) management
haloperidol (r_conj) climbing
given (r_advcl) developed
monotherapy (l_nmod) patients
reduces (l_nmod) disease
responded (l_nsubj) arrhythmias
pdtc (r_nmod) effect
a (r_nmod) administration
adenosine (r_compound) antagonist
scavenger (r_appos) alpha-tocopherol
pathophysiology (r_nsubj) antidepressant-induced
associated (r_acl) risk
channel (r_compound) retention
developed (l_dobj) leucopenia
deficits (l_conj) loss
creatinine (r_compound) levels
treatment (r_nsubj) blocked
screened (l_nmod) basis
tnfalpha (r_nmod) levels
anaesthesia (r_nmod) hypotensive
pindolol (r_conj) propranolol
observed (r_parataxis) showed
m (r_nmod) longer
increase (r_appos) ischemia
cisplatin (r_conj) paclitaxel
e-2020 (r_conj) tacrine
observed (l_nsubjpass) suppression
l-arginine (r_nmod) administration
standard (l_nmod) treatment
drugs (r_nsubjpass) given
dysfunction (r_nmod) areas
tp (r_appos) propionate
groups (l_acl) based
magnitude (r_nsubj) similar
physostigmine (r_nmod) attenuated
mdma-induced (r_amod) lesions
addition (r_nsubj) reduced
known (r_acl) agent
insufficiency (l_conj) hyperkalemia
rats (l_nmod) nephropathy
agent (l_appos) pneumonitis
bupivacaine (r_conj) ropivacaine
incidence (r_nmod) investigated
fluconazole-induced (r_amod) torsade
streptozotocin-induced (r_amod) mellitus
(na (r_nmod) affinities
tetracycline (r_nmod) induced
analgesia (r_dobj) improve
uses (r_conj) disorder
bupropion (l_nmod) dysfunction
fluoxetine (r_nmod) exposure
patients (r_dobj) evaluated
likely (r_conj) had
disappeared (l_nsubj) dysosmia
citalopram (r_nmod) treatment
modifications (l_nmod) wall
known (l_xcomp) have
induced (r_acl) patients
implications (l_nmod) management
iso (r_compound) treatment
group (r_nmod) assigned
back-diffusion (l_conj) permeability
thalidomide (r_dobj) using
studied (l_conj) reported
treated (r_acl:relcl) hypoparathyroidism
needed (l_advcl) reversible
rebound (l_dobj) hypertension
induced (r_acl) epilepticus
disorder (l_conj) psychoses
lenalidomide (r_nmod) efficacy
tobramycin (r_advcl) often
telaprevir (r_nmod) treated
retrieval (l_nmod) task
effects (l_nmod) tachycardia
doxorubicin (r_compound) nephrosis
arrhythmia (l_nmod) pvc
died (l_conj) exhibited
interview (l_nmod) psychosis
provide (l_dobj) model
rare (l_conj) is
cimetidine (r_nmod) doses
aconitine (r_nmod) cardiotoxicity
electrographic (r_amod) seizure
sirolimus (r_nmod) use
hypertension (r_nmod) effect
chloroquine (r_compound) retinopathy
likely (r_advcl) indicated
addition (l_advcl) experiencing
cpa/ee (r_dobj) taking
blockers (r_nsubj) prevented
s-limonene (r_nmod) effects
failure (l_conj) lesions
combined (r_acl) response
prevention (r_nmod) lamivudine
patients (l_amod) mono-infected
t-treated (r_amod) animals
administration (r_nmod) produced
started (l_xcomp) have
pethidine (r_nmod) seizure
occurred (l_nsubj) bradycardia
activity (r_nmod) accompanied
cromakalim (r_nmod) induced
adriamycin (r_nsubj) elicited
thiazide (r_compound) diuretics
cholesterol (r_compound) activity
pentylenetetrezol (r_nmod) dose
seems (r_conj) nephrotoxic
l-dopa (r_nsubj) enhances
function (r_conj) damage
complication (l_nsubj) toxicity
demonstrated (l_nmod) evidence
development (l_nmod) crf
% (l_dep) p<0.001
incidence (l_nmod) neurotoxicity
insecticide (r_appos) diazinon
tachycardia (r_conj) enlargement
headache (l_nmod) patients
therapy (r_nmod) associated
report (l_xcomp) resulting
treatment (r_dobj) restarting
rats (l_nmod) nephrosis
treated (r_acl) groups
relationship (r_nsubjpass) proved
synthase (r_nmod) expression
groups (r_dobj) combining
docetaxel (l_nmod) treatment
diphosphanilate (r_nmod) study
proteinuria (l_conj) aminoaciduria
therapy (r_nmod) hemolysis
infection (l_nmod) individuals
pilocarpine-treated (r_amod) group
corticosteroids (r_nsubjpass) used
encephalopathy (r_nmod) lesion
pyridoxine (r_nmod) withdrawal
group (l_nmod) addicts
treatment (l_nmod) patient
tests (r_nmod) results
val/hctz (r_nmod) therapies
depression (r_nmod) history
investigating (l_dobj) inflammation
effect (r_conj) protection
methamphetamine (r_compound) neurotoxicity
capsaicin (r_nmod) elicited
case (l_appos) jaw
diagnosis (l_nmod) hypertension
overdosages (r_nmod) volumetry
regimen (r_nmod) safety
suspected (l_conj) replaced
lsd (r_compound) consumption
channel (r_compound) blockers
reduction (l_nmod) intake
diagnosis (l_nmod) pneumonitis
haloperidol (r_dep) examined
repair (l_compound) tissue
estimate (r_xcomp) undertaken
system (l_nmod) damage
protocol (r_nmod) associated
dysfunction (r_nmod) contributes
risk (l_nmod) injury
antihyperalgesia (r_nmod) enhancement
factor (l_nmod) cystitis
model (l_compound) epilepsy
curcumin (r_nmod) effect
enhanced (l_nsubjpass) changes
respect (l_nmod) duration
spironolactone (r_nsubj) reduce
patients (r_nmod) difficult
hyperprolactinemia (l_conj) amenorrhea/galactorrhea
meth-induced (r_amod) patients
monkeys (r_nmod) study
microinjections (r_nmod) challenged
nitroglycerin (r_compound) application
investigated (r_ccomp) identified
neuroprotective (l_nmod) neurotoxicity
ventricular (r_conj) ligation-
increase (l_nmod) times
development (r_dobj) inhibited
suggests (l_dobj) relationship
known (l_nsubjpass) toxicity
ca(2 (r_compound) overload
carbachol (r_nmod) caused
erythromycins (r_conj) penicillins
counteracted (r_conj) prevented
associated (r_advcl) consisted
tetracycline (r_nmod) effects
produced (l_dobj) actions
using (r_xcomp) explore
nmda (r_compound) antibodies
recorded (l_nmod) occurrence
antagonizing (l_dobj) hypokalemia
see (l_ccomp) modified
treatment (l_nmod) pectoris
drugs (r_nmod) intake
methadone (r_dobj) receiving
rats (l_amod) dehydrated
patient (r_conj) summary
mice (r_nsubj) had
meth-induced (r_amod) deficits
duration (l_nmod) hallucinations
prevent (l_dobj) coma
5-fu (r_nmod) minutes
vinorelbine (r_nmod) therapy
models (l_compound) pain
ng-nitro-l-arginine (r_dep) rationale
presentation (l_conj) anxiety
5-ht (r_nmod) users
1-anisoyl-2-pyrrolidinone (r_appos) ro
model (l_nmod) nephropathy
indicating (l_dobj) activation
resulted (l_nmod) growth
concentration (r_nsubj) high
patient (r_nsubjpass) diagnosed
depression (l_appos) impulsiveness
morphine (r_compound) antihyperalgesia
effect (l_nsubj) nephrotoxicity
form (r_dobj) represents
induce (l_dobj) calcification
produce (l_dobj) hypotension
nmda (r_compound) activation
nortriptyline (r_appos) aventyl
(dex)-induced (r_amod) hypertension
rash (l_conj) aplasia
calcium (r_compound) channel
dyskinesias (r_conj) bradykinesia
effective (l_nmod) states
potassium (r_nmod) concentration
reduction (r_dobj) facilitate
metoclopramide (r_nmod) induced
consumed (r_acl:relcl) haemorrhage
amns (r_appos) puromycin-aminonucleoside
pretreatment (r_nsubj) affect
generation (r_nmod) sensitized
zidovudine (r_nsubj) triggers
than (r_prep) incidence
amp-activated (r_amod) kinase
deformations (r_nsubj) flexion
conclude (l_conj) mediates
indicate (l_ccomp) ranges
involved (l_nmod) development
rate (l_nmod) hemorrhage
data (l_nmod) patients
mtx (r_compound) neurotoxicity
oxidase (r_nmod) role
concentration (r_nsubj) reached
subjects (r_nmod) incidents
prilocaine (r_dobj) compares
ergotamine/caffeine (r_nmod) %
result (r_nmod) developed
chemotherapy (r_nmod) prediction
taking (r_conj) co-morbidity
cddp (r_nmod) caused
prevented (r_conj) affected
time (r_dobj) reverses
treatment (r_nmod) course
investigating (l_nmod) induction
effects (l_nmod) anxiety
showed (l_dobj) decrease
initiation (l_nmod) patient
reported (r_acl:relcl) properties
naloxazone (r_nmod) pretreatment
glutathione (r_nmod) change
conditions (l_conj) failure
morphine (r_nmod) attributed
wr242511 (r_appos) 5-(l-hexyloxy)-6-methoxy-4-methylquinoline
related (l_advmod) encephalopathy
tmp (r_appos) trimetaphan
induced (r_acl) amnesia
reduce (l_advcl) diminishing
likelihood (l_nmod) function
prompted (l_xcomp) conduct
pap (r_compound) nephrotoxicity
factor (l_conj) receptor
administration (l_nmod) adults
had (l_advcl) using
serotonin (r_conj) concentration
localization (l_nmod) antagonism
adriamycin (r_nmod) dose
fbal (r_compound) concentration
operating (l_nmod) granulomatosis
expression (l_nmod) seizures
rats (r_nmod) eighteen
groups (r_nmod) reduction
arabinoside (r_conj) it-methotrexate
women (r_nsubj) increased
overdose (r_nmod) production
desogestrel (r_conj) gestodene
causes (l_nsubj) dependency
manifested (l_nmod) serositis
associated (l_nmod) reductions
naproxen (r_nmod) necrosis
observations (r_nmod) line
folinic (r_amod) acid
sensitization (l_nmod) impairment
infants (r_nsubjpass) found
treatment (l_nmod) wounds
amiodarone (r_nmod) inability
developed (l_dobj) episode
occlusion (l_nmod) rats
high-dose (r_compound) therapy
initiated (l_conj) cause
those (r_nmod) fourfold
statin (r_nmod:npmod) induced
no-induced (r_amod) attack
b (r_nsubj) seems
ozone-sparing (r_amod) substitutes
seems (l_nsubj) hyperactivity
arteritis (r_nsubjpass) examined
characterized (l_nmod) hypertension
organs (r_nmod) necrosis
dihydropyridine (r_nsubj) controls
amphetamine (r_nmod) exhaustion
acidosis (r_dep) hepatitis
cause (r_conj) caused
dementia (l_compound) subacute
survivors (l_compound) se
succinylcholine (r_nmod) addition
formation (r_dobj) catalyze
hemorrhage (l_nmod) palsy
indomethacin (r_nmod) caused
relationship (r_dobj) demonstrate
cows (r_nmod) none
induced (r_acl) headache
displaying (l_dobj) effects
injected (l_conj) developed
behaviors (l_nmod) children
phenytoin (r_compound) treatment
leucovorin (r_nmod) treated
% (r_nsubj) experienced
loss (l_nmod) administration
no (r_det) deficiency
down (l_nmod) hypotension
increased (l_dobj) severity
pentazocine (r_compound) injection
rate (r_nmod) tachycardia
added (l_nsubj) encephalopathy
known (l_nmod) consequences
gr (r_dep) antagonist
aminonucleoside-induced (r_amod) dysfunction
relation (r_conj) assess
testosterone (r_nsubjpass) associated
triglyceride (r_nmod) %
shortened (l_dobj) occurrence
therapy (l_nmod) addiction
suppresses (l_conj) attenuates
trimethoprim (r_conj) persons
evaluated (l_nmod) disability
bevacizumab/irinotecan (r_nmod) treatment
effect (l_nsubj) myopathy
ribavirin (l_nmod) disease
group (r_dep) group
develop (l_dobj) neurotoxicity
estrogen (l_nmod) hypotension
acid (r_conj) acid
studied (l_nsubjpass) protection
treatment (l_nmod) contractions
patients (l_compound) aids
group (r_nmod) distinguish
ngf (r_nsubj) have
one (l_conj) other
3-methylcholanthrene (r_nmod) pretreatment
sulfate (r_nmod) effect
blocked (l_dobj) caffeine-
amifostine (r_appos) wr-2721
contraindication (r_nmod) those
accompanied (r_acl) levels
reduction (l_nmod) nephrotoxicity
rats (r_nmod) nephropathy
people (l_nmod) epilepsy
ip (r_nmod) influence
d-penicillamine (r_compound) compound
contributed (l_nmod) coagulopathy
paroxetine (r_nmod) treatment
older (r_conj) aged
induce (l_dobj) potentiation
elevations (l_conj) mucositis
smokers (r_nmod) seroconversion
jaundice (r_dep) hepatitis
administration (r_nmod) was
infusion (r_compound) pain
desogestrel (r_dep) third-generation
investigating (l_advcl) preventing
attenuate (l_dobj) proteinuria
tolerance (l_compound) pain
blocked (l_dobj) hyperactivity
gamma-vinyl-gaba (r_conj) isoniazid
5,7-dht (r_nmod) injection
block (l_nmod) patients
focus (l_nmod) di
represents (l_advmod) nephropathy
bd1018 (r_nmod) mice
showed (l_nmod) addition
protection (r_nsubj) afford
sensitivity (r_nsubjpass) determined
raise (r_acl) infusion
tacrolimus (r_appos) cyclosporine
associated (r_acl) myocarditis
cancer (l_conj) leukemia
inhibits (l_parataxis) evaluated
suffered (l_nmod) neutropenia
complications (l_nmod) confusion
motility (l_nmod) strains
evaluation (r_nmod) outcomes
serum (r_conj) dilevalol
lymphoma (l_conj) tumour
related (r_amod) block
haloperidol (l_conj) placebo
report (l_xcomp) intravitreal
effect (r_nsubj) myalgia
treatment (r_nmod) hypokalemia
evaluated (l_dobj) inhibitor
documented (l_nmod) models
pgi2 (r_nsubj) different
nimodipine (l_acl) administered
levodopa-induced (r_amod) movements
forms (l_nmod) hypertension
studies (r_nsubj) suggests
d-glucarate (r_nmod) obtained
animals (l_nmod) infarction
thrombosis (l_appos) dvt
propranolol (l_nmod) disease
neurophysiology (l_nmod) epilepsy
cisplatin-containing (r_amod) regimens
indicated (l_nsubjpass) studies
mechanism (r_nmod) contribute
developed (l_conj) became
evoked (l_advcl) evoked
use (l_nmod) age
estradiol (r_nmod) dependent
nsclc (r_nmod) patients
cisplatin (l_dep) e.g.
precipitated (l_nmod) patients
do (l_dobj) harm
use (r_conj) episodes
preventing (l_dobj) myoclonus
preceded (l_nsubjpass) hemolysis
effect (r_xcomp) appeared
(ee)-induced (l_dobj) cholestasis
reported (r_advcl) changed
patients (r_nmod) failure
ca2 (r_nsubj) causes
myopathy (r_nmod) recovery
deaths (l_amod) related
activity (l_nmod) toxicity
medication (l_conj) atrophy
hepatotoxicity (r_nsubj) is
treatment (r_nmod) related
isoproterenol-induced (r_amod) injury
signs (l_amod) indicative
s-53482 (r_nsubj) teratogenic
disturbance (r_nsubj) uncommon
lidocaine (r_nsubjpass) proven
ingestion (r_nmod) history
site (l_amod) responsible
misoprostol (r_compound) therapy
appears (l_xcomp) important
either (l_nmod) groups
latency (l_conj) rigidity
active (l_nmod) treatment
neonates (l_nmod) cases
levodopa (r_nmod) alleviating
fatal (r_amod) failure
carbimazole (r_nmod) cross-reactivity
stress (l_acl:relcl) promotes
valsartan (r_nsubj) effective
common (r_conj) reported
propranolol (r_nmod) pretreatment
decreased (l_nmod) nitroglycerin
associated (r_acl) arrest
remifentanil (r_nmod) administration
bupivacaine (r_compound) dose
trimethoprim-induced (r_amod) anemia
ethambutol (r_nmod) withdrawal
nephrotoxicity (r_nmod) induced
dexfenfluramine (r_conj) fenfluramine
risperidone (r_nmod) treated
bupivacaine-induced (r_amod) toxicity
atazanavir (r_conj) simvastatin
occurred (l_nmod) neuropathy
demonstrates (l_dobj) potential
tolazamide-induced (r_amod) wernicke
dysfunction (r_nmod) misoprostol
took (l_dobj) ibuprofen
induction (r_nmod) reduction
bicarbonate (r_compound) powders
growth (r_nsubj) enhance
succinylcholine (r_compound) administration
record (l_nmod) memory
effects (l_amod) cardiomyopathy
group (l_compound) myeloma
patients (l_nmod) mi
degree (l_advcl) fluctuating
users (r_nsubj) demonstrated
tended (l_xcomp) correct
elicited (l_nsubjpass) seizures
rats (l_acl) rendered
rapa (r_compound) levels
ulcer (l_nmod) rats
leukemia (r_nmod) patient
result (r_ccomp) concluded
sirolmus (r_nsubj) lacks
administration (r_nsubj) aggravate
tizanidine (r_nmod) initiation
isoproterenol (r_compound) ischemia
occurred (l_ccomp) occurred
hallucinations (l_acl:relcl) occur
detection (l_nmod) disease
thalidomide (r_nmod) combination
flaccid (l_conj) akinetic
induced (r_acl) hyperkalemia
prednisone (r_nmod) use
system (r_nmod) binding
patients (l_nmod) anemia
stimulated (l_nmod) zymosan
administration (r_nmod) dysrhythmogenicity
associated (r_acl) thromboembolism
produced (l_dobj) attenuation
infected (l_nmod) virus
experienced (l_dobj) diplopia
controlling (l_dobj) dyskinesias
marker (r_nmod) measure
5-fluorouracil (r_nsubj) therapies
nimodipine (r_compound) european
performed (l_xcomp) using
no (r_compound) activity
induced (l_nsubjpass) cystitis
meloxicam (r_nmod:npmod) related
q10 (r_compound) treatment
amiodarone (r_nmod) toxicity
replication (l_compound) b
phenylephrine-induced (r_amod) hypertension
metoprolol (r_nmod) effect
activity (r_conj) dehydrogenase
rats (r_nmod) dysfunction
lesion (l_appos) period
animals (r_nmod) none
reduced (l_nmod) hypotension
pb (r_nmod:npmod) treated
antioxidants (r_conj) dismutase
levetiracetam (r_nmod) induced
reversed (r_amod) hypotension
received (l_nmod) hypotension
patients (l_amod) seizure
behaviors (l_compound) pain
escalated (l_advcl) study
interact (r_xcomp) known
cases (l_nmod) scleroderma
cocaine (r_nsubj) factor
provoke (r_advcl) counteract
acid (l_conj) hydrocortisone
patient (l_nmod) hypoparathyroidism
bupivacaine-induced (r_amod) seizures
alkaloid (r_conj) cisplatin
fentanyl (r_nmod) dose
cm (r_compound) administration
associated (l_nmod) hypotension
suggests (r_conj) highlights
signs (l_nmod) fever
exhibiting (r_advcl) potent
concentration (r_nmod) correlation
expression (r_advcl) caused
diet (r_dobj) giving
gentamicin (r_conj) p
sodium (r_compound) excretion
provide (l_nsubj) delirium
dosage (l_amod) neurotoxic
demonstrating (l_nsubj) patient
observed (l_nsubjpass) reduction
cause (l_dobj) hemolysis
consumption (r_nmod) risk
deviation (l_amod) suggestive
suggested (l_xcomp) mimic
methadone-maintained (r_amod) abusers
morphine (r_conj) ketamine
, (l_dep) modifications
used (l_conj) defined
gtn (r_compound) infusion
aminophylline (r_nmod) effects
induced (r_acl) movements
thalidomide (r_conj) thromboembolism
% (l_nmod) patients
crude (l_nmod) events
lack (r_nmod) myopathy
sulfasalazine-induced (r_amod) erythematosus
angiogenesis (l_compound) tumor
metabolites (r_nmod) excretion
benzodiazepine (r_compound) flumazenil
acid (r_nsubj) retains
enflurane (r_appos) patient
prior (l_nmod) fibrillation
similar (l_nsubj) magnitude
decrease (l_dobj) events
using (l_nmod) anesthesia
associated (r_acl) myopathy
inhibits (l_dobj) incidence
reports (l_nmod) patients
case (l_nmod) incontinence
carboplatin (l_nmod) treatment
case (r_nsubj) demonstrates
reductase (r_compound) activities
manifested (l_nmod) hypotension
investigated (l_nmod) rats
chlorthalidone (r_appos) diuretic
withdrawal (l_nmod) woman
increase (r_nsubj) predictive
increase (l_nmod) sensitivity
iodixanol (r_nsubjpass) used
improved (l_dobj) dysfunction
initiation (r_nmod) frequencies
carteolol (r_nsubj) improves
5 (l_dep) that
removing (r_advcl) inefficient
activation (r_nsubj) contributes
cancer (l_conj) cancer
stimulation (r_compound) test
anti-cocaine (r_amod) effects
morphine-hc1 (r_nmod) mg/kg
aconitine (r_compound) poisoning
applied (l_nsubjpass) pain
tests (r_conj) plate
use (r_nmod) resulted
development (l_nmod) disease
effect (r_nsubjpass) observed
received (r_conj) enrolled
rg1 (r_nsubj) restores
beta-carboline (r_nmod) mg/kg
followed (l_nmod) leukopenia
injection (r_nsubj) decreased
rigidity (l_conj) hypotension
lenalidomide (r_appos) agent
mechanism (l_acl) underlying
modulating (l_dobj) neurotoxicity
moderate (r_nsubjpass) recognized
blockage (r_nsubj) restore
% (r_nmod) generation
lsd (r_compound) abuse
use (l_nmod) patients
suggest (l_ccomp) associated
syndrome (l_conj) microangiopathy
ethanol (r_conj) pb
ce (r_nmod) role
blocker (r_nmod) months
characterized (l_nmod) insufficiency
task (l_acl) induced
estrogen (r_nmod) dose
use (r_nmod) delirium
mtx (r_compound) administration
risperidone (r_nmod) monotherapy
hyperkalemia (l_nmod) patients
prolongation (l_conj) reporting
appeared (l_nsubj) seizure
effect (l_conj) outcome
iso (r_amod) infarction
doxorubicin (r_dep) myocet
ribavirin (r_nmod) dose
monitored (l_advcl) occur
risks (l_nmod) mortality
administration (r_nmod) anuria
activity (r_nsubjpass) modified
fentanyl (r_nmod) induction
preceded (l_nmod) thrombocytopenia
important (l_nmod) terms
result (r_nmod) decrease
history (l_nmod) abuse
determined (l_nmod) min
evidence (l_nmod) relation
calcium (r_compound) atpase
lindane-induced (r_amod) epilepsy
use (l_conj) association
iopromide (r_advmod) determined
number (l_conj) size
caused (r_acl) those
treatment (r_nmod) suffered
parkinsonism (r_nmod) types
pointes (r_nmod) torsades
developed (l_dobj) hyperkalemia
doses (r_nsubj) produce
conducted (l_dobj) analysis
overdose (r_nmod) induced
patients (r_nmod) pointes
documents (l_dobj) occurrence
patient (r_nmod) resulted
seizures (l_nmod) patient
mechanism (l_nmod) levels
antagonizes (l_dobj) dysrhythmogenicity
abuse (r_dobj) linked
rats (l_acl) bearing
p (r_dep) %
was (r_advcl) is
flourouracil-induced (r_amod) syndrome
superior (l_nmod) proportions
studied (l_dobj) patients
value (r_conj) sex
effect (l_nmod) reduction
capsaicin (r_nsubj) induced
phosphokinase (r_compound) isoenzymes
consider (l_dobj) risk
neutrophils (l_acl) stimulated
suggesting (l_ccomp) contribute
iron (r_compound) overload
cck-8 (r_nsubj) attenuates
drug (l_nmod) cardioversion
accompanied (l_nmod) bradycardia
content (r_nsubj) decreased
lidocaine (r_appos) lignocaine
phenacetin (r_nsubj) contribute
strychnine (r_conj) acid
amiodarone (l_nmod) animals
symptoms (l_nmod) anaphylaxis
man (l_nmod) glomerulosclerosis
treatment (r_nsubj) induce
users (r_nmod) users
induced (l_nsubjpass) epilepticus
prior (r_amod) administration
absence (l_nmod) toxicity
tobramycin (r_nsubjpass) given
compared (l_nsubjpass) incidence
worsening (r_dobj) shown
chloroquine (r_compound) discontinuation
associated (l_nmod) features
onset (l_nmod) hypothyroidism
sites (l_nmod) mice
% (l_compound) volume
adr (r_compound) nephropathy
tolerated (r_acl:relcl) patients
were (l_xcomp) reflecting
associated (l_advcl) developing
male (l_acl:relcl) taking
muscimol-induced (r_amod) jerks
odds (l_nmod) syncope
kidney (l_conj) insufficiency
sirolimus (l_conj) acidosis
reaction (l_nsubj) thrombocytopenia
dobutamine (r_amod) studies
evaluate (l_dobj) risk
assays (r_nmod) collected
gentamicin (r_conj) tobramycin
chloroquine (r_compound) therapy
improvements (l_nmod) functions
developing (l_dobj) cad
testosterone (r_dobj) determining
bort-dex (r_nsubj) treatment
induced (r_acl) arteritis
infusion (r_conj) day
sulfate (r_compound) therapy
decrease (l_conj) besides
seizures (l_amod) convulsive
doxorubicin-induced (r_amod) failure
gamma-hexachlorocyclohexane (r_nmod) effects
effects (r_conj) thrombocytopenia
ephedrine (r_nmod) doses
increase (r_acl:relcl) drugs
examine (l_ccomp) become
dogs (l_nmod) failure
alcohol (r_nmod) consumers
states (l_compound) hypersensitivity
prevents (l_dobj) deficits
received (l_xcomp) convert
tam (r_appos) tamoxifen
warfarin (r_compound) treatment
users (r_conj) prevalence
sensitive (r_acl:relcl) patients
results (r_dep) increased
drug (l_nmod) fibrillation
antagonists (r_nsubj) effective
effect (l_nsubj) neutropenia
propofol (r_nmod) combination
biperiden (r_nmod) bradycardia
treatment (r_nsubj) had
worsened (l_ccomp) resolving
improving (l_nmod) toxicity
treated (l_nsubjpass) seizures
isoflurane (r_conj) halothane
phenotype (l_amod) hemorrhagic
increase (l_dobj) strokes
caffeine (r_nmod) sensitive
mg (r_compound) tablet
activities (r_nmod) quantified
induced (l_dobj) hepatotoxicity
ammonia (r_amod) coma
deterioration (l_conj) phenomena
response (l_nmod) boy
epidemiology (l_nmod) infections
frequency (l_nmod) hematuria
l-dopa (r_dobj) receiving
glomerulosclerosis (r_nmod) progression
necrotizing (l_dobj) glomerulonephritis
designed (r_conj) seems
distribution (r_dobj) altering
pan (r_compound) nephrosis
concentrations (r_nsubj) had
suggesting (l_ccomp) control
presented (l_dobj) proteinuria
assessed (l_nsubjpass) patients
high-dose (r_amod) chemotherapy
order (l_acl) block
mangiferin (r_nmod) role
oxygen (r_nmod) flow
ribavirin (r_nmod) prodrug
mechanism (l_nmod) hemolysis
tacrolimus (r_nmod) triggered
furosemide (r_nsubj) deleterious
concentrations (r_dobj) containing
resulted (l_nmod) decline
naloxone (r_nmod) differences
present (l_nsubj) behaviors
vehicle- (r_nmod) identified
pentylenetrazol (r_nmod) seizure
hyperreactivity (r_conj) associated
combination (r_nsubj) facilitated
administered (l_nmod) agent
fs (r_nsubj) caused
combination (r_nmod) prescribed
linked (l_nmod) hemorrhage
vgb (r_nmod) associated
scopolamine (r_nsubj) reversed
toxicity (r_dobj) reduced
pyridoxine (r_amod) deficiency
observed (r_acl) window
trazodone (r_nsubj) induce
interaction (r_dobj) showing
patients (l_compound) mm
myositis (l_nmod) patient
anthracycline (r_compound) cardiotoxicity
patterns (r_nmod) distinguish
azelastine (l_conj) chlorpheniramine
bupropion (r_compound) sustained-release
lysine (r_conj) nicergoline
unchanged (r_conj) increased
placebo (l_nmod) days
determinant (l_nmod) gc-ht
comparison (l_conj) arrhythmias
receptor (r_nsubjpass) implicated
determine (l_xcomp) prevent
botox (r_compound) dose
provoke (l_dobj) migraine
therapy (r_nmod) received
produces (l_dobj) convulsions
infusion (r_dobj) received
toxicities (r_appos) cisplatin
had (r_conj) older
kinase (r_nmod) activation
paracetamol (r_conj) nimesulide
association (r_nmod) suggestion
headache (l_nmod) one
pre-treatment (r_nsubj) affected
blocker (r_nmod) discontinuation
gaba-mediated (r_amod) inhibition
induced (r_acl) arrhythmia
rats (l_conj) hernia
pac (r_nmod) neurotoxicity
nicotine (r_nmod) binding
hypotension (r_dep) observed
remained (l_conj) showed
minutes (l_appos) minutes
nicotine (r_nmod) induced
diuretic (r_nmod) treatment
preparations (r_nmod) users
morphine (r_nmod) synergy
sensations (l_conj) mastitis
highlighting (r_acl) patient
recording (l_nmod) protection
contribute (l_nmod) cells
administration (l_conj) syndrome
act (l_nmod) level
patients (l_amod) (hiv)-infected
patient (l_compound) apl
bha (r_compound) carcinogenesis
angiotensin (r_compound) system
bia (r_dep) acetate
induced (r_acl) failure
lithium-induced (r_amod) di
effects (l_nmod) thrombocytopenia
women (r_nmod) hypertriglyceridaemia
administration (l_nmod) prostaglandins
control (l_conj) regulation
low (r_conj) impaired
delineated (l_nsubj) foci
gamma-carboxylated (r_ccomp) showed
arrest (l_dobj) labor
develop (l_nsubj) rats
thalidomide (r_nsubj) limited
exposure (r_nsubj) predict
was (l_attr) suggestion
muscimol-induced (r_amod) myoclonus
catalyze (l_conj) attenuate
cyclosporine (r_nmod) recipients
stimulation (l_nmod) dogs
quality (l_appos) oab
patients (l_compound) cancer
intake (r_nmod) addition
enzyme (r_nmod) inhibitor
ax (r_nmod) reaction
azathioprine (r_compound) treatment
preserves (l_nmod) ndi
ocs (r_conj) third-generation
episodes (l_amod) hypercalcemic
start (l_nmod) hypotension
treatment (l_nmod) vasospasm
has (l_conj) managed
glutamate (l_dobj) fails
lt (l_nmod) alf
artesunate (r_nmod) treatment
mellitus (l_appos) dm
differences (r_nsubj) were
group (l_compound) inf-mi
dfo (r_nmod) other
treatment (l_nmod) anemia
tolerance (l_nmod) men
cases (l_amod) encephalopathy--19
organophosphorous (r_amod) compounds
subtypes (r_conj) mechanisms
tamoxifen (r_nmod) trial
tachycardia (l_appos) nsvt
proved (l_xcomp) technique
ethanol (r_compound) consumption
administration (l_conj) dose
serotonin (r_compound) therapy
resulted (l_nmod) proteinuria
chloride (l_conj) edema
dose (r_nsubj) suppressed
therapy (r_nmod) months
observed (r_conj) measured
levels (l_nmod) depression
cortisol-induced (r_amod) hypertension
hypertension (l_conj) disease
agents (r_nmod) exposure
infusion (r_nmod) using
na+-extrusion (l_amod) depressed
caused (l_ccomp) uncertain
vomiting (l_conj) phonophobia
case (l_nmod) patient
participation (r_dobj) demonstrates
associated (l_nmod) hemolysis
supplementary (l_nmod) groups
noted (l_nsubjpass) neuropathy
5-hydroxytryptamine-3 (r_amod) antagonist
diphenylhydantoin (r_nmod) ingestion
synergy (r_nsubj) best
doxorubicin-based (r_amod) chemotherapy
ability (r_nsubjpass) known
calcium (r_conj) arthritis
concentration (r_conj) receptors
efficacy (r_nmod) degree
use (r_nsubj) reduces
administration (r_nmod) rats
fluorescein (r_compound) angiography
responsive (l_nsubj) pain
carbon (r_dobj) given
shown (l_xcomp) cause
developed (r_conj) describe
activation (r_nsubj) contribute
eliminates (l_dobj) evidence
diet (r_dobj) feeding
had (l_dobj) loss
isoproterenol (r_nmod) injection
correlation (l_conj) ulcer
died (l_nmod) disease
octreotide (r_compound) therapy
anthraquinone (r_compound) derivatives
clarify (r_advcl) applied
patients (l_appos) mj
protect (l_nmod) pilocarpine-
revealed (l_dobj) changes
causing (l_dobj) anemia
drink (r_ccomp) describe
cycloheximide (r_nmod) treated
pentamidine (r_nmod) treatment
pressure (l_conj) output
lesions (l_conj) fibrosis
correlated (l_nsubj) incidence
appearance (r_nmod) relationship
mediated (r_advcl) useful
effects (l_nmod) hypertrophy
contaminants (r_nmod) role
caused (r_acl) effect
circled (r_conj) tended
polymerase (r_nmod) inhibitor
% (r_conj) results
agranulocytosis (l_nmod) thrombocytopenia
higher (r_advcl) recorded
occurred (r_acl:relcl) dysrhythmias
statin (r_amod) induced
damage (l_nmod) cells
sensitivity (l_nmod) effects
5-fu (r_nmod) combined
women (l_amod) dysfunctional
amelioration (l_nmod) some
adenomas (l_conj) hyperplasia
safety (l_nmod) setting
acetonide (r_nmod) safety
survived (l_dobj) failure
agents (r_conj) erythromycin
using (l_nmod) models
administration (r_nsubjpass) done
failure (l_amod) cardiomyopathy
resulted (l_conj) complained
prepared (l_nsubjpass) patients
infusion (r_nmod) end
succinylcholine (r_compound) mg/kg
efficacy (l_nmod) treatment
dexamethasone (r_nsubj) (dex)-induced
developed (l_dobj) mass
d-penicillamine (r_nmod) months
reported (r_acl:relcl) november
excretion (r_dobj) decreased
potassium (r_compound) level
content (r_nsubj) tended
switch (l_amod) manic
changed (l_nmod) focus
treatment (l_nmod) carcinoma
days (r_nmod) therapy
stopping (r_conj) developed
series (r_nsubjpass) tested
developed (l_dobj) dystonia
treatment (r_nmod) similar
exposure (r_nsubj) result
post-cocaine (r_amod) injection
synthesis/release (r_nmod) related
pge2 (r_compound) levels
underwent (l_conj) discovered
isotretinoin (r_nsubjpass) contraindicated
pravastatin (r_compound) discontinuation
tramadol (r_conj) drugs
therapy (l_nmod) fibrillation
effects (l_nmod) stroke
diclofenac (l_nmod) osteoarthritis
most (l_nmod) hepatomas
dose (r_dep) hours
had (l_advcl) potent
therapy (r_nmod) effects
observed (l_parataxis) revealed
a (r_nsubj) has
injection (r_nmod) administration
procaterol (r_nsubjpass) studied
proven (l_xcomp) agent
highlight (l_dobj) importance
prompt (r_conj) indicates
tramadol (r_nmod) intake
inhibitors (r_nsubj) hold
indinavir-associated (r_amod) nephrotoxicity
have (l_dobj) duct
cgrp (r_compound) release
nafcillin (r_nsubjpass) discontinued
recurrences (l_compound) glioblastoma
fluid (r_compound) levels
treatment (l_conj) patients
morphine (r_compound) analgesia-
carbamazepine (r_compound) treatment
penicillin (r_nsubjpass) reported
amoxicillin (r_nmod) responses
days (r_nmod) presents
administration (r_nmod) admitted
developed (l_dobj) rls
range (r_nmod) %
treatment (l_nmod) loiasis
urine (l_nmod) patients
agsd (r_dep) sulphadiazine
cocaine (r_nsubj) increased
scopolamine-induced (r_amod) impairments
rate (r_nmod) have
secondary (r_amod) block
5-fu (r_nmod) discontinuation
symptoms (l_nmod) pheochromocytoma
pb (r_compound) regimen
given (l_nmod) dogs
5-hiaa (r_appos) acid
nelarabine (r_nmod) caused
face (l_nmod) failure
minocycline-induced (r_amod) vasculitis
have (l_dobj) effect
tobramycin (r_compound) concentration
cases (l_nmod) injury
pan (r_nmod) dose
dose (r_dobj) reduced
adriamycin (r_nmod) use
increased (l_dobj) g
augmented (l_dobj) response
subjected (l_nmod) episodes
suggests (l_ccomp) effective
incidence (l_nmod) pain
material (r_nsubjpass) injected
follow-up (l_nsubj) findings
micrograms/kg (l_appos) response
dependent (l_nsubj) cardiotoxicity
group (r_nmod) tested
tamoxifen (r_nmod) ratio
associated (l_nmod) condition
suggest (l_ccomp) dysfunction
number (r_conj) angiogenesis
pneumonia (l_appos) infection
days (l_nmod) fits
modulation (l_nmod) response
block (l_dobj) lethality
headache (l_conj) dizziness
develop (l_nmod) effects
taking (r_acl) tolerance
patients (r_nmod) patients
agents (l_acl:relcl) reverse
everolimus (r_nmod) treated
reduce (l_dobj) damage
t (r_nmod) atrophy
preservatives (l_amod) neurotoxic
cocaine-dependent (r_amod) man
avoid (l_dobj) therapy
attempting (l_xcomp) identify
levels (r_nmod) evaluated
baby (l_acl:relcl) died
reactions (r_nmod) possibility
had (l_dobj) episode
submitted (l_nsubjpass) subjects
produced (l_dobj) changes
effect (l_conj) cardiotoxicity
elevation (r_nmod) had
therapy (r_dobj) initiated
abusers (r_nmod) injury
markers (r_nsubj) help
myelosuppression (l_conj) toxicity
phenobarbital (r_nmod) action
sensitized (l_nsubjpass) rats
showed (l_nsubj) analysis
sumatriptan (r_amod) use
amiodarone (r_conj) simvastatin
mk-801 (r_conj) antagonists
ingestion (l_conj) aplasia
aminoglycosides (r_nsubj) cause
anemia (l_acl:relcl) presented
agent (l_amod) anti-tumor
showed (l_dobj) atrophy
hyperkalemia (l_conj) failure
hoe-140 (r_conj) vehicle
123 (r_nummod) hcfc
drug (l_nmod) prevention
prevention (l_nmod) hyperactivity
ro4368554 (r_nsubj) improve
zidovudine (r_compound) suppression
induced (r_amod) bradycardia
stz-icv (r_compound) application
p-aminophenol (r_nmod) role
cisplatin (r_nmod) advantages
morphine (r_nmod) responsive
use (l_advcl) induce
dox (l_amod) cardiomyopathy
possibility (l_nmod) factors
carbachol (r_conj) nicotine
chemotherapy (r_dobj) receiving
hydroxytyrosol (r_conj) control
morphine (r_nsubj) reversed
smoking (r_nsubjpass) associated
cases (l_nmod) retention
acid-induced (r_amod) failure
associated (l_nmod) defects
had (l_dobj) reduction
account (r_dobj) help
symptoms (l_nmod) hyperhidrosis
active (r_acl:relcl) those
terminate (l_dobj) fibrillation
concentration (r_nsubjpass) altered
true (l_nmod) migraine
aminonucleoside (r_nmod:npmod) induced
warning (l_compound) heartbeat
women (l_nmod) diabetes
patient (l_conj) toxicity
cardiac (l_dep) thrombotic
carry (l_advcl) bleeding
manifest (l_dobj) regurgitation
models (l_compound) epilepsy
treat (l_dobj) hypertension
% (r_nmod) concentration
cocaine (l_nmod) anxiety
captopril (r_appos) inhibitor
death (r_nmod) haloperidol
history (r_conj) patient
isoflurane-induced (r_amod) hypotension
dyskinesias (r_conj) disease
ratio (r_nmod) evaluation
presented (l_nmod) rhabdomyolysis
was (l_nmod) decrease
% (r_dep) were
ctx (r_nmod) combined
asenapine (r_nmod) similar
diphenylhydantoin (r_compound) overdose
l-sotalol (r_nsubj) prevented
diazepam (r_nmod) rats
measured (l_nsubj) methods
alert (l_nmod) patient
therapy (r_nmod) type
acid (r_nmod) distribution
suggestive (r_amod) pattern
study (r_nmod) evaluated
remedy (r_conj) accompany
administration (r_nsubj) reverse
observed (r_advcl) established
effect (r_nsubj) necrotizing
attenuate (l_dobj) nephropathy
associated (l_nmod) cases
report (l_dobj) case
defined (r_acl) myopathy
nh3 (r_appos) ammonia
induces (l_dobj) changes
development (l_nmod) hypercalcemia
effects (l_nmod) cocaine
efficacy (l_nmod) steroids
5-fluorouracil (r_compound) cardiotoxicity
history (l_nmod) urticaria
information (r_nsubjpass) concealed
block (l_nmod) attacks
reduced (l_dobj) development
patients (r_nmod) effect
morphine (l_nmod) models
method (r_dobj) using
amiloride (r_compound) supplementation
injection (r_nmod) prevented
burden (l_compound) tumor
included (l_dobj) pain
microinjection (r_nsubj) attenuated
streptomycin (r_nmod) sensitive
sod (r_ccomp) suggest
aminoglycoside-iron (r_amod) complexes
developed (l_dobj) hypertension
effect (l_nmod) damage
administration (r_conj) coadministration
ethambutol (r_nmod) complication
pretreatment (r_nsubj) effective
atracurium-related (r_amod) paralysis
model (l_conj) model
experienced (r_acl:relcl) patients
order (l_acl) evaluate
onset (l_nmod) tremor
unrelated (l_nmod) seizures
evoked (r_acl) stimulation
considered (r_ccomp) reminds
effects (l_nmod) disorders
block (l_conj) persistence
combined (r_conj) given
mass (l_conj) proteinuria
maleate-induced (r_amod) nephropathy
cause (l_dobj) disorders
rats (l_amod) arrhythmic
atra (r_nsubj) seemed
mechanism (l_amod) ototoxic
changes (r_dobj) investigate
developed (l_dobj) changes
ca(2 (r_amod) inhibition
combined (l_nmod) failure
patients (r_nsubj) experience
risk (r_nsubj) related
induction (l_nmod) tci
cells (r_nmod) treatment
influence (l_nmod) hyperprolactinemia
administration (r_nmod) initiated
associated (l_nmod) myopathy
corticosteroid-treated (r_conj) androgen-
mz (r_amod) use
dismutase (r_nmod) enzymes
42)-infused (r_amod) rats
days (r_nmod) challenged
occurred (l_nmod) patients
examined (l_nsubjpass) correlation
levels (r_conj) reduction
symptoms (r_nsubj) identical
ptu-associated (r_amod) vasculitis
concentration (r_nmod) ratio
channel (r_compound) blockade
complained (l_advcl) complained
latency (l_nmod) ketamine-
case (l_nmod) hypotension
plate (r_dobj) using
proliferation (l_conj) inflammation
received (l_dep) group
increases (l_nmod) dyskinesia
signs (r_conj) aspiration
secondary (r_amod) coma
apomorphine (r_conj) agonist
developed (l_dobj) thrombocytopenia
induce (l_dobj) infarction
prescribed (l_nsubjpass) man
tolerated (l_conj) shows
produced (l_dobj) hernias
discontinued (l_conj) initiated
state (l_amod) dyskinetic
sodium (r_nsubj) displayed
injected (l_advcl) induce
tamoxifen (l_nmod) carcinoma
cases (l_nmod) encephalitis
gabapentin (l_appos) drug
pb (r_nmod) treated
pge1 (r_nmod) induced
two (l_nmod) jerks
increase (r_nsubj) occurred
acid (r_compound) tests
arrhythmia (l_dep) dysfunction
disorders (l_conj) agoraphobia
pulmonary (l_dep) occurring
courses (r_nmod) developed
galantamine (r_nmod) trial
mice (l_acl) suffering
failure (r_nmod) patient
use (r_nsubj) restricted
propranolol (r_conj) diazepam
mild (r_conj) developed
hyperalgesia (l_conj) aspects
dissociated (l_nmod) toxicity
line (l_nmod) evidence
therapy (r_nmod) male
doses (l_nmod) model
plays (r_advcl) investigates
alert (l_nmod) possibility
content (l_nmod) headache
induced (l_nsubjpass) hypotension
implicated (l_nmod) incidence
herbicides (l_conj) produced
carbamazepine (l_xcomp) presenting
cause (l_dobj) function
ops (r_nmod) toxicity
association (l_nmod) stroke
grains (r_nmod) concentration
deficit (l_nmod) accuracy
ethanol (r_compound) withdrawal
sirolimus (r_nsubj) agent
attributable (l_nmod) hypotension
neurotensin (r_nmod) effects
days (r_dobj) received
sodium (r_nmod) switch
cats (r_nmod) arrhythmias
tolerance (l_conj) phenomenon
lithium-associated (r_amod) hypercalcemia
women (r_nmod) performed
role (l_nmod) development
tna (r_nmod) dose
assessment (l_nmod) disease
substituted (l_advcl) important
warfarin-associated (r_amod) hemorrhage
penicillin (r_compound) model
seemed (l_conj) have
women (l_nmod) oab
occurred (l_xcomp) treat
patients (l_acl:relcl) developed
activities (r_conj) behavior
effects (l_amod) epilepsy-related
therapy (l_nmod) tuberculosis
relation (l_conj) disease
methadone (r_nmod) adjustment
optic (r_dobj) had
neuroprotective (r_ccomp) investigates
lumens (l_conj) atrophy
carries (l_nmod) depression
overdose (r_nmod) setting
dogs (l_nmod) lymphoma
accounted (l_advcl) indicating
anemia (l_appos) riha
trait (l_conj) leprosy
has (l_conj) causing
use (l_conj) toxicity
evidenced (l_nmod) changes
found (l_xcomp) cause
(kim)-1 (l_compound) molecule
occurred (l_nsubj) intensity
produced (r_acl) seizures
administering (r_advcl) prevented
attenuated (l_dobj) rigidity
doxorubicin (r_nmod) pre-induced
change (l_nmod) headache
daunorubicin (r_conj) etoposide
women (l_acl) treated
form (l_conj) scales
determination (r_nmod) discovered
rigidity (l_amod) parkinsonian-like
exhibited (l_dobj) bradydysrhythmias
induced (r_amod) fibrosis
cisplatin (r_nmod) induced
improve (r_xcomp) reported
chloride (r_nmod) effects
effect (l_nmod) ibuprofen
developed (l_advmod) encephalopathy
effect (r_dobj) studied
presented (l_dobj) hypoxia
had (l_nsubj) patients
histamine (r_compound) ligands
contribute (l_nmod) toxicity
meth (r_nmod) injections
cause (l_dobj) calcification
investigate (l_ccomp) triggers
a (r_nmod) conversion
treatment (r_nsubj) reduces
glutamine (r_conj) glutamate
treatment (r_nmod) underwent
therapy (r_nmod) added
developed (l_dobj) bradycardia
quetiapine (r_nsubj) derivative
cisplatin (r_nmod) combined
those (l_nmod) intoxication
use (l_nmod) management
climbing (l_conj) tests
verapamil (r_nmod) significant
embryolethality (l_conj) teratogenicity
isoproterenol (r_amod) infarction
events (r_nsubj) dizziness
effects (l_nmod) ischemia
modulate (l_dobj) impairment
cases (l_nmod) toxicity
loss (l_nmod) cells
displayed (l_dobj) proteinuria
induced (r_amod) catalepsy
micrograms/kg/hr (l_amod) larger
secondary (r_amod) nephrotoxicity
areas (r_nmod) transformation
overdose (r_nmod) failure
third-generation (r_nmod) users
pethidine (r_nsubj) cause
nicotine (r_conj) morphine
caused (l_nsubjpass) hypoaldosteronism
androgens (r_dobj) administered
everolimus (r_nmod) efficacy
captopril (r_compound) overdose
cocaine-dependent (r_amod) outpatients
obesity (l_conj) resistance
toxicity (r_nmod) effect
followed (r_ccomp) performed
activated (r_conj) delineated
type (l_nmod) syndrome
use (r_conj) disorder
amiodarone (r_amod) discontinuation
cells (r_nsubj) contribute
studies (l_acl:relcl) assessed
produced (l_dobj) impairments
d-med (r_appos) dexmedetomidine
was (l_nmod) deficits
nmda (r_compound) antagonists
eaca (r_nsubjpass) implicated
compensated (l_conj) decreased
tri (r_appos) experiment
patients (l_nmod) epilepsy
produced (r_acl) convulsions
thrombocytopenia (l_conj) hemorrhage
treatment (r_nmod) trial
hydrochloride (r_nmod) administration
exhibited (l_nsubj) patients
incapacity (l_acl) learn
injected (r_dep) assessed
induced (l_dobj) hemopoiesis
citalopram (r_nmod) adolescent
effects (r_nmod) aware
morphine (r_nsubj) inhibited
report (l_nmod) coma
duration (l_nmod) narcosis
introduction (l_conj) withdrawal
cisplatin-induced (r_amod) nephrotoxicity
insufficiency (l_appos) ari
increase (l_dobj) score
attention (r_nmod) affected
fluphenazine (r_nmod) induced
reduce (l_conj) reduce
twitches (r_dobj) completing
isoflurane (r_nmod) labetalol
challenge (r_compound) test
is (r_advcl) case
expression (r_nmod) changes
administration (r_nmod) treating
case (l_nmod) vasospasm
symptoms (r_conj) ratings
reproduce (r_xcomp) likely
amlodipine (r_nmod) %
used (l_conj) reviewed
seizure (l_nmod) collection
induction (l_nmod) cardiomyopathy
vasculitis (l_nmod) girl
manage (l_dobj) dosing
return (l_nmod) hyperkinesis
ischemia (r_nmod) mechanisms
prevented (l_nsubjpass) pain
increase (l_nmod) incidence
help (l_xcomp) avoiding
associated (l_nmod) progression
injury (l_conj) explore
phenylbutazone (r_conj) drugs
hypothesis (r_dobj) tested
baclofen (r_nsubj) useful
indicates (r_parataxis) continued
recommenced (r_advcl) developed
atenolol (r_nmod) week
mice (l_nmod) hepatitis
hypercalcemias (r_nmod) patients
glutamate-mediated (r_amod) mechanisms
diet (r_dobj) fed
5-fu-induced (r_amod) cardiotoxicity
associated (r_acl) proteinuria
predictors (r_dobj) identify
induction (r_nsubj) halts
hydrochloride (r_appos) background
effect (r_nmod) caused
defects (r_nmod) pathogenesis
combination (r_conj) feasibility
disappearance (l_nmod) nsvt
dyskinesias (r_nsubj) present
administered (r_acl) animals
incidence (l_nmod) anemia
implicated (l_advcl) reducing
given (r_dep) observed
detected (r_acl) vagina
cholesterols (r_nmod) changes
treated (l_nmod) bacteremia
aminonucleoside (r_nsubjpass) administered
increases (l_nmod) anxiety
potential (l_nmod) treatment
study (r_dobj) performed
stimulating (r_advcl) produced
lamivudine-na (r_amod) patients
involvement (l_compound) tumor
identify (l_dobj) subgroup
combination (r_nmod) associated
dexamethasone (r_nmod) treatment
treatment (r_dobj) initiating
ropivacaine-infused (r_conj) bupivacaine-
received (r_conj) implicated
trial (r_appos) active-w
gamma-hch (r_dep) h
intake (l_nmod) disease
had (l_dobj) gravis
hypotension (l_nmod) patients
reversible (r_amod) cholestasis
ketamine (r_nmod) pre-treatment
resulted (r_conj) high
inhibitor (l_acl:relcl) mediated
bearing (l_dobj) tumors
determine (l_dobj) safety
pilocarpine (r_nmod) protecting
mk-801 (r_nsubj) augments
reported (l_xcomp) option
determine (r_advcl) calculated
disulfiram (r_compound) overdose
show (l_amod) neuropathy
group (l_amod) non-mi
overdose (r_nmod) case
was (l_nsubj) response
population (l_acl:relcl) screened
felt (l_conj) showed
switching (r_nmod) risks
doxorubicin (r_nmod) index
prescription (r_nmod) policy
risk (l_nmod) infarction
caffeine (r_nmod) administration
injected (l_conj) attenuated
different (l_nsubj) events
mechanisms (r_dobj) examine
diminished (l_dobj) rigidity
h (r_nmod) presented
sirolimus (r_nsubjpass) associated
associated (l_nmod) hit
reducing (l_dobj) albuminuria
led (l_nsubj) concerns
application (r_nsubj) revealed
had (l_dobj) tnss
cc (r_dobj) received
took (r_conj) received
associated (r_xcomp) found
undergoing (l_dobj) cyclosporine
c (r_nsubjpass) suggested
acid (r_nsubj) benefit
considered (l_xcomp) reflect
indicating (l_dobj) damage
androgen-independent (r_amod) cancer
aimed (l_nmod) focus
lower (l_nmod) subjects
neurotransmitters (r_nmod) effects
effect (r_xcomp) considered
procaterol (l_conj) terbutaline
doses (r_nsubjpass) escalated
sufficient (l_xcomp) minimize
doxorubicinol (r_conj) doxorubicin
metoprolol (r_conj) sr
dog (l_nmod) agents
tac-related (r_amod) seizures
allopregnanolone (r_nsubj) inhibited
vpa-associated (r_amod) encephalopathy
reversible (r_ccomp) suggests
variables (l_nmod) age
drugs (r_advcl) offset
nitroglycerin (r_nmod) addition
suxamethonium (r_nmod) injection
glutamate (r_nmod) decrease
indomethacin (r_conj) phenylbutazone
have (l_nsubj) rats
induced (r_acl) ischemia
mazindol (r_compound) doses
gadolinium (r_compound) enhancement
cardiotoxicity (l_acl) characterized
influence (r_nmod) responsible
risperidone (r_nmod) reduction
interaction (r_nmod) cases
risk (l_nmod) necrosis
amikacin (r_nmod) treatment
kidney (r_nmod) man
nephrotoxicity (l_nmod) cohort
(-)-cibenzoline (r_conj) (+)-cibenzoline
had (r_advcl) explained
evidence (l_nmod) disease
myocet (r_nmod) receive
dexamethasone (r_nmod) administration
determined (l_nsubjpass) subtypes
features (l_nmod) dysfunction
importance (r_dep) tetany
ketoprofen (r_compound) group
a (r_conj) etoposide
fluoxetine (r_compound) exposure
gentamicin (r_nmod) doses
nitroglycerin (r_nmod) induced
olanzapine (r_conj) risperidone
rate (l_nmod) aes
resulted (l_dobj) titer
increases (l_conj) produce
produced (r_acl) hyperalgesia
chloramphenicol (r_nmod) response
women (r_nmod) patients
neuropathy (l_nmod) patients
effect (l_nmod) vestibulotoxicity
diethylstilbestrol (r_nmod) exposed
was (l_attr) reduction
study (l_dobj) biodistribution
ability (l_acl) improve
administration (r_nmod) weeks
recurrence (l_nmod) telangiectasia
implicate (r_conj) associated
effects (r_nsubj) (pge1)-induced
those (l_nmod) myalgia
therapy (r_nmod) vasculitis
pilocarpine (r_compound) seizures
drugs (r_nmod) treatment
receptors (r_nmod) binding
failed (l_xcomp) change
had (l_dobj) values
flumazenil (r_nsubj) antagonist
caused (r_acl) consolidation
pan (r_compound) nephropathy
adolescents (l_amod) depressed
carrageenan-induced (r_amod) inflammation
agoraphobia (l_nmod) attacks
factor (l_nmod) cardiotoxicity
studied (l_advcl) investigating
b. (r_dobj) incorporating
drug (l_nmod) patients
antifungal (r_amod) agents
complete (l_dobj) prevention
pretreatment (r_nsubjpass) justified
represents (l_dobj) example
acid (r_nmod) activity
hyperalgesia (r_nmod) modulation
trial (l_nmod) cancers
quantitated (l_nmod) hypertension
hepatotoxicity (r_nmod) protects
ability (l_acl) suppress
lignocaine (r_nmod) instillation
thp (r_conj) hyperactivity
efficacy (r_dobj) compared
cgmp (r_compound) excretion
oxytocin (r_nsubj) uterotonic
labetalol (r_nsubj) induces
methamphetamine (r_compound) toxicity
cefonicid (r_nmod) doses
sustained (l_dobj) tear
anaesthesia (r_nmod) h
inhibitor (r_nsubj) reduced
caused (r_acl) contractility
associated (l_dep) mortality
overdose (r_nmod) cases
results (l_appos) rate
angina (l_conj) patients
apomorphine (r_nsubj) inhibits
developing (l_dobj) necrosis
attenuated (l_advcl) improving
terfenadine (r_appos) blockers
protect (l_nmod) ototoxicity
piperacillin (r_nmod) associated
vincristine (r_nmod) treated
receptors (r_dep) d-1
associated (r_acl) mania
barium (r_nmod) month
dex-induced (r_amod) hypertension
pentazocine (r_conj) fentanyl
ziprasidone (r_nmod) drugs
cephalosporin (r_compound) antibiotics
trials (r_nmod) studied
relation (r_nmod) analyzed
development (l_nmod) cystitis
found (r_acl) fact
embryopathy (r_dobj) showed
occurrence (l_nmod) rash
resulted (r_ccomp) speculate
occurring (r_advcl) show
lapsed (l_nmod) coma
sch (r_conj) catalepsy
reported (l_nmod) disease
case (l_nmod) rigidity
relief (l_nmod) pain
incidence (l_nmod) angioedema
ritodrine (r_nmod) infusion
underlying (r_acl) mechanisms
ability (l_acl) detect
morphine (r_nmod) induced
woman (l_nmod) anomaly
kidney (r_compound) effects
pre-treated (r_amod) rats
cm (r_nmod) dosages
apomorphine (r_conj) catalepsy
role (l_nmod) anemia
amitriptyline (l_nmod) treatment
prone (l_xcomp) exhibit
consistent (l_xcomp) indicating
use (r_nmod) secondary
daptomycin (r_nsubjpass) initiated
suggest (l_dobj) risk
shunt (l_nmod) ovale
relationship (l_nmod) hypothermia
hepatitis (r_nmod) cases
delayed (l_dobj) damage
injections (r_nmod) treated
phenytoin (r_nmod) treatment
catalepsy (r_nmod) models
developed (l_dobj) dyskinesia
induced (r_acl) rhythm
treat (l_dobj) tuberculosis
results (l_nmod) dysfunction
cimetidine (r_nmod) associated
prevented (l_dobj) glomerulosclerosis
incidence (l_compound) cancer
suxamethonium (r_compound) rate
cause (l_nmod) delirium
induced (r_acl) ns
amisulpride (r_nmod) treated
delineate (r_acl) order
t (r_nsubj) had
associated (l_nmod) frequency
brought (l_nmod) decrease
bupivacaine (r_nmod) mg
doxorubicin (r_compound) administration
accelerated (l_nsubj) patients
tended (l_xcomp) reduce
use (r_nmod) metrics
lidocaine-kindled (r_amod) seizures
used (l_conj) found
dogs (r_nmod) met
fluid (r_dep) measured
appears (l_nsubj) arrest
methotrexate (r_compound) therapy
incidence (l_conj) frequency
affected (l_nmod) narcosis
model (r_nmod) studied
facilitate (l_dobj) bradycardia
propofol (r_nmod) content
causes (l_dobj) phenotype
factor (l_nmod) src
interferon (r_nmod) patients
myopathy (l_acl) associated
vincristine (r_nmod) produced
protection (l_nmod) syndrome
sch (r_conj) fluphenazine
complication (l_acl) associated
halothane (r_nmod) induced
rejection (r_nmod) differences
effects (l_nmod) model
results (l_appos) patients
potential (l_acl) inducing
scopolamine (r_nsubj) prevented
compared (l_nmod) order
thalidomide (r_nmod) addition
adenosine (l_nmod) hypersensitivity
induces (r_conj) variable
incidence (r_nmod) difference
dox (r_compound) rats
hypertension (l_conj) failure
asystole (r_acl:relcl) time
dermatitis (l_conj) lymphadenopathy
influenced (l_dobj) rate
was (l_attr) excess
furosemide (r_nmod) effect
patient (r_conj) patient
increases (l_nmod) toxicity
hypoglycemia (l_conj) hyperbilirubinemia
patients (r_nmod) studies
losartan (r_nmod) mg
induction (l_nmod) tumors
induce (r_ccomp) suggests
induced (r_acl) disease
headache (l_compound) migraine
hypotension (l_conj) hypotension
propranolol (r_compound) 24/76
nicotine-treated (r_amod) rats
propofol (r_nmod) caused
snp (r_compound) decreases
treatment (l_nmod) dermatoses
models (l_nmod) hyperactivity
streptozotocin-induced (r_amod) hyperalgesia
toxicity (r_nmod) tachycardia
head (l_conj) cancer
dogs (r_nmod) studied
observed (l_nsubjpass) parkinsonism
patient (l_nmod) aids
found (l_nmod) syndrome
k(+)-channels (r_dep) quinine-
cyclosporine (r_nmod) precipitated
models (l_compound) dementia
observations (l_nmod) patient
induced (r_amod) rats
inhibition (r_nmod) reduced
stones (l_conj) obstruction
warfarin-induced (r_amod) neuropathy
carrageenan-induced (r_amod) model
iodixanol (r_conj) medium
prolonged (l_parataxis) similar
tiapride (r_conj) tetrabenazine
disease (l_appos) ad
decreased (l_dobj) activity
observed (l_nsubjpass) prolongation
result (r_nmod) block
alterations (l_nmod) pd
patients (r_conj) malignancies
patients (l_appos) dysfunctions
decreases (l_dobj) incidence
measure (r_xcomp) found
assess (l_advcl) detecting
vasopressin (r_nmod) doses
treatment (l_nmod) seizures
disorder (r_nmod) outpatients
therapy (r_advcl) decreased
race/ethnicity (l_conj) obesity
radical (r_amod) production
synthase (r_nmod) products
administration (l_nmod) protection
placebo (l_nmod) events
divalproex (r_advcl) switching
associated (l_nmod) tachycardia
doses (r_dobj) escalating
associated (l_nsubjpass) differences
mechanism (r_dobj) have
glutamate (r_amod) injection
reducing (l_dobj) neutropenia
had (l_ccomp) resolve
doses (r_dep) toxicity
reduces (l_dobj) number
injection (r_nmod) observed
disulfiram (r_nmod) induced
inhibition (r_conj) markers
citrate (r_nmod) associated
estradiol (r_nmod) combination
decreased (l_nsubj) aggregation
bed (r_nmod) irradiation
pentylenetetrazole (r_conj) caffeine
projections (r_dobj) descending
demonstrate (l_dobj) defect
sirolimus-induced (r_amod) syndrome
demonstrate (l_dobj) action
event (r_conj) late
tamoxifen (r_nmod) women
thalidomide (r_nmod) completed
induction (r_nmod) investigating
ballistic (l_conj) dystonic
ascertain (l_ccomp) syndrome
cbz (r_nmod) measure
had (l_dobj) symptoms
effective (l_advcl) alleviating
administration (r_nmod) methods
have (r_xcomp) showed
b (r_compound) infusion
abundance (l_nmod) markers
used (l_xcomp) induce
gentamicin (r_nmod) induced
treatment (l_nmod) deficits
methamphetamine-induced (r_conj) lifetime
mg/kg (l_appos) convulsions
observed (l_nsubjpass) pain
adriamycin (l_acl) combined
fk506 (r_compound) therapy
a (r_nmod) therapy
amphetamine (r_dep) challenge
benzamide (r_appos) tiapride
catecholamine (r_compound) sensitivity
doses (r_nmod) reticulata
acid (r_nmod) synthesis
dobutamine-induced (r_amod) ischemia
observed (l_nsubjpass) hyperalgesia
antagonized (l_dobj) dexrazoxane
drugs (r_conj) therapy
treatments (r_nmod) adenocarcinomas
den (r_conj) den
patients (r_dobj) identified
observed (r_advcl) remained
ranitidine-induced (r_amod) nephritis
rendered (r_acl) rats
doses (r_dep) hyperalgesia/myoclonus
patients (r_nmod) increased
those (l_acl:relcl) need
alprazolam (r_nmod) randomised
influence (l_dobj) cardiotoxicity
cause (l_nmod) metabolite
getting (r_advcl) presented
value (r_nsubj) mg/kg
receptors (r_nmod) involvement
increased (l_nmod) patients
warfarin-induced (r_amod) calcification
ip (r_dobj) received
tac (r_compound) toxicity
time (l_nmod) seizure
risk (l_compound) tumour
lithium-associated (r_amod) cognitive
learning (l_nmod) rats
patients (l_nmod) apnea
suppressed (l_dobj) expression
testosterone (r_compound) replacement
ra (r_nsubj) co-administered
taking (r_advcl) worsened
infusion (l_acl) combined
p (r_dep) accompanied
levodopa/carbidopa (r_amod) administration
pretreatment (r_nsubj) reduced
treated (r_acl) boy
absence (r_nmod) modify
hypoxia (r_nmod) event
history (l_nmod) accident
evaluate (r_advcl) induced
hydroxytyrosol (r_conj) doxorubicin
increases (l_nmod) bp
documentation (l_nmod) sah
exacerbated (l_dobj) coagulopathy
developed (l_dobj) hypomania
therapies (r_nsubjpass) associated
nitroprusside (r_nsubj) caused
sensitive (l_nmod) site
cyclosporin (r_nmod) treated
associated (l_nsubjpass) hyperplasia
induced (r_acl) insult
diphosphate (r_compound) glucoronosyltransferases
strains (l_nmod) patients
occlusion (r_nmod) case
nifedipine (r_conj) verapamil
increased (l_advcl) whereas
ritodrine (r_nmod) effects
cluster (l_nmod) seizures
deleterious (l_advmod) nephropathy
preferred (r_acl:relcl) patients
granisetron (r_nmod) doses
requiring (l_dobj) pacemaker
azathioprine (r_nmod) treated
evidence (l_nmod) hepatotoxicity
occurs (l_nmod) patients
patients (r_dobj) converting
reduction (l_nsubj) standard
prevented (l_dobj) evolution
species (r_nmod) generation
rose (l_advcl) compared
isoproterenol (r_amod) tachycardia
activation (l_conj) hyperlipemia
received (l_dobj) doses
aminonucleoside (r_nmod) induced
elicit (l_dobj) response
resulting (l_nmod) rhabdomyolysis
given (l_conj) had
known (l_conj) polyneuropathy
spared (l_nmod) lesions
diagnosis (l_nmod) erythematosus
prevent (l_dobj) injury
survivors (r_dobj) differentiate
prevention (l_nmod) amnesia
(isph)-induced (r_amod) infarction
resulting (l_nmod) block
decontamination (r_dobj) received
aware (l_nmod) signs
vincristine (r_compound) infusion
analogue (l_acl:relcl) has
use (l_nmod) seizures
combining (r_acl) metastases
incidence (r_nsubj) correlated
reported (l_nsubj) symptoms
trazodone (r_nsubj) enhanced
indirect (r_ccomp) indicates
shown (l_xcomp) effective
describe (l_dobj) findings
bepridil (r_nmod) pronounced
shouts (l_conj) loss
exposure (r_conj) current
continues (l_nmod) proportions
methotrexate (r_compound) toxicity
dopamine-beta-oxidase (r_compound) inhibitor
anesthesia (r_nmod) acidosis
metformin (r_nsubj) prevents
occur (l_nmod) disease
responded (r_advcl) classified
metformin (r_nmod) use
signs (l_nmod) poisoning
hyperosmolar (l_dep) coma
consisting (r_acl) modification
induced (l_nmod) supplementary
revealed (l_ccomp) exhibited
excluded (l_nsubj) tumors
developed (r_parataxis) observed
amiloride (r_appos) diuretic
complication (l_nsubj) thromboembolism
useful (l_nmod) therapy
trifluoroacetyl (r_compound) adduct
limited (l_dep) trial
therapy (r_nmod) occurrence
subjected (l_nmod) attempt
discontinued (l_conj) excluded
frequently (r_advmod) occurred
role (r_dobj) suggest
bruising (l_conj) pain
hepatitis (l_acl) leading
regulated (l_dobj) system
hypertension (l_conj) spasticity
erdosteine (r_compound) groups
prevention (l_nmod) retrieval
patients (l_nmod) infections
maleate (r_nmod) injection
associated (l_nmod) anemia
effective (l_advcl) controlling
doxorubicin (r_nsubj) causes
isoproterenol (r_nmod) dosages
pilocarpine (r_nsubj) produced
rats (r_nmod) antagonists
developed (l_dobj) failure
desmethylimipramine (r_nmod) potentiated
3.10 (r_appos) oc
alterations (r_nsubj) syndrome
antituberculosis (r_compound) therapy
cases (r_dobj) found
study (l_appos) patients
srl (r_appos) sirolimus
syndrome (l_conj) defects
occurrence (l_nmod) nephrotoxicity
ngf (r_nmod) changes
took (l_nsubj) woman
found (l_xcomp) attenuate
androgen (r_nmod) rechallenge
verapamil (r_nsubj) caused
tremor (r_conj) speech
focus (l_nmod) models
decrease (l_conj) inhibition
cc (l_conj) infarction
fluphenazine (l_conj) catalepsy
cause (l_dobj) myopathy
troleandomycin-induced (r_amod) hepatitis
(gaba)-mediated (r_dep) acid
incidence (l_nmod) nephrotoxicity
prompted (l_dobj) episode
renin-angiotensin (r_amod) proteins
associated (l_nmod) atherosclerosis
pneumonitis (l_appos) effusions
presented (l_dobj) slight
( (r_punct) dfc
using (l_dobj) interview
adults (l_acl:relcl) risk
adr (r_nmod) effects
disease (r_nmod) patient
ax (r_nmod) test
clear (l_ccomp) influence
has (l_conj) used
cisapride (r_nmod) observed
nuclei (r_nmod) sites
ethambutol (r_nmod) dose
seizure (l_advcl) receiving
induced (l_dobj) anxiety
time (r_dobj) increasing
seen (l_nsubjpass) improvements
methyldopa (r_amod) dysfunction
streptozotocin (r_nmod) toxicity
reserpine (r_nsubj) produced
association (r_nmod) rhabdomyolysis
nystagmus (l_conj) oscillopsia
h (r_nmod) free
treatment (r_nmod) patient
standard (l_nmod) management
effects (l_conj) l-name
implications (l_nmod) treatment
had (l_nmod) irradiation
discontinuations (r_nmod) risk
undergone (l_nmod) patients
combination (r_nsubjpass) tolerated
lidocaine (r_nmod) activity
dose (r_nmod) associated
inhibited (l_nmod) causes
desipramine (r_nmod) treatment
closest (l_nmod) tolerance
vnb (r_nsubjpass) tolerated
patients (r_nmod) reported
alterations (r_nmod) risk
dox (r_compound) treatment
doxil (r_dep) combination
patients (l_compound) migraine
developed (l_dobj) disorder
imipramine (r_dobj) given
excitability (l_nmod) patients
tolerable (l_nmod) dogs
assessed (l_dobj) coordination
treatment (l_nmod) hypertension
able (r_advcl) relevance
progression (l_amod) nephropathy
glucose (r_compound) curve
results (l_advcl) measured
ivmp (r_appos) methylprednisolone
srl (r_nmod) switch
antagonists (r_nmod) infusion
atra (r_nmod) protocol
levels (r_nsubj) related
mice (l_acl:relcl) display
incidence (l_nmod) events
a-induced (r_amod) hypertension
increased (l_nmod) presence
acetonide (r_nmod) treated
l-alpha-glycerylphosphorylcholine (r_nmod) effects
had (l_nsubj) patient
methamphetamine (r_compound) uses
beta-lactam (r_amod) antibiotics
ergot (r_nmod) history
treatment (l_nmod) cats
blockade (r_nmod) accompanied
show (r_advcl) sacrificed
reabsorption (r_nmod) blockage
capable (l_advcl) reversing
predictors (l_nmod) dyskinesia
developed (l_dobj) proteinuria
had (l_dobj) anxiety
remains (l_dobj) model
k)-atpase (r_nsubj) increased
nystagmus (l_appos) nin
succimer (r_nmod) treatment
pemoline (r_nsubjpass) associated
describe (l_dobj) woman
adrenaline (r_conj) atropine
ecstasy-specific (r_amod) effects
5-hydroxytryptamine1a (r_compound) receptors
nonusers (r_nmod) users
role (l_nmod) disease
halothane (r_nmod) exposure
rare (l_conj) common
preserves (l_conj) prevents
cya (r_compound) cardiotoxicity
causes (l_conj) preserves
frequency (l_nmod) vte
rg1 (r_nsubj) ameliorate
adriamycin (r_nmod) exacerbated
lamivudine (r_nsubjpass) used
glucose (r_compound) transporter
went (l_advcl) return
have (l_dobj) insipidus
results (l_dep) catalepsy
recommend (l_nmod) risk
desipramine (r_dobj) receiving
attempt (r_nmod) information
bromocriptine (r_conj) hypogonadism
na(+ (r_compound) channels
measures (l_acl) fasting
activity (r_nmod) remedy
time (l_conj) risk
incidence (l_nmod) nausea
hydrochloride (r_nmod) treated
isethionate (r_nsubjpass) associated
described (l_dep) organization
isoniazid (r_nmod) unmasked
produced (r_acl) paralysis
dynamics (l_amod) related
telithromycin (r_nsubj) cause
developing (l_dobj) toxicity
one (r_nmod) cases
month (r_nmod) improved
achieve (r_xcomp) designed
dopamine (r_nmod) other
patients (l_conj) have
decreased (l_advcl) resulting
prevented (l_conj) attenuated
one (r_nmod) allocated
dysfunction (r_nsubj) dose-dependent
suggest (l_nsubj) contractility
hmm (r_compound) toxicity
deduced (l_nsubjpass) participation
cause (l_nmod) acidosis
arrhythmia (r_nmod) concentration
evoked (l_conj) caused
cimetidine (r_nsubjpass) replaced
determine (l_dobj) activity
tna (r_nmod) overdose
bolus (r_nmod) study
alterations (r_nmod) pattern
dexamethasone-induced (r_amod) hypertension
infusate (l_nmod) patients
cells (l_acl:relcl) known
dopamine (r_nmod) levels
blocked (l_conj) augmented
duration (l_nmod) disorder
ischaemia (r_nsubjpass) used
respect (l_nmod) damage
isoproterenol-induced (r_amod) cardiotoxicity
damage (r_conj) deterioration
role (l_nmod) reversal
deferoxamine (r_nmod) therapy
application (r_nsubj) suppressed
effects (l_nmod) nephritis
associated (r_acl) siadh
valproate-induced (r_amod) chorea
patient (l_acl) received
triad (l_nmod) hypercalcemia
factors (l_acl) operating
capecitabine (r_nmod) effects
nephrotoxicity (r_conj) effect
leading (l_nmod) syndrome
ascribed (l_nmod) suppression
passage (l_nmod) gliomas
treatment (r_nmod) ameliorated
hypotension (r_dobj) reverse
na+-binding (r_compound) properties
amisulpride (r_amod) therapy
azathioprine (r_compound) therapy
no (r_compound) sequestration
duration (r_dep) higher
zolmitriptan (r_dobj) took
akinesia (r_nmod) model
model (r_nmod) reaching
development (l_nmod) convulsions
studying (l_dobj) mechanisms
valdecoxib (r_compound) dose
indicated (r_acl) depletion
d-penicillamine (r_nsubj) caused
compared (r_acl) risk
magnitude (r_nsubj) consistent
response (r_dobj) examined
morphine (r_nmod) antinociception
induced (r_acl) attention
abuse (l_nmod) injury
bicuculline-induced (r_conj) picrotoxin-
cancer (l_nmod) ureter
was (l_nsubj) correlation
remained (l_parataxis) indicated
carbamazepine (l_nmod) epilepsy
incidence (l_conj) beats
isoproterenol (r_compound) pretreatment
zonisamide (r_compound) treatment
risk (l_nmod) anemia
doses (r_nmod) associated
enprofylline (r_conj) theophylline
association (l_nmod) hydroureteronephrosis
amphetamines (r_conj) cocaine
implications (r_dep) inhibit
produce (l_dobj) effects
advent (r_nmod) continue
studied (l_nmod) induction
underwent (l_dobj) swelling
developing (l_dobj) infection
assessment (l_nmod) presence
ecstasy (r_conj) mdma
heparin (r_compound) concentration
data (r_nsubjpass) analyzed
fk506 (r_compound) combination
reserpine (r_nmod) induced
pb-related (r_amod) dysfunction
known (l_nsubjpass) hyperkinesias
showed (l_advcl) observed
mesna (r_appos) sulphonate
f(33 (r_appos) difference
mice (r_nmod) polyuria
doses (l_case) of
lithium-induced (r_xcomp) likely
sodium (r_compound) mmol/l
stones (l_appos) history
exhaustion (r_nmod) susceptibility
reaction (l_acl) characterized
duration (r_nmod) coincident
differ (l_nmod) scores
patients (l_nmod) recurrence
antagonist (r_nmod) effect
phenobarbital (r_nsubj) has
induced (l_dobj) cases
result (l_nmod) complications
haloperidol (r_conj) random-assignment
acid-induced (r_dep) kainic
fucoidan (r_amod) treatment
treatment (r_nmod) used
zdv (r_compound) therapy
bupivacaine (r_appos) dysrhythmias
administered (l_nmod) onset
aspirin (r_nmod) non-users
patient (l_amod) ill
subjects (l_amod) neuropathy
phosphate (r_compound) reabsorption
ointment (r_conj) %
types (l_nmod) spasms
days (r_nmod) appeared
patients (l_acl:relcl) experienced
warfarin (r_nmod) absorption
difference (r_nmod) appeared
born (r_acl:relcl) infants
administration (r_nmod) connection
gamma-aminobutyric (r_amod) accounts
associated (l_nsubjpass) hypertension
placebo (l_nmod) tachycardia
bromide (r_conj) drug
reach (l_advcl) have
treated (l_conj) suffered
cause (l_ccomp) beat
otoprotectant (l_nmod) loss
promotes (l_dobj) occurrence
prevention (l_nmod) reactivation
suggesting (r_advcl) demonstrated
showed (r_parataxis) demonstrated
develop (l_dobj) test
trials (l_compound) arthritis
use (r_nmod) effects
ppa/caffeine (r_nsubj) lead
carbamazepine (r_compound) levels
glutamate (r_conj) naloxone
index (l_compound) glomerulosclerosis
power (l_nmod) oscillation
reverse (l_dobj) catalepsy
analyzed (l_xcomp) test
bnpp-induced (r_amod) reduction
women (r_nmod) 3.0
adults (l_nmod) treatment
any (l_nmod) conditions
phenotypes (l_amod) hemorrhagic
evidence (l_nmod) tamponade
bradydysrhythmias (r_dobj) exhibited
hepatotoxicity (r_nmod) example
neuroprotection (r_nsubjpass) associated
received (l_nmod) evidence
blockade (r_nmod) affected
agents (r_nmod) treated
selected (l_nmod) sensitivities
patients (r_nsubj) have
concerns (r_nsubj) led
jj (r_conj) jj
test (r_conj) test
instillation (r_nmod) treating
cyclophosphamide (r_nmod) toxicity
mhc-i (r_nmod) up-regulation
use (r_nsubj) increase
ccnu (r_appos) lomustine
was (l_attr) history
pge1 (r_nsubj) preferable
risk (r_nmod) to
cisplatin (r_nmod) addition
rats (l_amod) diabetic
implications (r_nsubj) become
peptide (r_nmod) markers
infusion (r_nmod) periods
phosphate (r_compound) binder
factors (r_nsubj) combination
propagation (l_acl:relcl) initiated
bigeminy (l_conj) runs
improved (l_nsubj) globulin
139317 (r_nummod) fr
reduced (l_dobj) intensity
developed (l_dobj) nodosum
bupivacaine-induced (r_amod) depression
reduce (l_nmod) disability
recipients (r_nmod) commonly
described (l_nsubjpass) leukoencephalopathy
case (l_nmod) dementia
patients (l_nmod) risk
events (l_appos) events
increased (l_nsubjpass) catalepsy
fluctuating (l_dobj) disease
induced (r_acl) aggregations
regrowth (l_nmod) tumors
tspa (r_appos) thiotepa
increase (l_nmod) deviation
melphalan (r_nmod) had
pointes (l_dep) supports
developed (l_dobj) moderate
mk-801 (r_nsubjpass) tested
sex (l_nsubj) factors
resection (l_nmod) tumors
avoided (l_nsubjpass) events
experienced (l_dobj) exacerbation
common (l_nmod) discontinuations
improvement (l_nmod) dyskinesia
use (l_nmod) combination
inhibitors (r_nmod) number
receptors (r_nmod) mediated
reversing (l_dobj) amnesia
sod (r_nmod) differ
compared (r_dep) lower
l-arginine (r_nmod) effects
antagonist (r_appos) granisetron
schedules (r_nmod) use
streptozotocin (r_nsubj) causes
cocaine (l_conj) cardiotoxity
reverses (l_dobj) catalepsy
patient (l_nmod) cardiomyopathy
prescribed (l_conj) developed
type (l_nummod) ii
treatment (l_conj) medicine
ketoconazole (r_nmod) doses
level (r_nsubj) concentration
substantial (l_nmod) rats
types (r_nmod) use
pattern (r_dobj) determined
testosterone (r_nmod) prevalences
media (r_xcomp) considered
treated (r_acl) woman
concentrations (r_nmod) spite
had (l_dobj) syndrome
effect (l_nmod) effect
increases (l_nmod) stress
concentration (r_dobj) reducing
caused (l_dobj) promotion
cavity (l_conj) function
greater (l_conj) occurred
assess (l_dobj) incidence
metronidazole (r_nmod) involvement
conducted (l_advcl) estimate
treatment (r_dobj) followed
treatment (r_nmod) years
pregnane-20-ones (r_appos) progesterone
glycine (r_nmod) accumulation
increases (r_nmod) effects
developed (l_dobj) deterioration
doses (r_dobj) log
sertraline (r_compound) administration
group (r_nmod) frequent
frequent (l_nmod) ich
cessation (r_nsubj) resulted
therapy (r_nmod) continuation
developed (l_dobj) vte
caa (r_appos) chloroacetaldehyde
mipafox (r_nmod) exposed
reducing (l_dobj) durations
cyclophosphamide-related (r_amod) toxicity
used (r_acl:relcl) anaesthetic
elevates (l_nmod) mice
isoniazid (r_nmod) pretreated
dopamine (r_compound) neurotransmission
fentanyl-dexamethasone (r_conj) fentanyl
produced (r_acl) that
pilocarpine (r_nmod) injected
treatment (l_nmod) steatosis
woman (l_nmod) syndrome
received (r_conj) total
sirolimus-treated (r_amod) patient
evaluated (l_parataxis) had
rad001 (r_appos) everolimus
remifentanil-related (r_amod) complications
results (l_nsubj) damage
produced (l_xcomp) seizure
used (r_conj) assessed
chlormethiazole (l_nmod) symptoms
side-effects (l_appos) sedation
degree (l_nmod) hypotension
have (l_dobj) contractions
fact (r_nsubj) suggests
reduces (l_dobj) injury
olanzapine (r_nmod) greater
docetaxel (r_nmod) combination
isradipine (r_compound) treatment
variable (l_nsubj) extension
remifentanil (r_nmod) dose
fa (r_nmod) preceded
treatment (r_nmod) months
reason (l_nsubj) relief
offspring (r_nmod) glomerulosclerosis
taking (l_nmod) prevention
na+-extrusion (r_nmod) accompanied
received (l_advcl) caused
effects (r_nmod) hospitalisation
skf (r_nmod) combination
medication (r_nmod) increase
gaba (r_nmod) increase
indicated (l_dobj) insipidus
h (r_nsubjpass) observed
those (r_dobj) identified
patients (l_compound) psychosis
anemia (r_nmod) strategies
rule (l_dobj) syndrome
iron (r_compound) staining
therapy (l_nmod) types
dexmedetomidine (r_dobj) receive
melatonin (r_nmod) action
continued (l_conj) had
development (r_nsubjpass) curtailed
therapies (r_nmod) trial
prevented (l_nsubjpass) coma
developing (l_dobj) function
episodes (l_nmod) mania
had (l_conj) hypertrophy
applicators (r_nmod) incidence
hypertension (r_nmod) association
antagonist (r_dep) administration
convulsions (r_nmod) appearance
peroxidase (r_conj) dismutase
developed (l_dobj) eps
alteration (l_nmod) sensitivity
presence (r_appos) patient
contributing (l_nmod) rotation
concentration (r_nmod) inhibition
treatment (l_nmod) epilepsy
head (r_conj) aggressiveness
effect (r_nmod) patient
calcium (r_compound) antagonists
tolerance (l_nmod) rigidity
combination (r_conj) tea
suggests (l_ccomp) is
cocaine- (l_dep) seizures
e2 (r_compound) release
had (l_dobj) regression
technique (l_acl:relcl) evaluate
seems (l_nmod) fact
associated (l_nmod) hypothyroidism
whereas (l_nsubj) %
provision (r_nmod) observed
levels (r_nmod) evident
hepatitis (r_nmod) mechanism
loss (l_nmod) vision
carboplatin (r_compound) phases
toxicity (r_dobj) potentiates
effects (l_nmod) carcinogenesis
hypotension (r_nmod) effect
assessed (l_dobj) risk
somnolence (l_conj) polydipsia
histamine (r_compound) receptors
pyridoxine (r_dobj) administering
clotiazepam (r_nmod) related
suspected (l_nsubjpass) toxicity
sulphate (r_nmod) effects
amphetamine-induced (r_amod) stereotypies
receptors (r_dobj) stimulating
estrogen-induced (r_amod) lh
d (r_nmod) treatment
mixture (r_conj) dox
melphalan (r_nmod) insufficiency
cocaine (r_nmod) intoxications
correlated (l_nsubjpass) injury
dexamphetamine- (r_nmod) effect
given (l_xcomp) resulting
withdrawal (r_nmod) mechanisms
doses (r_nsubjpass) associated
implicated (l_dep) describes
patient (r_nmod) report
precipitate (l_dobj) thrombocytopenia
injection (r_nmod) reduced
dilevalol (r_amod) antigens
domperidone (r_nsubj) potentiate
progestagens (r_dobj) containing
minutes (r_nmod) rats
1999 (r_dep) undergone
ratings (l_nmod) pain
effects (r_nsubjpass) determined
active (l_dep) reversal
oct (r_nsubj) decreased
given (r_advcl) reduces
metformin (r_nmod) effects
resolved (l_dobj) hiccups
encephalopathy (l_dep) syndrome
vpu (r_nsubj) reduce
rats (r_nmod) treatment
administration (r_nmod) results
creatinine (r_dep) failure
suppress (l_dobj) arrhythmias
recognition (l_nmod) angioedema
complication (l_nsubj) paralysis
metabolised (l_xcomp) form
effects (r_dobj) reversed
lithium-induced (r_amod) nephropathy
methods (l_acl:relcl) sensitive
studied (l_nmod) dyskinesia
treated (r_acl) acromegaly
dopamine (r_compound) antagonist
cleared (r_acl:relcl) patients
myopathy (r_nmod) woman
regimens (l_nmod) cancer
agitation (l_conj) death
alpha (r_nmod) saline
treated (l_nmod) schedule
seizures (r_nmod) increase
included (l_dobj) sweating
(+/-)-pg-9 (r_nsubj) able
that (r_nmod) degree
receptor (r_compound) antagonists
propranolol (r_dobj) taking
those (l_nmod) hypertension
hyperthermia (l_nmod) tumor
alpha-tc (r_appos) alpha-tocopherol
aminonucleoside (r_nmod) ascertain
influence (r_dobj) suggesting
severity (l_compound) symptom
occurred (l_nsubj) agranulocytosis
effective (l_advcl) suppressing
order (l_acl) clarify
exhibit (l_dobj) dyskinesias
received (l_nsubj) patients
disulfiram (r_compound) intoxication
include (l_dobj) phase
myeloma (l_conj) lymphoma
group (l_nmod) patients
reversed (r_conj) induced
enabled (l_nsubj) withdrawal
adr (r_compound) antitumor
trifluoroacetyl-altered (r_amod) proteins
analgesia- (l_conj) incoordination
formulation (r_nmod) volunteers
glipizide (r_conj) glibenclamide
performing (l_dobj) review
lithium (r_compound) concentration
reported (l_nsubjpass) cases
low (r_conj) resulted
urea (r_conj) creatinine
supports (l_dobj) frequency
rhabdomyolysis (r_dobj) illustrate
evident (l_advcl) indicating
events (l_compound) thromboembolic
cause (l_nmod) anemia
reduce (l_dobj) seizures
content (r_conj) permeability
glutamate (r_nmod) increases
regardless (r_prep) tended
observed (l_dep) hypotension
support (l_nsubj) relationship
polyneuropathy (r_dobj) superimposed
treatment (r_nsubj) presented
factor-beta1 (l_compound) tumor
salivation (l_conj) agitation
combinations (r_nmod) induced
prophylaxis (r_nsubjpass) associated
systolic (l_conj) dysfunction
elicited (l_nsubjpass) catalepsy
small (l_conj) rich
shed (l_nmod) mechanisms
morphine (r_amod) analgesia
bcnu (r_compound) chemotherapy
metronidazole (r_compound) treatment
change (l_dobj) tachycardia
administration (r_nmod) case
mg/min (r_conj) saline
bupivacaine (r_conj) prilocaine
dopamine (r_compound) receptor
dosing (l_nmod) patients
coincided (l_nsubj) infarction
severity (r_nmod) relationship
exceeded (r_advcl) discontinued
amplitudes (l_compound) tremor
steroid-induced (r_dep) transient
insipidus (r_nsubjpass) considered
therapy (r_nmod) observed
carbonate (r_conj) regurgitation
sustained-release (r_nmod) safety
valdecoxib (r_nmod) effects
relationship (l_nmod) cancer
episodes (l_nmod) hypotension
inpatients (l_nmod) eps
ifosfamide (r_nmod) administration
relationship (r_nsubj) support
induced (r_acl) responses
agonists (r_nsubj) reduce
rate (l_nmod) thalidomide
explanation (l_nmod) association
doses (r_dobj) vomiting
studied (l_nmod) seizures
vasopressin (r_nmod) influence
use (l_conj) risk
adriamycin (r_nmod) progression
aspirin (r_nmod) evidence
gains (l_dobj) popularity
denopamine (r_nmod) trials
schizophrenia (l_conj) episodes
lidocaine (r_nsubj) prevent
dex (r_appos) superoxide
ifx (r_nmod) use
symptoms (l_conj) anxiety
trihexyphenidyl (r_nmod) effects
6-ohda (r_appos) 6-hydroxydopamine
appears (l_nsubj) tachycardia
intravitreal (l_nmod) retinochoroidopathy
administration (l_acl) prevent
explored (l_nmod) rats
case (l_nmod) nephrolithiasis
hypokalemia (l_nmod) patients
lithium-treated (r_amod) insipidus
forms (l_nmod) functions
specific (r_xcomp) seems
pan (r_appos) amino-nucleoside
occurrence (l_nmod) bruising
third-generation (r_nmod) included
markers (l_compound) necrosis
reported (l_nsubjpass) toxicity
pentamidine (r_nmod) discontinuation
child (r_nmod) arising
= (l_dobj) model
severity (l_nmod) infarction
hydroxytyrosol (r_amod) ameliorates
shown (l_xcomp) counteract
pilsicainide (r_dobj) received
dipyridamole-induced (r_amod) hyperemia
conditions (l_acl:relcl) predisposed
pulmonary (l_dep) insufficiency
hoarseness (l_dep) thrush
administered (r_dep) reversal
ulcers (l_conj) polyarthralgia
bau (r_conj) azt
thought (l_nsubjpass) syndrome
application (r_nsubjpass) repeated
features (l_nmod) disease
case (l_nmod) rpgn
ethambutol (r_nmod) hazards
hydrochloride (r_nmod) induced
showed (l_dobj) protection
antibody (l_compound) hit
patients (l_nmod) hypercalcemia
neurons (r_nmod) loss
injury (r_appos) chloride
azt (r_compound) incorporation
administration (r_nmod) demonstrated
produced (l_dobj) jerks
discontinuation (r_nsubj) resolved
carboplatin (r_conj) cyclophosphamide
adriamycin- (r_amod) toxicity
carmofur-induced (r_amod) disorders
rats (l_acl) subjected
isradipine (r_nmod) studies
treatment (l_nmod) disorder
therapy (l_nmod) tachycardia
hydrochloride (r_nsubj) nitrite
pg (r_conj) ngf
lithium (r_compound) rats
diagnosis (l_compound) cancer
increased (l_dobj) bp
thrombocytopenia (l_conj) hypoaldosteronism
cardiotoxicity (r_nmod) cardiotoxicity
result (l_nmod) exposure
meth (r_nmod) treated
treated (r_acl) shr
had (r_conj) controlled
isoflurane (r_nsubj) cause
use (l_conj) tumors
stabilizer/rigidifier (r_nmod) use
cocaine (r_compound) benzoylecgonine
parkinsonism (l_acl) induced
bradykinin (r_nmod) synthesis/release
quinine (r_compound) infusion
rates (l_nmod) toxicity
topiramate (r_nmod) prevention
recurrence (l_nmod) vt
case (r_dobj) present
irradiation (r_nmod) experienced
administration (l_nmod) boy
method (l_nmod) treatment
monotherapy (r_nmod) treatment
severity (l_nmod) patients
subjects (r_nmod) observed
use (r_nmod) caused
use (r_appos) patients
doxorubicin (r_nmod) produced
protectors (l_nmod) cardiotoxicity
tmp (r_conj) pge1
therapy (r_nmod) supplementation
cocaine-induced (r_amod) paranoia
assessed (l_nsubjpass) incidence
gtn-induced (r_amod) headache
ptz (r_conj) les
fluoxetine-induced (r_amod) erections
amisulpride (r_advcl) cases
procyclindine (r_compound) treatment
isotretinoin (r_nmod) exposure
potentials (l_amod) convulsive
found (l_conj) discontinued
methotrexate (r_dep) available
cm (r_appos) media
activation (r_nmod) suppression
detection (r_dobj) confounds
event (l_nmod) toxicity
jerks (l_appos) mj
administration (r_nmod) prevented
blockade (r_nsubj) reduce
using (l_nmod) months
mip (r_compound) inhibition
initiate (l_dobj) myopathy
watch (l_conj) report
warrant (r_ccomp) suggest
injury (l_nmod) nephrosis
activity (r_dobj) antagonized
evaluated (l_advcl) dressing
use (l_nmod) patient
amiodarone-induced (r_amod) hypothyroidism
atenolol (r_conj) labetalol
msg (r_nmod) administration
induce (l_conj) symptoms
placebo (l_nmod) ratings
episodes (l_nmod) tdp
lines (l_compound) neuroblastoma
serotonin (r_compound) release
suggests (l_nsubj) finding
cns (l_conj) depression
infusion (r_nmod) rates
developed (l_nsubj) tachycardia
chloride (r_compound) ingestion
block (l_dobj) seizures
treatment (r_nmod) observed
increased (l_dobj) %
administration (r_nmod) frequency
melphalan (r_nmod) patients
deficiency (r_conj) fluoroacetate
precipitate (l_dobj) agitation
demand (r_nmod) increase
changes (l_acl) induced
minoxidil (r_compound) use
anthracyclines (r_appos) fluorouracil
derivative (l_acl:relcl) different
level (r_nsubj) meq/l.
role (l_nmod) pathogenesis
contributed (l_nmod) incontinence
following (r_advcl) developed
methylprednisolone (r_conj) dexamethasone
infusion (l_nmod) part
ether (r_nmod) induced
pan (r_compound) group
aes (l_amod) hypertension-related
decreased (l_nsubj) amplitudes
characteristics (l_nmod) hepatitis
proposed (l_nmod) prevention
exposure (r_nmod) characterized
absence (l_nmod) rigidity
vasospasm (l_conj) infarction
severe (l_nmod) migraineurs
flumazenil (r_nsubj) induces
sensitive (l_nmod) doses
treatment (r_nmod) changes
hypothesize (l_advcl) thought
l-dopa (r_conj) day
born (r_acl) infants
pimecrolimus (r_conj) tacrolimus
chloride (r_compound) supplementation
calcium-binding (r_amod) protein
carcinoma (l_nmod) cervix
cyclosporine-induced (r_amod) nephropathy
mechanisms (l_amod) operative
excretion (r_nsubjpass) decreased
substantiates (l_advcl) causing
mk-801 (r_compound) injection
timing (l_nmod) injury
pretreatment (r_nsubj) decreased
receptors (r_nmod) expression
ligation- (l_conj) arrhythmias
descending (r_advcl) lesion
compared (l_nmod) outpatients
effect (r_nmod) other
highlights (l_dobj) possibility
constructed (l_xcomp) using
risk (r_nmod) add
had (l_dobj) decreases
gspe (r_compound) preexposure
reduced (l_dobj) rate
caused (r_acl) gravis
remains (l_xcomp) indicating
continued (l_nmod) onset
lots (r_nmod) number
oxide (r_compound) synthase
effectiveness (r_conj) assessment
limit (l_compound) myelosuppression
hemorrhage (r_nsubj) type
bupivacaine (r_nmod) administration
movements (l_conj) protrusions
received (r_acl:relcl) mothers
treated (r_acl) group
acitretin (r_nmod) treated
occurred (l_advcl) suggesting
chloride (r_dobj) using
lamivudine (l_nmod) therapy
treated (l_conj) rose
tended (l_nsubj) rotation
nitrite (r_advmod) increased
injected (l_nmod) bupivacaine
contractility (r_nsubj) suggest
had (l_conj) occurred
bupivacaine (l_nmod) respect
symptoms (l_nmod) hepatitis
have (r_advcl) reach
stopping (r_advcl) consequences
syndrome (l_amod) cardiomyopathy
negative (l_nmod) mdm
fazadinium (r_nmod) dose
developed (l_dobj) reactions
related (l_nmod) vulnerability
piroxicam (r_nmod) exposed
b. (l_compound) group
loss (r_nmod) associated
induces (l_dobj) obesity
cisapride (r_dobj) taking
disease (l_appos) esrd
seen (l_nmod) psychosis
% (r_conj) occurred
glutamate-oxaloacetate (r_amod) transaminase
scoline (r_amod) pain
degree (l_nmod) degeneration
medications. (r_compound) antibody
busulfan (r_nsubjpass) known
patient (l_acl) known
occurred (r_xcomp) known
presence (l_nmod) hypothermia
established (l_nsubjpass) ns
bromocriptine (r_dobj) received
concentration (r_nsubj) higher
include (r_ccomp) fact
iodixanol (r_nmod) iopamidol
effect (r_dobj) overcome
coadministration (r_nmod) induced
attenuated (r_conj) impaired
users (l_nmod) is/tia
mesna (r_compound) doses
valproate (r_compound) therapy
bau (r_nsubj) reduced
produced (r_appos) results
recurrence (l_nmod) reaction
admitted (r_acl) pain
caused (l_dobj) failure
group (r_nmod) higher
clearance (r_conj) therapy
associated (r_advcl) lead
doses (l_amod) nephrotoxic
vindesine (l_conj) drugs
naproxen (r_conj) celecoxib
amount (r_nmod) replacing
observed (l_nmod) subjects
temsirolimus (r_compound) treatment
phosphate (r_nmod) levels
patients (l_nmod) cin
underwent (l_dobj) total
undergoing (l_nmod) anesthesia
reported (l_nsubjpass) case
nuclei (l_nmod) cells
lesion (r_dobj) produce
related (r_amod) toxicity
comparison (l_acl) assess
hypertension (l_conj) bradycardia
cause (l_dobj) anemia
reported (l_xcomp) cause
tolerated (l_nmod) adhd
required (r_parataxis) responded
users (r_nmod) recognition
effects (r_nsubjpass) examined
occurred (l_nsubj) material
treatment (r_nmod) attributed
amiodarone-induced (r_amod) block
signaling (r_nsubj) critical
with (r_prep) combined
salbutamol (r_nmod) beta-agonist
prevent (l_dobj) amnesia
5-ht (r_compound) content
diagnosed (l_nmod) jaundice
reduction (l_conj) prevention
mg/kg (r_nmod) infant
ondansetron (r_amod) prophylaxis
mg/kg (r_nsubj) reduced
assess (l_dobj) ability
use (r_nsubj) provided
dose (r_nmod) received
hypotension (l_conj) bradycardia
syndrome (l_nsubj) alterations
hbsag (r_compound) patients
co2 (r_compound) stimuli
occurring (r_acl) complication
acid (r_nsubj) showed
levobupivacaine (r_nsubj) have
induces (l_dobj) tachycardia
interaction (r_nmod) haemopericardium
improves (l_dobj) bradykinesia
vasopressin (r_nsubj) plays
dose-dependent (l_nsubj) neurotoxicity
amyloidosis (l_compound) al
replicate (l_conj) augment
was (l_attr) risk
sensitivity (l_nmod) rats
cocaine-associated (r_amod) ischemia
cocaine-related (r_amod) aneurysms
warfarin (r_nmod) report
minimize (l_dobj) impairment
warfarin-treated (r_amod) rats
erythromycin (r_nmod) profile
variety (l_nmod) diseases
context (r_nmod) resulted
incidence (l_nmod) thromboembolism
b-induced (r_amod) seizures
inhibit (l_dobj) hyperemia
seemed (l_nsubj) bradykinin
coadministration (l_nmod) agent
failure (r_dobj) develop
ecstasy-polydrug (r_amod) users
appears (r_conj) administered
cause (l_dobj) vasculitis
function (l_nmod) children
alfentanil (r_compound) kg-1
digoxin (r_nsubj) has
encephalopathy (l_conj) encephalitis
mechanisms (r_dobj) plausible
measured (r_acl) test
study (l_nmod) toxicity
tamoxifen (r_nmod) effects
antibiotic (r_dep) macrolide
hypothesis (l_ccomp) results
discontinuation (r_nmod) improved
contained (r_acl:relcl) diet
supplementation (r_conj) patients
e2-induced (r_amod) hyperalgesia
cause (l_nmod) microangiopathy
induced (r_acl) anesthesia
diclofenac (l_nmod) patients
correlated (r_ccomp) determine
followed (r_dep) develop
staining (r_dobj) exhibited
patient (r_nmod) glomerulonephritis
domperione (r_nmod) effect
patients (l_amod) diarrhoea-predominant
prescribed (r_advcl) consider
pretreatment (r_nmod) concentrations
associated (r_acl:relcl) disease
clarithromycin (r_nmod) increment
attribute (l_dobj) episodes
failure (r_nmod) pathogenesis
cause (l_nmod) hypercalcemia
neurotoxicity (l_amod) close
mmc-related (r_amod) cardiotoxicity
alfentanil (r_amod) group
occurrence (l_nmod) signs
model (l_amod) cardiomyopathy
change (l_nmod) hyperactivity
incidence (l_nmod) pressure
agent (l_nmod) neuropathy
convulsions (r_nmod) inhibitors
mechanism (l_amod) hypotensive
received (l_dobj) therapy
used (l_conj) improved
seizures (r_nmod) mechanism
presence (r_nmod) formed
high (l_dep) produce
retention- (r_nmod) prevention
latencies (r_dobj) had
mg (r_compound) bid
effective (l_nmod) patients
haloperidol (r_nsubj) enhanced
tests (l_compound) catalepsy
quality (l_nmod) life
curcumin (r_compound) administration
denopamine (l_nmod) failure
patients (l_nmod) reaction
relieved (r_parataxis) showed
suffered (l_dobj) infarction
nad-precursors (r_nmod) free
type (l_nmod) stroke
infusion (r_nmod) rats
treating (l_dobj) seizures
occur (l_nsubj) hypotension
decreased (l_dobj) hyperactivity
isoproterenol (r_nmod) pretreatment
acetaminophen-induced (r_amod) hypotension
found (l_nmod) sites
fluvastatin (r_nmod) treatment
indinavir (r_dobj) receiving
has (l_dobj) risk
progression (r_nmod) involved
protects (l_nmod) model
rofecoxib (r_nmod) those
beta-hydroxylase (r_compound) inhibitor
pretreatment (l_conj) increases
connection (r_nmod) intoxication
addition (r_nmod) considered
ca(2 (r_nmod) role
showed (l_dobj) degree
nimesulide (r_conj) safety
propranolol (r_compound) toxicity
recurred (l_nsubj) dyskinesia
thiotepa (r_conj) cyclophosphamide
phenytoin (r_compound) overdosages
results (l_dep) myelosuppression
magnesium (r_compound) levels
treated (r_acl) disorder
risk (l_nmod) hyperplasia
verapamil (r_nmod) withdrawal
agent (l_compound) tumor
doses (r_conj) levels
lt (r_dobj) undergoing
induced (r_amod) myocarditis
steroid (r_compound) groups
injury (r_nmod) markers
persons (r_nmod) similar
impact (r_nsubj) factor
progression (l_nmod) glomerulosclerosis
gluconate (r_nmod) treatment
valproate (r_nmod) started
ra (r_nmod) induced
risk (l_nmod) arrhythmias
treated (r_acl:relcl) patients
threshold (r_dobj) lowered
sample (l_nmod) addicts
case (l_nmod) poisoning
relieved (r_acl) spasm
levels (r_dobj) counteracted
ne (r_appos) norepinephrine
result (l_acl) deposited
acetate (r_nsubjpass) licensed
ratios (l_appos) estimate
estrogen (r_nmod) binding
d-penicillamine (r_nsubjpass) used
able (l_nsubj) measures
strains (l_nmod) co-infection
naloxone (r_conj) atropine
were (l_dep) cld
transmission (r_nsubj) reduce
associated (r_acl) secretion
background (r_nsubj) nephropathy
associated (r_amod) syndrome
methods (l_nmod) radiculopathy
factors (r_nmod) combination
hyoscine (r_compound) overdosage
effects (l_nmod) models
degree (l_nmod) abnormality
methylphenidate (r_conj) clonidine
time (r_conj) mean
calcium (r_nmod) importance
supplementation (r_nsubj) failed
mangiferin (r_compound) administration
use (l_conj) hypotension
reduce (l_dobj) frequency
methylprednisolone (r_nmod) responded
5 (r_conj) increasing
suffering (l_nmod) seizures
safety (r_nsubj) intravitreal
potassium (r_compound) currents
occurred (l_conj) associated
need (l_xcomp) assess
ccnu (r_compound) toxicity
% (r_dobj) using
role (r_nsubjpass) evaluated
azidothymidine-induced (r_amod) suppression
enflurane (r_conj) became
pretreatment (r_nmod) effect
quinine-associated (r_amod) syndrome
performed (r_advcl) produce
erythromycin (r_conj) cisapride
gamma-hch (r_compound) response
adrenaline-induced (r_amod) effect
chloride (r_nsubj) remedy
received (r_acl:relcl) those
l-arginine (r_conj) inhibitor
crocin (r_nsubjpass) considered
did (l_advcl) estimate
lead (l_nmod) disease
ribavirin-induced (r_amod) hemolysis
phenomenon (l_conj) dyspnoea
received (l_dobj) transplantation
case (l_acl:relcl) patient
ticlopidine (r_nmod) effect
assess (l_dobj) interaction
epinephrine (r_conj) bupivacaine
mz (r_compound) dose
modification (r_dobj) indicate
observed (r_conj) reported
reduces (l_dobj) incidence
dismutase (r_conj) increased
commencement (r_nmod) associated
injection (r_nmod) associated
dizziness (l_conj) inability
years (r_nmod) years
associated (l_nmod) cystitis
hypotension (r_nmod) decreased
using (r_advcl) showed
dizziness (l_nmod) nystagmus
proves (l_xcomp) alternative
mechanism (l_nmod) paralysis
receiving (r_advcl) contraindication
hexachloride (r_nmod) induced
accompanied (l_nmod) na+-extrusion
pdtc (r_nmod) treatment
patients (l_nmod) ibs
taking (r_acl) male
diltiazem (r_nmod) administration
focused (l_nmod) malformations
odds (l_appos) ratios
erythrodysesthesia (l_conj) stomatitis
induced (r_amod) ischaemia
use (r_acl:relcl) tests
presented (l_nmod) eruption
sodium (r_compound) level
ketoconazole (r_nmod) basis
corticotropin-releasing (r_amod) hormone
activity (l_conj) cardiotoxicity
accompanied (l_conj) tachycardia
sodium (r_compound) status
diagnosis (l_amod) consistent
vancomycin-induced (r_amod) nephrotoxicity
response (l_amod) pupillary
aspartate (r_conj) acid
concentrations (r_conj) had
ketamine (r_nmod) administration
development (l_nmod) insipidus
patients (l_nmod) co-infection
dysphonia (l_appos) adsd
glibenclamide-sensitive (r_amod) hypotension
subgroup (r_nmod) %
ocular (l_dep) toxicity
tacrolimus (r_nsubjpass) suspected
daunorubicin (r_nmod) myelosuppression
evaluation (l_nmod) treatment
bore (l_dobj) carcinomas
pge2 (r_conj) ngf
ppa (r_nsubj) increased
octapeptide (r_compound) ester
parallel (l_nmod) effect
order (l_acl) address
developed (l_dobj) dilation
induction (r_nmod) way
caa (r_nsubj) reacts
cocaine (r_conj) lidocaine
4.10 (l_nsubj) rate
studies (r_nsubjpass) seen
increased (l_dobj) preference
sulfate (r_nmod) mg/kg/day
spironolactone-induced (r_amod) insufficiency
ischemia (r_dobj) improves
system (r_nmod) blockade
pineal (l_dobj) idolamines
augment (l_dobj) effects
profile (r_dobj) have
hypothyroidism (l_conj) hypercalcemia
points (l_nmod) effect
prevalence (l_nmod) patients
role (l_nmod) occurrence
therapy (r_nmod) related
phenylpropanolamine (r_compound) overdose
amiloride (r_nmod) effect
medication (r_dobj) started
acid (r_compound) therapy
programs (l_dep) hypertension
that (r_nsubj) mg/kg
atra-induced (r_amod) myositis
glibenclamide (r_nmod) increased
patient (r_nmod) occurring
compared (l_nmod) measures
diazinon (r_compound) exposure
predictors (l_nmod) seizures
fatiguability (l_conj) dyspnoea
patient (r_nmod) rhabdomyolysis
pilocarpine-induced (r_amod) convulsions
injected (l_xcomp) induce
morphine-treated (r_amod) animals
antagonizing (l_dobj) effects
mice (r_nmod) treatment
catalepsy (r_nsubjpass) tested
anesthesia (r_nmod) role
methylphenidate (r_nmod) caused
succinylcholine (r_compound) apnoea
heparin (r_nmod) reaction
have (l_dobj) flutter
fact (r_nmod) attributed
usage (l_nmod) patients
5-ht (r_nsubjpass) involved
injury (r_nsubj) involves
incidence (l_nmod) haemorrhage
problematic (l_nmod) patients
treat (l_dobj) hypotension
stopped (l_advcl) headache
cimetidine-associated (r_amod) confusion
reaction (r_nmod) reports
addition (r_nsubj) increases
produce (l_dobj) complications
testosterone (r_conj) n-nitroso-n-methylurea
possibility (l_nmod) hyperkalemia
aorta (l_conj) atresia
tasks (r_conj) included
stz-induced (r_amod) model
serotonin (r_compound) inhibitor
inhibition (r_conj) density
oxprenolol (r_amod) pretreatment
carboplatin (r_nmod) combination
treatment (l_nmod) neutropenia
grade (l_nmod) fibrosis
nephrotoxicity (r_nmod) ascribed
associated (l_nmod) hypometabolism
glipizide (r_nmod) increased
develop (l_dobj) esrd
is (l_ccomp) cause
case (r_conj) case
required (r_advcl) required
clonidine (r_nmod) evoked
kg-1 (r_nmod) administration
objective (l_dep) monotherapy
tested (l_conj) determined
role (l_nmod) supplementation
(ptu)-associated (r_compound) vasculitis
atypia (l_conj) carcinoma
reactivation (l_compound) b
causes (l_xcomp) indicating
administered (l_conj) prevented
reduced (l_dobj) damage
carbamazepine (r_nmod) effect
treatment (r_nsubj) alters
defined (l_nsubjpass) syndrome
taken (r_advcl) prevented
mdma (r_nmod) users
development (l_nmod) toxicity
bilirubin (r_compound) deposition
suppressants (r_nmod) prescription
confined (r_conj) occurred
sirolimus (r_nmod) discontinuation
have (l_dobj) sensitivity
capecitabine (r_conj) identified
dose (r_appos) insult
rats (r_nmod) determined
alkali (r_conj) calcium
response (l_amod) hypertensive
type (l_dep) type
increased (l_dobj) malondialdehyde
balance (r_conj) function
4/heparin-reactive (r_amod) antibody
patient (r_conj) syndrome
application (r_nsubj) appeared
effects (r_nmod) sensitive
recognition (r_nsubj) resulted
dup (r_nsubj) prevents
topotecan (l_nmod) combination
occurring (r_advcl) suspect
association (l_nmod) initiation
treated (r_advcl) report
actions (l_acl) associated
seizures (l_compound) hallucinosis
dfp-atropine (r_nmod) given
males (l_appos) disorder
re (r_nsubj) inhibited
study (r_dep) valsartan
presented (l_nmod) near-syncope
patient (l_amod) schizophrenic
silver-stained (r_amod) ca3
infusion (r_nsubjpass) associated
taking (r_acl) women
cimetidine (r_compound) administration
patients (l_acl:relcl) develop
cycloheximide (r_conj) injected
targets (l_nmod) treatment
evaluated (l_xcomp) cause
effects (l_conj) substrate
acetate (r_dep) cab
benzodiazepines (r_nmod) decontamination
naloxone (r_nsubj) inhibited
pretreatment (r_nsubj) caused
constellation (l_nmod) dermatitis
warfarin (r_nsubj) inhibits
has (l_xcomp) considered
glibenclamide (r_nmod) attenuated
infusion (r_dobj) required
deficient (r_nmod) myopathic
4-phenylbutyrate (r_nmod) tm
commencement (l_nmod) therapy
ergot (r_compound) preparations
data (r_dobj) evaluated
case (l_nmod) deterioration
change (l_dobj) glutamate
those (l_nmod) cancer
associated (r_xcomp) appears
found (l_ccomp) is
occur (r_ccomp) demonstrating
comparison (l_nmod) toxicity
years (l_nummod) 3.4
receiving (l_dobj) clonidine
response (l_nmod) agents
completing (l_nmod) remd
aconitine-induced (r_amod) rat
ozone (r_nmod) disease
amide (r_nmod) effects
different (l_nmod) those
due (l_nsubj) weakness
induced (l_nmod) patients
carbimazole (r_nmod) treatment
obtained (l_nmod) rats
treatment (r_nsubj) prevented
bromide (r_nmod) effects
torsades (l_nmod) pointes
droperidol (r_compound) administration
caused (r_acl) failure
carbenicillin (r_nmod) combined
mg/day (l_nmod) disease
prednisolone (r_nmod) administration
carboplatin (r_nmod) injections
naa (r_nmod) inhibition
no (r_nmod) production
effect (l_nsubj) vasculitis
results (l_appos) induce
cy (r_nsubj) caused
pentylenetetrazole (r_nmod) induced
administration (r_nmod) present
described (l_nsubjpass) thrombosis
ethanol/aap-mice (r_nmod) given
caa (r_nsubj) reduced
tamoxifen (r_nmod) allocated
attributed (r_acl:relcl) hormone
exacerbates (l_compound) bradycardia
rg1 (r_conj) ginsenoside
effects (l_nmod) neutropenia
replacing (r_conj) withdrawing
patients (l_amod) psoriatic
evidence (l_nmod) association
showed (l_dobj) tendency
arrhythmias (l_acl:relcl) developed
polyphenol (r_appos) mangiferin
reproduce (l_dobj) dyskinesias
cream (r_conj) treated
effectiveness (l_nmod) sphincter
seen (l_nmod) addition
minimised (l_dep) use
vasopressin (l_nmod) contributor
action (r_xcomp) assumed
findings (l_nmod) man
dsp4 (r_nmod) action
syndromes (l_nmod) proteinuria
suffer (l_nmod) fever
apparent (l_nmod) cohort
seizure (l_nmod) pethidine
adjustment (r_nsubjpass) accomplished
activity (r_dep) inhibition
inhibitor (r_appos) boy
pravastatin (r_dobj) assumed
tranylcypromine (r_dobj) taking
most (l_nmod) rats
doxorubicin (r_nmod) courses
compared (l_nmod) maleate
demonstrated (l_nsubjpass) ischemia
possibility (l_ccomp) associated
inhibitor (r_appos) fla-63
adults (l_amod) hypertensive
contractions (l_conj) tachycardia
induced (r_acl) nephrotoxicity
standard (l_nmod) dysphonia
inhibitors (r_nmod) risk
appeared (l_nsubj) prolongation
cck-8 (r_nmod) function
lidocaine (r_nmod) injection
af (l_conj) cases
corticosteroid (r_compound) suspensions
concentrations (r_nsubjpass) monitored
enalapril (r_nsubj) had
occurred (l_nmod) infusion
development (l_appos) tdp
vancomycin (r_nsubj) constitutes
resulted (l_nmod) disappearance
assessment (l_nmod) resistance
6-months (l_nmod) hyperprolactinemia
reported (r_acl) carcinoma
fumarate (l_nsubj) investigation
ameliorated (r_acl:relcl) permeability
isoproterenol (r_nmod:npmod) induced
inappropriate (l_nsubj) reticulocytosis
polyuria (l_conj) polydipsia
everolimus (r_nmod) conversion
precipitated (r_conj) occurred
revealed (l_ccomp) took
children (r_nmod) seen
inducing (l_dobj) seizures
exacerbates (l_advmod) nephropathy
reintroduction (r_nmod) induced
therapy (l_nmod) anemia
development (l_nmod) thrombosis
effects (l_amod) hepatotoxic
catecholamines (r_conj) severity
occurrence (l_compound) dysrhythmia
mi (r_nmod) effect
dipyridamole (r_compound) infusion
incidence (l_nmod) mellitus
changes (r_dobj) follow-up
methylphenidate (r_nmod) treated
provided (l_nmod) exacerbation
picrotoxin (r_nmod) microperfusion
exposure (r_dobj) used
patients (r_nsubjpass) studied
induce (l_dobj) injury
rendered (l_xcomp) anemic
role (l_nmod) damage
documented (l_nsubjpass) neurotoxicity
losartan (r_nsubj) cause
compared (l_nsubjpass) edds
interfere (l_conj) induce
aminonucleoside (r_nmod) administration
disappearance (l_nmod) block
treated (r_conj) treated
increased (l_conj) thymus
alpha-glutathione (r_amod) s-transferase
disorder (l_nsubj) disease
associated (l_nsubjpass) symptoms
p-coumarate (r_nsubj) candidate
glucose (r_compound) transport
vte (r_nmod) ratios
vocalization (l_conj) fighting
had (l_dobj) features
caused (l_nmod) hypertensive
patients (r_nmod) thromboembolism
reports (r_nmod) infusion
testosterone (l_nmod) patients
frequency (l_amod) seizure
hcl (r_compound) exposure
capsaicin (r_nsubjpass) injected
methothexate (r_compound) concentration
preferred (l_nsubjpass) toxicity
reported (l_xcomp) present
deficits (l_acl) attributed
glutamate (r_compound) evaluation
treatment (l_nmod) malignancies
progression (l_nmod) atrophy
carbon-ate-sodium (r_compound) powders
patients (r_nmod) assessed
obese (l_appos) ob
fulfilling (l_dobj) criteria
decreased (l_dobj) bradycardia
evidence (l_nmod) neuropathy
volunteers (r_nmod) studies
cross-reactivity (r_nmod) one
cm (r_nmod) type
reducing (l_dobj) hyperactivity
associated (l_nmod) proteinuria
nephropathy (r_nmod) prevent
increasing (l_advcl) associated
reversal (l_nmod) licking
doses (r_nmod) efficacy
estradiol (r_nsubj) reduces
carrageenan-induced (r_amod) hyperalgesia
nd-nmbas (r_nmod) discontinuation
receive (l_advcl) developing
levels (l_conj) symptoms
min (r_conj) injection
simvastatin (l_conj) medications
induce (l_dobj) catalepsy
lesion (r_nmod) reported
epinephrine (l_dep) treatment
telithromycin (r_nmod) exposure
man (r_nmod) developed
considered (l_xcomp) involved
hypotension (l_conj) tachycardia
treatment (l_nmod) glaucoma
li/dvp (r_conj) qtp
patients (l_nmod) nsclc
decreased (l_dobj) rigidity
treatment (l_nmod) cells
3alpha-hydroxy-5alpha-pregnan-20-one (r_appos) allopregnanolone
timolol (r_nummod) solution
affect (l_dobj) temperature
ziprasidone (r_nmod) use
fluctuations (l_conj) behaviors
e4031 (r_conj) terfenadine
two-step (r_amod) assay
injection (r_nmod) deficit
confirm (l_nmod) effects
selegiline (r_dobj) receive
attribute (r_xcomp) enabled
patients (l_nmod) arthritis
levobupivacaine- (r_conj) bupivacaine-
deficits (r_dobj) have
upregulation (r_conj) elevation
excess (r_attr) was
hippocampus (r_nmod) region
patients (r_nmod) motility
groups (r_nmod) lower
dex (r_compound) administration
clonazepam (r_nmod) had
episode (l_nmod) seizure
cpa (r_nsubj) prevented
stz-icv-induced (r_amod) deficits
effects (l_nmod) hypertension
aspirin (r_nmod) reviews
patients (r_nsubj) suffer
tacrolimus (r_conj) acid
growth (l_conj) phenotypes
interval (r_nmod) associated
amisulpride (r_amod) overdose
therapy (r_nmod) recipients
enflurane (r_appos) anesthetics
cefazedone (r_conj) cefonicid
has (l_conj) believed
potent (l_conj) seizure
syndrome (l_appos) ibs
hydroxylase (r_conj) voltammetry
evaluated (l_nsubjpass) toxicity
rats (l_amod) nephrotic
investigate (l_dobj) virus
release (r_nmod) effects
related (r_amod) hepatonecrosis
combination (r_nmod) effects
compared (r_advcl) decreased
aap (r_nmod) presence
occurrence (l_nmod) hypercalcemia
cells (l_compound) hepatoma
conduct (l_dobj) study
play (l_nmod) therapy
mydriasis (l_conj) convulsions
risk (l_nmod) vte
gvg (r_nmod) effects
indomethacin-induced (r_amod) insufficiency
treatment (l_nmod) pharyngitis
halothane (r_dep) anaesthetics
achieve (l_dobj) estimates
metoprolol (r_nmod:poss) clearance
agents (r_nmod) combination
sulfate (r_compound) derivative
isoproterenol-induced (r_amod) dysfunction
inhibition (r_xcomp) appears
probable (l_ccomp) induced
resulted (l_nmod) albuminuria
phenytoin (r_compound) levels
recovery (r_nmod) recording
exposure (r_nmod) function
polyuria (l_conj) tremor
developed (r_acl:relcl) primigravida
suggesting (l_ccomp) develop
administration (r_nmod) decrease
induced (r_amod) modified
relating (l_nmod) severity
yield (l_nmod) tumours
induced (r_amod) toxicity
days (l_nmod) incidence
124 (r_nummod) hcfc
d (r_nmod) treated
episode (r_nmod) recommenced
incidence (l_nmod) studies
evaluated (l_nsubjpass) hypotension
cocaine-induced (r_amod) vasoconstriction
patients (l_nmod) fibrillation
dose (l_conj) incidence
shr (r_nmod) abolished
amnesia (r_nmod) prevention
risk (l_acl) developing
delayed (l_conj) shortened
increased (l_nsubjpass) drowsiness
metformin (r_compound) treatment
caffeine (r_compound) pretreatment
methotrexate (r_compound) neurotoxicity
users (r_nmod) increased
subjected (l_advcl) craniotomy
% (r_nmod) that
reabsorption (r_conj) measuring
accompanied (r_advcl) resistant
hypotheses (l_conj) stroke
treatment (l_nmod) poisoning
evaluated (l_nmod) treatment
paclitaxel/carboplatin (r_compound) liquid
ct (r_conj) prior
famotidine (r_nsubj) antagonist
receptors (r_compound) antagonists
theophylline (r_nmod) neurotoxicity
extraction (r_dobj) undergoing
exposure (r_nmod) developed
curcumin (r_nsubjpass) considered
hexabrix (r_nsubjpass) preferred
patients (l_compound) esrd
chronicity (l_conj) psychosis
mk-801 (r_nmod) pretreatment
glutathione (r_compound) levels
associated (l_nmod) loss
sulfate (r_nmod) mg
disappearing (l_nsubj) syndrome
described (l_nsubjpass) cases
level (r_dep) deficits
cyclophosphamide (r_nmod) developed
necrosis (r_conj) lumens
phenylephrine (r_nsubj) reduces
effect (l_nsubj) rigidity
animals (r_advcl) motionless
cyclophosphamide (r_conj) lomustine
diagnosed (l_nmod) ra
report (l_dobj) cases
levels (r_conj) pressure
induced (l_nsubjpass) seizures
therapy (l_conj) rupture
thalidomide (r_nsubj) agent
overdose (r_nmod) arrest
suppression (r_nmod) has
vincristine (r_compound) instillation
xylometazoline (r_conj) clonidine
day (r_nmod) present
effect (r_nsubj) nephropathy
fails (l_xcomp) protect
identify (r_xcomp) use
amb (r_conj) amb
is (r_ccomp) found
comparison (l_nmod) hypotension
celecoxib (r_nmod) toxicity
levels (r_conj) toxicity
dynamic (l_dep) hyperalgesia
factor (l_nmod) hypertension
performed (l_nmod) order
carbimazole (r_nsubj) induced
administration (l_nmod) end
suffering (l_nmod) disorder
excluding (l_dobj) mechanism
delirium (l_conj) dementia
model (l_nmod) cardiomyopathy
associated (l_nmod) nms
angiotensin-converting (r_amod) therapy
verapamil (r_nsubj) increased
inhibition (r_nmod) associated
damage (r_nmod) rats
induced (l_nmod) patient
effect (r_conj) effect
ketamine (r_nmod) combinations
hcbd (r_nmod) produced
superoxide (r_nmod) defects
taken (r_conj) uncertain
protect (l_nmod) seizures
rates (l_conj) symptoms
reduced (l_dobj) increase
transplantation (l_acl) prevent
agent (l_acl) known
dizziness (l_conj) nausea
present (l_nmod) one
onset (l_nmod) effects
development (l_nmod) proteinuria
infusion (r_nmod) developed
responses (r_nsubj) selective
plasma (l_conj) glucosuria
dinitrate (r_nmod) administration
accounts (l_nmod) necrosis
patients (r_nmod) nine
symptoms (l_amod) related
tremulous (l_nmod) rigidity
premedicated (r_acl) patients
administering (r_advcl) hours
exposure (l_conj) information
nanoparticles (r_nmod) treated
associated (l_nmod) hyperprolactinemia
morphine (r_conj) prostigmine
tet (r_nmod) administration
had (l_dobj) hepatitis
justified (l_xcomp) prevent
mice (r_nmod) performance
death (r_dobj) reduce
variability (r_nmod) occur
simvastatin-ezetimibe (r_conj) ezetimibe
doxorubicin (r_nmod) interaction
stz-icv (r_compound) model
results (r_conj) counts
consumers (l_conj) developed
metabolism (r_nmod) disorder
tamoxifen (r_nsubj) had
meth (r_compound) neurotoxicity
dogs (l_nmod) dysrhythmias
use (r_nmod) induced
losartan (l_compound) dysfunction
showed (l_dobj) rigidity
ribavirin (r_compound) reduction
combination (r_nsubj) has
erythromycin (r_conj) metronidazole
cocaine-associated (r_amod) mi
arrhythmia (l_nmod) patient
claimed (r_advcl) factor
prevented (l_dobj) occurrence
selected (l_dobj) ability
developed (l_dobj) obesity
appearance (l_nmod) effect
1,25(oh)2d (r_nmod) induced
activity (l_appos) therapy
myocet (r_nsubj) reduces
received (r_acl:relcl) rats
response (l_nmod) stimuli
blocking (l_dobj) jerks
tolerated (l_conj) improved
increasing (r_advcl) surmountable
agonist (r_nsubj) impaired
anemia (l_nmod) near-syncope
amount (r_dobj) increasing
mp (r_nmod) administration
treatment (l_nmod) osteoporosis
determined (l_nsubjpass) responses
ncq436 (r_nmod) treated
naphazoline (r_conj) clonidine
patients (l_acl) treated
nicotine-induced (r_amod) hyperactivity
administration (r_nmod) interval
impairment (l_nmod) reabsorption
antinociception (l_conj) constipation
leads (l_nsubj) nephropathy
led (l_nmod) cardiotoxicity
developed (l_dobj) paralysis
patient (l_nmod) haemorrhage
heroin (r_nmod) associated
evidence (l_nmod) mechanisms
aap (r_compound) hepatitis
randomised (l_nmod) london
management (l_nmod) headache
penicillamine (r_compound) therapy
ssris (r_nmod) side-effect
nitroglycerin (r_nmod) attack
free (l_nmod) toxicity
is (l_ccomp) s
lithium (r_compound) polyuria
tumors (l_dep) papilloma
bradycardia (r_nmod) relationship
administration (r_nmod) rose
heparin (r_nmod) exposure
creatinine (r_compound) concentration
treated (r_acl) women
patients (l_amod) allergic
lactate (l_nmod) aids
receptors (r_nmod) role
hallucinations (l_nmod) symptom
abolish (l_dobj) tachycardia
inhibitor (r_dep) effects
administration (r_nmod) prior
activity (l_nmod) nsclc
knowledge (r_nmod) minimised
propofol (r_compound) injection
dose (r_nmod) cross-sensitization
phosphate (r_nmod) relationship
exacerbations (l_amod) paranoid
severity (l_nmod) headache
alpha-methyldopa (r_nmod) response
woman (r_nsubj) had
oxygen (r_compound) consumption
reoccur (l_nsubj) tachycardia
sulindac (r_compound) therapy
initiating (l_dobj) fibrillation
treatment (r_conj) exposure
activate (r_xcomp) seemed
rate (l_conj) glomerulosclerosis
prevent (l_dobj) myoclonus
resistance (r_nmod) responsible
indicates (l_nsubj) appearance
snp (r_appos) nitroprusside
bradycardia (l_conj) hypotension
switches (l_nmod) hypomania
analyze (l_dobj) relationships
antinociception (r_nmod) enhancement
stent (r_nmod) implantation
blocked (l_xcomp) seizure
less (l_nsubj) incidence
hemorrhage (l_conj) events
nsaid-induced (r_amod) urticaria/angioedema
ciprofloxacin-induced (r_amod) failure
screened (l_nmod) macroprolactinemia
discriminate (l_dobj) magnitude
animals (l_nmod) tumor
blocker (r_conj) enzyme
calcium (r_nmod) elevation
showed (l_parataxis) observed
cardiomyopathy (l_nmod) arrhythmias
cholesterol (r_conj) multiple
potassium-losing (r_amod) diuretic
haloperidol-induced (r_amod) hyperprolactinemia
cardiotoxicity (r_nmod) sensitive
indicates (r_conj) activate
woman (r_nmod) syndrome
levels (r_nsubjpass) seen
evaluated (l_dobj) incidence
vnr (r_compound) events
patients (l_nmod) disease
h (r_nmod) examined
chlormethiazole (r_nmod) doses
cy (r_nmod) toxicity
b (r_nmod) infusion
resolved (r_acl) lesions
testosterone (r_nmod) mediated
treated (r_acl) disease
patterns (l_nmod) toxicity
role (l_nmod) disturbance
streptozotocin (r_compound) diabetes
patients (l_nmod) mdp
greater (r_conj) impaired
phenobarbitone (r_nmod) treated
end (l_nmod) surgery
argatroban (r_compound) dose
be-induced (r_conj) cocaine-
ampicillin (r_nmod) treated
kidney (r_nmod) infections
use (r_nmod) presented
clozapine (r_nmod) use
indomethacin (r_nsubj) failed
tacrolimus (r_compound) ointment
xanthine (r_compound) oxidase
increased (l_nmod) %
dose (r_nmod) treatment
pentoxifylline (l_appos) derivative
chorea (l_conj) encephalopathy
tolerated (r_advcl) aware
dl-sotalol (r_nmod) increase
levodopa-induced (r_amod) dystonia
detection (r_conj) made
doses (r_nmod) smaller
morphine (r_nmod) values
nausea (l_conj) anxiety
describe (l_conj) gain
h2o (r_dep) cm
size (r_appos) measures
prazosin (r_conj) pretreatment
digitalis (r_compound) arrhythmia
facilitates (l_dobj) bradycardia
therapy (r_nsubjpass) resumed
patients (l_acl:relcl) suffer
confirm (l_ccomp) predictor
tri (r_nsubj) increases
cyclophosphamide (r_compound) therapy
blockade (r_nsubjpass) observed
observed (l_dobj) block
metformin (r_nmod) effect
mg (r_nmod) inoculation
patients (r_nsubj) had
exposure (r_nmod) patients
effect (r_dobj) inhibiting
midazolam (r_nmod) associated
injection (r_nmod) followed
treated (r_acl) hyperprolactinemia
reported (r_acl) hyponatremia
replaced (l_nsubjpass) behavior
cyclosporine (l_conj) toxicity
higher (l_nsubj) frequency
complication (r_nsubj) optic
suggested (l_ccomp) induce
microg/kg (r_nmod) pretreatment
periods (r_conj) involvement
cbz (r_appos) carbamazepine
validate (r_advcl) shown
78-year-old (l_nmod) necrosis
agent (l_nmod) treatment
trimethoprim (r_appos) people
exacerbation (r_conj) hepatitis
gynecomastia (r_conj) desire
remission (l_nmod) depression
kg-1 (r_dep) prevent
livers (r_nmod) study
unaffected (l_advcl) reversed
sorafenib-induced (r_amod) spasm
valproate (r_dep) revealed
timolol (r_compound) treatment
withdrawal (r_nmod) responded
bronchiectasis (l_nmod) infection
rats (r_nsubjpass) subjected
individuals (l_nmod) infarction
represent (l_advcl) associated
had (l_dobj) recall
developed (l_dobj) cancer
propofol-remifentanil (r_amod) total
application (r_appos) patient
hcfc (r_appos) 1,1-dichloro-2,2,2-trifluoroethane
carbamazepine (r_compound) myocarditis
patient (l_compound) aids
incidence (l_nmod) pseudolithiasis
doses (r_conj) dynamics
schedule (l_nmod) hepatocarcinogenesis
patients (l_nmod) urticaria/angioedema
prolong (l_conj) induce
treatment (r_nmod) prolongation
hypothesis (r_nmod) consistent
apomorphine-induced (r_amod) erection
reported (l_nsubjpass) occurrence
fenfluramines (r_nmod) specificity
occurred (l_nsubj) case
blockers (r_nmod) one
d-med (r_compound) animals
showed (l_conj) epiphyses
caused (l_nsubjpass) akathisia
appearance (l_nmod) dyskinesias
other (l_nmod) dyskinesia
epirubicin (r_compound) exposure
pathogenesis (l_nmod) nephropathy
developed (r_acl:relcl) history
patient (r_nmod) suggest
completing (r_advcl) reduced
dl-threo-dihydroxyphenylserine (r_nsubj) had
received (l_nmod) order
treatment (r_dep) results
therapy (r_nmod) complication
frequency (l_nmod) haemorrhages
development (r_dobj) prevents
quetiapine (r_amod) monotherapy
rats (r_nsubj) had
kindled (r_acl) seizures
dxr (r_compound) dose
mothers (r_nmod) born
losartan (r_nmod) treated
reversal (l_nmod) models
nsc (r_appos) study
l-name (r_nmod) pretreatment
5-hydroxytriptamine (r_dep) serotonin
glutamate (r_compound) administration
relationship (l_nmod) sulindac
pg-9 (r_compound) microg
undergoing (r_advcl) died
study (r_nmod) subject
reduced (l_conj) clearance
reduces (l_dobj) area
effects (r_dobj) differentiate
thiopentone (r_compound) mg/kg
revealed (l_conj) associated
enhanced (l_nmod) persons
disease (l_dep) lid
assigned (l_nsubjpass) patients
nanoparticles (r_nmod) toxicity
nitrogen (r_compound) levels
improve (l_nmod) absence
produced (l_dobj) tolerance
rizatriptan (r_dep) h
cimetidine (r_compound) therapy
days (r_conj) patients
medium (r_nmod) resulted
toxicity (r_nmod) result
esrd (r_nmod) risk
showed (l_advcl) preventing
observed (l_nsubjpass) deaths
strains (r_nsubjpass) detected
amiloride (r_nmod) attenuation
immunization-induced (l_nmod:npmod) pertussis
brain (l_amod) parkinsonian
creatinine (r_conj) urea
woman (r_nsubj) dizziness
infusions (r_nmod) course
had (l_dobj) glomerular
developed (l_dobj) symptoms
mechanisms (l_nmod) hypertension
based (r_acl) radiopharmaceutical
naloxone (r_nmod) administration
b12 (r_conj) combination
incidence (r_dobj) reduced
cnsb002 (r_conj) morphine
caused (l_nsubj) hyperprolactinemia
picrotoxin- (r_conj) fluorthyl-
heparin (r_dobj) using
treatment (r_nmod) events
examine (r_xcomp) were
p (r_dep) group
non-acetaminophen-induced (r_amod) %
bortezomib (r_compound) (bort)-dexamethasone
srl (r_nmod) use
measurement (l_nmod) symptoms
use (r_conj) syndrome
caused (r_acl) patient
effect (l_nsubj) hepatitis
treated (l_nmod) nephropathy
ifosfamide (r_nmod) toxicity
reversed (l_dobj) changes
thirsty (r_xcomp) remained
patients (l_nmod) cle
amphetamine-induced (r_amod) chorea
arteriosclerosis (r_nsubjpass) mediated
impairments (l_nmod) learning
atp (r_conj) stimulation
sediment (l_conj) proteinuria
no (r_appos) oxide
effective (l_nmod) damage
5-fluorouracil (r_nmod) secondary
mt (r_compound) induction
d (r_nmod) prevented
study (r_dobj) conducted
fluconazole (l_conj) tdp
glibenclamide-sensitive (r_amod) channels
patients (l_conj) myalgia
measures (l_nmod) oscillation
cases (r_dobj) revealed
idraparinux (r_nsubjpass) evaluated
increase (r_nmod) defined
use (r_nmod) coupled
facilitates (l_conj) helpful
tacrolimus (r_nmod) switched
rats (r_nmod) media
associated (l_xcomp) suggesting
it-methotrexate (r_nmod) described
effects (l_nmod) development
showed (l_ccomp) associated
developed (r_acl:relcl) disorder
brain (r_compound) induced-behaviour
glutathione (r_conj) plasma
patients (l_amod) hypotensive
production (r_nmod) correlated
occurrence (l_nmod) mutants
complication (r_nmod) hypertension
ht (r_nsubj) increased
mazindol (r_nmod) attributable
suffer (l_dobj) morbidity
presence (r_conj) caused
seizures (r_nmod) incidence
intake (l_conj) mortality
behavior (r_appos) catalepsy
epirubicine-based (r_amod) chemotherapy
pump (r_nmod) placement
compare (l_dobj) conditions
available (l_nsubj) results
malondialdehyde (r_amod) content
cisapride (r_nsubjpass) given
famotidine-associated (r_amod) delirium
methadone (r_nmod) treated
predisposed (l_nsubj) disease
mice (l_compound) aids
developed (l_dobj) hepatitis
doxorubicin (r_nmod) efficacy
scopolamine (r_nsubj) blocked
treatment (r_nmod) associated
quinine (r_dobj) containing
co-carcinogen (l_nmod) carcinogenesis
losartan (r_nsubj) reduces
disease (l_conj) hyperplasia
streptozotocin-induced (r_amod) nephropathy
report (l_advcl) reported
ibuprofen (r_conj) diclofenac
reduced (r_conj) produced
althesin (r_appos) agent
dfp (r_nmod) toxicity
discontinuation (r_nmod) developed
phenobarbital (r_nmod) treated
vaccine (l_compound) rubella
isoflurane (l_appos) group
action (r_nmod) duration
warfarin-induced (r_amod) haemorrhages
da (r_compound) neurotoxicity
microm (r_nmod) induced
patient (l_nmod) ie
rats (r_nsubj) sensitive
niacin (r_conj) gemfibrozil
methadone (r_compound) users
ibuprofen (r_conj) memantine
papaverine (r_dep) received
dyscrasias (r_nmod) similar
(+)-cibenzoline (r_nsubj) suppressed
nicotine (r_xcomp) administered
ag (r_appos) antigen
anaesthetized (r_acl) cats
piperacillin/tazobactam (r_nmod) dose
case (l_nmod) palsy
doxorubicin-treated (r_amod) survivors
kf17837 (r_nmod) administration
using (r_advcl) admitted
benzylthiouracil (r_nmod) appeared
case (l_nmod) failure
whereas (r_advcl) increased
syndrome (l_appos) ns
nitrite (r_nsubj) had
patients (r_nmod) regurgitation
implantation (r_nmod) aneurysm
) (r_punct) polymerase
associated (l_nmod) output
introduction (r_nmod) coincided
modified (l_nsubjpass) hyperlocomotion
csa (r_appos) cyclosporine
remains (l_advcl) likely
found (l_xcomp) active
effect (r_nsubj) attributable
paclitaxel (r_dobj) received
indicated (r_advcl) displayed
confirm (l_ccomp) used
atorva (r_nmod) treated
caused (l_nmod) inhibition
methamphetamine (r_nsubj) causes
doses (r_nmod) effect
withdrawal (r_nsubj) resulted
caffeine (r_nmod) induced
daptomycin (r_nmod) penetration
hallucinations (l_nmod) patient
yield (l_nmod) cirrhosis
be-induced (r_amod) seizures
fluconazole (r_compound) agranulocytosis
thiopental (r_nmod) induced
assessing (l_dobj) use
csa (l_dep) nephrotoxicity
related (l_nsubj) disruption
3 (l_nmod) thrombopenia
d-penicillamine (r_compound) therapy
bupivacaine-induced (r_amod) cardiotoxicity
fluoxetine (r_nmod) capacity
noradrenaline (r_conj) responses
initiate (l_dobj) torsade
outcomes (r_dobj) report
antagonists (r_nmod) induced
aap (r_nmod) drugs
platinum-resistant (r_amod) cancer
potassium (r_compound) doses
calcium (r_compound) blocker
dyskinesias (r_nmod) assessed
acetaminophen (r_nmod) use
had (l_dobj) infarction
determined (l_nsubjpass) incidence
associated (r_acl) esrd
use (r_dobj) reported
patient (r_nmod) observations
nodule (l_conj) carcinoma
maleate (r_nmod) mg
concordance (l_nmod) autism
prostaglandins (r_nmod) relationship
pdtc-treated (r_conj) vehicle-
chow (r_conj) groups
improve (l_dobj) quality
infusion (r_nsubjpass) found
onset (l_nmod) myocarditis
effect (l_nmod) stress
enalapril (r_amod) treatment
aminonucleoside-induced (r_amod) syndrome
treatment (r_nmod) induction
agent (r_nmod) type
idolamines (l_nmod) catatonia
conduct (r_xcomp) prompted
woman (l_nmod) myeloma
adriamycin-induced (r_amod) injury
reversal (l_acl) hearing
rise (r_nmod) defined
propranolol (r_nmod) isomers
dobutamine (r_compound) treatment
modified (l_nsubjpass) movements
offset (r_conj) minor
involved (l_nmod) induction
using (r_advcl) tested
scopolamine-induced (r_amod) deficit
treatment (l_conj) cholestasis
clip (l_dobj) hypertension
slowed (r_acl:relcl) rate
sulpiride (r_conj) sch
vincristin (r_compound) administration
had (l_nmod) morning
some (l_nmod) consequences
drugs (r_dobj) receiving
depression (l_acl:relcl) resulted
occurred (l_conj) observed
users (r_nsubj) marked
recognition (r_nsubj) stimulated
sulfonylurea (r_conj) glyburide
modulate (l_conj) represent
experience (r_nsubjpass) recorded
provide (l_dobj) information
dopamine (r_compound) agonists
expression (r_nmod) mediate
trinitrate (r_nmod) effectiveness
hippocampal (r_compound) contents
potential (l_nmod) hit
effects (l_conj) gain
aggregation (l_nsubj) factor
correlates (l_nsubj) toxicity
ethinylestradiol (r_conj) acetate
gm (r_nmod) those
blocked (l_nmod) pretreatment
patient (l_nmod) psoriasis
abnormalities (l_amod) neuroinflammation
prevented (r_acl) nitroprusside
amb (r_appos) b
rate (l_nmod) progression
treatment (l_nmod) schizophrenia
greater (l_nmod) patients
limited (l_nmod) life
morphine (r_nsubj) plays
clonazepam (r_appos) benzodiazepines
suggest (l_ccomp) effective
l-sotalol (r_appos) d
dexamethasone (r_conj) lenalidomide
decreased (l_dobj) triad
bradycardia (l_conj) hypothermia
metoprolol (r_nmod) man
platinum- (l_conj) cancer
secretion (r_nsubj) promotes
extension (l_nmod) hemolysis
patients (l_nmod) agc
inflammatory (l_conj) neuropathic
cisplatin (r_compound) treatment
quetiapine (r_compound) therapy
shows (l_dobj) phase
be (r_appos) benzoylecgonine
nephropathy (r_nmod) rats
effect (l_acl) contributing
containing (r_acl) diet
obtain (l_nmod) toxicity
climbing (r_dobj) reducing
duration (r_nmod) correlated
dmtu (r_nsubj) reduced
treatment (r_nmod) susceptible
developed (l_dobj) psychosis
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (r_dobj) administered
drawbacks (l_acl:relcl) lead
flushing (l_conj) edema
developed (l_nsubj) episodes
had (l_advcl) have
chp (r_appos) phosphanilate
link (r_dobj) suggest
shown (r_advcl) neurons
powders (r_nmod) amounts
clonidine (r_dobj) receiving
toxicity (l_conj) syndrome
no (r_compound) ester
patients (r_nsubj) capacity
affected (l_conj) prevented
induced (l_dobj) bradycardia
related (l_nsubj) mechanism
plays (l_nmod) nephrotoxicity
didanosine (r_nsubj) has
using (r_advcl) avoided
growth (l_compound) tumor
lamivudine (r_nsubj) effective
naloxone (r_dep) state
down-regulation (r_nsubj) relevant
gestodene (r_nmod) users
modulation (l_nmod) hyperalgesia
dose (r_nsubj) microg/kg/min
aspirin (r_nmod) use
days (l_nmod) rats
prostaglandin (r_compound) synthesis
curves (r_nsubjpass) constructed
dose (r_nmod) amount
setting (r_nmod) woman
des-induced (r_amod) growth
calcium (r_dobj) containing
developed (l_dobj) insufficiency
antipsychotics (r_nmod) treated
age-dependent (l_conj) died
examine (l_dobj) role
inactivation (l_conj) actions
tetracycline (r_nmod) dose
omercazole (r_appos) carbimazole
rate (l_appos) hr
(pge1)-induced (l_dobj) hypotension
papaverine (r_nsubjpass) used
acid (l_conj) seizures
suggesting (l_ccomp) useful
model (l_conj) infection
azt (r_appos) 3'-azido-3'dideoxythymidine
ml (r_nmod) suspended
administration (r_nmod) women
case (l_nmod) necrosis
mi (r_nmod) setting
overexpression (r_nsubj) protects
of (r_case) mg.
seizure (r_dobj) augmented
patients (l_nmod) hyperthyroidism
focus (l_amod) epileptic
statins (r_nsubj) cause
therapy (r_nmod) use
mechanisms (l_compound) pain
cocs (r_appos) contraceptives
cocaine-kindled (r_amod) seizures
haloperidol (r_dep) subchronic
isomers (r_nsubj) capable
dipyridamole (r_conj) acid
capable (l_advcl) preventing
described (l_conj) reviewed
levobupivacaine (r_dobj) received
beclomethasone (r_nmod) use
timolol (r_nmod) amelioration
associated (l_conj) was
creatinine (r_nmod) levels
having (l_dobj) relatives
cholinomimetic (r_nmod) doses
increased (l_nsubjpass) risk
received (l_advcl) appeared
used (l_xcomp) evaluate
found (l_xcomp) drug
blocker (l_conj) alterations
metabolism (r_nmod) alterations
resolved (l_nsubj) symptoms
complication (l_nmod) dehydration
nitrofurantoins (r_nsubjpass) associated
cleft (l_nmod) palate
relationship (r_nsubj) was
levodopa (r_compound) responsiveness
developed (l_dobj) days
hyperkalemia (r_dobj) developed
estradiol-induced (r_amod) cholestasis
manage (r_xcomp) important
prevents (l_dobj) nephropathy
dexamethasone (r_compound) group
stopping (r_advcl) improved
kg-1 (r_nmod) use
type (r_dobj) used
alprazolam (l_conj) placebo
identical (l_nsubj) jitteriness
induction (l_compound) tumor
action (l_amod) convulsive
psychosis (r_nmod) associated
associated (l_nsubjpass) dementia
wk (l_compound) jaundice
outpatients (r_nsubjpass) compared
nociception (l_conj) model
consumption (r_conj) alterations
arrhythmias (r_conj) comparison
inhibition (r_nmod) neurons
neuropeptides (l_acl) caused
pretreatment (r_nsubj) useful
days (r_nmod) analyzed
limited (l_nmod) studies
pretreatment (r_nmod) reduced
potential (l_acl:relcl) regulated
associated (l_nmod) increase
have (l_dobj) cardiomyopathy
2-mercaptoethane (r_nmod) administration
verapamil (r_compound) stimulation
that (r_nmod) increased
therapy (l_conj) disease
atypicality (l_nmod) course
spironolactone (r_conj) amb
treatment (l_nmod) diabetes
suggest (l_dobj) function
lamivudine-resistant (r_amod) virus
choline-supplemented (r_amod) diet
doxorubicin (r_nmod) cardiotoxicity
administration (r_nsubj) ameliorated
aldosterone (r_compound) levels
ccl4 (l_conj) cardiotoxic
signs (l_nmod) neurotoxicity
cocaine (r_nsubj) has
diuresis (r_nmod) rats
mg (r_nsubjpass) exceeded
induced (l_dobj) amnesia
ketoprofen (r_dobj) receive
proliferation (l_compound) tumor
dialysate (r_nmod) anticoagulated
infusion (r_nmod) severe
pentothal (r_nsubjpass) infused
higher (l_nsubj) incidence
obtained (r_acl) results
risk (l_nmod) failure
play (r_conj) differ
days (r_nmod) found
meloxicam (r_compound) administration
knockout (r_nmod) performance
ablation (l_nmod) patient
modified (l_conj) decreased
organophosphate (l_amod) neurotoxic
predictor (l_nmod) seizures
reduce (l_advmod) encephalopathy
subjects (l_nmod) attack
achieve (l_dobj) dose
concentration (l_acl:relcl) caused
induce (l_advcl) administered
involved (l_xcomp) underlying
reported (r_acl:relcl) frequent
showed (l_nmod) evidence
parameters (l_amod) atherosclerotic
consists (l_nsubj) nephropathy
cholecystitis (r_conj) sludge
sulfasalazine (l_nmod) arthritis
aware (l_nmod) possibility
analysis (l_nmod) septal
cocaine (r_nmod) toxicity
formyl-methionyl-leucyl-phenylalanine (r_nmod) stimulated
gamma-hexachlorocyclohexane (r_appos) lindane
observed (l_nmod) schizophrenia
infusion (r_nmod) cpap
tacrine-lithium (r_compound) model
explored (l_dep) objectives
wore (l_nsubj) disturbances
kindling (r_nmod) induced
activity (r_nmod) participates
dobutamine (r_nmod) occurs
patients (l_acl) having
prescribed (r_acl:relcl) patients
sweating (l_conj) anxiety
have (l_dobj) thrombosis
) (r_punct) pge(2
ability (r_nmod) demonstrated
changes (l_amod) angina
ketorolac (r_dep) anti-inflammatory
resulting (r_acl) reversal
activates (l_conj) contribute
combination (r_conj) thromboembolism
feasibility (r_conj) recurrences
exposure (l_conj) development
model (l_nmod) dysplasia
exacerbations (r_nmod) vulnerability
caused (l_dobj) fall
aimed (l_conj) bound
cisplatin (r_nmod) treatment
evoked (l_xcomp) developed
incidence (l_nmod) symptoms
course (l_nmod) infection
nitroprusside (r_compound) hypotension
induced (l_nsubjpass) sphincter
involved (l_nmod) processes
ethinyloestradiol (r_nmod) desogestrel
acetaminophen (r_nmod) effect
reported (l_advcl) demonstrated
important (l_xcomp) recognize
attenuates (l_dobj) deficits
antitumor (r_compound) activity
hemolysis (r_nsubjpass) preceded
concentration (r_nmod) increase
often (r_advmod) occurred
secondary (r_amod) deficiency
treatment (l_nmod) hypercholesterolemia
events (l_amod) thrombotic
presented (l_nmod) type
overdose (r_nmod) resulting
smoking (l_nmod) factor
patient (r_nmod) period
valproate (l_nmod) migraine
syndrome (l_compound) pain
kf17837 (r_nsubj) drug
modulates (l_dobj) effect
available (r_advcl) given
triazolam-induced (r_amod) episodes
lidocaine- (l_dep) seizures
existence (l_nmod) disorder
reviews (l_dobj) mechanisms
literature (r_nmod) search
% (r_nmod) controlling
microinjection (r_nmod) produced
decreased (l_conj) ascites
transaminase (l_nsubj) toxicities
administration (r_nmod) infarction
used (l_nsubjpass) hypothermia
gaba(a (r_appos) acid
associated (r_conj) associated
naloxone (l_appos) paralysis
call (l_conj) raise
given (l_nmod) bronchiectasis
assessed (l_dobj) tremor
amp-alpha2 (r_compound) kinase
prevented (l_conj) delayed
induced (r_acl) hepatitis
considered (r_conj) report
e2 (r_nsubj) showed
therapy (l_nmod) granulomatosis
edema (r_nmod) consisting
levels (l_amod) hypertensive
occurred (r_conj) show
used (r_advcl) likely
affect (r_conj) prevent
modulate (r_acl:relcl) steroid
potassium (r_nmod) responsible
increasing (r_xcomp) l(-1
indicated (l_parataxis) seen
overdosage (r_nsubj) result
nicergoline (r_nmod) case
induced (l_dobj) incidence
protected (r_conj) prevented
converted (l_dobj) movements
lymphadenopathy (l_compound) fever
insights (l_nmod) cause
exposure (r_nmod) observed
blocked (l_nsubjpass) stereotypies
doxorubicin (r_conj) combination
trial (r_nmod) men
therapy (r_compound) mg/kg
consumption (l_acl:relcl) increased
microg/kg/min (r_nsubjpass) investigated
order (r_nmod) studied
busulfan (r_dative) given
transaminase (r_nmod) activities
patients (r_nmod) groups
produced (r_acl) hypotension
injections (r_conj) injections
implicated (l_nmod) reports
vt (l_conj) fibrillation
diagnosis (l_dep) amyloidosis
containing (r_acl) chemotherapy
aconitine (r_nmod) effects
form (l_nmod) treatment
cause (r_ccomp) indicate
model (l_nmod) pd
reduced (r_acl) deficits
seen (l_nmod) animals
improves (l_dobj) catalepsy
decreased (l_nsubjpass) activity
trials (r_dobj) warrant
therapy (r_nmod) present
impairment (r_conj) resistance
dexamethasone-containing (r_amod) regimens
melatonin (r_compound) pre-treatment
cases (l_nmod) allergy
paracetamol (l_nmod) patients
motility (l_nmod) syndrome
discontinued (l_conj) resolved
d-glucarates (r_nsubj) effective
cords (r_nmod) showed
responsible (l_nmod) generation
either (r_advcl) was
pain (r_nmod) occurrence
groups (l_appos) controls
function (l_conj) sclerosis
injection (r_nmod) scheduled
adenocarcinoma (r_nmod) treated
reflect (r_xcomp) presumed
effective (l_nmod) amlodipine
study (r_dobj) conduct
amiodarone (r_nmod) patients
associated (r_acl) ovary
contraceptives (r_nmod) risk
protocols (l_compound) leukemia
hooded (r_amod) rats
pretreatment (r_nsubj) enhanced
cause (l_dobj) hypertension
value (l_nmod) management
obtund (l_dobj) response
potential (l_acl) induce
determined (l_nsubjpass) effects
quetiapine (r_compound) monotherapy
has (l_nsubj) utilization
higher (r_conj) demonstrated
inability (r_nsubj) activate
types (l_acl) induced
isolated (l_amod) allodynia
effects (l_nmod) patients
ethopropazine (r_nsubjpass) compared
toxicities (l_acl) associated
derive (r_conj) dose-dependent
treatment (r_conj) prophylaxis
subgroup (l_nmod) patients
thiopentone (r_nsubj) reduces
determined (r_acl:relcl) damage
oxygen (r_compound) saturations
bupivacaine (r_conj) injection
effect (l_nmod) sensitization
used (l_nmod) adjunct
tiredness (l_nmod) symptoms
demographics (l_nmod:tmod) time
risperidone (r_nmod) antipsychotics
measure (l_dobj) variations
terbinafine (r_conj) metoprolol
pb-related (r_amod) increases
ifosfamide (r_nmod) use
sphincter (l_nmod) spasm
deficit (r_nmod) influence
acetazolamide (r_nmod) patients
case (l_nmod) aneurysm
microphthalmos (l_conj) hypertelorism
morphine (r_nsubj) induced
prove (l_xcomp) remedy
cc (r_nmod) induction
exposure (r_nmod) induced
clotting (l_conj) hemodilution
risperidone (r_nmod) treatment
contractility (r_nmod) characterized
induces (l_dobj) anxiety
followed (l_nmod) neurotoxicity
induced (r_advcl) undertaken
occurred (l_nsubj) impotence
effects (r_nsubj) arrhythmias
improvement (l_nmod) lid
inhibitor (r_conj) nitrendipine
admitted (l_nmod) days
overload (r_nsubj) lead
incidence (l_nmod) cysts
therapy (r_nmod) incidence
haloperidol (r_nmod) drugs
leading (l_nmod) hyperparathyroidism
decreases (r_nmod) produced
nimesulide (r_nmod) tolerability
users (r_nmod) none
aggravate (l_dobj) oih
cisapride (r_compound) therapy
effects (r_nsubj) interest
compound (r_nsubj) attenuates
basis (r_nmod) explained
safe (l_nmod) child
administration (r_nmod) appeared
observed (r_dep) evaluated
diclofenac (r_dep) nsaid
basis (r_dobj) assess
evidence (l_nmod) narrowing
identified (r_conj) screened
agent (l_nmod) process
popularity (l_nmod) control
doxorubicin (r_appos) groups
epinephrine-induced (r_amod) rats
chemotherapy (l_nmod) cancer
acid (r_nmod) effects
acetylcholine (r_compound) biosynthesis
was (l_attr) difference
inhibition (r_conj) induction
underlying (l_dobj) anemia
induced (r_acl) confusion
levodopa-induced (r_amod) dyskinesia
affected (l_nmod) hepatitis
patients (l_compound) neuroblastoma
represents (r_ccomp) characterized
incidence (l_nmod) cystitis
sulphasalazine (l_nmod) arthritis
hcl (r_compound) mg/kg
reduced (l_nsubjpass) frequency
decreased (l_conj) score
caffeine (r_nmod) specific
overdose (r_xcomp) believed
experiencing (l_dobj) deficits
history (l_nmod) encephalopathy
n (r_dep) enalapril-treated
acid (r_nmod:npmod) mrna-containing
method (l_appos) subjects
physostigmine (r_conj) clonidine
selective (r_advcl) hypothesized
identify (l_dobj) mechanisms
mu (r_nmod) dose
considered (l_nmod) factors
sensitized (l_nmod) cardiotoxicity
developed (l_dobj) polyuria
5-ht (r_nmod) caused
deterioration (l_conj) thrombosis
patients (r_nmod) noted
cream (l_appos) agent
products (r_dobj) using
dose (r_nmod) reviews
risk (l_amod) thrombotic
receive (r_acl:relcl) group
heparin-induced (r_amod) test
bromocriptine (r_nsubjpass) evaluated
system (r_nmod) selective
sulpiride (r_nmod) combination
antagonists (r_nsubjpass) used
gamma-vinyl-gaba (r_dep) inhibitor
case (l_nmod) anemia
bradykinesia (r_conj) patients
nitroglycerin-induced (r_amod) hypotension
similar (r_ccomp) suggest
changes (l_nmod) hypertension
administered (l_nmod:tmod) time
altered (l_xcomp) indicating
fungizone (r_nmod) that
streptozotocin (r_nmod:npmod) induced
(sn)-induced (r_compound) hypotension
likely (l_xcomp) reproduce
calcium (r_compound) homeostasis
trials (l_nmod) patients
appeared (l_nsubj) toxicity
aorta (l_conj) failure
administration (r_nmod) effects
contributes (l_nmod) development
adjustment (l_nmod) factors
captopril-induced (r_amod) insufficiency
patients (l_conj) patients
heparin (r_nmod) performed
syndrome (r_dobj) developed
resulted (l_nmod) hyperglycemia
resulted (l_nmod) reduction
crocin (r_nmod) effectiveness
associated (l_nmod) tachyarrhythmias
chemotherapy (r_nmod) failure
produced (l_conj) reduced
stopped (l_nsubjpass) seizures
clonidine (r_nmod) drugs
augments (l_conj) protects
incidence (l_nmod) injections
olanzapine (r_compound) risperidone
study (r_nsubj) levels
diazepam (r_conj) cpa
injections (r_nmod) induced
ameliorates (l_dobj) nephropathy
l-dopa-induced (r_amod) dyskinesias
received (l_conj) had
patient (l_nmod) thrombocytopenia
supervision (l_conj) discontinued
evidenced (l_advcl) determined
change (r_dobj) revealed
hcl (r_nmod) administration
studies (l_nmod) models
dyskinesias (r_conj) signs
learning (l_conj) deficits
undergoing (r_nmod) patients
side-effect (r_conj) rare
induction (r_nmod) pretreatment
results (l_nmod) biopsies
protected (l_nmod) convulsions
vigabatrin (r_nmod) specific
included (l_dobj) syndrome
increase (l_nmod) o-methylation
placebo (l_nmod) treatment
ctni (l_nmod) development
potentiates (l_dobj) antinociception
flurothyl (r_nmod) induced
no (r_nmod) precursor
observed (l_nsubjpass) attack
titer (l_conj) volume
incidence (l_nmod) tumours
% (r_dobj) missed
tiopronin (r_compound) group
characteristics (l_appos) induction
p-coumarate (r_nsubjpass) found
denominator (l_nmod) thrombosis
density (r_nmod) increases
inhibitor (r_appos) ouabain
precurarization (r_nsubj) dose
acid (r_nmod) reaction
ibuprofen (r_conj) indomethacin
use (r_nmod) use
highlighting (l_dobj) fact
developed (l_dobj) curves
occurrence (l_nmod) pain
ketoconazole (r_dobj) using
changes (l_conj) syndrome
degeneration (l_nmod) myelin
ketamine-induced (r_amod) tachycardia
onset (l_nmod) hyperammonemia
side-effects (l_appos) memory
blocked (l_dobj) behavior
benzene (r_conj) remoxipride
drug (l_amod) non-nephrotoxic
effect (l_nmod) analgesia
received (l_conj) assessed
changes (l_nmod) shape
patients (l_nmod) osteoarthritis
chloride-induced (r_amod) increase
model (l_nmod) nociception
paracetamol-induced (r_amod) injury
hydrochloride (r_nmod) treatment
temocapril (r_nmod) administration
hippocampus (l_nmod) seizures
preparation (l_nmod) asthma
followed (l_nmod) seizures
phenobarbital (r_nmod) challenge
regimen (l_nmod) tuberculosis
resulting (l_nmod) anoxia
epilepticus (r_nmod) evoked
higher (l_nmod) that
deaths (r_nmod) two
incidence (l_nmod) cardiotoxicity
conjunction (l_nmod) pericarditis
dose (l_conj) hypokalemia
epilepticus (l_acl) followed
octreotide (r_nmod) withdrawal
hypersensitivity (r_nmod) caused
crocin (r_conj) effects
caused (r_acl) deformations
determined (l_nmod) parallel
syndrome (l_acl) associated
digitalis-induced (r_amod) arrhythmia
p (r_appos) group
one (l_nmod) kindreds
use (l_conj) monitoring
related (l_nmod) loss
5057 (r_nummod) ro
characteristics (l_amod) myopathic
patients (l_amod) dyskinetic
5-fluorouracil (r_compound) treatment
valdecoxib (r_nmod) similar
tested (l_nmod) models
constructed (l_dep) inflammation
effect (l_nmod) amnesia
administration (r_nmod) developed
capsaicin (r_nmod) effect
encephalopathy (r_nsubj) syndrome
density (r_dep) patients
reduces (l_advcl) providing
has (r_ccomp) viewed
movement (l_amod) hyperkinetic
amphetamine (r_amod) injections
antibiotics (r_nsubj) cause
glutamate (r_amod) receptor
controls (r_nsubj) showed
induced (l_dobj) myodystrophy
cyclosporine (r_nmod) therapy
drugs (r_nmod) administration
patients (r_nmod) observed
sodium (r_compound) restriction
formation (l_compound) cyst
neutropenia (l_conj) failure
randomized (l_nsubjpass) total
begun (l_nmod) course
agents (r_conj) nitroglycerin
availability (r_nmod) improve
associated (r_acl) aplasia
etoposide (r_compound) therapy
induces (l_dobj) attacks
years (l_nmod) acne
evaluate (r_xcomp) aimed
treatment (r_nmod) described
distinguishing (l_nmod) malignancy
anticoagulant (r_nmod) exposure
cocaine (r_nmod) smoking
neurotransmission (r_nmod) dysfunction
improves (l_advcl) used
used (l_xcomp) reverse
exposure (r_nsubj) induce
increases (l_dobj) behavior
man (l_nmod) history
evaluating (l_dobj) ischemia
epinephrine (r_nmod) effects
cisplatin (r_nmod) injection
infusion (r_nmod) minutes
secondary (r_amod) hematomyelia
epinephrine (r_compound) administration
induces (l_dobj) catalepsy
gentamicin (r_dep) group
vcm-induced (r_amod) damage
complex (r_nmod) acts
caffeine (r_nmod) presence
acids (r_nmod) level
prevent (l_conj) doses
related (r_amod) hypercalcemias
plays (r_ccomp) hypothesized
tested (l_nmod) ability
efficacy (r_dobj) evaluate
led (l_nmod) elevation
administration (r_nmod) patients
dependence (l_conj) nucleosides
patient (l_acl) taking
sucrose (r_dobj) experienced
adriamycin (r_nmod) slowing
risperidone-induced (r_amod) elevations
decreased (r_ccomp) revealed
incidence (r_dep) symptoms
facilitated (l_dobj) appearance
decreased (l_dobj) time
individuals (l_amod) hiv-infected
mg/kg (r_compound) daily
mannitol (r_nmod) addition
promotes (l_dobj) af
blocking (r_advcl) releases
available (l_xcomp) detect
depression (l_conj) impulsiveness
considered (l_xcomp) cardiotoxicity
cimetidine (r_dobj) taking
pyrophosphate (r_nmod) km
copolymer (r_nmod) mixture
doxorubicin/kg (r_nmod) dose
suffered (l_dobj) fasciitis
patients (r_nmod) levels
receptor-linked (r_amod) channel
azathioprine-induced (r_dep) reversible
effect (l_nmod) carcinogenesis
met (l_nmod) agoraphobia
hour (r_nmod:tmod) increased
kindreds (l_nmod) history
used (l_nmod) therapy
groups (r_nmod) documented
dopamine (r_compound) activation
lower (l_nsubj) score
quinpirole (r_nmod) combination
induces (l_dobj) anomalies
secondary (r_amod) rhabdomyolysis
ecstasy-specific (r_amod) hyperactivity
administration (r_nsubj) studied
fentanyl (r_amod) nausea
glutamate (r_nmod) increase
use (l_nmod) level
gm (r_compound) nephrotoxicity
mannitol (r_dobj) receive
administration (r_nmod) caused
failure (l_conj) esrd
thyroxine (r_dobj) taking
5-fu (r_nmod) infusion
patients (l_acl:relcl) unrelieved
related (l_nmod) infection
compared (l_nsubjpass) patients
involves (l_nsubj) effect
atropine-mk801 (r_nsubj) offer
intravenous (l_compound) c.
ages (l_nmod) management
estrogens (r_nmod) women
function (l_nmod) impairment
rate (r_nmod) degree
expression (r_dobj) studied
pilocarpine (r_nmod) min
patients (l_nmod) md
calcium (r_nmod) resuscitation
dose (r_conj) had
activity (l_amod) convulsive
resulting (l_nmod) hypocalcemia
triazolam (r_nmod) doses
therapy (r_nmod) case
nephropathy (r_nsubj) consisted
(+)-cibenzoline (r_nmod) effects
effects (r_nmod) interactions
event (l_nmod) hypertension
allergic (r_amod) patients
influence (l_dobj) rigidity
use (l_nmod) prevention
magnesium (r_compound) administration
ha (r_nmod) imaging
sites (l_nmod) calcification
5-fu (r_compound) infusion
similar (l_nmod) those
taxol (r_compound) company
included (r_acl:relcl) c1
thrombocytopenia (r_nmod) associated
nicorandil (r_nmod) addition
unmask (l_dobj) seizures
leukoencephalopathy (r_nsubj) result
setting (r_nmod) neurotoxic
reduces (r_advcl) reduces
variations (l_conj) malformations
succinylcholine-associated (r_amod) myalgia
arteriosus (r_nmod) treatment
diagnosis (l_nmod) damage
indinavir-related (r_amod) nephrotoxicity
activity (r_conj) level
gentamicin (r_compound) ototoxicity
infusions (l_nmod) catalepsy
agent (l_nmod) activity
triazolam (r_nmod) action
indomethacin (r_nmod) agents
narrowing (l_conj) vasculitis
mirror (r_ccomp) hypothesized
chlorofluorocarbons (r_nmod) substitutes
have (l_dobj) comorbid
heart (r_nmod) effects
chloride (l_appos) injury
permitted (l_ccomp) permits
patients (l_compound) nsclc
cbz (r_nsubj) inhibited
diluents (r_nmod) use
banned (l_dobj) use
dose (l_acl:relcl) resulted
induce (l_dobj) proteinuria
observed (l_nsubjpass) dysfunction
effects (l_nmod) toxicity
interaction (l_nmod) stimuli
injection (r_nsubj) reduced
prevention (r_dep) studied
fact (l_acl) found
role (l_nmod) deficit
nocistatin (l_nmod) impairment
lhrh-a (r_appos) acetate
cpa/ee (r_nmod) women
long-term (r_amod) treatment
chow (r_conj) hyperactive
days (l_acl:relcl) produce
group (r_nmod) patients
therapy (r_nmod) institution
administration (r_nmod) angioedema
therapy (r_nmod) found
inhibition (l_conj) identical
steroid-treated (r_amod) groups
endpoint (l_advcl) being
assessed (l_dobj) intensity
potassium-conserving (r_amod) diuretic
therapy (r_nmod) cholecystitis
heparin (r_nmod) require
symptoms (l_nmod) rls
atropine (r_nmod) determined
had (l_advcl) manifested
typical (l_nmod) cystitis
complication (l_nsubj) glomerulonephritis
therapy (l_conj) proteinuria
metolachlor (r_compound) use
cause (l_advcl) score
abusing (r_acl) patients
methotrexate (r_nsubj) treatment
amiodarone (r_nmod) withdrawal
ach (r_appos) acetylcholine
calcium (r_compound) concentrations
effect (l_amod) pro-arrhythmic
creatinine (r_nmod) decrease
(-)-baclofen (r_conj) mk-212
dogs (l_nmod) tachycardias
corticosteroid (r_conj) androgen
olanzapine (r_nmod) differ
syndrome (l_nmod) excess
citrate (r_compound) synthase
similar (r_amod) properties
reaching (r_advcl) increased
evaluate (r_acl) order
patient (l_acl) demonstrating
assess (l_dobj) effect
warfarin (r_nmod) synergy
neoplasia (l_conj) carsinom
extent (l_nmod) failure
agent (l_nmod) toxicity
nephropathy (l_nmod) rats
glutathione (r_compound) transferase
adenosine (r_nmod) residence
response (l_conj) allodynia
classified (l_advcl) neoplasms
hypertension (l_acl:relcl) shown
synthesis (r_nmod) phase
cessation (r_nmod) stopped
tablet (l_nmod) patients
worsening (l_nmod) dyskinesia
caused (r_acl) vocalization
csa (r_nmod) effects
potassium (r_nmod) hypokalemia
presentation (l_amod) cholestatic
seen (l_advcl) eating
alcohol-related (r_amod) impairment
triggered (r_acl:relcl) dysfunction
response (l_nmod) hypertension
fzp (r_compound) toxocity
phenobarbitone (r_appos) drugs
rhabdomyolysis (r_nmod) hypotheses
5-ht (r_compound) receptors
reflex (l_conj) rigidity
hypotension (r_nsubjpass) attributed
pretreatment (r_nmod) occur
hypothesis (l_ccomp) confounds
use (r_nsubj) related
conducted (l_nmod) boys
dexamethasone (r_nsubj) induced
ifosfamide (r_nmod) efficacy
vasodilator (l_acl:relcl) produce
antigens (r_dobj) containing
cgrp (r_compound) concentration
clonidine (r_nmod) produced
acid (r_nsubjpass) administered
rats (r_nmod) failure
occurred (l_nsubj) ototoxicity
both (r_appos) protocol
nine (r_nsubj) had
treatment (r_nsubj) prevents
developed (l_nsubj) dyskinesia
cells (r_nmod) observed
therapy (r_nsubj) affect
included (r_acl) type
hypercalcemia (l_conj) hyperphosphatemia
protecting (l_nmod) seizures
outcomes (l_nmod) fluctuations
mg (r_nmod) occurred
administered (l_advcl) evoke
etomidate (r_amod) injection
ssris (r_nmod) induced
heroin (r_compound) use
di (l_amod) secondary
influences (l_dobj) nephrotoxicity
application (r_nmod) seizures
cocaine (r_nmod) toxicology
consistent (r_xcomp) promote
toxicity (l_nmod) patients
valproate (r_xcomp) added
associated (r_acl) development
developed (l_dobj) effects
retrieval (r_dobj) facilitated
role (l_acl) causing
infusion (r_nmod) compared
that (l_nmod) convulsions
cimetidine (r_nmod) case
relationship (l_nmod) cirrhosis
actions (l_amod) hypotensive
odds (r_dobj) calculate
missed (l_csubj) determining
rats (r_nsubj) have
phenylephrine (r_nmod) utilization
hospitalizations (r_nmod) went
ruled (l_nsubjpass) reasons
essential (l_nmod) development
group (l_conj) group
dexatrim (r_compound) injury
cyclophosphamide (r_compound) cytotoxicity
therapy (r_nmod) factor
ifosfamide (r_nmod) effect
agent (l_acl) used
bupivacaine (r_nmod) doses
case (l_nmod) neuropathy
induced (l_dobj) ischemia
mg/m(2 (r_nmod) treated
control (l_dobj) disorder
findings (l_amod) typical
administration (r_nsubj) reduces
mesna (r_nmod) prevention
reversal (l_nmod) coma
epinephrine (r_nsubj) produced
introduction (r_nmod) h
levels (r_nsubj) contributed
utility (l_nmod) treatment
trimethoprim-sulfamethoxazole (r_dobj) prescribed
examined (l_advcl) modulating
proteinuria (l_acl) associated
present (l_advcl) resulting
ischaemic (l_conj) nephrotoxic
5-ht (r_appos) 5-hydroxytryptamine
mydriasis (l_conj) tremor
symptoms (l_nmod) syndrome
also (l_nsubj) endpoint
incidence (l_nmod) toxicities
condition (r_ccomp) suggests
cocaine-induced (r_amod) seizures
sufficient (r_nmod) infusion
hyperprolactinemia (r_conj) increased
labetalol (r_nmod) induced
benzodiazepine (r_compound) lorazepam
those (l_acl:relcl) did
meloxicam (r_advcl) developed
hepatitis (r_dobj) follow
acid (r_nmod) response
carcinoma (l_nmod) cavity
induction (l_nmod) tachyarrhythmia
patient (l_compound) cancer
aminoglycoside (r_dobj) receiving
protects (l_nmod) damage
inhibition (r_nmod) induced
compare (l_conj) diclofenac
patients (l_acl:relcl) presented
that (r_nsubj) 34.0
absence (l_nmod) mr
placebo (r_compound) solution
acid (r_conj) phenylbutazone
adjustment (r_nmod) associated
da (r_compound) lesion
leading (l_nmod) accumulation
acid (r_appos) d
important (l_xcomp) manage
mimicking (l_dobj) hydronephrosis
coincident (l_nsubj) excitement
inhibitors (l_advmod) paranoia
reduction (r_attr) is
female (l_acl) presented
ltg (r_appos) lamotrigine
review (l_nmod) hepatotoxicity
attenuated (l_dobj) hyperactivity
microperfusion (r_nmod) dose
21680 (r_nummod) cgs
levetiracetam (r_nmod) treatment
confirmed (l_nsubjpass) absence
discontinued (l_nmod) patients
disorder (r_nmod) existence
prevented (l_dobj) remodeling
pre-existing (r_amod) proteinuria
thrombocytopenia (l_conj) priapism
produces (l_dobj) anemia
specificity (r_conj) magnitude
terodiline (r_conj) terfenadine
leading (l_nmod) uremia
halothane (r_compound) anaesthesia
ribavirin (r_dobj) treat
was (l_nsubj) increase
role (r_nsubj) remains
nephritis (l_conj) dermatitis
cases (l_nmod) adolescents
expression (l_nmod) irritation
other (r_conj) mediated
incidence (l_nmod) thrombosis
kainic (r_amod) seizures
withholding (r_advcl) returned
material (l_dep) woman
administration (r_nmod) occurred
is (r_ccomp) suggests
accompanied (r_acl) ulcers
characterized (r_advcl) marked
showed (l_ccomp) produces
present (l_nmod) failure
injection (l_nmod) dose
morphine-induced (r_amod) catalepsy
had (l_nmod) malignancy
effects (l_acl:relcl) used
epinephrine (r_nmod) role
administration (r_nmod) rigidity
deterioration (l_nmod) patients
statins (r_nsubj) drugs
anti-inflammatory (r_conj) administration
reduces (l_dobj) mortality
cause (l_nmod) patient
coincident (l_nmod) presence
damage (l_nmod) therapy
adriamycin (r_compound) nephrosis
dysrhythmias (l_conj) hypertension
(r)-alpha-methylhistamine (r_nsubj) cause
prevalence (r_nmod) occur
valproate (r_nmod) therapy
captopril (r_nmod) resulting
rats (r_nmod) decrease
potentiation (l_nmod) catalepsy
women (r_nmod) case
swallowing (r_advcl) originating
study (r_nmod) compared
acid-transmitted (r_dep) gamma-aminobutyric
myoclonus (r_nsubj) seems
nicotine (r_nsubj) activates
cells (l_compound) cancer
regurgitation (l_nmod) patients
characteristics (r_nmod) lacking
neutropenia (l_nmod) patient
patients (l_nmod) alf
simvastatinezetimibe-induced (r_amod) hepatotoxicity
episodes (l_nmod) anemia
anaesthesia (r_nmod) underwent
rats (r_nmod) induced
form (r_conj) drug
increase (l_nmod) sn
pathogenesis (r_nmod) role
therapy (r_acl:relcl) girl
des (r_dep) diethylstilbestrol
nifedipine (r_nmod) those
apomorphine-induced (r_conj) dexamphetamine-
agents (l_amod) seizure-inducing
remifentanil (r_compound) microg/kg
estrogen (r_compound) carcinogenesis
blockade (r_nsubj) protect
attempt (l_acl) control
mice (r_conj) challenge
benzodiazepines (r_nmod) administration
= (l_nmod) number
p (r_appos) phlorizin
seems (l_xcomp) suggesting
slower (l_conj) found
history (l_nmod) polyuria
effects (l_nmod) injury
long-evans (r_nsubj) hooded
cyclosporine (r_nmod) secondary
stroke (r_nsubj) occurs
flunitrazepam (r_nmod) injection
associated (r_acl) defects
offers (l_nmod) injury
infusion (r_dobj) had
srl (r_nmod) conversion
demonstrated (l_nsubj) cases
pyrazinamide (r_nmod) related
patients (l_nmod) psychosis
lesions (r_dobj) confirming
reported (l_nsubj) results
using (l_dobj) model
cases (l_nmod) hypoplasia
stimulation (r_nmod) syndrome
concerns (l_nmod) toxicity
initiation (l_nmod) process
ether (r_nsubj) seizure
aspects (l_nmod) thrombocytopenia
symptoms (l_conj) headache
recognized (l_conj) reported
demonstrate (l_ccomp) essential
reduces (l_dobj) rates
kidneys (r_nmod) examination
treatment (r_nmod) lesions
tacrolimus-related (r_amod) seizure
caused (r_acl) nephropathy
infusion (r_nmod) anaesthesia
cases (l_nmod) anemias
tacrolimus (r_conj) everolimus
withdrawal (r_nmod) reversible
pamidronate (r_compound) treatment
distinguishing (l_dobj) hyperplasia
developed (l_dobj) bradyarrhythmias
c (r_nsubj) increase
potentiates (l_dobj) toxicity
model (l_nmod) tle
risk (l_nmod) defects
resulting (l_nmod) anemia
reduces (l_dobj) myoclonus
presented (l_nmod) hiccups
regimen (r_nmod) cycles
exerts (l_nsubj) hyperammonemia
heparin (r_dobj) receiving
monotherapy (r_nsubjpass) associated
concentrations (r_nsubjpass) reported
concentrations (r_nsubj) arrhythmias
confusion (l_conj) coma
considered (l_advcl) remains
number (r_conj) catalepsy
generation (l_nmod) signs
cancer (l_nmod) pelvis
hypertension (l_nmod) normotensive
reviving (l_nmod) use
ami (r_conj) aap
parallel (l_acl:relcl) suggests
patients (l_nmod) torsade
model (l_amod) seizure
recorded (l_nsubjpass) abnormalities
dcf (r_conj) gtn
increased (l_nmod) group
represents (l_nsubj) palsy
one (r_xcomp) administered
dosage (r_nsubj) restricted
oxide (r_compound) production
activity (l_nmod) patent
described (l_nmod) patients
chemotherapy (l_conj) acid
% (l_appos) %
pretreated (l_nmod) seizures
life (l_nmod) carcinoma
povidone-iodine (r_conj) kanamycin-colistin
association (l_nmod) commencement
mg(2+)-free (r_compound) medium
valdecoxib (r_compound) doses
discontinued (r_advcl) resolved
xenon-133 (r_compound) anaesthesia
receive (r_xcomp) allocated
lacked (l_dobj) response
use (r_nsubj) continues
retinopathy (r_nmod) features
nephropathy (l_dep) diabetic
had (l_dobj) insufficiency
alcohol (r_conj) s-limonene
regimen (l_nmod) patients
dyskinesias (l_nmod) modification
metabolite (r_nmod) importance
acknowledged (l_nsubjpass) hit
effective (l_xcomp) terminate
short (l_conj) occur
trigger (l_nsubj) known
therapy (l_acl) monitored
compared (l_xcomp) placebo
ulcers (l_amod) hemorrhagic
associated (r_acl) delirium
anemia (r_dobj) underlying
evaluated (l_advcl) investigate
patient (r_nmod) delirium
groups (r_nsubj) displayed
effect (l_nmod) diabetes
had (l_dobj) chorea
period (l_nmod) rotation
ncq344 (r_nsubj) had
cefazedone)-treated (r_conj) cefonicid
had (l_dobj) migraines
patients (l_nmod) lv
exhibited (l_dobj) state
suggesting (l_ccomp) involved
lipid (r_nmod) attenuation
containing (r_acl) fs
acrolein (r_nmod) produce
patients (r_nmod) hypotension
levodopa (r_nmod) responses
treatment (r_nmod) administered
l-name (r_nsubj) reduced
dopamine (r_compound) transporter
reserpine- (l_conj) dyskinesia
observed (r_advcl) increased
treatment (r_nsubj) increases
methamphetamine (r_nmod) dose
tacrolimus-associated (r_conj) cyclosporine
superoxide (r_compound) dismutase
women (r_nmod) higher
proteinuria (l_conj) hypertension
disability (l_conj) dyskinesias
observed (l_nmod) reports
cisplatin (r_nmod) challenged
related (l_nmod) presence
risk (l_nmod) mortality
titrating (l_xcomp) achieve
appeared (r_advcl) protected
patients (l_nmod) sah
retention (r_nmod) deficit
usage (r_nmod) occurred
thiopental (r_nmod) produced
propranolol (r_nmod) diazepam
suspected (l_xcomp) cause
disulfiram (r_nmod) use
piroxicam (r_nmod) dose
normotensive (l_conj) animals
milrinone (r_nmod) inhibitors
induces (l_dobj) hemolysis
neuropathy (r_nmod) form
effect (l_nmod) incidence
5,7-dht (r_dep) 5,7-dihydroxytryptamine
complication (r_dep) thromboembolism
connected (r_xcomp) seems
states (l_nmod) symptoms
tacrolimus (r_compound) use
prevents (r_acl:relcl) agent
map (r_appos) methamphetamine
simvastatin-ezetimibe (r_nmod) hepatotoxicity
outpatients (l_nmod) hyperprolactinemia
induced (r_acl) tachycardia
mice (r_nmod) susceptibility
discontinued (l_nmod) nephrotoxicity
treated (l_nmod) inhibitor
apomophine (r_compound) injection
one (l_nmod) causes
donors (r_nmod) reaction
blockers (r_nmod) effects
manipulation (l_nmod) fracture
bd1063 (r_conj) bd1018
treatment (r_nmod) efficacy
acid (r_nmod) effect
model (r_nmod) doses
ltg (r_nsubj) exacerbated
picrotoxin (r_conj) flurothyl
higher (l_conj) age-dependent
groups (r_nmod) rejection
val/hctz (r_amod) combinations
propranolol (r_nmod) use
system (l_nmod) models
warfarin (r_nmod) initiation
is (r_advcl) started
morphine (r_conj) scopolamine
episodes (l_acl) associated
n-(2-hydroxypropyl)methacrylamide (r_amod) conjugates
creatinine (r_nmod) rise
suggesting (l_ccomp) importance
dph (r_nmod) case
ratio (l_nmod) vte
n-methyl-n-nitrosourea (r_conj) carcinogens
biodistribution (l_nmod) rats
doses (r_nmod) episodes
regulation (r_nmod) subjected
effect (r_dobj) produce
cocaine (r_compound) user
convulsions (r_nmod) that
busulfan (l_dep) cystitis
risk (l_advcl) developing
progress (l_dobj) grade
effects (r_nmod) reported
mimicking (l_dobj) accident
hydroxytyrosol (r_nmod) ameliorated
coagulopathy (r_nmod) case
vinorelbine (r_conj) gemcitabine
compared (r_advcl) observed
response (r_nmod) hyperactivity
symptoms (l_amod) akinetic
doxorubicin (r_conj) vincristine
factor (l_nmod) stroke
published (l_nsubjpass) events
criteria (l_nmod) disorder
carmustine (r_nmod:npmod) (bcnu)-induced
assess (l_dobj) association
levobupivacaine (r_nmod) doses
accentuante (l_dobj) progression
following (r_advcl) observed
diuretics (l_conj) arrhythmias
characterized (r_acl) dysfunction
phase (l_nmod) patients
excitement (l_amod) manic
cases (l_nmod) abortions
history (r_nmod) subjects
factor (l_acl) selecting
appetite (l_conj) mouth
improve (l_nmod) syndromes
ovarian (r_amod) cancers
developed (l_nsubj) failure
verapamil (r_compound) therapy
means (r_nmod) applied
causing (r_advcl) manifests
injury (l_amod) seizure-induced
acetonide (r_compound) implant
ability (l_acl) cause
scopolamine-induced (r_conj) cholinesterase
chloroquine (r_nmod) therapy
cause (l_xcomp) indistinguishable
nitroprusside (r_nmod) discontinuation
toxicity (l_nsubj) cystitis
clonidine (r_nmod) common
were (l_conj) played
developed (l_nsubj) papillomas
syndrome (l_nmod) secretion
prostigmine (r_dep) induced
cholesterol (r_dobj) contained
dexrazoxane (r_dobj) antagonized
matched (l_nmod) albuminuria
aneurysm (l_appos) taa
models (l_nmod) arrhythmia
mechanisms (l_nmod) anemia
6-hydroxydopamine (r_compound) lesion
inhibited (l_nsubj) administration
carbamazepine (r_nsubj) inhibits
acid-containing (r_amod) multivitamin
onset (l_nmod) thromboembolism
dysfunction (l_nmod) sclerosis
developed (l_dobj) lethargy
ramh (r_appos) (r)-alpha-methylhistamine
nephropathy (r_nsubj) leads
rats (r_nmod) function
effects (l_amod) anti-asthmatic
initiation (l_nmod) fluconazole
cisplatin-induced (r_amod) function
implant (r_nsubj) helps
exposed (r_acl:relcl) infants
interferon-alpha (r_compound) monotherapy
symptoms (l_nmod) schizophrenia
developed (l_conj) developed
vpa-therapy (r_nmod) associated
caused (r_acl) effects
utilization (l_acl) correct
disorder (l_conj) trichotillomania
rats (r_nmod) hypertension
suggest (l_nmod) patient
associated (l_advcl) shown
recruited (l_dobj) patients
exerts (l_dobj) effects
effects (r_nmod) protection
patients (r_nmod) determined
chemotherapy (r_dobj) complicating
modulates (l_nmod) models
injection (l_nmod) evaluation
alendronate (r_nmod) administration
benefit (r_conj) risk
triggered (r_acl) tachyarrhythmia
regimen (l_nmod) agc
caused (l_nsubj) female
withdrawal (r_nmod) disappeared
function (l_acl) induced
clonidine-induced (r_amod) hypotension
scores (l_conj) rating
episode (l_nmod) tdp.
women (l_acl:relcl) developed
5 (l_nmod) stroke
creatinine (r_compound) ratios
attributable (r_amod) effects
levels (r_nmod) patients
thalidomide (l_conj) neurotoxicity
protecting (r_advcl) exhibiting
monitoring (l_nmod) function
neurons (l_acl) induced
used (r_advcl) induced
bha (r_nmod) rats
hypoactivity (r_dobj) blunted
abolished (l_nmod) bradycardia
area (l_nmod) dysfunction
cidofovir (r_nmod) use
meq/l (r_appos) combination
4'-0-tetrahydropyranyladriamycin (r_nummod) bolus
hexamethonium (r_nmod) infusion
disappeared (l_nsubj) arrhythmia
olanzapine (r_nmod) randomized
accompanied (l_nmod) evidence
accompanied (l_nsubjpass) profile
remifentanil (r_nmod) concentration
lithium (r_nsubjpass) implicated
antipsychotics (r_nmod) combination
user (r_appos) man
triamterene (r_compound) nephrolithiasis
d (l_nmod) tachyarrhythmias
woman (l_acl) presented
mice (r_conj) mice
presumed (l_xcomp) stunning
morphine-treated (r_amod) mice
carboplatin (r_nsubj) appear
indomethacin (r_conj) allopurinol
cc (r_compound) intake
induction (l_nmod) syndrome
explain (l_nsubj) changes
increases (r_conj) hypercalcemia
fractionated (r_advcl) evaluated
rare (l_nsubj) syndrome
steroids (r_nsubj) caused
patients (l_conj) sweating
rizatriptan (r_amod) mg
tacrolimus (r_nmod) neuropathy
metoprolol (r_compound) attenuates
etoposide (r_nsubjpass) used
sulphate (r_compound) charge
lindane (r_nmod) ingredient
characterized (l_nmod) degrees
acetaldehyde (r_nmod) release
enalapril (l_nmod) pressure
dfo (r_compound) reduction
examine (l_dobj) relationship
cyclophosphamide (r_nmod) ability
women (r_nmod) increased
ca(2 (r_nmod) importance
symptoms (l_nmod) intoxication
zyban (r_appos) bupropion
detection (l_nmod) malformations
contributed (l_dobj) development
effects (l_nmod) cardiotoxicity
related (l_nmod) accumulation
microg/kg/min (l_dep) reduced
supplementation (r_nmod) importance
deficit (r_nmod) test
number (r_nsubj) increased
monotherapy (l_nmod) hypertension
plays (l_nmod) epilepticus
reported (l_ccomp) pain
trinitrate (l_nmod) diclofenac
lacking (r_acl) mice
tmp-smz (r_dobj) prescribed
injection (r_nsubj) causes
rosacea (l_conj) dermatitis
glycopyrrolate (r_nmod) treatment
review (l_nmod) patients
higher (l_nmod) meningioma
agonist (l_acl) used
infusion (r_conj) furosemide
causes (l_dobj) cardiotoxicity
had (l_conj) bundle
adolescent (l_amod) depressed
atropine (r_nmod) refractory
therapy (r_nmod) carcinoma
snp (r_compound) infusion
reduction (r_nmod) correlation
symptoms (r_nsubj) similar
cases (r_dobj) report
used (l_xcomp) manage
caused (l_dobj) hypertrophy
cases (l_nmod) hypoxaemia
drugs (r_advcl) reported
resulted (l_nmod) incidence
ciprofloxacin (r_conj) clarithromycin
furosemide (r_nmod) efficacy
planned (l_nmod) order
nitroglycerin (r_nmod:npmod) (ntg)-induced
tended (l_xcomp) lower
role (l_conj) association
development (l_nmod) seizures
p-choloroaniline (r_nsubj) factor
treatment (r_nsubj) increased
thalidomide (r_nmod) treated
injections (r_nmod) localization
allopregnanolone (r_nmod) derivative
% (r_nmod) decrease
gtn (r_dep) gtn
system (r_nmod) influence
involves (r_conj) suggest
found (l_nmod) rats
lidocaine (r_nmod) co-administration
cy (r_compound) toxicity
injection (r_nmod) case
effects (r_dobj) studied
treated (r_acl) adults
risk (r_dobj) examined
tolerable (l_nmod) infections
produced (l_nmod) rabbits
patients (r_nmod) prevalence
failed (l_conj) enhanced
needed (r_parataxis) suppressed
vpu (r_nsubj) potent
thrombocytopenia (r_nsubj) became
cm (r_nmod) higher
increased (l_nmod) re-infarction
tam-induced (r_amod) hemolysis
anotia (l_conj) malformation
inhibitor (r_appos) inhibitor
csa (r_nmod) effect
nephrotoxicity (l_nmod) patients
regimen (l_nmod) head
therapy (l_compound) ulcer
relation (l_conj) stroke
associated (r_acl) tumors
amiodarone (r_nmod) use
resembled (l_nsubj) lesions
addition (r_nsubj) minimize
patients (r_dobj) relieve
sulindac (l_conj) hyperkalemia
convulsions (r_conj) mydriasis
paramethasone (r_nmod) caused
effect (r_conj) speed
blocked (r_acl:relcl) organs
ribavirin (r_nmod) efficacy
exposure (r_nmod) associated
doses (r_nmod) scored
determine (l_dobj) rate
small (l_nsubj) stones
induce (l_conj) vsds
caused (r_acl) disease
decrease (l_nmod) threshold
patients (r_conj) infusion
caused (l_nsubjpass) atrophy
chloride (r_nmod) reversal
nh4ac (r_nmod) blocked
users (r_nsubj) show
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (r_compound) monkeys
haloperidol-controlled (r_conj) placebo-
establishes (l_dobj) model
treated (r_acl) patient
tizanidine (r_nmod) addition
maleate (r_amod) drops
diabetes (r_nmod) mice
containing (r_acl) oil
ly274614 (r_nsubj) antagonist
using (r_advcl) reported
proliferation (l_conj) hepatomegaly
exposure (l_nmod) infants
amca (r_appos) acid
effects (l_nmod) characteristics
children (r_nmod) cohort
reduces (l_dobj) nausea
compared (r_conj) determined
followed (r_acl) animals
steroid (r_compound) myopathy
specimen (l_nmod) patient
convert (l_dobj) arrhythmia
markers (l_nmod) impairment
metastases (r_nmod) patients
confusion (r_nsubj) reaction
nephrolithiasis (l_dep) implications
506-induced (r_amod) hypertension
occurred (l_nsubj) suppression
option (l_advcl) exhibits
ameliorated (l_nsubjpass) ulcer
developed (l_dobj) jaundice
rats (r_nmod) hippocampus
tremors (l_conj) convulsions
therapy (r_nmod) predictors
recorded (l_conj) five
result (l_nsubj) anemia
done (l_conj) administration
clonidine-induced (r_amod) bradycardia
skin (l_conj) hyperalgesia
clarify (l_dobj) nature
telithromycin (r_nmod) administration
produced (l_dobj) reactions
studying (l_dobj) pathophysiology
scores (r_nsubj) remained
causes (l_nmod) hepatotoxicity
pemoline (r_nsubj) induced
ifosfamide (r_nmod) g/m2
adjuvant (l_nmod) therapy
csa (r_conj) csa
propofol (r_compound) pain
patients (l_amod) myopathic
exhibiting (l_dobj) resistance
incidence (l_nmod) death
selected (r_conj) randomized
e (r_compound) concentration
observed (r_acl) toxicity
feasibility (l_acl) treat
acc-9653 (r_nmod) doses
acid (r_nmod) injection
remifentanil (r_compound) group
dobutamine (r_compound) therapy
suxamethonium (r_nmod) dose
induced (l_conj) caused
dyskinesia (l_nmod) complications
scavenging (r_nmod) showed
methylprednisolone (r_compound) therapy
effects (l_nmod) progression
synthase (r_nsubj) participates
azidothymidine (r_compound) anemia
victims (l_nmod) delirium
treatment (r_nmod) prolonged
melphalan (r_nmod) injury
t (r_appos) triamcinolone
patients (l_nmod) angina
clearance (r_conj) plasma
concentrations (r_nmod) remained
response (l_amod) cataleptic
conditions (l_nmod) hyperkalaemia
(+/-)-sm (r_conj) umb24
important (l_nmod) catalepsy
capsaicin-untreated (r_amod) condition
agonist (r_appos) doses
differ (l_nsubj) incidence
impairment (l_nmod) activity
led (r_acl:relcl) side-effect
effect (r_acl:relcl) tremor
gfc (r_nsubj) exert
phosphate (l_conj) susceptibility
lovastatin (r_nmod) efficacy
aluminum (r_compound) intoxication
morphine (r_nmod) infusion
effective (l_nmod) treatment
reduce (r_ccomp) shown
allowed (r_conj) provided
lidocaine (r_dobj) received
agonists (l_conj) antagonists
vulnerability (l_nmod) effects
phenomena (l_amod) ischemic
metabolism (r_dobj) decreased
thirst (r_dobj) have
found (l_xcomp) have
models (l_nmod) failure
exacerbation (l_conj) appearance
observed (r_acl) that
adriamycin-induced (r_amod) cardiomyopathy
digitalis (r_conj) ligation
failure (r_dobj) developed
prophylaxis (l_conj) patients
paroxetine (r_nmod) occur
test (r_nmod) attack
cocaine (r_nmod) actions
activity (l_amod) seizure
administered (l_conj) appears
sulfonamides (r_nsubjpass) associated
episode (l_nmod) anuria
patient (l_nmod) function
pilocarpine (l_acl) given
trial (l_nmod) b.
influenced (l_nsubjpass) hyperactivity
setting (r_nmod) received
anemia (r_appos) toxicities
necrosis (l_appos) rpn
dipyrone (l_nmod) analgesia
associated (l_nsubjpass) pattern
adriamycin (r_appos) cardiomyopathy
cbdca (r_compound) schedules
support (l_dobj) effect
cya (r_nmod) dose
dopamine (r_compound) sulpiride
antibodies (r_dep) changes
no (r_compound) inhibitors
death (r_dobj) prevented
fibrillation (r_nmod) aged
developed (r_acl:relcl) disease
decline (l_nmod) function
induced (r_acl) anaemia
levels (r_dobj) alter
demonstrating (l_dobj) apnoea
capsaicin-induced (r_amod) sensations
treatment (l_nmod) tumors
induction (l_nmod) diabetes
evaluate (r_xcomp) designed
secondary (r_amod) incontinence
gentamicin-treated (r_amod) patients
nmbas (r_dobj) involved
bicarbonate (r_nsubj) alleviates
fluoxetine (r_nsubjpass) given
instillation (l_nmod) girl
history (l_amod) psychiatric
undergoing (r_acl) patients
tam (r_nmod) effect
rats (r_nsubj) exhibited
dose (r_nmod) treated
cya (r_compound) dose
ethambutol (r_nsubjpass) withdrawn
cinacalcet (r_nmod) desipramine
tacrolimus (r_nsubj) induces
phenylethylbarbiturate (r_nmod) administration
injections (r_nsubj) standard
reserved (r_conj) collected
injury (l_nmod) cortex
secondary (r_amod) edema
sacrificed (r_acl:relcl) animals
media (r_nmod) incidence
reduction (l_nmod) type
discontinued (l_xcomp) resulting
abnormalities (l_nmod) use
anesthesia (r_nmod) associated
nmda (r_compound) enhancement
caused (r_acl) urticaria/angioedema
injections (r_nmod) case
efflux (r_nmod) reduction
vasopressin (r_nmod) action
role (r_dobj) clarify
e1 (r_nmod) flow
prevent (l_dobj) dex-ht
second-generation (r_conj) third-generation
occurred (l_nsubj) obstructive
nitroprusside (r_nsubj) vasodilator
patient (r_nmod) neuropathy
degeneration (l_nmod) interval
pathogenesis (l_nmod) disease
effect (l_amod) hyperglycemic
cyclosporine (r_nmod) exposed
formation (r_nsubj) accounts
spironolactone (r_nsubj) drug
failure (l_appos) chf
nanoparticles (r_compound) administration
effects (r_nsubj) apparent
desferrioxamine (r_compound) therapy
required (l_advcl) treat
oct (r_appos) hyperparathyroidism
giving (r_advcl) increased
cddp (r_nmod) influenced
haloperidol-induced (r_amod) symptoms
lidocaine-induced (r_amod) asystole
prazosin (r_dobj) received
months (r_nmod) treatment
describe (l_advcl) highlight
vpu (r_nsubj) protect
ibuprofen (r_amod) administration
ma (r_compound) abusers
metformin (r_nsubj) diminish
iiib (r_nsubj) received
symptoms (l_amod) nms-like
therapies (r_dep) immunosuppressive
patients (l_acl:relcl) risk
development (l_nmod) cells
attributed (r_acl) deficits
related (r_ccomp) indicating
presented (l_dobj) glomerulonephritis
fenoldopam-induced (r_amod) hypotension
chicks (r_nmod) occurred
tested (l_xcomp) using
evidence (r_dobj) provide
starting (r_advcl) investigated
increase (l_nmod) correlates
resulting (l_nmod) exposure
increased (l_nmod) rats
cab (r_dobj) received
increased (l_nmod) recovery
droperidol (r_nmod) dose
agents (r_conj) flecainide
trial (l_nmod) treatment
case (l_nmod) arrest
pathogenesis (l_nmod) toxicity
analyzed (l_advcl) include
vehicle (r_nmod) treated
enflurane (r_nsubj) produce
levodopa-induce (r_amod) dyskinesias
emphasis (l_nmod) characteristics
carcinomas (r_nmod) incidence
codine (r_conj) morphine
acid-induced (r_amod) hepatitis
similar (l_nsubj) doses
diuretic (r_nmod) period
flecainide (r_nsubjpass) started
measured (r_dep) results
atra-induced (r_amod) nodosum
children (r_nsubj) had
hexabrix (r_compound) polyvidone
demonstrated (l_dobj) responses
tolerated (l_nmod) therapy
depletion (r_nmod) treatment
combinations (r_nsubj) improve
mmol/l (l_amod) consistent
induced (l_nsubjpass) pain
trial (l_compound) group
lidocaine (r_nmod) combination
ouabain (r_nmod) effects
bzds/rds (r_nmod) use
produce (l_dobj) efficacy
screening (r_nmod) prevalence
runs (l_nmod) tachycardia
mdma (r_compound) use
density (l_compound) tumor
induced (l_dobj) episodes
changes (r_dobj) have
activity (l_nmod) preparation
documented (l_nsubjpass) stenosis
modification (r_nmod) result
analysis (l_conj) years
pilocarpine (r_nmod) prior
enhanced (l_nsubjpass) bradycardia
studied (l_dep) deliberate
accumulation (r_nmod) leads
caffeine (r_nmod) effects
physicians (r_nsubj) aware
nifedipine (r_conj) a
amiodarone (r_amod) (ami)-induced
exposure (l_nmod) variety
revealed (l_advcl) decreased
prodrugs (r_nsubj) actives
modifies (l_dobj) catalepsy
administration (r_nsubj) lead
reduced (l_dobj) hyperalgesia
abnormalities (l_acl) associated
resembled (l_nsubj) lesion
relief (l_compound) headache
ciprofloxacin-induced (r_amod) nephritis
treatment (r_nmod) start
prilocaine (r_nmod) db
prevention (r_nmod) use
respect (r_nmod) evaluated
cause (l_dobj) delirium
discontinued (r_advcl) improved
dobutamine (r_nsubj) provoke
resulted (r_conj) attenuated
protection (l_nmod) neurotoxicity
effects (r_nsubjpass) evaluated
prevention (l_nmod) myoclonus
left (l_dobj) systolic
occurred (l_nsubj) movements
metoprolol (r_conj) metoprolol
toxicity (l_conj) retardation
ceftriaxone-associated (r_amod) pseudolithiasis
cocaine (r_nmod) injection
androgen (r_compound) administration
animals (r_nsubj) motionless
hygiene (l_conj) wear
medications (l_compound) virus
number (l_conj) hypertension
mice (l_acl) rendered
has (l_dobj) association
estimate (l_dobj) risk
tested (r_conj) used
therapy-na (r_nmod) strains
associated (l_nsubjpass) diabetes
associated (r_acl) alterations
administered (l_conj) decreased
d-amphetamine-induced (r_amod) hyperactivity
signs (r_nmod) aware
trial (r_dobj) entered
fc (r_nmod) pretreated
risk (l_nmod) convulsions
doses (l_nmod) micrograms/kg
ischemia (l_acl) induced
vte (r_nmod) risk
relation (r_dep) prevents
presented (l_dobj) values
suggested (l_prep) based
creatinine (r_conj) had
neurological (l_dep) toxicity
erythematosus (l_conj) gravis
associated (l_advcl) hearing
hfde-induced (r_amod) seizures
oxygen (r_nmod) oxide
interaction (r_nmod) related
likely (l_xcomp) have
retention (l_conj) fibrosis
induced (r_acl) cardiotoxicity
sirolimus (r_nsubj) represents
decreased (l_nsubjpass) agents
recurrence (l_nmod) maha
uterotonic (l_acl:relcl) cause
form (r_nmod) cardiotoxicity
betaine (r_nmod) role
contribute (l_nmod) prolongation
disulfiram-like (r_amod) syndrome
attributed (r_parataxis) produced
hour (r_nmod) developed
volunteers (r_nmod) administered
currents (r_nmod) depression
resolved (r_conj) treated
propranolol (r_nmod) efficacy
effect (l_nmod) cases
injection (r_nmod) incidence
clearance (r_conj) reduced
nephropathy (l_conj) nephropathy
superior (l_nmod) terms
dose (l_nmod) hit
rats (r_nmod) severe
multiple (r_conj) small
angiotensin (r_compound) inhibitor
determined (l_conj) compared
overdose (r_nsubj) resulted
patients (l_nmod) group
levels (l_nmod) factors
expression (l_acl:relcl) increases
deaths (r_attr) were
lidocaine (r_nmod) incidence
copper (r_compound) accumulation
succinylcholine (r_nmod) myalgia
increased (l_nmod) hypotension
arag (r_nmod) combination
clonidine (r_nmod:poss) effects
indomethacin (r_nmod) induced
cocaine-induced (r_conj) amphetamine-
left (l_dobj) hemiparesis
effect (l_acl) mediated
sensitive (l_nsubj) rats
effects (l_nmod) conditions
exposure (r_nsubj) induced
prescribed (l_nmod) efficacy
aminoglycoside (r_amod) nephrotoxicity
excluded (l_nsubjpass) causes
induction (l_nmod) catatonia
escalating (r_advcl) response
treatment (l_nmod) disease
developed (l_dobj) tetany
occurred (l_nsubj) thrombophlebitis
determined (l_nsubjpass) toxicity
patients (l_compound) rrmm
indomethacin-induced (r_amod) dysfunction
age (l_conj) diagnosis
acid (r_dep) acid
patients (r_appos) results
interaction (r_dobj) indicates
mepivacaine (r_nmod) block
conclusion (l_dep) nausea
alleviates (l_xcomp) penile
mania (l_nmod) patients
treated (l_advcl) assess
yohimbine (r_dobj) evaluated
occurred (l_nsubj) deterioration
frequency (l_nmod) administration
effects (r_nmod) had
lidocaine (r_nmod) ph
combinations (l_nmod) morphine
switching (r_nsubjpass) reported
developed (l_nmod) arrest
release (r_conj) role
cocaine-induced (r_amod) delirium
timolol (r_compound) suspension
10-diol (r_appos) doses
induce (l_dobj) hypothermia
verapamil (r_nmod) treated
protection (l_nmod) toxicity
response (r_nsubj) shows
carbimazole (r_compound) therapy
manifests (l_dobj) activity
disorder (l_nmod) tissues
alpha-t (r_appos) alpha-tocopherol
changed (l_nmod) hand
suggesting (l_dobj) involvement
tolerance (r_nsubjpass) studied
secretion (r_dobj) pulsatile
model (l_compound) ulcer
synthase (r_compound) inhibitors
cost (l_nmod) return
developed (l_dobj) mania
unrelieved (l_nsubjpass) pain
n (r_dep) present
spasms (l_conj) tetany
cephalosporins (r_conj) penicillins
administration (r_nsubj) inhibited
regurgitation (l_appos) mr
stimuli (l_conj) areas
abuse (r_nmod) history
6,3-dilactone (r_compound) rats
accuracy (l_compound) recognition
patients (l_nmod) seizures
pentylenetetrazole-induced (r_amod) anxiety
continuing (r_advcl) managed
headache (r_nsubj) disappeared
changes (l_nmod) power
therapy (l_nmod) leukemia
model (l_amod) neuropathy
cases (l_conj) one
discontinuation (r_nmod) patients
decreasing (l_dobj) incidence
treated (r_acl) mothers
assess (l_nmod) patients
steatosis (l_nmod) liver
determine (l_nmod) resolution
doxorubicin (r_nmod) enhanced
weeks (l_nmod) progression
injections (r_dobj) received
associated (r_acl) hypertension
suppressants (r_nmod) associated
patients (l_nmod) infection
indinavir (r_nmod) treated
effects (l_appos) tremor
evoke (l_dobj) sensation
levetiracetam (l_nmod) adjunct
need (l_acl) search
patient (l_nmod) pheochromocytoma
placebo (r_dep) patients
labetalol (r_conj) pindolol
examined (l_nsubjpass) globulin
blockade (r_nsubj) caused
allergy (r_nmod) manifestation
differences (l_nmod) rejection
involvement (l_nmod) aetiology
evaluation (r_nsubj) revealed
evaluated (l_nmod) se
cholecystokinin (r_nmod) antagonism
vasopressin (r_conj) thirst
attenuates (l_conj) suggest
imaging (r_nmod) alteration
mazindol (r_nmod) trial
penicillin (r_nsubj) anaphylaxis
vincristine (r_nmod) syndrome
da (r_nmod) levels
5-(l-hexyloxy)-6-methoxy-4-methylquinoline (r_nmod) administration
complicating (r_acl) anuria
upregulation (l_nmod) (kim)-1
striking (r_nsubj) rate
induced (l_dobj) model
cardiotoxicity (l_nmod) patients
assess (l_nmod) pain
chemotherapy (r_nsubj) active
function (l_nmod) inhibitor
6-ohda (r_compound) lesion
bupivacaine (r_compound) levels
exerts (l_dobj) effect
conversion (r_nmod) displayed
chloride (r_dep) used
increment (r_nmod) association
nissl-staining (r_nsubj) served
patients (l_nmod) hypokalemia
replicated (l_conj) representative
resistant (l_nmod) polyuria
phosphokinase (r_nmod) %
sulindac (r_nmod) advantages
agonist (l_acl:relcl) causes
increased (l_nsubj) degree
incidence (l_nmod) changes
adriamycin (r_nmod) rise
use (r_nmod) associated
sequestration (l_nmod) nitrotyrosine
fever (l_conj) ulcers
inhibited (l_dobj) oih
binding (r_nsubj) elicits
increased (l_nsubj) hazard
rate (l_nmod) vte
naa (r_nsubjpass) given
had (l_ccomp) persist
olanzapine (r_nsubj) demonstrated
had (l_conj) had
decreased (l_dep) to
seizures (r_nsubjpass) characterized
misoprostol (r_nmod) micrograms
initiated (l_advcl) resulted
groups (r_nmod) divided
clentiazem (l_nmod) injury
transplanted (l_nmod) alf
temsirolimus (r_compound) therapy
jitteriness (r_nsubj) identical
mediating (l_dobj) hyperactivity
mk-801 (r_nsubj) administered
state (r_conj) sensitivity
use (r_nmod) complications
switched (l_nmod) nephrotoxicity
microinjections (r_nmod) pretreated
spiranolactone (r_nmod) doses
recovers (l_amod) myopathy
effect (l_nmod) sensitivity
obtunding (l_dobj) response
patients (l_nmod) oab
use (r_nmod) association
returned (r_conj) accompanied
users (r_nmod) sleepiness
prevention (l_nmod) vt
(na (r_nmod) response
derivative (r_appos) ganaxolone
induced (r_acl) profile
stabilized (r_acl) tolerance
exacerbation (l_conj) myoclonus
suppresses (l_dobj) vestibulotoxicity
studied (l_nmod) patients
bupivacaine (r_compound) consumption
streptozotocin-induced (r_amod) impairment
territory (l_amod) ischemic
current (r_dep) therapy
prevents (l_dobj) rigidity
having (l_dobj) disorder
dopamine (r_compound) d2
induction (l_conj) hepatomegaly
codeine (r_compound) catalepsy
cyclophosphamide (r_compound) tumor
levels (r_dobj) had
weeks (r_nmod) detected
reported (l_xcomp) induce
impairment (l_acl) caused
apomorphine-induced (r_amod) climbing
rats (r_nmod) model
intake (r_nmod) admitted
blockade (r_nmod) result
example (r_dobj) represents
increase (r_xcomp) shown
days (l_nmod) women
elicits (l_dobj) series
blocks (r_conj) swallowing
treated (l_nmod) weeks
hormone (l_appos) siadh
required (l_nmod) accumulation
stages (r_nmod) evaluated
therapy (l_advcl) unclear
(ma)-induced (r_amod) neurotoxicity
ly-171555 (r_conj) levodopa
penicillamine-induced (r_amod) glomerulonephritis
models (l_nmod) disease
option (l_nmod) syndrome
mexitil-perlongets (r_appos) form
incidence (r_dobj) determined
caused (r_advcl) arteriosclerosis
reported (l_nsubjpass) myopathy
incidence (l_nmod) syndrome
manifests (l_nmod) hepatitis
present (l_nmod) treatment
activity (l_amod) epileptic
devastating (l_advmod) pain
fever (l_conj) anemia
extent (l_nmod) loss
reducing (l_dobj) cognitive
phenomena (l_nmod) mydriasis
% (r_nmod) %
hypothesis (l_amod) adrenaline-hypertension
infusion (l_nmod) combination
associated (l_nsubj) stroke
occurred (l_nsubj) jaundice
measures (r_compound) assessment
reported (l_conj) used
bupivacaine (r_nmod) activity
benzo[a]-pyrene (r_appos) carcinogens
child (l_nmod) impairment
isoniazid (r_nmod) microinjections
involved (r_ccomp) hypothesis
result (l_nmod) injury
(snp)-induced (r_amod) hypotension
useful (l_nmod) monkey
discharged (l_advcl) result
leads (r_acl:relcl) disorder
seizures (r_nmod) risk
unlikely (l_xcomp) associated
metrizoate (r_advcl) lower
rate (l_conj) fasciculations
formation (l_compound) abscess
placebo- (r_amod) trial
enhancement (l_dep) leukoencephalopathy
chemotherapy (r_nmod) treated
aware (l_nmod) potential
apap (r_compound) nephrotoxicity
presents (l_nsubj) thrombocytopenia
developed (l_dobj) stunning
increase (l_nmod) map
thienodiazepine (r_compound) derivative
levodopa (r_nmod) increased
course (l_amod) nausea-free
summary (r_nsubjpass) stopped
importance (l_nmod) signaling
g (r_nmod) treated
potential (l_compound) tumor
daidzein (r_nsubj) play
tdf-related (r_amod) disease
estimates (l_nmod) thromboembolism
consumption (r_nmod) association
administered (l_advcl) resulting
causes (l_dobj) epilepticus
effects (r_dobj) clarify
influenced (r_acl:relcl) manifestations
dependent (r_ccomp) indicated
erythroderma (l_conj) eosinophilia
phenylpropanolamine (r_nmod) dose
tested (l_advcl) using
jaundice (l_conj) symptoms
nimodipine (r_conj) placebo
caused (r_acl:relcl) patients
showing (l_dobj) activity
atra (r_compound) therapy
response (l_amod) neurotoxic
association (r_nmod) case
hypersecretion (r_nmod) caused
paclitaxel (l_acl) combined
permits (l_compound) toxicity
determined (l_nmod) magnitude
applied (l_advcl) clarify
patients (l_nmod) impairment
swelling (l_dep) angioedema
sevoflurane (r_nmod) supplement
activity (r_dobj) had
evidence (l_nmod) efficacy
elevations (r_nmod) symptoms
administered (l_conj) had
p450 (r_nmod) inducer
mg/kg (l_conj) epilepticus
trental (r_appos) pentoxifylline
suffered (l_dobj) effects
have (l_conj) likely
sensitizes (l_nmod) cardiotoxicity
revealed (l_conj) taking
group (r_nmod) found
desipramine (r_nmod) administration
bcnu (r_compound) therapy
rats (l_nmod) cancer
pretreatment (r_nsubj) induce
association (l_nmod) presence
metabolite (r_ccomp) indicating
acid-induced (r_amod) neutropenia
d (r_conj) growth
mutants (r_nmod) occurrence
grams (l_nmod) proteinuria/day
memory (r_dobj) improve
levels (l_nmod) psychosis
hcfc (r_appos) 1-chloro-1,2,2,2-tetrafluoroethane
possibility (l_ccomp) reduced
patients (l_nmod) retinochoroidopathy
paracetamol-treated (r_amod) rats
started (r_conj) had
supplementation (l_nmod) women
operative (l_nmod) generalization
one (r_appos) changes
propranolol (r_nmod) effects
changes (l_amod) ischemic
profiles (r_nsubj) shown
glucose (r_dobj) fasting
increased (l_dobj) extent
potassium (r_compound) loss
estradiol (r_nmod) injection
administration (r_nsubjpass) followed
intake (l_conj) cause
regimen (r_nmod) produced
triglycerides (r_conj) cholesterols
neuralgia (l_amod) postzosteric
epinephrine (r_nmod) bolus
blockade (r_nsubj) sufficient
causes (l_dobj) toxicity
injection (r_compound) pain
hypertension (r_nmod) present
starting (l_dobj) increase
showed (l_dobj) calculi
resolved (l_advcl) continued
warfarin (r_nmod) resolved
vpa (r_compound) therapy
damage (r_nsubj) selective
fibrillation (l_conj) agitation
susceptibility (r_dobj) reflects
simvastatin (r_amod) increment
stroke (r_conj) determine
effect (l_nmod) hyperactivity
5-fluorouracil (r_conj) cisplatin
= (r_parataxis) differed
piperacillin (r_conj) netilmicin
cardiotoxicity (r_dobj) reduces
association (r_nmod) observed
vasopressin (r_compound) gene
prostigmine-morphine (r_amod) administration
resolve (l_conj) had
non-selective (r_amod) inhibitors
provoked (r_acl) attack
mothers (l_nmod) disease
did (r_acl:relcl) those
erp (l_conj) length
survivors (l_nmod) cancer
indomethacin (r_nmod) test
ouabain-induced (r_amod) tachycardia
acetylcholine (r_compound) expression
substantial (r_advcl) plays
failed (r_acl:relcl) findings
(vcm)-induced (r_amod) stress
ketamine (r_compound) sedation
effect (l_conj) effect
therapy (r_nmod) outcome
bcnu-induced (r_amod) dysplasia
bleeding (l_nsubj) ami/gi
switching (r_advcl) summarizes
prophylaxis (l_compound) pneumonia
company (r_dep) dose
group (r_nmod) that
(na (r_nmod) activity
(ach)-produced (r_amod) hypotension
alter (l_advcl) decreasing
report (l_nmod) pseudoacromegaly
proportions (l_nmod) patients
diethylstilbestrol (r_compound) treatment
mesna (r_nmod) use
model (l_compound) edema
mice (l_dobj) toxicity
calcium (r_compound) reabsorption
patients (l_nmod) head
women (l_nmod) angioedema
protecting (r_advcl) effective
demonstrate (l_dobj) ototoxicity
hydrochloride (r_conj) steroids
seizure-prone (l_conj) seizure-resistant
counteract (l_dobj) vasospasm
therapy (l_compound) migraine
cells (l_nmod) carcinomas
platinum/paclitaxel-refractory (r_amod) ovarian
level (l_nmod) disease
resolution (l_nmod) fistula
polymerase (r_nmod) activation
dopamine (r_compound) subtypes
sch (r_compound) mg
defects (l_appos) mds
sirolimus (r_conj) mofetil
associated (r_acl) vision
ranging (l_nsubj) hyperkalemia
neurons (r_nsubj) vulnerable
group (r_nmod) those
animals (l_compound) ich
acetaminophen (r_conj) nsaid
detect (l_dobj) hyperthermia
started (r_acl:relcl) hypertension
hepatotoxicity (r_nsubj) cause
treat (l_dobj) effects
induced (r_amod) increases
state (l_nmod) amnesia
cholestasis (l_acl) associated
chemotherapy (r_nsubjpass) associated
catecholamines (r_nmod) role
states (l_acl) induced
reported (r_ccomp) getting
nvp (r_compound) therapy
proteins (r_nsubjpass) involved
induced (l_nsubjpass) se
concerns (l_nmod) neurotoxicity
latencies (l_nmod) onset
dexamethasone (r_compound) programs
demonstrating (l_dobj) effects
dosages (r_nsubj) produced
showed (l_dobj) >
agents (r_nmod) complication
observed (l_nsubjpass) block
vulnerability (r_dobj) present
treatment (l_nmod) arthritis
22-oxacalcitriol (r_nsubj) suppresses
studied (l_nmod) dogs
enalapril (r_dep) assess
methylprednisolone (r_dep) patients
group (l_amod) fk506-nephropathy
1,2-dmh (r_appos) 1,2-dimethylhydrazine
associated (l_nmod) therapy
vds (r_appos) vindesine
induced (l_nsubjpass) glomerulopathy
cancers (l_appos) cancers
patients (l_nmod) factors
tamoxifen (r_conj) placebo
study (l_acl) assess
related (r_amod) tachycardia
benztropine (r_nsubj) drug
lithium (r_nmod) drugs
written (r_advcl) remain
acetaminophen (r_dep) role
performance (l_nmod) patients
testosterone (r_nsubjpass) determined
case (l_nummod) two
evaluated (l_nsubjpass) effect
d-med (r_nmod) treatment
sulfate (r_nmod) efficacy
fluvastatin (r_compound) therapy
vigabatrin-associated (r_amod) changes
levobupivacaine (r_nmod) administration
omeprazole (r_nmod) use
bepridil (r_nsubj) induced
neurons (r_nmod) cells
described (l_nsubj) child
nicotine (r_nsubj) play
receiving (l_nmod) treatment
treatment (l_nmod) chf
n-dimethylpropranolol (r_appos) n
patient (l_nmod) history
intense (r_conj) appeared
paroxetine (r_nmod) prescribed
thrombocytopenia (r_dep) two-step
amns (r_nmod) toxicity
difficult (l_xcomp) terminate
hexamethylmelamine (r_conj) cyclophosphamide
induced (r_acl) lidocaine
potential (l_conj) arrhythmias
resulted (l_dep) pain
trihexyphenidyl (l_conj) placebo
duration (l_nmod) patients
misoprostol (r_nmod) administration
risk (l_nmod) cad
fact (l_ccomp) correlates
factor (r_nmod) expression
injected (r_advcl) developed
hypertension (l_appos) gc-ht
induces (l_dobj) insipidus
bicarbonate (r_dobj) received
edaravone (r_nmod) alleviation
hctz (r_nmod) hypokalemia
ecstasy (r_appos) rationale
cacl2 (r_compound) therapy
antibiotic (r_appos) cardiotoxicity
has (l_dobj) toxicity
dexamethasone (r_conj) bortezomib
effects (l_nmod) levels
collection (l_conj) history
man (l_nmod) arthritis
treat (l_dobj) thrombosis
associated (r_acl) demand
thromboembolism (l_conj) thrombocytopenia
identify (l_dobj) potential
effect (l_nmod) impairment
acetaminophen (r_dobj) consider
l-dopa (r_nmod) treatment
induced (l_nsubjpass) ns
combination (l_nmod) prevention
development (r_nmod) influence
overdose (r_nmod) suffered
attenuated (l_conj) improve
attenuated (l_dobj) activation
prolongation (l_conj) pointes
induces (l_dobj) stones
carboplatin (r_nmod) injection
antagonist (l_nmod) treatment
indinavir (r_nsubjpass) discontinued
nicotine-induced (r_amod) seizures
crataegus (r_nmod) tincture
incidence (l_nmod) effects
effects (l_nmod) agents
l-dopa (r_conj) saline
have (l_dobj) abnormalities
atp (r_nsubjpass) stopped
explained (l_nsubjpass) deficit
transplantation (r_nmod) therapy
influence (l_dobj) narcosis
patients (r_nmod) detected
mi (r_nmod) patients
therapy (r_dobj) developed
prevent (l_dobj) gentamicin-arf
reverse (l_dobj) effects
downregulates (l_conj) i1-receptor-mediated
children (l_nmod) disorder
accompanied (l_nsubjpass) syndrome
increased (l_dobj) frequency
vomiting (l_conj) moderate
overdose (r_nmod) reversal
valproate (l_advmod) encephalopathy
subject (l_nmod) epilepticus
rise (l_nmod) proteinuria
bcc (r_appos) bicuculline
patients (r_nmod) loss
rad001 (r_dobj) received
contraceptives (r_nmod) use
treatment (r_nmod) exists
dogs (l_acl) analyzed
verapamil (r_nmod) effect
hepatitis (r_nsubjpass) followed
group (l_compound) cancer
vpa-induced (r_conj) pancreatitis
animals (r_nmod) that
reversal (r_parataxis) studied
release (r_conj) aggravation
patients (l_acl) complained
treatment (l_nmod) akathisia
entered (l_nsubj) patients
activity (l_conj) sensitivity
hepatotoxicity (r_nmod) evidence
control (l_dobj) seizures
vincristine (r_nsubjpass) given
treatment (l_nmod) impotence
markers (l_nmod) dysfunction
use (l_conj) disease
clomipramine-induced (r_amod) disturbance
exert (l_dobj) hyperalgesia
endografine (r_compound) group
use (r_conj) treated
therapy (l_conj) difficulty
carrageenan (r_amod) model
disruption (l_nmod) hypertension
cyclosporine- (r_compound) levels
induced (l_dobj) neurotoxicity
mg (r_nmod) dose
achieves (l_conj) induces
apoptosis (r_dobj) exhibit
frequency (r_dobj) reduce
contribution (l_nmod) form
ratios (l_nmod) vte
incidence (l_nmod) fasciculations
methylphenidate (r_conj) used
contaminated (l_nmod) derivative
associated (r_conj) have
similar (l_conj) greater
pelvis (l_conj) bladder
estrogens (l_acl:relcl) associated
blockers (r_dep) therapy
events (l_amod) hepatotoxic
acid (r_dobj) use
demonstrated (l_dobj) effect
chorea (l_nmod) hyperglycinemia
infusions (r_dobj) received
placebo (l_nmod) scores
assess (l_advcl) had
have (l_dobj) diabetes
development (l_nmod) deficits
cardiomyopathy (r_conj) cardiomyopathy
min (l_nmod) ischemia
complication (l_nsubj) failure
alleviation (l_nmod) vestibulotoxicity
ratings (l_nmod) slowness
placebo (l_nmod) agoraphobia
studied (l_dobj) response
alterations (l_nmod) pathways
leakage (r_nmod) preceded
report (l_conj) developed
lasted (r_acl:relcl) anuria
performed (l_nmod) disease
well-tolerated (l_conj) appeared
rats (l_amod) stroke-prone
shake (r_nmod) effect
eliminated (l_dobj) increase
eosinophilia (l_conj) failure
initiating (r_advcl) developed
amelioration (l_nmod) hypokalemia
known (l_nsubjpass) mechanism
arrhythmias (l_acl) characterized
causes (l_dobj) cardiomyopathy
acetylcholine (r_compound) release
paracetamol (l_nmod) tumours
feature (l_nmod) hepatotoxicity
effect (l_nmod) infections
studied (r_dep) background
administration (r_nmod) days
elevation (r_nmod) extent
were (l_nsubj) differences
phosphate (r_compound) nephrolithiasis
led (l_nmod) agitation
toxicity (l_conj) increase
model (r_nmod) similar
dacarbazine (r_compound) therapy
level (l_acl) inducing
correct (l_dobj) hypokalemia
rate (l_nmod) disease
reduces (l_advcl) increasing
whether (l_nsubj) reduction
predisposed (l_nmod) development
nitroglycerin (r_conj) hydralazine
magnesium (r_nmod) toxicity
methotrexate (r_nmod) induction
observed (l_nmod) seizure
complained (l_nmod) pain
performed (l_dobj) study
sites (r_nsubjpass) studied
effect (l_nmod) catalepsy
treat (l_dobj) episodes
greater (l_nsubj) bradycardia
mirtazapine (r_nmod) developed
those (r_nsubj) prolonged
pain (r_nmod) efficacious
therapy (r_nmod) absence
gentamicin-mediated (r_amod) failure
lower (l_nsubj) dysfunction
provide (l_dobj) assessment
occurred (l_nsubj) infections
bolus (r_nsubjpass) given
sm-5887 (r_compound) treatment
flutamide (r_nmod) administration
nitroglycerin (r_nmod) provocation
less (l_nmod) depression-inducer
spironolactone (r_nmod) benefits
propranolol (r_conj) carbimazole
rejection (l_nmod) groups
concentration (r_dobj) revealed
duration (l_compound) af
secondary (r_xcomp) described
group (r_nmod) acetaminophen
fact (r_dobj) highlighting
hyperkinesis (l_conj) irritability
flashbacks (r_nmod) experienced
concern (l_nsubj) bleeding
duration (l_amod) seizure
medication (r_compound) errors
possibility (r_dobj) highlights
patients (l_nmod) amyloidosis
phenotype (l_amod) depressive
changes (r_nmod) mediated
response (l_compound) headache
revealed (l_advcl) reducing
ranges (l_nsubj) risk
response (l_dep) <
man (l_nmod) macroglobulinaemia
bromide (r_nmod) nmbas
electrographic (r_dobj) blocked
nimo (r_conj) ntg
thiopentone (r_nmod) use
patient (r_nmod) developed
lower (r_parataxis) higher
crystals (r_nmod) caused
bort (r_nmod) day
correlation (l_nmod) improvement
loss (l_amod) polyneuropathy
continue (l_advcl) decreased
cephalosporin (r_compound) hematotoxicity
reduction (r_nmod) submitted
reserpine-treated (r_amod) mice
valsartan (l_conj) combinations
development (l_nmod) seizure
virus-related (l_nmod:npmod) b
patients (l_compound) c
performance (r_dobj) evaluated
solution (r_appos) timolol
5-azacytidine (r_conj) process
pentylenetetrazole-induced (r_amod) animals
ceftriaxone (r_dobj) ingesting
application (r_nmod) administered
etomidate (r_amod) induction
given (l_nmod) infusion
fibroblasts (l_nmod) patient
pathophysiology (l_nmod) dyskinesias
effects (r_dobj) demonstrated
group (l_acl:relcl) experienced
danger (l_nmod) persists
drop (l_nmod) pressure
nephritis (l_conj) anemia
affected (l_nmod) blockade
bradydysrhythmias (l_conj) tachycardia
caffeine (r_nmod) toxicity
h (r_nmod) found
incidence (r_nmod) effect
gentamicin (r_conj) dm
misoprostol (l_nmod) dysfunction
role (l_acl) eliciting
treatment (r_acl:relcl) patient
administration (r_nmod) inhibited
toxicity (r_nsubjpass) thought
affect (l_dobj) incidence
period (r_nmod) described
levels (r_dobj) delayed
patients (l_compound) chf
model (r_appos) patients
scale (r_nmod) identified
content (r_conj) activity
hoe (l_conj) des-arg10hoe
was (l_nmod) group
effects (l_amod) anti-amnesic
hepatotoxicity (r_nmod) review
receptors (r_nmod) antagonism
developed (l_conj) side-effects
acid (r_nmod) use
electroshock (l_conj) hypercapnia
effects (l_nmod) nausea
vincristine-treated (r_amod) patients
severity (r_nmod) associated
tmp-smz (r_nmod) exposed
increased (l_advcl) giving
levels (r_nmod) result
stroke (r_nmod) 5
model (l_nmod) pain
clozapine (r_dep) risperidone
related (r_amod) effect
ephedrine (l_nmod) dysfunction
busulfan (r_det) fluid
induced (r_acl) agitation
dxr (r_appos) doxorubicin
appeared (r_acl:relcl) episodes
(dox)-induced (r_compound) cardiotoxicity
exposure (r_dobj) included
photostimulation (r_nsubj) resulted
assess (r_xcomp) need
have (l_dobj) cancer
model (r_nmod) evaluated
doses (r_nmod) trial
occurred (l_conj) occurred
patients (r_nmod) possible
doxorubicin (r_nmod) nephrotoxicity
fluconazole (r_nmod) use
gammapathy (r_nmod) patient
drugs (l_conj) baclofen
alternative (l_nmod) patients
hypothesized (l_advcl) selective
doxorubicin-induced (r_amod) cardiomyopathy
changes (r_nsubjpass) accompanied
interactions (r_dobj) risk
isoproterenol-induced (r_amod) hypertrophy
afford (l_advcl) minimizing
epinephrine (r_conj) thrombosis
experienced (l_dobj) headache
induced (l_conj) evidence
prevent (l_dobj) arrhythmia
taking (r_advcl) suffered
paclitaxel (r_nsubj) demonstrated
women (r_nmod) reduction
restriction (r_nmod) influence
fentanyl (r_nsubj) reduces
lidocaine (r_compound) pretreatment
therapy (r_nsubj) increases
lindane (r_compound) dose
remodelling (l_acl) neuropathy
daily (r_nsubjpass) initiated
ra (r_appos) acetate
occurrence (l_nmod) toxicity
cause (l_dobj) dysfunction
depressed (l_mark) whether
users (r_nmod) hyperactivity
cause (l_dobj) cystitis
resolved (r_acl:relcl) pressure
fever (l_appos) ahf
inhibition (l_amod) hyperprolactinemic
doxorubicin (r_dobj) developed
symptoms (l_nmod) ibs
days (l_amod) headache-free
fall (l_nmod) rats
production (l_nmod) neutrophils
findings (l_nmod) epithelium
greater (l_nsubj) gain
hg (r_nsubj) down
relieved (l_dobj) deficit
model (r_nmod) action
month (r_nsubj) prevented
frequency (l_nmod) pvc
mg (r_nmod) efficacy
adrenaline (r_compound) infusion
amounts (r_nsubj) reach
pan (r_compound) injection
mdma (r_compound) users
decrease (l_nmod) 6-months
intoxication (r_nmod) caused
correlations (l_conj) parameters
nitroglycerin (r_nmod) decreased
patients (r_nmod) disturbances
suppresses (l_conj) has
describe (l_conj) revealed
administration (r_nmod) minutes
dose (r_nsubjpass) administered
dogs (l_nmod) infarction
ddi (r_appos) didanosine
steroid (r_nsubj) caused
observed (l_nmod) patients
hctz (r_compound) monotherapies
induction (l_compound) ich
assumed (r_acl:relcl) rigidity
appeared (l_xcomp) act
carboplatin (r_compound) injections
pgs (r_appos) prostaglandins
doxorubicin (r_nmod) toxicity
iiib (l_conj) nsclc
ca(2 (r_amod) blockers
epilepticus (l_conj) development
observed (l_nmod) angina
reversing (l_dobj) gradient
seizures (r_nmod) latency
descriptions (l_nmod) relationship
nephropathy (l_appos) can
angioedema (r_nmod) history
rate (l_conj) extent
production (l_nmod) overdose
models (l_compound) rat
causes (l_dobj) anemia
cisplatin (r_compound) use
scopolamine-induced (r_amod) learning
doxorubicin-induced (r_conj) heart
area (r_appos) years
pre-treatment (r_nsubj) delayed
arrhythmia (l_appos) contraction
co-administration (r_nsubj) resulted
precursors (r_nmod) free
became (l_acomp) hypercalcemic
control (l_nmod) course
ranged (l_conj) caused
lithium-induced (r_amod) failure
rationale (r_nsubj) induces
predicting (l_dobj) dysfunction
suffering (l_nmod) fibrillation
cyclophosphamide (r_amod) cardiotoxicity
tests (r_nmod) used
cocaine-benzodiazepine (r_amod) intoxication
nephropathy (r_nsubj) consists
rats (r_nmod) hyperactivity
is (l_nsubj) evidence
nitroprusside (l_amod) hypotensive
reason (l_nmod) period
oliguria (l_conj) failure
cardiomyopathy (l_acl) associated
effect (l_amod) neurotoxic
antiplatelet (r_nmod) use
withdrawal (r_conj) introduction
inhibitor (r_nmod) injection
% (l_nmod) failure
enhances (l_nmod) subjects
mipafox (l_appos) organophosphate
edema (l_conj) shock
setting (r_nmod) administration
containing (r_acl) serum
b1r(-/- (r_compound) mice
dosage (r_nsubj) causes
metformin (r_nsubj) agent
induced (l_conj) decreased
treated (r_acl) hypotension
block (r_xcomp) easy
produce (l_dobj) illness
treatment (r_nsubj) produced
respect (l_nmod) adenomyosis
enalapril-treated (r_amod) group
reduction (l_nmod) duration
induced-behaviour (r_nmod) status
destruction (r_nsubj) reduced
reported (l_nmod) man
closure (l_conj) telangiectasis
rg1 (r_nsubj) showed
atp (r_nmod) induced
dextran (r_compound) animals
argatroban (r_nmod) elevation
increase (l_dobj) risk
mannitol (r_nsubjpass) administered
pilocarpine (r_nsubj) delayed
oxygen (r_compound) supply
enhanced (l_nmod) bradycardia
nitroglycerin (r_dobj) received
syndrome (l_nmod) apnea
heparin (r_nsubjpass) added
uncommon (l_nsubj) disturbance
repair (r_dobj) underwent
pulsatile (r_dep) inhibited
include (l_dobj) thrombocytopenia
had (l_nmod) torsades
treated (l_nmod) tumors
paracetamol (r_compound) ingestion
incidence (r_dobj) increased
taking (l_nmod) depression
1-chloro-1,2,2,2-tetrafluoroethane (r_conj) 1,1-dichloro-2,2,2-trifluoroethane
tuberculosis (l_nmod) lung
pilocarpine (r_nmod) effects
application (r_dobj) received
contributed (r_conj) associated
stimuli (l_compound) pain
studies (l_nmod) prolactinomas
carboplatin (r_compound) chemotherapy
addition (r_nsubj) beneficial
suffering (l_nmod) neuralgia
patient (r_nmod) specimen
abilities (r_dobj) mice
cause (l_nmod) syndrome
chemotherapy (l_nmod) retinoblastoma
assessed (l_advcl) assessed
appearance (r_nmod) incidence
patient (l_nmod) glomerulosclerosis
marked (l_nsubjpass) ischemia
control (l_dobj) inflammation
compared (l_nmod) results
nephrotoxicity (r_dobj) reducing
acid (r_compound) exposure
administration (l_nmod) psoriasis
displayed (l_dobj) susceptibility
tdf (r_compound) kidney
da (r_appos) dopamine
levofloxacin (r_nmod) assessment
incidence (l_conj) severity
caffeine (r_nmod) actions
exhibit (l_dobj) behavior
developed (l_nsubj) hypothyroidism
n-(2-propylpentanoyl)urea (r_nmod) effects
overdose (r_nsubj) cause
corticosteroids (r_conj) replacement
went (l_nmod) thrombocytopenia
residence (r_nmod) due
naloxone (r_amod) reversal
rats (l_nmod) insipidus
demonstrated (l_dobj) consolidation
have (l_dobj) relevance
cocaine- (r_nsubj) differ
treatment (r_nmod) experienced
torsade (l_dobj) pointes
initiation (r_conj) monkeys
long (r_advmod) develop
administration (l_acl) i.e.
triglyceride-rich (r_amod) liver
insipidus (r_nmod) precipitated
olanzapine-treated (r_conj) clozapine-
suffered (l_nmod) moderate
reduced (l_dobj) systolic
serotonin (r_compound) receptors
anthracycline-induced (r_dep) human
transplanted (r_acl) those
eaca (r_compound) therapy
abusers (r_nmod) eleven
return (l_nmod) symptomatology
d-penicillamine (l_nmod) treatment
induced (l_nsubjpass) hypertension
seizures (l_conj) strokes
susceptibility (l_nmod) seizures
bromocriptine (r_nsubj) cause
individuals (l_amod) antibody-positive
use (r_appos) presence
temsirolimus (r_nmod) treated
samples (r_nmod) assessed
amikacin (r_compound) nephrotoxicity
enalapril (r_dobj) received
system (l_nmod) patients
haemorrhage (l_appos) sah
cardiomyopathy (r_nmod) model
verapamil (r_nmod) caused
ibuprofen (r_nmod:npmod) diclofenac
episode (l_nmod) convulsions
erythromycin (r_nmod) administration
infusion (l_nmod) treatment
comparing (l_nmod) treatment
propranolol (r_nsubj) inhibited
end (r_nmod) decreased
caused (l_dobj) decreases
increases (r_nmod) develop
developed (r_acl:relcl) eruptions
ifosfamide (r_nmod:npmod) related
woman (r_nmod) showed
received (r_acl:relcl) women
calcium (r_compound) values
sulfate (r_compound) sulfate
treatment (r_nsubj) produces
effect (r_dobj) indicating
influence (l_nsubj) abolition
resulted (l_nmod) survivors
cytostatic (l_nmod) lymphoma
analgesia (l_conj) catalepsy
dose (r_dobj) alter
pronounced (r_parataxis) modified
simvastatin (r_nmod) interaction
available (r_amod) preparations
remains (l_dobj) treatment
gentamicin (r_nmod) therapy
lamivudine (l_nmod) prevention
catalepsy (r_nmod) important
therapy (r_nmod) events
acted (l_nmod) emphasis
rats (l_compound) ob
associated (r_acl:relcl) expression
effect (l_conj) depression
patients (l_acl:relcl) met
withdrawal (r_nmod) ceased
toxicity (l_conj) hyperuricemia
caused (r_acl) learning
comparing (r_acl) studies
responses (l_compound) bradycardiac
lidocaine- (r_amod) seizures
administration (r_nsubjpass) suggested
induce (l_dobj) pain
stopped (r_conj) ruled
injections (l_nmod) addition
mk-801 (r_nmod) effects
unlikely (l_xcomp) reduce
hypotension (r_nsubjpass) paralleled
ma-induced (r_amod) damage
hydrochloride (r_nsubj) vasodilator
coma (l_conj) acidosis
captopril (r_nmod) actions
improved (l_nsubjpass) dysfunction
amiodarone (r_conj) dronedarone
female (r_nmod) report
ptz-induced (r_conj) fluorthyl-
man (l_nmod) factors
treated (l_nsubjpass) woman
e1 (r_nmod) effect
had (l_conj) tended
commencement (r_nmod) onset
ah6809 (r_nmod) blocked
infusion (r_nmod) changes
mtx (r_nmod) combination
factors (r_nmod) context
cisplatin (l_compound) patients
effect (l_nmod) sphincter
depletion (r_conj) inhibition
noted (l_nsubjpass) paralysis
therapy (r_nsubj) obtain
lithium (r_nsubjpass) associated
complication (l_nsubj) proteinuria
amount (r_nmod) discrepancy
patients (l_amod) acromegalic
selenium (r_compound) ions
changes (r_dobj) revealed
lorazepam (r_nmod) controlled
hepatitis (l_amod) mixed
coordination (l_nmod) disease
information (l_compound) incidence
oxide (r_nsubj) seem
event (l_nsubj) hypoxia
deletion (r_nmod) using
nicotine (r_nmod) effects
ccl4 (r_appos) tetrachloride
chloramphenicol (r_nmod) associated
csa-induced (r_amod) evolution
tacrolimus (r_compound) trough
asenapine (r_nmod) %
5-ht(1b/1d (r_compound) agonist
determine (l_nmod) control
taking (l_dobj) mesna
abnormalities (r_dobj) have
mediating (l_dobj) process
hypotension (r_nsubj) decrease
change (r_advcl) conclude
became (l_acomp) quadriplegic
structure (r_nsubj) determine
have (l_dobj) potency
bupivacaine/placebo (r_compound) group
used (l_nmod) order
treatment (l_acl) belonging
day (l_nmod) gestation
patients (l_nmod) hypercalcemias
vomiting (l_nmod) cases
developed (l_dobj) pa
3-methoxy-4-hydroxyphenethyleneglycol (r_nmod) levels
function (l_nmod) control
sirolimus (r_dobj) received
aminonucleoside (r_compound) model
heart (r_dobj) involving
synthase (r_compound) expression
libitum (r_dep) groups
pressure (r_dep) intolerance
ketoconazole (r_conj) b
history (l_nmod) nausea
effect (l_amod) cardiotoxic
aspirin (r_dobj) discuss
pb (r_compound) mg
pretreatment (l_nmod) poisoning
behavior (r_nmod) effect
hypertension (l_acl:relcl) developed
dopamine (r_nsubj) essential
lupus (r_dobj) had
drugs (l_amod) hepatotoxic
losartan (r_nsubjpass) prescribed
mediates (l_dobj) polyuria
aspirin (r_nsubj) decrease
dexrazoxane (l_conj) myelosuppression
conclusion (l_appos) reduction
related (l_advcl) play
acetate (r_nsubj) permitted
doxorubicin-induced (r_amod) cardiotoxicity
initiation (r_nmod) have
rats (r_nmod) pretreatment
no (r_compound) trinitrate
prevents (l_dobj) damage
feeding (r_acl) intervention
levodopa- (r_dobj) reduce
reaction (r_appos) confusion
bicarbonate (r_nmod) patients
optic (r_nmod) patients
threshold (l_compound) fibrillation
depletion (r_nmod) effects
impairment (r_nmod) factors
developed (l_dobj) block
excretion (r_nmod) reduction
mipafox (r_compound) exposure
was (l_attr) pain
disease (l_appos) lupus
patients (l_nmod) types
tremor (r_conj) catalepsy
controls (l_conj) crf
eaca (r_appos) acid
ratings (l_nmod) response
absence (r_nmod) learning
effects (r_dobj) investigate
doses (l_acl:relcl) produced
n (l_conj) tumors
b (r_dobj) incorporating
developed (l_dobj) interval
mechanism (r_nmod) specific
engineered (r_acl) mice
dose (r_nmod) administration
antidepressant-induced (r_amod) mania
dexamethasone-induced (r_conj) spontaneous
steroid (r_compound) structure
have (l_dobj) risk
(bcnu)-induced (r_amod) dysfunction
using (r_xcomp) found
responsible (l_nmod) cases
responsible (l_nmod) decrease
inhibit (r_acl:relcl) drugs
decrease (l_nmod) output
hours (r_nmod) felt
doxorubicin/kg (r_dep) dose
atorva (r_nsubj) reversed
allopurinol (r_dep) drugs
acid (r_nmod) reported
found (l_nsubjpass) hyperprolactinemia
channel (r_compound) antagonists
ato (r_appos) atorvastatin
infections (r_dobj) had
role (l_nmod) convulsions
pentetrazol (r_conj) flurothyl
developed (l_dobj) eyes
reported (l_xcomp) associated
doxorubicin (r_nmod) damage
produced (r_conj) affect
other (l_nmod) bronchopneumonia
cardiotoxin (l_conj) consequence
concentrations (l_conj) toxicity
increase (l_nsubj) randomized
syndromes (l_nmod) pain
lipoproteins (l_acl) found
women (l_nmod) incontinence
phenobarbitone (r_amod) rats
treated (r_acl) animals
retard (l_dobj) progression
busulfan (r_nmod) tendency
hydrocortisone (r_nmod) pressure
associated (l_nmod) depression
influenced (l_dobj) duration
participated (l_nsubj) women
impairment (r_dobj) had
effect (r_dobj) examined
remained (r_conj) increased
rare (l_nsubj) episodes
developing (l_dobj) neuropathy
bolus (r_nmod) administration
receptor (r_conj) factor
effect (r_dobj) evaluate
fluoxetine (l_nmod) treatment
safe (l_conj) effective
helpful (l_nmod) treatment
ccnu (r_nmod) treated
assess (r_xcomp) designed
suppresses (l_dobj) hyperparathyroidism
vancomycin (r_nsubj) curative
died (l_nmod) asystole
dosage (r_nsubj) offers
infusion (r_nsubj) caused
resolution (l_nmod) dysmenorrhea
p (r_nmod) reactions
assessed (l_nmod) rats
ethambutol (r_nmod) treated
increased (l_conj) hyperprolactinemia
developed (l_dobj) headache
tolerance (l_nmod) sample
severity (l_compound) tremor
birth (l_nsubj) administration
receiving (l_dobj) treatment
amino (r_compound) derivatives
neostigmine (r_conj) nicotine
thiazide (r_compound) therapy
diagnosis (r_dobj) had
encephalopathy (r_amod) presenting
given (r_acl) combination
octreotide (r_dep) treated
administration (r_conj) weakness
5 (l_appos) frequency
toxicity (l_nmod) cisplatin
doses (l_nmod) those
oxygen (r_compound) radical
evidence (l_nmod) ischemia
amounts (r_nmod) induced
heparin-induced (r_amod) aggregation
lasting (r_advcl) lapsed
carteolol (r_nsubj) evoke
risk (l_nmod) nephropathy
hemorrhage (l_appos) w-ich
treatment (r_nmod) group
suggesting (l_dobj) role
has (l_advcl) used
use (r_conj) rare
observed (r_acl) levels
ameliorates (l_dobj) stress
fas (l_nmod) patients
associated (l_conj) deficiency
development (r_nmod) factors
shown (l_dobj) ratio
if (r_nmod) treatment
ifs (r_appos) ifosfamide
attributed (r_acl) interaction
induce (l_dobj) mania
become (l_xcomp) arrhythmic
terms (l_nmod) incidence
associated (l_nmod) abuse
study (l_compound) active-w
therapy (r_nmod) role
report (r_ccomp) excluded
inhibited (l_dobj) proliferation
one (l_nsubj) nephropathy
reduce (l_dobj) dyskinesias
nitroprusside (r_nmod) infusion
stz-icv (r_nmod) injected
treatments (l_nmod) disease
potentiate (l_dobj) constipation
toxicity (l_appos) syndrome
recognized (l_nmod) factor
spect (r_nsubj) demonstrated
fluvoxamine (r_nmod) unaffected
parameters (l_nmod) patients
aspirin (r_nmod) superior
iron (r_compound) properties
disorder (l_appos) pd
frequency (l_nmod) vision
tamoxifen (r_nsubj) agent
mechanism (l_nmod) damage
exposure (r_dobj) intensified
tiopronin (l_conj) dermatitis
incidence (l_nmod) tdp
ecstasy (r_amod) mdma
showed (l_advcl) suggesting
ttc (r_nmod) staining
withdrawal (r_nmod) resolved
treatment (r_nmod) effects
literature (l_nmod) syndrome
lactate (r_conj) cardiomyopathy
those (r_nmod) were
caused (l_dobj) syndrome
evidenced (l_nmod) depression
nephritis (l_appos) ain
relative (l_nmod) disease
boys (l_nmod) dystrophy
cont./min (r_dep) frequency
complicating (r_acl) anemia
examined (l_conj) induced
ax (r_compound) allergy
doxorubicin (r_nmod) chemotherapy
oral (r_nsubj) prevents
use (l_nmod) treatment
androgens (r_nmod) treated
cause (l_nmod) disorders
infusion (r_nsubj) resulted
using (r_acl) patients
became (r_acl:relcl) history
antagonizing (l_dobj) deficits
busulfan (r_dobj) receiving
aminoglycoside (r_compound) levels
induce (l_dobj) tdp
seen (r_advcl) associated
exposure (r_nsubj) increased
included (l_nsubj) injury
salts (r_conj) salicylates
had (l_nmod) neuropathy
important (r_advcl) substituted
result (l_nsubj) seizures
penicillamine (r_nsubjpass) interrupted
anemia (l_nmod) patients
rendered (r_acl) neuroprotection
blockers (r_conj) inhibitors
ci-921 (r_nmod) study
suggesting (l_ccomp) late
treatment (r_nsubj) is
that (r_nmod) decreased
ether (r_nsubj) produced
corticosteroids (r_nsubj) agents
significant (l_nmod) disease
bcnu (r_nmod) clearance
bupivacaine (r_nmod) effects
responses (l_compound) pain
affect (l_dobj) hypotension
induce (l_dobj) blockade
acid (r_nsubj) factor
treatment (l_nmod) scleroderma
administration (r_nmod) worsening
patients (l_amod) psychotic
artesunate (l_nmod) malaria
symptoms (r_nmod) therapy
ingestion (r_nmod) failure
given (l_xcomp) control
adolescent (r_nmod) twitching
seem (l_xcomp) develop
ii (r_compound) type-1
suggest (l_conj) suggests
patients (r_nmod) nephrotoxicity
promoted (r_acl) stability
l-dopa (r_nmod) prevented
induction (l_nmod) insufficiency
respond (l_nsubj) patients
prevalence (l_nmod) syndrome
demonstrated (l_advcl) suggesting
avoided (l_nmod) reduction
ability (l_acl) reduce
respond (r_xcomp) appeared
adriamycin (r_compound) cardiotoxicity
stage (l_nmod) cancer
form (l_nmod) dystrophy
died (r_dep) results
benzodiazepines (r_appos) drugs
converted (r_advcl) usual
methyldopa (r_nmod) related
betaine (r_nmod) effects
symptoms (r_nsubj) result
combination (r_nmod) efficacy
treated (r_conj) matched
groups (r_nsubjpass) compared
rat (l_nmod) carcinoma
l-dopa (r_nmod) reversal
induced (l_nsubjpass) arrhythmias
agonist (r_nmod) treatment
methoxamine (r_nmod) doses
causes (l_dobj) alterations
dl-sotalol (r_nsubj) prolonged
associations (l_nmod) hyperkalemia
anions (r_nsubj) play
(-)-cibenzoline (l_nmod) arrhythmia
post-suxamethonium (r_compound) pains
consisted (l_nmod) hypogonadism
dipyridamole (r_nsubj) useful
edaravone (r_nmod) effect
ce (r_appos) cocaethylene
criteria (l_nmod) class
deficits (l_conj) impairments
failed (l_xcomp) promote
n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (r_nmod) co-administration
% (r_dep) groups
result (r_ccomp) consider
rizatriptan (r_nsubj) agonist
clonidine (r_nsubj) appears
score (l_compound) dyskinesia
valdecoxib (r_conj) placebo
db (r_conj) db
deprivation (l_appos) remd
pb (r_nsubjpass) given
optic (l_advmod) neuropathy
propranolol (l_nmod) effects
model (r_nmod) reduces
d-ribose (l_nmod) myocardiopathy
experienced (l_dobj) hallucinations
duration (l_nsubj) predictors
developed (l_nsubjpass) model
using (r_advcl) increase
co-trimoxazole (r_nmod) doses
result (r_nmod) leading
aminonucleoside (r_compound) syndrome
patient (r_nmod) anemia
raloxifene (r_nsubjpass) associated
vincristine (r_compound) administration
theophylline (r_nmod) response
increase (l_nmod) tremor
release (r_nmod) mechanisms
thrombosis (l_conj) embolism
patients (l_conj) hypotension
diarrhea (l_conj) nausea
acetaminophen (r_nmod) reduction
cocaine-associated (r_amod) stroke
repeated (r_conj) injected
mixed (l_dep) cholestatic
testing (l_nmod) protectors
demonstrated (l_dobj) hypertension
management (l_nmod) control
indicate (l_ccomp) modified
caused (l_dobj) neurological
treatment (l_nmod) attacks
pancreatitis (l_conj) suppression
days (r_nmod) had
protects (l_nmod) myelosuppression
patients (r_nmod) had
syndrome (l_nmod) ascites
complications (l_amod) psychiatric
patient (l_nmod) arthritis
infusion (l_nmod) stenosis
rats (r_nsubjpass) characterized
amiodarone (r_nmod) effects
reduction (r_nmod) accompanied
prevented (l_nsubjpass) rigidity
those (l_acl) reported
dismutase (r_nmod) overexpression
role (l_nmod) dysfunction
treatment (r_nmod) substantial
size (l_nmod) foci
effects (r_nsubj) related
patient (r_nmod) occlusion
decrease (r_nsubj) correlates
adding (l_nmod) infusate
offspring (l_acl) examined
treated (l_nmod) control
effusion (l_conj) eosinophilia
molindone (r_compound) administration
provided (l_conj) sufficient
demonstrated (l_nsubj) study
compare (l_dobj) incidence
disarrangement (l_conj) necrosis
alterations (l_nmod) relation
lead (l_nmod) hypertension
zolmitriptan (r_dobj) taking
efficacy (r_nmod) study
therapy (l_nmod) nsclc
succinylcholine-induced (r_amod) myalgia
l-dopa+benserazide (r_nmod) treatment
effects (r_dep) model
thalidomide (r_conj) bortezomib
combination (r_nmod) activity
hypotension (r_conj) disorders
blockers (r_nsubj) have
followed (l_nsubj) stroke
b (r_nmod) potential
characterized (l_nmod) bradycardia
interfere (l_nmod) establishment
those (r_nmod) doses
vigabatrin-attributed (r_amod) constriction
prevent (l_dobj) pain
users (r_nmod) mb
2a (r_nmod) treated
minocycline (r_dobj) taking
mirtazapine (r_nsubjpass) associated
mechanism (r_nsubj) pathogenesis
received (l_nmod) attempt
succinylcholine (r_nmod) patients
therapy (r_nmod) efficacy
used (l_xcomp) preceding
evidence (r_nmod) accompanied
oxacillin (r_nsubjpass) included
lidocaine (r_nmod) use
cocaine (r_dobj) using
acetate (l_nmod) model
csa (r_nmod) administration
sensitivities (l_nmod) seizures
demonstrates (l_ccomp) consists
cause (l_dobj) arrhythmias
cocaethylene (r_compound) cardiotoxity
caused (l_dobj) arrhythmia
therapy (r_nmod) encephalopathy
induced (l_nmod) disorder
admitted (l_nmod) hyperosmolar
sensitive (l_nsubj) lines
injury (r_conj) sarcolemma
associated (l_nmod) aneurysms
withdrawn (r_conj) suspected
gem (r_appos) gemcitabine
rifampicin (r_nsubjpass) administered
species (r_nmod) production
involvement (l_nmod) stress
patients (r_nmod) that
misoprostol (r_nmod) improved
alendronate (r_compound) administration
tg (r_appos) triglycerides
papaverine (r_dobj) received
value (l_nmod) population
17beta-estradiol (r_nmod) effects
exclusion (l_nmod) mi
cases (l_nmod) parkinsonism
produced (l_dobj) seizures
inducing (l_dobj) flaccidity
diazinon (r_nmod) evaluation
disorders (l_nmod) pd
nocistatin (r_conj) fq
administration (r_nmod) subsequent
acetyltransferase (r_dobj) activates
tam (r_nmod) effects
group (l_conj) pain
betaine (r_compound) attenuates
bundle (l_dobj) block
factor-alpha (l_compound) necrosis
attacks (l_nmod) sufferers
esters (r_dep) estradiol-
consequence (l_nsubj) hypokalemia
features (l_nmod) cholestasis
encouraged (l_nsubj) results
concentrations (r_nsubj) increased
mtx (r_conj) 5-fu
unrelated (l_nmod) mortality
incorporating (r_acl) lipid
assess (l_advcl) using
lithium (r_nmod) coadministration
exhibited (l_nsubj) phenotype
haloperidol (r_compound) infusions
tensions (l_amod) tetanic
caused (r_acl) impairment
improving (l_dobj) failure
activator (l_nmod) foci
received (l_conj) evaluated
elevation (r_nsubjpass) documented
users (r_nmod) depression
induced (r_acl) synthesis
renin-angiotensin (r_amod) system
dopamine (r_compound) beta-hydroxylase
tacrolimus (r_compound) therapy
adr-induced (r_amod) alterations
characterized (l_nsubjpass) deficiency
produced (l_advcl) delayed
observed (r_conj) resulted
received (l_nmod) doses
relationships (l_advmod) cardiomyopathy
propylthiouracil (r_nmod) treated
symptoms (r_nmod) chlormethiazole
doses (r_dep) single
suxamethonium (r_nmod) doses
benzodiazepine-gaba-chloride (r_compound) channel
frequent (r_conj) dizziness
lidocaine (r_conj) bupivacaine
related (l_conj) high
3alpha-hydroxy-5beta-pregnan-20-one (r_appos) pregnanolone
dyskinesias (r_dobj) reproduce
amisulpride (r_amod) treatment
agent (l_nmod) use
alf (r_nmod) transplanted
seems (r_advcl) sufficient
morphine (r_amod) administration
administration (r_nmod) associated
development (l_nmod) tumors
occurring (l_nmod) patient
models (r_nmod) number
overdose (r_nmod) caused
crisis (l_nmod) patient
shortened (r_advcl) affect
% (r_nmod) administration
lidocaine (r_compound) group
develop (l_dobj) lids
hypotension (r_nmod) allowed
activation (l_conj) post
incidence (r_nmod) days
reduces (l_nmod) result
catheterization (l_nmod) evaluation
responses (l_nmod) patients
bpd (r_nsubjpass) administered
unknown (l_conj) explanation
treated (l_nsubjpass) pneumonia
treatment (r_nmod) association
injury (r_nmod) involved
therapy (r_nmod) modifications
develop (l_dobj) deficits
study (l_nmod) therapy
levels (r_nmod) higher
related (l_nmod) eps
lithium (r_compound) use
comorbid (l_dobj) disorders
mechanisms (l_nmod) dysfunction
delay (l_nmod) onset
girl (r_nmod) occurrence
glutamate (r_amod) uptake
recovers (l_conj) recording
etomidate (r_compound) injection
theophylline (r_compound) neurotoxicity
remodeling (l_amod) tachycardia-induced
cirrhosis (r_nmod) relationship
mice (r_nmod) reversed
libitum (r_dobj) received
coupled (l_nmod) processes
dogs (l_nmod) stenosis
bea (r_appos) 2-bromoethylamine
interviewed (l_xcomp) using
cibenzoline (r_nmod) effects
left (l_nmod) patients
conversion (r_nmod) recovery
level (r_nmod) associated
formation (r_nmod) mediation
3.4-fold (l_nmod) that
one (r_dobj) received
induced (r_acl) models
progesterone (r_compound) hcl
rats (l_conj) rats
inserted (l_conj) reoccur
pdtc (r_nmod) administration
organization (l_appos) drug
adjunct (l_nmod) chemotherapy
assess (r_advcl) designed
preexposure (r_advcl) revealed
administration (l_nmod) globulin
anemic (l_conj) leukopenic
l-dopa-treated (r_amod) patients
malondialdehyde (l_dep) nag
restored (l_nmod) patients
registry (r_nmod) compared
abolished (l_dobj) tachycardia
pathogenesis (l_nmod) hypertension
administration (r_nsubj) reversed
involved (l_nmod) aura
cited (r_acl) reason
virus (l_compound) immunodeficiency
treated (r_conj) fed
determined (l_nsubjpass) extent
epinephrine (r_compound) infusion
developed (l_nsubj) symptoms
headache (r_appos) mouth
screened (l_conj) screened
infusion (l_nmod) sufferers
verapamil (r_conj) clonidine
related (l_nmod) vasculitis
exposure (r_dobj) repeated
succimer (r_compound) learning
elevates (r_acl:relcl) system
cases (r_nsubjpass) observed
tamoxifen (r_compound) use
combination (r_nsubjpass) used
causes (l_nmod) failure
risk (l_nmod) tachycardia
harm (l_acl) associated
alter (l_dobj) evolution
thyrotropin-releasing (r_conj) hormone
administration (r_nsubj) attenuated
response (l_amod) hypotensive
reserpine (r_conj) reduced
relationship (l_nmod) hyperalgesia/myoclonus
sensitivity (l_nmod) seizures
methylprednisolone (r_nsubj) became
encephalopathy (l_conj) chorea
animals (r_nmod) retrieval
suppressed (l_parataxis) needed
avoid (l_dobj) damage
celecoxib (r_nmod) safety
lead (l_xcomp) stroke
pilocarpine- (r_dobj) protecting
rd (r_nsubj) effective
neutropenia (l_nmod) females
increased (r_conj) study
reaction (r_dobj) slowed
extended (l_advmod) coagulopathy
administration (r_nmod) significant
sirolimus (r_nmod) due
case (l_nmod) congenita
paclitaxel (r_nmod) application
resistance (r_conj) count
increased (l_nsubjpass) index
ipratropium (r_nsubj) bronchodilator
animals (r_nsubj) demonstrated
those (l_acl:relcl) cause
gm (r_nmod) administration
phospholipid (r_nmod) that
helpful (l_advcl) reducing
admitted (l_nmod) failure
antidepressant (r_amod) drug
threshold (l_amod) convulsive
levels (r_dobj) correlated
gaba (r_conj) glutamate
vnb (r_appos) vinorelbine
performing (r_advcl) aware
terbutaline (l_appos) agonist
agent (r_xcomp) demonstrated
valdecoxib (r_nmod) data
use (r_nmod) reaction
developed (l_dobj) rs
mg/kg (r_conj) capable
antagonists (r_dobj) receiving
ingestion (l_conj) lymphadenopathy
patients (r_nmod) five
ciprofloxacin (r_nmod) treatment
ketamine (r_nsubj) reduced
developed (l_dobj) microangiopathy
hypotension (r_dobj) caused
chloroform-adrenaline (r_nmod) induced
attracted (l_nmod) drug
nanoparticle (r_compound) toxicity
tested (l_nsubjpass) severity
nimo (r_nmod) effect
experienced (l_nsubj) children
antigen (r_compound) carriers
levels (r_nsubjpass) measured
glutamate (r_nsubjpass) claimed
adjunct (l_amod) toxicity-free
diltiazem (r_nsubj) affect
heparin-induced (r_amod) thrombosis
hypotension (l_conj) block
olanzapine (r_nmod) occurred
attenuate (l_dobj) deficits
result (l_nmod) atrophy
isoenzymes (r_conj) dehydrogenase
glimepiride (r_conj) gliclazide
curative (l_nmod) %
rendered (l_xcomp) myopathic
patients (l_nmod) b
silver (r_amod) cream
acetyltransferase (r_nsubj) factor
form (l_nmod) hypertension
property (r_nsubj) plays
preventing (l_dobj) damage
reducing (l_dobj) proteinuria
paracetamol (r_amod) consumption
normotensive (l_conj) rats
flecainide (r_amod) concentrations
carboplatin (r_dobj) received
chlorpromazine (r_appos) thorazine
present (r_parataxis) reported
methods (l_compound) degeneration
iopamidol (r_nmod) comparison
failure (l_nmod) hypotension
courses (l_appos) concentration
dfu (r_compound) phenyl-2(5h)-furanon
managed (l_nsubjpass) %
relationship (r_dep) levels
gtn (r_compound) scores
lack (r_conj) conclude
optic (l_conj) neuropathy
prior (r_amod) gr
5,7-dcka (r_appos) acid
measure (l_dep) cle
related (r_xcomp) thought
suppressed (l_conj) ameliorated
adenosine (r_nsubj) produced
phentolamine (r_conj) injection
doses (r_nsubj) caused
mp (r_compound) therapy
aminonucleoside (r_nmod) pathogenesis
evoke (l_dobj) signs
confusion (l_conj) disorientation
rate (l_compound) tumor
supply (l_nmod) tissue
stz-injected (r_amod) group
associated (l_nsubjpass) complications
acid (r_dep) aspirin
develop (l_dobj) loss
i.v. (r_nsubjpass) injected
lidocaine (r_nmod) adjustment
simvastatinezetimibe (l_acl:relcl) taking
investigated (l_nmod) incidence
diphenylhydantoin (r_compound) medication
(ntg)-induced (r_amod) hypotension
nephrotoxicity (l_conj) nephrotoxicity
ergotamine/caffeine (r_nmod) superior
patients (l_compound) infertility
sensitive (l_conj) capable
animals (l_amod) nephropathy
treatment (r_nsubj) reduced
sevoflurane (r_nmod) effects
latency (l_nmod) seizures
isoniazid (r_nmod) secondary
glycopyrrolate (r_compound) kg-1
remoxipride (r_nsubj) induce
treatment (l_nmod) toxicity
hydrocortisone-induced (r_amod) hypertension
reversion (l_nmod) normal
option (l_nmod) setting
defects (l_conj) effects
patients (r_nmod) severity
doses (r_nmod) discriminate
cardiomyopathy (r_nmod) found
conclusions (r_dep) consider
prevent (l_dobj) nephrotoxicity
scopolamine-induced (r_amod) impairment
txa (r_nmod) use
suggest (l_dobj) decrease
arag (r_nmod) attributable
did (r_conj) increased
effective (l_conj) tolerated
detected (l_nsubjpass) damage
addition (l_nmod) total
found (l_xcomp) factor
severity (l_nmod) fasciculations
d-penicillamine (r_compound) treatment
associated (l_nmod) prolongation
scopolamine (r_compound) overdosage
5-azacytidine (r_nmod) induced
case (l_nmod) encephalopathy
changes (l_nmod) pattern
monkeys (r_nsubj) developed
related (r_amod) infections
propranolol (r_nmod) angina
activity (l_nmod) cardiomyopathy
administration (r_nmod) respond
startle (r_ccomp) suppressed
months (l_nmod) hyperprolactinemia
produced (l_dep) signs
na+ (r_nmod) transport
sample (r_nmod) disorder
appearance (l_appos) hypercholesterolemia
incidence (l_nmod) infection
epilepsies (r_nmod) patients
antibody (r_conj) transplantation
desogestrel (r_compound) ethinyloestradiol
cyclophosphamide (l_conj) cancer
regimen (r_dobj) methotrexate
accompany (l_nsubj) tetany
alpha-tocopherol (r_nmod) concentrations
investigate (l_dobj) effects
pinacidil (r_conj) cromakalim
dextromethorphan (r_nmod) abuse
received (l_conj) is
limited (l_nmod) treatment
administration (r_nmod) toxicity
model (r_nmod) deficits
case (l_nmod) cystitis
failed (l_xcomp) influence
believe (l_nmod) onset
model (l_compound) arrhythmia
nicotine (r_nmod) role
relationship (l_nmod) use
risk (l_advcl) discontinuing
gene (r_nmod) association
vasoconstriction (r_nsubj) produced
reduces (l_dobj) cardiotoxicity
levodopa-treated (r_amod) marmoset
limited (l_advcl) nephrotoxicity
controlling (l_dobj) vomiting
abolition (l_nmod) fasciculations
presenting (r_acl) gravis
exacerbates (l_advcl) supporting
group (r_nmod) area
icrf-187 (r_nmod) provided
production (r_conj) dysfunction
compared (r_acl) pre-treatment
kanamycin-colistin (r_amod) irrigations
pcc (r_dobj) suggesting
nh4cl (r_nmod) intraperitonealinjection
comorbid (l_nmod) dyspepsia
history (l_conj) smoking
combined (l_nmod) drugs
n-methyl-d-aspartate (r_compound) receptor
dexamethasone (r_dep) corticosteroids
model (l_nmod) epilepsy
increasing (l_dobj) duration
cgrp (l_conj) migraine
blockers (r_nmod) administration
development (l_nmod) behavior
prophylaxis (r_nmod) used
l-arginine (r_compound) system
types (l_nmod) arrhythmia
survivors (l_nmod) tumors
effective (l_nmod) alleviation
attack (l_compound) migraine
acid (r_nsubj) predictor
diseases (r_nmod) resulting
be-injected (r_amod) rats
neurons (r_nmod) number
affecting (r_advcl) decrease
phases (r_conj) paclitaxel
seen (l_nmod) syndrome
fk506-nephropathy (r_amod) group
valproate (r_nmod) month
k(+ (r_nmod) leakage
pharmacology (l_nmod) paranoia
appear (l_conj) exacerbated
effects (l_nmod) neuropathy
aida (r_nsubj) diminished
doxorubicin (r_dobj) demonstrated
stz-icv (r_nmod) caused
ergometrine-induced (r_amod) behavior
pain (l_nmod) block
pattern (l_nmod) heart
screened (l_dobj) patients
administered (r_advcl) promotes
reported (l_nsubjpass) hallucinations
presented (l_nmod) impotence
epidemics (l_nmod) gangrene
promotion (l_compound) af
impairment (r_nmod) severity
treatment (l_nmod) enteropathica
phenacetin (r_nmod) consumption
weakness (l_nmod) vasospasm
sch (r_nmod) blocked
incidence (l_nmod) episodes
patients (r_nmod) hyperalgesia
l-dopa (r_nmod) treated
rats (r_nmod) ulcer
increases (r_nsubj) indicate
patients (r_nsubj) change
cibenzoline (r_nsubj) had
induction (r_dobj) undergoing
prazosin (r_compound) treatment
rapamycin (r_conj) a
exposed (r_acl) mice
intermediates (l_acl:relcl) implicated
maleate (l_conj) neuropathy
levels (r_nmod) presence
chemotherapy (l_nmod) treatment
paclitaxel (r_nmod) dose
administration (r_dobj) advocate
gyrus (l_nmod) rats
dose (r_nsubjpass) followed
tendency (l_acl) aggravate
continued (l_xcomp) have
gentamicin (r_nmod) caused
clozapine-treated (r_amod) inpatients
intake (r_nmod) reported
cysteine (r_compound) protease
higher (l_nsubj) levels
cocaine-induced (r_conj) lidocaine-kindled
had (l_dobj) interval
cocaine (r_conj) heroine
tablets (r_nmod) event
prevented (l_xcomp) indicating
glyburide (r_nsubj) produce
thiabendazole (r_nmod) exposure
underwent (l_nsubj) patients
aldosterone (r_conj) potassium
disease (l_conj) arrhythmia
make (l_dobj) contribution
stroke (l_nmod) women
aggressiveness (l_conj) disorder
chloride (r_compound) channels
sufficient (l_advcl) seems
level (r_conj) diabetes
2,3,5-triphenyltetrazolium (r_compound) staining
subjected (l_nmod) se
tacrolimus (r_nmod) discontinuation
mechanism (l_nmod) rs
pathogenesis (r_nmod) plays
corticosteroids (r_appos) junction
associated (l_nmod) ts
dextran (r_compound) solution
prophylaxis (l_nmod) development
lithium (r_compound) therapy
onset (r_nmod) believe
doses (r_dobj) administered
effects (r_nsubj) appeared
women (r_nmod) follow-up
s-312-d (r_nmod) effects
theophylline (r_conj) bromide
pentobarbital (r_nmod) caused
supplementation (r_nsubj) ameliorated
channels (r_nmod) interact
reversion (l_nmod) decrease
anesthesia (l_compound) hypotension
arthritis (r_nmod) patients
caused (l_nmod) injection
presents (l_nmod) emergency
albuminuria (r_nmod) increased
rifampin (r_nmod) developed
complicated (l_nmod) hypertension
injection (r_dobj) performing
degree (r_nmod) proportional
simvastatin (r_nmod) discontinued
rocuronium (r_nmod) dose
terbutaline (r_compound) treatment
role (r_dobj) elucidate
age (l_conj) patients
plays (l_nmod) pathogenesis
increases (l_nmod) flow
conversion (l_nmod) patients
carbonate (r_nmod) switching
responses (l_nmod) duration
% (r_conj) decrease
atropine (r_nsubj) converted
dfu (r_appos) comparison
produced (l_dobj) symptoms
mk-801-treated (r_amod) group
tachycardia (r_dobj) abolished
lamivudine-containing (r_amod) active
alcohol (r_conj) nitrate
59 (l_nmod) eps
doses (r_nsubj) induce
developed (l_nsubj) hypertension
patients (l_compound) crf
produced (l_nsubjpass) damage
therapy (l_nmod) c.
syndrome (l_conj) tachycardia
go (l_nmod) exploration
tremor (l_dep) convulsions
episodes (l_amod) ischemic
diazinon (r_nmod) exposed
decrease (r_xcomp) tend
pilsicainide (r_nmod) dose
crisis (l_compound) migraine
quinine (r_nmod) ingestion
symptoms (r_nmod) account
induces (l_dobj) hypotension
6-hydroxydopamine (r_compound) model
presentation (l_nmod) encephalopathy
desvenlafaxine (r_nmod) associated
models (l_nmod) damage
included (l_dobj) patients
alfentanil (r_advcl) prevented
associated (l_nmod) cardiotoxicity
h (r_conj) cells
um-272 (r_nmod:npmod) converted
reduced (l_conj) had
hearts (l_compound) ob
response (r_nmod) adults
associated (l_nsubjpass) potential
lidocaine (r_compound) anesthesia
etoposide (r_nmod) effect
b-related (r_amod) hypokalemia
stroke (r_conj) increasing
controls (l_amod) schizophrenic
patients (l_amod) hypothyroid
patients (l_nmod) infarction
desipramine (l_acl) linking
receptor (r_compound) agonists
343499 (r_nummod) nsc
lithium (r_compound) anticonvulsants
caffeine-induced (r_amod) arrhythmia
burden (l_nmod) esrd
showed (l_dobj) outcome
doxorubicin (r_nmod) cytotoxicity
considered (l_nsubjpass) insipidus
reviews (l_nmod) prevention
lorazepam (r_nmod) administration
safety (l_nmod) treatment
lamivudine (r_compound) therapies
hypertension (r_nmod) female
effect (l_nmod) anxiety
mptp (r_compound) model
investigates (l_ccomp) neuroprotective
drug (l_acl) prescribed
duration (r_conj) age
anticoagulated (r_acl) transplantation
administration (r_nsubj) impaired
injection (r_nsubj) induced
correlations (l_nmod) volume
option (l_acl) protect
dx (r_conj) dxnp
continue (l_xcomp) play
incidence (l_nmod) cin
improvements (l_nmod) fever
ranitidine (r_nmod) replaced
potentiated (l_dobj) hyperactivity
patients (r_nmod) hepatotoxicity
attenuation (l_nmod) tachycardia
series (r_nmod) used
use (l_nmod) models
case (r_nsubj) emphasizes
toxocity (r_nmod) signs
suggest (r_conj) demonstrate
interactions (r_nmod) evaluate
heroine (r_dobj) abusing
use (r_nsubj) caused
enhance (l_dobj) bradycardia
risk (r_conj) cisplatin
caa (r_nmod) effects
combination (r_nmod) treated
acetaminophen-induced (r_dep) fatal
course (l_acl) shed
rate (l_compound) toxicity
morphine (r_nmod) cross-tolerance
administered (l_nmod) bolus
glutamate (r_nmod) induced
supplementation (r_conj) b12
5-ht6 (r_amod) receptors
results (l_appos) experienced
clotiazepam (r_nsubj) induce
recorded (l_nsubjpass) rashes
paralysis (r_nsubjpass) described
increase (l_dobj) hypotension
occurred (l_advcl) experienced
temsirolimus (r_nmod) effects
absorption (l_acl) causing
raise (l_dobj) risk
mediated (r_acl) angiotensinogen
clopidogrel (r_dep) therapy
implications (l_nmod) autism
operated (l_nmod) cholecystitis
scoline (r_compound) pain
had (r_conj) observed
escape (r_xcomp) appears
mannitol (r_nmod) quantities
patients (l_acl) treating
likely (l_ccomp) indicates
improved (l_dobj) prognosis
argatroban (r_amod) concentration
vincristine (r_nmod) antagonists
use (l_nmod) microphthalmos
difference (r_nmod) increased
alters (l_dobj) dysrhythmogenicity
complete (l_conj) obtained
monitoring (l_nmod) proteinuria
alcohol (r_compound) recognition
clonidine (l_acl) used
concentration (r_dep) mean
caused (l_advcl) indicating
loss (l_advcl) righting
affected (l_nmod) disease
inhibitors (l_nmod) treatment
rest (l_conj) stimulation
favor (r_nmod) also
antigen-positive (r_amod) mothers
group (l_compound) nephritis
streptozotocin (r_nmod) induction
factors (l_acl) associated
exposed (r_conj) experienced
34.0 (r_advcl) showed
due (l_nsubj) anuria
pd (l_conj) mdp
quinpirole (r_conj) d-amphetamine
l-dopa (r_amod) treatment
results (l_conj) presumed
receiving (r_advcl) itching
demonstrated (l_advmod) effective
d (r_nmod) use
trial (l_nmod) dystrophy
dce (r_nsubj) prove
reactivation (r_nmod) prevention
da (r_compound) neurons
verapamil (r_nmod) induced
administration (r_nsubj) enhances
risperidone-treated (r_amod) subjects
inspired (r_amod) concentration
implicated (l_nmod) mechanisms
obtain (l_dobj) convulsions
lometrexol (r_nmod) development
normality (l_acl:relcl) lead
invariable (l_nsubj) hypoglycemia
factor (r_dobj) encoding
administration (r_nsubj) failed
tobramycin (r_nmod) netilmicin
potent (r_conj) di-
infarction (l_nmod) women
induced (r_acl) pain
discontinued (l_advcl) was
levodopa-induced (r_amod) morning
concentration (r_nmod) decreased
reviewed (l_advcl) score
confirmed (l_dobj) fhf
score (l_compound) disease
amiodarone-induced (r_amod) hepatotoxicity
asenapine (r_nsubjpass) approved
model (r_nmod) phase
considered (l_nmod) patients
cells (l_compound) ganglion
metoclopramide (r_nsubj) provokes
caused (l_dobj) hypocalcemia
bupropion (r_compound) toxicity
stimulant (l_acl:relcl) increases
encoding (r_acl) mrna
adriamycin (r_nsubj) cardiotoxin
suggesting (r_advcl) showed
medication (l_acl:relcl) prescribed
s-53482 (r_nsubj) herbicides
epinephrine-induced (r_amod) injury
had (l_dobj) thrombosis
atorvastatin (r_nmod) effects
mice (r_nmod) increase
studied (r_advcl) alter
isoflurane (r_conj) labetalol
oc (r_compound) preparations
sulfasalazine-induced (r_amod) syndrome
monkeys (r_nsubj) resistant
lithium=0.85 (r_compound) meq/l
elicited (r_acl) pain
tremor (l_conj) catalepsy
acid (r_compound) treatment
propranolol (r_nmod) that
incidence (l_nmod) parkinsonism
rats (r_nmod) improve
estrogen-testosterone (r_amod) therapy
faster (r_advmod) decreased
sevoflurane (r_nmod) reduces
conjunctiva (r_nmod) application
treat (r_acl) combination
tetracycline (r_nmod) production
injection (l_dep) dose
period (r_nmod) found
effects (l_nmod) performance
injection (l_nmod) dysphonia
concentration (r_nsubj) rose
report (l_dobj) comorbid
results (l_nmod) patients
predominate (r_xcomp) appears
hypotension (l_nmod) disease
suggested (l_ccomp) responsible
climbing (r_conj) locomotion
treatment (l_nmod) convulsions
injection (r_nmod) prevent
lactate (r_dobj) elevates
hypotension (r_nsubjpass) associated
compared (l_nmod) relation
inhibitors (r_conj) antagonists
worsened (l_dobj) symptoms
(dox)-induced (r_acl) model
women (r_nmod) infarction
resolved (r_acl:relcl) case
disorder (l_appos) cimd
lindane (r_compound) seizures
levels (r_nmod) increase
kinase (r_dobj) decreased
decrease (l_xcomp) seizure
patients (r_nsubjpass) suspected
receiving (r_acl) group
function (r_nmod) attention
cause (l_nmod) atrophy
cardiomyopathy (l_appos) cm
status (l_conj) confusion
lysozymuria (l_conj) score
suggests (r_conj) considered
prolongation (l_compound) syncope
given (l_dep) resulted
hepatitis (l_advcl) recorded
cases (l_acl:relcl) demonstrated
overexpression (r_nsubj) protect
fever (l_conj) eyes
level (r_nsubjpass) discontinued
rapamycin (r_nmod) target
concentration (l_conj) ratings
(cyp)-induced (r_amod) cystitis
decreased (l_dobj) incidence
l-name (l_acl) observed
magnitude (l_nmod) injury
failed (l_xcomp) accentuante
doses (l_acl) calculated
flushing (l_nmod) face
measures (l_appos) impairment
resolved (r_acl) abnormalities
sulfate (r_nmod) patients
atrophy (r_conj) groups
bortezomib (r_nmod) combination
abuse (r_nsubjpass) considered
adenosine (r_nsubj) plays
hearing (l_dobj) loss
cocaine-induced (r_amod) anxiety
contribute (l_nmod) mechanism
preventing (l_conj) reducing
protecting (l_dobj) seizures
argatroban (r_nsubj) inhibitor
succinylcholine (r_nmod) administration
dopamine (r_compound) formation
pyrrolidone (r_compound) derivative
use (l_nmod) chemotherapy
attributed (l_nsubjpass) cardiomyopathy
cisapride (r_conj) cont./min
patients (r_nsubj) continue
presence (l_conj) hypertension
toxicity (r_nmod) concluded
protection (r_nsubjpass) studied
scale (l_compound) disease
nmda (r_compound) ketamine
rose (l_nmod) hypotension
discontinued (l_advcl) suspected
da (r_nmod) independent
form (r_conj) association
patients (l_nmod) headache
blockers (r_nsubj) decreased
medication (l_nmod) rhinitis
azt (r_appos) azidothymidine
pathogenesis (r_nmod) implicated
ketamine (r_nsubj) provided
optic (r_amod) neuropathy
apoptosis (r_nmod) protects
determined (l_dobj) incidence
patients (r_nmod) most
dox (r_nmod) cardiotoxicity
factors (l_nmod) disease
sevoflurane (r_nmod) decreased
used (r_acl) agonists
precipitated (r_acl) coma
mp (r_nsubjpass) contraindicated
diseases (l_nmod) disease
inhibitor (r_nmod) influence
absence (r_nmod) evidenced
d (r_compound) concentrations
cases (l_compound) afl
complications (r_nsubjpass) assessed
produces (l_dobj) movements
history (l_nmod) schizophrenia
nefiracetam (r_nmod) ability
phenyl-2(5h)-furanon (r_compound) inhibitors
ncq344 (r_conj) ncq436
associated (l_nsubj) cases
administration (r_nmod) attenuated
hemorrhage (l_conj) formation
d3 (r_nmod) toxicity
ifosfamide (r_nmod) day
suxamethonium (r_nmod) hypersensitivity
produced (r_acl) hyperactivity
test (l_nmod) assessment
inhibitors (r_nmod) treatment
therapy (r_nmod) dose
effects (r_dep) cytostatic
sm-5887 (r_appos) derivative
bortezomib (r_nsubj) treatment
patients (l_nmod) hypersensitivity
mesna (r_nsubj) reduces
mg (r_nmod) temperature
described (l_nsubjpass) toxicities
administration (l_nmod) desipramine
nd-nmba (r_appos) junction
echocardiography (r_nmod) safety
therapy (r_nmod) caused
deterioration (l_nmod) hyperkinesis
content (r_nsubjpass) estimated
rigidity (l_nmod) dose
responded (r_acl:relcl) tma
sirolimus (r_nmod) conversion
alleviating (r_advcl) efficacious
dose (l_acl) given
carvedilol (r_nmod) protection
dysfunction (r_nmod) relationship
efficacy (r_dobj) investigating
serum- (r_nsubjpass) shown
antagonists (r_nsubjpass) shown
action (r_nsubj) appears
treated (r_acl) cells
cohort (l_nmod) women
da (r_compound) neurotransmission
treatment (l_nmod) lines
induced (r_acl) endpoints
responsible (r_xcomp) appear
experienced (l_advcl) multiforme
groups (l_nmod) patients
administered (l_nmod) group
induced (l_nmod) administration
monitored (l_nsubjpass) toxicity
discontinued (r_conj) diagnosed
indicate (l_conj) use
hpma (r_compound) copolymer
testosterone (r_nsubj) ameliorates
prostaglandins (r_nmod) hypersecretion
associated (l_nmod) exacerbation
resistant (r_acl:relcl) groups
dtg (r_appos) di-o-tolylguanidine
patients (l_compound) alf
correlated (l_nsubj) proteinuria
patient (l_nmod) carcinoma
patients (r_nmod) reducing
carboplatin (r_compound) application
chelator (r_appos) deferoxamine
verapamil-induced (r_amod) neurotoxicity
risk (l_nmod) delirium
muscimol (r_nsubj) produced
intake (l_nmod) persons
potent (l_advcl) protecting
caa (r_nmod) reaction
development (l_nmod) insufficiency
ro (r_appos) blocker
s-312-d (r_conj) s-312
prevent (l_nmod) nephropathy
received (r_conj) had
subjects (r_nmod) ventricles
1.52 (r_nummod) interval
occurred (l_nsubj) hemorrhage
cause (l_nsubj) syndrome
chlormethiazole (r_compound) intoxication
ii (r_nummod) antagonist
heparin (r_nmod) treated
inhibition (l_nmod) nigra
clearance (r_dobj) decreased
aspects (l_amod) isolated
iohexol (r_conj) iopentol
occurrence (l_nmod) seizures
risk (l_nmod) function
apomorphine (r_conj) locomotion
prognosis (r_nsubj) cause
sulfasalazine-induced (r_amod) lupus
(iso)-induced (r_punct) ischemia
increase (l_nmod) fasciculations
picrotoxin (r_nmod) induced
found (l_nsubjpass) deficit
calculated (l_advcl) correlates
were (l_nsubj) incidents
locomotion (l_compound) hyper
symptoms (l_compound) depression
inhibited (l_dobj) effects
concentrations (r_nsubjpass) administered
reverse (r_acl:relcl) agents
caused (l_conj) protect
therapy (l_nmod) head
induction (l_nmod) leukemia
oxytocin (r_nmod) response
lacking (r_acl) diet
treatment (l_nmod) diseases
encephalopathy (l_acl) evidenced
treatment (l_nmod) sphincter
pretreatment (r_nsubj) increased
causing (l_dobj) convulsions
improvement (l_nmod) deficits
amiodarone-induced (r_amod) proarrhythmia
necrosis (l_acl) characterized
pemoline (l_acl:relcl) experienced
dipyridamole (r_compound) therapy
associated (r_acl) tachycardia
detection (r_dobj) allowed
seen (r_xcomp) remains
vpa (r_appos) acid
contractility (l_conj) disturbances
triglyceride (r_nmod) secretion
radiation (l_conj) cystitis
vnb (r_nsubj) agent
experienced (l_nmod) irradiation
amisulpride (r_advmod) unmasked
n-methyl-d-aspartate (r_compound) antibodies
aminoglycoside-related (r_amod) failure
therapy (r_nsubj) become
concentration (r_nsubj) %
leading (r_acl) cases
concentration (r_nmod) increased
allowed (l_parataxis) line
decreased (l_dobj) length
co2 (r_appos) dioxide
using (l_parataxis) examined
synergistic (l_advcl) resulting
dipyridamole (r_nmod) administration
concentration (r_dobj) determine
amlodipine/benazapril (r_amod) 10/5
les (r_nmod) startle
paramedics (l_nmod) patients
cystitis (r_nsubjpass) characterized
patient (r_nmod) pheochromocytoma
injection (r_nmod) ratings
fentanyl (r_amod) groups
generation (l_nmod) epilepticus
content (r_dobj) increased
serotonin (r_compound) 5,7-dihydroxytryptamine
c (r_compound) treatment
stimulation (l_nmod) area
synchrony (r_nmod) therapy
stz (r_nsubj) causes
potassium (r_compound) requirements
risk (l_nmod) nephrotoxicity
modify (l_dobj) seizures
effective (l_nmod) cases
risk (l_nmod) arthritis
administered (r_advcl) compare
areas (l_amod) compatible
vomiting (l_conj) fever
observed (l_nmod) dose
doses (l_acl:relcl) prevent
cystitis (r_nmod) model
prolongation (l_nmod) interval
deficiency (r_nsubj) increases
patients (l_acl:relcl) received
responses (r_conj) rate
gr (r_nsubj) attenuated
drugs (l_conj) cause
nephrosis (r_nmod) injury
administration (r_nmod) hour
argatroban (r_nmod) treated
treatment (l_nmod) catalepsy
valsartan (r_dobj) receive
nicotine (r_compound) injection
failure (l_nmod) hyperkalemia
mm (r_dep) score
levodopa-induced (r_amod) fluctuations
followed (l_nmod) development
used (r_advcl) limits
measured (l_conj) inhibited
related (r_amod) encephalopathy
morphine (r_nsubj) alter
excess (l_acl:relcl) consists
mk-212 (r_nmod) value
patients (r_nsubjpass) followed
l-dopa-induced (r_amod) dyskinesia
defined (l_dep) atrophy
cases (l_nmod) hyperplasia
amphetamine (r_conj) stroke
facilitated (r_conj) reversed
controlling (l_nmod) %
potentiates (l_dobj) initiation
have (l_dobj) diuresis
participates (l_nmod) hyperalgesia
suggesting (r_advcl) reversed
action (r_nsubjpass) associated
log (r_nsubjpass) administered
pericarditis (l_conj) fever
combined (l_nmod) infections
latency (l_nmod) loss
dopamine (r_compound) concentrations
amphetamine-induced (r_amod) neurotoxicity
appear (l_xcomp) related
departments (l_nmod) patients
effects (r_conj) relationship
blocked (l_nmod) incidence
1.9 (l_nsubj) concentrations
cause (l_dobj) failure
presented (l_nmod) arrhythmia
atropine-like (r_amod) drugs
treatment (l_nmod) range
propofol (r_nmod) sedation
reported (l_nmod) patient
thiopentone (r_conj) althesin
abuse (r_nmod) symptoms
undergoing (r_dep) palsy
use (r_dobj) involving
one (l_conj) nausea
infections (l_nmod) patients
cause (l_dobj) hypotension
that (r_nmod) treatment
control (l_compound) pain
shown (l_xcomp) reverse
antagonist (r_nmod) use
d3 (r_compound) toxicity
patients (r_nmod) trials
pathogenesis (l_nmod) nephrotoxicity
estimated (l_nmod) rats
metabolite (r_appos) cocaethylene
produced (l_dobj) effect
tenofovir (r_nsubjpass) implicated
reported (r_advcl) frequent
medication (l_compound) diabetes
hypotensive (l_nmod) block
overdose (r_nmod) left
infusion (r_appos) injury
gradient (l_appos) edema
adriamycin (r_compound) dose
challenge (r_nmod) effects
doses (l_nmod) rats
marker (l_nmod) prediction
aspirin (r_conj) diltiazem
24/76 (r_nsubj) stop
appears (l_xcomp) predominate
exposure (r_nmod) duration
done (l_conj) dose
morphine-induced (r_amod) hyperactivity
found (l_dobj) correlation
means (r_nmod) occurrence
ketamine (r_nsubj) exacerbates
ginsenoside (r_nmod) rg1
haloperidol (r_nsubj) demonstrated
dextromethorphan (r_nmod) enhancement
woman (l_nmod) arthritis
order (l_acl) obtund
occurs (r_conj) increasing
fluoxetine (r_nsubjpass) reported
nephrosis (r_nmod) model
apap (r_compound) administration
blocker (r_appos) pilsicainide
k (r_compound) drugs
n-methyl-d-aspartate (r_nmod) induced
cck-8-se (r_appos) ester
histamine (r_compound) concentration
ingesting (r_acl) rats
diazepam (r_compound) group
tumors (l_conj) malignancies
drops (r_conj) nitrate
mexiletine (r_compound) group
measured (l_advcl) recording
therapy (r_nmod) basis
associated (l_nmod) cause
ritanserin (r_nmod) effect
reserpine (r_nsubj) change
tolterodine (r_compound) treatment
increase (r_conj) appearance
developed (l_dobj) hemolysis
nsaid (r_conj) times
status (r_nmod) patients
deficits (r_dobj) compensated
those (r_nmod) latencies
demonstrated (l_nsubjpass) cardiotoxicity
complete (l_dobj) protection
contributed (l_nmod) rate
influence (l_nmod) toxicity
discussion (r_nsubj) includes
thiamine-dependent (r_amod) enzyme
dyskinesia (l_nmod) child
contribute (l_nmod) action
induced (l_dobj) dyskinesia
failure (l_amod) secondary
frequent (l_nmod) which
elevation (r_conj) duration
impaired (r_advcl) high
nitrendipine (l_nmod) nephrosclerosis
sucrose (r_appos) libitum
exposure (r_nsubj) have
oxidation (l_nmod) ob
superimposed (r_conj) case
meshwork (l_amod) similar
suppress (l_dobj) expression
patients (l_compound) b
cause (l_advcl) pro-arrhythmic
develop (l_nsubj) polymyositis/dermatomyositis
botox (r_nmod) diffusion
case (l_nmod) suffering
courses (r_dobj) received
woman (l_amod) epileptic
bupivacaine- (r_nmod) toxicity
marked (r_xcomp) becomes
ifosfamide (r_nmod) infusion
hit (l_nmod) thrombosis
have (l_dobj) role
aspirin (r_conj) corticosteroids
given (l_advcl) overcome
acid (r_dep) cross-clamp
dose (r_nmod) developed
adriamycin-evoked (r_amod) cardiotoxicity
p (r_nsubj) induced
convulsions (r_dep) tremor
cyclophosphamide (r_nmod) increment
that (r_dobj) decreased
returned (r_conj) require
cases (l_nmod) hiccups
found (l_conj) withdrawn
prudent (l_xcomp) avoid
m (r_appos) methylprednisolone
timing (l_nmod) therapy
duration (l_acl) accompanying
chlorpheniramine (l_conj) placebo
vasodilation (l_nmod) vessels
induced (r_acl) vessels
deferoxamine (r_dobj) receiving
days (r_nmod) decreased
complications (r_nmod) one
refractory (r_dep) developed
prochlorperazine (r_nsubjpass) administered
amphotericin (r_nsubj) activate
elicited (l_dobj) psychosis
dopamine (r_compound) receptors
shown (l_xcomp) benefit
plays (l_nmod) damage
fr (r_nmod) effect
hazards (l_nmod) toxicity
presenting (l_nmod) coma
syndrome (r_conj) polymorphisms
e1-induced (r_amod) hypotension
apap-induced (r_amod) necrosis
synthetase (r_compound) inhibitors
amount (l_nmod) bleeding
fear (l_conj) restlessness
bha (r_dobj) given
3717 (r_nummod) cytotoxicity
reached (l_advcl) developed
development (l_nmod) lidocaine-
isoniazid (r_nmod) remodelling
frequency (l_nmod) neutropenia
nocistatin (r_nsubjpass) isolated
observed (l_nmod) nephropathy
antigen (r_nmod) reactivation
had (l_advcl) placebo
alterations (l_nmod) susceptibility
doxorubicin (r_nmod) provoked
emb-induced (r_amod) optic
acetaminophen (r_conj) phenacetin
min (r_nmod) combination
buffered (r_conj) quantify
administered (l_nmod) dose
patients (l_nmod) gravis
volume (r_nmod) regardless
rats (l_amod) cardiomyopathy
tachycardia (l_conj) arrest
found (l_xcomp) measure
cyclophosphamide (r_nmod) cytotoxicity
exposed (r_acl) newborns
nephrosclerosis (l_nmod) rats
decreases (l_dobj) duration
factors (l_compound) coagulation
propylthiouracil-associated (r_amod) syndrome
group (r_nmod) overstimulation
enflurane (r_conj) halothane
persistence (l_nmod) amnesia
aminonucleoside (r_compound) nephrosis
induced (r_amod) results
diazepam (r_nmod) treated
appear (r_ccomp) hypothesis
stimulated (l_nsubj) recognition
methylprednisolone (r_nmod) hypotension
occurred (l_nsubj) interest
facilitate (l_nsubj) familiarity
frequency (l_nmod) syndrome
increased (l_nsubj) aggregation
model (l_nmod) seizures
model (l_nmod) hemorrhage
precursor (r_nmod) isolated
model (l_amod) nephropathy
violet (r_amod) staining
prescribed (l_xcomp) treat
csa (r_compound) toxicity
degeneration (l_nmod) cells
seizures (l_conj) neurotoxicity
clozapine (r_dep) groups
association (l_nmod) tumor
time (r_nmod) observed
pain (l_conj) contracture
suffer (l_nmod) disorders
protocol (l_appos) society
cocaine (r_nmod) amount
increase (l_nmod) dyskinesia
protect (l_nmod) effects
atropine (r_nmod) combination
nephropathy (r_nmod) clearance
ca3 (r_compound) neurons
trial (r_dobj) conducted
species (r_dobj) showed
occurred (l_nsubj) reaction
bromocriptine (l_nmod) hyperprolactinemia
effect (r_dobj) potentiate
suxamethonium (r_nmod) occur
showed (l_nsubj) patients
associated (l_nmod) toxicity
caa (r_nsubj) contribute
viramidine (r_nsubj) has
part (l_nmod) regimens
den (r_nmod) obtained
conditions (l_amod) neurologic
receive (r_advcl) allocated
complications (l_acl:relcl) arise
alpha-methyl-para-tyrosine (r_nmod) effect
decreased (l_conj) remained
ischemia (l_nmod) pallidus
vpa (r_compound) levels
relation (l_nmod) sensitization
potency (l_acl) prevent
hypometabolism (l_nmod) ad
administered (l_nmod) treatment
prolonged (l_conj) resulted
products (r_nmod) lots
mesna (r_dobj) administering
sulfadiazine (r_compound) nephrotoxicity
sc-48334 (r_compound) level
a (r_nsubj) caused
cholesterol (r_conj) calcium
antidepressant-induced (r_amod) jitteriness
severity (l_compound) pain
phosphate (r_compound) levels
inpatients (l_amod) psychiatric
ltg (r_compound) withdrawal
cohort (l_nmod) children
gentamicin (r_conj) methylprednisolone
hemorrhage (l_dep) hem
patient (l_nmod) signs
disorders (l_nmod) atypicality
sensitivity (l_nmod) convulsions
dyskinesias (r_nmod) development
lorazepam (r_conj) phenytoin
involves (r_advcl) problem
data (l_nmod) pathophysiology
provide (l_conj) indicate
carbamazepine (r_compound) therapy
deficit (l_nmod) memory
effect (r_xcomp) seems
heparin (r_nmod) administration
pb (r_conj) den
clentiazem (r_nmod) treatment
degrees (l_nmod) anaemia
treated (r_xcomp) likely
methadone (r_compound) therapy
quinidine (r_compound) hepatotoxicity
supply (r_nmod) effects
known (r_acl) drugs
became (l_acomp) hypotensive
administration (r_nmod) reduced
ribavirin (r_nmod) received
blocked (r_dep) resulted
mania (l_conj) hypomania
present (l_nsubj) dyskinesia
% (l_nsubj) index
needle (l_conj) pain
smoking (r_nmod) influence
caused (r_acl) pain
pentobarbital (r_nmod) dysfunction
rationale (r_nsubj) drug
carbimazole (r_nmod) drugs
level (r_nummod) minutes
therapy (r_conj) prompt
related (r_amod) nystagmus
beta-blockers (l_nmod) hearts
produce (l_dobj) effect
remains (l_xcomp) treat
development (l_nmod) hypokalaemia
nmda (r_compound) nr1(neo-/-
nitroglycerin (r_nmod) effect
mutations (r_nsubj) co-infected
ppa (r_nmod) dose
developed (l_dobj) prolongation
sedation (l_conj) complications
desogestrel (r_nmod) users
early (r_amod) bradycardias
5-fluorouracil (r_conj) paclitaxel
symptoms (l_amod) schizophrenic-like
signs (l_amod) parkinsonian
reverses (l_nmod) task
system (r_nmod) upregulation
receptor (r_compound) subtypes
counteract (l_dobj) headache
eleven (r_nsubj) had
cardioversion (l_nmod) fibrillation
developed (l_dobj) transplantation
acetaminophen-induced (r_amod) alf
hypercalcemia (l_conj) alkalosis
adenosine (r_nmod) studies
quinine (r_nsubj) available
persons (l_amod) diabetic
administration (r_nsubj) unmask
water (r_nmod) group
seems (l_xcomp) depend
resuscitation (r_dep) arrest
haloperidol (r_conj) bid
cotrimoxazole (r_nsubjpass) involved
gm-induced (r_amod) vasoconstriction
serotonin (r_compound) antagonist
demonstrate (r_advcl) used
fluctuations (l_conj) dyskinesia
use (r_nsubjpass) implicated
lithium (r_nsubj) induced
% (r_nsubj) free
developed (l_conj) vomiting
diazepam (r_nmod) potent
experiencing (r_advcl) addition
case (l_nmod) episodes
pilocarpine (r_nsubj) resulted
cognitive (l_dep) deficits
caused (l_dobj) increase
pregnancy (r_nmod) infarction
fourfold (r_conj) died
induce (l_dobj) fever
patients (r_nmod) alert
nitrazepam (r_nmod) patient
curtailed (l_nmod) toxicities
reduces (l_dobj) risk
diclofenac (l_dep) %
dsp4 (r_compound) pretreatment
reduced (l_conj) inhibited
pilocarpine (r_compound) model
endorsing (l_dobj) cip
post (l_dobj) neurotoxicity
mk-801 (r_conj) antagonist
modulation (l_nmod) neurotoxicity
globulin (l_conj) lamivudine
patients (r_nmod) found
effects (l_nmod) impairments
excretion (r_nsubj) reached
exhibited (r_advcl) exhibited
associated (r_acl) failure
data (l_nmod) studies
hypercalcemias (l_amod) related
associated (l_nmod) hypereosinophilia
acid (r_nsubj) exerts
channel (r_compound) complex
discriminated (l_nmod) damage
atherosclerosis (r_nmod) rats
ability (r_dobj) assess
dfp (r_compound) toxicity
had (l_dobj) effect
desvenlafaxine (r_dobj) included
effects (l_nmod) disease
order (l_acl) determine
incidence (l_conj) morbidity
ability (r_nsubjpass) confirmed
suprofen (r_nmod) syndrome
cisplatin (r_nsubj) has
anemia (l_conj) thrombocytopenia
enalapril (r_nmod) effect
carbamazepine (r_nmod) treated
review (r_conj) presented
advocated (l_advcl) observed
vehicle (r_appos) course
resulted (r_acl:relcl) case
test (l_dobj) hypothesis
tablets (r_conj) effects
norepinephrine (r_nmod) caused
patients (r_nmod) cohort
ppa (r_compound) injury
induced (r_acl) nephritis
factors (l_nmod) delirium
tamoxifen (r_dobj) received
responsible (l_nmod) influence
potentiates (r_xcomp) seems
induced (l_nsubjpass) rigidity
agent (r_appos) cyclophosphamide
steatosis (l_conj) hepatitis
site (l_nmod) pain
suspected (l_advcl) having
mcpp (r_nsubj) suppressed
iopamidol (r_nmod) increases
sulphasalazine (r_nmod) course
channel (r_compound) inhibition
served (l_xcomp) detect
frequency (l_nmod) installation
produce (l_dobj) decreases
had (l_dobj) vte
subjects (l_nmod) neuropathy
ocs (r_nmod) use
evaluate (l_nmod) doses
action (r_dobj) prevents
combinations (r_nmod) lower
continued (l_advcl) available
mc (r_appos) 3-methylcholanthrene
agonists (r_nsubj) decreased
catalepsy (r_dobj) potentiating
weakness (l_nmod) extremities
doses (r_conj) atropine
warfarin (r_nmod) rate
nitrate (r_dep) took
attenuate (l_dobj) effects
performed (l_xcomp) establish
improved (l_nsubj) anemia
cases (l_nmod) exacerbation
506 (r_nummod) fk
risperidone (r_nmod) symptoms
properties (l_nmod) seizures
temsirolimus (r_nsubj) had
bromocriptine (r_nmod) effects
triphosphate (r_nsubjpass) administered
setting (l_nmod) infarction
taking (r_acl) patients
develop (l_dobj) features
disorder (l_appos) hypokalemia
uroprophylaxis (r_nmod) trial
lead (l_nmod) incidence
dxr-cm (r_compound) damage
tcr (r_nmod) effect
tamoxifen (l_appos) drug
ginsenosides (l_nmod) hyperalgesia
rats (r_nmod) developed
efficacy (r_dobj) demonstrated
paclitaxel (r_conj) cisplatin
reported (l_conj) experienced
associated (r_amod) pain
use (r_nsubj) lead
scopolamine- (r_conj) diazepam-
amiodarone (r_compound) therapy
adalat (r_appos) nifedipine
receiving (r_advcl) appeared
cases (r_nsubjpass) described
halothane (r_appos) 1-bromo-1-chloro-2,2,2-trifluoroethane
confirmed (l_dobj) closure
octreotide-induced (r_amod) hypoxemia
reported (l_nmod) years
mitoq (r_nsubjpass) shown
associated (r_acl) fibrillation
exposure (r_dobj) following
associated (r_acl) pregnancy
a-86929 (r_nmod) administration
exacerbations (l_compound) paranoid
potassium-losing (r_amod) therapy
exposure (r_nmod) report
heroin-dependent (r_amod) male
develop (l_nsubj) neoplasms
provides (l_dobj) model
neuropathy (r_nsubj) common
gaba(a (r_compound) modulators
acid (r_nmod) confusion
effect (l_conj) toxicity
methotrexate (r_nmod) treated
dsp4 (r_nmod) induced
fanft (r_appos) n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide
edema (l_conj) icp
di-o-tolylguanidine (r_nsubj) worsened
prophylaxis (l_nmod) recurrence
interaction (r_nsubj) contributed
model (l_nmod) adenomyosis
patient (r_nsubj) overdose
ribavirin (r_nmod) tolerance
levodopa (r_nmod) challenge
cocaine (r_compound) exposure
area (r_nmod) microinjection
ps (r_nmod) administration
involve (r_conj) uncertain
thalidomide (r_compound) dose
associated (r_xcomp) thought
pg (r_nmod) doses
disoprivan (r_nmod) occurred
nag (l_appos) marker
prevent (l_dobj) toxicity
attempt (l_acl) induce
consumption (r_nmod) patients
exhibited (r_conj) used
produce (l_nsubj) atherosclerosis
presented (l_conj) had
effect (l_nmod) cardiotoxicity
rats (r_dobj) prevented
lidocaine (r_nsubj) reduces
survivors (l_nmod) failure
conjugates (r_nmod) form
caused (r_acl) that
rd (r_appos) dexamethasone
model (l_nmod) sclerosis
ameliorates (l_dobj) amnesia
haloperidol (r_dep) classical
sulphadiazine (r_dep) silver
re-exposure (r_advcl) followed
disorder (l_conj) disorder
n (r_dep) controls
progestagen (r_nmod) therapy
differentiate (r_xcomp) using
methotrexate (r_nmod) paraplegia
diazinon (r_nsubjpass) associated
ifosfamide-induced (r_amod) neurotoxicity
associated (l_nmod) carcinoma
dox (r_conj) aap
decrease (l_conj) lysozymuria
resolve (l_nsubj) seizures
thalidomide (r_nmod) treatment
associated (r_acl) reaction
buspirone (r_nmod) analogues
consequences (r_nmod) course
nociceptin-induced (r_amod) allodynia
esterase (l_conj) enzyme
asa (r_dep) acid
study (l_dep) agent
blocker (r_nmod) induced
hyperalgesia (r_nmod) attention
course (l_nmod) syndrome
yohimbine (r_nmod) effects
level (r_nsubjpass) described
aspirin (r_nsubj) reduces
amphetamines (r_nmod) different
tolerance (r_nmod) cases
cis-ra (r_nmod) resolved
induce (l_dobj) change
produce (l_dobj) dyskinesia
5-fluorouracil (r_nmod) followed
developed (r_acl:relcl) schizophrenic
course (l_nmod) psychosis
patients (r_nmod) outcomes
sensitization (r_nmod) detection
two (l_nmod) those
effective (l_advcl) reducing
nifedipine (r_nmod) tocolysis
mechanism (r_nsubj) caused
nra0160 (l_dep) hyperactivity
% (r_dep) higher
severity (r_dobj) increased
treatment (l_nmod) tuberculosis
attributed (l_nmod) patients
testing (r_nmod) evaluation
therapy (l_nmod) epilepsy
permeability (r_conj) aggravation
crf (l_conj) esrd
signs (l_nmod) tma
adopted (r_advcl) induce
giving (l_dobj) dose
increase (r_xcomp) tended
involved (l_nmod) mechanisms
induced (r_acl) haemorrhage
doses (r_xcomp) considered
outpatients (l_nmod) sinusitis
rebleeding (l_nmod) patients
preferable (l_nmod) anaesthesia
had (l_dobj) effects
adr (r_compound) cardiotoxicity
rats (r_nmod) necrosis
regimens (r_nsubjpass) determined
abusers (r_nmod) group
patients (l_nmod) bladder
lead (l_nmod) hemorrhage
doses (r_nsubj) slow
ketamine (r_nsubj) elicited
cyclophosphamide (r_conj) cisplatinum
that (r_nmod) similar
elucidate (l_dobj) effect
women (r_nmod) vte
levetiracetam (l_acl) administered
measured (l_nmod) hypotension
dm (r_nmod) use
blockers (r_nmod) each
phase (l_nmod) proteinuria
failure (r_nmod) associated
attenuates (l_dobj) dysfunction
recognition (l_nmod) neuropathy
indicate (l_advcl) allowing
symptoms (l_nmod) mania
lumens (l_conj) necrosis
risk (l_nmod) cancer
ameliorate (l_dobj) neurotoxicity
test (r_dobj) using
effect (l_nmod) convulsions
therapy (r_dobj) starting
experienced (r_acl:relcl) animals
infusion (l_conj) nephrotoxicity
exclusively (l_nmod) women
cya (r_compound) mg/kg/d
patient (l_nmod) granulomas
gall (l_dobj) dissolution
recognized (l_nsubjpass) tma
methyldopa (r_advmod) taking
specimen (r_nsubj) had
cisapride (r_conj) patients
related (r_amod) compound
aggravate (l_dobj) toxicity
model (r_nmod) effect
treatment (l_nmod) arteriosus
heparin (r_nmod) patients
attribute (l_dobj) agitation
hallmark (l_nmod) dysfunction
lithium (r_nmod) alternative
randomized (l_xcomp) starting
caused (l_nmod) anemia
resulted (l_nmod) rate
increases (l_nmod) tremor
secretion (r_nsubj) accounted
produced (l_dobj) degree
alf (r_nmod) lt
phenylephrine (l_nmod) effects
cs (r_nmod) form
markers (l_nmod) cm
concentrations (r_nmod) prevented
enzyme (r_dobj) studied
aminoglycosides (r_nsubj) act
paclitaxel (r_compound) infusions
vancomycin (r_compound) nephrotoxicity
excretion (r_conj) patients
received (r_acl:relcl) 9
patients (l_amod) schizophrenic
assessed (l_dobj) behaviour
schizophrenic (l_conj) patients
incidence (l_nmod) malformations
nephrotoxicity (r_nmod) plays
dex (r_appos) (bort)-dexamethasone
lesions (l_nmod) bladder
threshold (l_nmod) seizures
associated (r_acl) vte
wall (l_nmod) edema
doses (r_nsubj) restored
protector (l_nmod) ototoxicity
chemotherapy (r_nmod) factor
carbimazole (r_conj) bupropion
nicergoline-associated (r_amod) ain
patients (l_nmod) dysfunction
(aap)-hepatitis (r_nmod) suffering
infusion (r_nmod) presence
norethisterone (r_dep) courses
anxiety (l_conj) depression
haloperidol (r_nsubj) produced
infusing (r_advcl) prevented
enalapril (r_conj) placebo
able (l_xcomp) reverse
prevent (l_dobj) nephropathy
amount (r_nsubj) causes
carbonate (r_compound) therapy
prevention (l_compound) cancer
needed (l_nmod) appearance
sensitive (r_amod) mice
gaba (r_compound) transaminase
boy (r_dobj) present
prostaglandins (l_nmod) responses
dysfunction (l_nmod) infarction
salt (r_compound) injection
models (l_nmod) neurotoxicity
indicate (r_conj) provide
reported (l_nmod) pain
neutralizes (l_dobj) metabolite
mexiletine (r_compound) report
included (l_dobj) upregulation
interval (l_nmod) ischemia
apart (l_nmod) headaches
diuretic (r_compound) therapy
prescribed (r_acl:relcl) physician
subsided (l_nsubj) contractions
patients (l_dep) diagnostic
hospital (l_nmod) syndrome
acid (r_compound) supplementation
dose (r_nmod) effects
show (l_dobj) areas
considered (l_xcomp) tolerable
but-relative (l_nmod) increase
reduced (l_dobj) burden
present (l_dobj) problem
rapamycin (r_compound) inhibitors
antagonists (r_nsubj) induced
woman (l_amod) depressed
mice (l_acl) treated
celecoxib (r_conj) rofecoxib
doses (r_nmod) replacement
presented (l_nsubjpass) findings
cyclophosphamide (r_nmod) dose
therapy (l_acl) preventing
reported (r_appos) methods
dysfunction (l_conj) myopathy
ouabain (r_nmod) injection
is (l_acomp) likely
dosing (r_dobj) manage
paclitaxel (r_dobj) combined
score (l_dobj) incidence
dysfunction (r_nmod) safety
ratio (r_nmod) increase
levels (r_nsubj) induce
those (r_advcl) randomized
nicotine (r_nmod) caused
presented (l_dobj) rash
remained (r_parataxis) continued
risperidone (r_compound) administration
monkeys (r_nmod) dyskinesias
3,4-methylenedioxymethamphetamine (r_nsubjpass) shown
diazepam (r_conj) l-name
had (r_conj) enhanced
developed (r_acl:relcl) block
has (l_advcl) reversing
trimethoprim-sulfamethoxazole (r_nmod) study
amb. (r_compound) depletion
use (r_nsubjpass) regarded
kainate (r_compound) receptor
suggest (l_dobj) existence
associated (l_nmod) reactions
cause (l_nmod) seizures
rd (r_dobj) received
normal (l_conj) diabetic
trinitrate (r_nmod) efficacy
actives (l_nmod) models
monitoring (r_nsubj) predict
triphenyltetrazolium (r_compound) staining
safety (l_nmod) phase
slope (r_nmod) =
papaverine (r_nmod) deficits
number (l_nmod) seizures
readministration (l_conj) motility
using (r_acl) dilation
demonstrate (l_dobj) role
caused (r_acl) bradycardia
agent (r_nmod) caused
results (r_nsubj) minutes
haloperidol (r_nmod) treated
cardiotoxicity (r_xcomp) considered
report (l_conj) irritability
free (r_amod) diet
sirolimus (r_nsubj) share
binding (l_nmod) nuclei
different (l_conj) used
presented (l_nmod) block
woman (l_nmod) block
interact (r_acl:relcl) agents
animals (r_nmod) reticulata
pretreatment (l_nmod) agent
group (r_nsubj) reported
led (l_nmod) relief
di (r_dobj) self-treating
p (r_nsubj) prevent
(+/-)-pg-9 (r_nmod) induced
controls (r_dep) assigned
became (l_acomp) apparent
estrogens (r_dobj) received
dexamethasone-treated (r_amod) eyes
compared (r_acl) ct
thrombocytopenia (l_conj) thrombosis
levodopa (r_nmod) improved
blocked (l_nsubjpass) effect
reversed (l_nsubjpass) effect
acid (r_compound) decarboxylase
warrant (l_nmod) treatment
bromide (l_conj) theophylline
received (l_advcl) occurred
male (r_nmod) resulted
effective (l_nmod) children
ephedrine/propofol/mixtures (r_nmod) any
tobramicyn (l_nmod) concentrations
d2 (r_nmod) that
useful (l_advcl) preventing
areas (l_nmod) onset
factor (l_nsubj) illness
rats (l_nmod) atherosclerosis
mg (r_nmod) administration
channel (r_compound) nitrendipine
cr (r_compound) or=2.5
receiving (r_acl) %
activity (r_dobj) reduce
investigate (r_advcl) evaluated
mpa (r_appos) acid
exposure (r_nsubj) produced
anesthesia (r_nmod) occluded
synthesis/release (r_nmod) role
consistent (l_nmod) diagnosis
hepatotoxicity (r_nmod) feature
disorder (r_conj) drug
dph (r_compound) toxicity
carbamazepine-associated (r_amod) dysfunction
cisplatin (r_dobj) received
mice (l_amod) seizure
psychosis (r_conj) hypotension
acetylcholine (r_compound) hypotension
defined (l_conj) ascites
effect (r_dobj) investigated
pb (r_nsubjpass) associated
estrogen (r_nsubj) downregulates
haloperidol-induced (r_amod) dyskinesia
produces (l_dobj) myelodysplasia
amounts (r_nmod) precipitated
commencing (r_advcl) developed
hyperalgesia (r_conj) active
cephalexin (r_conj) trimethoprim
warfarin-drug (r_conj) warfarin
case (r_nsubjpass) described
neurologic (l_conj) psychiatric
evaluated (r_acl:relcl) bbb
had (l_dobj) activity
administered (l_dobj) days
active (l_advcl) given
associated (r_acl) sah
report (l_nmod) dermatitis
prilocaine (r_nsubj) preferable
injection (r_dobj) received
inhibit (l_dobj) gamma-carboxylation
defects (l_conj) defects
pneumonia (l_conj) ptld
treatment (l_nmod) epilepticus
neuroleptics (l_acl) used
present (l_nmod) hygiene
developed (l_dobj) anemia
implanted (l_conj) developed
pretreatment (r_nsubj) attenuated
hypothesized (r_conj) exhibits
confirmed (l_ccomp) reduced
incidence (l_nmod) infants
testing (l_amod) seizure
overdose (r_nmod) greater
measures (l_nmod) symptoms
course (l_nmod) treatment
accompanied (l_nsubjpass) hypotension
thiotepa (r_nmod) chemotherapy
mk-801 (r_compound) administration
lindane (r_nsubj) toxic
activation (r_nmod) attributable
presence (r_dep) performed
carboplatin (l_acl) administered
incidence (l_nmod) tnss
switched (l_nmod) schizophrenic
administration (r_nmod) myoclonus
cisplatin (r_nmod) treated
action (r_nmod) time-course
antagonized (l_nsubjpass) rigidity
developed (l_dobj) death
acid (r_compound) infusion
allopurinol (r_nsubj) failed
drug (l_amod) anti-arrhythmic
p (r_nmod:npmod) treated
whether (l_dep) acidity
protect (l_nmod) nephrotoxicity
treated (r_acl:relcl) survivors
etoposide (r_conj) anthracyclines
dosage (r_dobj) maintaining
tspa (r_nsubj) agent
found (l_dobj) mortality
aggressiveness (r_nmod) effects
effects (r_nmod) mechanisms
efficacy (l_nmod) trial
dose (r_nsubj) decreased
prevent (l_dobj) seizures
methods (r_nsubjpass) assessed
studied (l_dep) patients
infusion (r_dobj) using
model (r_nmod) differences
hydrochloride-induced (r_amod) seizures
patient (l_compound) malaria
measured (l_nmod) patients
morphine (r_nmod) interaction
inhibition (r_nmod) regulation
pretreated (r_acl) patients
it-tspa (r_conj) it-methotrexate
nafcillin-induced (r_amod) nephritis
levels (l_nmod) patients
dogs (l_conj) dogs
acted (l_nmod) agent
oxide (r_dep) %
similar (r_amod) acceleration
subjects (l_acl:relcl) experienced
effect (l_nmod) acetaminophen
effect (r_dobj) reflect
blocked (l_nsubjpass) hyperalgesia
exacerbates (l_nmod) patients
tests (l_compound) function
ketoprofen (r_nsubjpass) used
a (r_compound) therapy
placed (r_acl:relcl) patients
dapsone (r_nmod) dose
toxicity (l_conj) hepatotoxicity
reduces (l_conj) carries
failure (r_appos) risk
steroid (r_compound) injections
cpa/ee (r_nmod) use
patients (l_amod) ill
synthase (r_conj) inhibition
pyrazinamide (r_compound) withdrawal
carbimazole (r_nmod) induced
patients (l_nmod) decrease
administered (r_dep) conclusion
fasting (l_conj) index
exhibited (r_conj) died
sm-5887 (r_nsubj) have
remained (l_nsubj) hyperactivity
carcinogens (r_nmod) induced
use (r_nmod) increase
no (r_dobj) liberate
matter (l_nmod) disease
receptor (l_nmod) development
phosphorus (r_nsubjpass) known
cells (r_nmod) applied
salbutamol (r_amod) method
myelosuppression (l_conj) loss
cocaine (r_nsubj) induced
patients (r_nmod) ocular
acetaminophen (r_amod) (aap)-hepatitis
incidence (l_nmod) disease
maleate-induced (r_amod) nephrotoxicity
treatment (r_nmod) pallidotomy
clopidogrel (r_compound) trial
tacrolimus (r_nsubjpass) associated
inhibition (l_nmod) hyperthermia
hyperactivity (r_nsubj) seems
a (r_nmod) treatment
treatment (r_nsubjpass) associated
adriamycin-induced (r_amod) death
amphetamine-induced (r_amod) behavior
estrogen-induced (r_amod) tumor
induced (r_acl) vasoconstriction
steroid (r_nmod) dose
g. (r_nmod:npmod) lower
disulfiram (l_nmod) dependence
cisapride (r_appos) terfenadine
phlorizin-induced (r_amod) glycosuria
chemotherapy (r_conj) iiib
test (l_nmod) disorder
nitrite (r_amod) levels
combined (r_acl) globulin
activity (l_nmod) animals
antidepressant (r_amod) use
bupivacaine (r_nmod) db
captopril (r_nmod) injection
important (l_nmod) development
da (r_compound) concentrations
fla-63 (r_nsubj) have
mediated (l_nsubjpass) arteriosclerosis
cases (l_compound) malaria
efficacy (r_dobj) preserved
i (r_nummod) concentration
c (r_conj) 5-fu
methotrexate (l_nmod) leukaemia
understanding (l_nmod) syndromes
mismatch (r_nsubj) explanation
searched (l_conj) database
sodium (r_compound) tolerability
procaterol (r_nmod) effects
bound (l_dobj) infarction
lithium (r_nmod) attributed
phenylephrine (r_compound) hypertension
inhibitors (r_nmod) cases
sevoflurane (r_compound) induction
risk (l_nmod) malignancy
developed (l_nsubj) man
correction (r_conj) markers
related (r_amod) interval
were (l_dep) %
methylergonovine (r_nmod) dose
reported (r_parataxis) lacks
metoclopramide (r_dobj) took
attenuated (l_dobj) catalepsy
derivative (r_nmod) effects
diclofenac (r_conj) tolerability
subsequent (r_conj) produce
inhibition (r_nsubj) reduces
neuroleptics (r_conj) marked
considerations (l_nmod) thrombocytopenia
dronedarone (r_nmod) effects
dose (r_dobj) given
cause (l_advcl) leading
cabergoline (r_nsubj) useful
correlated (r_acl:relcl) hypothermia
plays (l_nsubj) damage
lithium (r_nmod) effects
man (l_amod) hypertensive
therapy (r_nmod) cardiotoxicity
volume (l_compound) hematoma
concentrations (r_nmod) falls
suxamethonium (r_nmod) use
telithromycin (r_compound) usage
carbamazepine (r_nsubjpass) contraindicated
metformin (r_nsubj) protects
urea (r_nmod) increase
dissociate (l_dobj) vocalization
temperature (l_conj) hyperthermia
criteria (r_dobj) analysed
that (r_nmod) showed
activity (l_compound) antihuman
treatment (l_nmod) malaria
progestagen (r_nmod) days
drugs (l_amod) ototoxic
mediate (l_nmod) expression
alcohol (r_compound) consumption
use (r_nmod) verapamil
supports (l_dobj) hypothesis
lower (r_conj) higher
srl (r_conj) csa
epinephrine (r_conj) mepivacaine
effect (r_nsubjpass) examined
ntg (r_nmod) injection
developed (l_dobj) incidence
activity (l_acl:relcl) associated
ma (r_appos) methamphetamine
included (r_acl:relcl) hospitalizations
l-dopa (r_amod) dyskinesia
d-penicillamine-induced (r_amod) anemia
treated (r_acl) arthritis
limits (r_acl:relcl) complication
capsaicin (r_compound) doses
induced (l_dobj) reduction
determined (l_advcl) exerted
consider (l_nmod) returns
patients (l_nmod) damage
diclofenac (r_conj) enrolled
fenfluramines (r_nsubj) had
therapy (r_advcl) induced
have (r_ccomp) indicating
cyclosporine (r_amod) microangiopathy
cpa/ee (r_appos) estradiol
hyperactivity (r_dobj) blocked
vasculitis (r_nmod) reports
acid (r_nmod) provision
complication (r_nmod) report
males (l_nmod) models
induced (l_xcomp) seizure
azithromycin (r_dobj) beginning
prilocaine (r_nmod) incidence
prevented (l_dobj) hyperactivity
development (l_nmod) anemia
subjects (r_nmod) resistance
had (l_dobj) bacteremias
sm-5887 (r_nmod) effect
trimethaphan-induced (r_amod) hypotension
acetaminophen (r_nsubj) rofecoxib
component (l_nmod) therapy
neurons (r_dobj) releases
stereotypy (l_conj) hyperlocomotion
lithium-induced (r_amod) rat
phenytoin (r_compound) dph
cells (l_acl:relcl) mediate
effects (r_nmod) those
lithium (r_compound) effects
hypotension (r_nmod) min
mice (r_nmod) control
trial (l_compound) clopidogrel
acetaminophen (r_nsubj) modify
dose (r_nsubj) increase
nd-nmba (r_appos) use
nitroglycerin (r_nmod) magnitude
ribavirin-associated (r_amod) anemia
activity (l_nmod) myeloma
bp (l_conj) injury
similar (l_dobj) development
etoposide (r_nmod) administration
seizure (r_xcomp) decrease
differences (r_conj) mechanisms
rate (l_nmod) defects
effect (r_dobj) exerts
tumors (l_amod) hemorrhagic
chloramphenicol (r_nmod) treatment
exhibited (l_dobj) evidence
thalidomide (l_nmod) carcinoma
supply (r_nmod) mismatch
tendency (l_nmod) arrhythmias
agonists (r_conj) analogues
thiol (r_compound) 2-mercaptoethane
ketamine (r_nsubj) improve
therapeutic (l_conj) associated
known (r_acl) patients
apomorphine-induced (r_amod) behavior
use (r_nmod) weeks
adenosine (r_nmod) trial
indicating (r_xcomp) data
potentials (r_conj) supersensitivity
symptoms (l_compound) oab
txa (r_compound) usage
none (r_nsubj) showed
patients (l_nmod) tachycardia
heptylate (r_nmod) consisted
therapy (l_nmod) leukaemia
modifications (l_nmod) therapy
presence (r_nmod) increased
treatment (r_nmod) days
no (r_compound) inhibitor
gabapentin-induced (r_amod) modulation
patients (l_amod) bipolar
treatment (r_nmod) pointes
exerted (l_dobj) toxicity
morphine-induced (r_amod) bradycardia
none (r_nsubj) had
serotonin (r_conj) hydroxylase
dopamine (r_compound) levodopa
onset (l_nmod) seizures
totp (r_dep) hr
risperidone (r_nmod) differ
associated (l_conj) examined
9-months (l_nmod) hyperprolactinemia
patient (l_compound) failure
diphenhydramine (r_compound) hydrochloride
infusion (r_dobj) starting
changing (l_dobj) epidemiology
assessment (l_nmod) treatment
patients (l_compound) arthritis
caused (l_dobj) necrosis
given (l_conj) divided
induced (r_acl) mice
cyclosporine (r_compound) patients
related (l_nsubj) hemolysis
fibrillation (l_conj) infarction
mda (r_compound) concentration
indicates (l_nsubj) score
induces (l_conj) delayed
series (l_conj) series
studied (l_conj) obtained
triggers (l_conj) cause
death (r_nsubj) plays
snp (r_conj) hem
proportions (l_conj) treatment
progression (l_conj) toxicity
% (l_dep) 3/20
use (r_conj) use
rigidity (l_conj) myalgia
treatment (l_nmod) transplantation
angiogenesis (r_dobj) mediate
compared (r_conj) studied
folate (r_compound) concentrations
b (r_nmod) administration
tamca (r_nsubjpass) shown
methylphenidate (r_conj) syndrome
dopamine (r_compound) knockout
administration (r_nsubj) s
administration (l_nmod) children
e2 (r_conj) d2
changes (l_amod) related
involved (l_nmod) carcinogenesis
had (l_dobj) levels
infusion (r_nmod) produced
bpa (r_compound) exposure
received (l_conj) suffered
combination (l_nmod) patients
followed (l_nmod) decrease
susceptibility (r_nmod) qtls
atropine (r_nmod) administration
patients (r_nmod) nystagmus
testosterone (r_nmod) cases
associated (r_acl) mortality
growth (l_nmod) tumors
associated (l_nmod) odds
seemed (r_conj) similar
reserpine (r_nmod) effects
vision (l_conj) mouth
ondansetron (r_nmod) depression
seen (l_nsubjpass) levels
monkey (l_nmod) form
appears (l_nsubj) reduction
course (l_nmod) tachycardia
saline (r_nmod) injection
lack (r_acl:relcl) mice
cobalt (r_compound) cardiomyopathy
injected (r_acl) those
reduction (l_nmod) hepatitis
pdn (r_nsubj) produces
effects (r_nsubj) included
effects (l_nmod) symptoms
assess (l_dobj) risk
mk-801 (r_conj) clonidine
reduction (r_nsubj) led
daidzein (r_nmod) administration
experienced (l_dobj) choreoathetosis
two (r_conj) overdose
mr (l_conj) mp
provided (l_advcl) facilitate
predictors (r_nsubj) results
sacrifice (r_nmod) enlarged
rats (r_dobj) protected
schedule (l_acl:relcl) encourages
carbonate (r_compound) toxicity
c. (r_nmod) induced
incidence (l_nmod) stroke
haloperidol (r_conj) asenapine
caused (r_acl) obstruction
mdma (r_appos) ecstasy
syndrome (l_appos) tdfs
cessation (l_nmod) migraine
experienced (l_dobj) symptoms
injection (r_dobj) followed
melatonin (r_nsubj) affects
spironolactone (r_nmod) ability
propylthiouracil (r_nmod) administration
followed (l_conj) caused
vasculitis (r_nmod) manifestation
ah6809 (r_conj) antagonist
damage (l_conj) any
rapa (r_compound) conversion
administration (r_nsubjpass) shown
number (l_nmod) episodes
transaminase (r_conj) transaminase
etiology (l_acl:relcl) explain
azt (r_nmod) administration
subjects (r_advcl) displayed
ouabain-induced (r_amod) models
applied (l_conj) induced
telmisartan (r_compound) mg
underlie (l_dobj) impairments
cisplatin (r_dobj) receive
carbamazepine (r_nmod) withdrawal
studied (l_conj) clip
dose (l_conj) reporting
blindness (l_nmod) response
amiloride (r_compound) treatment
included (l_dobj) salivation
associated (r_acl) myoclonus
response (r_dep) h
tramadol (r_nsubj) opioid
excretion (r_nmod) kinetics
challenge (r_nsubj) ineffective
prevent (l_dobj) fasciculation
helodermin-induced (r_amod) hypotension
produced (l_nsubjpass) coma
encephalopathy (l_nmod) seizures
licking (l_conj) hyperalgesia
methylphenidate (r_nsubjpass) replaced
control (l_nmod) tachyarrhythmias
association (l_nmod) cancer
increased (l_advcl) blocked
hospitalisation (r_nmod) incidence
group (r_nmod) patient
studied (l_dobj) enzyme
capsaicin-induced (r_amod) pain
calculated (r_acl:relcl) patients
improves (l_dobj) amnesia
increased (l_nmod) anaemia
effects (l_nmod) induction
signs (r_dobj) developed
phenobarbital (r_amod) treatment
risperidone (r_nmod) administration
quipazine-induced (r_amod) head
cck-8-ns (r_appos) octapeptide
add (l_nmod) toxicities
timing (l_nmod) reduction
melphalan (r_dobj) suggests
blunted (l_conj) enhanced
irritability (l_conj) headaches
observed (l_nsubjpass) impairment
cyclophosphamide (r_nmod) relationship
therapy (r_conj) inhibitor
correlated (l_nsubj) nin
mg/kg (l_conj) prevented
zidovudine (r_nmod) induced
episodes (l_nmod) activity
diazepam (r_nmod) incoordination
patient (l_amod) epileptic
ro (r_dep) effect
sn (l_acl:relcl) causes
influence (r_dobj) evaluates
sensitive (l_advcl) patients
ptu (r_compound) therapy
gamma-hch (r_appos) gamma-hexachlorocyclohexane
5-ht6 (r_amod) receptor
effects (l_nmod) hypoglycaemia
naloxazone (r_nsubj) attenuated
use (l_nmod) tachyarrhythmias
lamivudine-resistance (r_nmod) associated
necessary (l_xcomp) assess
dose (r_dobj) identified
occurrence (r_nsubjpass) reported
cases (l_appos) cause
adr-induced (r_amod) glomerulosclerosis
therapies (l_nmod) patients
diclofenac (r_advcl) lower
inducing (l_dobj) turnover
lometrexol (r_nmod) toxicity
diminish (l_conj) prevent
originating (r_acl) reflexes
patient (l_conj) history
results (l_nsubj) tachycardia
decrease (l_nmod) values
likely (l_nsubj) nephropathy
formation (l_compound) lesion
pretreatment (r_nsubj) resulted
migraine (r_nmod) patients
halothane (r_compound) anesthesia
protection (r_nmod) recording
e. (r_compound) characteristics
ly274614 (r_nmod) rodents
aminonucleoside (r_nmod) invoked
elevation (r_nmod) effect
exposure (r_nmod) monkeys
presenting (l_nmod) reaction
cause (l_dobj) convulsions
fibrillation (l_appos) vf
contained (r_ccomp) showed
busulfan (r_compound) levels
diltiazem (r_conj) nifedipine
receptors (r_nsubjpass) involved
urge (l_conj) hyperactivity
given (r_advcl) reduced
isoproterenol (r_nmod) obtained
protection (l_nmod) nephrotoxicity
model (l_nmod) akinesia
model (l_compound) taa
failed (l_xcomp) control
mellitus (r_nmod) rats
shown (l_xcomp) decrease
receiving (r_advcl) restarted
polydipsia (l_conj) polyuria
mediated (l_nsubjpass) types
therapy (r_nmod) occurring
features (l_nmod) calculi
animals (l_amod) hypertensive
flushing (l_conj) tachycardia
effects (r_dobj) explored
patients (r_nmod) psychosis
streptomycin-induced (r_amod) vestibulotoxicity
chloroquine (r_compound) related
developed (l_nmod) patients
vasoconstriction (l_conj) vasculitis
prevention (l_nmod) cystitis
discontinuation (r_nsubj) led
oxide (r_compound) ester
phz (r_nmod:npmod) treated
amiodarone-induced (r_amod) coma
trypan (r_conj) determined
pac (r_compound) neurotoxicity
moderate (l_nmod) edema
process (l_amod) hypertensive
vulnerable (l_nmod) damage
maintained (l_nmod) development
fluoxetine-induced (r_amod) akathisia
failure (l_acl) induced
penicillin-induced (r_amod) periods
tam (r_dep) microm
acetaminophen (r_nmod) reduced
concentration (l_nmod) hypotension
drawbacks (l_nmod) hypercalcemia
alcohol-related (r_amod) disorder
thrombolysis (r_nmod) use
caffeine (r_nsubjpass) tolerated
iiib (l_conj) patients
sequence (l_conj) absence
enalapril (l_nmod) progression
(azt)-induced (r_amod) inhibition
occurring (r_advcl) occlusion
examine (r_advcl) induced
shortened (r_conj) increased
pilsicainide (r_nmod) drugs
pose (l_dobj) factor
history (r_nmod) man
aware (l_nmod) symptoms
remains (r_advcl) considered
had (l_dobj) angina
transplantation (l_compound) failure
haloperidol (r_compound) treatments
propofol (r_nmod) injection
ester (r_nmod) effects
bisphosphonate-related (r_amod) pain
model (l_acl) test
effect (r_xcomp) known
improve (l_dobj) claudication
mice (r_nsubj) develop
rats (l_amod) streptozotocin-diabetic
sulfate-treated (r_amod) chicks
antidepressant (r_amod) fluoxetine
potential (r_nsubj) nephropathy
dose (l_nmod) peak
cocaine (r_nmod:npmod) associated
intensity (l_nmod) aggressiveness
occurs (l_nsubj) stroke
consisted (l_nmod) vacuolization
ligands (r_nmod) effects
errors (r_appos) treatment
contributor (l_nmod) hypertension
study (l_acl) aimed
exercise (l_conj) ischaemia
5-ht6 (r_amod) antagonist
use (r_conj) colitis
sulphoxide (r_nmod) ml
active-w (l_appos) trial
challenge (r_nmod) associated
dysfunction (l_nmod) pathophysiology
received (r_acl:relcl) patients
accomplished (l_conj) results
gentamicin (r_nmod) potential
hand (l_appos) mydriasis
degree (r_dobj) evaluated
received (l_dobj) pump
decreased (l_conj) doses
losartan (r_amod) treatment
stopped (l_nsubj) convulsions
catecholamine (r_compound) rate
infant (l_nmod) anomalies
doses (r_nmod) effects
have (l_dobj) roles
dexatrim (l_nmod) cause
death (l_appos) effect
dopamine (r_compound) neurotoxicity
incidence (l_nmod) patients
ameliorate (r_xcomp) claimed
resulted (l_nmod) anuria
rats (l_nmod) mellitus
intoxications (r_nmod) model
gtn (r_nmod) minutes
determined (r_advcl) had
effect (l_nsubj) hyperparathyroidism
cocaine (r_nsubj) result
cimetidine (r_compound) trough-concentrations
seizure (r_nsubjpass) used
is (l_attr) report
mt (r_dobj) hippocampal
reversibility (l_nmod) case
stimuli (r_nmod) response
involvement (r_dep) hyperactivity
nifedipine (r_nsubj) induced
doxorubicin-induced (r_amod) apoptosis
impaired (l_conj) attenuated
administration (r_nmod) occurs
cortisol-induced (r_amod) increases
loss (l_amod) epilepticus-associated
presented (l_nmod) room
cisplatin (l_conj) risk
occlusion (l_acl) preceded
development (l_nmod) myelosuppression
fetuses (r_nmod) performed
glucose (r_nmod) negative
hypotension (r_dobj) attenuated
patients (r_nmod) documented
complication (r_ccomp) suggests
dex-ht (r_appos) hypertension
management (r_nmod) terms
epinephrine (r_dobj) received
isoproterenol-induced (r_amod) elevation
drug (l_nsubj) cause
indomethacin (r_compound) therapy
exacerbation (l_nmod) disorder
counts (l_appos) onset
actions (l_nmod) model
reduced (l_conj) maintained
telaprevir (r_conj) interferon
responses (l_amod) cataleptic
testosterone (r_compound) concentration
conversion (r_nmod) observed
complication (r_nmod) review
viewed (l_nsubjpass) hypertension
correction (l_nmod) contracture
fluconazole (r_nmod:poss) role
indicate (l_ccomp) protects
events (l_compound) cvd
self-treating (l_conj) developed
report (l_ccomp) boy
effects (r_dobj) enhance
treat (l_dobj) infarction
effects (l_amod) antinociceptive
epinephrine (r_nsubj) has
presence (l_nmod) preservatives
reintroduction (r_conj) withdrawal
attractive (l_xcomp) use
influence (l_nmod) damage
righting (l_dobj) reflex
wk (r_nmod) onset
cause (l_dobj) catalepsy
combination (l_nmod) development
ethambutol-induced (r_amod) neuropathy
suggests (l_nsubj) timing
induction (l_nmod) rigidity
lower (l_nsubj) incidence
eliciting (l_dobj) ischemia
investigating (r_advcl) studied
details (l_nmod) induction
weeks (r_nmod) %
cisapride (r_nmod) effects
syndrome (l_conj) coarctation
differentiate (l_dobj) survivors
administration (r_nmod) examined
control (l_nmod) cystitis
observed (r_acl) impairment
secondary (l_conj) relapsing
patient (l_acl:relcl) had
reflect (l_nsubj) incidence
prevention (l_nmod) cancer
no (r_nsubj) plays
3'-azido-3'dideoxythymidine (r_nmod) induced
subtypes (r_nsubjpass) determined
prostaglandins (r_nmod) role
injury (l_acl) defined
busulfan (r_nmod) neurotoxicity
dose (l_amod) neurotoxic
involved (l_nsubjpass) overdose
risk (l_nmod) seizures
flecainide (r_nsubjpass) prescribed
curve (r_appos) hyperglycemia
prevented (l_dobj) vomiting
weeks (r_dobj) occurred
effect (l_amod) hypertensive
paclitaxel (r_nmod) combination
oxide (r_nsubj) has
adrenaline-induced (r_amod) arrhythmia
vigabatrin (r_compound) therapy
tiapride-induced (r_conj) amisulpride-
resistance (r_nmod) observed
contraindicated (l_nmod) patients
improved (l_nsubj) delirium
clozapine (r_conj) nra0160
patients (l_nmod) likelihood
administration (l_nmod) abortions
serotonin (r_compound) cells
therapy (r_dep) those
sludge (l_conj) gallstones
enhanced (l_dobj) response
receiving (r_acl) patient
pge(2 (r_ccomp) conclude
midazolam (r_nmod) frequent
controlled (l_nsubjpass) akathisia
analyzed (l_nmod) factors
degrees (l_nmod) impairment
associated (r_acl) edema
fentanyl (r_nmod) omission
hyperprolactinemia (l_conj) effects
213 (r_nummod) vp-16
related (l_nmod) injury
proteinuria (l_amod) nephrotic
glu (r_appos) k
margin (l_nmod) doses
receptors (r_dobj) block
nifedipine (r_nmod) contrast
variables (r_dobj) did
mptp-induced (r_amod) neurodegeneration
administration (l_nmod) preeclampsia
dobutamine (r_compound) infusion
antidepressants (r_nmod) associated
seizure (l_appos) gtcs
persons (l_amod) hypertensive
heparin (r_nmod) use
became (r_conj) developed
cinacalcet (r_conj) desipramine
nephropathy (l_nsubj) potential
modifications (r_nmod) led
mptp-lesioned (r_amod) marmoset
controlled (l_nsubjpass) seizures
thiabendazole (r_compound) administration
syndrome (l_conj) hypoxia
increasing (l_dobj) pain
result (l_nsubj) overdosage
mofetil (r_appos) agents
leading (l_advcl) mimicking
calcium-independent (r_amod) release
rats (l_conj) mds
metabolism (l_nmod) patients
less (l_conj) akinetic
naloxone (r_conj) binding
venlafaxine-maoi (r_amod) interaction
affect (l_dobj) pain
tacrolimus (r_nmod) immunomodulators
effects (r_nsubj) suggest
induce (l_dobj) dementia
protection (r_nsubjpass) determined
enzymes (r_nsubjpass) altered
infusion (r_nmod) dose
levels (r_nmod) alter
d15 (r_conj) methylprednisolone
kg-1 (r_nsubj) inhibits
hexamethonium (r_conj) atropine
reports (l_nmod) infarction
glutamate (r_nmod) injections
hypercholesterolemia (l_conj) dyslipidemia
developed (l_dobj) hoarseness
alpha-2b (r_nmod) therapy
influence (l_nmod) hepatotoxicity
recommended (l_nsubjpass) screening
apraclonidine (r_nmod) administration
study (l_acl) comparing
precedes (l_dobj) onset
reduced (r_conj) prevented
acrolein (r_nmod) metabolized
etomidate (r_nsubj) prove
reaction (l_compound) hypersensitivity
accelerated (l_dobj) onset
form (l_nmod) dyskinesia
cause (l_dobj) depression
immunohistochemical (l_conj) microscopic
achieved (l_nmod) induction
locomotion (l_conj) irritability
treatment (r_nsubj) has
protein (r_nmod) reacts
flushing (l_conj) anorexia
anxiety (l_conj) confusion
ornithine (r_compound) activity
symptoms (r_nsubj) indistinguishable
selecting (l_dobj) agent
vpa (r_compound) withdrawal
associated (l_nmod) anencephaly
lower (l_nsubj) rate
deterioration (l_nmod) functions
pathways (l_nmod) brains
fear (l_conj) nausea
diuretics (r_nmod) treated
warfarin (r_nmod) treated
scopolamine (r_nmod) caused
b12 (r_nsubj) seem
with (l_conj) arterial
fentanyl (r_nmod) infusion
bupivacaine (r_nmod) concentration
vasopressin (l_nmod) treatment
children (r_nmod) study
levels (r_conj) drug
involves (l_nsubj) injury
trial (r_conj) doses
blunted (l_dobj) hypoactivity
level (r_conj) inhibitors
methadone (r_nsubjpass) associated
produced (l_dobj) methemoglobinemia
accelerated (l_nsubjpass) calcification
ticlopidine (r_nmod) initiation
botox (r_dobj) receiving
neurotoxicity (r_nmod) plays
exposure (r_nmod) occurred
cocaine-injected (r_amod) animals
antibiotics (r_nmod) injection
given (r_advcl) suggestive
included (r_conj) presented
found (l_xcomp) contaminated
crocin (r_nsubj) attenuated
cocaine (r_compound) sufficient
estimate (r_advcl) conducted
identify (l_dobj) history
administered (l_conj) produce
dextran (r_nsubj) increase
extent (l_nmod) injury
preventing (l_dobj) suppression
radicals (r_nmod) formation
dexmedetomidine (r_nmod) syncope
safety (r_nsubj) allowed
death (r_nmod) result
locomotion (l_conj) climbing
accumulation (l_nmod) pneumonitis
induces (l_dobj) hypertrophy
dexamphetamine (r_conj) apomorphine
implicated (l_nmod) hepatotoxicity
reported (r_acl) cancer
observed (r_acl) death
epinephrine (r_nmod) administration
diazepam (r_nmod) mg
patients (r_nmod) infections
mg/m2 (r_dobj) receiving
patient (l_nmod) hepatitis
catalepsy (r_nmod) expression
characterized (l_nmod) death
stage (l_nmod) development
effect (l_nmod) rls
adding (r_advcl) triggered
ax (r_appos) amoxicillin
alpha-2b (r_nmod) administration
involving (r_xcomp) reported
using (r_acl) schizophrenic
penicillamine (r_nmod) caused
reported (l_xcomp) reduce
had (l_dobj) dysfunction
aminophylline (r_appos) agents
l(-1 (l_nsubj) threshold
increased (l_dobj) factor-alpha
corticosteroids (r_conj) tacrolimus
140 (r_nummod) hoe
remain (l_nsubj) effects
women (r_dep) results
counteract (l_dobj) dysfunction
resolved (r_conj) started
examined (l_nsubjpass) arteritis
challenge (r_nmod) slowing
attention (l_conj) produces
cue (r_nmod) respond
pneumonia (l_conj) ulcers
effects (l_nmod) thrombosis
resulted (l_nmod) neutralization
zidovudine (r_nmod) intolerant
features (l_conj) block
randomized (l_nsubjpass) patients
anticoagulants (r_nmod) therapy
mipafox (r_nmod) dosages
diazepam (r_nmod) frequent
clozapine (r_dobj) received
commonly (r_advmod) described
fruits (r_nmod) extract
steroids (r_nmod) types
indomethacin (r_nsubjpass) implicated
multiforme (l_compound) glioblastoma
use (r_nmod) common
model (r_nmod) epilepticus
exposure (r_nsubj) increases
toxicity (r_dobj) aggravate
consequences (l_nmod) seizures
domperidone (r_nmod) reduced
hydroxytyrosol (l_nmod) rats
interaction (r_nmod) role
patients (l_amod) glaucomatous
trihexyphenidyl-induced (r_amod) effects
retardation (l_appos) iugr
disease (r_nmod) criteria
chloride (r_compound) channel
history (l_nmod) stones
considered (l_nmod) agent
therapy (r_nmod) superior
experienced (r_appos) summary
atorvastatin (r_nsubj) prevented
escalating (r_xcomp) incorporate
model (r_nsubjpass) developed
increase (l_nmod) pressure
leukoencephalopathy (l_acl) mimicking
receiving (r_acl) women
acetazolamide (r_nmod) complication
use (r_nmod) effect
effects (l_conj) expression
developed (l_dobj) bigeminy
barium-induced (r_amod) disturbances
increased (l_conj) remained
administration (r_nmod) incidence
dexmedetomidine (r_nsubj) capable
relevance (l_nmod) anemia
patients (l_amod) uremic
stopped (r_acl:relcl) hallucinations
cases (l_nmod) arrest
treated (r_acl) hyperthyroidism
injection (r_nsubj) reproducible
cocs (r_nmod) women
chlorpromazine (r_conj) haloperidol
flumazenil (r_compound) group
syndrome (l_compound) leukoencephalopathy
a (l_nmod) rats
diazinon-induced (r_amod) hyperlipemia
metabolite (l_acl:relcl) causes
doxorubicin (r_compound) studies
presence (l_nmod) disease
prevents (l_dobj) impairment
resistance (r_nmod) increase
cocaine (r_nmod) response
combined (l_nmod) carboplatin
poisons (r_nmod) deactivated
factor (l_amod) ototoxic
alpha-2b (r_nmod) patient
leads (l_nmod) development
acid (r_nmod) dose
structural (l_dep) impairment
pentobarbital (r_nmod) system
ethanol (r_compound) diluent
treatment (r_nmod) duration
detection (l_nmod) cardiomyopathy
levels (l_nmod) states
associated (l_nmod) risk
expression (r_nsubjpass) investigated
found (l_dobj) rate
ptu (r_nmod) withdrawal
fluconazole (r_dobj) commencing
recurrence (l_nmod) polyps
vpa-induced (r_amod) hepatotoxicity
attributed (r_acl:relcl) abnormalities
cocaine-induced (r_amod) infarction
model (r_dobj) using
patients (r_nmod) group
ribavirin (r_compound) anemia
abolished (r_ccomp) attenuated
prednisone (r_compound) pdn
sulphate (r_nmod) rectified
studied (l_dep) prevention
augment (r_dep) induce
sirolimus (r_nmod) replaced
hypotension (l_conj) haemodilution
associated (l_nmod) anophthalmia
paracetamol (r_nmod) doses
fragments (r_nmod) stimulated
140 (r_nummod) des-arg10hoe
isoproterenol (r_nmod) injections
show (l_ccomp) improves
reduce (l_dobj) myalgia
history (l_nmod) hitt
methamphetamine (r_nmod) induced
report (l_dobj) syncope
reported (r_acl:relcl) complication
treated (l_nsubjpass) mice
microm (r_nsubj) induces
activation (r_nmod) role
incidence (l_nmod) cancer
treatment (l_nmod) arrhythmias
induce (r_advcl) improved
precipitated (r_acl) microangiopathy
tmp (r_nmod) preferable
increased (l_dobj) scores
infrequent (l_conj) result
implicated (l_nmod) damage
neuropathy (r_advmod) constructed
fentanyl (r_amod) anesthesia
effect (r_nmod) plays
received (l_conj) developed
influence (r_nsubjpass) estimated
induces (l_dobj) seizures
development (l_nmod) mania
back-diffusion (r_nmod) factors
lisinopril (l_nmod) chf
occurred (l_parataxis) had
diazepam (r_dobj) had
measuring (l_dobj) plasma
estrogen (r_nmod) administration
protection (l_nmod) amnesia
alanine (r_compound) transaminase
mptp (r_nmod) parkinsonian
methamphetamine (r_nmod:npmod) (meth)-induced
worst (l_conj) showed
elicits (l_dobj) response
prolongation (l_conj) tdp
exacerbations (r_nmod) call
show (l_dobj) association
effects (r_dobj) assess
acetate (r_nmod) utility
nmda (r_compound) seizures
correlation (r_conj) increase
decrease (l_dobj) fasciculation
children (l_nmod) adhd
minutes (r_dep) 0.05
any (r_dobj) affecting
developed (l_dobj) telangiectasia
nephrosis (r_nmod) rats
ischemia (r_nmod) effects
calculate (r_acl) study
ropivacaine (r_conj) bupivacaine
case (r_attr) was
role (l_dep) effect
ssris (r_nmod) treated
ptz (r_nmod) activity
antagonists (r_nsubj) enhance
aplasia (l_conj) dermatitis
use (r_nmod) corrected
amino (r_compound) compounds
suffered (l_nsubj) 78-year-old
develop (l_dobj) hoarseness
greater (l_nsubj) toxicity
abnormalities (r_nsubjpass) substituted
(ros)/nitrogen (r_compound) species
changes (r_dobj) produce
metformin (r_nmod) treatment
prevent (l_nsubj) glycosuria
unclear (r_xcomp) remains
monitor (l_conj) advise
dose (r_nsubj) mg/kg
cisplatin (r_compound) d15
decline (l_acl:relcl) eliminated
levels (r_nmod) produced
increased (r_amod) startle
if (r_appos) effect
upregulation (l_nmod) pvn
revealed (l_dobj) disorders
harm (l_nmod) injury
action (r_dobj) produced
caused (l_dobj) haemorrhage
verapamil (r_nmod) treatment
increases (r_advcl) make
levcromakalim-produced (r_amod) decrease
had (l_ccomp) rare
depression (l_amod) ischemic
dnr (r_nmod) failure
patients (l_nmod) hyperlipidemia
pain (r_nmod) five
bortezomib (r_nmod) treatment
protocol (l_nmod) dogs
catecholamines (r_nmod) excess
indinavir (r_conj) zidovudine
d-penicillamine (r_nmod) treated
groups (r_nmod) treatment
hypotension (l_amod) hem-induced
gemcitabine (r_conj) day
examination (l_conj) vigilance
type (r_nmod) impact
higher (l_nmod) controls
cataracts (l_conj) disease
group (r_advcl) greater
acted (l_nmod) co-carcinogen
produced (l_conj) tremors
doses (r_nmod) controlled
vnr (r_dobj) comparing
caffeine (r_nsubj) antagonist
have (l_dobj) bradycardia
epinephrine (r_nmod) induced
adrenaline-induced (r_amod) hypertension
have (l_nmod) models
regurgitation (r_dobj) valve
experienced (l_dobj) devastating
related (l_xcomp) stroke
timolol (r_conj) randomized
achieved (l_nsubjpass) oih
l-noarg (r_appos) ng-nitro-l-arginine
contributes (l_nmod) rats
patients (r_nmod) results
dexamethasone (r_nmod) pretreatment
effects (l_amod) locomotor
induce (l_dobj) damage
have (l_conj) worth
rifampin (r_compound) therapy
phenylpropanolamine (r_appos) dexatrim
had (l_dobj) ari
methadone (r_nmod) doses
mg (r_dep) dex
nociceptin (r_nmod) precursor
suggests (l_nsubj) fact
addition (r_nsubj) reduce
anemia (l_conj) immunodeficiencies
doses (r_conj) mr
paclitaxel (r_nsubj) have
bacteremia (l_nmod) meningitis
number (l_conj) glomerulosclerosis
effect (r_dobj) determined
used (l_nmod) patients
had (l_dobj) diagnosis
aminoglycoside-induced (r_amod) ototoxicity
capecitabine (r_nsubj) has
related (r_amod) dilated
dopamine (r_conj) levodopa
roles (r_dobj) examined
clarify (l_conj) pineal
effects (l_nmod) doses
diagnosis (l_nmod) disorder
etoposide (r_conj) cisplatinum
examined (l_conj) concentration
ngf (r_nmod) correlations
clarithromycin (r_nmod) dose
revealed (l_dobj) oxidation
contrast (r_conj) demonstrate
altered (l_nmod) rats
excess (l_nmod) mb
acid (r_compound) level
hydroxychloroquine (r_dobj) taking
improving (r_xcomp) seems
assessed (l_nsubjpass) nephrotoxicity
those (l_nmod) rest
increased (l_nsubjpass) behavior
e.g. (l_conj) nephrotoxicity
hypoactivity (r_dobj) prevent
receptors (r_nmod) activation
was (l_nsubj) relationship
generation (r_nsubj) plays
recurrence (l_compound) b
effects (l_nmod) rats
lithium-induced (r_amod) syndrome
related (l_nsubj) pointes
occurred (r_acl:relcl) deficit
galactose (r_dep) oral
systems (l_conj) abnormalities
agents (r_appos) drugs
response (l_nmod) patients
blockers (r_nmod) treatment
administration (l_nmod) fibrillation
carbimazole (r_compound) vasculitis
observations (l_ccomp) catalyze
arrhythmias (l_nmod) arrhythmia
possibility (l_conj) patients
subchronic (r_conj) reserpine
localize (l_dobj) genes
m(3)-machr. (r_dobj) stimulating
diazepam (r_conj) amnesia
vacuolization (l_conj) form
isph-induced (r_amod) mi
received (l_nsubj) iiib
attenuated (l_dobj) deficit
prophylaxis (l_nmod) disease
lidocaine-induced (r_amod) convulsions
present (l_nmod) incontinence
effect (r_conj) potential
found (l_nmod) patients
unnecessary (l_nmod) age
aggravated (l_nsubjpass) injury
mptp (r_conj) meth
vasculitis (r_dobj) developed
cocaine (r_nmod) use
doubled (r_acl) risk
glucose (r_nmod) slope
results (l_dep) suggested
estimate (r_advcl) did
bupropion (r_compound) use
metoprolol (l_nmod) hypokalemia
minutes (r_nmod:tmod) experienced
effect (l_amod) rare
risk (l_advcl) causing
haloperidol (r_conj) risperidone
reduction (l_nmod) number
result (l_nmod) dysfunction
acid (r_compound) nephropathy
those (r_nmod) similar
reacts (l_advcl) mediating
administration (r_nmod) induction
implicated (l_nmod) hypertension
development (l_nmod) arrhythmia
propofol (r_nmod) addition
delay (r_dobj) produced
progression (l_nmod) nephropathy
cases (l_nmod) patients
scopolamine (r_nmod) potentiated
iodixanol (r_conj) iopamidol
dexrazoxane (r_nsubjpass) recommended
finding (l_ccomp) differ
pretreatment (r_nmod) blocked
tiapride (r_nsubj) reduced
symptoms (l_amod) similar
1,1-dichloro-2,2,2-trifluoroethane (r_nmod) mixture
piperacillin-treated (r_conj) tobramycin
associated (l_advcl) initiating
vancomycin (r_conj) aminoglycoside
mg (r_nmod) effect
ecg (l_amod) non-ischemic
metoclopramide (r_nmod) arrest
neurotoxicity (r_conj) event
amiodarone (r_nmod) related
prevent (l_dobj) myalgia
busulfan (r_nmod) fluid
buspirone (r_appos) drug
stopping (r_csubj) reduced
clonazepam (r_nmod) infusion
suprofen (r_nsubjpass) associated
naloxone (r_nsubjpass) shown
induces (l_nmod) tachycardia
maleate (r_nmod) induced
everolimus (r_nmod) prophylaxis
improved (l_dobj) disturbances
type (l_compound) disease
role (r_dobj) highlight
reduced (l_dobj) tachycardia
length (l_nmod) af
cardiotoxicity (r_nsubj) highlights
occlusion (l_nmod) thrombi
progesterone (r_nmod) metabolites
provide (l_dobj) evidence
relaxants (r_nmod) use
hypersensitivity (r_conj) contractility
days (r_conj) number
secondary (l_nsubj) increase
vgb (r_appos) vigabatrin
relation (r_conj) risks
l-sotalol (r_nsubj) lower
areas (l_nmod) fibrosis
6-thioguanine (r_nmod) months
isoniazid (r_nmod) administration
contributing (l_nmod) anemia
ketamine (r_nsubj) induced
man (r_nsubj) became
increased (l_nmod) difference
thought (l_nsubj) constriction
atorva (r_appos) dex
organophosphate-induced (r_amod) convulsions
ketamine (r_acl:relcl) drug
simvastatin-ezetimibe-induced (r_amod) failure
complications (r_nmod) relationship
setting (r_nmod) developed
adriamycin (r_compound) treatment
dose (l_conj) predominance
switch (r_nmod) development
desferrioxamine (r_nmod) doses
performed (r_conj) avoided
fluoxetine (r_compound) mania
cases (l_nmod) hyponatremia
injection (r_nmod) induced
captopril (r_nmod) introduction
abolished (l_nsubjpass) rigidity
reported (l_nsubjpass) hypokalemia
consider (r_parataxis) initiated
signs (l_nmod) ischemia
treatment (r_nmod) data
hydrochloride (r_appos) drug
retching (l_conj) tremors
result (r_nmod) reduces
inhibitor (r_appos) hydrochloride
1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (r_dobj) receiving
ethopropazine (r_nsubjpass) found
haloperidol (r_appos) series
isomers (r_nmod) properties
describe (l_dep) pointes
mechanism (r_nmod) reaction
alpha2-adrenergic (r_amod) hypotension
values (l_compound) virus
risks (r_dep) cancer
thyroxine (r_amod) abuse
likelihood (l_nmod) drowsiness
caffeine (r_compound) challenge
had (l_nsubj) seizures
expression (r_nmod) upregulation
patients (l_compound) disorder
nephrolithiasis (r_nmod) case
arise (r_acl:relcl) complications
steroid-induced (r_amod) pressure
administration (r_nmod) min
pneumonia (l_nmod) patients
antagonizes (l_dobj) catalepsy
failure (l_conj) thrombocytopenia
stroke (l_amod) hemorrhagic
order (l_acl) identify
reversed (l_dobj) depression
thrombi (l_nmod) patients
injection (r_nmod) paralysis
inhibitory (r_nmod) consisting
famotidine (r_nmod) removal
mechanisms (r_nmod) role
observed (l_dep) %
experienced (l_nmod) attacks
estimate (l_dobj) degree
cacl2 (r_compound) group
haloperidol (r_nmod) treatment
underlying (l_dobj) toxicity
phonophobia (l_conj) photophobia
distinguished (l_nmod) those
poisoning (r_nmod) presentation
dx (r_nmod) treated
histamine (r_compound) release
hr (l_punct) )
e (r_conj) folate
duration (r_nsubj) increase
cyclophosphamide (r_compound) cystitis
onset (r_nmod) period
fanft (r_compound) carcinogenesis
states (l_nmod) function
estrogens (r_nsubj) induce
cocaine (r_compound) abusers
acetylcholine (r_compound) receptors
group (r_nmod) hg
independent (r_amod) mechanisms
effects (r_nmod) relationship
weight (r_dep) mangiferin
olanzapine (r_nmod) efficacy
appearance (l_nmod) proteinuria
role (l_nmod) cardiotoxicity
interaction (l_acl:relcl) distinguished
bacl2 (r_conj) chloroform-adrenaline
suppressed (l_dobj) arrhythmia
lithium (r_nsubjpass) stopped
efficacious (l_advcl) account
99 (l_conj) tachycardia
cocaine-exposed (r_amod) group
fenfluramine (r_nmod) users
treated (r_acl) children
documented (l_nsubjpass) anxiety
associated (l_nmod) anaemia
suxamethonium (r_nsubj) induced
neuropathy (l_nmod) short-
omission (r_nmod) unaffected
spironolactone (r_nmod) discontinuation
seen (l_nsubjpass) block
% (r_nmod) observed
model (l_nmod) epilepticus
levels (r_nsubj) similar
used (r_acl) type
etoposide (r_dobj) containing
norepinephrine (r_nmod) responses
new (l_dep) infarct-avid
ingestion (r_nmod) hour
minutes (l_nmod) impairment
dhea (r_nsubj) displays
thrombosis (l_nmod) artery
consisted (l_nsubj) disturbance
performed (l_dobj) assay
responding (l_nsubj) man
undergoing (l_nsubj) patient
carbamazepine-induced (r_amod) myocarditis
secretion (l_compound) hormone
accompanies (r_acl:relcl) dysfunction
demonstrated (l_advcl) common
women (l_nmod) bladder
cephalothin (r_compound) therapy
ratio (l_acl:relcl) responsible
addition (r_nsubj) appears
edema (l_compound) mcao
result (r_xcomp) thought
incorporation (r_nmod) related
changes (l_nmod) meshwork
initiation (r_dep) months
alprazolam (r_compound) patients
piperacillin/tazobactam (r_nmod) doses
window (r_dobj) concluded
evidence (l_nmod) insipidus
prevented (l_dobj) seizures
cases (l_nmod) self-poisoning
reported (r_appos) results
cddp (r_appos) cisplatin
caffeine-containing (r_amod) foods
add (l_nsubj) deprivation
carbamazepine (r_conj) phenobarbitone
occurred (l_nsubj) gain
tacrolimus-induced (r_amod) neurotoxicity
resistant (l_advcl) developing
injury (r_nmod) cholestasis
failure (l_nmod) aki
use (r_conj) risk
citrate (r_compound) anticoagulation
prior (r_advmod) develop
insufficiency (l_conj) anemia
suppressed (r_advcl) startle
attenuates (l_dobj) nephrotoxicity
alleviate (l_dobj) cardiotoxicity
week (r_nmod) disappeared
diltiazem (r_nsubj) prevented
therapy (r_nmod) reports
intensity (l_compound) pain
showed (r_advcl) showed
induced (l_dobj) development
concentration (r_nmod) occurred
induced (l_dobj) injury
adp/o (r_conj) ratio
hold (l_nmod) fibrillation
ameliorated (l_nsubjpass) toxicity
srl (r_conj) fk506
associated (r_acl) woman
gtn (r_compound) day
had (r_conj) age
toxicity (r_dobj) recognize
case (l_nmod) polymyositis
mismatch (l_conj) demand
folate (l_dobj) levels
avoiding (r_advcl) benefit
bupropion-associated (r_amod) seizures
treated (r_acl:relcl) subjects
salicylate (r_appos) drugs
antagonism (l_nmod) hypertension
caused (l_nmod) neurotoxicity
hydrochloride (r_nmod) effect
represented (r_conj) had
amn082 (r_nsubj) reduces
electroshock (r_conj) flurothyl
developed (l_xcomp) enhance
(+/-)-pg-9 (r_nmod) profiles
potentiating (l_dobj) catalepsy
returned (r_conj) rose
digitalis- (r_conj) ligation-
experienced (l_advcl) cardiomyopathy
bupivacaine (r_dobj) received
had (l_dobj) number
dexmedetomidine (r_nsubj) prevents
behavior (l_amod) anxiety-like
had (r_acl:relcl) findings
clonidine (r_nmod) interaction
treatment (l_nmod) mild
patients (r_nmod) electrocardiograms
paclitaxel (r_nmod) total
noted (r_conj) observed
capacity (r_conj) activity
aap-induced (r_amod) injury
inhibited (l_dobj) gain
increased (l_advcl) produce
reduced (l_dobj) catalepsy
epilepticus (r_nmod) induced
mda (r_appos) malondialdehyde
induced (l_dobj) glycosuria
patients (l_conj) others
said (l_ccomp) known
man (l_nmod) mg/day
sirolimus (r_nmod) initiation
lidocaine (r_compound) convulsions
mean (r_conj) recorded
doxorubicin-treated (r_amod) animals
patients (l_nmod) labor
adriamycin (r_nsubjpass) administered
lindane (r_appos) gamma-hexachlorocyclohexane
steroids (r_nsubj) produced
resolved (r_acl) toxicities
doses (r_nmod) treated
exposed (r_acl) applicators
k (r_compound) responses
systolic (l_dep) dysfunction
methylergonovine (r_nmod) administration
levodopa (r_compound) dose
reach (r_dep) conclusions
dopamine (r_compound) turnover
neuropathy (r_nmod) map
necessary (l_nmod) seizures
vgb (r_nmod) exposure
creatinine (r_dobj) have
atracurium (r_nmod) use
users (r_ccomp) met
reduced (l_conj) increased
switching (r_advcl) became
subjected (l_nmod) aneurysms
rilmenidine (r_amod) hypotension
onset (l_nmod) distress
observed (r_parataxis) associated
isoproterenol (l_nmod) tachycardia
fibroblasts (r_nmod) enzyme
gentamicin (r_nsubj) nephrotoxicity
fetuses (r_nmod) alterations
incidence (l_nmod) nodules
case (l_nmod) thyrotoxicosis
resulted (l_conj) reversal
patients (r_nmod) lower
granisetron (r_compound) doses
isoproterenol (r_nmod) examined
consistent (l_nmod) effect
result (l_nsubj) toxicity
pentoxifylline (r_nsubj) inhibits
part (l_acl) assess
tetrachloride (r_nmod) dose
corticosterone (r_nmod) concentrations
ep (r_appos) epinephrine
thc (r_nmod) induced
haloperidol (r_nsubj) failed
diazinon-associated (r_amod) risk
superoxide (r_nmod) induction
animals (r_nsubj) hyperactive
immunity (r_conj) proteinuria
weight (r_dobj) had
patients (l_compound) stroke
indicating (l_dobj) effect
ephedrine (r_nsubj) has
illustrates (l_dobj) derangements
lithium (r_nmod) effect
so (r_advmod) associated
produce (r_xcomp) known
risperidone (r_dep) groups
patients (l_dep) 3
formulation (r_nmod) efficacy
dx (r_nmod) animals
d (r_dep) gamma-vinyl-gaba
methotrexate (r_amod) action
capsaicin-evoked (r_amod) hypersensitivity
myocarditis (r_dobj) had
succinylcholine (r_nmod) prevent
reversal (l_nmod) paralysis
failure (l_appos) att-alf
role (l_nmod) arf
patients (l_dep) constipation-predominant
% (l_conj) death
valproate (r_nmod) contribution
b (r_nmod) incorporation
cause (l_nmod) failure
a (l_nmod) infarction
advantages (l_conj) nausea
doxorubicin (r_compound) toxicity
sirolimus (r_compound) cells
evaluates (l_advcl) attempting
failure (l_appos) arf
testosterone (r_nsubj) contributes
patient (l_nmod) neuropathy
hydrochlorothiazide (r_nmod) safety
factors (r_conj) efficacy
patients (r_nmod) appeared
dose (r_conj) type
exert (l_conj) reduce
mannitol (r_nmod) concentrations
apply (l_nmod) neuroleptics
bicuculline (r_conj) electroshock
deposited (l_conj) produced
containing (r_acl) products
failure (l_conj) neutropenia
mk-801 (r_conj) amphetamine
min (l_nmod) occlusion
initiation (r_nmod) presentation
anesthetics (r_nsubjpass) associated
victims (l_nmod) overdose
pamidronate (r_dobj) illustrates
months (l_nmod) men
cyclophosphamide (r_conj) nelarabine
optic (r_nsubj) neuropathy
temocapril (r_nsubj) effective
incidence (l_nmod) urolithiasis
bnpp (r_nmod) animals
min (r_nmod) observed
infusion (r_nsubj) shown
concentrations (r_conj) patients
similar (l_nmod) dyscrasias
ribavirin (l_nmod) c
treated (r_acl) dogs
gentamicin-induced (r_amod) failure
patients (r_nsubjpass) discharged
administration (r_nmod) induced
amb. (r_nmod) toxicity
effects (r_dep) convulsive
developed (l_dobj) cholestasis
glutathione (r_compound) content
papaverine (l_nmod) treatment
cocaine (r_dobj) used
matter (r_conj) ratio
cycle (r_nmod) fibrillation
have (l_conj) associated
propylthiouracil-induced (r_amod) damage
d3 (r_appos) doses
had (l_dobj) association
patient (l_nmod) bradycardia
salbutamol (r_nsubj) increased
alf (l_conj) lt
groups (r_nmod) differed
lithium-induced (r_amod) ndi
improvement (l_nmod) pain
treatment (r_nmod) anemia
patients (r_nsubj) risk
required (l_nmod) function
injection (l_nmod) areas
causes (l_dobj) arrhythmia
intake (r_nmod) quintiles
associated (l_nmod) leukemia
depression (l_conj) disease
characteristics (l_conj) symptoms
mediated (l_nmod) hyperammonemia
bupropion (r_nsubj) treatment
predict (l_dobj) damage
1,2-dimethylhydrazine (r_conj) carcinogens
calculated (l_advcl) cause
eruptions (l_amod) rosacea-like
activation (r_nmod) setting
acid (r_nsubj) neuroprotective
isoproterenol-induced (r_amod) infarction
complained (r_advcl) complained
commenced (l_nmod) recurrence
treatment (l_nmod) sarcoma
arabic (r_compound) treatment
epilepsy (r_nmod) history
consistent (l_nmod) cardiotoxicity
anxiolysis (r_dobj) measured
observed (l_advmod) nephropathy
apomorphine-induced (r_amod) amnesia
using (r_advcl) mandates
administration (r_nsubj) interfere
serotonin (r_compound) content
action (l_nmod) toxicity
abuse (r_nsubj) causes
edrophonium-induced (r_dep) early
paranoia (r_nmod) marker
believed (l_advcl) toxicity
increase (r_dobj) exhibited
cases (r_nmod) 2
levels (r_dobj) augment
room (l_nmod) pain
haloperidol-induced (r_amod) model
acid (r_nmod) 7alpha-hydroxylation
incidence (l_dep) convulsions
rate (r_nmod) decrease
phase (l_conj) phase
caused (l_parataxis) developed
reported (r_conj) demonstrated
prevent (l_dobj) tachycardia
analysis (r_dep) functional
treatment (r_nmod) neuropathy
heparin (r_nsubj) remains
influence (r_nsubjpass) studied
stz (r_appos) streptozotocin
induced (r_acl) convulsions
interaction (r_dobj) likely
management (l_nmod) riha
challenged (l_xcomp) induce
demonstrated (l_dobj) efficacy
locomotor (l_conj) dyskinetic
case (l_nmod) hematoma
arrest (l_amod) cardiac
problems (r_dobj) demonstrated
completed (r_acl:relcl) men
catecholamines (r_conj) levels
female (r_nmod) case
cause (l_nmod) disorder
warfarin (r_compound) use
patient (l_acl) resulting
milrinone (l_nmod) treatment
study (l_nmod) cancer
reduce (l_dobj) edema
subjects (r_nmod) had
concentrations (r_nmod) evaluation
apap (r_compound) deacetylation
risk (r_dobj) demonstrated
leading (l_nmod) tdp
levels (r_nmod) most
effects (r_conj) activity
infusion (r_conj) treatment
noradrenaline (r_compound) infusion
active (l_nmod) hyperactivity
application (l_conj) min
changes (l_acl:relcl) include
picloxydine (r_compound) irrigations
flunarizine (r_nmod) that
cases (l_nmod) hepatotoxicity
identified (l_dobj) reports
sought (l_xcomp) examine
prevented (l_dobj) loss
use (r_nmod) stimulated
development (l_nmod) cancer
associated (l_nmod) pseudoprolactinoma
fluoxetine (r_dobj) receiving
media (r_nmod) consumption
assigned (r_acl) patients
diagnosis (l_nmod) infarction
increased (l_conj) affected
events (l_amod) eps-related
associated (r_acl) bleeding
administration (r_nmod) ratio
review (r_conj) describe
thiols (r_conj) protein
loss (l_nmod) activity
receiving (r_acl) prevention
trimethaphan (r_conj) flow
serotonin (r_conj) da
induce (l_dobj) cystitis
, (r_punct) conclusion
mg/kg (r_nmod) seizure
indicate (l_conj) predict
no-synthase (r_nmod) inhibition
drugs (r_nsubj) able
analysis (l_nmod) grade
reported (r_advcl) detected
atorva (r_appos) atorvastatin
requirements (r_dobj) reduce
patients (r_nmod) include
aspect (r_nsubj) hypersensitivity
disease (l_appos) gvhd
induction (l_nmod) coagulation
proteins (r_nmod) concentration
appear (l_dep) presence
protect (l_nmod) seizure
result (l_nmod) coadministration
treatment (r_nsubj) potentiated
evidence (l_nmod) clotting
risperidone (r_appos) f(33
suggests (l_ccomp) complication
amoxicillin-clavulanate (r_nsubj) stands
beginning (r_advcl) presented
nitroglycerin (r_nmod) reversed
developed (l_nsubj) individuals
incidence (l_nmod) convulsion
reduces (l_dobj) hyperalgesia
represent (l_dobj) targets
amlodipine (r_conj) valsartan
pdtc (r_conj) inhibitor
fk506 (r_nsubj) seem
des-arg10hoe (l_nmod) neuropathy
mb (l_nmod) users
treatment (r_nmod) effect
exacerbated (l_nmod) adriamycin
bnpp (r_appos) phosphate
associated (l_nmod) development
overcome (l_dobj) effects
side-effect (l_nsubj) sd
reaction (r_nmod) marker
time (l_acl) obtain
loss (l_nmod) hypertension
use (r_nmod) underwent
most (l_nmod) cancers
ceftriaxone (r_compound) treatment
venlafaxine (r_nmod) overdose
agitation (l_conj) delirium
involvement (l_nmod) development
dosages (r_nmod) related
diazepam- (l_dep) amnesia
inhibitor (r_appos) fluoxetine
ischemia (l_nmod) dogs
cause (l_nmod) dermatitis
ions (r_nmod) reductions
limited (l_dobj) activity
reabsorption (r_nmod) patients
1,3-butadiene (r_nmod) studies
effects (r_dobj) evaluates
revealed (l_dobj) pattern
developed (l_dobj) constellation
reasons (l_nmod) seizures
areas (l_compound) ulcer
replacement (r_nsubj) prevent
level (r_nmod) contrast
cancer (l_conj) warrant
concentration (r_nsubj) normal
performed (l_nmod) patients
dizziness (r_conj) headache
hyperalgesia (l_conj) myoclonus
ngf (r_appos) results
(att)-associated (r_nsubj) alf
propofol (r_nmod) formulations
develop (l_nsubj) sclerosis
galactose (r_nmod) effects
provided (l_dobj) course
cardiotoxicity (l_nmod) cardiotoxicity
exposure (l_conj) hepatotoxicity
marrow (r_nmod) prepared
role (l_nmod) injury
hepatitis (l_conj) anemia
had (l_nmod) severity
folate (r_compound) elevation
induces (l_dobj) withdrawal
play (l_nmod) hypotension
testosterone-treated (r_amod) rats
haloperidol (r_nsubj) decreased
controls (l_conj) macroprolactinoma
reversal (l_nmod) overdose
morphine (r_nsubj) induces
suggests (l_nsubj) excess
amitriptyline (r_advcl) less
sr (r_amod) treatment
gamma-carboxyglutamate (r_amod) residues
produced (l_dobj) dysrhythmias
dxnp (r_nmod) difference
modification (l_nmod) disability
den (r_nmod) treated
alleviation (l_nmod) pain
propofol (r_compound) sedation
antibiotic (r_appos) acid
pergolide (r_nmod) treated
female (l_nmod) fhf
play (l_nsubj) sedation
barium-supplemented (r_amod) long-evans
associated (r_acl) stones
use (r_conj) presence
administration (r_nmod) complications
morphine (r_nmod) combination
addictive (l_dep) stimulant
adrenaline-induced (r_amod) bradycardia
galactose (r_amod) treatment
play (l_advcl) accelerating
group (l_compound) ant-mi
doses (l_amod) necessary
enlargement (l_conj) wastage
incidence (l_nmod) apnoea
reverse (l_dobj) hypotension
occurrence (l_nmod) fibrillation
capsaicin (r_nmod) induced
dyskinesia (r_nmod) characterize
treated (r_advcl) started
osteoarthritis (l_conj) arthritis
rare (r_xcomp) going
doses (r_nmod) margin
efficacy (l_nmod) prevention
development (l_nmod) cardiotoxicity
patients (l_acl) receiving
treatment (r_nsubj) dysfunction
produces (l_dobj) anxiety
excretion (r_conj) species
presented (l_parataxis) had
methotrexate (r_dep) included
cause (l_conj) used
correlates (l_nmod) pain
increased (l_conj) decreased
pattern (l_nmod) anemia
demonstrate (l_dobj) rate
had (l_dobj) incidence
hyperkalemia (l_conj) insufficiency
observed (l_nsubjpass) disorder
increase (l_nmod) output
lnna (r_nmod) weeks
protection (l_nmod) effects
proteinuria (l_nmod) markers
cessation (r_nmod) result
compared (l_dobj) patients
ranitidine (r_compound) treatment
scavengers (r_nmod) effects
adriamycin (r_nmod) effects
combined (r_acl) ccnu
test (r_nmod) inhibited
alendronate (r_nsubj) effective
chloride (r_compound) incidence
had (l_conj) found
occurred (l_nsubj) pain
failed (l_xcomp) proteinuria
aminonucleoside (r_conj) hexachloro-1:3-butadiene
mg/kg (l_nmod) parameters
studies (l_nmod) paclitaxel
caused (l_dobj) reversion
have (l_dobj) disturbance
risk (l_nmod) eps
akathisia (r_nmod) symptoms
found (l_xcomp) exhibit
system (r_nmod) involvement
induced (l_nmod) seizures
topiramate-induced (r_amod) nephrolithiasis
apparent (l_nmod) presentation
diseases (l_acl:relcl) occurs
% (r_nmod) associated
rats (r_nmod) found
ethambutol (r_compound) toxicity
resistant (l_nmod) calcification
prophylaxis (l_nmod) thrombocytopenia
levofloxacin-induced (r_amod) seizures
mediated (r_conj) elicited
receiving (r_acl) those
episode (l_nsubj) gtcs
agent (r_nmod) use
acid (r_compound) neurotransmitters
use (r_appos) those
treatment (r_nmod) pharmacodynamics
gamma-vinyl-gaba (r_nmod) microinjections
nmda (r_compound) antagonist
peak (r_nmod) dose
infusion (r_dobj) undergoing
b. (r_dobj) attenuates
aminonucleoside-induced (r_amod) abnormalities
therapy (r_nmod) giving
alpha-tc (r_nsubj) attenuated
effects (r_nsubj) involved
followed (l_nsubjpass) hyperprolactinemia
representative (l_nmod) hypertensives
induced (r_acl) erythroblastocytopenia
produced (l_nmod) hypoventilation
da (r_nsubj) essential
affecting (r_ccomp) unclear
administered (l_conj) recorded
pilocarpine (r_conj) tropicamide
toxicity (r_nmod) potentials
ifosfamide (r_advcl) suspect
effects (r_dobj) compared
demonstrated (l_nsubjpass) toxicity
amlodipine (r_compound) mg
implicated (l_nmod) pathogenesis
drug (l_acl) used
clonidine (r_compound) mg
syndrome (l_conj) acidosis
information (r_dobj) provide
combined (l_nmod) regimen
(li)-induced (r_amod) polyuria
tested (l_dobj) hypothesis
virus (l_compound) leukaemia
ifosfamide (r_nsubj) is
atenolol (r_nmod) therapy
pharmacokinetics (l_acl) administered
cb (r_nsubj) inhibitor
potassium (r_appos) diuretics
patients (l_nmod) carcinoma
amiodarone-related (r_amod) mass
duration (r_nmod) related
compared (l_conj) subjects
tetrandrine (r_nmod) effects
cultures (r_dobj) exposing
inhibitors (r_nmod) dose
incidence (l_compound) convulsion
score (l_compound) pain
halothane (r_nmod) anaesthetized
midazolam-associated (r_amod) cardiorespiratory
amounts (r_dobj) consumed
increased (l_nmod) course
therapy (l_acl:relcl) developed
sc-48334 (r_appos) n-butyl-deoxynojirimycin
different (l_nsubj) incidence
cases (l_nmod) delirium
contraceptive (r_amod) steroids
patients (r_nmod) immunity
adr (r_nmod) treated
encephalopathy (l_conj) vasospasm
cross-reacting (r_conj) had
associated (r_acl) seizure
captopril (r_nmod) abnormality
tea (r_nmod) effects
doxorubicin (r_conj) myocet
increases (l_dobj) incidence
theophylline (r_nmod) lower
palsy (r_nmod) child
beta-carboline-induced (r_amod) seizures
combining (r_csubj) revealed
antibiotic (r_dobj) withholding
developed (r_acl:relcl) third
sulfonylureas (r_nmod) reported
groups (l_dep) alf
acid (r_compound) levels
seizures (r_nmod) protective
idea (r_nmod) led
methamphetamine (r_dobj) abusing
development (l_nmod) hypertension
rate (l_appos) patients
therapy (l_acl) treat
value (r_nmod) revealed
clonidine (r_conj) clonidine
conclusions (r_nsubj) result
did (l_conj) study
stimulation (r_dobj) increases
bea (r_conj) hcbd
higher (l_nmod) frequency
ingestion (r_nmod) induced
coarctation (l_nmod) aorta
attenuated (l_dobj) ischemia
greater (l_conj) group
a (r_nmod) effect
erdosteine (r_nmod) role
treatment (r_nmod) immunohistochemical
had (l_dobj) hematomas
naloxone (r_nmod) role
neurotoxicity (r_nmod) action
glucose (r_compound) test
benefit (l_nmod) models
prednisolone-induced (r_amod) dysfunction
was (l_xcomp) compare
encouraged (l_nmod) changes
incidence (l_nmod) cause
levomepromazine-fluvoxamine (r_amod) seizures
cases (l_nmod) hypertension
induced (r_acl) task
settings (l_nmod) prevention
protected (l_dobj) rats
disease (l_conj) failure
stroke (l_conj) myocardiopathy
induced (l_nmod) injections
model (l_nmod) aids
midazolam (r_nmod) complications
patient (l_nmod) presentation
haloperidol (r_nmod) injections
verapamil (r_dobj) administered
showed (l_dobj) ability
discovered (l_nsubjpass) tumors
treated (r_acl) meningitis
scopolamine-injected (r_amod) rats
linking (l_nmod) alteration
therapy (r_nmod) unrelenting
contractility (l_conj) hypersensitivity
antibody (l_appos) antibody
reserpine (r_compound) hypothermia
help (l_advcl) providing
known (r_acl) medications
patients (l_nmod) dermatoses
pentylenetetrazol-induced (r_conj) picrotoxin-
presented (l_dobj) torsades
develop (l_dobj) hyperactivity
treatment (r_nmod) study
explained (l_nmod) hypothesis
therapy (r_nmod) resulted
catecholamines (r_nmod) content
produced (l_dobj) anaemia
incidence (l_nmod) bradycardia
captopril (r_compound) treatment
effusion (l_conj) abnormalities
cardioprotection (l_nmod) cardiotoxicity
levetiracetam (l_acl) (lev)-induced
oct (r_nsubj) prevent
contribute (l_nmod) urge
locus (r_nsubj) remains
content (r_conj) glomerulosclerosis
suspect (l_advcl) occurring
given (r_conj) with
effects (l_nmod) dynamic
dopac (r_conj) dopamine
enalapril (r_nmod) trial
2pam (r_conj) diazepam
developed (l_dobj) fibrillation
indicating (l_ccomp) involved
clarithromycin (r_appos) antibiotic
associated (r_acl) nephrotoxicity
case (l_nmod) hamartoma
reduce (l_conj) prevent
noradrenaline-uptake (r_amod) agent
(ami)-induced (r_amod) toxicity
enlargement (r_nmod) peak
patients (l_acl:relcl) complained
nifedipine (r_nmod) slowed
patients (l_dep) patients
propionate (r_conj) adenocarcinomas
morphine-induced (r_amod) sphincter
calculated (l_advcl) determine
naloxone (r_nmod) reversed
injection (r_nmod) neuropathy
methylphenidate (l_nmod) children
rats (r_nmod) evaluation
triglyceride (r_nmod) accumulation
sparteine/debrisoquine (r_compound) polymorphism
warrant (l_compound) lymphoma
compared (r_prep) had
la (r_nmod) cm
adr (r_appos) adriamycin
effects (l_nmod) overdosage
reduced (r_conj) associated
therapy (r_nsubj) caused
seizure (r_xcomp) occur
episodes (l_amod) hypotensive
elucidate (r_advcl) studied
produced (l_nsubjpass) models
account (l_nmod) activity
diltiazem (r_nmod) comparison
associated (r_acl:relcl) anemia
established (l_nmod) gastroenteritis
model (r_nmod) less
evidence (l_conj) score
diethylnitrosamine (r_nmod) action
improved (l_nsubjpass) dyskinesias
effects (r_nsubjpass) assessed
fluphenazine (r_conj) raclopride
weeks (l_compound) admission
treatment (r_nmod) cardiotoxicity
use (r_nsubj) factor
tacrolimus (r_compound) toxicity
followed (r_acl) groups
indications (l_nmod) effect
lesions (l_conj) deterioration
cause (l_dobj) pointes
letrozole (r_conj) administration
erythrodysesthesia (l_appos) syndrome
reduces (l_nsubj) anemia
potassium (r_compound) patient
(dox)-induced (r_amod) cardiotoxicity
review (l_dobj) literature
cause (l_dobj) concern
association (l_nmod) risk
believed (l_nsubjpass) cause
induce (l_dobj) defects
absence (l_nmod) induction
disorder (l_appos) rates
prolongation (r_nmod) initiate
effects (r_nmod) comparison
propranolol (r_nmod) withdrawal
short- (l_dep) deficits
failure (l_compound) stroke
levels (r_nmod) associated
lower (l_nmod) patients
undertaken (l_conj) aggregation
dox (r_nmod) induced
pressure (r_conj) remained
transplantation (r_nmod) frequencies
venlafaxine (r_dobj) taking
dextrose (r_compound) hour
meth (r_compound) dose
intake (r_nsubj) unrelated
corticosteroid (r_compound) therapy
benefit (l_conj) toxicity
behaviors (r_conj) evaluated
users (r_nmod) generation
patients (l_nmod) af
reduces (l_dobj) cytotoxicity
methylphenidate (r_compound) vasculitis
caused (r_acl) exacerbation
patient (l_acl) starting
selected (l_nsubjpass) reviews
development (l_nmod) syndrome
producing (l_dobj) hypertrophy
series (l_nmod) respect
carbamazepine-induced (r_amod) dysfunction
rabbits (l_acl:relcl) seen
calcium (r_compound) chelation
initiation (r_nmod) rate
pointes (l_appos) tdp
documented (l_nsubjpass) effect
therapy (l_nmod) transplantation
effects (l_nmod) markers
test (l_compound) catalepsy
therapy (r_dobj) beginning
died (r_acl:relcl) patients
ap7 (r_conj) antagonists
accompanied (r_advcl) revealed
potential (r_dobj) evaluated
gaba (r_nmod) concentration
caused (l_nmod) ablation
time (l_nmod) rats
acquired (l_dobj) tdp.
warfarin (r_nmod) interaction
accompanied (r_acl:relcl) one
block (r_nmod) beats
duration (l_conj) regurgitation
patient (r_nmod) fibroblasts
amine (r_compound) infusion
anthraquinone-containing (r_amod) agent
layer (l_nmod) rats
induce (l_dobj) hepatitis
static (l_dep) hyperalgesia
case (r_dobj) describe
capsaicin (r_compound) model
discovered (l_xcomp) developed
interaction (r_nmod) result
quetiapine (r_nmod) incidence
dyskinesia (l_conj) hallucinations
minimize (l_dobj) ischaemia
effects (l_amod) other
deficiency (r_nmod) induced
therapy (l_amod) anti-tumor
relatives (l_acl) affected
symptoms (l_nmod) disease
implies (l_nsubj) model
appeared (l_xcomp) beneficial
users (r_nmod) reported
taking (l_nmod) disorder
no (r_compound) precursor
risk (l_nmod) torsades
enhances (l_nsubj) hyperthermia
compared (l_nsubjpass) toxicity
resolved (l_nsubj) hypertrophy
administration (r_nmod) secondary
evaluated (l_nmod) trial
instituted (l_conj) reduces
treatment (r_advcl) resulted
% (r_dobj) evaluated
e2 (r_compound) pituitary
beats (r_nmod) caused
sumatriptan (r_nmod) administration
lnna (r_compound) hypertension
failure (r_nmod) arrhythmias
myopathic (r_xcomp) rendered
rats (r_nmod) examined
bilirubin (r_dobj) showed
imaging (r_nsubjpass) performed
fbal (r_nsubj) related
inducing (l_dobj) impairment
efficacy (l_advcl) treating
influence (l_nmod) development
aetiology (l_nmod) syndrome
cause (l_ccomp) neuropathy
days (l_nmod) ahf
carbonate (r_dobj) taking
hypoparathyroidism (r_nmod) patient
efficacy (l_nmod) symptoms
urd (r_compound) catabolism
eyes (r_nmod) significant
inhibitors (l_acl) used
led (l_nmod) investigation
doses (r_nmod) bolus
nmda (r_compound) receptor
death (l_nmod) events
e1 (r_nmod) effects
turnover (l_nmod) dogs
optic (l_acl) neuropathy
prazosin-induced (r_amod) incontinence
epinephrine (r_dobj) administer
those (r_nmod) higher
episodes (l_nmod) syncope
thalidomide-induced (r_amod) neuropathy
acetate (r_nmod) treatment
effects (l_compound) tremor
seemed (r_advcl) participates
release (r_nmod) correlation
enhancement (r_nsubjpass) seen
nephrotoxicity (r_nmod) role
fk506-associated (r_amod) maha
acetaminophen (r_advmod) prevent
onset (l_nmod) asystole
patients (l_nmod) hemorrhage
decreased (r_advcl) disappeared
persisted (l_nsubj) polyuria
scopolamine (r_nmod) premedicated
acquired (l_nsubj) exacerbates
methotrexate (r_xcomp) has
(stz)-induced (r_amod) diabetic
psychosis (l_nmod) patients
exposure (r_nmod) model
u-ii (r_nmod) injection
patient (l_amod) infected
receive (r_xcomp) randomized
occur (l_nmod) signs
patients (r_nmod) report
role (r_nmod) focus
consequence (l_nmod) arrest
patients (l_nmod) solid
c (r_dep) rats
n (l_conj) sarcoma
dyskinesia (r_nmod) one
asa (r_nmod) induced
stimulating (r_acl) drugs
mptp-induced (r_amod) parkinsonism
tacrine-loaded (r_amod) nanoparticles
vcm-induced (r_amod) nephrotoxicity
protocol (r_nmod) included
had (l_dobj) factors
activity (l_nmod) arrhythmias
treatment (r_nmod) assigned
complained (l_nmod) drowsiness
dyskinesias (l_nmod) disease
develops (l_nsubj) failure
therapy (r_nmod) damage
vomiting (l_nmod) improvement
effect (l_nmod) mi
aggression (l_conj) dyscontrol
determining (l_dobj) ad50
fucoidan-treated (r_amod) rats
coma (l_appos) failure
ethambutol-associated (r_amod) neuropathy
animals (r_nmod) pronounced
development (l_compound) chf
atropine (r_conj) blocker
dose (r_nmod) ingestion
reversal (l_nmod) hypotension
act (l_nmod) systems
acetaminophen (r_conj) ccl4
instillation (r_nmod) treatment
associated (l_compound) tumors
loss (l_conj) seizures
tiapride (r_conj) amisulpride
dyskinesia (r_nmod) predictors
apomorphine (r_compound) infusions
effective (r_advcl) unlikely
induce (l_conj) suggests
administration (r_nmod) effectiveness
concluded (l_ccomp) used
induced (l_conj) marker
fucoidan (r_advmod) tested
treatment (l_nmod) symptoms
treatment (r_nmod) hypertension
improves (l_conj) expected
contaminants (l_conj) deficiency
incorporating (r_acl) chemotherapy
target (r_nmod) conversion
ischemia (r_nsubj) result
paranoia (l_appos) cip
toxin (r_compound) injections
augments (l_dobj) seizure
administration (r_conj) reduction
presence (l_nmod) leukemia
use (r_nmod) experienced
seem (l_advcl) preventing
include (l_nsubj) search
therapy (r_nmod) induced
seizures (l_conj) hypolocomotion
associated (r_acl) mhc-i
maintained (l_dobj) characteristics
treatment (r_nmod) follow-up
sulfadiazine (r_compound) acute
tropicamide (r_nmod) administration
treatment (r_nmod) periods
response (l_acl) combined
use (r_nmod) strategies
improved (l_conj) seizure
ccnu/ctx (r_nmod) treatment
cause (l_nmod) infarction
appear (l_xcomp) responsible
role (l_nmod) arrest
conversion (r_nmod) developed
paroxetine (r_dep) patients
dsp4 (r_nmod) pretreatment
increases (l_dobj) prevalence
penicillin-induced (r_amod) activity
oxitropium (r_nmod) effects
took (r_ccomp) revealed
val (r_appos) valsartan
proteinuria (l_conj) damage
use (r_nsubjpass) reserved
protocols (r_nsubjpass) used
co-morbidity (r_nmod) associated
died (l_conj) lesions
effect (r_nmod) change
anaemia (r_nsubj) due
aspirin (r_nsubj) seem
had (l_dobj) onset
dipyridamole-thallium-201 (r_compound) imaging
uncertain (l_nsubj) anemia
associated (l_conj) hernia
result (r_xcomp) appear
blocker (r_conj) morphine
acetylcholine (r_nmod) production
use (l_nmod) individuals
receiving (r_acl) cancer
5-fu (r_nmod) administration
treatment (r_nmod) advised
6-ohda-lesioned (r_compound) rats
msh/acth (r_dep) neuropeptide
cocaine (r_nmod) half-life
reductions (r_dobj) attenuated
terminated (l_nsubjpass) vt
tnss (r_dobj) receiving
failure (l_nmod) hepatitis
increase (l_nmod) markers
regimen (r_nsubj) achieves
patients (l_compound) seizure
carbamazepine (r_nmod) administration
imaging (r_nmod) implications
titrated (l_nmod) symptoms
behaviours (l_amod) convulsive
(mptp)-exposed (r_amod) monkeys
pretreatment (r_nmod) antagonized
bupivacaine (r_compound) arrhythmia
those (r_nmod) two
chlorhexidine-digluconate (r_amod) cystitis
trazodone (r_nmod) pretreatment
dose (r_nsubj) triggered
levels (r_nmod) elevation
steroids (r_nmod) therapy
hold (l_nmod) remodelling
abuse (r_nmod) deterioration
norepinephrine (r_amod) function
data (l_dep) study
dose (r_nmod) abolition
synthase (r_nmod) inhibitor
induced (r_acl) hypertension
gsh (r_appos) glutathione
clozapine (r_appos) threshold
hitt (l_conj) osteoporosis
day (r_nmod) receive
infusion (r_nmod) ischemia
acetate (r_nmod) cases
blockade (r_nsubj) promote
hyperprolactinemia (l_conj) amenorrhea/oligomenorrhea
diagnosis (l_nmod) lesion
infusion (r_nmod) associated
acid (r_nmod) associated
induced (r_acl) aggregation
regard (l_nmod) spasm
block (l_nmod) blindness
effects (r_nmod) explained
assess (r_advcl) studied
dobutamine (r_conj) exercise
psychosis (r_nmod) symptoms
have (r_xcomp) said
catalepsy (l_conj) tremor
had (l_advcl) indicating
had (l_nmod) glomerulosclerosis
dyskinesias (l_nmod) patients
vicinity (l_nmod) hematoma
vincristine (r_nmod) exposed
ptz-induced (r_amod) seizures
naloxone (r_nsubj) reverses
injections (r_nsubj) produced
desipramine (r_nmod) treated
(hbsag)-positive (r_amod) donors
produced (l_conj) protect
tolerated (l_conj) occurred
induce (l_nsubj) alterations
development (l_nmod) cardiomyopathy
lamivudine (l_nmod) prophylaxis
cause (l_dobj) variety
developed (l_dobj) tumors
combined (r_advcl) suggested
l-alpha-glyceryl-phosphorylcholine (r_nmod) effect
tacrolimus (r_nmod) application
episodes (l_conj) strokes
pilsicainide (r_nmod) concentration
effect (r_dobj) enhances
developed (l_conj) treated
cocaine (r_conj) stroke
associated (r_acl) complications
occurred (l_nsubj) shunt
reducing (r_advcl) prevent
wernicke (r_nmod:poss) encephalopathy
cyclophosphamide (r_amod) cancer
result (r_nmod) retention
disease (l_nsubj) hypertension
controls (l_amod) hypertensive
prevented (l_nsubjpass) damage
formalin-induced (r_amod) licking
doses (r_nsubj) synergistic
acid (r_compound) antagonist
study (l_dobj) degeneration
evoked (r_advcl) evoked
exacerbates (l_appos) model
suggesting (l_xcomp) treatment
company (r_dep) 5-fluorouracil
testosterone (r_compound) impairment
ketamine (r_nmod) doses
vasodilation (l_conj) hypotension
safety (l_nmod) respect
activation (r_nmod) resulted
exhibited (l_advcl) potentiating
bromocriptine (r_nmod) injection
raloxifene (r_compound) evaluation
tolerability (r_dobj) diclofenac
mg/dl (r_nmod) addition
injections (r_nmod) retinoblastoma
bradydysrhythmias (l_conj) fibrillation
albuterol (l_nmod) exacerbations
patients (l_nmod) attack
giving (r_advcl) safety
appeared (l_nsubj) forms
behavior (l_conj) confusion
exposure (r_nsubj) resulted
characterized (l_nsubjpass) seizures
gold (r_nmod) caused
response (l_nmod) hypotension
aggravates (l_conj) causes
prevent (r_xcomp) sufficient
survival (r_dobj) improved
events (l_nmod) akathisia
risk (l_nmod) development
crisis (l_amod) hypertensive
resulted (l_nmod) mice
expression (l_nmod) course
induced (l_parataxis) confirmed
resolved (l_nsubj) jaundice
transporter (r_nmod) alterations
complete (l_nmod) seizures
cows (l_conj) margin
reported (r_conj) documented
cbz (r_nsubj) had
respect (l_nmod) haematological
omeprazole (r_nmod) therapy
pharmacotherapy (r_nmod) developed
treated (l_nsubjpass) site
caused (l_dobj) calcification
nausea (l_conj) pain
resulting (r_acl) kindling
encephalopathy (r_nmod) characteristic
tobramycin (r_dep) infusion
diuretics (r_nsubj) cause
has (l_advcl) mitigating
disorder (l_appos) disorder
cibenzoline (r_nmod) concentrations
co-administration (r_nmod) induced
l-name (r_appos) ester
valve (l_dobj) toxicity
administration (r_dep) hours
inhibiting (l_dobj) arrhythmia
drugs (r_nmod) action
contraceptives (r_conj) type
clarify (l_ccomp) true
taking (r_acl) patient
study (l_acl:relcl) confirmed
changes (r_nsubj) changes
thrombocytopenia (r_nmod) prophylaxis
cisapride (r_conj) agent
effect (l_amod) nephrotoxic
treatment (r_nsubjpass) initiated
doxorubicin (r_conj) daunorubicin
activity (l_nmod) models
nondepolarizing (r_acl) paralysis
vasculitis (r_conj) mpo-anca
incidence (l_nmod) cancers
toxicity (l_conj) cardiotoxicity
acid-mediated (r_amod) mechanisms
cm (r_dep) levels
methoxamine (r_nsubj) evoked
profile (l_nmod) impairment
diagnosed (l_xcomp) have
level (r_conj) dehydrogenase
neurons (r_nmod) extent
ascites (l_conj) hypoalbuminemia
cisplatin (r_nmod) observed
levels (r_nmod) suggestion
doxorubicin (r_nmod) doses
cefotetan (r_nmod) use
dox-induced (r_amod) damage
dothiepin (r_appos) study
pergolide (r_nsubjpass) discontinued
glyburide (r_nmod) reports
replaced (r_advcl) disappeared
pressure (l_nmod) convulsions
morphine-induced (r_amod) amnesia
examined (l_nsubjpass) tolerance
therapy (l_nmod) menorrhagia
group (r_nmod) weeks
presented (l_nmod) deterioration
daidzein (r_nmod) effects
ppa/caffeine (r_amod) administration
fluoxetine (r_nmod) connected
infused (l_xcomp) minimize
dexamethasone (r_conj) safety
membranes (l_nmod) rats
supplement (r_xcomp) appears
pregs (r_nmod) ability
inhibiting (r_advcl) restored
intake (r_nmod) features
alpha-fluoro-beta-alanine (r_nmod) induced
incidence (r_nsubj) high
administration (r_nsubj) induced
step (l_nmod) nephrotoxicity
start (r_nmod) develops
induced (l_dobj) hypertension
measures (l_nmod) parkinsonism
therapy (r_nmod) pulmonale
prevented (l_nsubjpass) effect
superoxide (r_compound) activity
schedule (r_dobj) using
rats (l_amod) tumor-bearing
recovery (l_nmod) hypertension
administered (l_xcomp) control
beta-blocker (r_nsubj) blocks
metabolite (l_amod) neurotoxic
injection (r_nsubj) prevented
aorta (l_conj) arrest
destroy (r_xcomp) used
use (r_nmod) result
models (r_nmod) disease
containing (r_acl) sealants
contraception (r_nmod) associated
receiving (r_acl:relcl) man
coniine-induced (r_amod) arthrogryposis
identified (l_advcl) eliminating
methadone (r_compound) treatment
dose (l_conj) considered
cocaine (r_nmod) smokers
aminonucleoside (r_compound) nephropathy
sedation (r_nsubjpass) associated
% (l_nmod) seizures
suggests (l_ccomp) determinant
associated (l_nmod) decrease
veralipride (r_nmod) symptoms
presence (l_nmod) stenosis
associated (l_nsubjpass) conclusion
provides (l_dobj) opportunity
remained (l_nsubj) degree
retention (r_nmod) accompanied
dehydrogenase (r_nmod) activity
misoprostol (r_nsubjpass) shown
resulting (l_nmod) proteinuria
syndrome (l_conj) stroke
target (r_nmod) inhibitor
use (r_nsubjpass) associated
type (r_appos) sd
k)-atpase (r_conj) (na
greater (r_amod) apoptosis
agitation (l_conj) shouts
pain (l_conj) jaundice
role (l_nmod) onset
associated (r_acl) occlusion
cisplatin-induced (r_amod) injury
extended-release (r_nmod) treated
part (l_nmod) prophylaxis
decrease (l_conj) problematic
fixed (l_conj) convulsive
pan (r_appos) aminonucleoside
diazepam (r_nmod) doses
help (r_xcomp) recommended
nefiracetam (r_nsubj) reverses
containing (r_acl) sera
induced (r_acl) appearance
have (l_dobj) nephrotoxicity
presence (l_nmod) asterixis
parkinsonian-like (l_dep) signs
augment (l_dobj) seizures
evaluation (r_conj) increase
muscarine (r_compound) receptors
addicts (r_nmod) population
nephrotoxicity (l_conj) ototoxicity
activation (l_conj) neurotoxicity
clioquinol (r_nmod) dose
doses (r_nsubj) have
designed (r_acl:relcl) regimen
echocardiography (l_nmod) severity
occurs (l_nsubj) proteinuria
association (l_nmod) drugs
those (r_nmod) appeared
patients (l_nmod) disorders
safe (l_nmod) rrmm
pallidotomy (r_dobj) underwent
infusion (r_nmod) related
injection (r_dobj) use
complications (l_nmod) vasoconstriction
sulindac (r_compound) administration
ciprofloxacin- (r_amod) rats
women (l_nmod) risk
1-bromo-1-chloro-2,2,2-trifluoroethane (r_nmod) way
potential (l_advcl) slowing
prevented (l_dobj) death
management (l_nmod) hyperparathyroidism
treatment (l_nmod) conditions
effect (l_nmod) patients
testosterone-dependent (r_amod) hypertension
rate (l_nmod) tremor
seizures (r_nmod) susceptibility
methods (l_dep) evaluate
stent (r_dobj) receiving
rats (r_nmod) ctnt
suggest (l_dobj) link
pre-induced (r_acl) cardiotoxicity
bupivacaine (r_nmod) induced
warfarin (r_nsubj) reduces
block (r_acl:relcl) drugs
cyclophosphamide (r_conj) 5-fluorouracil
estrogen (r_nmod) role
episodes (l_amod) hypomanic
had (l_nsubj) 12
potentiate (l_dobj) syndrome
, (l_dep) ratios
alcohol (r_compound) intake
incidence (l_nmod) toxicity
seems (l_nsubj) toxicity
ii (r_nummod) losartan
csa (r_appos) a
reported (l_conj) include
implicated (l_nsubj) association
vasculitis (l_nmod) conjunction
morphine-induced (r_amod) increase
improvement (l_nmod) patient
patients (r_nmod) neuropathy
surmountable (l_nsubj) blockade
consider (l_dobj) thrombocytopenia
group (r_nmod) so
agents (l_nmod) treatment
occur (l_nsubj) rigidity
syndrome (l_compound) stomatitis
overtreatment (r_nmod) due
treatment (r_nmod) symptoms
isoproterenol (r_nsubjpass) injected
raclopride (r_nmod) blocked
reversible (l_nsubj) cin
prepared (r_conj) correlates
was (l_advcl) determined
results (l_conj) antagonized
seen (r_acl) dysfunction
changes (r_nmod) derive
pge1 (r_dobj) starting
clarify (l_dobj) effects
doubled (l_parataxis) remained
creatinine (r_dep) pressure
pge1 (r_appos) e1
ketamine (r_compound) catatonia
stereotypy (r_dobj) potentiates
prazosin (r_nmod) case
dopamine (r_nmod) effect
reminds (r_conj) illustrates
added (r_ccomp) report
risperidone (r_nmod) syndrome
proteinuria (r_nsubjpass) reported
selegiline (r_nsubjpass) associated
induced (l_nsubjpass) proteinuria
grafting (r_acl) marrow
factor (l_dep) thromboembolism
finding (l_ccomp) protect
remained (l_conj) increased
adenocarcinomas (l_appos) pas
fed (r_conj) developed
studies (l_nmod) dysfunction
evidence (l_nmod) prevention
phenobarbitone (r_compound) therapy
acetonide (r_nmod) outcomes
related (r_amod) tiapride
zyban (r_nsubj) caused
52021 (r_nummod) bn
identical (r_ccomp) reported
incidence (l_nmod) diskinesia
shortened (l_dobj) duration
patients (r_nmod) undergone
combination (r_nsubj) induce
of (r_case) handling
role (l_nmod) nephropathy
suggests (r_conj) induce
challenge (r_nmod) severity
tachykinins (r_nmod) involvement
sumatriptan (r_nmod) treated
easy (r_advcl) difficult
doses (r_dobj) receiving
caused (r_acl) fasciculations
citrate (r_compound) anticoagulant
tacrolimus (r_nmod) induced
h (r_compound) concentration
infarction (l_nmod) spasm
methotrexate (l_dobj) toxicity
given (r_acl) tetrachloride
effects (l_amod) cardiotoxic
evaluated (l_conj) effects
ifosfamide-induced (r_amod) hallucinations
isoproterenol-induced (r_amod) tachycardia
effects (l_nmod) impairment
cefonicid (r_conj) dogs
antihuman (l_dep) virus
is (l_nsubj) hepatotoxicity
feasibility (l_conj) toxicity
blockers (r_nmod) advent
% (r_nmod) accounted
endocarditis (l_appos) ie
women (r_nsubj) likely
different (r_amod) corticosteroids
developed (l_dobj) complications
fatal (l_nmod) %
venlafaxine (r_compound) tablets
caused (r_acl) hemolysis
sm-5887 (r_compound) administration
dfmo (r_compound) group
patients (l_nmod) cancer
brains (l_nmod) mice
occurrence (l_nmod) hypertension
diet (r_dobj) consuming
raloxifene (r_nsubj) increase
performed (l_advcl) investigate
exhibiting (r_acl) subjects
cq (r_appos) chloroquine
warfarin-related (r_amod) bleeding
diclofenac (r_conj) rofecoxib
corticosteroids (r_conj) androgens
withdrawal (r_nmod) ameliorated
tolerate (r_conj) prevented
reserpine (r_nsubj) administered
haloperidol-induced (r_amod) catalepsy
results (l_dobj) proliferation
disability (l_conj) dyskinesia
(dox)-induced (r_acl) doxorubicin
vulnerability (r_nsubj) reduced
cause (l_nmod) death
showed (l_ccomp) pronounced
methysergide (r_conj) clonidine
cardiotoxicity (r_conj) nephrotoxicity
treating (l_dobj) ist
study (l_dobj) effects
induced (r_amod) angiogenesis
discuss (l_dobj) role
antinociception (r_nsubjpass) increased
rizatriptan (r_nsubj) superior
exhibit (l_advcl) evaluate
(nmda)-induced (r_conj) acid-
associated (l_nmod) function
methadone (r_nmod) effect
hmm (r_appos) hexamethylmelamine
administration (l_nmod) patient
administration (l_nmod) suspect
ligation (r_conj) concentrations
described (l_nsubjpass) syndrome
analog (r_nmod) effects
study (r_nsubj) revealed
adduct (r_appos) product
release (r_conj) headache
daptomycin (r_nsubj) option
ought (l_advcl) faced
ad50 (l_dep) concentration
isoproterenol-induced (r_amod) damage
followed (l_nmod) asystole
syndrome (l_amod) dystonia-like
require (r_acl:relcl) prophylaxis
la (r_appos) lactate
bisphosphonates (r_conj) caused
dose (r_nmod) response
consuming (l_conj) developed
plays (l_nmod) cascade
lindane (r_nmod) treated
administration (r_nmod) rhabdomyolysis
tam (r_nsubj) induces
increase (r_nmod) occurred
profile (r_nmod) related
verapamil (r_compound) responsiveness
3.49 (l_nsubj) odds
infrequent (r_conj) follow
associated (l_nmod) failure
methylprednisolone (r_nsubj) do
suggesting (l_ccomp) potentiate
attenuated (l_dobj) injury
effective (l_nmod) models
followed (r_acl) chow
marked (r_acl:relcl) hypotension
vcm (r_compound) administration
calcium (r_compound) supplementation
belonging (l_nmod) group
peptide (r_compound) concentration
therapy (r_nmod) withdrawal
resulting (l_nmod) grade
frequencies (l_nsubj) seizure
tolazamide (r_nmod) treated
morbidity (l_nmod) patients
provoke (l_dobj) spasm
understanding (l_nmod) coupling
tna (r_appos) acid
associated (l_nmod) disorder
dilated (l_dobj) cardiomyopathy
prevent (l_dobj) rebleeding
received (r_conj) investigate
demonstrated (l_ccomp) changes
status (r_nmod) association
others (l_nmod) pectoris
risk (l_nmod) stroke
digoxin (l_compound) fibrillation
glucagon (l_nmod) ischemia
parameters (l_amod) seizure
thrombosis (r_nmod) effects
taking (r_acl:relcl) another
showed (l_conj) increased
patients (l_dep) total
nh4ac (r_compound) treatment
women (r_nmod) that
cancer (l_appos) mbc
dph (r_compound) treatment
compounds (r_nmod) exposed
underestimate (l_dobj) incidence
cefonicid (r_nmod) administration
associated (r_acl) hepatitis
gm-induced (r_amod) necrosis
attempt (l_acl) determine
stereotypy (r_appos) results
weeks (r_nmod) developed
common (l_nsubj) proteinuria
changed (l_nsubj) treatments
initiation (r_dep) wk
cancer (l_nmod) granulomatosis
timolol (r_dep) long-term
activation (r_conj) synthase
non-acetaminophen-induced (r_amod) alf
synthesis (l_conj) hypoaidosteronism
umb24 (r_nmod) pretreatment
patients (r_nmod) etiology
induced (r_acl) mania
occurred (l_nmod) subjects
caproate (r_xcomp) related
no-synthase (r_compound) inhibition
rendered (r_acl) mice
nitroprusside (r_conj) hypertension
cross-tolerance (r_dobj) induce
morphine (r_dobj) received
indomethacin (r_nmod) treatment
infusion (r_nmod) treated
induce (l_dobj) myopathy
suffering (l_nmod) dyskinesia
have (l_nmod) nephropathy
tacrolimus (l_acl:relcl) developed
safety (l_nmod) women
deficiency (r_nmod) neuropathy
suppression (l_nmod) motility
score (r_dobj) had
randomized (r_ccomp) found
gold (r_compound) thiosulphate
connected (r_acl) delirium
diphenylhydantoin (r_dobj) taking
dysfunction (r_nmod) associated
hypotensive (r_acomp) became
toxicity (r_nmod) blockade
postulate (l_ccomp) provided
cp-induced (r_amod) cystitis
generation (l_nmod) hypertension
cb (r_nmod) potent
level (r_nsubj) factor
increased (l_nmod) history
cocaine (r_compound) overdose
wt (r_nmod) observed
induce (r_appos) results
effects (r_nsubj) twitches
metoclopramide (r_nmod) caused
morphine (r_nmod) dose
indinavir (r_compound) therapy
extremities (l_conj) paralysis
users (r_nmod) risk
eaca (r_nmod) treated
dogs (l_amod) susceptible
abolished (r_acl:relcl) hypotension
amounts (r_nmod) treatment
thiopentone (r_compound) pretreatment
manage (l_dobj) vasospasm
hydroxychloroquine (r_conj) chloroquine
induction (l_nmod) patients
ischemia (r_nsubjpass) demonstrated
consists (l_advcl) shivering
etomidate (r_nmod) reduces
melphalan (r_conj) paclitaxel
essential (r_conj) precise
observe (l_dobj) features
hydrochloride (r_nmod) bradycardia
quinine- (r_nmod) connected
study (r_dobj) compared
efficacy (r_dobj) maintain
cocaine-and (r_nmod:npmod) amphetamine-induced
incidence (l_appos) tremor
improves (l_dobj) ischemia
use (r_nsubj) decreased
cimetidine (r_compound) levels
promotes (l_dobj) carcinogenesis
given (r_nsubj) increased
characterized (l_nmod) failure
carcinoma (l_nmod) bladder
administration (l_conj) onset
insipidus (l_conj) hypothyroidism
developed (l_dobj) signs
enhancement (l_nmod) hyperthermia
determined (l_nmod) subjects
models (l_amod) ischaemic
appeared (l_nsubj) vt
channel (r_compound) expression
acid (r_conj) infusion
induced (r_acl) exencephaly
mk-801 (r_nmod) actions
venlafaxine (r_nmod) developed
assessed (l_nmod) dyskinesias
reduction (l_nmod) frequency
ability (r_appos) toxicities
agitation (l_conj) rhabdomyolysis
remained (l_xcomp) thirsty
tachycardia (r_conj) 99
hyperactivity (r_dobj) prevented
potential (l_acl) maintain
patient (r_nmod) failure
presented (l_nsubj) woman
acetaminophen (r_nmod) presence
duration (l_conj) latency
target (r_appos) sirolimus
toxicity (r_dobj) manifest
lithium (r_nmod) induced
fentanyl (r_amod) administration
oxide (r_compound) inhibitor
use (r_nmod) days
resulted (l_advcl) produced
maleate (r_nmod) complication
suppressed (l_dobj) decrease
dogs (r_nsubj) received
oxitropium (r_nsubj) proves
carteolol (r_nmod) effects
inhibitor (l_acl) used
antagonized (r_conj) results
steroid (r_compound) therapy
rats (r_nmod) contributes
zdv-induced (r_amod) myelotoxicity
methysergide (r_nmod) ingestion
psychosis (l_nmod) disease
represents (r_ccomp) believe
groups (r_nmod) either
metoclopramide (r_compound) administration
therapy (r_dobj) accompanies
increase (l_nmod) 9
available (l_advcl) banned
inhibitors (r_nmod) associated
pilocarpine (r_nmod) doses
group (l_nmod) liver
lead-induced (r_amod) hypertension
arising (r_acl) disease
levodopa (r_nmod) competing
cessation (r_dobj) mandates
treatments (l_nmod) failure
fentanyl (r_conj) morphine
sedation (r_nmod) persistence
utility (r_conj) dermatitis
underlie (l_dobj) development
fumarate (r_dobj) receiving
toxicities (l_appos) anemia
prior (r_dep) behaviors
verapamil (r_compound) withdrawal
decrease (r_compound) toxicity
each (r_nmod) treated
aminonucleoside-induced (r_conj) pre-existing
hepatitis (r_nmod) episode
efficacy (l_nmod) women
cases (l_nmod) adenomyosis
cpa (r_compound) therapy
treatment (l_nmod) psychosis
treatment (r_nmod) 1
elevations (l_nmod) factor-alpha
causes (l_dobj) deterioration
fluoxetine (r_compound) medication
regarded (l_nmod) cause
hemorrhage (l_conj) dementia
results (l_dep) developed
reduction (l_nmod) pressure
those (r_nmod) whereas
patients (r_nmod) encephalopathy
cephalothin-gentamicin (r_amod) regimen
controls (l_conj) patients
injections (r_conj) therapy
benefit (l_nmod) patients
effects (l_nmod) stage
mg/m(2 (r_dobj) receive
subjects (l_nmod) snhl
normotensive (l_conj) hypertensive
disease (l_appos) history
treatment (r_conj) nicardipine
patients (l_nmod) obstruction
procainamide (r_compound) therapy
desvenlafaxine (r_nsubj) cause
spasm (l_nmod) patient
morphine-induced (r_amod) impairment
developed (l_dobj) pain
cocaine-induced (r_conj) lidocaine-
propranolol (r_conj) atenolol
investigate (r_xcomp) undertaken
healthy (l_dep) women
epilepsies (l_appos) ige
therapy (r_nmod) responses
nitric-oxide (r_amod) synthase
revealed (l_xcomp) moderate
administration (r_nmod) different
rate (r_nsubj) low
resulted (l_nmod) changes
arise (l_nmod) patients
chloroacetaldehyde (r_nsubj) metabolite
decrease (l_nmod) mbp
% (r_nsubj) developed
propranolol (r_nmod) administration
withdrawal (r_nsubjpass) associated
duration (l_nmod) action
property (l_amod) anti-arrhythmic
nicergoline (r_dobj) taking
epidemic (l_nmod) disease
induce (l_dobj) tdp.
levofloxacin (r_conj) warfarin
action (l_nmod) tnss
antagonist (r_appos) risperidone
aldosterone (r_nmod) regulation
profile (l_amod) depressive-like
ammonium (r_compound) levels
selective (l_nmod) system
parallel (l_nmod) hemolysis
echocardiography (r_nsubj) useful
inpatients (r_nmod) %
induces (l_dobj) hypertension
increased (l_dobj) behavior
thp (r_nsubj) exhibited
5-fu (r_compound) treatment
becomes (l_nsubj) agitation
referred (l_nmod) catheterization
patients (l_nmod) pd
man (l_nmod) syndrome
creatinine (r_nmod) concentrations
both (r_nmod:npmod) event
experienced (r_acl) those
disease (l_dep) cld
receptors (r_nmod) inhibition
fluorouracil (r_nmod) associated
alfentanil (r_nmod) followed
headache (l_conj) flushing
fentanyl (r_nmod) discharge
propofol (r_nmod) adding
inhibition (r_dep) increase
e2-induced (r_amod) hyperactivity
cisplatin (r_nmod) associated
woman (l_nmod) pain
detected (l_nsubjpass) calcification
administration (r_nmod) time
tissue (l_amod) post-necrotic
case (l_amod) complete
anastrozole (l_conj) group
cyclosporine (r_nmod) withdrawal
heparin (r_conj) sodium
depends (l_cc) nor
drug (r_nmod) demographics
taking (l_nmod) occlusion
useful (r_amod) test
diabetes (r_nmod) woman
potassium (r_dobj) effect
state (r_nmod) modification
excellent (l_nmod) patients
properties (l_nmod) arrhythmias
administered (l_conj) developed
induced (r_acl) src
improves (l_dobj) deficits
decrease (r_dep) gentamicin-arf
used (l_conj) associated
determine (r_advcl) evaluate
supplementation (r_nmod) effect
use (r_nsubj) disrupts
dose (l_nmod) prophylaxis
treat (l_dobj) patients
women (l_compound) rubella
tested (l_nmod) group
piroxicam (r_dep) non-selective
resulted (l_nmod) ratings
examined (l_nmod) resistance
associated (r_acl) lesions
enhanced (l_dobj) catalepsy
selective (l_nmod) men
gspe (r_nmod) blocked
symptoms (l_appos) eps
iso (r_nsubj) induced
gemfibrozil (r_conj) patients
lidocaine (r_nmod) idiosyncrasy
no (r_nmod) effects
cases (l_nmod) seizures
treated (l_nsubjpass) animals
treatment (r_nmod) arise
receptors (r_nmod) density
naloxone (r_nmod) treated
caffeine (r_compound) administration
effects (l_nmod) mice
evidence (l_nmod) dysfunction
rashes (l_appos) proteinuria
caused (r_acl) patients
magnitude (r_nmod) comparable
dose (r_nmod) lasting
participants (l_nmod) trial
infarction (l_appos) ami
adr (r_compound) adducts
affected (l_nsubjpass) ratings
appeared (l_nsubj) proteinuria
cancer (r_nmod) women
thiols (r_nmod) loss
offers (l_dobj) schedule
glucosuria (l_conj) proteinuria
inoculation (r_nsubjpass) followed
reducing (r_conj) reducing
nimodipine (r_nmod) effect
therapy (l_nmod) colitis
woman (r_nmod) occurred
subjects (l_acl:relcl) become
seems (l_xcomp) displaying
have (l_nsubj) reports
factor (r_advcl) weighed
model (l_acl) used
comparison (r_nmod) resolution
cocaine (r_nmod) metabolite
reduces (l_advcl) increases
association (r_nsubj) was
injection (r_nmod) occlusion
acid (l_nmod) leukemia
consumption (l_conj) depression
i.v. (r_nmod) dose
sodium (r_compound) affinities
neurotensin (r_nmod) infusions
isolated (l_conj) blocks
developed (l_nsubj) ari
facilitation (r_nmod) involved
done (l_nmod) tumors
cardiotoxicity (l_nmod) rats
acetaminophen (r_nmod) pretreatment
verapamil (r_nsubj) enhanced
resulting (l_nmod) angioedema
increased (l_dobj) aggressiveness
growth (r_nsubj) exhibited
exposed (r_acl:relcl) disorders
cytotoxicity (r_nmod) reduction
production (r_dobj) involves
hoarseness (l_conj) candidiasis
fluconazole (r_nmod) initiation
fentanyl (r_nmod) fentanyl
assessed (l_nsubjpass) score
evaluate (l_dobj) symptoms
reproducible (l_nmod) hyperalgesia
enhanced (l_dobj) rigidity
results (l_nmod) studies
act (l_nmod) otoprotectant
methyldopa-induced (r_amod) hepatitis
observed (l_nsubjpass) necrosis
pronounced (l_nsubj) atrophy
vincristine (r_compound) signs
torsade (l_appos) tdp
tacrolimus (r_conj) cyclosporine
hypothesis (l_ccomp) occur
nephropathy (l_appos) cin
nitrazepam (r_nmod) overdose
mice (r_nmod) effects
dose (r_nsubjpass) decreased
proportional (l_nsubj) damage
corrected (l_nsubjpass) hyperactivity
diagnosis (r_dobj) make
nmda (r_compound) receptors
lnna (r_compound) hypertensive
basis (l_nmod) desire
nicotine (r_nmod) response
patient (r_nsubjpass) presented
use (l_conj) incidence
azt-induced (r_amod) toxicity
receptors (r_nmod) group
adriamycin (r_nmod) caused
sumatriptan (r_nmod) infarction
possibility (l_nmod) movements
ppa (r_appos) phenylpropanolamine
glioma (l_conj) metastases
administration (r_nmod) rendered
(stz)-induced (r_amod) impairment
prevalences (l_nmod) dysfunction
users (r_nmod) ratio
dogs (r_nmod) injection
clarithromycin-associated (r_amod) hallucinations
macrolide (r_compound) rapamycin
ketanserin (r_dobj) received
disorder (l_conj) agoraphobia
followed (l_nmod) cholestasis
gain (l_conj) damage
therapy (r_dobj) undergoing
show (l_dobj) symptoms
failed (l_xcomp) modulate
produce (l_dobj) pain
groups (l_conj) diabetes
abbott-53693 (r_conj) cirazoline
steroid (r_compound) treatment
given (r_ccomp) described
use (r_nsubjpass) avoided
chloride (r_nmod) analyzed
organophosphorus-induced (r_amod) neuropathy
deferoxamine (l_nmod) neurotoxicity
provocation (l_nmod) neuropathy
available (l_nsubj) patients
controls (l_dobj) angina
dog (r_nmod) potentiated
potencies (r_nmod) effects
caused (l_nmod) cddp
observed (l_nsubjpass) regression
warfarin-induced (r_amod) embryopathy
acid (r_appos) cb
signs (r_nsubj) consciousness
produced (l_dobj) block
prazosin (r_nmod) treated
present (l_dobj) patients
suffering (l_nmod) erythematosus
tacrolimus (r_nmod) introduction
block (l_conj) hypotension
n-(2-hydroxypropyl)methacrylamide (r_compound) conjugates
compromising (l_nsubj) anemia
prevention (l_nmod) infarctions
schedule (l_nmod) children
methotrexate (r_compound) doses
evaluated (l_nsubjpass) a
lidocaine (r_nmod) trial
isoproterenol-induced (r_amod) ischemia
doxorubicin-induced (r_amod) lesions
increases (l_dobj) formation
systolic (l_conj) pressures
delirium (l_amod) hyperkinetic
rats (l_nsubj) dm
disorder (l_appos) adhd
pj34 (r_nmod) treatment
rate (l_acl) resulting
etoposide (r_dep) drugs
verapamil (l_nmod) patients
succinylcholine-induced (r_amod) fasciculation
occurred (l_nsubj) enlargement
gaba(a (r_compound) ligands
transient (r_amod) rise
metabolites (r_conj) lindane
suppressed (l_dobj) arrhythmias
cardiac (l_acl) associated
pharmacotherapy (r_nmod) development
gaba (r_dobj) involves
administration (r_nmod) presented
sulfadiazine (r_nmod) treatment
torsades (r_nmod) factors
overexpression (r_nmod) protection
iso (r_nmod) response
common (l_conj) presented
administration (r_nsubjpass) discontinued
dysmorphism (l_conj) disorder
dysfunction (r_nsubj) defect
correlation (l_nmod) reduction
types (r_nmod) using
torsades (r_compound) pointes
resulted (l_nmod) death
vincristine (r_nmod) infusion
hypothesis (r_dobj) validate
studied (l_nmod) prevention
ng (r_appos) nitrogranulogen
ns-nsaids (r_appos) inhibitors
found (l_nsubjpass) areas
presented (l_nmod) symptoms
lower (l_nsubj) scores
phlorizin (r_nmod) reabsorption
resulted (l_nmod) duration
betaine (r_amod) pretreatment
older (l_nsubj) patients
fan (r_conj) tet
treatment (l_nmod) tinnitus
administration (r_nmod) decreased
levodopa-induced (r_amod) dyskinesias
captopril (r_nmod) prevented
cyclosporine (r_nmod) dosages
o2- (r_amod) production
reports (l_nmod) cases
correlates (l_nmod) timing
yohimbine (r_nsubj) reduced
areas (r_dobj) paralleling
hematoxylin (r_nmod) analyzed
tachykinins (r_nmod) release
reduced (l_nsubjpass) incidence
infusion (r_nsubj) causes
effects (r_nmod) information
ketoconazole (r_nsubj) induced
showed (r_ccomp) cows
phosphorus (r_nmod) poisoning
glioma (l_conj) meningioma
zonisamide (r_nsubj) drug
incidence (r_dobj) comparing
risks (r_nmod) concerns
synthesis (r_nmod) inhibition
docetaxel (r_dobj) received
patients (r_nmod) demonstrated
sulfasalazine (r_nmod) associated
developed (r_acl:relcl) gammapathy
derivatives (r_nmod) cross-reacting
halothane (r_compound) hepatitis
stereotypy (r_dobj) enhanced
mmc (r_appos) c
cisapride (r_nsubj) affects
illustrating (l_dobj) generation
dhea (r_nsubj) reduced
cases (l_nmod) nystagmus
nsaid-induced (r_amod) angioedema
combination (r_nmod) tested
caffeine (l_nmod) men
induce (l_dobj) hypotension
administration (r_nsubjpass) advocated
prochlorperazine (r_nmod) treated
seizures (r_dobj) block
glutamate (r_compound) receptors
caused (l_dobj) arrhythmias
pressure (l_nmod) fasciculations
pattern (l_compound) block
model (l_appos) agent
reduces (l_dobj) damage
manifestation (r_nmod) hypotension
rate (l_acl) administered
induced (l_dobj) torsades
score (l_compound) necrosis
agitation (l_conj) hyperthermia
using (l_dobj) center
reported (l_nmod) syndrome
detection (l_nmod) activity
showed (l_dobj) reduction
reversal (r_dep) active
convert (l_dobj) fibrillation
aim (l_advcl) improving
cross-sensitization (r_dobj) causes
administration (r_nmod) presenting
didanosine (r_nmod) returned
l-sotalol (r_conj) tolerate
effects (r_dobj) have
excretion (l_conj) glomerulosclerosis
produced (l_dobj) reduction
comparison (r_nmod) result
association (l_nmod) depression
prompted (r_conj) developed
receiving (r_advcl) seizure
dexamethasone (r_nmod) days
caffeine (r_compound) doses
reported (l_dep) diarrhea
induced (r_acl) disorder
phenylpropanolamine-induced (r_amod) hypertension
studied (l_nmod) rats
aconitine (r_nmod) induced
stones (r_conj) duct
switched (r_acl:relcl) patients
complicating (l_nmod) patient
prevent (l_dobj) isoproterenol
doses (r_nsubj) reduced
bcnu (r_compound) administration
children (l_nmod) refractory
amount (l_nmod) disability
fbal (r_appos) level
prevents (l_dobj) action
alter (l_parataxis) demonstrate
protection (l_acl:relcl) offers
dysfunction (r_nmod) characterized
contraceptives (r_nmod) women
diazepam (r_nmod) greater
induced (l_nsubjpass) cardiomyopathy
piroxicam (r_nmod) interaction
discharge (r_advcl) reduce
predictive (l_nmod) development
treated (r_acl) subjects
crocins (l_nmod) disease
neuralgia (l_appos) phn
use (l_dobj) rupture
values (l_compound) depression
emission (r_compound) tomography
heroin (r_nmod) presented
rates (r_dobj) using
ethambutol (r_nsubjpass) known
ne (r_appos) benzylthiouracil
safety (l_nmod) populations
production (r_nsubjpass) implicated
pancreatitis (l_conj) hepatotoxicity
pgs (r_nsubjpass) involved
high (l_dep) patients
characterized (l_nmod) increases
pilocarpine- (l_dep) seizures
enhancement (r_nmod) differences
captopril-treated (r_amod) rats
specific (l_nsubj) effect
nmda (r_nmod:npmod) receptor-associated
represents (l_dobj) drug
associated (r_acl) thrombocytopenia
lidocaine (r_nsubj) reduce
verapamil (r_nsubj) unresponsiveness
paclitaxel (r_nmod) neurotoxicity
cisplatin (r_nmod:npmod) induced
vision (l_conj) fatiguability
gain (l_conj) pressure
objectives (l_acl) correlate
combination (r_nmod) receive
paroxetine (r_nmod) interaction
lamivudine (r_compound) group
designed (l_conj) investigate
women (r_nmod) thromboembolism
simvastatin (r_amod) exposure
droperidol (r_nmod) case
fs (r_nsubj) evoked
treatment (r_nmod) incidence
nik-247 (r_nsubj) improves
meningioma (l_conj) metastases
lead (l_nmod) impairments
analyzed (l_nmod) hyperemia
injury (l_compound) ischemia-reperfusion
increased (l_nmod) reversal
creatinine (r_conj) age
pilocarpine (r_nmod) induced
inhibited (l_conj) induce
rats (l_amod) hypertensive
activity (r_conj) expression
potentiated (l_nmod) dog
trials (r_nsubj) indicate
clonazepam (r_nmod) fluid
patient (l_nmod) sah
combination (r_conj) hypertension
complications (l_amod) thrombotic
licl (r_nmod) treated
spv (l_nmod) hypotension
bupivacaine (r_compound) ad50
indicated (r_parataxis) remained
properties (r_conj) scavenging
patients (l_nmod) psoriasis
risk (l_nsubj) patients
evaluation (l_nmod) sediment
metamizol (r_dep) evaluates
patients (l_nmod) leprosy
patients (l_nmod) granulomatosis
treated (r_acl) layer
creatinine (r_compound) concentrations
therapy (l_nmod) seizures
vasculitis (l_acl) fulfilling
decreased (l_dobj) tachycardia
prevented (l_nsubjpass) induction
norpethidine (r_appos) metabolite
ca(2 (r_pobj) of
ribavirin (r_nmod) effect
hypokalemia (l_conj) hypomagnesemia
problem (l_nsubj) ototoxicity
cardiorespiratory (r_amod) arrest
exception (l_nmod) cases
frequency (l_nmod) treatment
ciprofloxacin (r_nmod) administration
pilocarpine-induced (r_amod) electrographic
phenylpropanolamine (r_nsubj) drug
acids (r_nmod) any
etoricoxib (r_nmod) higher
lend (l_nmod) patients
nausea (l_conj) vomiting
(att)-associated (l_dobj) failure
glomerulonephritis (l_appos) rpgn
alanine (r_compound) aminotransferase
animals (r_nsubj) flaccid
patients (r_nmod) therapy
background (r_nsubj) produces
had (l_dobj) disease
host (l_nmod) disorders
terbinafine (r_nsubj) decreased
studies (r_nmod) reported
diagnosis (r_nmod) relationship
warfarin (r_nmod) doses
isoniazid (r_nmod) injections
pyridoxine-dependent (r_amod) disorder
considered (l_nsubjpass) complication
5-hydroxytryptophan (r_amod) head
cb (r_nmod) studies
dopamine (r_compound) precursor
amiodarone (r_nsubj) agent
times (r_nmod:tmod) receive
caused (r_acl) myocarditis
mellitus (l_conj) disease
induced (r_acl) hepatomas
glycopyrrolate (r_nmod) comparison
dyskinesia (r_nmod) movement
alprazolam (r_compound) treatment
warfarin-associated (r_amod) ich
tiapride (r_conj) mg
complications (l_nmod) polymyositis/dermatomyositis
mirtazapine (r_nmod) use
disease (r_nmod) woman
lowered (l_dobj) threshold
clozapine (r_compound) treatment
other (l_conj) alopecia
describe (l_dobj) case
surgery (l_nmod) aneurysms
treatment (r_nsubj) ameliorates
alter (r_conj) modify
tend (l_nsubj) those
reserpine (r_nmod:npmod) induced
trial (r_nmod) report
avoiding (l_dobj) occurrence
combination (r_nmod) safety
shown (r_acl:relcl) patient
mg (r_nsubj) treatment
smoking (r_nsubjpass) found
associated (l_nmod) hiccups
olanzapine (r_nmod) induced
lidocaine (r_nmod) safety
restarted (l_conj) exception
dilevalol (r_nmod) reactivity
level (r_nmod) occurs
reported (l_nsubjpass) myasthenia
den (r_appos) diethylnitrosamine
chemotherapy (r_nmod) side-effect
shown (r_advcl) help
bau (r_appos) benzylacyclouridine
identify (r_xcomp) used
observed (r_dep) revealed
information (l_nmod) effects
amiodarone-related (r_amod) lesion
revealed (l_dobj) consciousness
played (l_nsubj) infection
morphine (r_compound) group
anesthesia (r_dobj) maintaining
snp (r_conj) halothane
proved (l_xcomp) effective
omeprazole (r_conj) blockers
activity (l_nmod) beta-blockers
status (r_nsubj) influences
reproduces (l_dobj) sequelae
ciprofloxacin (r_nsubjpass) associated
creatinine (r_nmod) increase
describe (l_conj) died
reduction (l_nmod) myalgia
treated (l_nmod) order
treated (l_nsubjpass) pointes
events (r_nmod) risk
initiation (l_conj) development
facilitated (l_dobj) propagation
fmlp (r_appos) formyl-methionyl-leucyl-phenylalanine
absence (l_dep) seizures
albumin/creatinine (r_compound) ratio
consequences (l_nmod) lesions
increases (l_dobj) hyperactivity
remifentanil (r_conj) propofol
used (l_xcomp) arrest
csa (r_compound) exposure
speed (r_nmod) influence
elevation (l_conj) loss
prophylaxis (r_nsubjpass) used
examined (l_dobj) relationship
patients (l_amod) ax-allergic
associated (r_acl) brain
k(atp (r_amod) channels
patients (r_nsubjpass) interviewed
dose (l_acl) considering
site (r_nmod) affinity
injection (r_dobj) receive
cause (l_dobj) disruption
inhibition (r_nsubj) replicate
investigated (l_advcl) antagonizing
treatment (r_nmod) had
azelastine (r_nsubjpass) compared
impairment (l_acl) induced
protected (l_dobj) damage
used (l_nsubjpass) types
decrease (l_nmod) density
levels (r_nmod) change
b (r_compound) therapy
aspirin (r_nmod) treatment
lipid (l_conj) toxicity
microg (r_nsubj) able
cardiomyopathy (l_nmod) children
studied (l_nsubjpass) development
effect (l_conj) mydriasis
effect (l_nmod) occurrence
inhibitor (r_nmod) application
fluid (l_nmod) children
elevated (l_nmod) hypertension
occurring (r_acl) hallucinations
carbachol (r_nmod) evoked
appeared (l_nsubj) ototoxicity
took (l_advcl) had
presented (l_nmod) trigger
caused (r_acl) neuropathy
develop (l_dobj) nephrotoxicity
drugs (r_nsubj) cause
injection (r_nmod) blocked
mg. (r_nmod) doses
dependence (r_nmod) cases
patients (l_nmod) diabetes
diagnosis (r_nmod) value
expression (l_conj) pain
loss (l_conj) ataxia
disturbances (l_conj) parasomnias
induced (r_acl) tremor
thalidomide (r_nmod) toxicity
antagonist (r_nmod) injection
died (l_nmod) failure
amiodarone (r_nsubjpass) administered
glycosuria (r_nsubj) prevent
saline (r_nmod) infusion
progression (r_nmod) rate
behavior (l_amod) mania-like
infarction (l_conj) ischemia
option (l_nmod) bacteremia
dosulepine (r_conj) paroxetine
cm (r_nmod) effect
those (l_nmod) non-a
rls (r_nmod) effect
fed (l_conj) developed
potential (r_nmod) administration
ingestion (r_nsubj) phenomenon
remain (r_conj) indicated
response (r_nmod) hypotension
pretreatment (r_nsubj) reduces
lipoproteins (r_nmod) alterations
overstimulation (r_nmod) caused
produced (l_parataxis) unclear
presence (l_nmod) lid
manner (r_nmod) inhibited
periods (r_nsubj) increased
patent (l_compound) aids
benzodiazepine (r_compound) antagonist
presentation (l_nmod) complications
withdrawing (r_advcl) produced
ribavirin (r_nmod) treated
exposure (r_nsubj) aggravated
methods (r_conj) stages
impairment (r_nmod) events
amlodipine (r_nmod) side-effect
folate (r_nmod) intakes
n-methyl-d-aspartate (r_compound) receptors
cocaine-diazepam (r_amod) intoxications
test (r_nmod) administered
movements (l_amod) choreoathetoid
caused (l_advcl) increasing
associated (l_nmod) evidence
cimetidine (r_nmod) infusions
herbicides (l_conj) retardation
established (r_advcl) suggest
accident (l_conj) trauma
trimetaphan (r_amod) hypotension
biomarker (r_xcomp) seems
syndrome (l_appos) pcos
jj (r_nmod) damage
oxide-redox (r_compound) imbalance
da (r_compound) deficits
replacement (r_nsubj) increased
preceded (l_xcomp) excluding
window (r_nsubj) apply
increased (l_dobj) duration
pain (l_acl) induced
unaffected (l_nsubjpass) hypotension
fighting (l_nmod) phenomena
reduce (l_dobj) risk
penicillins (r_dobj) receiving
cyclophosphamide (r_conj) azathioprine
suggest (l_ccomp) underlie
neurotransmitters (r_nmod) acting
treatment (r_nmod) cessation
increased (l_dobj) sequestration
previous (r_amod) microinjection
patients (l_nmod) mellitus
esters (r_conj) phospholipid
was (l_attr) case
acetaminophen (r_conj) ns-nsaids
excess (l_nmod) users
controls (l_conj) microprolactinoma
inhibitor (r_appos) ng-nitro-l-arginine
ethambutol (r_compound) treatment
reversal (l_nmod) oih
granisetron (r_nmod) dose
apap-induced (r_amod) nephrotoxicity
developed (l_advcl) increasing
morphine (r_conj) cnsb002
types (l_nmod) hyperalgesia
development (l_nmod) fibrosis
implants (r_nmod) treated
hyperactivity (r_nmod) secondary
administration (r_nmod) persisted
temocapril (r_nsubj) attenuate
morphine (r_nmod) unrelieved
difficulty (l_advcl) distinguishing
higher (l_nsubj) risk
used (l_conj) indicate
related (r_amod) stroke
antituberculosis (r_compound) failure
overdose (r_nmod) survived
pge1 (r_nmod) degree
performed (l_nmod) part
pentamidine-induced (r_amod) torsade
dose (r_nmod) similar
estimate (l_conj) compare
standard (l_nmod) comparison
patient (r_nmod) aplasia
ndi (r_nmod) preserves
treated (l_nmod) cancer
etoricoxib (r_nmod) results
found (l_xcomp) potent
had (l_dobj) gain
associated (r_ccomp) hypothesize
syndromes (r_nmod) patients
mbp (l_conj) hr
associated (r_acl) toxicity
presented (l_dobj) signs
receiving (r_advcl) had
methyldopa (r_nmod) treated
provocation (l_nmod) hypotension
cystitis (l_dep) approach
argatroban (r_amod) thrombolysis
ecg (l_nmod) patients
reverse (l_dobj) effect
treated (r_advcl) had
implicated (l_conj) changed
bid (r_nmod) %
mangiferin (l_acl) given
expressions (r_nmod) examined
change (r_attr) was
displayed (l_dobj) resistance
studies (r_dep) unassigned
background (l_dep) was
prevented (l_dobj) rigidity
omeprazole (r_nmod) mechanism
effects (l_nmod) dysrhythmias
thrombocytopenia (r_dobj) developed
context (r_nmod) occurred
hematotoxicity (l_amod) similar
therapy (r_nmod) drug
associated (l_conj) associated
imipenem (r_compound) therapy
included (l_nsubjpass) patients
patients (l_compound) ibs
viracept (r_nsubj) cause
cocaine-abusing (r_amod) patients
testosterone (r_nmod) effects
revealed (l_dobj) features
vomiting (l_conj) stomatitis
l-dopa (r_conj) selegiline
amn082 (r_appos) dihydrochloride
withdrawal (l_nmod) cause
caa (r_nmod) toxicity
defect (l_nmod) alf
cisplatinum (r_dobj) incorporating
lamivudine (r_nmod) augmented
mediates (l_dobj) toxicity
recognition (l_nmod) importance
mz (r_nmod) doses
correlation (l_nmod) hemorrhage
aldosterone (r_compound) concentration
q10 (r_nsubj) represents
amiodarone (r_amod) toxicity
rats (r_nmod) exposure
assess (l_dobj) use
contribute (l_nmod) efficiency
abusers (r_nmod) common
enhanced (l_dobj) analgesia-
procainamide (r_nsubj) produce
cortisol (r_conj) 3-methoxy-4-hydroxyphenethyleneglycol
proteinuria (l_conj) hypoalbuminemia
magnitude (l_nmod) modulation
tumor (r_nmod) separation
restarting (r_acl) glomerulonephritis
no (r_nmod) interactions
therapy (l_nmod) myeloma
procainamide (r_nsubjpass) administered
injury (l_amod) related
erections (r_conj) behavior
anaphylaxis (r_nmod) case
hypothesis (l_ccomp) plays
differ (r_conj) have
shown (l_xcomp) protect
model (l_nmod) hematotoxicity
potentiate (l_nsubj) dysrhythmias
taking (r_acl:relcl) woman
prevent (l_dobj) cystitis
mimic (r_acl:relcl) neuropathy
associated (l_nmod) incidence
allodynia (r_conj) hyperalgesia
cause (l_dobj) prolongation
determined (l_xcomp) using
pan (r_compound) animals
providing (l_dobj) efficacy
curves (l_amod) characteristic
change (l_nsubj) excretion
significant (r_conj) significant
encephalopathy (r_nmod) development
n-methyl-d-aspartate (r_compound) antagonist
developed (l_nsubj) child
associated (l_dobj) agranulocytosis
disappeared (l_nsubj) mj
targets (l_nmod) injury
adjunct (l_nmod) treatment
associated (l_nsubjpass) infarctions
unknown (l_nsubj) mechanism
report (l_nmod) anemia
effects (l_nmod) cholinesterase
treatment (l_nmod) hyperthyroidism
value (r_dobj) investigated
age (l_conj) aneurysms
inducing (l_dobj) ischemia
tet (r_conj) tests
subset (l_nmod) patients
helodermin (r_nsubj) produced
indistinguishable (l_nmod) carcinoma
5-fu (r_nmod) cause
heparin (r_nmod) effect
azithromycin (r_compound) therapy
tamoxifen (l_nmod) cancer
model (r_ccomp) indicate
acid (r_nsubj) reduce
quetiapine (l_nmod) patients
increase (l_dobj) excitability
combination (l_nmod) radiotherapy
assigned (l_nsubjpass) method
meth (r_nmod) dosage
succinylcholine (r_nmod) associated
telithromycin (r_dobj) prescribed
amisulpride (r_dep) of
content (r_conj) gain
increasing (r_advcl) less
sevoflurane-sparing (r_amod) effect
evoked (r_acl) sphincter
needle (r_nmod) time
encephalopathy (l_amod) immunization-induced
prevent (l_dobj) dysfunction
clarify (l_dobj) mechanisms
induced (l_dobj) catalepsy
animals (r_nmod) observed
caused (l_nsubjpass) death
compared (l_nmod) benztropine
gaba (r_compound) involvement
prevented (l_dobj) development
patients (l_amod) hypertensive
appears (l_xcomp) medication
man (l_nmod) lymphoma
patients (r_nmod) seen
% (r_conj) %
inhibitor (r_compound) intolerance
lamivudine (r_nsubjpass) added
owing (l_nmod) damage
doses (r_nmod) defined
associated (r_acl) syndrome
therapy (r_nmod) report
improving (r_advcl) attenuated
overload (r_nmod) relationship
is (l_nsubj) association
hcfcs (r_nmod) exposure
addition (r_nmod) treated
route (r_dobj) follow
lovastatin (r_nsubjpass) associated
recorded (r_dep) results
hydromorphone (r_dep) administration
plays (l_nmod) initiation
briefly (r_nsubj) reversed
meth (r_nmod) caused
38393 (r_nummod) skf
shown (l_dobj) hypokalaemia
cystitis (l_amod) haemorrhagic
transaminase (l_conj) elevations
variety (l_nmod) hepatocarcinogens
i (r_nsubj) course
using (r_xcomp) measured
fibrillation (l_conj) flutter
ap7 (r_conj) mk-801
placebo (r_compound) groups
dose (r_nsubj) contribute
detection (l_nmod) toxicity
events (r_nsubj) included
treatment (r_nmod) recurrence
op-induced (r_amod) signs
suggests (l_ccomp) associated
starting (r_dep) months
responsible (l_nmod) damage
hexamethylmelamine (r_conj) treated
patients (r_nmod) using
pilocarpine-induced (r_nmod) rats
inhibitors (r_nmod) secondary
asenapine (r_nmod) efficacy
doxorubicin (r_compound) dosage
hg (r_nsubjpass) induced
abnormalities (l_nmod) systems
adenosine (r_nmod) treated
induced (r_acl) net
decreased (l_nsubj) incidence
chloramphenicol (r_nmod) therapy
10 (l_nmod) cases
clonidine-associated (r_amod) arrest
users (r_nmod) deficits
bortezomib (r_nmod) regimen
rise (r_nmod) angiographies
lamivudine-resistant (r_amod) strains
ketoconazole (r_compound) treatment
blocking (l_dobj) hc
development (l_nmod) adenocarcinoma
reverses (l_dobj) paralysis
derangements (l_nmod) function
scale (l_compound) probability
remoxipride-induced (r_amod) anemia
prednisone (r_conj) diphenhydramine
chemotherapy (r_nmod) loss
gentamicin (r_conj) ampicillin
sotalol (r_appos) agent
activity (l_nmod) leukemia
disease (l_conj) lid
preferring (r_acl) patients
addition (r_nmod) observed
prescribed (l_nmod) treatment
actions (r_nsubjpass) enhanced
syndrome (l_conj) leukemia
performed (l_dep) presence
lomustine (r_nmod) protocol
rizatriptan (r_nmod) favor
methamphetamine (r_nsubj) triggers
val/hctz (r_compound) 160/12.5
inhibitor (r_nmod) target
rejection (l_conj) nephropathy
aldosterone (r_compound) antagonist
lindane (r_amod) neurotoxicity
associated (l_nmod) gain
produced (l_dobj) increases
started (l_xcomp) attempt
effect (l_nmod) dysfunction
development (l_nmod) treatments
lower (l_nsubj) dosage
report (l_nsubj) patients
wr242511 (r_nmod) postinjection
pathogenesis (r_nsubj) reaction
injection (r_nmod) failure
ibuprofen (r_nmod) arteriosus
have (l_dobj) anomalies
company (r_appos) paclitaxel
bupivacaine (r_nsubj) antagonizes
pancreatitis (l_conj) encephalopathy
affect (l_dobj) mortality
cyclophosphamide (l_conj) risk
quantified (l_nsubjpass) injuries
nephrotoxicity (l_conj) neuropathy
efficacious (l_advcl) alleviating
syndrome (l_appos) mds
strategies (l_acl:relcl) prevent
bupropion (r_conj) deprivation
patients (r_nmod) occurring
led (l_csubj) changing
reduced (r_conj) increased
assess (l_dobj) presence
hyperactivity (r_nmod) reduction
quintiles (r_nmod) intakes
extent (r_conj) toxicity
hemosiderosis (l_acl) resulting
severe (r_xcomp) appeared
effect (l_nmod) nephrotoxicity
capsaicin (r_nmod) amount
therapy (l_nmod) glioma
induction (l_compound) adenomyosis
induced (r_acl) morphine
genes (l_amod) seizure
bepridil (r_amod) administration
isoniazid (r_compound) therapy
started (l_nsubjpass) man
cocaine (r_compound) pain
delay (r_dobj) caused
effect (r_nmod) report
gfc (r_nsubj) produced
anthracycline-induced (r_amod) cardiotoxicity
arabinoside (r_nsubj) therapy
itching (r_conj) had
trial (r_appos) 12-week
iron (r_compound) capacity
decrease (l_nsubj) hypotension
aminoglycoside-induced (r_amod) loss
identifying (l_dep) relationship
toxicity (r_dobj) enhance
related (r_amod) concentration
forms (l_nmod) epilepticus
have (l_dobj) symptoms
charcoal (r_compound) meal
intoxication (r_nmod) unmask
eighteen (r_nsubj) died
midazolam (r_nmod) administration
have (l_dobj) reduction
carcinoma (l_appos) nsclc
concentrations (r_dobj) maintain
akathisia (r_nmod) pathophysiology
case (r_nmod) caused
failure (r_conj) acidosis
woman (l_nmod) cancer
animals (r_nsubj) show
prednisolone (r_conj) tacrolimus
hours (r_nmod:tmod) had
cardiovascular (l_conj) toxicity
methicillin-sensitive (r_amod) bacteremia
therapy (r_nmod) initiation
damage (l_compound) dxr-cm
bendrofluazide (l_nmod) treatment
tacrolimus (r_dobj) receiving
injection (r_nmod) effect
1,3-bis-(2-chloroethyl)-1-nitrosourea (r_appos) bcnu
rats (l_conj) calcification
absence (l_nmod) history
patients (l_nmod) arrhythmias
contraception (r_nmod) had
produced (r_acl) ischemia
associated (l_nmod) cancer
capsaicin (r_compound) injection
conversion (r_nmod) proteinuria
protease (r_compound) inhibition
found (l_dobj) case
associated (r_acl) dysfunction
dyskinesia (r_conj) reserpine-
angiotensin (r_compound) enzyme
human (r_amod) cardiomyopathy
inhibitor (r_appos) amide
nifedipine (r_conj) blocker
liquid (r_compound) phases
increased (l_conj) developed
addition (l_nmod) myopathy
developed (l_dobj) disease
had (l_dobj) hematuria
pathogenesis (l_nmod) hiccups
headache (l_conj) vomiting
dna (l_compound) b
development (l_nmod) ulcers
amikacin (r_nmod) treated
n-acetylcysteine (r_nmod) use
transit (r_dobj) inhibited
dosed (r_conj) appear
subjects (l_nmod) schizophrenia
decreases (r_conj) alleviated
seen (l_nsubjpass) patients
two (l_nmod) nephrolithiasis
seizures (r_conj) bradydysrhythmias
bradykinin (r_compound) receptors
carbamazepine (r_acl) hypersensitivity
activity (r_nsubjpass) tested
potential (l_conj) effect
disease (l_amod) hypertensive
reduction (l_nmod) flow
reaction (r_nmod) case
response (l_nmod) stimulation
isoproterenol (r_nmod) effect
lidocaine (l_nmod) phase
implicated (l_advmod) nephropathy
investigate (r_xcomp) aimed
maintained (l_dobj) status
had (l_advcl) seizure
warfarin-drug (r_amod) interaction
terminate (l_dobj) epilepticus
evaluate (l_punct) ,
concentrations (r_nmod) patient
b (r_compound) administration
methotrexate (r_amod) contaminants
screening (l_nmod) b
mice (r_nmod) thresholds
phenobarbital (r_amod) mg
confirm (l_ccomp) decrease
had (l_dobj) treatment
haloperidol (r_dobj) using
reducing (l_dobj) myelotoxicity
lt (r_nmod) diagnosis
sensitivity (l_acl) associated
species (r_nmod) scavenger
prevention (l_nmod) syndrome
susceptibility (l_nmod) calcification
milrinone (r_nmod) effect
diluent (r_nmod) concentration
excellent (l_dep) sweating
doses (r_nmod) hypotension
suggesting (l_dobj) influence
is (l_attr) agent
produced (l_dobj) hypotension
apomorphine (r_nsubjpass) used
caused (r_acl) report
steroids (l_nmod) disease
somnolence (l_conj) difficulties
intoxication (r_nmod) those
ccnu (r_nmod) dose
animals (l_nmod) seizures
combined (l_nmod) support
pain (l_compound) cancer
disease (l_conj) cardiomyopathy
warfarin (r_conj) d
necessary (l_xcomp) convert
multivitamin (r_compound) supplementation
pac-induced (r_amod) neuropathy
lesion (r_nmod) circled
effect (l_amod) anti-tachycardial
greater (l_nmod) group
efficacy (l_nmod) patients
irritation (l_nmod) tract
mechanism (l_nmod) injury
acid (r_compound) clearances
reported (l_parataxis) associated
line (r_nmod) increases
effects (r_nsubj) dependent
had (l_dobj) evidence
had (r_conj) greater
time (l_acl:relcl) developed
showed (l_advcl) remains
woman (r_dobj) report
, (l_dep) patients
decreased (l_dobj) prevalence
tam (r_nmod) caused
diazepam (r_nsubj) acts
decarboxylase (r_appos) isoniazid
catecholamine (r_compound) release
salt (r_compound) synthesis
administration (r_nmod) seizure
administered (l_nmod) adjunct
cisapride (r_dep) treatment
prevent (r_ccomp) indicate
shock (l_conj) syndrome
days (l_compound) tdp
prior (r_advmod) pretreatment
beginning (l_nmod) treatment
enzyme (r_compound) inhibitor
yohimbine (r_nsubj) facilitates
cyclophosphamide-induced (r_amod) cystitis
serve (r_ccomp) has
pursued (l_advcl) dissociated
predilection (l_nmod) thrombosis
lamivudine (r_dobj) receiving
altering (r_advcl) causes
suxamethonium (r_nmod) caused
abuse (l_dep) case
neurotransmission (r_nmod) interfere
task (r_nmod) retention-
score (r_dep) score
residues (r_nsubjpass) required
risk (l_nmod) toxicity
use (l_nmod) toxoplasmosis
cis-ra (r_nmod) pharmacokinetics
flumazenil (r_nsubj) unmask
defects (r_nmod) history
s-312 (r_nsubj) showed
improved (r_advcl) impair
dopamine (r_compound) release
gspe (r_appos) extract
galactose (r_amod) deterioration
advantages (l_nmod) patients
time (r_appos) smoking
appear (l_xcomp) add
effects (r_dobj) reported
paclitaxel (l_conj) chemotherapy
presence (l_nmod) mellitus
continued (l_parataxis) indicates
verapamil (r_compound) test
acid-induced (r_amod) nodosum
h2o2 (r_dobj) reduced
infection (l_nmod) virus
prompted (l_ccomp) known
ketoconazole (r_dobj) taking
paclitaxel (r_conj) epirubicin
capacity (l_conj) selected
diagnosis (r_nsubj) difficult
ifosfamide (r_compound) protocol
radiotherapy (r_nmod) combination
developed (r_acl:relcl) case
creatine (r_compound) kinase
evidenced (l_nmod) intensity
stress (l_conj) hypertension
emphasizes (l_dobj) need
receiving (r_acl) users
dothiepin (r_nsubjpass) found
glaucoma (l_conj) hypertension
prazosin (r_dobj) taking
reversed (l_nsubjpass) tachycardia
randomized (l_dep) decrease
timolol-induced (r_amod) bradycardia
occurrence (l_nmod) syndrome
cases (l_nmod) occlusions
frequent (l_advcl) recognized
melphalan (l_nmod) patients
cows (r_nmod) toxicity
associated (l_nsubjpass) action
resulting (r_acl) patients
studied (l_advcl) elucidate
induction (l_nmod) attacks
dose (r_nmod) time
studied (l_advcl) measuring
initiated (l_dobj) episodes
admitted (l_nmod) mi
comparison (r_dep) use
pointes (l_dobj) tachycardia
nmda (r_compound) n-methyl-d-aspartate
induced (r_acl) dysfunction
appear (l_xcomp) enhance
modulation (r_conj) nephrotoxicity
patients (l_nmod) relapsed
administration (r_nsubj) elicited
suggested (l_ccomp) reduced
induce (l_dobj) malformations
inhibitor (l_nmod) hypertension
(zdv)-induced (r_amod) suppression
aminoglycoside-associated (r_amod) ototoxicity
ketoconazole (r_nmod) treatment
macrolides (r_nmod) reaction
intake (r_nmod) vasculitis
reduces (l_dobj) dysfunction
cocaine (r_nmod:npmod) related
decreased (r_conj) resolved
study (l_conj) supplementation
patients (l_nmod) mm
memory (l_acl) impaired
persistence (l_nmod) bradycardia
sodium (r_compound) channel
dyskinesia (l_nmod) patients
contraceptive (r_nmod) type
associated (l_nmod) neutropenia
ee (r_appos) estradiol
(adriamycin)-loaded (r_case) nanoparticles
observed (l_nmod) correction
patients (l_nmod) gallstones
digoxin (r_conj) hypokalemia
increases (l_nmod) pressure
oxide (r_nmod) role
attributable (l_nsubj) hypotension
injection (r_nmod) days
include (l_dobj) anemia
diuresis (l_conj) glycosuria
peptide (r_nmod) increase
control (l_xcomp) bleeding
movements (l_acl:relcl) related
examined (l_nmod) order
hyperglycemia (l_appos) glucosuria
indicate (l_ccomp) effective
etiology (l_nmod) hypercalcemia
incidence (r_nsubj) increasing
caused (r_acl) rigidity
anaesthesia (r_nsubj) provided
causing (l_dobj) coagulopathy
treatment (l_nmod) acne
dopamine (r_compound) agonist
tetrachloride-induced (r_amod) cirrhosis
treatment (l_nmod) spasticity
aspirin (r_compound) use
potassium (r_compound) levels
block (l_nmod) pattern
blockade (l_nmod) hypotension
suggestion (l_nmod) risk
licl (r_nmod) administration
cyclosporine (r_dep) drug-related
nitroprusside (r_nmod) dogs
associated (r_acl) ulcers
had (l_dobj) decrease
derivatives (r_nmod) amounts
aniracetam (r_compound) doses
pattern (l_nmod) injury
test (r_nsubjpass) used
reaction (l_nsubj) lv
assessed (l_nmod) techniques
drugs (r_nsubjpass) used
nephropathy (r_nsubj) condition
polymyositis (l_conj) evidence
intensity (l_nmod) layer
compare (r_conj) estimate
precede (l_dobj) circling
deficits (l_acl) associated
duration (r_dobj) shortened
tacrolimus (r_nmod) conversion
steroids (r_nsubj) potent
produced (l_dobj) tremor
carbidopa-levodopa (l_nmod) point
monitored (l_nmod) proteinuria
decreased (l_nmod) induction
compared (l_nsubjpass) signs
therapy (l_nsubj) treatment
effect (l_nmod) ulcers
penile (l_dobj) pain
patients (r_nsubj) experienced
monitored (l_nmod) signs
aminoglycosides (r_dep) appeared
corrected (l_nsubjpass) hypothyroidism
administration (r_nmod) seizures
history (l_nmod) priapism
described (l_nsubjpass) case
creatine (r_dobj) linked
using (r_xcomp) induced
heart (l_amod) hypertrophied
conversion (r_nsubj) prevented
inhibits (l_conj) increases
penicillamine-related (r_amod) dermatitis
magnesium (r_nmod) effects
bcnu (r_dobj) received
administration (r_nsubj) had
findings (r_nsubj) suggests
potent (l_advcl) blocking
given (l_parataxis) had
development (l_nmod) shock
ngf (r_nsubj) correlate
agent (l_nmod) burns
gamma-hch (r_nmod) exposure
displays (l_conj) used
have (l_dobj) features
duration (l_nmod) diabetes
cisplatin (l_conj) those
mg/kg (r_dobj) received
c1 (l_acl:relcl) included
magnesium (r_compound) supplementation
lapsed (r_conj) developed
fk506 (r_appos) fujimycine
occurring (l_nmod) trauma
slowing (r_advcl) potential
hemisuccinate (r_acl:relcl) stabilizer/rigidifier
models (l_nmod) dyskinesia
have (l_nmod) cardiotoxicity
production (l_nmod) cancer
fasciculation (l_conj) myalgia
bradycardia (l_conj) block
riboflavin (r_conj) thiamine
effects (l_amod) nephrotoxic
formation (r_nsubj) step
5-ht (r_compound) nerves
related (l_nmod) impairment
function (l_conj) those
pac-containing (r_amod) regimen
ampicillin (r_nmod) caused
recording (l_dobj) states
determined (l_conj) related
csa (r_dep) a
bupivacaine (r_nmod) injection
assay (l_nmod) myocardium
role (l_nmod) manifestation
exploration (l_conj) sedation
combined (r_acl) inhibitor
ibuprofen (r_amod) use
pain (r_nmod) presenting
adrenaline (r_conj) concentrations
addition (r_nmod) injections
need (l_dobj) control
lovastatin (r_nmod) dose
drugs (r_nsubj) reduced
% (r_advcl) increasing
woman (r_nsubj) developed
syncope (l_conj) bradycardia
antagonists (r_nmod) microinjections
induced (l_dobj) hyperalgesia
has (l_nmod) incidence
case (l_nmod) overdose
induce (l_dobj) tachycardia
compares (l_conj) bupivacaine
anaesthesia (l_amod) hypotensive
factors (l_nmod) syndrome
incidence (l_nmod) myalgia
treatment (l_nmod) epicondylitis
examined (l_nmod) expressions
common (l_nsubj) infections
cyclosporine (r_nmod) use
analyzed (l_nsubjpass) degree
patients (r_nmod) use
study (l_nmod) monkeys
inhibitor (r_nmod) therapy
vomiting (l_conj) tremors
diseases (l_conj) patients
triggered (l_nsubjpass) asterixis
associated (r_acl) hyponatremia
efficacy (r_nmod) duration
acetaminophen (l_acl) produce
produce (l_dobj) torsades
lamivudine-resistance (l_nmod) patients
doxorubicin (r_nmod) drugs
administration (r_dobj) accompany
magnesium (r_compound) depletion
treated (r_dep) investigated
patient (l_compound) psp
levels (r_nsubjpass) increased
radiopharmaceutical (l_amod) new
have (l_dobj) toxicity
aetiology (r_dobj) suggesting
s-23121 (r_nmod) administration
failure (l_acl) receiving
injury (r_nsubj) caused
infant (l_nmod) tuberculosis
relationship (l_nmod) ctni
disulfiram-induced (r_amod) optic
fluoxetine (r_nmod) improved
bendrofluazide (r_compound) treatment
dl-sotalol (r_nsubj) induced
cc (r_nmod) patients
ifosfamide (r_compound) toxicity
showed (l_dobj) characteristics
produced (l_nsubjpass) failure
dimer-x (r_compound) group
although (l_nmod) common
derivatives (r_dobj) contained
nad (r_nmod) depletion
cyclophosphamide (r_nmod) treated
developed (l_dobj) tachycardias
was (r_appos) objective
developed (l_dobj) chorea
decrease (l_conj) cardiomyopathy
risk (l_nmod) events
applied (l_nmod) patients
complication (l_nsubj) hepatitis
patients (r_nmod) higher
scored (l_nsubjpass) characteristics
participation (l_nmod) ototoxicity
dose (r_nmod) elicited
aracytine-c (r_nmod) edema
placement (r_nmod) presented
evoked (r_acl) convulsions
symptoms (l_compound) rls
acid (r_nmod:npmod) overdosage-induced
doses (r_nsubj) increase
induced (r_acl) paralysis
trihexyphenidyl (r_nmod) dose
glycol (r_nmod) effect
sedation (l_conj) apnea
antagonize (l_dobj) blockade
ability (l_acl) reverse
gem-p (r_nsubj) chemotherapy
effect (l_nmod) days
evaluate (l_nmod) treatment
unassigned (r_dep) classified
effective (l_dep) mg/kg
doxorubicin (r_nsubj) agent
containing (r_acl) combination
zinc (r_conj) selenium
considered (l_nsubjpass) recognition
hypothesis (l_ccomp) inhibits
implicated (l_nmod) pathophysiology
patients (l_nmod) iiib
smoking (l_conj) mellitus
reduced (l_nsubjpass) threshold
frequencies (l_nmod) hit
appears (l_conj) tolerated
agents (r_nsubj) have
induced (r_acl) activity
features (l_acl:relcl) associated
advantages (r_nmod) striking
ointment (r_nmod) complication
aspirin (r_nsubj) increase
suxamethonium (r_nmod) administration
preventing (l_dobj) impairment
induce (l_nmod) hypokalemia
mca (l_nmod) rats
scores (l_compound) behaviors
tet (r_nmod) effects
fenoldopam (r_conj) vasodilators
mortality (l_nmod) women
combined (l_nmod) indications
studies (r_nsubj) revealed
differ (r_ccomp) finding
supplementation (r_nmod) associated
treatment (l_conj) impotence
frequency (l_compound) breast-cancer
nh4ac (r_conj) verapamil
offset (l_nsubj) risk
development (r_nmod) role
enhances (l_dobj) bradycardia
catecholamines (l_conj) hyperkinesia
suffered (l_dobj) hemiparesis
known (l_nsubjpass) disease
lower (l_nmod) those
withdrawal (r_nmod) stopped
anxiety (r_dobj) had
reported (l_nmod) damage
modulate (l_dobj) catalepsy
effect (l_nmod) toxicity
ibuprofen (r_amod) prophylaxis
speculate (r_conj) prompted
related (r_amod) cin
voltammetry (r_dobj) used
infants (r_nmod) done
cytosine (r_compound) analogue
years (r_dep) monitored
oxide (r_nmod) loss
shortened (l_nmod) convulsion
tmp (r_nsubj) decreased
doses (l_nmod) chlormethiazole
cbz (r_nmod) effects
cisapride (r_nsubjpass) prescribed
diazepam (r_nmod) injection
enrolled (l_nmod) years
stz-icv (r_compound) administration
protocol (r_nmod) treated
ptx (r_conj) ptz
accompanies (l_dobj) therapy
5-fluorouracil (r_nmod) infusion
associated (r_acl) movements
performed (l_nmod) women
patients (l_amod) parkinsonian
effects (l_amod) cataleptic
drug (l_acl:relcl) associated
chloroacetaldehyde (l_dep) role
day (l_nmod) infarction
association (r_dobj) show
duration (r_nmod) respect
nicotine (r_nmod) morphine
treatment (r_nmod) impact
incidence (l_conj) induction
enflurane (r_nsubj) prove
paracetamol (r_nsubj) cause
similar (l_parataxis) occurred
estradiol (r_compound) treatment
included (l_dobj) score
drugs (r_nsubjpass) prescribed
groups (r_nmod) randomized
course (l_conj) toxicity
levels (r_nmod) lower
assessment (l_compound) measures
agent (l_advcl) associated
promotes (l_dobj) catalepsy
anesthesia (r_nmod) operated
carbamazepine (r_nmod) hypersensitivity
minutes (r_nmod:tmod) developed
seems (r_advcl) prevented
adriamycin-induced (r_amod) myocardiopathy
patients (r_nmod) marked
sodium (r_compound) channels
aggravation (r_nmod) produce
agonist (r_nmod) administration
shortness (l_nmod) breath
approach (l_nmod) carcinoma
sevoflurane (r_nmod) induction
cocaine-associated (r_amod) infarction
response (r_dobj) enhanced
anomalies (l_dep) anotia
five (l_nmod) thrombosis
encephalopathy (r_nmod) patient
observed (l_nsubjpass) hypokalemia
developed (r_acl:relcl) dyspepsia
response (r_nmod) associated
trinitrate (r_nsubj) induces
presented (l_nmod) pain
induced (r_acl) hyperprolactinemia
increase (l_nmod) patients
literature (l_nmod) complications
protects (r_ccomp) indicate
patients (l_nmod) nephropathy
hydroxyquinolines (r_nmod) neurotoxicity
q10 (r_nsubj) compensated
administration (r_nsubj) exert
(adr)-induced (r_punct) cardiotoxicity
developed (r_acl) case
ziprasidone (r_nmod) nms
scales (l_compound) anxiety
treated (r_acl) syndromes
patients (r_nmod) compared
reduce (r_ccomp) finding
indicate (l_conj) cause
topotecan (r_conj) radiotherapy
affected (l_dobj) incidence
statins (r_nsubj) initiate
n-highly (r_conj) p
elicit (l_dobj) dyskinesia
cefotetan (r_dobj) receiving
cells (r_nmod) contribute
stress (l_conj) dysfunction
anesthesia (r_dobj) follow
rats (l_nmod) glycosuria
salicylates (r_nmod) association
cardiotoxicity (l_conj) dysfunction
users (r_nmod) observed
models (l_nmod) catalepsy
complications (l_nmod) leukemia
thrombocytopenia (r_nmod) patients
pointes (r_nsubj) related
extended-release/lovastatin (r_nsubj) product
l-noarg (l_conj) catalepsy
disrupted (l_dobj) catalepsy
induced (l_nmod) drugs
unlikely (l_dep) begun
extent (r_nsubjpass) evaluated
phenomenon (l_nsubj) syndrome
bupivacaine (r_nsubj) alters
treatment (r_nsubj) improved
cd-832 (r_conj) nifedipine
change (l_nmod) bradycardia
patient (l_nmod) disease
compared (r_dep) occurred
patient (l_acl) highlighting
5,7-dihydroxytryptamine (r_nmod) injection
received (l_nmod) progression
imaging (r_nmod) stopped
absence (l_nmod) explanation
aminoglycoside (r_compound) antibitocis
toxicology (r_nmod) those
hydrochloride (r_dobj) ingesting
mediating (l_dobj) injury
blocker (r_appos) cnsb002
vpa (r_compound) treatment
incoordination (r_conj) analgesia-
thrombocytopenia (l_conj) osteoporosis
levels (l_conj) activity
syndrome (l_appos) hus
fa (r_appos) acetonide
that (r_mark) releases
rats (r_nsubj) showed
consistent (l_conj) precipitate
administration (r_nmod) pain
tac (r_conj) csa
score (l_appos) score
used (l_dobj) model
agonist-induced (r_conj) levodopa-
randomized (l_conj) selected
placebo (l_nmod) response
anesthesia (r_nmod) caused
diarrhea (l_dep) syndrome
haloperidol (r_nmod) profile
activity (r_nsubj) increased
amiloride (r_compound) administration
spironolactone-induced (r_amod) hyperkalemia
adenosine (r_compound) antagonists
treated (l_nmod) argatroban
investigate (l_dobj) relationship
lidocaine-induced (r_amod) convulsion
imipenem/cilastatin (r_nmod) doses
due (r_amod) neuropathy
manifestation (l_nmod) cardiotoxicity
olanzapine (r_nmod) treatment
accepted (l_advcl) cause
phenylephrine (r_nmod) effect
involved (r_ccomp) indicating
increase (l_nmod) variations
groups (r_advcl) hyperactive
increase (r_nsubj) appear
ethopropazine (r_nmod:npmod) treated
nmdar (r_nmod) effects
cin (r_nmod) incidence
msg (r_compound) evaluation
ethanol (r_nmod) inhibited
receive (l_conj) placebo
grouped (l_nsubjpass) people
cases (r_nmod) recorded
required (l_nmod) neutropenia
cause (r_acl:relcl) myopathy
prior (r_amod) 0.05
ergotamine/caffeine (l_nmod) migraine
improved (l_nsubj) movements
rats (r_nsubj) died
rifampin (r_nmod) regimen
cocaine (r_nmod) exposed
disappearance (l_nmod) tumor
iron (r_compound) chelator
seizures (l_conj) epilepticus
levels (r_dobj) decrease
amphetamine-induced (r_amod) models
incidence (r_nsubj) similar
prevention (l_nmod) hc
activity (l_nmod) patients
upregulation (l_nmod) paraventricular
aspirin (r_compound) ingestion
effective (l_conj) utility
alpha-fluoro-beta-alanine (r_nmod) level
returns (l_nmod) thromboembolism
responsible (r_xcomp) seems
caproate (r_nmod) derivatives
dyskinesias (r_nsubjpass) reported
observed (l_nsubjpass) anemia
memory (l_compound) pain
increased (l_advcl) hr
choreic (l_conj) ballistic
thrombocytopenia (r_nmod) patient
consider (l_dobj) likelihood
suggest (l_advcl) known
clozapine (r_nsubj) remains
block (l_conj) reverse
decreased (r_conj) induced
methamphetamine (r_nmod) use
had (l_nsubj) total
gtn (r_dep) hour
molecule (l_compound) injury
erythrocytes (r_nmod) hemolysis
dose (r_nmod) pre-treatment
ginsenosides (l_nmod) oih
saline (r_nmod) pretreated
associated (r_acl) tolerance
complained (l_nmod) myalgia
damage (r_dobj) reduces
injection (r_nsubj) induces
cbdca (r_nsubj) neurotoxic
anthracycline-based (r_amod) chemotherapy
anticoagulant (r_nmod) reaction
abnormalities (l_conj) failure
effects (r_conj) aspects
cranial (l_nmod) growth
fact (r_nmod) spite
impairment (l_nmod) recall
flurothyl (r_compound) exposure
feeding (r_nmod) arose
appearance (l_nmod) convulsions
e (r_compound) supplementation
therapy (r_conj) rash
chp (r_compound) cream
administration (r_nmod) achieved
sodium (r_nsubjpass) used
peg-asparaginase (r_nmod) encephalopathy
acids (r_nmod) use
toxicity (r_nsubjpass) reported
argatroban (r_conj) microg/kg/min
d-penicillamine-induced (r_amod) angiopathy
hemolysis (r_nmod) result
acetylcholine (r_conj) glutamate
thiamine (r_compound) deficiency
cardiotoxicity (r_nmod) consistent
hyperalgesia (r_dobj) reduced
congenita (l_appos) mc
frequency (l_nmod) beats
attenuated (l_dobj) amnesia
volumetry (l_nmod) patients
effects (l_nmod) seizures
linezolid (r_amod) therapy
depression (l_conj) headache
reduction (l_nmod) lesions
ribavirin (r_conj) interferon
measure (l_nmod) oscillation
biperiden (r_conj) propranolol
inhibitor (r_appos) rad001
synthesis (r_nmod) pathway
produced (r_acl) blockage
evaluated (l_nmod) activity
provide (l_dobj) events
be (r_nmod) induced
risks (l_compound) cancer
reduce (l_dobj) inhibition
adults (l_acl:relcl) suffering
enanthate (r_nmod) induced
blockers (l_acl:relcl) reported
complication (r_nsubj) important
woman (l_nmod) colitis
improve (l_conj) tolerated
discontinuation (r_nmod) disappeared
received (l_nsubj) man
gave (l_dobj) history
induced (r_acl) pentobarbital
caused (l_dobj) hypotension
p (r_nmod) documented
prescribed (l_nmod) onychomycosis
secondary (r_amod) angioedema
that (l_nsubj) 10
dose (l_amod) convulsive
mechanisms (r_nsubjpass) studied
margin (r_conj) cows
receive (r_acl:relcl) gemcitabine
ribavirin (r_nmod) therapies
resolve (l_nsubj) incontinence
injury (r_nsubj) included
replaced (r_conj) suspected
argatroban (r_nmod) concentrations
cya (r_appos) a
tremor (r_nmod) rate
determine (l_dobj) effects
melatonin (r_nmod) dose
digoxin (r_nmod) administration
interaction (r_conj) bradycardia
augmented (r_conj) blocked
relative (l_conj) placebo
those (r_nmod) faster
induced (l_conj) documented
ketanserin (r_nmod) pretreatment
enhanced (l_nsubj) hyperthermia
reduced (r_conj) mediated
active (l_nmod) nsclc
injection (r_nmod) toxicity
use (r_conj) likely
donor (r_appos) trinitrate
restores (l_dobj) performance
morphine (r_nmod) treated
conclude (l_ccomp) caused
institution (r_nmod) developed
dose (r_nsubj) g.
responsiveness (r_nmod) value
initiation (r_nmod) experienced
side-effect (l_nsubj) tdp
relapse (l_nmod) leukemia
point (l_advcl) appeared
ag (r_compound) patients
suitable (l_nmod) treatment
developed (l_dobj) dementia
cream (r_nmod) 0.25
sarcolemma (r_nmod) integrity
factors (r_nmod) accompanied
propofol (r_nmod) pre-treatment
group (r_nsubj) had
proteinuria (l_amod) nephrotic-range
ephedrine (r_nmod) effects
dox (r_compound) cardiomyopathy
chemotherapy (r_nsubjpass) limited
remained (l_advcl) observed
reported (r_advcl) focused
importance (r_dobj) emphasizes
tincture (r_nmod) effect
lindane (r_amod) convulsions
catalepsy (l_conj) hypothermia
occurring (r_acl) block
mechanisms (r_nsubj) warrant
pressure (l_conj) albuminuria
la (r_nmod) determination
course (r_dobj) prescribed
scores (l_compound) severity
edema (l_nmod) periphery
kanamycin-induced (r_amod) loss
production (r_nmod) association
diethylpropion (r_nmod) efficacy
design (l_nmod) patients
paroxetine (r_conj) flecainide
doxorubicin-induced (r_amod) rats
suffering (l_nmod) disease
injection (r_nmod) was
infusion (r_nmod) attributed
estrogen-induced (r_amod) tumors
amine (r_amod) pretreatment
related (r_amod) pain
morphine (r_nmod) cessation
responded (r_conj) appeared
loss (l_nmod) seizures
taking (l_dep) associated
verapamil (r_nmod) effects
linked (r_acl) proteinuria
fentanyl (r_nmod) combination
comparable (l_nsubj) outcomes
dose (r_dobj) increasing
diethylstilbestrol (r_nmod) associated
heparin (r_nmod) injection
necrosis (l_nmod) pelvis
sensitive (r_ccomp) indicating
cocaine (r_nmod) prior
carboplatin (r_nsubj) free
tests (r_nsubj) have
blood (r_compound) concentrations
symptoms (l_nmod) encephalopathy
ouabain (r_nmod) induced
ca(2 (r_conj) nitrite
sarcoma (l_conj) cancers
developed (l_dobj) torsade
accelerated (l_nsubj) injection
patients (l_acl:relcl) have
isoflurane (r_compound) anaesthesia
ifosfamide (r_compound) chemotherapy
tachycardia (l_conj) rebound
diagnosis (l_nmod) hyperprolactinemia
induce (l_dobj) hyperfiltration
problem (l_conj) need
simvastatin (r_amod) concentration
explain (l_dobj) prolongation
function (l_acl) seen
abnormalities (l_nmod) function
amphetamine-induced (r_amod) activity
methamphetamine-induced (r_amod) psychosis
added (l_nmod) infection
olanzapine (r_nsubj) =
amiodarone (r_dobj) continuing
recovery (l_nmod) neuritis
association (l_nmod) treatment
baclofen (l_dobj) jerks
using (r_advcl) assess
evident (l_nsubj) fibers
activity (r_dobj) decreased
cocaine-induced (r_amod) hyperactivity
induced (r_acl) damage
describe (l_dobj) patients
pvn (r_nmod) upregulation
glut4 (r_nmod) transport
methoxyflurane (r_nmod) anesthesia
rats (r_nmod) decline
outcomes (r_nsubj) enrolled
calcium (r_nmod) effect
levofloxacin (r_nmod) treatment
combination (r_conj) licensed
everolimus (r_nmod) tacrolimus
mortality (l_nmod) cvd
documented (l_nsubjpass) vasculitis
tamca (r_nsubj) retains
dopamine (r_nmod) agents
cisplatin (r_nmod) combination
experienced (l_dobj) urticaria/angioedema
nifedipine (r_conj) performed
prevent (l_dobj) fever
acid-induced (r_amod) dementia
development (l_nmod) symptoms
group (l_acl:relcl) greater
manifestation (l_nsubj) pericarditis
meeting (l_dobj) criteria
(+)-propranolol (r_nmod) that
develop (l_dobj) strategy
starting (r_advcl) decreased
acc-9653 (r_compound) sodium
carcinogenesis (r_nmod) effect
produced (l_nsubjpass) hypertension
cyp (r_nmod) wt
ikr (r_nmod) action
potential (r_dobj) identify
developed (l_advcl) included
changes (l_conj) decrease
present (l_nmod) hypertension
movements (l_amod) dystonic
sodium (r_dobj) divalproex
iopamidol (r_nmod) less
effects (l_nmod) coagulation
addition (l_nmod) damage
cows (r_nsubj) developed
selegiline (r_dobj) receiving
factor (l_compound) psychosis
headache (l_nmod) aura
was (l_nsubj) improvement
factors (l_appos) type
solid (l_dep) malignancies
cases (l_nmod) paralysis
attack (r_dobj) developed
using (r_acl) design
nra0160 (r_nsubj) induced
inducing (l_nmod) concentrations
snp (r_compound) group
blockers (r_nmod) caused
administration (r_nmod) behaviors
contraceptives (r_nmod) associated
patients (l_acl:relcl) failure
interaction (l_acl) resulting
monohydroxyethylrutoside (r_nsubj) showed
succinylcholine-induced (r_amod) rigidity
secondary (l_nmod) nephritis
negative (r_advcl) gave
dogs (r_nmod) infusion
is (l_nmod) epilepsy
induced (r_acl) changes
dexrazoxane (r_nmod) coadministration
associated (l_nmod) rls
l-dopa (r_nmod) effect
unrelieved (r_acl:relcl) patients
using (r_acl) pre-treatment
attempt (l_xcomp) titrate
age (l_conj) race/ethnicity
impairment (r_dobj) improving
induces (l_dep) correlation
glomerulosclerosis (r_conj) hypertrophy
men (l_conj) strokes
function (r_conj) cavity
associated (l_nmod) hypertension
patients (r_nmod) tremor
triggers (l_dobj) death
syndrome (r_nmod) found
diazepam (l_nmod) patients
polyvidone (r_nsubjpass) considered
fk506 (r_nmod) discontinuation
post (r_dep) study
dose-dependent (l_nmod) atrophy
reabsorption (r_nmod) parameters
glutamate (r_amod) photostimulation
myasthenia (l_acl) associated
factor (l_nmod) incidence
present (r_acl:relcl) patients
agent (l_nmod) hyperlipemia
those (r_nmod) compared
demand (l_nmod) hypotension
l-dihydroxyphenylalanine (r_nmod) ability
effects (r_nmod) plays
% (l_nmod) group
loading (r_nmod) initiation
leg (l_conj) pain
apomorphine (l_appos) therapy
helodermin (r_nmod) produced
developed (l_xcomp) clinical
effect (l_nmod) decrease
increase (r_conj) decrease
rifampicin (r_nmod) use
vpa-associated (r_amod) stress
mimic (l_dobj) symptoms
type (l_conj) presence
cibenzoline (r_nsubj) suppressed
heparin (r_compound) injection
d-tubocurarine (r_nmod) curves
nomega-nitro-l-arginine (r_compound) hypertension
people (r_nmod) study
conclude (l_ccomp) left
correlated (r_dep) exhibited
dox (r_nmod) injury
cardiotoxicity (r_nmod) incidence
taking (r_advcl) present
triacylglycerol (r_conj) acids
t (r_conj) c
opioid (l_nmod) effects
found (l_xcomp) beneficial
cases (r_nmod) described
antagonist (r_appos) clentiazem
frequency (r_conj) duration
bromocriptine (r_nsubjpass) implicated
primigravida (r_nmod) case
pretreatment (r_nsubj) did
used (l_xcomp) treat
disorder (l_conj) depression
agents (r_nmod) doses
aconitine-induced (r_amod) ca2
streptozotocin (r_conj) inflammation
acetazolamide-induced (r_amod) nephrolithiasis
complication (l_nsubj) thrombosis
use (r_dobj) evaluating
k(+ (r_appos) hyperkalemia
damage (r_nsubjpass) discriminated
dep (r_nmod) changes
dose (r_nmod) recurred
ifn (r_compound) therapy
dipyridamole (r_conj) replacement
associated (l_nsubjpass) schizophrenia
administration (l_nmod) presence
patients (r_nsubj) likely
managed (r_conj) had
randomized (l_nmod:tmod) weeks
prevented (r_conj) dose-dependent
patients (l_amod) epileptic
serotonin (r_compound) group
nodules (l_amod) painful
enalapril (r_nmod) 1.52
needed (l_xcomp) suppress
group (r_nmod) returned
% (l_compound) alf
verapamil (r_compound) treatment
methylphenidate (r_compound) therapy
familiarity (r_nsubj) facilitate
features (r_dobj) revealed
ifosfamide-induced (r_amod) cystitis
preferable (l_advcl) has
cases (l_nmod) tachycardia
concentration (r_nsubj) evoked
tocopherols (r_nmod) protection
da (r_compound) concentration
sucralfate (r_conj) blockers
nitroglycerin (l_nmod) subjects
increasing (r_advcl) decrease
corticosteroid (r_compound) myopathy
met (l_dobj) criteria
showed (l_dobj) loss
used (l_xcomp) produce
efficacy (r_nmod) screen
effective (l_conj) safe
intoxication (l_acl) conformed
suggest (l_ccomp) mediated
pretreatment (r_nsubj) abolish
consistent (l_nmod) hypothesis
responsible (l_nmod) antinociception
pilocarpine (r_nmod) protected
acid (r_nsubj) induce
suggest (l_ccomp) have
valsartan (l_appos) antagonist
increase (l_acl) accompanied
etoposide (r_nmod) synchrony
reduction (l_nmod) glomerulosclerosis
reported (l_nsubjpass) risk
docetaxel (r_nmod) addition
evidence (l_nmod) cardiotoxicity
abuse (r_conj) disruption
impact (l_acl) reducing
had (l_dobj) jaundice
reduced (l_dobj) movements
children (l_nmod) neuroblastoma
ethanol (r_conj) cocaine
bupivacaine (r_nmod) likely
induce (l_dobj) atherosclerosis
consumption (r_dobj) increasing
recognized (l_nsubjpass) hyperkalemia
comparable (r_amod) dysfunction
involved (l_nmod) toxicity
relationship (l_nmod) dysfunction
led (l_nmod) reaction
amitriptyline (r_appos) elavil
na (r_compound) channel
progression (l_nmod) rats
ascribing (l_nmod) osteoporosis
study (r_nmod) participated
pain (l_conj) hyperalgesia
ca(2 (r_compound) blockade
observed (r_acl) reaction
made (l_nsubjpass) diagnosis
ro4368554 (l_appos) deficits
rats (r_nmod) doses
cause (l_dobj) hypokalemia
dobutamine (r_nsubjpass) administered
women (l_nmod) acne
male (r_nmod) stroke
contributes (l_nsubj) impairment
model (r_nmod) diagnosis
d-treated (r_amod) rats
appetite (l_conj) symptoms
induced (r_acl) erythrocytes
aspirin (r_nmod) put
injury (r_nmod) exacerbates
estimate (l_nmod) grams
go (l_nmod) seizures
bromocriptine (r_nmod) tachycardia
smaller (l_nsubj) doses
prevented (r_conj) inhibited
combination (r_conj) fentanyl
famotidine (r_nmod) associated
difficult (r_amod) diagnosis
cbdca (r_appos) advantages
inhibitors (r_nmod) use
associated (l_nmod) injury
analogues (r_conj) cholecystokinin
lidocaine (r_nsubj) reduced
management (l_nmod) patients
phenytoin (l_conj) hypothermia
determinant (l_nmod) cytotoxicity
reduced (l_nmod) paraparesis
curve (r_nmod) area
amlodipine (r_nsubj) cause
advised (l_nsubjpass) monitoring
performance (r_nmod) min
changes (l_acl:relcl) maintained
rise (r_nsubjpass) associated
injection (r_nmod) occurred
demonstrated (l_dobj) activity
minimize (l_dobj) bradycardias
levofloxacin (r_nmod) efficacy
oestrogen-only (r_amod) ht
have (l_dobj) potential
animals (r_advcl) demonstrated
capsaicin (r_compound) cream
neurotransmitters (r_nmod) reduction
nsaids (r_nmod) caused
rates (l_nmod) patients
supersensitivity (r_conj) response
toxicity (r_nsubj) intermediate
effect (r_nmod) enhanced
use (r_conj) pressure
inhibits (l_dobj) development
correlates (l_nsubj) cardiotoxicity
gemfibrozil-lovastatin (r_compound) treatment
isotretinoin (r_dobj) received
reported (l_advcl) compared
cavity (l_conj) cirrhosis
metabolites (r_nmod) induction
induced (l_dobj) hypotension
receiving (r_advcl) experienced
alpha-tc (r_nsubj) ameliorate
administration (r_nmod) affected
alterations (l_acl) occurring
studied (r_advcl) paid
associated (l_nmod) somnolence
attenuated (l_dobj) lesions
risk (l_nmod) cataracts
developed (l_xcomp) study
terbutaline (r_compound) concentrations
correlates (l_conj) prepared
assigned (l_conj) showed
administered (l_dep) induce
potentiating (l_conj) reducing
acid (r_nsubjpass) used
cocaine (r_nsubj) causes
hypertension (l_conj) injury
heroin (r_compound) addicts
sulfate (r_conj) puromycin-aminonucleoside
(stz)-induced (r_amod) diabetes
steroid (r_nmod) use
preventing (l_dobj) hypotension
chloroform-adrenaline (r_nmod) used
40 (r_nummod) ro
clopidogrel (r_nmod) reports
induced (l_nmod) stage
patients (l_nmod) failure
pg (r_nmod) negative
patients (l_conj) insufficiency
levels (l_nmod) neuropeptides
attenuates (l_conj) eliminates
increase (r_ccomp) suggests
group (r_nmod) %
paclitaxel-refractory (r_amod) cancer
use (r_nmod) failure
incidence (l_nmod) seizures
installation (l_nmod) epilepticus
administration (r_nmod) evoked
thalidomide (r_conj) regimen
assay (l_compound) cytotoxicity
utilizes (l_ccomp) objectives
therapy (r_nsubj) related
test (r_nsubjpass) investigated
pattern (l_nmod) regurgitation
rat (l_amod) arrhythmic
male (l_nmod) schizophrenia
seem (l_xcomp) affect
vasodilator (l_acl) used
d3 (r_nsubjpass) used
gtn (r_nsubj) has
recorded (l_nmod) nitroprusside
dopamine (r_nsubj) enhances
% (r_dep) implications
phosphokinase (r_nmod) increase
quinine (r_nsubj) alkaloid
head (l_dep) cancers
resulted (l_nmod) injury
order (l_acl) elucidate
epinephrine (r_compound) overdose
collagen (r_nmod) induced
neuropeptide (r_compound) stimulation
feature (r_ccomp) fact
use (r_nsubj) increased
fluorthyl- (l_dep) convulsions
cyp-induced (r_amod) cystitis
flurothyl (r_compound) testing
associated (r_acl) defect
mice (r_nmod) improved
concentration (r_conj) therapy
factor (r_dobj) required
factors (l_nmod) tdp
mechanisms (l_dep) comparison
disorders (l_acl) indicating
case (l_nmod) complaining
lamivudine-na (r_amod) carriers
calcitonin (r_compound) injections
toxicity (l_nmod) cows
carboplatin (r_compound) treatment
alprazolam (r_conj) paroxetine
complications (l_nmod) patients
asenapine (r_nmod) treatment
evoked (l_nsubjpass) infarcts
methamphetamine-induced (r_amod) toxicity
revealed (l_dobj) areas
damage (l_conj) glomerulosclerosis
site (l_compound) burn
encephalopathy (r_nmod) episodes
exposure (r_nmod) alleviate
tolerability (l_nmod) group
treatment (l_nmod) cancer
prostaglandins (l_nmod) urine
occurrence (l_nmod) glomerulonephritis
mitigating (l_dobj) deterioration
withdrawal (r_compound) severity
output (r_nmod) depression
cisapride (r_conj) terfenadine
botox (r_compound) injections
srl (r_nsubjpass) used
deoxycholate (r_acl:relcl) that
derives (l_nmod) atrophy
status (l_amod) angina
concentration (l_nmod) areas
hd-mtx (r_appos) methotrexate
subunits (r_nsubj) necessary
nicotine (r_compound) potentiation
decreased (r_conj) reduced
retention (r_dobj) leads
fluoxetine (r_compound) pharmacotherapy
periphery (l_nmod) territory
provide (l_dobj) advantage
) (r_punct) dose
tests (l_compound) spasm
vessels (r_nmod) vasodilation
mg/day (r_dobj) developed
dose (r_dobj) received
citrate (r_compound) dialysate
acid (r_compound) glutamine
taken (r_advcl) was
eating (l_dobj) disorders
rad001 (r_nmod) evaluation
aspirin (r_nsubj) induces
limited (l_nmod) effects
dopamine (r_nsubj) appeared
luminal (r_amod) content
all (r_nsubj) suppressed
clioquinol (r_dobj) received
total (l_nmod) patients
group (r_nmod) compared
developed (l_dobj) hyperplasia
failed (l_xcomp) produce
patients (l_amod) stroke
succinylcholine (r_nmod:npmod) induced
model (r_dobj) utilized
dose (l_compound) birth
morphine-induced (r_amod) constipation
hydroxylase (r_conj) dopamine
influence (r_dep) loss
degrees (l_conj) contracture
evaluate (l_dobj) susceptibility
hypoglycemia (l_conj) bradycardia
induced (r_acl) impairment
induced (l_nsubjpass) neurotoxicity
mice (r_nmod) number
describe (l_dobj) cases
epinephrine-induced (r_amod) cardiomyopathy
induced (r_acl) hypertrophy
measured (l_nmod) testing
determination (r_nmod) patients
aspirin (r_conj) clopidogrel
capsaicin (r_conj) glutamate
risk (l_nmod) hyperkalemia
presence (l_nmod) impairment
adjust (r_acl) addition
loss (l_nmod) filaments
vigabatrin-attributed (r_amod) loss
bupivacaine (r_nmod) infrequent
amb (r_dobj) receive
disorder (r_nsubjpass) associated
necrotizing (l_dobj) myocarditis
child (l_amod) hypothermic
had (l_nsubj) nine
tetrachloride (r_nmod) doses
icrf-187 (r_nmod) protection
charge (r_compound) barrier/density
rechallenge (r_nmod) reproduced
intake (r_nsubj) promote
duration (l_compound) seizure
na(+)/k(+)-atpase (r_nmod) expression
prior (r_advmod) block
onset (l_nmod) hypotension
colorectal (l_dep) cancers
acetaminophen (r_amod) hepatotoxicity
hypomania (l_conj) mania
treatment (r_nmod) link
studied (l_nmod) treatment
non-users (r_nmod) rofecoxib
syndrome (r_nmod) patient
process (l_amod) necrotic
tocolysis (r_dobj) received
methotrexate (r_amod) diluents
pathogenesis (l_nmod) thrombi
defect (r_nsubj) leads
dose (r_nmod) rats
demonstrated (l_dobj) defect
patients (r_nmod) eleven
caused (l_conj) underwent
adriamycin (r_nmod) injection
mechanisms (l_nmod) buildup
associated (r_acl) hyperkalemia
increases (r_dobj) reduce
using (r_xcomp) evaluated
no (r_nsubjpass) involved
introduction (r_nmod) developed
meal (r_compound) test
morbidity (l_nmod) hypothyroidism
reveals (r_conj) supports
methyldopa (r_nmod) action
concern (r_nmod) conducted
syndrome (l_dep) aml
% (r_nmod) developed
development (l_nmod) hyperplasia
tolerance (l_nmod) patients
levels (l_conj) patients
doxorubicin (r_nsubj) therapeutic
induced (l_dobj) apnea
treatment (l_nmod) benefit
test (l_compound) aggregation
argatroban (r_nmod) restarted
effect (l_nmod) enalapril
derivative (r_conj) patient
have (l_nsubj) patients
degrees (l_nmod) fibrosis
levobupivacaine (r_nmod) amounts
cpm (r_appos) cyclophosphamide
dexamphetamine (r_compound) stereotypy
oxidase (l_nmod) hypertension
using (l_dobj) schedule
discontinuing (l_nmod) aes
combination (r_nmod) assessed
important (r_advcl) have
heparin (r_appos) anticoagulants
used (r_ccomp) concluded
inpatient (r_nmod) induced
advantage (l_nmod) administration
5-fluorouracil (r_nmod) fluoropyrimidines
years (r_nmod) reported
dehydrogenase (r_nmod) activities
combined (r_acl) acetate
da (r_compound) agonist
hypoactivity (r_dobj) affected
thalidomide (r_nmod) activity
synthase (r_nmod) type
attenuation (l_nmod) neurotoxicity
considered (l_nmod) cases
vnb (r_conj) gem
observed (r_acl) anaemia
metronidazole (r_compound) intake
ranitidine (r_conj) doses
amikacin-associated (r_amod) nephrotoxicity
percentage (r_nsubjpass) associated
ecstasy (r_conj) effects
increase (l_nmod) 9-months
revealed (r_parataxis) increased
levels (l_appos) percentage
propranolol (r_nmod) treatment
da (r_compound) system
treatment (l_nmod) headache
caused (r_conj) induced
remedy (l_nmod) management
anemia (r_dobj) reversed
improvement (l_nmod) propranolol
acid (r_conj) 5-fluorouracil
older (l_conj) likely
terbutaline (r_nsubjpass) associated
mediation (l_nmod) bradycardia
increased (l_dobj) catalepsy
was (l_conj) none
fluoxetine (r_nmod) effect
cleft (l_dobj) lip
associated (r_acl) deaths
norepinephrine (r_compound) rate
rescues (l_dobj) toxicity
hypoplasia (l_conj) epiphyses
consisted (l_advmod) exclusively
had (l_nmod) locomotion
treatment (l_nmod) women
fibrillation (r_nmod) older
fields (l_nmod) tumor
induced (r_acl) catalepsy
related (r_amod) flashbacks
regimen (r_nmod) treated
users (l_nmod) ich
combination (l_nmod) history
useful (l_conj) monitored
episodes (l_nmod) potentials
estrogen (r_compound) sites
stimulation (r_nmod) rats
administration (r_nsubj) led
cpa (r_compound) treatment
combination (l_nmod) face
dose (l_nmod) healthy
induced (l_nmod) nephrotoxicity
cancer (r_nmod) agent
syndrome (l_conj) epilepsy
zolmitriptan (r_nmod) secondary
seems (l_conj) designed
increasing (l_dobj) somnolence
inhibitor (r_dobj) receiving
use (r_nmod) reported
reduced (l_conj) prevented
returned (l_nmod) cessation
regimen (r_nsubj) results
subjects (r_nmod) %
theophylline (l_nmod) asthma
treated (r_amod) mice
aggregation (l_conj) coagulation
propranolol (r_conj) effects
respond (l_nsubj) cells
etoricoxib (r_nmod) lower
smokers (r_acl:relcl) participants
paroxetine (r_nmod) association
desferrioxamine (r_nmod) caused
pad (r_nmod) application
transporter (r_nmod) observed
evaluated (l_dobj) ability
overdose (r_nmod) victims
analyzing (l_conj) nsaid
den (r_compound) treatment
phenylpropanolamine (r_nmod) associated
treatment (r_nsubj) resulted
presence (l_nmod) ischemia
minutes (r_nmod) developed
atp-binding (r_amod) site
report (l_nmod) asthenia
malignancies (r_nmod) related
population (r_nmod) prolongation
exacerbation (l_amod) paranoid
symptoms (l_nmod) changes
effects (l_conj) effects
effects (l_nmod) motility
administration (r_conj) instances
safety (r_dobj) determine
scopolamine-induced (r_amod) amnesia
administration (r_nsubj) caused
proteinuria (r_nmod) effect
prove (l_xcomp) activator
malignancies (l_nmod) infection
quetiapine (r_nmod) introduction
relationship (l_nmod) cgrp
trinitrate (r_nmod) induced
received (r_acl:relcl) mice
associated (r_acl) glomerulonephritis
permitted (r_conj) interrupted
des (r_compound) treatment
marker (r_conj) one
metabolite (r_nmod) potential
overdose (l_conj) two
ribavirin (r_nmod) reduction
related (l_nmod) scores
prostigmine-morphine (r_amod) provocation
adults (l_nmod) gbm
placebo (r_dep) nonusers
drugs (r_nmod) taken
induced (r_acl) hyperalgesia
patients (r_nsubj) present
arthritis (r_nmod) man
transgene (l_amod) hypoxia-responsive
tamoxifen (r_nsubjpass) used
treatment (l_nmod) hypotension
promotes (l_conj) investigate
quantities (r_nsubj) available
reports (l_nmod) delirium
resulted (l_nmod) episode
form (r_conj) abilities
acid (l_appos) component
isoniazid (r_nsubj) increased
prevents (r_conj) preserves
pyrazinamide (r_nsubj) have
hypertension-related (l_conj) oedema-related
induced (l_nsubjpass) catalepsy
phase (r_nsubjpass) associated
temsirolimus (r_nmod) effect
isoniazid (r_nmod) dose
produced (l_nsubjpass) haemodilution
bortezomib (r_nmod) related
therapy (l_acl) leading
activity (r_nmod) inhibitor
those (r_conj) nsclc
risperidone (r_conj) olanzapine
improve (l_nsubj) proteinuria
use (l_xcomp) identify
risperidone (r_nmod) observed
associated (l_nsubjpass) hypomagnesemia
decreased (l_nmod) stage
reversed (l_dobj) hypertension
combination (l_nmod) bortezomib/dexamethasone
norepinephrine (r_nmod) effects
methamphetamine (r_amod) psychosis
quinine (r_compound) amblyopia
activity (r_nsubjpass) decreased
discontinuation (l_nmod) hyperkalemia
cocaine (l_acl) engendered
sodium (r_compound) beta
exposed (r_acl) women
withdrawn (r_conj) improve
demonstrated (l_xcomp) agent
no (r_compound) activation
pain (l_amod) neuropathy
fzp (r_appos) dose
cnsb002 (r_nmod) co-administration
acetaminophen (l_conj) edema
done (l_nmod) effect
wounds (l_compound) burn
beneficial (l_nmod) management
tests (r_nsubjpass) performed
complication (r_nmod) recognized
beginning (r_advcl) appeared
use (r_nmod) patterns
less (l_dep) patients
inhibition (l_nmod) lactation
2 (r_nmod) contributed
populations (l_nmod) patients
ribavirin (r_compound) treatment
ethanol (r_nmod) presence
had (r_acl:relcl) case
bipolar (l_nmod) bipolar
epinephrine (r_conj) collagen
methadone-maintenance (r_compound) treatment
episodes (l_amod) bleeding
naa (r_nmod) application
features (l_nmod) encephalopathy
verapamil (r_dep) extended-release
precursor (r_appos) inhibitor
imipramine (r_nmod) induced
subject (r_acl:relcl) man
models (l_compound) arrhythmia
glycol (r_appos) vehicle
treatment (r_nmod) caused
causing (l_dobj) episodes
appearances (l_nmod) busulfan
paclitaxel (r_nmod) neurons
frequencies (l_nmod) fibrillation
transport (r_nmod) followed
variables (l_appos) age
provides (l_dobj) evidence
studied (l_dobj) groups
uses (r_nmod) continued
wound (l_compound) burn
0.05 (l_nsubj) incidence
studied (l_advcl) clarify
study (r_nsubj) demonstrated
consistent (r_acl:relcl) changes
clozapine (r_nmod) similar
recognize (l_dobj) toxicity
alcohol (r_nsubj) relieved
patient (l_conj) one
designed (l_ccomp) incidence
dose (r_nsubj) resulted
receiving (r_advcl) quantify
treated (r_amod) patients
decreasing (l_dobj) risk
caffeine (r_compound) ingestion
gestodene (r_dep) higher
ribavirin (r_nsubj) effective
had (l_dobj) tendency
ecstasy-associated (r_amod) dysfunction
management (l_compound) dependence
model (r_nsubj) model
bn (r_conj) antagonist
aneurysms (l_conj) malformations
disease (l_compound) stroke
receive (r_acl:relcl) patients
discontinuation (r_nmod) treated
carmofur-induced (r_amod) leukoencephalopathy
rats (r_nsubj) develop
include (l_dobj) hemorrhage
ulcer (l_amod) hemorrhagic
injury (l_acl) induced
actions (l_nmod) models
neoplasia (l_dep) n
ta-064 (r_appos) denopamine
compared (l_conj) group
depend (r_conj) plays
hydrochlorothiazide (r_compound) hctc
apap (r_nmod) reduction
presents (l_prep) with
induces (l_dobj) nephropathy
phenylalanine (r_nsubj) reduced
manifest (l_nmod) individuals
reversed (l_nsubjpass) amnesia
placebo (r_dobj) receive
use (l_advcl) occurs
reduces (l_dobj) frequency
gentamicin-arf (l_dep) decrease
propranolol (r_conj) receiving
measure (l_advmod) neuropathy
subchronic (r_conj) induced
antagonist (r_appos) spiranolactone
increase (l_nmod) volume
aconitine (r_nsubj) aggravates
effect (l_nmod) phenobarbitone-
penicillin (r_compound) anaphylaxis
induced (l_advcl) evidenced
indicating (l_ccomp) unlikely
durations (l_amod) seizure
associations (l_nmod) disease
caused (r_acl) epidemic
malondialdehyde (r_nmod) higher
reported (l_nsubjpass) hypoplasia
similar (l_nmod) vindesine
cases (r_nsubjpass) screened
unclear (l_nsubj) mechanisms
effects (l_nmod) ccl4
ribavirin (r_nsubjpass) found
developed (l_nsubj) woman
increase (l_nmod) disability
caused (r_acl:relcl) anemia
creatine (r_compound) elevations
postinjection (r_dobj) noted
history (l_nmod) thrombocytopenia
implicated (l_nmod) development
converted (l_dobj) tachycardia
chx (r_appos) cycloheximide
locomotion (r_conj) catalepsy
ameliorated (l_dobj) responses
involve (l_dobj) systems
microscopic (l_dep) studies
cocaine (r_nmod) stroke
inhibitors (r_nsubj) appropriate
determine (l_ccomp) was
combination (r_nmod) selegiline
appeared (l_nsubj) injury
sensitivity (l_nmod) convulsants
developed (l_dobj) episodes
093 (r_nummod) bia
treatment (l_nmod) anaphylaxis
amiodarone (r_nsubj) drug
administered (l_nmod) form
pretreated (r_acl) rats
expected (l_xcomp) effective
level (r_nsubjpass) observed
dexrazoxane (r_dobj) combining
trials (r_nsubj) ongoing
caffeine (r_nmod) concentration
report (l_conj) hypothesize
consequence (l_nsubj) effects
curves (r_conj) tensions
calcitriol (r_compound) therapy
tam-induced (r_amod) anemia
suspected (l_nsubjpass) mass
risks (l_nmod) ami
acetaminophen (l_dep) edema
nifedipine-induced (r_amod) telangiectasia
aza (r_conj) cyclosporine
remains (r_conj) circumstantial
known (l_xcomp) nephrotoxic
olanzapine (r_conj) clozapine
infusion (r_nmod) hypertension
marker (l_nmod) injury
induced (l_nmod) addition
used (l_parataxis) found
assessed (l_conj) evaluated
msg (r_compound) treatment
pregs (r_nmod) effects
increasing (l_dobj) factors
similar (r_conj) low
treated (r_acl) leukemia
ratios (l_nmod) hospitalization
toxicity (l_dep) syndrome
studies (r_nsubj) remain
observed (l_nsubjpass) damage
misoprostol (r_nsubjpass) associated
pressure (l_nmod) women
produced (r_acl) nerves
accelerating (l_dobj) atherosclerosis
role (r_nmod) suggestive
attenuated (l_dobj) convulsions
overdose (r_nmod) role
b (r_nmod) effect
dialysate (r_nsubj) alternative
effect (r_dobj) attenuates
modulation (l_nmod) intensity
indicates (l_dobj) damage
discharged (l_nsubjpass) patients
exacerbated (r_conj) appear
prior (r_advmod) received
subjects (l_acl) reporting
part (l_nmod) neurophysiology
doxorubicin (r_compound) cardiomyopathy
a (r_nmod) exposure
tolerated (l_nmod) reports
convulsions (r_nmod) incidence
mda (r_conj) tnfalpha
amphetamine (r_nmod) chow
qtls (l_appos) model
advocate (l_nmod) hours
azathioprine (r_nmod) treatment
disease (r_nmod) models
amines (r_nmod) results
report (l_conj) helpful
associated (l_nmod) myoglobinuria
failed (r_conj) reversed
exposed (l_nmod) hypercapnia
course (r_nmod) suffered
rating (l_compound) hyperkinesia
reverse (l_dobj) amnesia
designed (l_xcomp) using
administration (l_conj) development
subsequent (r_amod) failure
associated (l_nsubj) seizure
added (r_advcl) revealed
cis-ra (r_compound) levels
membrane (l_nmod) rats
tachycardia (l_nmod) patient
glucose (r_conj) protein
that (l_acl) administered
described (l_nsubjpass) newborn
srl (r_nsubjpass) combined
recurred (r_xcomp) episode
case (l_nmod) erythema
occurred (l_nsubj) confusion
received (l_nmod) onset
induced (r_acl) nausea
intake (r_nmod) observed
argatroban (r_acomp) administered
developed (l_nsubj) nodules
alternative (l_nmod) theophylline
norfloxacin-treated (r_conj) ciprofloxacin-
toxicity (r_nmod) case
using (l_nmod) types
gemcitabine (r_conj) paclitaxel
cardiotoxicity (r_nmod) sensitized
vincristine (r_compound) use
suxamethonium (r_nmod) loss
mortality (l_nmod) disease
ibuprofen (r_nmod) effect
wr-2721 (r_conj) cisplatin
treatment (r_nsubj) results
application (r_nmod) gel
cause (l_dobj) psychosis
similar (r_conj) derivative
receive (r_advcl) recruited
androgen- (r_nmod) patients
reported (l_dobj) risk
trazodone (r_nmod) dose
gaba(a)r (r_conj) nmdar
collected (l_nsubjpass) data
propafenone (r_compound) overdose
factor (l_nmod) hypothyroidism
combination (r_nmod) weeks
augmented (r_conj) triggered
39.5+/-8.4s (l_nsubj) duration
atropine (r_nmod) uses
presented (r_acl:relcl) patient
mepivacaine (r_nmod) exposure
pb (r_nmod) exposed
pgf2alpha (r_appos) ngf
isoproterenol (r_nsubj) activates
known (l_conj) remains
drug (r_attr) remains
gentamicin (r_nmod) treated
interaction (r_nsubjpass) kept
efficiency (l_nmod) mcl
received (r_acl:relcl) animals
inhibition (l_acl) inhibited
sensitive (l_nmod) cardiotoxicity
drugs (r_nmod) effect
trial (l_nmod) hypertension
clipping (l_nmod) artery
6-hydroxydopamine-lesion (r_compound) model
therapy (r_nmod) history
metronidazole-induced (r_amod) encephalopathy
switching (l_dobj) patients
weighed (l_nmod) risk
score (l_nmod) scale
variety (l_nmod) disturbances
case (r_appos) metoclopramide
cacl(2))-induced (r_amod) injury
carried (l_nmod) order
azidothymidine-induced (r_amod) anemia
paralysis (r_nmod) patients
ototoxicity (l_conj) nephrotoxicity
pap (r_compound) formation
> (r_dep) hypercalcemia
produced (l_advcl) evidenced
effect (r_nsubj) seems
ifo (r_nmod) therapy
prevent (r_conj) reduce
toxicity (r_nmod) pathogenesis
maintaining (r_advcl) consumed
acting (r_acl) agents
patients (r_nmod) method
found (l_nsubjpass) seizures
neurons (r_nmod) neurodegeneration
developed (l_dobj) life
improved (l_dobj) duration
combination (l_nmod) adults
nifedipine (r_nsubj) useful
abnormalities (l_dep) implications
spironolactone (r_conj) inhibitor
scattered (l_dep) degeneration
effect (l_nmod) calcification
consists (r_ccomp) demonstrates
glomeruli (r_nmod) %
increase (r_dobj) included
bisphosphonates (r_nsubj) aggravate
signs (l_nmod) toxicity
treatment (l_nmod) acromegaly
decrease (r_nmod) associated
cimetidine (r_dobj) receiving
resulted (l_nmod) failure
number (l_nmod) admissions
picrotoxin- (r_amod) seizures
combination (r_nmod) dexamethasone
haloperidol (r_nmod) observed
terbutaline-induced (r_amod) hypokalemia
initiated (l_conj) subsided
treated (r_acl) those
return (l_nmod) complications
hypothesis (l_nmod) dysfunction
lidocaine (r_compound) infusion
cocaine (r_nmod) effects
chlorpropamide (r_compound) therapy
dealt (l_nmod) infarction
alpha-tac (r_appos) acetate
quinine (r_compound) ingestion
doxorubicin (r_nmod:npmod) cardiomyopathy-induced
ephedrine (r_nsubj) maintains
tacrolimus (r_nmod) switching
agents (l_conj) placebo
case (l_nmod) tdp
produced (l_dobj) ischemia
pentobarbital-induced (r_amod) failure
s-23121 (r_nmod) exposure
cpdd (r_appos) cisplatinum
conditions (l_nmod) amount
b12 (r_nmod) correlation
effect (l_nmod) ammonia
gentamicin (r_nmod) injections
suggests (r_conj) demonstrates
carbamazepine (r_dobj) adding
sensitization (l_nmod) seizures
types (l_nmod) epilepsy
total (r_amod) anesthesia
methadone (r_compound) dose
dronedarone (r_nsubj) reduced
investigated (l_dobj) patients
vpa (r_nmod) treated
experienced (l_dobj) hepatitis
man (l_nmod) ischemia
adrenaline-induced (r_amod) ventricular
administered (r_csubj) leads
resulted (l_nsubj) delirium
improved (r_acl:relcl) subthalamotomy
suxamethonium (l_conj) bradycardia
gtn (r_compound) administration
counteract (l_advcl) provoke
initiation (r_dep) weeks
paclitaxel (r_nmod) both
sirolimus (r_nmod) administration
determine (l_ccomp) correlated
induction (l_nmod) dermatitis
treated (r_acl) mcl
microangiopathy (l_appos) tma
ce (r_nmod) reaction
onset (r_dobj) developed
administration (r_nmod) antagonize
vcm-treated (r_amod) rats
lamivudine (r_dobj) receive
signaling (l_nmod) poisoning
amphetamine (r_conj) cocaine
cause (l_dobj) neurotoxicity
oxygen (r_compound) therapy
involving (r_acl) thrombosis
opportunity (l_acl) observe
therapy (r_nmod) comparison
bed (l_compound) tumor
buildup (l_nmod) activity
reserpine- (r_nsubj) models
therapy (r_nsubjpass) started
improving (l_nmod) syndromes
observed (l_nsubjpass) evidence
acid (r_nmod) glucuronidation
associated (r_acl) jaundice
chloroprocaine (r_compound) group
phase (r_nmod) rats
patients (r_nmod) frequently
dose (r_nmod) correct
treated (l_nmod) p9605
enalapril (r_nmod) safety
efficacious (l_conj) likely
treatment (l_nmod) woman
papilloma (l_conj) carcinoma
efficacy (r_nmod) data
arabinoside (r_nmod) toxicity
n (r_dep) um-272
discuss (l_nmod) adults
reported (r_conj) recognized
aspirin (r_dobj) taking
srl (r_compound) combination
cacl2 (r_nmod) administration
reduces (r_conj) reduces
developed (l_dobj) leukemia
frequency (r_conj) effect
had (l_dobj) torsades
carriers (r_nmod) dna
recorded (l_nsubjpass) latencies
transplanted (r_acl) patients
effect (r_dobj) support
action (l_amod) neurotoxic
d-amb (r_dep) compared
terfenadine (r_appos) withdrawal
effects (r_nsubjpass) preserved
number (l_nmod) cells
exception (l_nmod) mice
impact (l_nmod) prevention
patients (l_amod) asthmatic
fluoxetine (r_nsubj) caused
appeared (r_acl:relcl) hepatitis
caused (r_acl) loss
activity (r_nsubjpass) mediated
angiotensinogen (r_nmod) upregulation
predictors (l_nmod) disease
labetalol (l_nmod) isoflurane
injections (r_nsubj) increased
benzodiazepines (r_nmod) induced
initiated (l_conj) increased
effects (r_nsubj) include
angiotensin (r_compound) blocker
c (r_appos) cholesterols
addicts (r_nmod) group
had (l_conj) developed
cisplatin (l_nmod) carcinoma
blocks (l_dobj) allodynia
decreased (r_conj) increased
responses (r_dobj) had
influence (l_nmod) convulsions
estradiol (l_conj) dm
severity (l_nmod) pain
has (l_nmod) effects
carried (l_conj) aware
increased (l_xcomp) indicating
complete (l_dobj) block
mechanisms (r_dobj) identifying
no (r_compound) synthase
difference (l_nmod) index
roles (l_nmod) development
activate (l_nmod) disruption
seizures (r_nmod) onset
accompanied (r_acl:relcl) bradycardia
heparin (r_nmod) concentration
seizures (l_dobj) %
those (r_dobj) resembled
propranolol (r_compound) group
catalepsy (r_dobj) improves
injection (r_nsubj) caused
glutamate (l_dep) variability
induced (l_dobj) amelioration
inhibitors (r_nmod) those
metamizol (r_nsubj) potentiates
losartan (r_nsubj) reduced
subacute (l_amod) alzheimer-like
medication (r_nmod) associated
course (l_nmod) osteomyelitis
medicine (l_nmod) impairment
outcome (l_nmod) signs
isoflurane (r_nmod) dose
antagonists (r_nmod) doses
tissues (l_nmod) rats
hctc (r_nmod) hypertension
etoposide (r_conj) nelarabine
cells (l_compound) adenoma
screening (r_nsubj) provide
primary (l_dep) thrombotic
symptoms (l_nmod) confusion
received (l_nmod) vasospasm
induce (l_dobj) relapse
neurons (r_nmod) effect
selegiline-induced (r_amod) hypotension
affected (r_conj) enhanced
drop (r_conj) revealed
associated (l_nmod) nephrotoxicity
had (l_dobj) failure
animals (r_nmod) pretreatment
randomized (r_nsubj) increase
treatment (r_nmod) stabilized
developing (l_dobj) failure
users (r_nmod) 3.10
apomorphine (r_conj) stereotypy
effective (l_advcl) preventing
anthracycline (r_compound) derivative
complicated (l_nmod) fluctuations
steroid (l_dep) receptor
studies (r_attr) been
transplantation (l_nmod) atresia
produced (l_dobj) delay
provide (l_dobj) treatment
lines (r_nmod) data
had (l_nsubj) women
acid (r_nsubjpass) given
acetaminophen (r_amod) overdose
treatment (l_nmod) rhinitis
mg/caffeine (r_dep) ergotamine
examined (l_nmod) patients
rats (l_nmod) damage
amphetamine (r_compound) hyperactivity
thalidomide (r_amod) neuropathy
methylprednisolone (r_dep) high-dose
cumulative (l_dep) cardiomyopathy
lindane (r_nmod) induced
pilocarpine (r_conj) lithium
veralipride (r_nmod) use
mechanisms (l_nmod) ic
suggesting (l_ccomp) involves
group (r_nmod) greater
l-arginine (r_compound) transport
b (r_compound) nephrotoxicity
azt-treated (r_amod) mice
resulted (r_advcl) initiated
condition (r_nmod) had
prevented (l_nmod) min
highlight (r_conj) downregulates
concentration (l_conj) proteinuria
doxorubicin (r_nmod) model
effects (l_amod) anti-dementia
belonging (r_acl) patients
test (l_dobj) validity
oxide (r_conj) factor-alpha
features (l_nmod) failure
presented (l_nmod) loss
usage (l_conj) seizures
measured (l_nmod) levels
encephalopathy (r_dobj) developed
occasions (l_nmod) history
rashes (l_appos) erythematosus
occurs (l_nmod) vomiting
point (l_nmod) normality
dementia (l_nmod) type
age (r_nmod) variables
increased (l_nsubj) expression
development (l_nmod) nafld
terms (l_acl) neuropathy
atra (r_nsubj) choice
experienced (l_dobj) hypotension
gfc (r_compound) effects
rizatriptan (r_dobj) taking
thrombi (r_conj) deterioration
lithium (r_compound) level
vte (r_nmod) cases
b12 (r_nmod) role
morphine (r_compound) administration
urd (r_compound) administration
evaluates (l_dobj) effects
used (r_acl:relcl) subjects
carbonate (r_nmod) treated
option (l_conj) maintained
patients (r_nmod) anxiety
child (l_acl:relcl) developed
involvement (r_nsubjpass) established
evidence (l_nmod) impairment
preparation (r_conj) type
occurred (l_dobj) agent
ammonia (r_conj) blood
retrieved (l_nsubj) analysis
antagonism (l_nmod) seizures
ketoconazole (r_nmod) ingestion
hyperemia (r_nmod) had
cd-832 (r_nsubj) improves
present (l_nsubj) acidosis
resulted (l_nmod) hypertension
used (l_xcomp) improve
ma-induced (r_amod) hyperthermia
patients (r_dobj) switching
reduction (l_nmod) incidence
toxicity (r_nsubjpass) ameliorated
channel (r_compound) blocker
feeding (l_dobj) diet
treatment (l_nmod) treatment
mtx (r_dep) 5-fluorouracil
toxic (l_nmod) system
conclude (l_advcl) affirming
incorporate (l_conj) permitted
dose (l_dep) causing
plays (l_nmod) patients
mechanism (r_nmod) cause
patients (r_nmod) slower
animals (r_nmod) hearts
considered (l_nsubjpass) possibility
beat (l_conj) known
matched (r_acl) subjects
dexamphetamine- (l_dep) stereotypies
contraceptives (r_dobj) receiving
qtp (r_conj) low
microinjection (r_nsubj) improves
caused (r_acl) hypoxia
% (r_nmod) compared
criteria (l_nmod) vte
treatment (r_nmod) safety
had (l_nsubj) edds
antagonists (r_nmod) potencies
refractory (l_dep) leukaemia
toxicity (r_nsubjpass) recognized
induced (l_nsubjpass) arrhythmia
diagnosis (r_nmod) patients
guanethidine (r_nmod) injection
changes (r_nsubjpass) studied
hypothesize (l_ccomp) needed
fluoxetine (r_nsubj) gaining
induce (l_dobj) hematotoxicity
feature (l_nsubj) cholestasis
role (l_nmod) stress
fentanyl (r_dep) superior
produced (r_acl) rigidity
receptors (r_nmod) blockage
tmp (r_appos) trimethaphan
distinguish (l_dobj) group
amantadine (r_compound) activity
pg (r_dobj) tolerated
months (r_nmod) developed
alf (l_conj) cld
irrigations (r_nmod) percentage
taking (r_acl) those
agonist (r_conj) antagonist
reducing (l_nmod) patients
immunosuppression (r_nmod) switch
prazosin (r_conj) enalapril
suxamethonium (r_nsubj) causes
subjects (l_conj) subjects
rats (r_nmod) damage
remain (l_nsubj) pharmacology
e (r_compound) synthase-1
used (l_nmod) tumours
prevent (l_dobj) hypertension
thalidomide (l_nmod) patients
cyclophosphamide-induced (r_amod) lesions
bradyarrhythmia (l_acl) requiring
vpa (r_nmod) potent
seizure (r_conj) left
preference (l_conj) aggression
ufh-related (r_amod) hit
assessed (l_xcomp) using
rate (l_nmod) nephropathy
reversal (l_nmod) catalepsy
kept (l_nmod) therapy
incidence (l_conj) seizures
ma (r_compound) abuse
ccnu-associated (r_amod) toxicity
etoricoxib (r_nsubj) demonstrated
presented (l_nmod) weakness
haloperidol (r_nmod) neuroleptics
triggered (r_appos) conclusions
p-chlorophenylalamine (r_nmod) pretreatment
hyperalgesia (r_nmod) participates
disease (l_conj) prognosis
erythrocytes (l_conj) anemia
has (l_nmod) replication
cisapride-treated (r_amod) patients
reaction (l_acl) resulting
presented (l_nsubjpass) patient
sodium (r_nmod) therapy
lithium-pilocarpine-induced (r_amod) se
rad001 (r_nsubj) shown
became (l_acomp) manic
picrotoxin (r_compound) microperfusion
remifentanil (r_nmod) doses
salbutamol (r_nmod) triggered
changes (l_nmod) women
relation (l_nmod) defects
co2 (r_nmod) pulses
fluvoxamine (r_nmod) treatment
measured (r_conj) performed
developed (r_acl:relcl) patients
ecgs (l_nmod) controls
transplantation (l_nmod) tumors
thiopental (r_nmod) treated
function (l_nmod) patients
present (l_nmod) cardiotoxicity
epinephrine (l_nmod) glaucoma
respond (l_nsubj) %
effect (l_nmod) bruising
1999 (l_nmod) alf
caffeine (r_nmod) frequency
tp (r_nsubj) acted
stimulates (l_dobj) expression
presence (l_nmod) history
use (r_nmod) resulting
developed (l_dobj) chf
users (r_nmod) abnormalities
phenytoin (r_compound) encephalopathy
iron (r_compound) level
treatment (r_nmod) failure
arabic (l_nmod) nephrotoxicity
history (r_nmod) discussion
system (r_nmod) activation
myoclonic (l_conj) seizures
syndrome (r_nmod) case
small (l_conj) have
noted (l_nmod) treatment
finding (r_nsubj) suggests
children (l_nmod) autism
hypotension (r_nmod) duration
instructed (l_xcomp) watch
bicarbonate (r_nmod) addition
example (l_nmod) hepatotoxicity
seems (l_nsubj) action
neuroleptic-associated (r_amod) hyperprolactinemia
media (r_nmod) extent
complete (l_conj) complete
duration (l_nmod) hypotension
releases (l_conj) potentiates
induced (l_nsubjpass) hyperalgesia
converted (l_nmod) chorea
known (l_xcomp) neurotoxic
suggest (l_advcl) established
model (l_compound) pain
developed (l_conj) had
ointment (r_nsubjpass) used
cream (r_nmod) treated
phenobarbital (r_amod) therapy
receptors (r_dobj) involves
benzylacyclouridine (r_nsubj) reverses
group (l_conj) nausea
malformations (r_nmod) detection
stz (r_compound) treatment
given (l_nsubjpass) patients
erythroderma (l_conj) hyponatremia
investigate (l_dobj) strains
attributable (r_amod) vasculitis
induction (l_nmod) dysfunction
had (r_dep) observations
bupivacaine (r_nsubj) stimulates
reverses (l_dobj) rigidity
use (r_nmod) setting
memory (l_acl) functioning
reported (l_nsubjpass) glomerulonephritis
ritanserin (r_nmod) microinjection
side-effects (l_conj) loss
infusion (l_conj) superior
therapy (r_nmod) onset
treatment (r_nmod) syndrome
c (r_nmod) intake
narrowing (l_nmod) arteries
cause (l_dobj) nephrotoxicity
man (l_nmod) cardiotoxicity
azelastine (r_compound) group
lines (l_acl) selected
injection (r_nmod) severity
evidence (l_nmod) damage
group (r_nmod) incidence
groups (r_nmod) showed
claimed (l_xcomp) ameliorate
random-assignment (r_dep) method
given (r_acl) lometrexol
induced (l_dobj) convulsions
oct (r_nmod) effects
administration (r_nsubj) ameliorates
enflurane (r_nmod) activated
isoflurane (r_compound) concentration
prolonged (l_conj) decreased
sedation (l_conj) confusion
related (l_nsubj) azotemia
induced (r_acl) bradycardia
l-noarg (r_amod) administration
dose (r_conj) therapy
aggravates (l_dobj) proteinuria
selegiline (r_nmod) patients
lidocaine (r_nmod) administration
hydralazine (r_nmod) induced
reported (l_nsubjpass) encephalopathy
doxorubicin (r_conj) groups
girl (l_nmod) syndrome
doses (r_nmod) injections
attenuate (l_dobj) amnesia
administered (r_advcl) induce
diagnosis (l_nmod) sah
hydrochlorothiazide (r_amod) (hctz)-monotherapy
seven (r_nmod) injection
prevented (l_parataxis) remained
reported (r_advcl) described
treatment (r_nmod) restarting
cause (l_nsubj) hypokalemia
salicylates (r_conj) calcium
dyskinesias (l_conj) parkinsonian
cases (l_nmod) adenoma
thrombopenia (l_conj) hemolysis
hpma (r_compound) conjugates
increasing (l_conj) follow
showed (l_dobj) contraction
(na (r_nmod) properties
cyclophosphamide-based (r_dep) high-dose
induced (r_acl) psychosis
clozapine (r_compound) risperidone
hypertension (l_conj) hypotension
initiated (r_acl) treatment
adriamycin (r_appos) doxorubicin
instances (r_nmod) required
licensed (l_conj) combination
tumors (l_nsubj) most
increase (r_dep) attack
had (l_ccomp) neuropathy
substantiate (r_xcomp) unable
apomorphine (r_conj) haloperidol
therapy (r_nmod) increased
metformin (r_nmod) unchanged
tachycardia (l_conj) fibrillation
myelin (l_conj) axons
enlargement (l_appos) relationship
ester (r_nmod) inhibition
signs (l_nmod) nms
using (r_advcl) developed
occlusions (l_nmod) blindness
those (r_nmod) better
included (l_conj) decrease
hydrocortisone (l_nmod) injury
trazodone (r_nsubj) induced
attention (l_conj) memory
patients (l_nmod) angio-oedema
indicated (l_nsubj) absence
followed (r_conj) administered
developed (l_dobj) eruptions
found (l_nsubjpass) proteinuria
glaucoma (l_conj) glaucoma
situations (l_acl:relcl) is
induction (l_nmod) tachycardia
compound (l_nmod) treatment
woman (l_nmod) depression
morphine (r_compound) therapy
capsaicin (r_nmod) doses
impairments (l_acl) coupled
benzodiazepines (r_nsubjpass) found
given (l_nmod) days
contributes (l_nmod) effect
evaluates (r_conj) acts
malignancies (l_conj) patients
reaction (l_conj) eosinophilia
decreases (l_nmod) indices
calcification (r_nmod) resistant
halide (r_compound) intermediates
clozapine (r_conj) chlorpromazine
therapy (r_nmod) insipidus
showed (l_dobj) signs
administration (r_nmod) drop
period (l_nmod) apnea
nsvt (l_conj) contractions
induced (r_amod) degeneration
patient (r_nmod) case
measured (l_advcl) induced
reduction (l_nmod) pain
superoxide (r_dobj) decreased
injected (l_conj) markers
experienced (l_dobj) somnolence
used (l_conj) methylphenidate
age (r_nmod) function
detachment (l_amod) owing
had (l_nmod) dyskinesia
subtypes (l_acl) involved
pursued (l_nmod) pretreatment
intravitreal (l_nmod) patients
amphetamine (r_nmod) induced
amifostine (r_nmod) addition
min (l_conj) haemodilution
urea (r_dep) biochemical
warfarin (r_nmod) induced
pain (l_conj) nausea
sulpiride (r_compound) therapy
antagonize (l_dobj) hypothermia
efficacy (r_nsubj) assessed
distress (l_conj) rash
degree (l_nmod) tolerance
carmustine-[1,3-bis (r_compound) (2-chloroethyl)-1-nitrosoure
diltiazem (r_conj) performed
controlling (l_dobj) pain
vigabatrin (r_nmod) associated
presented (l_nmod) syndrome
malondialdehyde (r_nmod) determination
consumption (r_nmod) associated
effects (l_acl:relcl) model
report (l_nmod) trial
nifedipine (r_nmod) impact
disorder (l_conj) disorders
consistent (l_nmod) that
gemcitabine (r_compound) combination
events (r_dobj) reported
suffering (l_nmod) psoriasis
types (l_nmod) arrhythmias
suspected (r_conj) acknowledged
malondialdehyde (r_conj) mt
appeared (l_xcomp) responsible
irradiation (l_nmod) bed
women (r_nmod) adenomas
increased (l_conj) returned
organochlorine (r_compound) insecticide
resulted (l_nmod) seizures
monophosphate (r_compound) excretion
found (l_nmod) nephritis
adriamycin (r_compound) administration
treat (l_dobj) types
delirium (l_appos) edds
nerves (r_nsubjpass) involved
mdma (r_dep) 3,4-methylenedioxymethamphetamine
dizziness (l_conj) palpitation
mecamylamine (r_conj) atropine
related (r_acl:relcl) m(3)-machr.
used (l_nmod) surgery
intervention (r_nsubj) sensitizes
number (l_nmod) patients
involved (r_ccomp) investigate
blockers (r_nsubjpass) tolerated
lidocaine (r_conj) ketamine
catalepsy (r_nmod) potentiation
exhibited (l_dobj) twitching
blockage (r_dobj) trough
osteoarthritis (l_dep) patients
fat (r_amod) diet
chlorpropamide (r_nmod) treated
didanosine (r_nmod) use
inducing (r_advcl) followed
history (r_conj) patients
observed (l_nsubjpass) 99
similar (l_nsubj) toxicity
history (r_nmod) patients
disruption (r_dobj) triggers
busulfan (r_compound) dose
sodium (r_nsubj) have
receiving (l_dobj) drug
naloxone (r_nmod) influence
effects (r_nsubj) nephrotoxicity
anthracyclines (r_conj) cyclophosphamide
use (r_nmod) seizure
copper/zinc-superoxide (r_amod) dismutase
occurred (r_dep) suffered
ketanserin (r_compound) pretreatment
patients (r_nsubj) complained
animals (r_nsubj) developed
estradiol (r_nmod) effects
domperidone (r_nsubj) induce
mivacurium (r_conj) suxamethonium
evaluate (l_dobj) mechanisms
preventing (l_dobj) hepatitis
ezetimibe (r_nmod) published
contribute (l_nmod) disease
effect (l_nmod) model
terfenadine (r_dep) clinic
induce (l_dobj) angiogenesis
tobramycin (r_nmod) nephrotoxicity
active-w (r_compound) study
doses (r_nmod) prevent
fluorouracil (l_nmod) cancer
protein (l_appos) inhibitor
sedation (l_conj) tremors
hemorrhage (l_appos) sah
evaluation (l_nmod) pain
anaesthesia (r_nmod) leg
ibuprofen (r_appos) agents
biopsies (l_compound) lesion
u-ii (r_nmod) administration
confirmed (r_advcl) prudent
association (l_nmod) calcification
decreased (l_dobj) that
warfarin (r_nmod) fibrillation
enzyme (l_nmod) fibroblasts
desferrioxamine (r_dobj) receiving
amisulpride- (r_amod) crisis
associated (r_acl:relcl) development
lidocaine (r_nmod) preferable
treatment (l_nmod) c
reduction (r_nsubj) resulted
olanzapine (r_dep) =
fludrocortisone (r_nmod) reversed
contrast (r_compound) material
demonstrated (l_xcomp) occur
inhibitors (l_nmod) convulsions
history (l_nmod) aggressiveness
day (r_nmod) developed
related (l_nsubj) protection
caused (l_nmod) studies
protection (l_nmod) hemolysis
lid (l_compound) disease
suggests (l_ccomp) condition
calcium (r_nmod) addition
activity (l_nmod) tumours
nelarabine (r_nmod) d
patients (r_nmod) common
comparison (l_nmod) treatment
control (l_nmod) seizures
weeks (r_nmod) elevated
yohimbine (r_nsubj) treatment
streptozotocin (r_compound) rats
doxorubicin-loaded (r_amod) nanoparticle
compatible (l_nmod) repair
complexes (r_nsubj) catalyze
effective (l_nmod) infusion
lipopolysaccharide (r_compound) pretreatment
treated (r_conj) patients
dexamethasone (r_nsubj) had
corticosteroids (r_nmod) reactions
levodopa (r_nsubj) therapy
pilsicainide-induced (r_amod) torsades
< (l_dep) vomiting
cardiomyopathy (r_nmod) development
increased (l_dobj) dysfunction
developed (l_nsubj) blindness
relative (r_amod) users
resulted (l_conj) low
produces (l_acl) lasting
injected (l_conj) studied
contribute (l_nmod) degeneration
treatment (r_nmod) abnormalities
diethylstilbesterol (r_nmod) nuclei
cessation (r_nmod) polyuric
infusion (r_nmod) case
history (l_nmod) disease
salbutamol (r_nmod) treatment
animals (r_nmod) cords
concentrations (r_nmod) treatment
included (l_nmod) drugs
showed (l_dobj) dysfunction
result (r_nmod) case
unconjugated (l_dobj) hyperbilirubinemia
bortezomib/dexamethasone (l_nmod) induction
used (l_nsubjpass) seizure
girl (r_nmod) case
incidence (l_nmod) fasciculation
monotherapy (l_nmod) treatment
treatment (l_nmod) mania
suffering (r_acl) mice
two (r_nmod) continued
treated (r_acl) area
thiosulphate (r_nmod) dermatitis
treatment (r_dobj) beginning
treatments (r_conj) albuterol
physician (r_nmod) communicated
isoproterenol (l_advcl) producing
groups (r_nmod) differ
patients (l_nmod) depression
risk (l_nmod) impairment
concentrations (r_dobj) measuring
value (l_nmod) prevention
nucleosides (r_conj) increase
case (r_dobj) report
t (r_conj) m
contraceptives (r_conj) hypertension
combination (l_nmod) dogs
cocaine (r_nmod) screening
variations (l_nmod) amplitude
stenosis (l_acl) combined
treatment (r_nsubj) caused
angiotensin-converting (r_amod) enzyme
enhance (l_dobj) toxicity
prescribed (r_advcl) occur
oliguria (l_conj) pain
hexamethonium (r_conj) increased
risk (r_dobj) estimate
aware (l_ccomp) cause
agsd (r_nmod) closest
induced (l_nsubjpass) anemia
relationship (l_nmod) diagnosis
patients (l_nmod) apl
kanamycin-dextran (r_nmod) induced
evaluation (r_nmod) injection
1,5-benzothiazepine (r_amod) antagonist
dtic (r_amod) therapy
associated (r_acl:relcl) effect
dysfunctioning (r_nmod) idea
decreased (l_nsubj) pressure
sotalol (r_nmod) properties
report (l_dep) one
group (l_dep) dm
2-chloroprocaine-ce (r_dobj) received
doxorubicin-associated (r_amod) toxicity
induced (l_dobj) hepatomegaly
had (l_dobj) likelihood
developed (l_nsubj) patients
% (r_nsubj) had
incidence (l_nmod) tachyarrhythmias
rifampicin (r_nmod) administration
ifosfamide (r_nmod) chemotherapy
chlorpromazine-induced (r_amod) eps
desipramine (r_compound) toxicity
escitalopram (r_conj) simvastatinezetimibe
arag (r_appos) nelarabine
pattern (l_nmod) absence
prophylaxis (l_amod) seizure
attenuated (l_advcl) affected
those (l_nmod) akathisia
bupivacaine (l_appos) reversion
= (r_dep) correlation
prolonged (l_advcl) characterized
of (l_pobj) seizure
capsaicin (r_nmod) response
co-administered (r_nsubj) showed
bupivacaine (r_dobj) receiving
amantadine (r_nmod) readministration
detachment (l_conj) edema
admitted (l_nmod) exclusion
effect (l_nmod) injury
induction (l_nmod) relapse
effects (r_conj) rate
course (r_nmod) developed
represented (l_dobj) treatment
doxorubicin (r_nsubj) induces
thrombocytopenia (r_nmod) history
mentioned (l_advcl) associated
month (r_nmod:tmod) disappeared
effect (l_nmod) rats
man (l_acl:relcl) developed
treatment (r_nmod) was
involved (l_advcl) mediating
persists (l_amod) fire
% (l_nsubj) relief
treated (l_conj) use
head (r_nsubj) twitches
have (l_nsubj) sensitization
tolerability (l_conj) paracetamol
weekly (r_dep) alpha-2b
treat (l_dobj) nsclc
pentobarbital (r_nmod) produced
increased (r_conj) defined
degeneration (l_nmod) neurons
carbamazepine (r_compound) neurotoxicity
simvastatin (r_nmod) maintained
induce (l_nsubj) hypomagnesemia
induced (r_amod) neurotoxicity
loss (l_nmod) creativity
alcohol (r_dobj) use
concentration (r_nmod) maintained
behaviour (l_amod) depressive-like
disorder (l_appos) ptld
hypercalcemia (r_nmod) patients
presented (l_nmod) department
induced (r_acl) antinociception
definition (l_nmod) combination
november (r_nmod) searched
association (r_nmod) reported
sirolimus (r_nsubj) induces
prevent (l_dobj) oih
evaluation (l_nmod) testing
associated (r_acl) slowing
suggest (l_nsubj) action
combination (r_nmod) treatment
lesions (l_acl) mimicking
interaction (r_nsubj) exacerbated
intakes (r_conj) assessed
associated (l_nsubjpass) use
pregs (r_nsubj) able
activity (l_conj) apnea
ergotamine/caffeine (r_nmod) patients
ability (l_acl) attenuate
activity (l_acl) observed
lactate (r_compound) level
lidocaine (r_dobj) had
exhibit (l_conj) inhibited
gtn (r_dobj) using
distinguish (l_nsubj) studies
hypotension (r_dobj) affect
difficult (r_ccomp) possibility
events (r_dep) activation
day (r_nmod) exhibited
d (l_nmod) calcification
concentration (r_conj) effect
arthritis (l_appos) ra
volume (l_compound) hemorrhage
gets (r_acl:relcl) apnea
rats (l_amod) neprotic
produced (r_acl:relcl) catalepsy
reduction (l_conj) activity
nephrotoxicity (r_nsubj) reviving
sm-5887 (r_nmod) potential
had (r_conj) had
use (l_conj) symptoms
cholesterol (r_nmod:npmod) rich
amn082 (r_nsubj) reverses
patient (r_nmod) seizure
benzodiazepines (r_conj) 5-htp
improvement (l_nmod) dyskinesias
assess (l_nmod) case
patients (r_nmod) necrosis
vancomycin (r_conj) amikacin
adr (r_nmod) mice
carboplatin (r_conj) paclitaxel
groups (r_nmod) hg
patients (r_advcl) accelerated
case (r_dobj) describes
pilocarpine- (r_nmod) activity
reported (l_nsubjpass) abnormalities
nitrendipine-treated (r_amod) group
measured (l_nmod) gain
identify (l_dobj) factors
case (l_nmod) occlusion
agent (l_amod) nephrotoxic
prescribed (l_nmod) chemotherapy
values (r_nmod) experiencing
offer (l_dobj) protection
cimetidine (r_nmod) caused
resulting (r_acl) seizure
patients (l_nmod) coagulation
concentration (l_nmod) virus
patient (l_appos) arrhythmia
appeared (l_nsubj) akathisia
hemorrhagic (l_conj) ischemic
starting (r_advcl) infusing
levodopa-induced (r_conj) overflow
17alpha-ethinylestradiol (r_nsubj) (ee)-induced
mk-801 (r_conj) pentobarbital
chloride (r_nmod) establish
b (r_nmod) study
sulfasalazine (r_nmod) hepatotoxicity
convulsions (l_nmod) damages
affect (l_dobj) atherosclerosis
non-a (l_nmod) hepatitis
olanzapine (r_dep) classical
appeared (l_nsubj) tachycardia
one (l_nmod) dyskinesia
cocaine-induced (r_amod) increase
caused (l_nmod) atrophy
examined (l_nsubjpass) tumorigenesis
sunitinib (r_nmod) inhibitors
cyclosporine (r_dep) inhibitors
poisoning (r_nsubj) manifests
patients (r_nmod) manifestation
neither (r_dep) meter
reports (l_nmod) paralysis
days (l_appos) tumors
barbiturate (r_compound) narcosis
inositol (r_compound) model
bradykinin (r_conj) products
labetalol-induced (r_amod) hypotension
seems (l_nsubj) myoclonus
patient (l_acl) manifest
sevoflurane (r_nmod) concentrations
6-thioguanine (r_nmod) caused
applying (r_advcl) excellent
necrosis (l_conj) steatosis
copper (r_compound) metabolism
injection (r_nsubj) effect
trial (l_nmod) patients
neuroleptic-induced (r_amod) catalepsy
that (r_dobj) surpasses
thp (r_nmod) administration
woman (l_nmod) failure
herbicides (l_nmod) studies
evaluate (l_dobj) effects
interval (l_nmod) administration
inflammation (r_dep) constructed
investigated (l_nmod) number
reduced (l_advcl) reducing
administration (r_nsubjpass) continued
reaction (l_nmod) patients
dose (r_nmod) injection
carried (l_conj) instructed
lomustine (r_appos) ccnu
use (r_nsubj) cause
experienced (l_dobj) incontinence
involved (l_nmod) production
man (l_nmod) allergies
patients (l_nmod) syndrome
study (l_nmod) group
compared (r_dep) free
sotalol-induced (r_amod) spasm
ara-c (r_nsubjpass) associated
piroxicam (r_conj) dfu
composition (l_nmod) stones
results (l_appos) occurred
improves (l_advcl) reducing
ecstasy (r_compound) users
amino-nucleoside (r_nmod) injection
case (l_advcl) is
models (l_amod) seizure
effects (r_nmod) knowledge
research (l_nmod) administration
patients (r_nsubj) underwent
men (r_nmod) found
concentrations (r_nmod) each
reporting (l_dobj) nausea
lithium-induced (r_amod) malformations
reversion (l_nmod) cases
caused (l_nsubj) maneuver
models (l_nmod) deficiency
mg/kg/d (r_dobj) receive
wr242511 (r_nmod) doses
type (r_nmod) investigated
treatment (l_nmod) hyperprolactinemia
adrenaline (r_nmod) infusion
injections (l_nmod) deterioration
metronidazole (r_dobj) taking
used (l_xcomp) study
5-azc (r_appos) 5-azacytidine
remifentanil (r_compound) infusion
shows (l_ccomp) (ee)-induced
patients (l_acl) referred
used (l_advcl) proposed
administration (r_nmod) concern
cisplatin (l_appos) toxicities
induced (r_acl) syndrome
patients (l_nmod) encephalopathy
pressure (r_nmod) rise
pan (r_nmod) produced
role (r_dep) delirium
angina (r_nmod) treatment
predominate (l_conj) mask
indicating (l_dobj) involvement
fluoropyrimidines (r_dep) importance
potentiation (l_conj) prevention
methamphetamine (r_compound) abuse
ingestion (r_nmod) related
treatment (r_nmod) patients
treatment (r_nmod) factors
donors (r_dobj) preventing
levels (r_nmod) diagnosis
formation (l_nmod) cysts
deferoxamine (r_compound) therapy
nodosum (l_nmod) patients
patients (l_nmod) mbc
acidification (r_nsubj) attenuate
desipramine (r_appos) agent
synthesis (r_nmod) attributed
treatment (r_nmod) occur
acknowledged (l_nmod) predilection
experienced (l_dobj) drop
administered (l_conj) offspring
calcium (r_compound) antagonist
superior (r_acl:relcl) prevention
developed (r_acl) patients
responsible (l_nmod) resistance
had (l_dobj) cystitis
presenting (r_acl) patients
doxorubicin (r_nmod) both
consolidation (r_nmod) disruption
indomethacin (r_nmod) anemia
1 (r_nummod) day
respond (l_nmod) hypotension
risk (l_nmod) women
hypertension (l_acl) accompanied
protects (l_nmod) loss
enhanced (r_acl) disturbances
study (l_dobj) symptoms
stz (r_appos) streptozocin
mtx (r_nmod) nephrotoxicity
defined (l_nsubjpass) function
concentration (l_nmod) model
expression (r_nmod) associated
have (l_dobj) syndrome
tamoxifen (r_nmod) prevention
impairments (r_dobj) protects
attacks (l_nmod) aura
prevent (l_dobj) hc
quetiapine (r_nmod) treatment
induced (l_nmod) carcinogens
search (l_nmod) methods
associated (r_acl) mutations
role (l_nmod) cancer
observation (l_ccomp) produce
effects (r_dobj) prevent
contribute (l_nmod) damage
received (l_conj) took
reduction (l_conj) outcome
steroids (r_nsubj) have
become (l_acomp) hemorrhagic
receptors (r_nmod) affinity
had (r_conj) occurred
responses (l_nmod) asthmatics
oxycodone (r_nmod) dose
actions (l_amod) convulsive
mg (r_dep) mepivacaine
ratio (r_dep) associations
depletor (r_appos) pretreatment
histories (l_amod) psychiatric
suppressed (l_conj) suppressed
patients (l_nmod) lymphoma
agonist (r_appos) beta-carboline-3-carboxylate
iii/iv (l_amod) encephalopathy
cycloheximide (r_nsubj) failed
incidence (r_nmod) associated
increased (l_parataxis) increased
exposure (r_nmod) effect
nephrotoxicity (l_conj) anemia
ablated (l_conj) seizure-free
p (r_nmod) studied
incidence (l_nmod) hypertension
accumulation (r_nmod) change
women (l_acl:relcl) reported
daunorubicin (r_dep) anthracyclines
factor (l_conj) agitation
flestolol (r_compound) infusion
using (l_nmod) induction
curcumin (r_nsubj) prevents
streptozocin (r_nmod) induced
dox-induced (r_amod) cardiomyopathy
lowered (r_conj) have
trial (l_acl:relcl) neutralizes
reported (l_xcomp) precede
ibuprofen (r_compound) acid
propranolol (r_compound) therapy
pemoline (r_nsubj) derivative
developed (l_nsubj) nodule
iodide (r_compound) drops
acetylsalicylate (r_nmod) recorded
resolved (r_acl) angioedema
revealed (l_ccomp) resulted
involved (r_ccomp) suggest
therapy (r_nsubjpass) associated
cycloheximide-induced (r_amod) amnesia
ticlopidine (r_dobj) receiving
glycopyrrolate (r_dobj) applying
incorporation (r_nsubj) induced
l-dopa (r_nmod) reduction
lometrexol (r_compound) clearance
infusion (r_dep) 5-fluorouracil
resulted (l_nmod) eradication
occurs (l_nsubj) thrombosis
developed (l_dobj) syndrome
showed (l_dobj) inhibition
induce (l_dobj) anemia
trinitrate (r_nmod) effect
macrolides (r_nmod) reported
production (l_conj) pain
administration (l_nmod) vaccine
inhibit (r_xcomp) found
alpha-methyldopa-estrogen (r_compound) interaction
matter (r_advmod) is
receptors (r_nsubj) modulate
dose (r_nmod) basis
correlation (r_dobj) found
explore (l_dobj) role
iodine-125-metaiodobenzylguanidine (r_nmod) detection
have (l_dobj) inflammation
days (r_nmod) prepared
pre-treatment (r_nsubj) reduces
designed (l_xcomp) assess
aspartate (r_conj) glutamate
caused (l_nmod) hyperkalemia
cause (l_nmod) hyperkalemia
toxicity (r_dobj) enhances
milrinone-induced (r_amod) hypotension
drug (r_nsubj) tended
increased (l_dobj) incidence
introduction (r_nsubj) resulted
streptozotocin (r_compound) impairment
developed (l_dobj) oliguria
induces (l_nmod) seizures
tachycardia (l_appos) vt
appeared (r_advcl) given
man (l_nmod) leukemia
valproate (r_dep) encephalopathy
group (r_nsubj) received
ischemia (l_nmod) spasm
thought (l_xcomp) result
epinephrine (r_conj) lidocaine
administration (r_nsubj) resolved
inhibited (l_conj) had
well-tolerated (l_nmod) effects
n-butyl-deoxynojirimycin (r_nmod) safety
thalidomide (r_nmod) potential
tumors (l_appos) papillomas
amnesia (r_dobj) reverse
therapy (r_nmod) responding
some (l_nmod) indices
mice (l_nmod) injury
observed (l_nsubjpass) thrombi
acitretin-induced (r_amod) dysphonia
determining (l_nmod) cases
enhances (l_conj) produces
gaining (l_dobj) acceptance
opsonized (l_nmod) serum
dyazide (r_compound) therapy
months (r_nmod:tmod) developed
ii (r_compound) receptor
result (l_nmod) convulsions
similar (l_nsubj) risk
had (r_advcl) delineate
reduced (r_acl:relcl) effect
incidence (l_nmod) myoclonus
cefotetan-induced (r_amod) anemia
had (l_dobj) increase
increasing (l_nsubj) incidence
each (r_nmod) exposure
rate (l_nmod) patients
csa (r_nmod) role
disinhibition (l_conj) aggression
added (l_xcomp) correcting
remains (l_xcomp) standard
developed (l_dep) lymphadenopathy
intensity (l_compound) headache
heparin (r_compound) areas
exposure (r_dobj) relate
losartan (r_amod) administration
attenuated (l_dobj) hypotension
expression (r_nmod) intact
hypotension (r_nsubjpass) accompanied
placebo (l_nmod) patients
prevents (l_dobj) nephrotoxicity
cardiac (r_amod) arrhythmias
responsible (l_nmod) dyskinesias
antipsychotics (r_nmod) treatment
defects (l_appos) vfd
evidence (l_nmod) hepatitis
azithromycin (r_nmod) mediated
sodium (r_dep) bisphosphonate
challenge (r_conj) ly-171555
ethambutol-associated (r_amod) optic
discontinued (l_advcl) observed
cephalosporins (r_conj) erythromycins
included (l_dobj) increase
naproxen (r_conj) diclofenac
has (l_dobj) activity
azithromycin-induced (r_conj) recurrent
doses (r_nmod) challenge
development (l_nmod) failure
infusion (r_nmod) demonstrated
hypothyroidism (r_nmod) secondary
overcome (r_xcomp) able
chp (r_compound) concentrations
due (l_conj) remained
galactosamine-induced (r_conj) chloroform-
metoclopramide (r_nsubjpass) used
capsaicin (r_compound) treatment
used (r_advcl) pose
interaction (r_dobj) show
hypertension (l_conj) microangiopathy
cells (l_acl:relcl) experience
diabetic (l_dep) neuropathy
produced (l_dobj) increase
glycosides (r_nmod) effects
ouabain (r_nsubj) induced
properties (r_nmod) induced
gemcitabine (r_compound) mg/m(2
dilevalol-associated (r_amod) hepatitis
girl (l_conj) man
methylphenidate-induced (r_amod) symptoms
influence (l_dobj) occurrence
induced (r_acl) hypersensitivity
higher (l_dep) reduction
apomorphine (r_nmod) administration
treated (l_nsubjpass) block
ribavirin-induced (r_amod) anemia
valsartan/hydrochlorothiazide (r_amod) therapy
duration (r_nmod) relation
acetazolamide (r_nmod) induced
treated (r_acl) uveitis
species (l_acl) reported
factor (r_nmod) injection
dfc (r_nmod) those
oxygen (r_compound) species
history (l_nmod) hypertension
produce (r_acl) injection
produced (l_dobj) embryolethality
dose (r_dobj) taking
dose (l_acl:relcl) less
no (r_compound) deficiency
therapy (l_nmod) infections
was (r_dep) results
inhibitors (r_conj) doses
defined (l_conj) splenomegaly
tm (r_nmod) reduction
effects (l_nmod) fasciculation
cystitis (r_conj) radiation
therapy (r_nmod) convulsions
involving (r_acl) anaesthesia
5-fluorouracil/folinic (r_compound) therapy
amiodarone (r_compound) loading
synergy (r_nmod) studies
demonstrates (l_advcl) antagonizing
transport (l_nmod) humans
effects (l_nmod) learning
exposed (r_acl) patients
ticlopidine-induced (r_amod) cholestasis
sleeping (l_dobj) difficulties
development (l_nmod) fluctuations
patients (l_nmod) two
stage (l_amod) pre-nephrotic
case (l_nmod) necrolysis
causes (l_nmod) hyperprolactinemia
induced (r_acl) inflammation
trial (r_nmod) patients
tachycardia (l_acl) inducing
development (l_nmod) neuropathy
digoxin (r_nsubj) increase
trial (l_compound) stroke
therapy (r_nmod) duration
patients (l_compound) pain
adriamycin (l_nmod) carcinoma
gtn (r_dobj) receive
drug (r_nmod) treated
octreotide (r_advmod) developed
affinity (r_nmod) increased
treatment (l_nmod) scabies
administration (r_nsubj) produces
contrast-induced (r_amod) nephropathy
tolterodine (r_nsubjpass) tolerated
investigate (r_conj) reflecting
bicuculline (r_conj) acid
treatment (r_nmod) presented
clinical (l_dep) features
domperidone (r_compound) therapy
monitor (l_dobj) alterations
resulted (r_ccomp) suggest
responsiveness (l_conj) correlations
use (r_dobj) limits
octreotide (r_appos) analog
obtained (l_nmod) departments
lamivudine (l_nmod) patients
controlling (l_dobj) symptoms
persist (l_nsubj) seizures
dexamethasone- (r_compound) hypertension
reported (l_nsubjpass) proteinuria
receptor (r_compound) blockers
failure (l_conj) disease
csa-induced (r_amod) nephropathy
vomiting (r_conj) developed
medium (r_amod) nephrotoxicity
rizatriptan (r_dobj) preferring
effects (r_nsubjpass) observed
erdosteine (r_nmod) modulation
polymorphism (r_nmod) phenotype
development (l_nmod) bradyarrhythmias
tamoxifen (r_conj) anastrozole
interferon (r_conj) ribavirin
motionless (l_nmod) absence
decrease (r_dobj) induced
acetate (r_nmod) women
development (r_nmod) receptor
association (l_nmod) patient
volume (l_nmod) dyskinesias
decreased (l_nsubj) frequency
sufficient (l_xcomp) prevent
risk (r_dobj) substantiate
improving (l_dobj) impairment
antinociception (l_conj) effect
giving (r_advcl) induced
hypertension (l_conj) hemorrhage
therapy (r_nmod) exhibited
antibiotics (r_nmod) doses
caused (r_acl) epilepsy
proarrhythmia (r_nmod) resulted
dep (r_appos) diethylpropion
caused (l_dobj) hypertension
adriamycin-mediated (r_amod) effect
% (l_nsubj) incidence
superior (r_advcl) %
altering (l_dobj) thresholds
enhancing (r_advcl) reduce
seems (r_parataxis) improves
had (l_dobj) cancer
prevented (l_nsubjpass) development
s-23121 (r_conj) s-53482
patients (l_compound) pd
system (r_nmod) abnormalities
depend (l_nmod) stimulation
myocarditis (l_compound) hypersensitivity
simvastatin (r_conj) telaprevir
cirrhosis (l_nmod) liver
deliberate (l_dobj) hypotension
heparin (r_nsubj) enhanced
day (r_nmod) combination
summary (l_appos) man
examine (l_advmod) nephropathy
dobutamine (r_dobj) describe
potentiated (r_conj) reduced
doses (r_nmod) occur
cytotoxicity (r_nmod) treatment
absence (l_nmod) hypotension
hypertension (r_nmod) pathogenesis
bilirubin (r_nmod) increase
determined (l_nmod) cases
reported (l_nmod) patients
analyzing (r_advcl) determined
suggest (r_conj) show
period (r_nmod) female
cyclosporine (r_pobj) of
epinephrine (r_nmod) produced
amlodipine (r_compound) group
adriamycin-induced (r_amod) damage
phenytoin (r_nsubj) induced
fk506 (r_conj) csa
implicated (l_nmod) di
99 (r_nsubjpass) observed
groups (l_acl) matched
mirtazapine-associated (r_amod) rls
dihydropyridine (r_compound) blockers
prevention (l_nmod) hypokalemia
blocked (r_advcl) increased
underwent (l_dobj) echocardiography
inhibitor (r_appos) temocapril
caused (l_nsubjpass) dyskinesias
indinavir (r_nmod) curve
system (r_nmod) participation
symptoms (l_conj) quality
effects (r_nsubj) mirror
decrease (r_dobj) rats
cyclophosphamide (r_conj) cis-platinum
effect (r_dobj) reduces
serotonin (r_compound) projections
signs (l_amod) suggestive
replacement (r_conj) discontinuation
contraindicated (l_nmod) abnormalities
infrequent (l_conj) limited
saline (r_nmod) irrigation
tachyarrhythmias (l_nmod) pointes
used (l_nmod) settings
characteristics (l_nmod) epilepsy
purpose (l_appos) limit
developed (l_nsubj) male
mrna (r_nmod) underwent
man (l_nmod) epilepsy
exhibits (l_conj) induces
cardiotoxicity (r_nmod) sensitizes
bupivacaine-induced (r_amod) effects
nitroprusside (r_nmod) hypertensive
diclofenac (r_advcl) higher
applicators (r_nmod) risks
clearances (r_conj) analysis
agent (l_amod) useful
contraction (l_appos) pvc
severity (l_nmod) stenosis
dysrhythmias (l_conj) behavior
other (r_amod) factor
london (l_conj) patients
paracetamol-treated (r_amod) groups
reviews (l_appos) cvd
examine (l_advcl) modulating
dex (l_nmod) treatment
methamphetamine (r_compound) levels
periods (r_nmod) assessed
resulted (l_nmod) increase
magnitude (l_nmod) association
metabolized (r_acl:relcl) cyclophosphamide
sulfate (l_nmod) cramps
induced (l_conj) reduced
recipients (r_nmod) episodes
thrombocytopenia (l_conj) hit
induction (r_conj) reduction
medications (l_conj) underlying
association (l_nmod) attacks
tendency (r_nsubj) ought
rats (l_amod) obese
rapamycin (r_appos) sirolimus
received (l_nmod) complication
effect (r_nsubjpass) studied
electrocardiograms (r_nsubjpass) compared
diltiazem-induced (r_amod) tetany
took (l_nmod) disorder
induce (l_conj) contribute
associated (r_ccomp) suggest
presenting (l_nmod) asterixis
p-aminophenol (r_conj) acetaminophen
clearance (r_dobj) enhancing
p (r_appos) %
values (l_acl) divided
findings (r_dobj) present
forms (l_dobj) gel
acid (r_nmod) treated
clomiphene-induced (r_amod) ovulation
suggest (l_ccomp) reverses
mg/kg (r_nmod) that
caused (r_acl) syncope
promotes (l_nsubj) remodeling
profile (r_nsubj) produce
observed (l_nsubjpass) cases
exhibited (l_conj) had
indicating (l_ccomp) have
achieved (l_dobj) levels
alcohol (r_nmod) case
biosynthesis (r_nmod) play
improve (l_dobj) duration
developed (l_ccomp) was
showed (l_dobj) rate
prevalence (l_nmod) disease
haloperidol (r_nmod) doses
those (l_nmod) group
tamoxifen-induced (r_amod) dysfunction
rizatriptan (r_nmod) %
suggested (l_advcl) have
pravastatin (r_nmod) use
mice (r_nmod) increased
fluoxetine (r_compound) effect
gene (r_nmod) expression
infarction (l_nmod) pallidus
decreased (l_dobj) elevations
resulted (l_conj) alter
one (l_nmod) hyperplasia
reduces (l_dobj) extent
employing (r_advcl) studied
rats (r_nmod) produced
intake (r_nmod) relation
dose (r_conj) 10-
patient (l_nmod) leukemia
nadph-diaphorase (r_amod) neurons
therapy (l_conj) atherosclerosis
deficits (l_nmod) deficits
pilocarpine-induced (r_amod) model
sodium (r_compound) retention
interval (l_nmod) ecg
doxorubicin/kg (r_nmod) observed
reduction (r_nmod) patients
pan (r_compound) treatment
induced (r_amod) myalgia
amantadine (r_nmod) caused
effect (r_nsubjpass) assessed
accompanied (l_nmod) fibrillation
giving (r_advcl) evaluated
glutamate (r_amod) supplementation
pentobarbital (r_conj) scopolamine
patients (l_nmod) c.
ketamine (r_nmod) dose
gives (l_nmod) pulmonary
morphine (r_nsubj) facilitated
effect (l_conj) deferoxamine
morphine (r_nmod) produced
anthracycline (r_compound) antibiotic
dose (r_nsubjpass) associated
methods (l_nmod) cancers
blockers (r_nmod) suppressed
patients (l_nmod) leukemia
bradykinin (l_compound) hyperalgesia
developed (l_conj) torsades
formation (l_compound) taa
used (r_acl:relcl) studies
induced (r_acl) crisis
serum (l_compound) alf
mdma (r_dep) users
aminophylline (r_nmod) infusions
spironolactone (r_nmod) treated
avp (r_nmod) effects
doxorubicin (r_nmod) caused
contents (r_conj) factor-alpha
naloxone (r_nmod) reversal
cy (r_compound) injection
subjects (l_amod) normal
led (l_nsubj) onset
acid (r_nmod) mg/dl
expressions (l_nmod) type
disappeared (l_advcl) occurred
pancuronium (r_nmod) pretreatment
etoposide (r_nmod) doses
victim (l_nmod) pain
effect (l_amod) primary
differences (l_dep) comparisons
showed (l_dobj) effects
two (l_nmod) failure
chebula (l_nmod) injury
plays (r_acl) view
death (l_conj) mortality
cause (l_nmod) cardiotoxicity
resulted (l_nmod) findings
therapy (r_nmod) achieved
tacrine (r_nmod) solution
20 (l_nmod) cardiomyopathy
hyperfiltration (l_nmod) failure
produced (l_advcl) induce
group (r_nmod) reduced
mediates (r_ccomp) believed
weakness (l_conj) lethargy
treatment (l_nmod) hit
result (l_nsubj) ischemia
assessed (l_conj) followed
inhibitors (r_nmod) acidosis
5-htp (r_nsubj) decreased
mice (r_nsubj) developed
g/m2 (r_nmod) dose
activity (r_nsubj) induces
impairment (l_nmod) patients
infarction (l_nmod) men
moderate (l_nmod) damage
clonidine (r_nmod) treated
secretion (l_nmod) hormone
model (l_nmod) hypertension
ergotamine/caffeine (r_conj) rizatriptan
blockage (r_nmod) induced
carboplatin (r_nmod) dose
forms (l_nmod) cystitis
ceased (r_acl:relcl) status
group (r_dep) day
effect (r_conj) activity
levels (r_nmod) relationship
incidents (l_nmod) bradycardia
pan (r_nmod) injection
usage (r_nmod) associated
etoposide (r_acl) sensitivity
tacrolimus (r_compound) treatment
iron (r_compound) accumulation
pathogenesis (l_nmod) neurotoxicity
manifesting (l_nmod) pericarditis
failure (l_appos) alf
use (r_nmod) neuropathy
role (l_conj) combination
follow (r_conj) increasing
characteristics (r_dobj) utilizes
found (r_conj) common
chemotherapy (l_nmod) glioblastoma
dopamine (r_dobj) raise
stimulation (l_conj) hypersensitivity
pacemaker (l_nmod) patients
had (l_dobj) myocarditis
reduction (r_nmod) developed
dfo (r_nmod:poss) role
reduction (l_nmod) hyperactivity
therapy (r_dep) consider
treatment (l_nmod) leukemia
chlordiazepoxide (r_nsubj) failed
injections (l_nmod) globulin
restored (l_dobj) bradycardia
ethambutol-induced (r_amod) optic
aminoglycoside (r_nmod) treatment
believed (l_advcl) enhance
discontinuation (r_nmod) showed
done (l_dep) screening
complication (r_nmod) noted
esterase (l_amod) neurotoxic
suggestive (l_nmod) relationship
using (l_dobj) stimulation
women (r_conj) achieve
risperidone (r_nmod) profile
recurrence (l_nmod) b
bed (l_conj) necroses
provided (l_nsubj) management
associated (l_nsubj) nodosum
exposure (l_nsubj) mechanism
levetiracetam (r_compound) treatment
complication (l_amod) bleeding
reduced (l_nsubjpass) number
years (l_acl:relcl) had
leads (l_nmod) states
aged (r_amod) people
patients (l_nmod) status
tobramycin (r_conj) netilmicin
predisposing (l_nmod) hypocalcemia
metabolism (r_nsubjpass) blocked
effect (l_nmod) phn
given (l_nsubjpass) prophylaxis
outcomes (l_nmod) patients
induced (l_dobj) anemia
experiment (r_nmod) antagonize
showed (l_dobj) effect
patients (l_nmod) asthma
tissues (l_conj) disorders
tendency (l_acl) produce
re-resection (l_amod) multiforme
encourages (l_dobj) compliance
patients (l_acl) pretreated
evidence (l_nmod) injury
cardiotoxicity (r_nmod) stress
effect (l_amod) anti-amnesic
susceptibility (l_amod) seizure
sertraline (r_conj) paroxetine
infusion (r_nmod) had
adducts (r_dobj) showed
taking (l_nmod) headache
mesna (l_acl:relcl) experiences
succinylcholine (r_nsubj) produces
treatment (r_conj) obesity
metamizol (r_nsubj) potentiate
presumed (r_acl) adenosine
treated (r_amod) animals
effect (r_nmod) parallel
thiamine (r_nmod) deficiency
emulsion (r_nmod) regimens
danazol (r_compound) treatment
prevented (l_dobj) catalepsy
treatment (r_nsubj) induced
tropicamide (r_nmod) dilation
one (l_nsubj) anemia
mortality (l_conj) infarction
affect (l_dobj) loss
amiodarone (r_nmod) administration
present (l_conj) discuss
analyzed (l_nsubjpass) lesions
disease (l_appos) pd
capable (l_advcl) predicting
incidence (l_nmod) most
model (l_compound) epilepticus
metolachlor (r_appos) unassigned
result (r_advcl) discharged
rats (l_nmod) amnesia
acts (l_xcomp) facilitate
3.0 (r_dep) increased
developed (r_ccomp) report
patients (l_nmod) ssc
lidocaine (r_dobj) receiving
erdosteine (r_nmod) protection
examine (l_dobj) contribution
complication (l_nsubj) cystitis
raloxifene (r_compound) treatment
disappeared (r_conj) related
causes (l_dobj) cystitis
treatment (r_nsubj) progress
associated (l_nsubjpass) obesity
sensory (l_conj) neuropathy
stz (r_nmod:npmod) induced
discontinuation (r_nmod) occurred
impaired (r_acl) memory
msg (r_appos) glutamate
azathioprine (r_nsubj) triggers
observed (l_nsubjpass) hepatitis
using (r_xcomp) determined
concerns (r_nsubj) continue
no (r_nmod) removal
vancomycin (r_compound) course
treated (l_nsubjpass) tachycardia
period (r_conj) weeks
fluoxetine (r_nmod) administration
seizures (r_nmod) complete
presented (l_nmod) erythroderma
haloperidol (r_nsubj) efficacious
chlorthalidone (r_compound) administration
cocaine (r_compound) metabolite
dmcm (r_appos) 6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate
attenuates (l_dobj) learning
cause (l_conj) suggested
superoxide (r_compound) anions
useful (l_nmod) test
developed (r_acl:relcl) cases
caused (l_nmod) patient
immunomodulators (r_nmod) use
vasospasm (r_nmod) cases
ribavirin (r_conj) alpha-2b
underwent (l_dobj) fracture
testing (r_nsubj) proved
used (r_conj) cause
finding (l_conj) echoes
treated (l_dobj) patients
adjustment (l_nmod) diabetes
investigated (l_nmod) disease
incidence (l_nmod) mortality
synthesis (r_nmod) changes
users (r_nmod) compare
myelosuppression (r_dep) results
cocaine (r_nmod:poss) effects
effects (l_conj) dysfunction
interferon (r_compound) treatment
induce (l_dobj) atypia
course (r_nmod) patients
treated (r_acl) epilepsies
investigated (l_nmod) tool
formed (r_acl) metabolite
days (l_appos) delay
bupivacaine (r_nsubj) dysrhythmias
dipyridamole (r_conj) heparin
cancer (l_conj) necrosis
hemolysis (l_conj) failure
induced (r_acl) dysosmia
hr (l_nmod) remd
derivative (l_acl:relcl) has
dipyridamole-thallium-201 (r_amod) imaging
induced (r_acl) that
misoprostol (r_nmod) effect
obtained (l_conj) ratings
disorders (r_dobj) experienced
differentiate (r_xcomp) follow-up
techniques (l_nmod) patients
correlate (l_dobj) inhibition
avp (r_compound) gene
quinidine (r_compound) hepatitis
relationship (l_nmod) stress
acid-induced (r_amod) seizures
administration (r_nmod) h
dilevalol-induced (r_amod) injury
amlodipine (l_nmod) treatment
hypothesis (l_ccomp) appear
children (l_acl) treated
causes (l_dobj) apnea
levels (r_conj) therapy
patient (l_conj) documentation
model (l_compound) seizures
arteries (l_conj) evidence
occurred (l_nsubj) collapse
acid (r_nmod) therapy
induced (l_dobj) loss
ligands (r_nmod) effect
free (r_amod) influence
caffeine (r_nmod) combination
attenuated (l_dobj) dysfunction
rats (l_nmod) polyuria
mortality (l_amod) seizure-related
use (l_nmod) paramedics
likelihood (l_nmod) hypotension
failure (l_nmod) anuria
received (r_acl:relcl) subjects
influence (l_nmod) mechanisms
l-dopa (r_nsubj) restored
cocaine (r_xcomp) exposed
supports (l_advcl) monitored
involved (l_nmod) pathogenesis
attenuated (l_nsubjpass) anxiety
octreotide (r_nmod) associated
(-)-propranolol (r_nmod) dose
sleeping (r_conj) had
created (r_acl) hypertension
reported (l_dobj) rate
ciprofloxacin (r_nsubj) precipitate
risk (l_nmod) bradyarrhythmia
triamterene (r_amod) nephrolithiasis
nicotine (r_nmod:npmod) sulfate-treated
den (r_nmod) given
diphosphate (r_nmod) microm
c (r_conj) cerruloplasmin
drug (l_nmod) tachycardia
thp (r_appos) thioperamide
women (l_conj) gout
compound (r_appos) tiopronin
leading (r_acl) hemolysis
methamphetamine-induced (r_amod) damage
seemed (l_xcomp) carry
depletion (r_conj) scopolamine
propranolol (r_dobj) received
srl (r_appos) sirolmus
2-chloroprocaine-ce (r_compound) seven
hcbd (r_appos) hexachloro-1:3-butadiene
exposed (r_acl) infants
included (l_dobj) appetite
ica (l_conj) sinus
suspect (l_ccomp) due
identified (l_nmod) inpatients
pregnanolone (r_appos) allopregnanolone
induction (r_nmod) reported
cause (l_advcl) associated
generalized (r_amod) seizure
rhabdomyolysis (l_conj) stroke
exposure (r_dep) days
levels (r_nmod) mechanism
occurring (r_advcl) presented
used (l_advcl) study
precipitated (r_conj) cause
atp/adp (r_compound) ratio
bromocriptine (l_nmod) cells
available (l_dobj) test
pretreatment (r_nsubj) doubled
activate (l_dobj) human
prostanoids (r_nsubj) contribute
predicted (r_conj) included
discontinuation (r_nmod) resolved
fluoxetine (r_compound) treatment
patient (r_nmod) diagnosis
ergotamine (r_nmod) tablet
inefficient (l_parataxis) terminate
dexrazoxane (r_nmod) doses
nephrotoxicity (r_nmod) protection
no (r_nmod) availability
hoarseness (r_conj) candidiasis
nephrotoxicity (l_conj) toxicity
nh4ac (r_compound) pretreatment
service (l_amod) psychiatric
lt (l_dep) alf=0/35
quinidine (r_nmod) alkaloid
hypotension (r_conj) hypotension
treated (l_nsubjpass) methods
tamoxifen (r_dobj) receiving
haemopericardium (l_conj) haemorrhage
reversal (l_nmod) hyperalgesia
model (r_nmod) increase
naloxone (r_nmod:npmod) reversed
mptp (r_compound) exposure
glucoronosyltransferases (r_nmod) undergoes
doses (r_dep) dexrazoxane
that (l_nmod) hepatitis
calcification (l_nmod) rats
diagnosed (l_nsubjpass) cholestasis
immunosuppressive (r_acl:relcl) diseases
upregulation (r_nmod) dimorphism
ratios (r_appos) odds
appropriate (l_nmod) degree
antithyroidmedications (r_nmod) effect
study (l_nmod) patients
glutathione (r_compound) level
propranolol (r_nmod) those
lisinopril (r_compound) therapy
found (l_advcl) was
cyp (r_nmod) administration
contraceptives (r_dobj) taking
had (l_dobj) infections
useful (l_advcl) controlling
hemopoiesis (l_nmod) cells
amphetamine (r_compound) injection
cabergoline (r_nmod) treated
treatment (r_nmod) initiation
occur (l_nsubj) mutants
received (l_advcl) had
acid (r_nsubj) decreased
cases (r_nmod) %
rigidity (l_conj) bradycardia
used (l_nmod) models
produced (l_dobj) depression
action (l_amod) nephrotoxic
administered (l_nmod) patients
noted (l_dobj) development
types (l_nmod) cancers
% (r_nsubjpass) compared
model (r_nmod) activity
administration (r_nmod) onset
fluoxetine-induced (r_amod) hypertension
mechanism (l_nmod) seizures
address (l_dobj) memory
oxygen (r_compound) difference
c (r_nmod:npmod) associated
included (l_nsubj) predictors
ester (l_dep) protector
related (r_advcl) assessed
dfo (r_appos) deferoxamine
higher (l_parataxis) conclude
toxicity (l_nmod) children
induces (l_dobj) sle
cirrhosis (l_conj) ascites
increased (l_dobj) interval
prevention (l_nmod) loss
hctz (r_dep) val
doxorubicin (r_nmod) trial
treatment (r_nsubj) led
declines (l_nmod) function
propylthiouracil-induced (r_amod) manifesting
clonidine (r_nsubj) induces
nitrendipine-treated (r_amod) albuminuria
reductase (r_compound) activity
role (l_nmod) contaminants
worsening (r_nmod) associated
agent (r_nmod) effects
marked (l_dobj) impairments
antagonism (r_dobj) involved
one (l_conj) ketosis
assessed (l_nsubjpass) magnitude
development (l_nmod) polyuria
failure (r_nmod) progression
busulfan (r_compound) neurotoxicity
yohimbine (r_dobj) given
efficient (r_xcomp) found
no (r_compound) pathway
phenobarbital (r_nsubjpass) added
terminate (l_conj) block
isoproterenol (r_compound) administration
decrease (l_acl) caused
concluded (l_nmod) toxicity
differences (l_nmod) model
apraclonidine-treated (r_amod) eyes
arabinoside (r_compound) treatment
produce (l_dobj) hyperprolactinemia
flurothyl (r_compound) ether
investigation (l_nmod) pattern
preventing (l_dobj) arrhythmias
yohimbine (r_nsubj) increased
tetrachloride- (r_conj) adriamycin-
assay (r_dobj) trypan
choline (r_compound) acetyltransferase
depression (l_conj) angina
challenge (l_nsubj) study
action (r_dobj) exerts
chemotherapy (r_nmod) cycle
total (l_acl) diagnosed
fentanyl (r_amod) reports
using (r_advcl) obtained
using (r_xcomp) stopped
treatment (r_nsubj) failed
recorded (l_conj) 35
addicts (r_nsubj) faint
effects (r_dep) objective
halothane (r_nmod) hepatotoxicity
exacerbated (r_amod) mj
treated (r_advcl) stopping
calcium (r_nmod) amounts
increased (l_conj) reduced
rectified (l_advcl) experienced
users (l_conj) nonusers
beneficial (l_nmod) treatment
ceftriaxone (r_nsubj) leads
suggest (l_conj) confirm
activity (l_nmod) seizures
clozapine (r_nmod) antipsychotics
agonist (r_nmod) challenge
induced (r_amod) rhabdomyolysis
treatment (l_nmod) fractures
prevent (l_dobj) development
succinylcholine (r_nmod) pretreated
morphine-chloralose (r_amod) dogs
treatment (r_nmod) recur
simvastatin (r_nmod) use
assessed (l_nsubjpass) myalgia
order (r_nmod) investigated
thalidomide (r_conj) docetaxel
scores (l_nmod) factor
pentoxifylline (r_nsubj) inhibit
engendered (l_nmod) administration
dose (r_nmod) controls
showing (r_acl) findings
undergone (l_dep) 1999
involved (r_ccomp) suggests
reduced (r_conj) antagonized
induced (r_acl) hepatotoxicity
caused (l_xcomp) become
digitalis- (r_amod) arrhythmias
produce (r_conj) selected
receptors (r_nmod) effect
duration (r_nmod) patients
suffered (l_nmod) seizures
propylthiouracil (r_compound) vasculitis
common (l_dep) hitt
leads (l_nmod) symptoms
suggesting (l_dobj) mechanism
hours (l_nmod) infarction
responses (r_dep) fev1
group (l_amod) hypotensive
exhibited (l_dobj) glomerulosclerosis
99mtc-glucarate (r_nsubj) easy
urea (r_compound) concentrations
prevent (l_dobj) thrombosis
alternative (l_nmod) support
restarted (l_nmod) rate
management (l_nmod) effects
way (r_nmod) metabolised
acid (r_nsubj) unlikely
fq (r_nsubj) modulate
diagnosis (l_nmod) lt
injected (l_nmod) groups
systems (l_acl) involved
diagnosed (l_nmod) malaria
show (l_conj) occurred
associated (l_nsubjpass) pain
induce (l_conj) augmented
5,7-dihydroxytryptamine (r_nmod) abolished
similar (l_nmod) subjects
srl (r_nmod) treated
daunorubicin (r_compound) regimen
trinitrate (r_nmod) infusion
cpa (r_nsubjpass) given
propranolol (r_amod) antagonism
had (l_conj) increased
dose (r_nmod) increase
have (l_dobj) profile
pemoline (r_compound) disorder
cases (l_nmod) desire
cocaine-associated (r_amod) hemorrhage
containing (r_acl) pills
anemia (l_conj) failure
jj (r_nmod) compared
bupivacaine (r_nmod) those
identified (l_advcl) prevent
interest (l_nmod) presence
products (r_nsubjpass) involved
reduction (l_nmod) nox
warfarin-like (r_amod) anticoagulant
thrombocytopenia (l_appos) hit
calcium (r_compound) blocking
ecstasy (r_nmod) effects
dysfunction (r_nsubjpass) caused
cataracts (l_conj) cancer
nmda (r_nmod) produced
screened (l_nmod) symptoms
acetate (r_conj) alpha-tocopherol
catecholamine-induced (r_amod) cardiomyopathy
inhibition (l_nmod) assay
nicotine-induced (r_amod) nystagmus
desire (l_conj) gynecomastia
use (r_nsubj) increases
glucuronidation (r_dobj) inhibited
noradrenaline (r_amod) levels
naloxone (r_dobj) administered
determine (l_dobj) dose
nifedipine (r_nmod) resolved
vpa (r_nmod) administration
pre-treatment (l_nmod) depression
3-methyladenine (r_appos) methods
cu/zn-superoxide (r_amod) dismutase
paracetamol (r_appos) safety
times (l_compound) catalepsy
newborn (l_nmod) regurgitation
observed (l_nsubjpass) days
received (l_nmod) setting
reducing (r_conj) potentiating
mechanism (r_nsubj) unknown
dogs (r_nmod) incidence
interaction (r_nmod) portion
tolerability (r_dobj) investigated
administered (l_conj) rats
staining (r_dobj) using
background (r_dep) documented
disease (r_nmod) studied
l-arginine (r_compound) treatment
interfere (r_acl:relcl) drugs
acetate (r_nmod) pretreatment
lidocaine (r_compound) level
pretreatment (l_nmod) catatonia
patients (r_nmod) other
attenuated (r_conj) potentiated
doses (r_nmod) arrhythmias
given (r_conj) proteinuric
action (l_amod) hyperalgesic
bpa (r_nmod) exposed
tachycardia (l_conj) dyspnea
desipramine (r_compound) ip
penicillins (r_nmod) allergy
doxorubicin (r_conj) monoher
suggestion (r_nsubj) finding
induce (l_dobj) glomerulonephritis
patients (l_nmod) features
bcnu (r_dep) designed
promoted (l_dobj) af
processes (l_nmod) cancer
increased (l_nmod) disease
tacrolimus (r_nmod) patient
verapamil (l_nsubj) woman
effect (r_dobj) study
therapy (r_nmod) failure
lamotrigine (r_nsubj) associated
performed (r_acl) study
methylprednisolone (r_nsubj) cause
onset (l_amod) epileptic
lidocaine (r_dobj) buffered
worsening (l_nmod) parkinsonism
procainamide (r_nmod) mg
quetiapine (r_nmod) effect
resistance (r_dobj) causes
infusions (r_nmod) monotherapy
3717 (r_nummod) cb
phenacetin (r_nmod) use
focused (l_nmod) possibility
penicillamine (r_nmod) treated
receptor (r_compound) antagonist
compared (r_dep) subjected
s-53482 (r_nmod) rats
capable (l_advcl) inducing
therapy (r_nsubj) (att)-associated
injection (r_nmod) treated
presence (r_dep) appear
zdv (r_dobj) receive
necrosis (r_nmod) case
acetaminophen (r_nmod) administration
dose (r_dobj) calculated
failure (l_conj) hypotension
warfarin (r_compound) interactions
treatment (r_nmod) showed
fever (l_conj) myalgias
patients (l_nmod) chf
urea (r_compound) clearance
placebo (r_nmod) frequency
lidocaine (r_nmod) relieved
loss (l_conj) increase
administered (l_dep) methods
lignocaine (r_nmod) use
evolution (l_nmod) infarction
onset (l_nmod) convulsions
amphetamine (r_conj) apomorphine
developed (l_nsubj) pneumonitis
cancers (l_conj) carcinoma
naloxone (r_dep) sensitivity
children (l_conj) two
acute (r_amod) nephrotoxicity
scopolamine (r_conj) pentobarbital
seizure (r_dobj) augments
reduces (l_dobj) oxygenation
azt (r_nmod) comparable
symptoms (l_nmod) edema
5-hydroxytryptamine (r_nmod) synthesis/turnover
treatment (r_dobj) undergoing
dose (r_conj) duration
sulpiride-induced (l_dobj) dyskinesia
resulting (l_nmod) syndrome
l-dopa (r_nmod) hypotension
pilocarpine-induced (r_amod) se
ptz (r_nmod) induced
treatment (r_dobj) required
seen (l_nmod) aes
occurred (r_acl:relcl) case
development (l_nmod) disorders
nomifensine (r_nmod) induced
nightmares (l_conj) hallucinations
dipyridamole (l_appos) depression
nifedipine (r_conj) sulfate
treatment (l_nmod) pneumonia
secondary (r_acl) syndrome
enlargement (l_nmod) pressure
patients (l_nmod) retinoblastoma
associated (r_acl) toxicities
carbamazepine (r_nsubjpass) switched
daptomycin (r_compound) mg/kg
docetaxel (r_nmod) treated
treatment (l_nmod) forms
lead (l_nmod) toxicity
attenuate (l_dobj) convulsive
maleate-induced (r_amod) injury
associated (r_acl) nystagmus
agents (r_dobj) nondepolarizing
occurred (l_nsubj) instances
anesthesia (r_nmod) induced
difficult (l_nsubj) diagnosis
haloperidol (r_nmod) prior
cirrhosis (l_conj) sporotrichosis
ezetimibe (r_nsubj) undergoes
objective (r_dobj) measured
associated (r_advcl) represent
depends (l_conj) needed
causing (l_dobj) hemorrhage
induced (r_acl) diuresis
puromycin-aminonucleoside (r_nmod) administration
supplemented (r_parataxis) available
beta-ccm (r_appos) beta-carboline-3-carboxylate
serotonin (r_compound) neurons
responsible (l_nmod) hepatitis
tam (r_compound) incorporation
underlying (l_dobj) conditions
ketamine (r_nmod) effect
recurrence (l_nmod) attack
report (l_compound) pain
content (r_conj) back-diffusion
cases (l_nmod) ahf
% (r_conj) fatal
used (r_conj) reported
that (l_acl) observed
cause (l_nmod) weakness
infants (r_nmod) reported
gem-p (r_appos) days
bolus (l_nmod) patients
antagonists (l_conj) hypotension
glycopyrronium (r_compound) kg-1
common (l_nsubj) artery
km (r_appos) abnormality
responsiveness (l_nmod) outcome
ketamine (r_nmod) effects
bromocriptine (r_nsubjpass) associated
manifestation (l_nmod) catalepsy
led (l_nmod) modifications
treatment (r_nmod) enhanced
fk506 (r_compound) nephropathy
higher (l_nmod) those
seemed (l_xcomp) result
furosemide (r_nmod) pretreated
diuretic (l_acl:relcl) cause
vigabatrin (r_compound) defects
norepinephrine (r_dobj) lack
associated (r_acl) myasthenia
inhibitors (l_appos) bouts
d2 (r_dobj) containing
seen (l_nmod) males
follow-up (l_nmod) cancer
movements (l_conj) deafness
failed (l_xcomp) prevent
receiving (r_advcl) developed
methadone (r_compound) group
hyperactivity (r_dobj) decreased
dox (r_dobj) received
propranolol (r_nmod) bradycardia
licl (r_dobj) contained
bradyarrhythmias (l_conj) delay
fever (l_conj) syndrome
utility (r_nsubjpass) complicated
occur (r_acl:relcl) symptoms
leukoencephalopathy (r_nmod) onset
recognized (l_nsubjpass) toxicity
hepatitis (r_nmod) that
system (r_nmod) dysfunction
depression (l_conj) disinhibition
rats (l_amod) atherosclerotic
estrogen (r_nsubj) modulates
condition (l_amod) similar
increase (l_nmod) seizures
increase (l_nmod) binding
cnsb002 (r_nmod) model
bevacizumab/irinotecan (r_nmod) combination
therapy (r_nmod) commencement
patients (l_acl) subjected
risk (l_nmod) thromboembolism
echoes (l_dobj) observation
poisoning (r_nmod) case
fanft (r_nmod) effect
extraction (l_amod) cataract
remained (l_nmod) adjustment
causes (l_dobj) degeneration
thrombocytopenia (r_nmod) effects
propensity (l_acl) cause
noted (l_nsubjpass) hemoglobinuria
patients (l_nmod) dyskinesia
caused (l_nmod) absence
caffeine (r_nmod) responses
isph-induced (r_amod) rats
ointment (r_nmod) treated
ability (l_acl) induce
0.5%/12h (r_nmod) treated
incidence (l_nmod) vte
galantamine (r_nmod) use
cardiomyopathy (r_nmod) impairment
case (l_appos) anemia
combination (r_nsubj) showed
bromide (r_nmod) dose
co-administration (r_nsubj) reversed
movements (l_amod) dyskinetic
tended (l_xcomp) have
amphetamine (r_nsubj) has
monophosphate (r_nmod) induced
uveitis (r_nmod) patients
% (l_nmod) cases
carboplatin (r_nsubjpass) said
underwent (r_acl:relcl) patients
effective (l_nmod) rosacea
therapy-na (r_nmod) lamivudine-resistance
lithium (r_compound) treatment
ensure (l_dobj) protection
associated (l_nmod) hypercalcemia
herbs (r_nmod) caused
handling (r_nmod) improvement
cause (l_dobj) cardiomyopathy
exposure (r_nmod) hit
drug (l_acl) associated
concentration (r_dobj) containing
produce (l_nmod) tachycardia
report (l_acl) leading
% (r_nmod) reported
pressor (l_conj) bradycardia
developed (l_conj) pronounced
discontinued (l_conj) showed
disorders (l_compound) schizophrenia
norepinephrine (r_compound) signaling
anticonvulsants (r_appos) use
utilized (l_advcl) provide
detected (l_nsubjpass) hyperalgesia
hg (r_dep) mm
ingredient (r_appos) gamma-hexachlorocyclohexane
ulcer (r_conj) hemorrhage
condition (l_conj) neurotoxicity
pentobarbital (r_nmod) hypersensitivity
demonstrated (l_dobj) risk
occurred (l_nmod) patient
suprofen (r_nmod) mg
malondialdehyde (r_nsubjpass) recorded
woman (l_nmod) trait
bipolar (l_nummod) ii
possibility (l_ccomp) difficult
trial (l_nmod) disorder
doxorubicin (r_conj) carboplatin
evaluated (l_advcl) using
reduce (l_conj) had
reserpine-induced (r_amod) akinesia
lignocaine (r_nmod) syndrome
causing (l_dobj) tdp
changes (l_acl:relcl) consistent
lindane (r_nmod) metabolism
suxamethonium-induced (r_amod) fasciculations
drug (l_nmod) tubulopathies
injections (r_nmod) studied
reduced (l_nsubj) frequency
homeostasis (r_nmod) preservation
combination (r_nsubjpass) dosed
going (l_nsubj) dysguesia
stz-induced (r_amod) nephropathy
administered (l_advcl) determine
way (r_nmod) respond
humans (l_nmod) hypertension
suppressants (r_dobj) taken
reversed (l_nmod) bradycardia
patient (r_nmod) crescents
patient (r_nsubj) developed
expected (r_conj) improves
stroke (r_nmod) incidence
5-fu (r_compound) therapy
affect (l_dobj) hyperactivity
activities (l_nsubj) esterase
greater (l_nsubj) incidence
effect (l_conj) influence
has (l_dobj) action
blockers (r_nmod) induced
(iso)-induced (r_amod) infarction
treatment (l_nmod) hyperhidrosis
occurred (l_nsubj) switches
developed (l_dobj) seizures
factors (l_nsubj) activation
acetylcholine-synthesis (r_amod) inhibitor
therapy (r_dobj) allowing
prevention (l_nmod) nausea
lead (l_nmod) outcomes
treatment (l_nmod) disorders
levels (l_nmod) brain
induces (l_dobj) hyperactivity
half-life (r_nsubj) short
arrest (r_nsubj) appears
test (l_nmod) hyperprolactinemia
phase (l_nmod) model
cancer (l_conj) hepatoma
reduces (l_dobj) rate
clonazepam (r_nmod) potent
metabolism (r_dobj) inhibit
decreases (l_dobj) sleepiness
effects (l_advmod) apart
causes (l_conj) points
adriamycin (l_amod) cardiomyopathy
persisted (r_conj) considered
level (r_nmod) present
safety (r_dobj) assess
relapsing (l_dobj) bacteremia
cgrp (r_compound) concentrations
albuterol (r_dobj) received
system (r_nmod) hypersensitivity
lithium-induced (r_amod) insipidus
treated (r_acl) measure
patients (l_amod) neutropenic
inhibited (l_dobj) hypertrophy
carbonate (r_nmod) amounts
timolol (r_nmod) less
known (r_advcl) appreciated
presented (l_conj) paresthesia
encephalitis (r_conj) encephalopathy
pravastatin-associated (r_amod) myopathy
role (l_acl) activate
dmtu (r_conj) sod
recorded (l_nmod) ischemia
group (l_amod) adr-nephropathy
courses (r_nsubj) caused
inhibition (l_nmod) impairment
accumulation (l_conj) depression
associated (l_nmod) seizures
denopamine (r_nmod) doses
leukemia (l_appos) cml
cause (l_dobj) seizures
d-penicillamine (r_nmod) treatment
osteoid (l_conj) fibrosis
resolved (l_nsubj) tdp
sevoflurane (r_nmod) influence
exposure (r_nmod) occurs
dose (r_nmod) correlated
ameliorates (l_dobj) impairment
cardiomyopathy (r_nmod) implicated
phz (r_appos) phenylhydrazine
rapa (r_nsubjpass) discontinued
valproate (l_nsubj) features
rats (l_nmod) infarction
fat (r_amod) rats
antagonists (r_nsubj) produce
ribavirin (r_nsubj) has
effects (l_acl) initiating
admitted (r_acl:relcl) women
or=2.5 (r_dep) patients
experienced (l_dobj) seizure
cisplatin (r_compound) administration
importance (r_nsubj) mainstay
investigate (l_advcl) develop
plasma (r_nmod) concentrations
use (l_conj) development
effect (l_nmod) loss
drugs (r_nmod) protects
developed (l_nmod) coccidioidomycosis
acid (l_conj) epilepsy
hemorrhage (l_conj) headache
scintigraphy (r_nsubj) method
associated (l_advcl) cause
antagonized (l_nsubjpass) enhancement
5-fluorouracil (r_compound) administration
dose (l_nmod) drugs
overflow (r_amod) dyskinesias
pressure (r_nmod) decrease
increases (l_dobj) pain
rate (l_nmod) hyponatremia
given (l_conj) induced
hypotension (r_nmod) greater
stage (l_nmod) hypertension
vancomycin (r_compound) stress
treatment (r_nsubj) showed
safety (l_nmod) evaluation
occur (l_nsubj) symptoms
ibuprofen (l_nmod) fever
prevention (r_dep) contributes
remained (l_nsubj) tachyarrhythmia
developed (l_dobj) akathisia
dexrazoxane (r_nsubj) protects
production (r_dobj) promotes
phenylhydrazine (r_nmod) compared
pb-exposed (r_amod) children
nephrotoxicity (r_conj) activity
associated (r_acl) sites
allocated (l_nsubjpass) patients
paracetamol (r_conj) treatment
moderate (l_nmod) signs
zidovudine (r_nmod) combination
operated (l_conj) developed
infusion (r_nmod) assessed
report (r_ccomp) presented
baclofen (r_nmod) discontinuation
ccnu (r_nsubjpass) used
apomorphine (r_nmod) dose
event (l_parataxis) presented
patients (r_nmod) disease
given (l_nmod) patients
thalidomide (l_nmod) lymphomas
decreased (r_conj) associated
believe (l_ccomp) caused
resulted (r_acl:relcl) patient
blocks (l_ccomp) antagonized
dobutamine (r_amod) infusion
had (l_dobj) rhabdomyolysis
receiving (r_advcl) reported
lidocaine (r_compound) toxicity
toxicity (r_nmod) schedule
protection (r_nsubj) ensure
cocaine-induced (r_amod) dysfunction
levels (r_nsubjpass) associated
agent (l_amod) hypotensive
phenobarbital-induced (r_amod) dyskinesia
treated (r_conj) known
common (l_nsubj) drowsiness
nausea (l_conj) pruritus
cephalothin-induced (r_amod) anemia
induced (l_dobj) fibrosis
tac (r_compound) level
remain (l_advcl) written
phenylethylbarbiturate-induced (r_amod) hepatitis
azathioprine-induced (r_amod) anemia
methamphetamine (r_nsubj) addictive
effect (l_nmod) dexamphetamine-
day (r_nmod:tmod) developed
infant (r_nsubjpass) admitted
valproate (r_compound) encephalopathy
simvastatin (r_nmod) conversion
mediate (r_acl:relcl) cells
intoxication (r_nmod) combination
need (l_nmod) development
lactate (r_nmod) infusion
taking (l_dobj) fever
choice (l_nmod) patients
combination (l_nmod) disorder
amitriptyline (r_conj) fluoxetine
ethopropazine (l_nmod) parkinsonism
neutralization (l_nmod) viremia
precursor (r_conj) l-arginine
d. (r_conj) growth
causes (l_dobj) increases
reduces (l_nsubj) pb
dobutamine (r_nmod) pointes
dependent (l_nsubj) levels
candidate (l_nmod) disease
erythematosus (l_conj) polymyositis
cases (l_nmod) uveitis
flecainide (r_nsubj) cause
directed (l_nmod) patients
erythroderma (l_conj) reaction
amisulpride (r_nmod) dose
indicating (r_xcomp) increased
leukemia (r_nmod) developed
coma (r_nmod) case
patients (r_nmod) variability
olanzapine (l_nmod) patients
myopathy (r_nsubj) represent
patients (l_amod) nephropathy
glutamate (r_amod) antagonists
had (l_conj) counts
picrotoxin (r_conj) ptz
angiographies (l_dep) deteriorated
associated (l_conj) syndrome
comparable (l_nmod) those
have (l_dobj) diseases
developed (r_conj) admitted
ratio (r_nmod) characterized
spite (r_nmod) cause
induced (l_dobj) hyperlocomotion
atp (r_compound) generation
dfp-atropine (r_nmod) treated
octreotide (l_appos) treatment
lactate (r_compound) dehydrogenase
dox (r_compound) mice
evaluate (l_dobj) frequency
gentamicin-induced (r_amod) loss
days (r_nmod) treated
chemotherapy (l_amod) nephrotoxic
timolol (r_compound) group
women (r_nmod) stroke
patients (r_nmod) confined
saline (r_nmod) treated
paraventricular (l_nmod) rat
zidovudine (r_conj) n-butyl-deoxynojirimycin
induced (l_nmod) electroshock
necrotizing (l_dobj) myopathy
slices (l_nmod) survivors
combination (l_nmod) therapy
headache (l_nmod) duration
lignocaine (r_nmod) neurotoxicity
dexamethasone (r_dobj) administered
dosage (r_conj) bed
antagonist (r_appos) ly274614
induces (l_dobj) malformations
estrogen-induced (r_amod) prolactinomas
tetrachloride (r_nmod) effects
test (l_advcl) evaluating
development (l_nmod) model
aza (r_compound) patients
effects (l_amod) neurotoxic
etiology (l_nmod) nodosum
dexmedetomidine (r_nmod) administration
drug (r_dobj) stopping
drugs (r_nsubj) failed
condition (l_nsubj) nephropathy
incidence (l_nmod) arrhythmias
cycloheximide (r_nmod) induced
review (r_nmod) present
containing (r_acl) stones
patients (r_nsubj) supervision
dogs (r_nmod) reproduced
completing (l_dobj) twitches
anthracycline (r_dobj) experienced
chlorpromazine (r_nmod) induced
t (r_compound) therapy
dosage (r_nmod) reduction
turnover (r_nmod) changes
treated (r_acl) cirrhosis
psychosis (l_conj) behaviors
activity (r_nmod) enhancement
etoricoxib (r_nmod) tolerability
involved (r_acl:relcl) paraparesis
susceptibility (r_dobj) evaluate
application (r_dobj) see
initiation (l_nmod) disease
given (r_advcl) prevented
injected (l_conj) left
administration (r_nsubj) prevented
agent (l_acl:relcl) treat
hr (l_nmod) controls
individuals (l_amod) epileptic
those (l_acl) experienced
prevent (r_xcomp) help
neurotransmission (r_nsubj) modulate
reaction (l_conj) toxicity
dopamine (r_compound) antagonists
unassigned (r_nsubj) suggest
unaffected (r_xcomp) remained
hyperactivity (r_dobj) reducing
pdn (r_nmod:npmod) treated
reversal (l_nmod) tetany
consider (l_xcomp) sign
generation (l_conj) excitotoxicity
case (l_nmod) history
case (l_nmod) mcl
clozapine- (r_amod) groups
resulted (l_nmod) infection
atropine (r_nmod) injection
dose (r_conj) paralysis
one (r_nsubj) nephrotoxicity
preparation (l_acl) illustrating
worth (l_xcomp) investigating
control (l_nmod) cases
trinitrate (r_nsubj) able
b (r_nmod) therapy
loss (r_dobj) reducing
enhancement (l_conj) toxicities
indicating (l_ccomp) reason
vasospasm (l_conj) ischemia
increased (l_nmod) patient
cases (l_nmod) colitis
propofol (r_nmod) tci
differences (l_nmod) latency
lowered (l_conj) factor-alpha
pg (r_nmod) tolerance
non-acetaminophen-induced (r_amod) alf=0/35
taking (l_advcl) treat
flurbiprofen (r_nmod) treated
angiotensin-converting (r_amod) inhibitors
that (r_nmod) magnitude
threshold (l_conj) seizure
kytril (r_dep) assess
containing (r_acl) contraceptives
dosage (r_nmod) correlates
effective (l_nmod) toxicity
suffered (l_nmod) strokes
15-f(2t)-isop (r_nmod) levels
plays (l_nsubj) death
bid (r_acl) addition
increased (l_nmod) mice
morphine (r_nmod) effect
contrast (r_nmod) prevented
correlations (r_dobj) found
levels (l_conj) inhibition
pemoline (r_compound) overdose
topiramate (r_nsubj) medication
penicillin (r_compound) derivatives
mechanisms (l_nmod) promotion
ameliorated (l_dobj) hypertension
shown (l_xcomp) attenuate
hydrochlorothiazide-triamterene (r_compound) therapy
serotonin (r_compound) system
duration (r_appos) variables
amphetamine (r_compound) use
died (l_nsubj) survivors
administration (r_nsubj) related
meq/l. (r_conj) reduced
analogues (r_nmod) series
protein (r_nmod) nissl-staining
associated (l_nmod) necrosis
% (r_nmod) found
leak (l_nmod) gliomas
norepinephrine (r_nmod) decreased
antidepressants (r_nmod) secondary
indicating (l_dobj) neurotoxicity
unmasked (r_acl) pheochromocytoma
nicardipine (r_nmod) recovered
potentiate (l_dobj) toxicity
adenosine (r_compound) agonists
unclear (l_nsubj) relationship
administration (l_nmod) potential
group (r_nmod) revealed
bendrofluazide-induced (r_amod) hypokalemia
induced (r_acl) effect
investigations (l_nmod) lesions
demonstrates (l_conj) suggests
cp (r_appos) agonist
caused (l_dobj) hyperprolactinemia
result (l_nmod) individuals
patients (l_nmod) schizophrenia
demonstrated (l_dobj) effects
results (l_nmod) reduction
cyclophosphamide (r_conj) melphalan
reduction (l_amod) anemia-induced
amphetamine (r_compound) exposure
daidzein (r_nsubj) activates
patients (r_nmod) %
flutter (l_appos) afl
cardiomyopathy (r_nmod) detection
users (r_nmod) common
ethambutol (r_nmod) association
caused (r_acl) tachycardia
o-methylation (l_acl:relcl) account
use (r_nmod) infarcts
recognizing (l_nmod) management
resulted (l_nmod) decrease
examined (l_nmod) rats
mechanism (r_conj) effect
la (l_nmod) mice
obtained (l_nsubjpass) csseps
stands (l_nmod) drug
offspring (r_nmod) development
morning (l_nmod) dystonia
shown (r_conj) involved
treated (l_nsubjpass) patients
patients (l_amod) constipation-predominant
ceftriaxone (r_nmod) induced
thiol (r_compound) donors
decrease (l_nmod) activity
occurring (l_nsubj) hamartoma
effects (r_dobj) potentiate
adenosine (r_compound) receptor
constipation-predominant (l_dep) diarrhoea-predominant
improves (l_nmod) stenosis
administration (r_nsubj) produced
effect (r_nsubj) occurred
mm (r_dep) higher
raise (l_nmod) paranoia
database (r_nmod) diagnosed
protrusions (l_conj) catalepsy
did (l_dobj) variables
ephedrine (r_nmod) use
coadministered (r_advcl) reduced
microangiopathy (l_dep) characterized
used (l_nmod) treatment
started (r_advcl) acquired
avp (r_nmod) administration
cpap (r_nsubj) produced
pattern (r_nsubjpass) observed
prevent (l_dobj) bruising
bacl2 (r_nmod) used
flavonoid (r_compound) monohydroxyethylrutoside
consumption (r_conj) resistance
epilepticus (r_nmod) installation
developing (l_advcl) developing
percentage (l_nmod) patients
parkinsonism (l_acl:relcl) choreic
level (r_nmod) elevation
observed (r_advcl) showed
pressure (l_conj) injury
catecholamines (r_nmod) levels
anticoagulation (r_conj) unsafe
cause (l_dobj) dysguesia
crf (r_dep) divided
drugs (l_amod) cardiotoxic
aminoglycoside (r_amod) antibiotics
macrolides (r_nmod) experience
determined (l_advcl) determining
pointes (r_nmod) case
based (l_nmod) presence
paracetamol-induced (r_amod) failure
carboplatin (l_nmod) rhabdomyosarcoma
causes (l_dobj) declines
treatment (l_nmod) psoriasis
infusion (r_nmod) result
mipafox-induced (r_amod) damage
present (l_nsubj) disorders
developed (l_dobj) polymyositis
produced (r_acl) calcium
glibenclamide (r_nmod) treatment
biochemical (l_conj) indices
induced (r_acl) thrombosis
steroids (l_nmod) kindled-seizures
ptu (r_dobj) discontinuing
3'-azido-2',3'-deoxythymidine (r_dep) zidovudine
effects (l_nmod) respect
fa (r_compound) c
induced (r_amod) insipidus
induction (l_amod) seizure
gm (r_nmod) rats
increased (l_nmod) phase
use (l_xcomp) treat
azithromycin (r_nmod) induced
protects (l_nmod) hepatotoxicity
uncommon (r_advcl) include
sulfate (r_nsubj) continue
rate (l_nmod) effects
hypertension (l_conj) glomerulonephritis
rash (r_dobj) developing
metformin (r_nsubj) suppressed
propofol (r_nmod) response
management (r_nmod) written
amiodarone (r_nmod) dosage
spontaneous (r_dep) greater
cancer (r_nmod) survivors
overdosage-induced (r_amod) generalized
patient (l_nmod) polymyositis
effects (l_nmod) fibrillation
nifedipine (r_compound) controls
5-ht(6 (r_compound) antagonists
abnormalities (r_nmod) associated
warfarin-induced (r_amod) vasculitis
rocuronium (r_nmod) precurarization
stimulation (l_amod) tetanic
test (r_nmod) hyperreactivity
induced (l_nmod) woman
periods (l_compound) activity
factors (l_compound) disease
occurred (r_conj) compromising
attack (l_compound) avrt
caffeine (r_compound) exposure
exhibit (r_xcomp) tended
seizures (r_nmod) %
cardiotoxicity (r_nmod) effect
comparison (l_nmod) patients
occurs (r_conj) observed
upregulation (r_nmod) contributes
importance (l_advcl) recognizing
followed (l_xcomp) indicating
ropivacaine-induced (r_amod) arrest
pretreatment (r_nmod) unaffected
unresponsiveness (r_amod) discriminates
ligation- (r_dobj) using
iron (r_nsubj) causes
therapy (l_nmod) hyperprolactinemia
aventyl (l_acl) produced
intoxications (r_nmod) abnormalities
cirazoline (r_nmod) pressor
treatment (r_nmod) introduction
suspensions (r_nmod) injection
patients (r_nsubj) developed
neostigmine (r_conj) methscopolamine
hypertension (l_conj) nephritis
cocaethylene (r_dep) toxicity
man (l_acl) suffering
increasing (l_conj) stroke
that (r_nmod) compared
statin (r_nmod) concentration
dogs (l_compound) arrhythmia
acid (r_compound) inhibition
fev1 (l_conj) tremor
ratios (r_dep) samples
obesity (r_nsubjpass) associated
vigilance (l_nmod) deterioration
isoflurane (r_nmod) exposure
levobupivacaine (r_compound) %
obtained (l_nmod) damages
msg-treated (r_amod) mice
signs (l_compound) toxicity
states (l_conj) seizures
activity (l_conj) seizures
insufficiency (l_nmod) patients
adr-induced (r_amod) nephrosis
prolonged (l_advcl) leading
dosage (r_nmod) depends
reduce (r_conj) exert
3/20 (l_appos) rat
intermediate (l_nsubj) toxicity
increasing (l_conj) 5
ratings (r_nmod) effects
found (l_nsubj) trial
patients (l_acl) suffering
enhances (r_advcl) increased
estradiol (r_nmod) combined
man (l_nmod) amyloidosis
damage (r_conj) inhibition
infusion (r_dobj) got
indicate (l_ccomp) influenced
levobupivacaine (r_nmod) toxicity
time-course (r_conj) evaluate
catalepsy (r_nmod) effect
treatment (r_nmod) reported
effective (l_nmod) prevention
patients (l_nmod) hemolysis
disorder (l_nmod) metabolism
lovastatin (r_nsubj) effective
gaba (r_appos) acid
results (r_nsubj) suggest
initiation (l_acl) induced
55562 (r_nummod) gr
cyclophosphamide (r_conj) etoposide
vasoconstriction (r_nmod) locus
amyloidosis (l_amod) secondary
examined (l_nmod) day
lamivudine-untreated (r_amod) patients
ro4368554 (r_nsubj) restores
effects (l_amod) amnesic-like
tmp-smz (r_appos) people
elevation (r_conj) levels
prazosin (r_advcl) blocked
aminoglycosides (r_nmod) trials
leading (l_nmod) palsy
sided (r_acl) one
effect (l_nmod) polydipsia
phenobarbitone- (l_dep) impairment
appears (r_conj) increased
described (l_nsubjpass) anemia
reversible (r_conj) severe
helodermin-produced (r_amod) hypotension
azithromycin (r_nmod) discontinuation
reduction (l_nmod) fractures
fact (r_nmod) seems
correct (r_nsubj) is
fever (l_compound) pustulosis
expression (l_acl:relcl) associated
side-effect (r_nsubj) dysguesia
timolol (r_appos) drug
mk-801 (r_conj) seizure
paclitaxel (r_nmod) chemotherapy
penetration (l_nmod) meningitis
effects (l_nmod) dysplasia
cause (r_conj) initiated
antibiotics (r_nmod) induced
treated (r_acl:relcl) arthritis
adriamycin (r_nmod) mg/m2
model (l_nmod) aneurysm
nimodipine (r_nsubj) prevents
caused (r_acl) polyneuropathy
outcomes (r_nsubj) comparable
acetylcholine (r_nmod) injection
cyclophosphamide (l_nmod) vasculitis
treated (l_nmod) headache
ointment (r_nmod) treatment
compared (l_conj) etiology
artery (l_dep) disease
mmol/l (r_dep) mosmol/kg
metoprolol-terbinafine (r_amod) combination
dose (r_nsubj) caused
amiodarone-induced (r_amod) torsade
decrease (l_dobj) threshold
presented (l_nmod) obstruction
indicating (r_xcomp) prevented
elevations (r_nmod) males
aniracetam (r_nmod) effect
toxicity (l_acl) resulting
group (r_nmod) learning
min (r_nmod) suffered
sodium (r_nmod) conjunction
attenuates (l_dobj) injury
animals (r_nmod) 2.3+/-1.2
responsiveness (r_nsubj) finding
admitted (l_nsubjpass) patient
consequence (l_nsubj) leukemia
day (r_conj) mg
relationship (r_dobj) indicate
protein (r_nmod) excretion
dapsone (r_nsubj) cause
receiving (r_acl) patients
ameliorates (l_dobj) dysfunction
lower (r_advcl) decreased
treatment (r_nsubj) attenuated
defects (l_acl) observed
decreased (l_conj) increased
cyclosporine (r_nmod) effect
sclerosis (l_appos) fsgs
electrolyte (l_conj) leukocytosis
similar (l_nsubj) variations
etiology (l_nmod) disease
% (r_dep) %
occurring (r_xcomp) published
participation (r_nsubjpass) deduced
diphenylhydantoin (r_compound) treatment
thought (l_xcomp) involved
propranolol (r_dep) blockers
stimulation (r_nsubj) causes
evident (r_acl:relcl) hypertension
aminophylline (r_nmod) infusion
thalidomide (r_nmod) doses
5-fluorouracil (r_nmod:npmod) folinic
assigned (l_advcl) was
dyskinesia (l_nmod) pd
disulfiram (r_nmod) administration
easy (l_conj) used
inhibited (l_dobj) enlargement
rats (l_acl) developing
granisetron (r_nmod) efficacy
incidence (l_amod) relative
induced (r_amod) carcinomas
5-ht6 (r_amod) gene
suggests (l_nsubj) association
acid-induced (r_amod) test
remains (l_conj) decreases
aminonucleoside-induced (r_amod) nephrosis
paid (l_nmod) states
accelerated (l_conj) decreased
contribute (l_nmod) reversal
kindreds (l_amod) diabetic
view (r_nmod) lend
pentobarbital (r_nsubj) protected
12 (l_nmod) dogs
9-tetrahydrocannabinol (r_nmod) induced
sle (l_dep) acid
metoprolol (r_nsubjpass) given
highlights (l_conj) suggests
mesna (r_nmod) combination
assess (l_nmod) treatment
p9605 (l_dep) protocols
prevent (r_advcl) studied
amlodipine (r_conj) telmisartan
those (l_acl) observed
produced (l_conj) calcification
prevention (l_nmod) cvd
expression (l_nmod) rats
concentration (r_dobj) increasing
indices (l_compound) necrosis
treatment (r_nmod) responded
prevention (r_conj) causes
xylometazoline (r_conj) naphazoline
methimazole (r_dobj) receiving
avoided (l_nsubjpass) recurrence
preserved (r_conj) cardiotoxicity
arabinoside (r_nmod) course
patients (l_acl) undergoing
fibrillation (l_appos) af
case (l_amod) attributable
group (l_nmod) neonates
use (l_conj) deprivation
implicated (l_advcl) playing
appeared (l_acomp) related
allodynia (l_conj) hyperalgesia
tool (l_nmod) diagnosis
blockers (r_nsubj) induce
continue (l_dep) danger
carbimazole (r_nmod) had
lithium (r_dobj) received
prostaglandin (r_compound) synthetase
effect (l_amod) hyperalgesic
amphetamine (r_compound) locomotion
tremor (l_conj) problems
dox (r_appos) doxorubicin
event (l_conj) neurotoxicity
suggestive (l_nmod) ischemia
ingestion (l_conj) occurrence
had (l_dobj) hypotensive
assumed (l_nmod) hypercholesterolemia
apomorphine (l_nmod) hypothermia
establish (l_dobj) diagnosis
have (l_dobj) incidence
treatment (r_nmod) interaction
reserpine (r_nmod) pretreatment
profile (l_compound) toxicity
experienced (l_dobj) seizures
inhibitors (r_nmod) target
used (l_nmod) action
test (r_nmod) induction
combined (l_nmod) prevention
insult (r_nmod) degree
ketamine (r_nsubj) induces
fluconazole (r_nsubj) associated
low (l_nsubj) incidence
intoxication (r_nmod) infarction
therapy (l_nmod) disease
diagnosed (r_acl) cancers
establishment (l_nmod) paradigm
type (r_conj) age
appreciated (l_ccomp) associated
develop (r_advcl) performed
cases (l_nmod) hypercalcemia
beta-lactam (r_compound) antibiotics
thought (r_acl:relcl) cardiotoxicity
amb. (r_nmod) substituted
migraine (l_nmod) aura
difference (l_nmod) incidence
effect (l_appos) suspension
counts (l_conj) measurement
became (l_acomp) marked
(+)-cibenzoline (r_nmod) concentrations
preservation (r_nmod) attributable
competing (r_acl) phenylalanine
glomerulosclerosis (l_conj) fibrosis
impact (l_nmod) cause
mortality (r_dobj) reduced
abandoned (l_advcl) considered
halothane-anesthetized (r_amod) dogs
diethylstilbestrol (r_nmod) adenocarcinoma
release (r_conj) back-diffusion
hydroxychloroquine (r_compound) treatment
hypersensitivity (r_nsubj) presented
obtained (r_conj) implies
apomorphine-induced (r_amod) aggressiveness
activity (r_nmod) determined
warfarin (r_nmod) groups
bilirubin (r_conj) transaminase
reduction (r_nmod) associated
dopamine (r_compound) sufficient
efficacy (l_nmod) mania
caffeine (r_appos) experiment
cyclosporine (r_nmod) patients
incontinence (l_conj) hallucinations
occurred (l_nsubj) angiosarcoma
oil (r_nmod) ml/kg
development (l_nmod) myasthenia
therapy (l_nmod) mbc
prevention (l_nmod) recurrence
cephalosporin-induced (r_amod) dyscrasias
risperidone (r_nmod) occurred
etomidate (r_compound) administration
bradycardia (l_conj) dysarthria
interferon-alpha-2b (r_dobj) received
neuroleptics (r_nmod) produced
cardiotoxity (r_conj) cocaine
controls (l_conj) macroprolactinemia
used (l_nmod) model
blocked (l_nsubjpass) hyperactivity
exposing (r_advcl) mimic
collected (r_conj) interviewed
movements (l_compound) choreoathetoid
administered (r_advcl) complete
appeared (l_nsubj) necrosis
reversed (l_dobj) formation
documented (l_nsubjpass) reaction
hemorrhage (r_nmod) model
ratings (l_compound) pain
nmda (r_compound) dysfunction
effects (r_conj) ligation-
mesna (r_nmod) uroprophylaxis
resolved (r_acl) pain
inhibited (l_dobj) development
8-phenyltheophylline (r_dep) effects
potassium (r_compound) concentrations
preceded (r_acl) mg/m(2
acetaminophen (r_nsubj) produces
obtained (l_nsubjpass) epilepticus
mortality (l_nmod) rats
treated (r_acl) epilepsy
starting (l_nmod) diagnosis
vpa-induced (r_amod) encephalopathy
infusion (r_nmod) hours
glyburide-induced (r_amod) hepatitis
delirium (r_nsubj) provide
bradykinesia (r_nmod) treatment
dysfunction (l_nmod) patients
suppresses (l_dobj) levels
ritodrine (r_compound) therapy
treatment (l_nmod) gliomas
risk (l_nmod) hypocalcemia
comparison (l_dep) study
bilirubin (l_conj) iii/iv
mg (r_nmod) injected
patients (l_nmod) diagnosis
side-effect (r_advcl) determine
nitroprusside (r_compound) infusion
association (l_nmod) patients
resulted (l_nmod) dyskinesias
used (l_xcomp) localize
serotonin (r_compound) excess
intolerance (r_nmod) risk
markers (r_nmod) showed
gaba-synthesizing (r_amod) enzyme
lidocaine (r_compound) tnss
done (l_nmod) women
developed (l_dobj) h
mg/kg (r_nmod) effect
different (l_nmod) controls
developed (l_nsubj) disease
increased (l_nmod) min
6-thioguanine (r_nmod) related
rats (r_nmod) glomeruli
use (r_nmod) related
supply (l_conj) demand
group (r_nmod) deteriorated
gtn (r_appos) trinitrate
considerations (l_nmod) hit
arrest (l_nmod) overdose
attributable (l_amod) chorioretinopathy
failed (l_xcomp) reverse
inhibitors (r_dep) chemotherapy
haloperidol (r_nmod) role
level (r_nsubj) decreased
hexamethonium (r_conj) injection
weakness (l_nmod) dystrophy
furosemide-treated (r_amod) group
has (l_dobj) role
correlated (l_nsubjpass) toxicity
effect (r_dobj) unaffected
concentrations (l_nmod) patient
testosterone (r_conj) gynecomastia
levels (r_nsubj) remained
assessed (l_dep) adjustment
initiated (l_nsubjpass) epilepticus
association (r_dobj) evaluated
caused (l_nmod) ages
injection (r_nsubj) produced
treatment (r_nmod) cases
functions (r_nmod) lesions
combination (r_nmod) using
cisplatin (r_dobj) receiving
enzyme (l_amod) neuropathy
discontinuations (l_nmod) aes
contractions (l_conj) flutter
superoxide (r_compound) production
furosemide (r_conj) aminoglycosides
attacks (l_appos) mdp
pain (l_conj) ecg
effects (l_nmod) threshold
task (l_acl) used
response (r_nsubjpass) detected
produce (l_dobj) symptoms
toxicity (l_compound) ami/gi
history (l_nmod) urticaria/angioedema
sera (r_nmod) sensitization
s-312-d (r_nsubj) useful
remain (l_xcomp) hypotensive
administration (r_nmod) worsened
bradykinin (r_nmod) influence
disappeared (l_nsubj) effusion
exposure (r_nsubj) induces
increase (r_nmod) paraparesis
risperidone-induced (r_amod) hyperprolactinemia
prevent (l_advcl) was
selegiline (r_dobj) stopping
failed (l_xcomp) potentiate
injections (r_nmod) incidence
decrease (r_nmod) predictors
enalapril (r_compound) use
arrhythmia (r_dobj) suppressed
impaired (l_dobj) learning
ointment (l_nmod) dermatitis
disturbances (r_nmod) basis
investigated (l_conj) vasculitis
remoxipride (r_compound) metabolites
activities (l_nmod) infarction
ethambutol (r_compound) dosing
polyuric (r_conj) thirsty
inhibits (l_nmod) inhibitor
antagonist (r_conj) involves
to (r_xcomp) presumed
signs (l_conj) symptoms
$UNK$